
<html lang="en"     class="pb-page"  data-request-id="3df3a7fd-62c5-45dd-9f35-21d5ee02ae27"  
><head data-pb-dropzone="head"><meta name="pbContext" content=";article:article:10.1021/acs.jmedchem.9b00623;requestedJournal:journal:jmcmar;journal:journal:jmcmar;page:string:Article/Chapter View;ctype:string:Journal Content;wgroup:string:ACHS website Group;website:website:acspubs;issue:issue:10.1021/jmcmar.2019.62.issue-20;pageGroup:string:Publication Pages;subPage:string:Full Text"/></meta>




        <link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /></link><meta name="citation_journal_title" content="Journal of Medicinal Chemistry" /></meta><meta name="dc.Title" content="Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo" /></meta><meta name="dc.Creator" content="Matthias  Scheiner" /></meta><meta name="dc.Creator" content="Dominik  Dolles" /></meta><meta name="dc.Creator" content="Sandra  Gunesch" /></meta><meta name="dc.Creator" content="Matthias  Hoffmann" /></meta><meta name="dc.Creator" content="Massimo  Nabissi" /></meta><meta name="dc.Creator" content="Oliviero  Marinelli" /></meta><meta name="dc.Creator" content="Marina  Naldi" /></meta><meta name="dc.Creator" content="Manuela  Bartolini" /></meta><meta name="dc.Creator" content="Sabrina  Petralla" /></meta><meta name="dc.Creator" content="Eleonora  Poeta" /></meta><meta name="dc.Creator" content="Barbara  Monti" /></meta><meta name="dc.Creator" content="Christina  Falkeis" /></meta><meta name="dc.Creator" content="Michael  Vieth" /></meta><meta name="dc.Creator" content="Harald  Hübner" /></meta><meta name="dc.Creator" content="Peter  Gmeiner" /></meta><meta name="dc.Creator" content="Rangan  Maitra" /></meta><meta name="dc.Creator" content="Tangui  Maurice" /></meta><meta name="dc.Creator" content="Michael  Decker" /></meta><meta name="dc.Description" content="We have designed and synthesized a series of 14 hybrid molecules out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and..." /></meta><meta name="Description" content="We have designed and synthesized a series of 14 hybrid molecules out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and..." /></meta><meta name="dc.Publisher" content="American Chemical Society" /></meta><meta name="dc.Date" scheme="WTN8601" content="October 14, 2019" /></meta><meta name="dc.Type" content="research-article" /></meta><meta name="dc.Format" content="text/HTML" /></meta><meta name="dc.Identifier" scheme="doi" content="10.1021/acs.jmedchem.9b00623" /></meta><meta name="dc.Language" content="en" /></meta><meta name="dc.Coverage" content="world" /></meta><meta name="dc.Rights" content="Copyright © 2019 American Chemical Society" /></meta>
        
        

        
            <link rel="meta" type="application/atom+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00623" /></link>
            <link rel="meta" type="application/rdf+json" href="https://doi.org/10.1021%2Facs.jmedchem.9b00623" /></link>
            <link rel="meta" type="application/unixref+xml" href="https://doi.org/10.1021%2Facs.jmedchem.9b00623" /></link>
        
    
    

<title>Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo | Journal of Medicinal Chemistry</title>












<meta charset="UTF-8">




<meta name="robots" content="noarchive"/></meta>
<meta name="pb-robots-disabled">









        <meta property="og:url" content="https://pubs.acs.org/doi/full/10.1021/acs.jmedchem.9b00623" /></meta><meta property="og:title" content="Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo" /></meta><meta property="og:image" content="https://pubs.acs.org/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0016.jpeg" /></meta><meta property="og:description" content="We have designed and synthesized a series of 14 hybrid molecules out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and investigated them in vitro and in vivo. The compounds are potent ChE inhibitors, and for the most promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their ability to interfere with AChE-induced aggregation of β-amyloid (Aβ), and Aβ self-aggregation was assessed. All hybrids were evaluated for affinity and selectivity for hCB1R and hCB2R. To ensure that the hybrids retained their agonist character, the expression of cAMP-regulated genes was quantified, and potency and efficacy were determined. Additionally, the effects of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated. The most promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer’s mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at high dose (3 mg/kg, i.p.)." /></meta><meta property="og:type" content="Article" /></meta><meta property="og:site_name" content="ACS Publications" /></meta><meta name="twitter:card" content="summary_large_image" /></meta><meta name="twitter:site" content="@ACSPublications" /></meta>
    


    <meta name="viewport" content="width=device-width,initial-scale=1,maximum-scale=10, user-scalable=0"/></meta>















    

    <meta name="dc.identifier" content="10.1021/acs.jmedchem.9b00623"/></meta>



<meta name="format-detection" content="telephone=no">













<link rel="stylesheet" type="text/css" href="/wro/kfa7~product.css">


    <link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-roboto/font-roboto.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/css/build-f32cfd249ff7cb4cf9c7.css"/></link><link rel="stylesheet" href="/products/achs/releasedAssets/fonts/achs-fonts/font-lato/font-lato.css"/></link>




<meta http-equiv="X-UA-Compatible" content="IE=edge">
<meta http-equiv="content-type" content="text/html; charset=UTF-8">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/achs-1625058702970.css">
<link rel="stylesheet" type="text/css" href="/pb-assets/styles/acs-1622125181777.css">
<script type="text/javascript" src="/templates/jsp/js/jquery-3.1.1.min.js"></script>
<script type="text/javascript" src="/pb-assets/javascript/eloqua-1619549134767.js"></script>
<script async="" type="text/javascript" src="https://www.googletagservices.com/tag/js/gpt.js" rel="preconnect"></script>

<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"5200035e6e4d5180","startTime":1570117212010}'></script>






    








    
        
            <script type="text/javascript">
                (function (i, s, o, g, r, a, m) {
                    i['GoogleAnalyticsObject'] = r;
                    i[r] = i[r] || function () {
                        (i[r].q = i[r].q || []).push(arguments)
                    }, i[r].l = 1 * new Date();
                    a = s.createElement(o), m = s.getElementsByTagName(o)[0];
                    a.async = 1;
                    a.src = g;
                    m.parentNode.insertBefore(a, m)
                })(window, document, 'script', '//www.google-analytics.com/analytics.js', 'ga');
                ga('create', 'UA-7663985-4'
                    
                    
                    , 'auto'
                    
                    );
                
                
                ga('send', 'pageview');
            </script>
            
        
    















    
    
            
                
                

                <link rel="canonical" href="https://pubs.acs.org/doi/10.1021/acs.jmedchem.9b00623">
            
        




























    
    

    
    
    
    
    <script src="//unpkg.com/@theidentityselector/thiss-ds"></script>

    <script type="text/javascript">

        var SeamlessAccessService = {
            spUrl: "/action/ssostart",
            returnURL: window.location.href,
            my_context: 'seamlessaccess.org',
            timeout: 5000,

            getWAYFLessUrl: function (entityId) {
                return this.spUrl + "?idp=" + encodeURIComponent(entityId)
                    + "&redirectUri=" + encodeURIComponent(this.returnURL);
            },
            retrieveEntity: function (ms) {
                var self = this;
                var persistService = new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                if(ms == undefined || ms === ''){
                    ms = this.timeout;
                }

                return new Promise(function (resolve, reject) {
                    persistService.entities(self.my_context)
                        .then(function (res) {
                            // get the results
                            var results = res.data;
                            return resolve(results);
                        }, function (err) {
                            // failed
                            reject('retrieve entity error: ' + err);
                        });
                        // Set up the timeout
                        setTimeout(function() {
                            reject('Promise timed out ' + ms + ' ms');
                        }, ms);
                });
            },
            updateEntity: function (entitydata) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                var jsonObj = {};
                try {
                    //try to parse it, if it is a json string
                    jsonObj = JSON.parse(entitydata.val());
                } catch (e) {
                    jsonObj = entitydata;
                }
                return new Promise(function (resolve, reject) {
                    persistService.update(self.my_context, jsonObj)
                        .then(function (res) {
                            // Process the results
                            var ssoInstitutions = res.data;
                            return resolve(ssoInstitutions);
                        }, function (err) {
                            // failed
                            console.log('failed to update the local storage duo to: ' + err);
                            reject(err);
                        });
                })
            },
            removeEntity: function (entityId) {
                var self = this;
                var persistService =  new thiss.PersistenceService('https://service.seamlessaccess.org/ps/');

                return new Promise(function (resolve) {
                    persistService.remove(self.my_context, entityId)
                        .then(function (res) {
                            return resolve(res);
                        }, function (err) {
                            // failed
                            console.log('failed to remove from local storage duo to: ' + err);
                        });
                })
            },
            getAccessibleEntityStatus: function (doi, entityId) {
                return new Promise(function (resolve) {
                    $.ajax({
                        type: 'POST',
                        url: '/action/seamlessAccess',
                        accept: {
                            text: "application/json"
                        },
                        data: {doi: doi, entityid: entityId}

                    }).done(function (status) {
                        return resolve(status);
                    });
                });
            },
            getEntitiesWithAllInfo: function (doi) {
                let self = this,
                    arrayOfPromises = [];
                return new Promise(function (resolve, reject) {
                    self.retrieveEntity().then(function (res) {
                        let allSsoInstitutions = res;
                        for (i = 0; i < allSsoInstitutions.length; i++) {
                            let ssoInstitution = allSsoInstitutions[i];
                            arrayOfPromises.push(new Promise(function (resolve) {
                                self.getAccessibleEntityStatus(doi, ssoInstitution.entity.entityID)
                                    .then(function (entityStatus) {
                                        resolve({
                                            entityID: ssoInstitution.entity.entityID,
                                            entityTitle: ssoInstitution.entity.title,
                                            entityStatusObj: entityStatus,
                                            entitySsoUrl: self.getWAYFLessUrl(ssoInstitution.entity.entityID)
                                        });
                                    }, function (err) {
                                        console.log('failed to get the entity status: ' + err);
                                    });
                            }));
                        }
                        Promise.all(arrayOfPromises)
                            .then(function (finalResponse) {
                                resolve(finalResponse);
                            });

                    }).catch(function (err) {
                        reject(err);
                    })
                });
            }
        };

        window.addEventListener('load', function () {
            document.querySelectorAll(".sso-institution").forEach(function (institution) {
                var entityId = institution.getAttribute('data-entityid');
                var entityName = institution.getAttribute('data-name');
                var entitydata = {
                    entityID: entityId,
                    title: entityName
                };
                institution.addEventListener("click", function (e) {
                    e.preventDefault();
                    var self = this;
                    SeamlessAccessService.updateEntity(entitydata).then(function (res) {
                        console.log(res);
                        window.location.href = self.href;
                    }).catch(function (err){
                        window.location.href = self.href;
                    });
                });
            });
        });

    </script>




























    






    <meta name="google-site-verification" content="uBHpu2M2kL7VihPCSRXWyBSxooDf7L_BGgfHA3cjSfY" /></meta>


<link rel="prefetch" href="https://tpc.googlesyndication.com/safeframe/1-0-29/html/container.html"></head>
<body class="pb-ui">


























<script type="text/javascript">

    if(false) {
        document.getElementById("skipNavigationLink").onclick =function skipElement () {
            var element = document.getElementById('');
            if(element == null || element == undefined) {
                element = document.getElementsByClassName('').item(0);
            }
            element.setAttribute('tabindex','0');
            element.focus();

        }

    }

</script>











    <div id="pb-page-content" data-ng-non-bindable>
        <div data-pb-dropzone="main" data-pb-dropzone-name="Main">










        <div data-widget-def="UX3HTMLWidget" data-widget-id="ed6ae788-7707-48f4-b02c-3187c75e10db" class="hide">
        



        
        

        </div>
    




        
        




        
        



        <div class="pb-ad">
            <script type="text/javascript">
	var dartInstitutionType = 'none';
	var dartMember = 'false';
</script>
        </div>
    





        
        <script type="text/javascript">
$(document).ready(function() {
	setTimeout(function() {
		// var journalTitle = 'medicinal_chemistry';
		var taxonomyKeywords = $('.article_header-taxonomy');
		var articleKeyword = $('meta[name="keywords"]');
		var articleTitle = $('meta[name="dc.Title"]');
		var articleDescription = $('meta[name="dc.Description"]');
		var abstractKeyword = $('p.articleBody_abstractText:contains("Keywords: ")');
		var searchTerms = [];

		if (taxonomyKeywords.length > 0) {
			$(taxonomyKeywords).children(".rlist--inline").children("li").each(function() {
				searchTerms.push($(this).text());
			});
		}
		else if (articleKeyword.length > 0) { 
			searchTerms = searchTerms.concat(articleKeyword.prop('content').split(', '));
		}
		else if (abstractKeyword.length > 0) {
			searchTerms = searchTerms.concat(abstractKeyword.text().split("Keywords: ")[1].split('; '));
		}
		else if (articleDescription.length > 0) {
			$(articleDescription).each(function() {
				articleDescriptionKeywords = $(this).prop('content');
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/.,/g,"");
				articleDescriptionKeywords = articleDescriptionKeywords.replace(/\s{2,}/g," ");
				searchTerms = searchTerms.concat(articleDescriptionKeywords.split(' '));
			});
		}

		if (articleTitle.length > 0) {
			searchTerms = searchTerms.concat(articleTitle.prop('content').split(' '));
		}

		googletag.cmd.push(function() {
			var mappingLeader = googletag.sizeMapping().
			addSize([320, 400], [320, 50]).
			addSize([320, 700], [320, 50]).
			addSize([750, 200], [728, 90]). 
			addSize([980, 690], [728, 90]).
			addSize([1024, 768], [728, 90]).
			build();
			//leaderboard
			googletag.defineSlot('/8868/journal/medicinal_chemistry/article', [728, 90], 'dfp-journal-article-leaderboard').defineSizeMapping(mappingLeader).setTargeting('location', 'leaderboard1').setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//recommend
			googletag.defineSlot("/8868/journal/medicinal_chemistry/article", [1, 1], "dfp-journal-article-recommend").setTargeting("ntvPlacement", ["1100167"]).setTargeting("location", "recommend").setTargeting('Keyword', searchTerms).addService(googletag.pubads());
			//googletag.pubads().enableSingleRequest();
			googletag.pubads().collapseEmptyDivs();
			googletag.pubads().setTargeting('inst',dartInstitutionType).setTargeting('memb',dartMember);
			googletag.pubads().addEventListener("slotRenderEnded", function(event) {
				if((event.isEmpty === false) && (event.slot.getSlotElementId() != "dfp-journal-article-recommend")) {
					$("#" + event.slot.getSlotElementId()).parents(".advertisement").slideDown();
				}
			});
			googletag.enableServices();
		});
	}, 1000);
});
</script>





        
        <script src="https://common.ccdc.cam.ac.uk/ccdc-widget/1.0.0.76/Widget.min.js"></script>




        
        <header class="header header_article_inactive">



        
        <div class="header_topbar hidden-sm hidden-xs">



        
        <div class="container"><div class="row"><div class="col-lg-3 col-md-4 col-sm-5 header_topbar_left">









        <div data-widget-def="UX3HTMLWidget" data-widget-id="0be92cec-36a8-4b4d-9a08-a28c790ce306" class="header_mainmenu">
        



        
        <ul>
	<li>
		<a href="http://www.acs.org">ACS</a>
	</li>
	<li class="header_mainmenu_current">
		<a href="/">ACS Publications</a>
	</li>
	<li>
		<a href="https://cen.acs.org">C&EN</a>
	</li>
	<li>
		<a href="https://www.cas.org">CAS</a>
	</li>
</ul>

        </div>
    
</div><div class="col-lg-9 col-md-8 col-sm-7 header_topbar_right">



        
        <div class="institution"><span class="institution-info-wrapper"><span class="institution__intro">Access provided by</span><span class="institution__name">Hong Kong University of Science and Technology Library</span></span></div>




        
        <div class="user-login-bar"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" name="heartBeatReloadInterval" value="1740000" class="heartBeatReloadInterval"/></input><input type="hidden" name="logoutUrl" value="https://pubs.acs.org/action/doLogout?logoutRedirectUrl=https%3A%2F%2Fsso.acs.org%2Fidp%2Fglogout%3Fappid%3Datypon-live%26returnURL%3Dhttps%253A%252F%252Fpubs.acs.org%252F" class="logoutUrl"/></input><img src="https://sso.acs.org/idp/heartbeat?appid=atypon-lives&amp;max_auth_age=2592000" alt="Blank image" class="ssoHeartBeatImg"/></img><span class="user-login-bar__value"><a href="https://pubs.acs.org/action/ssoRequestForLoginPage" class="user-login-bar__Login">Log In</a></span><input type="hidden" name="isUserLoggedIn" value="false" class="user-login-bar_is-loggedin"/></input><input type="hidden" name="isPaired" value="false" class="pair-device-is-paired"/></input><input type="hidden" name="isStronglyAuthenticated" value="false" class="isStronglyAuthenticated"/></input></div>
</div></div></div>
</div>




        
        <div class="header_content">



        
        <div class="container"><div class="row"><div class="header_content_main">



        
        <div class="header_content_row">



        
        <div class="header_content_left pull-left">



        
        <a href="/" title="ACS Publications. Most Trusted. Most Cited. Most Read"><img id="" alt="ACS Publications. Most Trusted. Most Cited. Most Read" src="/pb-assets/ux3/pubs-logo-481x82-1523435513963.png"/></img></a>




        
        <div class="pj-badge"></div><a href="/journal/jmcmar" title="journal logo" class="header_article-logo"><img src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo"></a><div class="header_article-separator"></div>
</div><div class="header_content_center">



        
        <div class="header_contnav">
    <div class="header_contnav-row">
         <a href="#" title="Previous" class="header_contnav-pre">
                <i class="icon-angle-left"></i>
        </a>
       <div class="header_contnav-title">
            <span>
                <a href="#" title=""></a>
            </span>
        </div>
         <a href="#" title="Next" class="header_contnav-next">
                <i class="icon-angle-right"></i>
            </a>
    </div>
</div>
</div><div class="header_content_right pull-right">



        
        <div class="header_qv-link"><a href="#" title="Quick View" data-slide-target=".article_qv-xs-container" class="w-slide__btn slide-active icon-quickview">Quick View</a></div>




        
        <div class="header_article-share">



        
        <script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="527d28d6-3414-4cb2-9560-99e677e62c0d" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone1" title="ShareDropzone1"></div><div class="pb-dropzone" data-pb-dropzone="ShareDropzone2" title="ShareDropzone2"></div><div data-db-target-of="527d28d6-3414-4cb2-9560-99e677e62c0d" id="527d28d6-3414-4cb2-9560-99e677e62c0d_Pop" class="share__block dropBlock__holder fixed"><div class="pb-dropzone" data-pb-dropzone="shareBlock" title="shareBlock"></div><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>WeChat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li><li><a role="link" class="addthis_button_email"><i aria-hidden="true" class="at-icon-wrapper icon-envelope-o"></i>Email</a></li></ul></div></div>
</div>




        
        <div class="header_article-separator"></div>




        
        <div class="quick-search"><a href="#" aria-label="quick search" class="quick-search_icon icon-search"></a><div class="quick-search_content"><form action="/action/checkIsValidDoi" name="defaultQuickSearch" method="get" title="Quick Search" autocomplete="off" class="quick-search_default"><input type="search" name="AllField" placeholder="Search text, DOI, authors, etc." aria-label="Search text, DOI, authors, etc." data-auto-complete-max-words="7" data-auto-complete-max-chars="32" data-contributors-conf="3" data-topics-conf="3" data-publication-titles-conf="3" data-history-items-conf="3" value="" required="true" class="quick-search_all-field autocomplete"/></input><button type="submit" title="Search" class="icon-search"></button><div role="radiogroup" aria-labelledby="journal filter" class="quick-search_journal-filter"><label for="thisJournalRadio" tabindex="0" aria-checked="true" role="radio" class="radio--primary"><input id="thisJournalRadio" type="radio" value="jmcmar" name="SeriesKey" checked="checked" class="all-content"/></input><span>J. Med. Chem.</span></label><label for="allPubRadio" tabindex="0" aria-checked="false" role="radio" class="radio--primary"><input id="allPubRadio" type="radio" value="" name="SeriesKey" class="all-content"/></input><span>All Publications/Website</span></label></div></form><p>OR SEARCH CITATIONS</p><form action="/action/quickLink" name="citationQuickSearch" method="get" title="Quick Search" class="quick-search_citation"><input type="hidden" name="quickLink" value="true"/></input><select name="quickLinkJournal" class="quick-search_journals-select"><option value="jmcmar">Journal of Medicinal Chemistry</option><option value="achre4">Accounts of Chemical Research</option><option value="amrcda">Accounts of Materials Research</option><option value="aastgj">ACS Agricultural Science & Technology</option><option value="aabmcb">ACS Applied Bio Materials</option><option value="aaembp">ACS Applied Electronic Materials</option><option value="aaemcq">ACS Applied Energy Materials</option><option value="aamick">ACS Applied Materials & Interfaces</option><option value="aanmf6">ACS Applied Nano Materials</option><option value="aapmcd">ACS Applied Polymer Materials</option><option value="abmcb8">ACS Bio & Med Chem Au</option><option value="abseba">ACS Biomaterials Science & Engineering</option><option value="accacs">ACS Catalysis</option><option value="acscii">ACS Central Science</option><option value="acbcct">ACS Chemical Biology</option><option value="achsc5">ACS Chemical Health & Safety</option><option value="acncdm">ACS Chemical Neuroscience</option><option value="acsccc">ACS Combinatorial Science</option><option value="aesccq">ACS Earth and Space Chemistry</option><option value="aelccp">ACS Energy Letters</option><option value="aeacb3">ACS Engineering Au</option><option value="aeacc4">ACS Environmental Au</option><option value="aeecco">ACS ES&T Engineering</option><option value="aewcaa">ACS ES&T Water</option><option value="afsthl">ACS Food Science & Technology</option><option value="aidcbc">ACS Infectious Diseases</option><option value="amlccd">ACS Macro Letters</option><option value="amacgu">ACS Materials Au</option><option value="amlcef">ACS Materials Letters</option><option value="amachv">ACS Measurement Science Au</option><option value="amclct">ACS Medicinal Chemistry Letters</option><option value="ancac3">ACS Nano</option><option value="anaccx">ACS Nanoscience Au</option><option value="acsodf">ACS Omega</option><option value="aoiab5">ACS Organic & Inorganic Au</option><option value="aptsfn">ACS Pharmacology & Translational Science</option><option value="apchd5">ACS Photonics</option><option value="apcach">ACS Physical Chemistry Au</option><option value="apaccd">ACS Polymers Au</option><option value="ascefj">ACS Sensors</option><option value="ascecg">ACS Sustainable Chemistry & Engineering</option><option value="asbcd6">ACS Synthetic Biology</option><option value="ancham">Analytical Chemistry</option><option value="bichaw">Biochemistry</option><option value="bcches">Bioconjugate Chemistry</option><option value="bomaf6">Biomacromolecules</option><option value="bipret">Biotechnology Progress</option><option value="cgeabj">C&EN Global Enterprise</option><option value="cenear">Chemical & Engineering News Archive</option><option value="chlseg">Chemical Health & Safety</option><option value="chlseg0">Chemical Health & Safety</option><option value="crtoec">Chemical Research in Toxicology</option><option value="chreay">Chemical Reviews</option><option value="cmatex">Chemistry of Materials</option><option value="cgdefu">Crystal Growth & Design</option><option value="enfuem">Energy & Fuels</option><option value="esthag">Environmental Science & Technology</option><option value="estlcu">Environmental Science & Technology Letters</option><option value="iepra6.2">I&EC Product Research and Development</option><option value="iechad">Industrial & Engineering Chemistry</option><option value="iecac0">Industrial & Engineering Chemistry Analytical Edition</option><option value="iecjc0">Industrial & Engineering Chemistry Chemical & Engineering Data Series</option><option value="iecfa7">Industrial & Engineering Chemistry Fundamentals</option><option value="iepdaw">Industrial & Engineering Chemistry Process Design and Development</option><option value="iepra6">Industrial & Engineering Chemistry Product Research and Development</option><option value="iecred">Industrial & Engineering Chemistry Research</option><option value="iecnav">Industrial and Engineering Chemistry, News Edition</option><option value="inocaj">Inorganic Chemistry</option><option value="jaaucr">JACS Au</option><option value="jacsat">Journal of the American Chemical Society</option><option value="jafcau">Journal of Agricultural and Food Chemistry</option><option value="jceaax">Journal of Chemical & Engineering Data</option><option value="jci001">Journal of Chemical Documentation</option><option value="jceda8">Journal of Chemical Education</option><option value="jchsc2">Journal of Chemical Health & Safety</option><option value="jchsc20">Journal of Chemical Health & Safety</option><option value="jcics1">Journal of Chemical Information and Computer Sciences</option><option value="jcisd8">Journal of Chemical Information and Modeling</option><option value="jctcce">Journal of Chemical Theory and Computation</option><option value="jcchff">Journal of Combinatorial Chemistry</option><option value="iechad.1">Journal of Industrial & Engineering Chemistry</option><option value="jmcmar.1">Journal of Medicinal and Pharmaceutical Chemistry</option><option value="jnprdf">Journal of Natural Products</option><option value="joceah">The Journal of Organic Chemistry</option><option value="jpchax">The Journal of Physical Chemistry</option><option value="jpchax.2">The Journal of Physical Chemistry</option><option value="jpcafh">The Journal of Physical Chemistry A</option><option value="jpcbfk">The Journal of Physical Chemistry B</option><option value="jpccck">The Journal of Physical Chemistry C</option><option value="jpclcd">The Journal of Physical Chemistry Letters</option><option value="jprobs">Journal of Proteome Research</option><option value="jamsef">Journal of the American Society for Mass Spectrometry</option><option value="jamsef1">Journal of the American Society for Mass Spectrometry</option><option value="jamsef0">Journal of the American Society for Mass Spectrometry</option><option value="langd5">Langmuir</option><option value="mamobx">Macromolecules</option><option value="mpohbp">Molecular Pharmaceutics</option><option value="nalefd">Nano Letters</option><option value="neaca9">News Edition, American Chemical Society</option><option value="orlef7">Organic Letters</option><option value="oprdfk">Organic Process Research & Development</option><option value="orgnd7">Organometallics</option><option value="iepra6.1">Product R&D</option><option value="scimts">SciMeetings</option><option value="jpchax.1">The Journal of Physical and Colloid Chemistry</option></select><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkVolume" autoComplete="false" placeholder="Vol" required="required" class="quick-search_volume-input"/></input><input type="search" inputmode="numeric" pattern="[0-9]*" name="quickLinkPage" autoComplete="false" placeholder="Page" required="required" class="quick-search_page-input"/></input><button type="submit" title="Search" class="icon-search"></button></form></div></div>




        
        <div class="header_my-activity">



        
        <a href="#"><i class="icon-id-badge" aria-hidden=”true”></i><span>My Activity</span></a>
<div class="header_my-activity-content">
    <div class="header_my-activity-single">
        <i aria-hidden="true" aria-label="close" class="icon-close"></i>
        <div class="" data-name="recentlyViewedDropzone">



        
        <div class="show-recently"><div class="show-recently-header">Recently Viewed</div><h6 class="show-recently-empty">You have not visited any articles yet, Please visit some articles to see contents here. </h6></div>
</div>
    </div>
</div>
</div>




        
        <div class="header_publications">



        
        <a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>Publications</span></a>

</div>




        
        <div class="header_burger-menu">



        
        <a href="#?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuIcon&amp;utm_campaign=Pubs_Refere" class="header_burger-menu_button" title="menu button" aria-label="menu button"><i class="icon-navicon"></i><i
        class="icon-close"></i></a>
<div class="header_burger-menu_content">
    <ul class="hidden-lg">
        <li><a href="#" class="pubModal_button"><i class="icon-book" aria-hidden=”true”></i><span>publications</span></a></li>
        <li class="myActivityMobile"><a href="#" class="openTabletActivity"><i class="icon-id-badge" aria-hidden=”true”></i><span>my Activity</span></a>
            <ul>
                <li><a href="javascript:void(0)" class="recentlyViewed--open">Recently Viewed</a></li>
            </ul>
        </li>
    </ul>
    <ul>
        <li><a href="#">user resources</a>
            <ul>
                <li><a href="/page/remoteaccess"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Access Options');">Access Options</a></li>
                <li><a href="https://publish.acs.org/publish/"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Authors & Reviewers');">Authors &
                        Reviewers</a></li>
                <li><a href="http://www.acs.org/content/acs/en/membership-and-networks/acs/benefits/professional/publications-benefits.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS Members');">ACS Members</a></li>
                <li><a href="https://preferences.acspubs.org/journals"
                        onclick="ga('send', 'event', 'Home_MainMenu', 'Click', 'eAlert');">eAlerts</a></li>
                <li><a href="/page/follow.html?widget=follow-pane-mobile"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'RSS & Mobile');">RSS & Mobile</a></li>
            </ul>
        </li>
		<li><a href="#">for organizations</a>
			<ul>
			    <li><a href="https://solutions.acs.org/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Products & Services');">Products & Services</a></li>
				<li><a href="https://solutions.acs.org/access-options/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Get Access');">Get Access</a></li>
				<li><a href="https://solutions.acs.org/resources/manage-my-account/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Manage My Account');">Manage My Account</a></li>
			</ul>
		</li>
        <li><a href="#">support</a>
            <ul>
                <li><a href="/page/demo/index.html">Website Demos & Tutorials</a></li>
                <li><a href="https://acs.service-now.com/acs"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Support FAQs');">Support FAQs </a></li>
                <li><a href="#"
                        onClick="SnapEngage.startLink();return false; ga('send', 'event', 'Top Nav', 'Menu', 'Live Chat with Agent');"
                        class="help help-chat">Live Chat with Agent</a></li>
                <li><a href="https://acsmediakit.org/digital/acs-pubs/?utm_source=Nav&amp;utm_medium=Pubs&amp;utm_campaign=CEN"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Advertisers');">For Advertisers</a></li>
                <li><a href="https://solutions.acs.org/help/?utm_source=Pubs_Solutions_Referer&amp;utm_medium=Pubs_MenuBotton&amp;utm_campaign=Pubs_Referer"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'For Librarians & Account Managers');">For
                        Librarians & Account Managers</a></li>
            </ul>
        </li>
        <li class="hidden-sm hidden-xs"><a href="#">pairing</a>
            <ul>
                <li><a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a></li>
                <li><a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Pair this device');">Pair this device</a></li>
                <li><a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
                </li>
            </ul>
        </li>
        <li class="hidden-lg hidden-md">
            <a class="header_burger-menu_my-profile-link" href="/action/showPreferences">My Profile</a>
            <a class="header_burger-menu_login-link" href="/action/ssoRequestForLoginPage">Login</a>
            <a class="header_burger-menu_logout-link" href="#">Logout</a>
            <a class="header_burger-menu_pairadevice-link" href="/pairdevice">Pair a device</a>
            <a class="header_burger-menu_pairthisdevice-link" href="/action/devicePairingSubmitCode">Pair this
                device</a>
            <a class="header_burger-menu_pairedstatus" href="/action/devicePairingSubmitCode">Paired status</a>
        </li>
        <li><a href="#">about us</a>
            <ul>
                <li><a href="/page/about-us.html"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Overview');">Overview</a></li>
                <li><a href="http://acsopenscience.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'ACS & Open Access');">ACS & Open Access</a>
                </li>
                <li><a href="/#partners" onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Partners');">Partners</a></li>
                <li><a href="http://acsoncampus.acs.org"
                        onclick="ga('send', 'event', 'Top Nav', 'Menu', 'Events');">Events</a></li>
            </ul>
        </li>
    </ul>
</div>
<div class="activity-container-tablet"><i aria-hidden="true" class="icon-close"></i></div>


<script type="text/javascript">
  (function() {
    var se = document.createElement('script'); se.type = 'text/javascript'; se.async = true;
    se.src = 'https://storage.googleapis.com/code.snapengage.com/js/921a4ec7-cecf-43a6-afa5-6cd1346520b1.js';
    var done = false;
    se.onload = se.onreadystatechange = function() {
      if (!done&&(!this.readyState||this.readyState==='loaded'||this.readyState==='complete')) {
        done = true;
        /* Place your SnapEngage JS API code below */
        /* SnapEngage.allowChatSound(true); Example JS API: Enable sounds for Visitors. */
      }
    };
    var s = document.getElementsByTagName('script')[0]; s.parentNode.insertBefore(se, s);
  })();
</script>

<style>
    #SnapABug_Button,
    #designstudio-button {
        display: none;
    }
</style>

</div>
</div>
</div>
</div></div></div>
</div>




        
        <div class="pub"><div aria-live="polite" aria-atomic="true" class="pub-modal"><div class="pub-modal_content loop-trap"><a href="#" aria-label="close" tabindex="0" class="pub-modal_close icon-close pull-right"></a><div class="pub-modal_row"><div class="pub-modal_left"><div class="pub-modal_left-content"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_types"><h6>CONTENT TYPES</h6><ul class="pub-modal_types-list"><li data-type="all" id="allID" class="pub-modal_types-active"><a href="#"><h4>All Types</h4></a></li></ul></div><div class="pub-modal_subjects hidden-sm hidden-xs"><h6>SUBJECTS</h6><ul class="pub-modal_subjects-list"></ul></div></div></div><div class="pub-modal_right"><div class="pub-modal_control hidden-lg hidden-md"><span class="pub-modal_control-text">Publications: All Types</span><a href="#" title="Back button" class="pub-modal_back"><i class="icon-angle-left"></i></a></div><div class="pub-modal_right--inner"><div class="pub-content"></div></div></div></div></div><input type="hidden" name="pubModalData" value="{&quot;types&quot;:[{&quot;code&quot;:&quot;journals&quot;,&quot;label&quot;:&quot;Journals&quot;},{&quot;code&quot;:&quot;books&quot;,&quot;label&quot;:&quot;Books and Reference&quot;},{&quot;code&quot;:&quot;news&quot;,&quot;label&quot;:&quot;News&quot;}],&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;,&quot;label&quot;:&quot;Analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;,&quot;label&quot;:&quot;Applied&quot;},{&quot;code&quot;:&quot;cat_biological&quot;,&quot;label&quot;:&quot;Biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;,&quot;label&quot;:&quot;Materials Science &amp; Engineering&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;,&quot;label&quot;:&quot;Organic-Inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;,&quot;label&quot;:&quot;Physical&quot;}],&quot;publications&quot;:[{&quot;char&quot;:&quot;A&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achre4/2021/achre4.2021.54.issue-15/achre4.2021.54.issue-15/20210803/achre4.2021.54.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;achre4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Chemical Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achre4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amrcda/2021/amrcda.2021.2.issue-7/amrcda.2021.2.issue-7/20210723/amrcda.2021.2.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amrcda&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Accounts of Materials Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amrcda&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aastgj/2021/aastgj.2021.1.issue-3/aastgj.2021.1.issue-3/20210621/aastgj.2021.1.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aastgj&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS Agricultural Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aastgj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aabmcb/2021/aabmcb.2021.4.issue-7/aabmcb.2021.4.issue-7/20210719/aabmcb.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aabmcb&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Bio Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aabmcb&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaembp/2021/aaembp.2021.3.issue-7/aaembp.2021.3.issue-7/20210727/aaembp.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaembp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Electronic Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaembp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aaemcq/2021/aaemcq.2021.4.issue-7/aaemcq.2021.4.issue-7/20210726/aaemcq.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aaemcq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Energy Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aaemcq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aamick/2021/aamick.2021.13.issue-30/aamick.2021.13.issue-30/20210804/aamick.2021.13.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;aamick&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Materials &amp; Interfaces&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aamick&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aanmf6/2021/aanmf6.2021.4.issue-7/aanmf6.2021.4.issue-7/20210723/aanmf6.2021.4.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aanmf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Nano Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aanmf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aapmcd/2021/aapmcd.2021.3.issue-7/aapmcd.2021.3.issue-7/20210709/aapmcd.2021.3.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aapmcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Applied Polymer Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aapmcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/abmcb8/largecover.png&quot;,&quot;code&quot;:&quot;abmcb8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;}],&quot;name&quot;:&quot;ACS Bio &amp; Med Chem Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abmcb8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/abseba/2021/abseba.2021.7.issue-7/abseba.2021.7.issue-7/20210712/abseba.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;abseba&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Biomaterials Science &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/abseba&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/accacs/2021/accacs.2021.11.issue-14/accacs.2021.11.issue-14/20210716/accacs.2021.11.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;accacs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Catalysis&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/accacs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acscii/2021/acscii.2021.7.issue-7/acscii.2021.7.issue-7/20210728/acscii.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acscii&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Central Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acscii&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acbcct/2021/acbcct.2021.16.issue-7/acbcct.2021.16.issue-7/20210716/acbcct.2021.16.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;acbcct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acbcct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/achsc5/2021/achsc5.2021.28.issue-4/achsc5.2021.28.issue-4/20210726/achsc5.2021.28.issue-4.largecover.jpg&quot;,&quot;code&quot;:&quot;achsc5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Health &amp; Safety&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/achsc5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acncdm/2021/acncdm.2021.12.issue-15/acncdm.2021.12.issue-15/20210804/acncdm.2021.12.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;acncdm&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Chemical Neuroscience&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acncdm&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsccc/2020/acsccc.2020.22.issue-12/acsccc.2020.22.issue-12/20201214/acsccc.2020.22.issue-12.largecover.jpg&quot;,&quot;code&quot;:&quot;acsccc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Combinatorial Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsccc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aesccq/2021/aesccq.2021.5.issue-7/aesccq.2021.5.issue-7/20210715/aesccq.2021.5.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aesccq&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Earth and Space Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aesccq&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aelccp/2021/aelccp.2021.6.issue-7/aelccp.2021.6.issue-7/20210709/aelccp.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aelccp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Energy Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aelccp&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacb3/largecover.png&quot;,&quot;code&quot;:&quot;aeacb3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Engineering Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacb3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aeacc4/largecover.png&quot;,&quot;code&quot;:&quot;aeacc4&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;}],&quot;name&quot;:&quot;ACS Environmental Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeacc4&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aeecco/2021/aeecco.2021.1.issue-7/aeecco.2021.1.issue-7/20210709/aeecco.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aeecco&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;ACS ES&amp;T Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aeecco&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aewcaa/2021/aewcaa.2021.1.issue-7/aewcaa.2021.1.issue-7/20210709/aewcaa.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aewcaa&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS ES&amp;T Water&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aewcaa&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/afsthl/2021/afsthl.2021.1.issue-6/afsthl.2021.1.issue-6/20210716/afsthl.2021.1.issue-6.largecover.jpg&quot;,&quot;code&quot;:&quot;afsthl&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Food Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/afsthl&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;styleguide&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;}],&quot;name&quot;:&quot;ACS Guide to Scholarly Communication&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/styleguide&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;infocus&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS In Focus&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/infocus&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aidcbc/2021/aidcbc.2021.7.issue-7/aidcbc.2021.7.issue-7/20210709/aidcbc.2021.7.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;aidcbc&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Infectious Diseases&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aidcbc&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlccd/2021/amlccd.2021.10.issue-7/amlccd.2021.10.issue-7/20210720/amlccd.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amlccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Macro Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amacgu/largecover.png&quot;,&quot;code&quot;:&quot;amacgu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Materials Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amacgu&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amlcef/2021/amlcef.2021.3.issue-8/amlcef.2021.3.issue-8/20210802/amlcef.2021.3.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;amlcef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Materials Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amlcef&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/amachv/largecover.png&quot;,&quot;code&quot;:&quot;amachv&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;}],&quot;name&quot;:&quot;ACS Measurement Science Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amachv&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/amclct/2021/amclct.2021.12.issue-7/amclct.2021.12.issue-7/20210708/amclct.2021.12.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;amclct&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Medicinal Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/amclct&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancac3/2021/ancac3.2021.15.issue-7/ancac3.2021.15.issue-7/20210727/ancac3.2021.15.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ancac3&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Nano&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancac3&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/anaccx/largecover.png&quot;,&quot;code&quot;:&quot;anaccx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Nanoscience Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/anaccx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/acsodf/2021/acsodf.2021.6.issue-30/acsodf.2021.6.issue-30/20210803/acsodf.2021.6.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;acsodf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Omega&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/acsodf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/aoiab5/largecover.png&quot;,&quot;code&quot;:&quot;aoiab5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;}],&quot;name&quot;:&quot;ACS Organic &amp; Inorganic Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aoiab5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/aptsfn/2021/aptsfn.2021.4.issue-3/aptsfn.2021.4.issue-3/20210611/aptsfn.2021.4.issue-3.largecover.jpg&quot;,&quot;code&quot;:&quot;aptsfn&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Pharmacology &amp; Translational Science&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/aptsfn&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/apchd5/2021/apchd5.2021.8.issue-7/apchd5.2021.8.issue-7/20210721/apchd5.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;apchd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Photonics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apchd5&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apcach/largecover.png&quot;,&quot;code&quot;:&quot;apcach&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;}],&quot;name&quot;:&quot;ACS Physical Chemistry Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apcach&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/apaccd/largecover.png&quot;,&quot;code&quot;:&quot;apaccd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;}],&quot;name&quot;:&quot;ACS Polymers Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/apaccd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/reagents/2017/acsreagents/acsreagents/20170228/acsreagents.largecover.png&quot;,&quot;code&quot;:&quot;reagents&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;ACS Reagent Chemicals&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/reagents&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascefj/2021/ascefj.2021.6.issue-7/ascefj.2021.6.issue-7/20210723/ascefj.2021.6.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;ascefj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sensors&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascefj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ascecg/2021/ascecg.2021.9.issue-30/ascecg.2021.9.issue-30/20210802/ascecg.2021.9.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ascecg&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Sustainable Chemistry &amp; Engineering&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ascecg&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/books/content/symposium/2021/bk-2021-1379/bk-2021-1379/20210430-01/bk-2021-1379.largecover.jpg&quot;,&quot;code&quot;:&quot;symposium&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;ACS Symposium Series&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/symposium&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/asbcd6/2021/asbcd6.2021.10.issue-7/asbcd6.2021.10.issue-7/20210716/asbcd6.2021.10.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;asbcd6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;ACS Synthetic Biology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/asbcd6&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;advances&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;category.books&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;383784032&quot;}],&quot;name&quot;:&quot;Advances in Chemistry&quot;,&quot;type&quot;:&quot;books&quot;,&quot;url&quot;:&quot;/series/advances&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/ancham/2021/ancham.2021.93.issue-30/ancham.2021.93.issue-30/20210803/ancham.2021.93.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;ancham&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Analytical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/ancham&quot;}]},{&quot;char&quot;:&quot;B&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bichaw/2021/bichaw.2021.60.issue-30/bichaw.2021.60.issue-30/20210803/bichaw.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;bichaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biochemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bichaw&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bcches/2021/bcches.2021.32.issue-7/bcches.2021.32.issue-7/20210721/bcches.2021.32.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bcches&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Bioconjugate Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bcches&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/bomaf6/2021/bomaf6.2021.22.issue-7/bomaf6.2021.22.issue-7/20210712/bomaf6.2021.22.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;bomaf6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Biomacromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bomaf6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/covergifs/bipret/largecover.jpg&quot;,&quot;code&quot;:&quot;bipret&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;Biotechnology Progress&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/bipret&quot;}]},{&quot;char&quot;:&quot;C&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgeabj/2021/cgeabj.2021.99.issue-28/cgeabj.2021.99.issue-28/20210802/cgeabj.2021.99.issue-28.largecover.jpg&quot;,&quot;code&quot;:&quot;cgeabj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;}],&quot;name&quot;:&quot;C&amp;EN Global Enterprise&quot;,&quot;type&quot;:&quot;news&quot;,&quot;url&quot;:&quot;/journal/cgeabj&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/crtoec/2021/crtoec.2021.34.issue-7/crtoec.2021.34.issue-7/20210719/crtoec.2021.34.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;crtoec&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Research in Toxicology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/crtoec&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/chreay/2021/chreay.2021.121.issue-14/chreay.2021.121.issue-14/20210728/chreay.2021.121.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;chreay&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;articletoc&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemical Reviews&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/chreay&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cmatex/2021/cmatex.2021.33.issue-14/cmatex.2021.33.issue-14/20210727/cmatex.2021.33.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;cmatex&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Chemistry of Materials&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cmatex&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/cgdefu/2021/cgdefu.2021.21.issue-8/cgdefu.2021.21.issue-8/20210804/cgdefu.2021.21.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;cgdefu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Crystal Growth &amp; Design&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/cgdefu&quot;}]},{&quot;char&quot;:&quot;E&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/enfuem/2021/enfuem.2021.35.issue-14/enfuem.2021.35.issue-14/20210715/enfuem.2021.35.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;enfuem&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Energy &amp; Fuels&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/enfuem&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/esthag/2021/esthag.2021.55.issue-15/esthag.2021.55.issue-15/20210803/esthag.2021.55.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;esthag&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/esthag&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/estlcu/2021/estlcu.2021.8.issue-7/estlcu.2021.8.issue-7/20210713/estlcu.2021.8.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;estlcu&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Environmental Science &amp; Technology Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/estlcu&quot;}]},{&quot;char&quot;:&quot;I&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.2&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;I&amp;EC Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.2&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecac0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Analytical Edition&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecac0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecjc0&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Chemical &amp; Engineering Data Series&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecjc0&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iecfa7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Fundamentals&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecfa7&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepdaw&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Process Design and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepdaw&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Product Research and Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/iecred/2021/iecred.2021.60.issue-30/iecred.2021.60.issue-30/20210804/iecred.2021.60.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;iecred&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Industrial &amp; Engineering Chemistry Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iecred&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/inocaj/2021/inocaj.2021.60.issue-15/inocaj.2021.60.issue-15/20210802/inocaj.2021.60.issue-15.largecover.jpg&quot;,&quot;code&quot;:&quot;inocaj&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Inorganic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/inocaj&quot;}]},{&quot;char&quot;:&quot;J&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jaaucr/2021/jaaucr.2021.1.issue-7/jaaucr.2021.1.issue-7/20210726/jaaucr.2021.1.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jaaucr&quot;,&quot;subjects&quot;:[],&quot;name&quot;:&quot;JACS Au&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jaaucr&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jafcau/2021/jafcau.2021.69.issue-30/jafcau.2021.69.issue-30/20210804/jafcau.2021.69.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jafcau&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Agricultural and Food Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jafcau&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceaax/2021/jceaax.2021.66.issue-7/jceaax.2021.66.issue-7/20210708/jceaax.2021.66.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceaax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical &amp; Engineering Data&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceaax&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jci001&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Documentation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jci001&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jceda8/2021/jceda8.2021.98.issue-7/jceda8.2021.98.issue-7/20210713/jceda8.2021.98.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jceda8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;divched&quot;}],&quot;name&quot;:&quot;Journal of Chemical Education&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jceda8&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jcics1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Computer Sciences&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcics1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jcisd8/2021/jcisd8.2021.61.issue-7/jcisd8.2021.61.issue-7/20210726/jcisd8.2021.61.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jcisd8&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Information and Modeling&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jcisd8&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jctcce/2021/jctcce.2021.17.issue-7/jctcce.2021.17.issue-7/20210713/jctcce.2021.17.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jctcce&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Chemical Theory and Computation&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jctcce&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iechad.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Industrial &amp; Engineering Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iechad.1&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jmcmar.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal and Pharmaceutical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar.1&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jmcmar/2021/jmcmar.2021.64.issue-14/jmcmar.2021.64.issue-14/20210722/jmcmar.2021.64.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;jmcmar&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jmcmar&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jnprdf/2021/jnprdf.2021.84.issue-7/jnprdf.2021.84.issue-7/20210723/jnprdf.2021.84.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jnprdf&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Natural Products&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jnprdf&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/joceah/2021/joceah.2021.86.issue-14/joceah.2021.86.issue-14/20210716/joceah.2021.86.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;joceah&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Organic Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/joceah&quot;},{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;jpchax&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpchax&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcafh/2021/jpcafh.2021.125.issue-29/jpcafh.2021.125.issue-29/20210729/jpcafh.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcafh&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry A&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcafh&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpcbfk/2021/jpcbfk.2021.125.issue-29/jpcbfk.2021.125.issue-29/20210729/jpcbfk.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpcbfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry B&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpcbfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpccck/2021/jpccck.2021.125.issue-29/jpccck.2021.125.issue-29/20210729/jpccck.2021.125.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpccck&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry C&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpccck&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jpclcd/2021/jpclcd.2021.12.issue-29/jpclcd.2021.12.issue-29/20210729/jpclcd.2021.12.issue-29.largecover.jpg&quot;,&quot;code&quot;:&quot;jpclcd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;The Journal of Physical Chemistry Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jpclcd&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jprobs/2021/jprobs.2021.20.issue-7/jprobs.2021.20.issue-7/20210702/jprobs.2021.20.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;jprobs&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of Proteome Research&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jprobs&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jacsat/2021/jacsat.2021.143.issue-30/jacsat.2021.143.issue-30/20210804/jacsat.2021.143.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;jacsat&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_analytical&quot;},{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Chemical Society&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jacsat&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/jamsef/2021/jamsef.2021.32.issue-8/jamsef.2021.32.issue-8/20210804/jamsef.2021.32.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;jamsef&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;1&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Journal of the American Society for Mass Spectrometry&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/jamsef&quot;}]},{&quot;char&quot;:&quot;L&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/langd5/2021/langd5.2021.37.issue-30/langd5.2021.37.issue-30/20210803/langd5.2021.37.issue-30.largecover.jpg&quot;,&quot;code&quot;:&quot;langd5&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_physical&quot;},{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Langmuir&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/langd5&quot;}]},{&quot;char&quot;:&quot;M&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mamobx/2021/mamobx.2021.54.issue-14/mamobx.2021.54.issue-14/20210727/mamobx.2021.54.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;mamobx&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Macromolecules&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mamobx&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/mpohbp/2021/mpohbp.2021.18.issue-8/mpohbp.2021.18.issue-8/20210802/mpohbp.2021.18.issue-8.largecover.jpg&quot;,&quot;code&quot;:&quot;mpohbp&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_biological&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Molecular Pharmaceutics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/mpohbp&quot;}]},{&quot;char&quot;:&quot;N&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/nalefd/2021/nalefd.2021.21.issue-14/nalefd.2021.21.issue-14/20210728/nalefd.2021.21.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;nalefd&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_matscieng&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Nano Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/nalefd&quot;}]},{&quot;char&quot;:&quot;O&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orlef7/2021/orlef7.2021.23.issue-14/orlef7.2021.23.issue-14/20210716/orlef7.2021.23.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orlef7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Letters&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orlef7&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/oprdfk/2021/oprdfk.2021.25.issue-7/oprdfk.2021.25.issue-7/20210716/oprdfk.2021.25.issue-7.largecover.jpg&quot;,&quot;code&quot;:&quot;oprdfk&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;cat_app&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organic Process Research &amp; Development&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/oprdfk&quot;},{&quot;imgUrl&quot;:&quot;/na101/home/literatum/publisher/achs/journals/content/orgnd7/2021/orgnd7.2021.40.issue-14/orgnd7.2021.40.issue-14/20210726/orgnd7.2021.40.issue-14.largecover.jpg&quot;,&quot;code&quot;:&quot;orgnd7&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;cat_organic_inorganic&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Organometallics&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/orgnd7&quot;}]},{&quot;char&quot;:&quot;P&quot;,&quot;publications&quot;:[{&quot;imgUrl&quot;:&quot;&quot;,&quot;code&quot;:&quot;iepra6.1&quot;,&quot;subjects&quot;:[{&quot;code&quot;:&quot;journals&quot;},{&quot;code&quot;:&quot;all journals less jce&quot;}],&quot;name&quot;:&quot;Product R&amp;D&quot;,&quot;type&quot;:&quot;journals&quot;,&quot;url&quot;:&quot;/journal/iepra6.1&quot;}]}]}"/></input></div></div>
</header>




        
        <main data-widget-id="28284a6d-730d-4a56-93ad-909787c5ac1b" id="" class="content article"><article data-figures="https://pubs.acs.org/action/ajaxShowFigures?doi=10.1021%2Facs.jmedchem.9b00623&amp;ajax=true" data-references="https://pubs.acs.org/action/ajaxShowEnhancedAbstract?doi=10.1021%2Facs.jmedchem.9b00623&amp;ajax=true" data-enable-mathjax="true"><div class="figure-viewer"><div class="figure-viewer_row"><div class="figure-viewer_col loop-trap"><div aria-live="polite" aria-atomic="true" class="figure-viewer_modal"><a href="#" title="Close" aria-label="close" tabindex="0" class="figure-viewer_close icon-close"></a><h2 class="figure-viewer_label"><span class="figure-viewer_current"></span></h2><div class="figure-viewer_image"><a href="#" title="Next" class="figure-viewer_next icon-angle-right"></a><a href="#" title="Previous" class="figure-viewer_prev icon-angle-left"></a><div class="figure-viewer_image-content"><img src="" alt="Figure 1" class="fv-img"/></img><img src="/pb-assets/ux3/loading-1525090748317.gif" alt="Loading Img" class="loading-img"/></img></div></div><div class="figure-viewer_links"><a href="#" title="Download Hi-Res Image" target="_blank" class="figure-viewer_hi-res-link"><i class="icon-file-image-o"></i><span>Download Hi-Res Image</span></a><span class="fv-separator"></span><a href="#" title="Download to MS-PowerPoint" class="figure-viewer_ms-p-link"><i class="icon-file-powerpoint-o"></i><span>Download to MS-PowerPoint</span></a><span class="cit-this-container"><a href="/action/showCitFormats?doi=10.1021/acs.jmedchem.9b00623&amp;href=/doi/10.1021/acs.jmedchem.9b00623" title="Cite This" class="figure-viewer-cite-this-link"><i class="icon-check-circle"></i><span><strong>Cite This:</strong></span></a><span class="article_header-cite-this figure-viewer-cite-this"><span class="cit-fg-title"><i>J. Med. Chem.</i></span><span class="cit-fg-year"> 2019</span><span class="cit-fg-volume">, 62</span><span class="cit-fg-issue">, 20</span><span class="cit-fg-pageRange">, 9078-9102</span></span></span></div></div></div></div></div><div class="article_fullPage"><div class="article_header"><div class="articleHeaderDropzone5" data-pb-dropzone="articleHeaderDropzone5"><div class="advertisement">
	<div class="advertisement-link">
		<a href="http://acsmediakit.org">ADVERTISEMENT</a>
	</div>
	<div id="dfp-journal-article-leaderboard">
		<script type="text/javascript">
			$(document).ready(function() {
				setTimeout(function() {
					googletag.cmd.push(function() { googletag.display("dfp-journal-article-leaderboard"); });
				}, 1400);
			});
		</script>
	</div>
</div></div><div class="container container_scaled-down"><div class="row"><div class="col-xs-12.clearfix"><div class="article_header-left pull-left"><div class="article_header-dropzone-1"><div class="articleHeaderDropzone1" data-pb-dropzone="articleHeaderDropzone1"><div class="content-navigation clearfix"><a href="/toc/jmcmar/62/20" title="Return to Issue" id="returnToIssues" class="content-navigation__btn--return"><span>RETURN TO ISSUE</span></a><a href="/doi/10.1021/acs.jmedchem.9b00607" title="Previous" id="prevID" class="content-navigation__btn--pre"><i class="icon-angle-left"></i><span>PREV</span></a><span class="content-navigation__contentType">Article</span><a href="/doi/10.1021/acs.jmedchem.9b00876" title="Next" id="nextID" class="content-navigation__btn--next"><span>NEXT</span><i class="icon-angle-right"></i></a></div></div></div><div class="headerLogo_e-alertsMobile_container"><div class="article_header-logo hidden-lg"><div class="pj-badge"></div><a href="/journal/jmcmar" title="Journal Logo"><img src="/specs/ux3/releasedAssets/images/loader.gif" data-src="/na101/home/literatum/publisher/achs/journals/covergifs/jmcmar/title.png" alt="Journal Logo" /></img></a></div><div class="e-alertsMobile_container hidden-md hidden-lg"></div></div><h1 class="article_header-title"><span class="hlFld-Title">Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo</span></h1><ul class="loa"><li><span><span class="hlFld-ContribAuthor">Matthias Scheiner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias Scheiner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Scheiner">Matthias Scheiner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Dominik Dolles</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Dominik Dolles</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Dominik++Dolles">Dominik Dolles</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sandra Gunesch</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sandra Gunesch</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sandra++Gunesch">Sandra Gunesch</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Matthias Hoffmann</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Matthias Hoffmann</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Matthias++Hoffmann">Matthias Hoffmann</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Massimo Nabissi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Massimo Nabissi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Massimo++Nabissi">Massimo Nabissi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Oliviero Marinelli</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Oliviero Marinelli</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">School of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Oliviero++Marinelli">Oliviero Marinelli</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Marina Naldi</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Marina Naldi</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Marina++Naldi">Marina Naldi</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Manuela Bartolini</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Manuela Bartolini</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, Via Belmeloro 6, 40126 Bologna, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Manuela++Bartolini">Manuela Bartolini</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Sabrina Petralla</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Sabrina Petralla</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Sabrina++Petralla">Sabrina Petralla</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Eleonora Poeta</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Eleonora Poeta</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Eleonora++Poeta">Eleonora Poeta</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Barbara Monti</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Barbara Monti</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Department of Pharmacy and Biotechnology, University of Bologna, Via Selmi 3, 40126 Bologna, Italy</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Barbara++Monti">Barbara Monti</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Christina Falkeis</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Christina Falkeis</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pathology, Clinical Center Bayreuth, Preuschwitzer Straße 101, 95445 Bayreuth, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Christina++Falkeis">Christina Falkeis</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Michael Vieth</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Vieth</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pathology, Clinical Center Bayreuth, Preuschwitzer Straße 101, 95445 Bayreuth, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Vieth">Michael Vieth</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Harald Hübner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Harald Hübner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Harald++H%C3%BCbner">Harald Hübner</a></span></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Peter Gmeiner</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Peter Gmeiner</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Medicinal Chemistry, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Peter++Gmeiner">Peter Gmeiner</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4127-197X" title="Orcid link">http://orcid.org/0000-0002-4127-197X</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Rangan Maitra</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Rangan Maitra</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Center for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Rangan++Maitra">Rangan Maitra</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6663-6800" title="Orcid link">http://orcid.org/0000-0001-6663-6800</a></div></div></span></li><span class="comma-separator">, </span><li><span><span class="hlFld-ContribAuthor">Tangui Maurice</span><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Tangui Maurice</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">MMDN, University of Montpellier, INSERM, EPHE, UMR-S1198, 34095 Montpellier, France</div></div><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Tangui++Maurice">Tangui Maurice</a></span></div></div></span></li><span class="comma-separator">, and </span><li><span><span class="hlFld-ContribAuthor">Michael Decker</span><strong>*</strong><div class="loa-info hlFld-Affiliation"><div class="loa-info-name">Michael Decker</div><div class="loa-info-affiliations"><div class="loa-info-affiliations-info">Pharmaceutical and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</div></div><span class="conrtib-corresp"><strong>*</strong>E-mail: <a href="/cdn-cgi/l/email-protection#87eaeee4efe6e2eba9e3e2e4ece2f5c7f2e9eeaaf0f2e2f5fde5f2f5e0a9e3e2"><span class="__cf_email__" data-cfemail="15787c767d7470793b7170767e706755607b7c38626070676f776067723b7170">[email protected]</span></a>. Tel.: +49-931-31-89676.</span><span class="conrtib-corresp"></span><div class="loa-info-scifinder"><span>More by <a href="/action/doSearch?field1=Contrib&amp;text1=Michael++Decker">Michael Decker</a></span></div><div class="loa-info-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6773-6245" title="Orcid link">http://orcid.org/0000-0002-6773-6245</a></div></div></span></li><span class="comma-separator"></span></ul><div class="article_header-meta clearfix"><div class="article_header-meta-left pull-left"><input type="hidden" name="journalCodeForjhpLink" value="jmcmar" /></input><input type="hidden" name="journalNameForjhpLink" value="Journal of Medicinal Chemistry" /></input><div class="article_header-cite-this"><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00623&amp;href=/doi/10.1021%2Facs.jmedchem.9b00623" title="Cite This"><i class="icon-check-circle"></i><strong>Cite this: </strong></a><span class="cit-title"><i>J. Med. Chem.</i></span> <span class="cit-year-info"><span>2019</span></span><span class="cit-volume">, 62</span><span class="cit-issue">, 20</span><span class="cit-pageRange">, 9078–9102</span></div><div class="article_header-epubdate"><span class="pub-date epub-date">Publication Date</span><span class="web-text"> (Web)</span><span class="date-separator">:</span><span class="pub-date-value">October 14, 2019</span><div class="article_header-history base dropBlock"><a href="#" data-db-target-for="article_header-history" title="History" target="_self" class="" aria-expanded="false"><i class="icon-angle-down"></i><i class="icon-angle-up"></i></a><div data-db-target-of="article_header-history" class="dropBlock__holder" aria-hidden="true"><div class="articleHeaderHistoryDropzone" data-pb-dropzone="articleHeaderHistoryDropzone"><h4>Publication History</h4>




        
        <ul class="rlist article-chapter-history-list"><li><span class="item_label"><b>Received</b></span>30 April 2019</li><li><span class="item_label"><b>Published</b> online</span>14 October 2019</li><li><span class="item_label"><b>Published</b> in</span><span class="item_label-issue">issue</span> 24 October 2019</li></ul></div></div></div></div><div class="article_header-doiurl"><a href="https://doi.org/10.1021/acs.jmedchem.9b00623" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.9b00623</a></div><div class="article_header-article-copyright"><strong>Copyright © 2019 American Chemical Society</strong></div><div class="article_rightPermissionsLink"><div class="articleHeaderDropzone4" data-pb-dropzone="articleHeaderDropzone4"><div class="articleRightsPermissionsLink"><a href="/servlet/linkout?type=rightslink&amp;url=startPage%3D9078%26pageCount%3D25%26copyright%3DAmerican%2BChemical%2BSociety%26author%3DMatthias%2BScheiner%252C%2BDominik%2BDolles%252C%2BSandra%2BGunesch%252C%2Bet%2Bal%26orderBeanReset%3Dtrue%26imprint%3DAmerican%2BChemical%2BSociety%26volumeNum%3D62%26issueNum%3D20%26contentID%3Dacs.jmedchem.9b00623%26title%3DDual-Acting%2BCholinesterase%25E2%2580%2593Human%2BCannabinoid%2BReceptor%2B2%2BLigands%2BShow%2BPronounced%2BNeuroprotection%2Bin%2BVitro%2Band%2BOveradditive%2Band%2BDisease-Modifying%2BNeuroprotective%2BEffects%2Bin%2BVivo%26numPages%3D25%26pa%3D%26issn%3D0022-2623%26publisherName%3Dacs%26publication%3Djmcmar%26rpt%3Dn%26endPage%3D9102%26publicationDate%3DOctober%2B2019">RIGHTS & PERMISSIONS</a></div></div></div><div class="article_header-access-block"><div class="article_header-open-access"></div><div class="article_header-access-icon"><img src="/products/achs/releasedAssets/images/subscribed.svg" alt="Subscribed Access" /></img></div></div></div><div class="article_header-meta-center pull-left"><div class="articleHeaderDropzone3" data-pb-dropzone="articleHeaderDropzone3"><div class="articleMetrics"><div class="articleMetrics_table"><div class="articleMetrics_row"><input type="hidden" name="articleMetricsDoi" value="10.1021/acs.jmedchem.9b00623"/></input><div class="articleMetrics_metric"><h6>Article Views</h6><div class="articleMetrics-val">1674</div></div><div class="articleMetrics_altmetric"><h6>Altmetric</h6><div class="articleMetrics-val articleMetrics_score">-</div><div class="altmetric-donut hidden"><div data-badge-details="right" data-badge-type="donut" data-hide-no-mentions="false" data-condensed="true" class="altmetric-embed"></div></div></div><div class="articleMetrics_count"><h6>Citations</h6><div class="articleMetrics-val"><a href="#citeThis" class="internalNav">17</a></div></div></div></div><div class="articleMetrics_about"><div class="base dropBlock"><a href="#" data-db-target-for="aboutArticleMetrics" class="article_aboutLink">LEARN ABOUT THESE METRICS</a><div data-db-target-of="aboutArticleMetrics" aria-live="polite" aria-atomic="true" role="alert" class="dropBlock__holder"><i aria-hidden="true" class="icon-close_thin"></i><p>Article Views are the COUNTER-compliant sum of full text article downloads since November 2008 (both PDF and HTML) across all institutions and individuals. These metrics are regularly updated to reflect usage leading up to the last few days.</p><p>Citations are the number of other articles citing this article, calculated by Crossref and updated daily.<a href="https://www.crossref.org/services/cited-by/" title="Find more information about Crossref citation counts"> Find more information about Crossref citation counts.</a></p><p>The Altmetric Attention Score is a quantitative measure of the attention that a research article has received online. Clicking on the donut icon will load a page at altmetric.com with additional details about the score and the social media presence for the given article. Find more information on<a href="https://help.altmetric.com/support/solutions/articles/6000233311-how-is-the-altmetric-attention-score-calculated" title="The Altmetric Attention Score and how the score is calculated"> the Altmetric Attention Score and how the score is calculated.</a></p></div></div></div></div></div></div><div class="article_header-meta-right"><div class="articleHeaderDropzone6" data-pb-dropzone="articleHeaderDropzone6"><div data-widget-def="UX3share" data-widget-id="787b5b92-0445-40f4-bdd2-9591d56f4a67" class="article_header-share share_label_visible">
        



        
        <script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript" async="async" src="//s7.addthis.com/js/300/addthis_widget.js#pubid=xa-4faab26f2cff13a7"></script><div class="share"><div class="share_button"><span class="share__label">Share</span><a href="#" data-db-target-for="787b5b92-0445-40f4-bdd2-9591d56f4a67" data-db-switch="icon-close_thin" aria-label="share button" class="share__ctrl"><i aria-hidden="true" class="icon-Icon_Share"></i></a></div>



        
        <div class="achs-addto-mendeley"><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><input type="hidden" class="doi" value="10.1021/acs.jmedchem.9b00623" /></input><span class="achs-addto-mendeley_label achs-addto-mendeley_addToLabel">Add to</span><span class="achs-addto-mendeley_label achs-addto-mendeley_viewInLabel">View In</span><a title="Add to mendeley button" class="achs-addto-mendeley_button" tabindex="0"><i class="achs-addto-mendeley_icon icon-mendeley"></i><i class="achs-addto-mendeley_close icon-close"></i></a><div data-db-target-of="5423a74c-bbd8-47b1-9f43-99423ee72e5c" class="achs-addto-mendeley_list dropBlock__holder"><ul><li><a href="#" title="Add Full Text with Reference" class="achs-addto-mendeley_disabled-button add-full-document"><i class="icon-bookmark-o"></i><span>Add Full Text with Reference</span></a></li><li><a href="#" title="Add Description" class="achs-mendeley_button add-metadata-description"><i class="icon-mendeley"></i><span>Add Description</span></a></li></ul></div><a href="#" title="View in mendeley button" class="achs-addto-mendeley_viewin-button"><i class="icon-mendeley"></i></a><div class="achs_loader"><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div><div class="achs_loader_dot"></div></div><input type="hidden" name="meta-data" value="{&quot;title&quot;:&quot;Dual-Acting Cholinesterase–Human Cannabinoid Receptor 2 Ligands Show Pronounced Neuroprotection in Vitro and Overadditive and Disease-Modifying Neuroprotective Effects in Vivo&quot;,&quot;type&quot;:&quot;journal&quot;,&quot;authors&quot;:[{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Scheiner&quot;},{&quot;first_name&quot;:&quot;Dominik&quot;,&quot;last_name&quot;:&quot;Dolles&quot;},{&quot;first_name&quot;:&quot;Sandra&quot;,&quot;last_name&quot;:&quot;Gunesch&quot;},{&quot;first_name&quot;:&quot;Matthias&quot;,&quot;last_name&quot;:&quot;Hoffmann&quot;},{&quot;first_name&quot;:&quot;Massimo&quot;,&quot;last_name&quot;:&quot;Nabissi&quot;},{&quot;first_name&quot;:&quot;Oliviero&quot;,&quot;last_name&quot;:&quot;Marinelli&quot;},{&quot;first_name&quot;:&quot;Marina&quot;,&quot;last_name&quot;:&quot;Naldi&quot;},{&quot;first_name&quot;:&quot;Manuela&quot;,&quot;last_name&quot;:&quot;Bartolini&quot;},{&quot;first_name&quot;:&quot;Sabrina&quot;,&quot;last_name&quot;:&quot;Petralla&quot;},{&quot;first_name&quot;:&quot;Eleonora&quot;,&quot;last_name&quot;:&quot;Poeta&quot;},{&quot;first_name&quot;:&quot;Barbara&quot;,&quot;last_name&quot;:&quot;Monti&quot;},{&quot;first_name&quot;:&quot;Christina&quot;,&quot;last_name&quot;:&quot;Falkeis&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Vieth&quot;},{&quot;first_name&quot;:&quot;Harald&quot;,&quot;last_name&quot;:&quot;Hübner&quot;},{&quot;first_name&quot;:&quot;Peter&quot;,&quot;last_name&quot;:&quot;Gmeiner&quot;},{&quot;first_name&quot;:&quot;Rangan&quot;,&quot;last_name&quot;:&quot;Maitra&quot;},{&quot;first_name&quot;:&quot;Tangui&quot;,&quot;last_name&quot;:&quot;Maurice&quot;},{&quot;first_name&quot;:&quot;Michael&quot;,&quot;last_name&quot;:&quot;Decker&quot;}],&quot;source&quot;:&quot;Journal of Medicinal Chemistry&quot;,&quot;year&quot;:&quot;2019&quot;,&quot;month&quot;:&quot;10&quot;,&quot;day&quot;:&quot;14&quot;,&quot;issue&quot;:&quot;20&quot;,&quot;volume&quot;:&quot;62&quot;,&quot;pages&quot;:&quot;9078-9102&quot;,&quot;identifiers&quot;:{&quot;doi&quot;:&quot;10.1021/acs.jmedchem.9b00623&quot;},&quot;abstract&quot;:&quot;We have designed and synthesized a series of 14 hybrid molecules out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB2R) agonist and investigated them in vitro and in vivo. The compounds are potent ChE inhibitors, and for the most promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their ability to interfere with AChE-induced aggregation of β-amyloid (Aβ), and Aβ self-aggregation was assessed. All hybrids were evaluated for affinity and selectivity for hCB1R and hCB2R. To ensure that the hybrids retained their agonist character, the expression of cAMP-regulated genes was quantified, and potency and efficacy were determined. Additionally, the effects of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated. The most promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer’s mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at hig&quot;}" class="meta-data"/></input><input type="hidden" name="mendeley-api-endpoint" value="https://api.mendeley.com/documents" class="mendeley-api-endpoint"/></input><input type="hidden" name="pub-access" value="full" class="pub-access"/></input><input type="hidden" name="library-url" value="https://www.mendeley.com/library/" class="library-url"/></input><input type="hidden" name="selected-share-option" class="selected-share-option"/></input></div>




        
        <div class="cit-download-dropdown"><span class="cit-download-dropdown_label">Export</span><a href="#" data-db-target-for="cit-download-dropdown_content" title="Download citation button" class="cit-download-dropdown_button"><span>RIS</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div data-db-target-of="cit-download-dropdown_content" class="cit-download-dropdown_content"><ul><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00623&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00623" title="Citation"><span>Citation</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00623&amp;include=abs&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00623" title="Citation and abstract"><span>Citation and abstract</span></a></li><li><a href="/action/downloadCitation?doi=10.1021%2Facs.jmedchem.9b00623&amp;include=ref&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00623" title="Citation and references"><span>Citation and references</span></a></li><li><a href="/action/showCitFormats?doi=10.1021%2Facs.jmedchem.9b00623&amp;include=cit&amp;format=ris&amp;direct=true&amp;downloadFileName=acs.jmedchem.9b00623&amp;href=/doi/10.1021/acs.jmedchem.9b00623" title="Cite This"><i class="icon-plus-square"></i><span>More Options</span></a></li></ul></div></div>
<div data-db-target-of="787b5b92-0445-40f4-bdd2-9591d56f4a67" id="787b5b92-0445-40f4-bdd2-9591d56f4a67_Pop" class="share__block dropBlock__holder fixed"><span class="sr-only">Share on</span><ul class="rlist w-slide--list addthis addthis_toolbox addthis_default_style addthis_32x32_style"><li><a role="link" class="addthis_button_facebook"><i aria-hidden="true" class="at-icon-wrapper icon-facebook"></i>Facebook</a></li><li><a role="link" class="addthis_button_twitter"><i aria-hidden="true" class="at-icon-wrapper icon-twitter"></i>Twitter</a></li><li><a role="link" class="addthis_button_wechat"><i aria-hidden="true" class="at-icon-wrapper icon-wechat"></i>Wechat</a></li><li><a role="link" class="addthis_button_linkedin"><i aria-hidden="true" class="at-icon-wrapper icon-linkedin"></i>Linked In</a></li><li><a role="link" class="addthis_button_reddit"><i aria-hidden="true" class="at-icon-wrapper icon-reddit"></i>Reddit</a></li></ul></div></div>

        </div></div></div></div><div class="article_header-footer"><div class="article_header-footer-left pull-left clearfix"><div class="article_header-links pull-left"><input class="pub-doi" type="hidden" name="pub-doi" value="10.1021/acs.jmedchem.9b00623" /></input><a href="/doi/pdf/10.1021/acs.jmedchem.9b00623" title="PDF" target="_blank" class="button_primary pdf-button"><i class="icon-file-pdf-o"></i><span>PDF (6 MB)
                            </span></a><a href="/servlet/linkout?suffix=s0&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.9b00623&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fid%3Ddoi%3A10.1021%252Facs.jmedchem.9b00623%26sid%3Dliteratum%253Aachs%26pmid%3D31609608%26genre%3Darticle%26aulast%3DScheiner%26date%3D2019%26atitle%3DDual-Acting%2BCholinesterase%25E2%2580%2593Human%2BCannabinoid%2BReceptor%2B2%2BLigands%2BShow%2BPronounced%2BNeuroprotection%2Bin%2BVitro%2Band%2BOveradditive%2Band%2BDisease-Modifying%2BNeuroprotective%2BEffects%2Bin%2BVivo%26jtitle%3DJournal%2Bof%2BMedicinal%2BChemistry%26title%3DJournal%2Bof%2BMedicinal%2BChemistry%26volume%3D62%26issue%3D20%26spage%3D9078%26epage%3D9102%26issn%3D0022-2623" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a><div class="articleHeaderDropzone8" data-pb-dropzone="articleHeaderDropzone8"><div class="external-alerts-management"><input type="hidden" name="pub-type" value="article" class="pub-type"/></input><input type="hidden" name="is-enabled" value="true" class="is-enabled"/></input><input type="hidden" name="is-authenticated" value="false" class="is-authenticated"/></input><input type="hidden" name="pub-code" value="jmcmar" class="pub-code"/></input><input type="hidden" name="linkout-url" value="https://preferences.acspubs.org/journals" class="linkout-url"/></input><button data-toggle="modal" data-target="#ealertsModal" class="ealerts-toggle-btn hidden"></button><a class="button_primary_2 niHeader_getEAlerts jhHeader_sub_info"><i class="icon-send"></i><i class="icon-envelope"></i><i class="icon-check"></i><span class="ealerts-btn-text">Get e-Alerts</span><i aria-hidden="true" aria-label="close" class="icon-close"></i></a><div class="ux-modal-container"><div id="ealertsModal" style="display: none;" aria-live="polite" aria-atomic="true" class="modal"><div class="modal__dialog"><div class="modal__body"><iframe src="" class="ealerts-frame"></iframe></div></div></div></div><input type="hidden" id="ealertsModalSrc" value="https://preferences.acspubs.org/jmcmar?ifr=1"/></input></div></div></div><div class="article_header-suppInfo pull-left"><i class="icon-supporting-info"></i><span class="article_header-suppInfo-text">Supporting Info (2)</span><span class="article_header-suppInfo-arrow">»</span><a href="#" data-slide-target=".tab__pane-suppInfo" title="Supporting Information" class="article_header-suppInfo-link-mobile hidden-sm hidden-md hidden-lg w-slide__btn">Supporting Information
                </a><a href="#article_content-right" title="Supporting Information" data-scrollDuration="1000" class="article_header-suppInfo-link internalNav hidden-xs">Supporting Information
                </a></div></div><div class="article_header-footer-right"><div class="articleHeaderDropzone7" data-pb-dropzone="articleHeaderDropzone7"><div class="article_header-footer-right"><div class="article_header-taxonomy"><span>SUBJECTS:</span><ul class="rlist--inline loa"><li><a href="/action/doSearch?ConceptID=291350" title="Assays">Assays</a>,</li><li><a href="/action/doSearch?ConceptID=291793" title="Inhibition">Inhibition</a>,</li><li><a href="/action/doSearch?ConceptID=292524" title="Peptides and proteins">Peptides and proteins</a>,</li><li><a href="/action/doSearch?ConceptID=292589" title="Agonists">Agonists</a>,</li><li><a href="/action/doSearch?ConceptID=292462" title="Central nervous system">Central nervous system</a></li></ul></div></div></div></div></div></div><div class="article_header-right pull-left hidden-md hidden-sm hidden-xs"><div class="articleHeaderDropzone2" data-pb-dropzone="articleHeaderDropzone2"><div class="cover-image"><div class="cover-image__image"><a href="/toc/jmcmar/62/20" title="Go to Journal of Medicinal Chemistry "><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/jmcmar.2019.62.issue-20/20191024/jmcmar.2019.62.issue-20.largecover.jpg" alt="Go to Journal of Medicinal Chemistry "/></img></a></div></div>




        
        
<script>
 $(document).ready(function() {
   $('.article_header .external-alerts-management .niHeader_getEAlerts').each(function(){
	 var Tab = $(this).attr("href");
	   if(typeof Tab != undefined && Tab != false){
		 console.log("Testing Tab");
		 $(this).attr('href','#');
	   }
   });
 });
 $(document).on('click', '.article_header .external-alerts-management .niHeader_getEAlerts', function (e) {
	 //do something
	 if($(this).hasClass('registered')){
	  //send data to analytics for registered users
	      ga('send','event','Registered e-Alert','Article Page Click','jmcmar');
	  }else{
	     //send data to analytics for non-registered users
	      ga('send','event','Get e-Alert','Article Page Click','jmcmar');
	  }
  });
</script>





        
        <div class="pj-badge"></div>




        
        <div class="aJhp_link"></div>
<a href="/action/doUpdateAlertSettings?action=addJournal&amp;journalCode=jmcmar" class="button_primary_2"><i class="icon-send"></i><span>Get e-Alerts</span></a></div></div></div></div></div></div></div><div class="article_abstract"><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><h2 class="article_abstract-title" id="Abstract">Abstract</h2><div class="article_abstract-content hlFld-Abstract" id="abstractBox"><figure id="_i1" data-index="0" class="article__inlineFigure article_abstract-img"><img class="inline-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><p class="articleBody_abstractText">We have designed and synthesized a series of 14 hybrid molecules out of the cholinesterase (ChE) inhibitor tacrine and a benzimidazole-based human cannabinoid receptor subtype 2 (hCB<sub>2</sub>R) agonist and investigated them in vitro and in vivo. The compounds are potent ChE inhibitors, and for the most promising hybrids, the mechanism of human acetylcholinesterase (hAChE) inhibition as well as their ability to interfere with AChE-induced aggregation of β-amyloid (Aβ), and Aβ self-aggregation was assessed. All hybrids were evaluated for affinity and selectivity for hCB<sub>1</sub>R and hCB<sub>2</sub>R. To ensure that the hybrids retained their agonist character, the expression of cAMP-regulated genes was quantified, and potency and efficacy were determined. Additionally, the effects of the hybrids on microglia activation and neuroprotection on HT-22 cells were investigated. The most promising in vitro hybrids showed pronounced neuroprotection in an Alzheimer’s mouse model at low dosage (0.1 mg/kg, i.p.), lacking hepatotoxicity even at high dose (3 mg/kg, i.p.).</p></div></div></div></div></div><div class="article_content"><ul class="tab-nav-shortcut"><li><i class="icon-image"></i></li><li><i class="icon-link"></i></li><li><i class="icon-supporting-info"></i></li></ul><div class="container container_scaled-down"><div class="row"><div class="col-xs-12"><div class="article_content-table hlFld-FullText"><div class="article_content-row"><div class="article_content-left"><div id="sec1" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i2">Introduction</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84145" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84145" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">About 50 million people worldwide had to live with dementia in 2018.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> In about 30 years, an increase of cases up to 152 million is expected. The most common form of dementia is Alzheimer’s disease (AD). People aged 65 and over are considered at risk and are most likely to be affected.<a onclick="showRef(event, 'ref1'); return false;" href="javascript:void(0);" class="ref ref1">(1)</a> Unfortunately, pharmacotherapy is very limited. Currently, only four drugs are approved for the treatment of AD. Three of them (donepezil, rivastigmine, and galantamine) are cholinesterase (ChE) inhibitors, while the fourth (memantine) is an <i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate (NMDA) receptor noncompetitive antagonist. All approved drugs are only symptomatically effective in the moderate stages of the disease and reduce but do not stop the progression and do not affect the cause of the disease.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The exact molecular mechanisms, as well as the causes for an AD outbreak still remain unknown. However, a variety of biochemical changes during the pathological process take place. AD hallmarks are the formation of amyloid-beta (Aβ) plaques in the extracellular brain parenchyma,<a onclick="showRef(event, 'ref3'); return false;" href="javascript:void(0);" class="ref ref3">(3)</a> the abnormal hyperphosphorylation of the microtubule-associated tau protein, and the formation of neurofibrillary tangles (NFTs) within neurons.<a onclick="showRef(event, 'ref4'); return false;" href="javascript:void(0);" class="ref ref4">(4)</a> Both the Aβ aggregates and the NTFs lead to a progressive loss of cholinergic neurons in the brain, memory deficits, and cognitive dysfunction.<a onclick="showRef(event, 'ref5 ref6 ref7'); return false;" href="javascript:void(0);" class="ref ref5 ref6 ref7">(5−7)</a> Aβ itself has been shown to exert cytotoxic effects on cultured neurons,<a onclick="showRef(event, 'ref8'); return false;" href="javascript:void(0);" class="ref ref8">(8)</a> induce oxidative stress, and modify ionic homeostasis.<a onclick="showRef(event, 'ref9 ref10'); return false;" href="javascript:void(0);" class="ref ref9 ref10">(9,10)</a> Furthermore, in the post-mortem analysis of AD brain, an increased expression of inflammatory mediators has been observed.<a onclick="showRef(event, 'ref11 ref12'); return false;" href="javascript:void(0);" class="ref ref11 ref12">(11,12)</a> The increase seems to be partly triggered by microglia activation. Microglia cells are activated by various stimuli, including misfolded Aβ, its precursor protein (APP), and misfolded tau.<a onclick="showRef(event, 'ref13 ref14'); return false;" href="javascript:void(0);" class="ref ref13 ref14">(13,14)</a> In the early stage of AD, stimulation leads to a neuroprotective M2 microglia phenotype and can, therefore, promote Aβ clearance via microglia’s scavenger receptors (SRs), which hinder AD progression.<a onclick="showRef(event, 'ref15 ref16'); return false;" href="javascript:void(0);" class="ref ref15 ref16">(15,16)</a> However, it has been shown that there is a switch from the neuroprotective M2 to a more classically activated M1 phenotype at the later stage of AD. The M1 phenotype generally mediates defense from pathogens and tumor cells, and it is characterized by the production of proinflammatory cytokines, such as TNF-α, IL1β, or reactive oxygen species (ROS), which are associated with the loss of neurons. Therefore, this switch can lead to an increased Aβ production, a decreased Aβ clearance, and, ultimately, to neuronal damage and progression of AD.<a onclick="showRef(event, 'ref16'); return false;" href="javascript:void(0);" class="ref ref16">(16)</a></div><div class="NLM_p">The human endocannabinoid system has been intensively investigated, and two cannabinoid receptor (hCBR) subtypes have been discovered. The hCBR subtype 1 (hCB<sub>1</sub>R) is the most abundant metabotropic receptor in the brain, and it is involved in a variety of physiological processes.<a onclick="showRef(event, 'ref17 ref18 ref19'); return false;" href="javascript:void(0);" class="ref ref17 ref18 ref19">(17−19)</a> The psychoactive effect of tetrahydrocannabinol (THC), the main psychoactive constituent of cannabis, is due to hCB<sub>1</sub>R agonism.<a onclick="showRef(event, 'ref20'); return false;" href="javascript:void(0);" class="ref ref20">(20)</a> The hCB<sub>2</sub>R is mainly expressed in peripheral immune cells and has been originally described as the peripheral CBR,<a onclick="showRef(event, 'ref21'); return false;" href="javascript:void(0);" class="ref ref21">(21)</a> but later, it was found also in the central nervous system (CNS) where it is expressed on microglia and astrocytes.<a onclick="showRef(event, 'ref22 ref23'); return false;" href="javascript:void(0);" class="ref ref22 ref23">(22,23)</a> While the expression of the hCB<sub>1</sub>R remains unchanged, the hCB<sub>2</sub>R is abundantly and selectively expressed in neuritic plaque-associated astrocytes and microglia.<a onclick="showRef(event, 'ref24 ref25'); return false;" href="javascript:void(0);" class="ref ref24 ref25">(24,25)</a> In several in vitro and in vivo models of acute and chronic neurodegenerative disorders, the activation of the hCB<sub>2</sub>R was shown to exert beneficial effects.<a onclick="showRef(event, 'ref26'); return false;" href="javascript:void(0);" class="ref ref26">(26)</a> hCB<sub>2</sub>R agonists can suppress microglia activation and the production of neurotoxic factors such as ROS, nitric oxide (NO), and proinflammatory mediators (TNF-α and cytokines).<a onclick="showRef(event, 'ref27 ref28 ref29'); return false;" href="javascript:void(0);" class="ref ref27 ref28 ref29">(27−29)</a> Administration of an hCB<sub>2</sub>R agonist to rats, previously and intracerebrally treated with Aβ<sub>40</sub>, the forty-amino acid long isoform of Aβ, promoted Aβ clearance, decreased secretion of proinflammatory mediators, and, ultimately, led to an increased synaptic plasticity, cognition, and memory.<a onclick="showRef(event, 'ref30'); return false;" href="javascript:void(0);" class="ref ref30">(30)</a> Furthermore, in vivo studies with transgenic Tg2576 mice overexpressing hAPP<sub>Swe</sub> showed a lower Aβ production, reduced reactive microglia cells, and improved cognition performance upon treatment with an hCB<sub>2</sub>R agonist.<a onclick="showRef(event, 'ref31'); return false;" href="javascript:void(0);" class="ref ref31">(31)</a> Additionally, an hCB<sub>2</sub>R knockout experiment with APP transgenic mice supports the potential of cannabinoid therapies targeting hCB<sub>2</sub>R to reduce Aβ, as the knockout results in an increased Aβ pathology and an alternation in tau processing.<a onclick="showRef(event, 'ref32'); return false;" href="javascript:void(0);" class="ref ref32">(32)</a></div><div class="NLM_p">Acetylcholinesterase (AChE)-inhibiting drugs for symptomatic cognition improvement in AD patients are related to the oldest theory of AD pathophysiology, the cholinergic hypothesis.<a onclick="showRef(event, 'ref2'); return false;" href="javascript:void(0);" class="ref ref2">(2)</a> The theory describes the loss of cholinergic neurons and reduction of the neurotransmitter acetylcholine (ACh).<a onclick="showRef(event, 'ref33'); return false;" href="javascript:void(0);" class="ref ref33">(33)</a> Inhibition of the metabolizing enzyme AChE raises ACh levels, leading to an improved cognitive performance. However, since AChE level decreases with the progression of AD,<a onclick="showRef(event, 'ref34 ref35 ref36'); return false;" href="javascript:void(0);" class="ref ref34 ref35 ref36">(34−36)</a> AChE inhibition seems to be only effective at early stages of disease. On the other hand, the levels of the less specific butyrylcholinesterase (BChE) remain unaltered or increase with AD progression.<a onclick="showRef(event, 'ref35 ref36 ref37 ref38'); return false;" href="javascript:void(0);" class="ref ref35 ref36 ref37 ref38">(35−38)</a> BChE can hydrolyze ACh and, thereby, compensate the reduction of AChE activity. An experiment with AChE knockout mice supported this hypothesis. Indeed, no cholinergic hyperactivation in the absence of AChE was observed since BChE can take over the hydrolysis of ACh.<a onclick="showRef(event, 'ref39'); return false;" href="javascript:void(0);" class="ref ref39">(39)</a> Results from further studies were in accordance with the role of the BChE in AD brains and showed a positive correlation between selective BChE inhibition and improved cognitive performance and memory.<a onclick="showRef(event, 'ref40 ref41 ref42 ref43 ref44'); return false;" href="javascript:void(0);" class="ref ref40 ref41 ref42 ref43 ref44">(40−44)</a></div><div class="NLM_p">There is even more diversity in the pathological processes and reasons for AD beyond the ones herein described. Because of this multifactorial and sporadic nature of AD, the classical approach “one target–one disease” reaches its limits or even makes it ineffective to develop an effective drug.<a onclick="showRef(event, 'ref45'); return false;" href="javascript:void(0);" class="ref ref45">(45)</a> Conversely, a more promising approach seems to be the development of a multitarget drug capable of simultaneously acting at different targets.<a onclick="showRef(event, 'ref46'); return false;" href="javascript:void(0);" class="ref ref46">(46)</a> To obtain such multitarget drugs, there are two common strategies: the hybrid and the “merged ligand”.<a onclick="showRef(event, 'ref47'); return false;" href="javascript:void(0);" class="ref ref47">(47)</a> In the merged ligand strategy, two pharmacophores are fused into a single small molecule. The hybrid strategy foresees the combination of two molecules with two different pharmacologically active moieties by using a linker to form a larger molecule.<a onclick="showRef(event, 'ref45 ref47'); return false;" href="javascript:void(0);" class="ref ref45 ref47">(45,47)</a> Through the merged ligand strategy, we have recently achieved low-molecular-weight hCB<sub>2</sub>R ligands endowed with hBChE inhibitory activity, which proved to exert neuroprotection even in vivo.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> The design and improvement of such multi-target directed ligands (MTDLs) are challenging since minor chemical alternations can improve affinity at one target and diminish activity at the second one. Here, we describe hybrids out of similar benzimidazole units with the established tacrine unit to yield higher affinity at both targets.</div><div id="sec1_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i3" class="anchor-spacer"></div><h3 class="article-section__title" id="_i3"> Design</h3><div class="NLM_p">Since AChE is a well-established target for the treatment of AD at the early and moderate stages, while BChE is a promising target for the moderate-to-advanced forms of AD, an inhibitor that is able to tackle both ChEs should be effective for a longer time span along AD progression. Such dual inhibitors have been described in the literature, among which tacrine <b>1</b>.<a onclick="showRef(event, 'ref49'); return false;" href="javascript:void(0);" class="ref ref49">(49)</a> Tacrine was the first approved drug for the treatment of AD but was withdrawn from the market because of its dose-dependent hepatotoxicity.<a onclick="showRef(event, 'ref50 ref51'); return false;" href="javascript:void(0);" class="ref ref50 ref51">(50,51)</a> Due to its low molecular weight and excellent ChE inhibitory activity, tacrine <b>1</b> is an ideal starting point for the development of multitarget drugs (for recent review articles, see refs <a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> and <a onclick="showRef(event, 'ref53'); return false;" href="javascript:void(0);" class="ref ref53">(53)</a>).</div><div class="NLM_p">In developing tacrine hybrids, it is important to keep the potential hepatotoxic effect in mind. Linking or coupling with hepatoprotective compounds can reduce or even eliminate such a side effect.<a onclick="showRef(event, 'ref54 ref55 ref56'); return false;" href="javascript:void(0);" class="ref ref54 ref55 ref56">(54−56)</a></div><div class="NLM_p">In addition to the inhibition of the ChEs, the activation of the hCB<sub>2</sub>R, as previously mentioned, represents a promising strategy in the treatment of AD. An example of a selective hCB<sub>2</sub>R agonist is the benzimidazole-based derivative <b>2</b> described by AstraZeneca (see <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig1" id="" class=" internalNav">1</a></a>)<a onclick="showRef(event, 'ref57'); return false;" href="javascript:void(0);" class="ref ref57">(57)</a> and further investigated by us.<a onclick="showRef(event, 'ref48 ref58 ref59 ref60'); return false;" href="javascript:void(0);" class="ref ref48 ref58 ref59 ref60">(48,58−60)</a></div><figure id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0001.jpeg" id="gr1" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tacrine <b>1</b> and selective hCB<sub>2</sub>R agonist <b>2</b>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div></div><div id="sec2" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i4">Results and Discussion</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_71617" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_71617" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">Following the hybrid concept, coupling of structures <b>1</b> and <b>2</b> into a single molecule through a linker should yield a molecule with inhibitory properties toward ChEs and affinity for the hCB<sub>2</sub>R. Defining a suitable connecting position for the linker chain is a crucial task because an unsuitable connection between the two pharmacophore units can easily lead to a complete loss of activity or can reverse the behavior of the drug at the target, especially with regard to the hCB<sub>2</sub>R (e.g., turn an agonist into an antagonist).<a onclick="showRef(event, 'ref60'); return false;" href="javascript:void(0);" class="ref ref60">(60)</a> Linkage at the primary amine moiety at the position 9 of <b>1</b> is chemically easy to access, and substituted derivatives still show pronounced inhibitory properties toward ChEs.<a onclick="showRef(event, 'ref61'); return false;" href="javascript:void(0);" class="ref ref61">(61)</a></div><div class="NLM_p">Taking advantage of the previous work on the structure–activity relationships (SARs) of the hCB<sub>2</sub>R ligand <b>2</b>, two possible attachment positions for a linker were identified, that is, the amide moiety and the <i>N</i><sup>1</sup> of the imidazole.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> Connection of structures <b>1</b> and <b>2</b> through these two connection points lead to two sets of hybrid compounds: <b>3a</b>–<b>e</b> and <b>4a</b>–<b>e</b> (see <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig2" id="" class=" internalNav">2</a></a>).</div><figure id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0002.jpeg" id="gr2" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Designed hybrids <b>3a</b>–<b>e</b> and <b>4a</b>–<b>e</b> used to investigate the optimal spacer length and the attachment point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Modification of the tertiary amide group of the parent molecule <b>2</b> into a secondary amide group in derivatives <b>4a</b>–<b>e</b> might affect affinity and activity at the target. Hence, to investigate a possible effect of the number of substituents at this position, we designed a tertiary amide hybrid (hybrid <b>5</b>). After optimizing the spacer length, we designed hybrids with a functionalized linker. Therefore, we introduced a 2-poly(ethylene glycol) (PEG) linker for higher rigidity and polarity (hybrids <b>6</b> and <b>7</b>). In addition, cystamine was introduced as a linker at the amide position to archive neuroprotective and putative hepatoprotective properties (<b>8</b>, see <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig3" id="" class=" internalNav">3</a></a>).<a onclick="showRef(event, 'ref62'); return false;" href="javascript:void(0);" class="ref ref62">(62)</a></div><figure id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0003.jpeg" id="gr3" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Designed hybrids <b>5</b>–<b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div id="sec2_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i5" class="anchor-spacer"></div><h3 class="article-section__title" id="_i5"> Synthesis</h3><div class="NLM_p">Based on these design strategies, tacrine-amine derivatives <b>12a</b>–<b>g</b> and <b>14</b> were synthesized and coupled to the benzimidazole core. Anthranilic acid <b>9</b> and cyclohexanone <b>10</b> were heated up with an excess of phosphoroxylchloride to yield the tetrahydroacridine derivative <b>11</b>.<a onclick="showRef(event, 'ref63'); return false;" href="javascript:void(0);" class="ref ref63">(63)</a> By substitution with the corresponding diamine in excess, the tacrine-amine derivatives <b>12a</b>–<b>g</b> were obtained (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><figure id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0012.jpeg" id="gr12" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tacrine-Amine Intermediates <b>12a</b>–<b>g</b> and <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) POCl<sub>3</sub>, reflux; (b) respective diamine, hexanol, reflux; (c) Ac<sub>2</sub>O, r.t.; (d) LiAlH<sub>4</sub>, THF, reflux.</p></p></figure><div class="NLM_p">For the synthesis of derivative <b>14</b>, the primary amine of tacrine-amine derivative <b>12c</b> was acetylated to form amide <b>13</b> in quantitative yield. In the next step, the amide was reduced to the secondary amine <b>14</b> in the presence of lithium aluminum hydride (<a class="ref internalNav" href="#sch1" aria-label="Scheme 1">Scheme 1</a>).</div><div class="NLM_p">Synthesis of derivatives <b>3a</b>–<b>e</b> and <b>6</b> started with 4-fluoro-3-nitrobenzoic acid <b>15</b>. To form the diethylamide <b>16,</b> oxalyl chloride and a catalytic amount of DMF were used, and then diethylamine was added. In the next step, the fluorine atom was substituted with the respective amine derivatives <b>12a</b>–<b>f</b> to form compounds <b>17a</b>–<b>f</b>, the reaction gave good to quantitative yield. The nitro moiety was then reduced with tin(II) chloride dihydrate to obtain the anilinic amines <b>18a</b>–<b>f</b>, which were directly used for the next step. 2-(4-Ethoxyphenyl)acetic acid was activated with HBTU and added to amines <b>18a</b>–<b>f</b>. In the last step, the amides <b>19a</b>–<b>f</b> were cyclized in acetic acid to yield compounds <b>3a</b>–<b>e</b> and <b>6</b> (<a class="ref internalNav" href="#sch2" aria-label="Scheme 2">Scheme 2</a>).</div><figure id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0013.jpeg" id="gr13" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Hybrids <b>3a</b>–<b>e</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HNEt<sub>2</sub>, cat. DMF, (COCl)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub> at 0 °C → r.t.; (b) respective amines <b>12a</b>–<b>f</b>, THF, NEt<sub>3</sub>, r.t.; (c) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, reflux; (d) 2-(4-ethoxyphenyl)acetic acid, HBTU, NEt<sub>3</sub>, DMF, r.t.; (e) AcOH, reflux.</p></p></figure><div class="NLM_p">4-Fluoro-3-nitrobenzoic acid <b>15</b> served as the starting material for derivatives <b>4a</b>–<b>e</b>, <b>5</b>, <b>7</b>, and <b>8</b>. In the first step, the ethyl ester was formed as a protection group, and the fluorine atom was substituted with 3-methylbutan-1-amine to yield substituted ester <b>20</b> in a good yield. In the next step, the nitro moiety was reduced with hydrogen over Pd/C to yield amine <b>21</b>, which was then directly reacted with HBTU-activated 2-(4-ethoxyphenyl)acetic acid to form amide <b>22</b>. Benzimidazole <b>23</b> was formed by stirring <b>22</b> in acetic acid under reflux. The ester was hydrolyzed under basic conditions. In the last step, acid <b>24</b> was activated with HBTU and reacted with the respective amines <b>12a</b>–<b>g</b> and <b>14</b> to yield hybrids <b>4a</b>–<b>e</b>, <b>5</b>, <b>7</b>, and <b>8</b> (<a class="ref internalNav" href="#sch3" aria-label="Scheme 3">Scheme 3</a>).</div><figure id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0014.jpeg" id="gr14" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Hybrids <b>4a</b>–<b>e</b>, <b>5</b>, <b>7</b>, and <b>8</b><i><sup>a</sup></i></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (I) cat. H<sub>2</sub>SO<sub>4</sub> (97%), EtOH, reflux; (II) NEt<sub>3</sub> 3-methylbutan-1-amine, r.t.; (b) cat. Pd/C (10%), MeOH, H<sub>2</sub> atm, 8 bar, r.t.; (c) 2-(4-ethoxyphenyl)acetic acid, HBTU, NEt<sub>3</sub>, DMF, r.t.; (d) AcOH, reflux; (e) LiOH, H<sub>2</sub>O, reflux; (f) respective amines <b>12a</b>–<b>g</b>, <b>14</b>, HBTU, NEt<sub>3</sub>, DMF, r.t.</p></p></figure></div></div><div id="sec3" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i9">Pharmacological Profile</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_62035" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_62035" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec3_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i10" class="anchor-spacer"></div><h3 class="article-section__title" id="_i10"> Inhibition of Cholinesterases</h3><div class="NLM_p">All synthesized compounds were assayed for their ability to inhibit human butyrylcholinesterase (hBChE) and human acetylcholinesterase (hAChE) using the colorimetric Ellman’s assay (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>).<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> Tacrine <b>1</b> was selected as the reference compound and showed an pIC<sub>50</sub>(hBChE) = 7.9 and pIC<sub>50</sub>(hAChE) = 6.8. Previous studies showed no significant ChE inhibitory activity of the hCB<sub>2</sub>R agonist <b>2</b> at 10 μM.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a> According to our expectations, all synthesized hybrids acted as ChE inhibitors. Compared to <b>1</b>, hybrids <b>3a</b>, <b>3b</b>, <b>3e</b>, and <b>4b</b> showed an increased inhibitory potency toward hBChE, while <b>3a</b> and <b>4b</b>, in addition, also showed a higher inhibitory activity toward hAChE. The higher inhibitory potency might be due to interaction with the PAS of the AChE (see <a class="ref internalNav" href="#sec3_2" aria-label="Inhibition and Mode of Action toward hAChE">Inhibition and Mode of Action toward hAChE</a>), which was consequently followed up (cf. <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). For a better overview of the selectivity, we correlated pIC<sub>50</sub> values of hAChE and hBChE in <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig4" id="" class=" internalNav">4</a></a>.</div><figure id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0004.jpeg" id="gr4" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of pIC<sub>50</sub> values toward hBChE against pIC<sub>50</sub> values toward hAChE of all hybrids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_table-wrap" id="tbl1"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 1. Results of the in Vitro Evaluation of the Inhibitory Effect of AChE/BChE and Radioligand Binding Studies at hCB<sub>1</sub>R/hCB<sub>2</sub>R<a onclick="showRef(event, 'ref69 ref70'); return false;" href="javascript:void(0);" class="ref ref69 ref70">()</a><a class="ref internalNav" href="#t1fn1" aria-label="a">a</a></div></div></div><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0015.gif" alt="" id="gr15" /></img><div class="NLM_table-wrap-foot" id="IDtable-wrap-foot-t1fn1"><div class="footnote" id="t1fn1"><sup><sup>a</sup></sup><p class="last">n.a. activity lower than 10% at the highest tested concentration (10 μM); n.d., not determined.</p></div><div class="footnote" id="t1fn2"><sup><sup>b</sup></sup><p class="last">Values are the means of at least three independent determinations; hBChE from human serum.</p></div><div class="footnote" id="t1fn3"><sup><sup>c</sup></sup><p class="last">Values are the means of at least three independent determinations; recombinant hAChE.</p></div><div class="footnote" id="t1fn4"><sup><sup>d</sup></sup><p class="last">Selectivity index (SI) toward hBChE = IC<sub>50</sub>(hAChE)/IC<sub>50</sub>(hBChE).</p></div><div class="footnote" id="t1fn5"><sup><sup>e</sup></sup><p class="last">Screened on membranes of HEK cells stably expressing hCB<sub>2</sub>R using 10 μM of the compound; values are mean values from at least two independent experiments, each performed in triplicate.</p></div><div class="footnote" id="t1fn6"><sup><sup>f</sup></sup><p class="last">Screened on membranes of CHO cells stably expressing hCB<sub>1</sub>R using 10 μM of the compound; values are mean values from at least two independent experiments, each performed in triplicate.</p></div></div><div></div></div></div><div id="sec3_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i12" class="anchor-spacer"></div><h3 class="article-section__title" id="_i12"> Inhibition Constants and Mode of Action toward hAChE</h3><div class="NLM_p">To get further insights into the inhibition of hAChE, the mechanism of inhibition was investigated for one hybrid of each set with a pronounced inhibition of AChE. Specifically, hybrid <b>3e</b> of set 1 and <b>4b</b> of set 2 were selected. Additionally, cystamine hybrid <b>8</b> was investigated.</div><div class="NLM_p">For the three selected compounds, the mechanism of inhibition was investigated by monitoring the catalytic rate at several substrate and inhibitor concentrations (see <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a> for details). Lineweaver–Burk reciprocal plots showed increasing slope (decreasing <i>V</i><sub>max</sub>) and increasing <i>x</i> intercept (increasing <i>K</i><sub>m</sub> values) at increasing inhibitor concentration (see <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>). This trend indicates a mixed-type inhibition, and thus, the inhibitor could bind simultaneously with the CAS and the PAS of hAChE. The inhibitor inhibition constant <i>K</i><sub>i</sub> and the inhibition constant for the enzyme–substrate–inhibitor complex (<i>K</i><sub class="stack">i</sub><sup class="stack">′</sup>) were estimated for each hybrid and are reported in <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig5" id="" class=" internalNav">5</a></a>.</div><figure id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0005.jpeg" id="gr5" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinetic study on the mechanism of hAChE inhibition by <b>3e</b>, <b>4b</b>, and <b>8</b>. Lineweaver–Burk reciprocal plots of hAChE initial velocity at increasing substrate (acetylthiocholine, ACth) concentration in the absence of the inhibitor (control) and the presence of increasing concentrations of the inhibitor are shown. Values are the means of at least three independent determinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i13" class="anchor-spacer"></div><h3 class="article-section__title" id="_i13"> Inhibition of Aβ Aggregation</h3><div class="NLM_p">Compounds able to bind the AChE’s PAS may interfere with the AChE-induced Aβ oligomerization and fibrillization.<a onclick="showRef(event, 'ref65 ref66'); return false;" href="javascript:void(0);" class="ref ref65 ref66">(65,66)</a> Hence, given the ability of <b>3e</b>, <b>4b</b>, and <b>8</b> to contact AChE’s PAS, the inhibitory activity on AChE-induced Aβ<sub>40</sub> aggregation was investigated by a thioflavin T (ThT)-based fluorometric assay<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> and compared with that of the anti-AD drug <b>1</b> (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>). Results showed that compounds <b>3e</b> and <b>4b</b> were able to significantly reduce the proaggregating action of hAChE, while <b>1</b> was inactive, in agreement with a previous study.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> Interestingly, percent inhibition values archived for <b>3e</b> and <b>4b</b> are close to activity values previously obtained for the well-known multifunctional compound bis(7)tacrine (68.0% inhibition in the same assay conditions).<a onclick="showRef(event, 'ref67'); return false;" href="javascript:void(0);" class="ref ref67">(67)</a> In the same experimental conditions, the cystamine derivate <b>8</b> was not able to significantly inhibit the AChE-induced Aβ<sub>40</sub> aggregation.</div><figure id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0006.jpeg" id="gr6" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AChE-mediated and self-induced Aβ aggregation. Footnote a denotes inhibition of Aβ<sub>42</sub> self-aggregation investigated by the thioflavin T fluorescence assay. Assays were carried out in the presence of 50 μM inhibitor and 50 μM Aβ<sub>42</sub> ([I] = [Aβ<sub>42</sub>]). Values are expressed as means ± SEM of two independent experiments, and each was performed in duplicate. Footnote b denotes % inhibition of hAChE-induced Aβ<sub>40</sub> aggregation at [I] = 100 μM. The Aβ<sub>40</sub>/hAChE ratio was equal to 100:1. Values are expressed as means ± SEM of two independent experiments, and each was performed in duplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Although <b>1</b> is not able to inhibit amyloid self-aggregation at a significant extent, several studies have shown that tacrine homo- and heterodimers may be endowed with such a beneficial property.<a onclick="showRef(event, 'ref52'); return false;" href="javascript:void(0);" class="ref ref52">(52)</a> Hence, the three selected hybrids were also assayed for their ability to inhibit Aβ<sub>42</sub> self-aggregation by a similar ThT fluorescence assay.<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> Quite interestingly, compounds <b>3e</b> and <b>8</b> strongly inhibited Aβ<sub>42</sub> aggregation when assayed at a 1:1 ratio with Aβ<sub>42</sub>, while, in the same conditions, inhibition by <b>4b</b> was quite weak (see <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig6" id="" class=" internalNav">6</a></a>) since each compound is representative of a different subset of hybrids, SARs cannot be derived. However, it is clear that the spatial arrangement of pharmacophore fragments and the nature of the spacer chain strongly affect the inhibitory ability toward the spontaneous aggregation of the 42-amino acid isoform of Aβ.</div><div class="NLM_p last">The three hybrids showed different inhibition profiles toward the two aggregation phenomena. While hybrid <b>8</b> was able to significantly interfere with Aβ self-aggregation but not with the chaperonic action of hAChE toward Aβ, hybrid <b>4b</b> was able to significantly interfere with the chaperonic action of hAChE toward Aβ but only weakly with Aβ self-aggregation, and, finally, hybrid <b>3e</b> able to significantly inhibit both aggregation phenomena. Because of the strong inhibitory potency toward Aβ self-aggregation exerted by <b>3e</b>, it cannot be excluded that this activity can also synergistically contribute to the good inhibitory potency recorded in the AChE-induced amyloid aggregation assay. This might also explain the high inhibition value recorded in this assay, notwithstanding a <i>K</i><sub class="stack">i</sub><sup class="stack">′</sup> value in the submicromolar range.</div></div><div id="sec3_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i14" class="anchor-spacer"></div><h3 class="article-section__title" id="_i14"> Radioligand Binding Assays at hCB<sub>1</sub>R and hCB<sub>2</sub>R</h3><div class="NLM_p last">All synthesized compounds were tested for affinity to hCB<sub>1</sub>R and hCB<sub>2</sub>R using radioligand binding assays. Briefly, hCBRs were isolated from cell lines stably expressing receptors (CHO cells for hCB<sub>1</sub>R or HEK cells in the case of hCB<sub>2</sub>R). [3H]CP 55,940 was used as radioligand. As a positive control, the hCB<sub>2</sub>R selective ligand <b>2</b> was used. In our tests, we measured a <i>K</i><sub>i</sub>(hCB<sub>2</sub>R) = 37 nM and selectivity over hCB<sub>1</sub>R [24% replacement (hCB<sub>1</sub>R) of radioligand at 10 μM)]. All compounds showed affinity to hCB<sub>2</sub>R within single- to two-digit micromolar range. In the case of compounds <b>3a</b>–<b>e</b>, the affinity toward hCB<sub>2</sub>R increased with the length of the spacer, from <i>K</i><sub>i</sub> = 38.5 μM (<b>3a</b>) to <i>K</i><sub>i</sub> = 4.5 μM (<b>3e</b>). Part of this effect might be due to an increasing lipophilicity, which is a favorable feature for high-affinity hCB<sub>2</sub>R ligands.<a onclick="showRef(event, 'ref71'); return false;" href="javascript:void(0);" class="ref ref71">(71)</a> Compounds <b>4a</b>–<b>e</b> all show a single-digit micromolar affinity toward hCB<sub>2</sub>R. Experimental data did not support the correlation between affinity and chain length. The tertiary amide derivative <b>5</b>, which is the equivalent of derivative <b>4c</b>, showed the same affinity toward hCB<sub>2</sub>R but a higher affinity toward hCB<sub>1</sub>R, resulting in low selectivity. Hence, the number of substituents at the amide group influences selectivity. Hybrids <b>6</b> and <b>7</b> with a 2-PEG-linker, which confers a higher hydrophilicity and rigidity, showed a weaker affinity toward hCB<sub>2</sub>R compared to the compounds with the longest alkylene linkers (<b>3e</b> and <b>4e</b>). The disulfide bond in hybrid <b>8</b> has no significant effect on affinity toward hCB<sub>2</sub>R as the equivalent derivative <b>4e</b> showed almost the same affinity (<a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">Table <a class="ref showTableEvent internalNav" data-ID="tbl1" href="#tbl1">1</a></a>). Overall, the linkage of the two molecules has been associated with a loss of affinity at the hCB<sub>2</sub>R compared to the parent molecule <b>2</b>, but the ligands still retain moderate affinity and good selectivity at hCB<sub>2</sub>R. Since parent molecule <b>2</b> shares a high structural similarity with the known μ-opioid receptor (MOR) ligand etonitazene,<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> we investigated potential affinity and found a significant affinity of hybrids <b>3a</b>, <b>4a</b>, and <b>4e</b> (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Table 1</a>). In our previous work, we were able to show that an MOR “design out” approach is possible, if this is required with regard to the side effect profile.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec3_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i15" class="anchor-spacer"></div><h3 class="article-section__title" id="_i15"> Efficacy at hCB<sub>2</sub>R</h3><div class="NLM_p">The hCB<sub>2</sub>R is coupled through G<sub>i/0</sub> protein, so adenylate cyclase is inhibited in the case of activation. This results in a lower level of intracellular cAMP in the case of agonist binding or to an increased cAMP level in the case of an inverse agonist binding.<a onclick="showRef(event, 'ref72'); return false;" href="javascript:void(0);" class="ref ref72">(72)</a> The cAMP increase by forskolin (FSK) is further enhanced by an antagonist/reverse agonist binding, while the binding of an agonist reverts the effect.<a onclick="showRef(event, 'ref73'); return false;" href="javascript:void(0);" class="ref ref73">(73)</a> This makes the intracellular detection of cAMP levels by immunoassays a common method for the characterization of the efficacy of hCB<sub>2</sub>R ligands. Going down the signaling pathway mediated by a conformational change of the receptor, the resulting difference in the cellular cAMP level changes the expression of cAMP-regulated genes (the reporter). The transcription of these genes is regulated by the transcription factor cAMP response element-binding protein (CREB). Binding of CREB to the cAMP responding element (CRE) is upstreaming gene expression.<a onclick="showRef(event, 'ref74'); return false;" href="javascript:void(0);" class="ref ref74">(74)</a> A high cAMP level, induced by an antagonist binding, leads to a high expression of cAMP-regulated genes, while an agonist leads to the opposite effect. By quantifying the expression of these genes, it is possible to investigate the behavior of the ligand at the receptor. An example of a cAMP-regulated gene is the macrophage migration inhibitory factor (MIF) with a CRE in the proximal promoter region.<a onclick="showRef(event, 'ref75'); return false;" href="javascript:void(0);" class="ref ref75">(75)</a> A further example is the signal transducer and activator of transcription (STAT-3) gene, which expression is also under CRE promoter control.<a onclick="showRef(event, 'ref76'); return false;" href="javascript:void(0);" class="ref ref76">(76)</a> Both genes are highly expressed in multiple myeloma cells.<a onclick="showRef(event, 'ref77 ref78'); return false;" href="javascript:void(0);" class="ref ref77 ref78">(77,78)</a> Compounds <b>3e</b> and <b>4c</b> were evaluated, as previously described, at a concentration of 50 μM.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a> In general, before examining the efficacy of the compounds, an MTT assay was carried out on U266 myeloma cells to evaluate a nontoxic concentration of the compounds (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 1</a>). The efficacy of the compounds was investigated by the quantification of the cAMP-regulated MIF and STAT-3 genes by a qRT-PCR methodology. AM630 was measured as a reference antagonist/reverse agonist. Cells were treated with compound <b>2</b> as a reference agonist, <b>3e</b> and <b>4c</b> alone, and in combination with AM630. Compared to the vehicle, compounds <b>2</b>, <b>3e</b>, and <b>4c</b> show a decreased expression of both genes. Also, in combination experiments, all three compounds show a decreased level of both genes compared to the levels of only the AM630-treated cells (see <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig7" id="" class=" internalNav">7</a></a> and <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 2</a>).</div><figure id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0007.jpeg" id="gr7" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Test compounds (<b>2</b>, <b>3e</b>, and <b>4c</b>) reduce MIF and STAT-3 gene expression. U266 cells were treated with hybrid compounds (50 μM), FSK (10 μM), or AM630 (25 μM) for 2 h. In a combined experiment (AM630 plus test compounds), U266 cells were preincubated with AM630 for 30 min. Before adding the test compounds, MIF and STAT-3 mRNA levels were determined by qRT-PCR. GAPDH was used for normalization. Data are expressed as relative fold with respect to vehicle-treated cells used as the control. Values are means of at least two independent experiments, and each was performed in duplicate. Data are expressed as means ± SD *<i>p</i> < 0.01 vs untreated; # vs AM630.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p">Furthermore, compounds <b>3e</b> and <b>4c</b> were characterized using a functional fluorescent hCB<sub>2</sub>-activated G<sub>αq16</sub>-coupled intracellular calcium mobilization assay in CHO-K1 cells overexpressing the receptor.<a onclick="showRef(event, 'ref79 ref80'); return false;" href="javascript:void(0);" class="ref ref79 ref80">(79,80)</a> Briefly, CHO-K1 cells were engineered to stably co-express hCB1 or hCB2 and G<sub>αq16</sub>. Activation of hCB<sub>1</sub>/CB<sub>2</sub> by an agonist then leads to generation of inositol phosphatase 3 (IP3) and activation of IP3 receptors, which, in turn, mobilizes intracellular calcium. Compounds <b>3e</b> and <b>4c</b> were identified as agonists of hCB<sub>2</sub>R with an EC<sub>50</sub> of 911 ± 42 nM for compound <b>4c</b> and an <i>E</i><sub>max</sub> = 39%. Compound <b>3e</b> shows an EC<sub>50</sub> of 3.05 ± 0.2 μM and an <i>E</i><sub>max</sub> = 51%. Therefore, both compounds are partial agonists at hCB<sub>2</sub>R. Both compounds were devoid of activity at hCB<sub>1</sub>R. (see <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig8" id="" class=" internalNav">8</a></a>).</div><figure id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0008.jpeg" id="gr8" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Calcium mobilization assay in CHO-K1 cells overexpressing hCB<sub>1</sub> or hCB<sub>2</sub> and G<sub>αq16.</sub> Compounds were tested in each cell type as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Agonism was noted in cells expressing hCB<sub>2</sub> (left) but not in cells expressing hCB<sub>1</sub> (right). The synthetic full agonist CP 55,040 served as a comparator and positive control. No significant signal was noted in vehicle control cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><div class="NLM_p last">Compounds <b>3e</b> and <b>4c</b> are therefore partial agonists at the hCB<sub>2</sub>R as confirmed in two different assays. Since in our previous work, we also found agonist behavior for structurally related derivatives and because of the high structural similarity of all the hybrids described, we assume that all hybrids are agonists.<a onclick="showRef(event, 'ref48'); return false;" href="javascript:void(0);" class="ref ref48">(48)</a></div></div><div id="sec3_6" class="NLM_sec NLM_sec_level_2"><div id="ac_i16" class="anchor-spacer"></div><h3 class="article-section__title" id="_i16"> Effects on Microglia Activation</h3><div class="NLM_p">To test a possible immunomodulatory effect, that is, the shift from the M1 neurotoxic to the M2 neuroprotective phenotype, of compounds <b>2</b>, <b>3e</b>, and <b>4a</b>, the murine microglial cell line N9 was exposed to 100 ng/mL lipopolysaccharide (LPS), which induces an M1 activation state, in the presence or absence of increasing concentrations (1, 2.5, and 5 μM) of the test compounds. After 24 h of treatment, microglial conditioned media were collected, partly used for nitrite measurement, and partly concentrated for Western blot analysis. In parallel, microglial cells were collected, and the protein content was determined. Accumulation of nitrite in microglial conditioned media was measured by a colorimetric assay based on the Griess reaction, while the release of IL1β and the expression of iNOS, TREM2, and TGFβ2 were tested through Western blot analysis.</div><div class="NLM_p">Nitrite production due to iNOS induction and IL1β release is the marker of M1, neurotoxic activated microglia, and induced by the LPS treatment, while the phagocytic proteins TREM2 and TGFβ2 are both makers of M2, neuroprotective microglia. As shown in <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig9" id="" class=" internalNav">9</a></a>, compound <b>3e</b> strongly reduces in a dose-dependent way IL1β release and nitrite accumulation, as well as iNOS expression induced by LPS-mediated activation of microglial cells, with no parallel change in TREM2 and TGFβ2 expression, thus indicating an immunomodulatory effect of the compound, which is similar to compounds <b>2</b> and <b>4a</b>.</div><figure id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0009.jpeg" id="gr9" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of compounds <b>2</b>, <b>3e</b>, and <b>4a</b> on microglial activation in N9 cells previously activated by LPS (100 ng/mL). IL1β release and expression of iNOS, TREM2, and TGFβ2 were tested through Western blot analysis after 24 h of treatment with LPS in the presence of increasing concentrations (1, 2.5, and 5 μM) of compounds (A) <b>2</b>, (B) <b>3e</b>, and (C) <b>4a</b>, respectively, and (G–R) quantified through densitometry. NO release was evaluated through the Griess reaction in media conditioned for 24 h by microglial cells treated by LPS in the presence of compounds (D) <b>2</b>, (E) <b>3e</b>, and (F) <b>4a</b>, showing an increase in NO release in media conditioned by LPS-treated cells that are reduced by the co-treatment with the compounds, with the strongest effect of compound <b>2</b>. Both (G–I) IL1β release and (J–L) iNOS expression, which are markers of M1 neurotoxic microglia, strongly increase in LPS-treated cells but significantly decrease in cells co-treated with compounds (G, J) <b>2</b>, (H, K) <b>3e</b>, and (I, L) <b>4a</b> in a dose-dependent way, while the expression of the M2 microglial markers (M–O) TREM2 and (P–R) TGFβ2 is not reduced by co-treatment with the compounds. All quantitative data are presented as means ± SEM from at least three independent experiments. Statistical significance between different treatments was calculated by using one-way analysis of variance (ANOVA) followed by post hoc comparison through Bonferroni’s test. *<i>p</i> < 0.05; **<i>p</i> < 0.01 compare to control; <sup>#</sup><i>p</i> < 0.05; <sup>##</sup><i>p</i> < 0.01 compare to LPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_7" class="NLM_sec NLM_sec_level_2"><div id="ac_i17" class="anchor-spacer"></div><h3 class="article-section__title" id="_i17"> Neuroprotective Properties on HT-22 Cells</h3><div class="NLM_p">For the biological evaluation of compound <b>8</b> regarding its effects on murine hippocampal neurons (HT-22), we performed a glutamate assay as previously described.<a onclick="showRef(event, 'ref81 ref82'); return false;" href="javascript:void(0);" class="ref ref81 ref82">(81,82)</a> This neuronal cell line is derived from murine hippocampal tissue and is glutamate sensitive.<a onclick="showRef(event, 'ref83'); return false;" href="javascript:void(0);" class="ref ref83">(83)</a> HT-22 cells lack ionotropic glutamate receptors. The addition of extracellular glutamate at high concentrations can be used to introduce intracellular ROS accumulation by blocking the cystine/glutamate antiporter, resulting in glutathione depletion. This neuronal oxidative stress results in cell injuries and eventually cell death.<a onclick="showRef(event, 'ref84 ref85 ref86'); return false;" href="javascript:void(0);" class="ref ref84 ref85 ref86">(84−86)</a> Before performing the neuroprotectivity assays, potential neurotoxicity of both compounds <b>4e</b> and <b>8</b> were evaluated in an MTT assay (see <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>A). Compound <b>8</b> showed concentration-dependent neuroprotectivity starting at 1 μM (see <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>C). Treatment with 5 μM compound <b>8</b> leads to neuroprotection comparable to the positive control quercetin at 25 μM. Compound <b>4e</b> shows a similar neuroprotective behavior but decreases viability at 10 μM due to the neurotoxic effect at this dose (see <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig10" id="" class=" internalNav">10</a></a>B). The use of cystamine as a linker yielded a hybrid with lower neurotoxicity compared to the sulfur-free analogue <b>4e</b> with a neuroprotective behavior at a comparable low concentration. Furthermore, compounds <b>3a</b>, <b>3d</b>, <b>3e</b>, <b>4a</b>, and <b>4b</b> were also investigated toward their neurotoxicity and neuroprotective behavior. In summary, compounds <b>3a</b>, <b>3d</b>, and <b>3e</b> show no neurotoxicity at the doses tested (max. 10 μM), while <b>4a</b> is toxic above 5 μM, and <b>4b</b> shows first toxicity effects at 5 μM. Compounds <b>4b</b> and <b>4a</b> show neuroprotective behavior only at 5 μM, while other compounds tested showed low neuroprotective behavior (<b>3e</b>) or none (<b>3a</b> and <b>3d</b>) (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 3</a>).</div><figure id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0010.jpeg" id="gr10" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compounds <b>4e</b> and <b>8</b> were studied on neuronal HT-22 cells for (A) neurotoxicity effects and (B, C) neuroprotection against glutamate-induced oxidative stress at 1–25 μM. Results of the modified MTT test are presented as means ± SD of three independent experiments, each performed in sextuplicate, and refer to untreated control cells, which were set as 100% values. Statistical analysis was achieved by applying one-way ANOVA followed by Dunnett’s multiple comparison post-test. Levels of significance: *<i>p</i> < 0.005; **<i>p</i> < 0.01; ***<i>p</i> < 0.001. Treated cells were compared to (A) untreated cells and (B) cells treated with glutamate only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_8" class="NLM_sec NLM_sec_level_2"><div id="ac_i18" class="anchor-spacer"></div><h3 class="article-section__title" id="_i18"> In Vivo Studies</h3><div class="NLM_p">The most promising compounds were tested regarding their procognitive effects in an in vivo AD mouse model. To induce AD such as neuroinflammation and cognitive deficits, oligomerized Aβ<sub>25–35</sub> peptide was intracerebroventricularly injected into the mouse brain.<a onclick="showRef(event, 'ref44 ref87 ref88'); return false;" href="javascript:void(0);" class="ref ref44 ref87 ref88">(44,87,88)</a> Since the addressed targets are located in the brain, hybrids must be able to penetrate the BBB. We first tested compounds, with the shortest spacer lengths, <b>3a</b> and <b>4a</b> with a low molecular weight. After the first positive results, we also tested compounds with a more pronounced in vitro profile.</div><div class="NLM_p">Compounds were injected once daily (o.d.) and intraperitoneally (i.p.) from day 1, 20 min after the peptide injection, until day 7. Compounds were solubilized in pure DMSO at a concentration of 2 mg/mL and then diluted in water. Final DMSO concentration in the vehicle solution remained, however, high (60%), and innocuity was controlled by a daily observation on the mice behavior and weight gain control. None of the treatment affected significantly the weight gain during the week of treatment. Animals lost up to 1 g after the peptide injection but then regained regularly between 0.2 and 0.4 g daily (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 4</a>).</div><div class="NLM_p">Behavioral examination was performed between day 8 and 10 according to the procedure schematized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 5</a>. All animals were sacrificed on day 11 (see <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 5</a>).</div><div class="NLM_p">Spontaneous alternation performance, which is an index of spatial working memory, was tested on day 8 in the Y-maze test. Long-term memory response was measured on day 10, in a step-through type passive avoidance task, with retention assessed for 24 h after training. Results confirmed that Aβ<sub>25–35</sub> induced significant learning impairments in the behavioral tests. Moreover, all compounds tested showed significant attenuations of Aβ<sub>25–35</sub>-induced learning impairments in both the short-term and the long-term memory responses (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a>)</a>. Effective doses were slightly lower in the spontaneous alternation test (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, upper panels) than in the passive avoidance test (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>, lower panels) and appeared often bell-shaped (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>d,f,i,j). Compound <b>3a</b> significantly prevented Aβ<sub>25–35</sub>-induced learning impairments at doses of 1 mg/kg and higher (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>b, 1). All other compounds, namely, <b>3d</b>, <b>3e</b>, <b>4a</b>, and <b>8</b>, significantly prevented the learning deficits at the lower dose of 0.3 mg/kg (see <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">Figure <a data-tab="pane-pcw-Figures" href="#fig11" id="" class=" internalNav">11</a></a>c–j). Notably, compounds <b>3e</b>, <b>4a</b>, and <b>8</b> completely prevented Aβ<sub>25–35</sub> impairments in both tests at the most effective doses (resp., 0.3, 1, and 0.3 mg/kg), outlining the high efficiency of the compounds. It should be noted, at this point, that the hybrids show a significantly higher efficacy compared to the parent molecules <b>1</b> and <b>2</b>, which were also investigated in vivo in our previous work.<a onclick="showRef(event, 'ref48 ref87'); return false;" href="javascript:void(0);" class="ref ref48 ref87">(48,87)</a> It is possible that MOR activity of the compounds may marginally contribute to the neuroprotective effect observed here. However, the only indirect measure we get from our experiments was that no significant change in pain sensitivity to footshock was measured, even at the highest drug dose during the passive avoidance training session. Shock sensitivity was 1.1 ± 0.3 for the group treated with compound <b>3a</b>, 3 mg/kg, and 0.9 ± 0.3 for compound <b>4a</b>, 1 mg/kg, versus 1.4 ± 0.3 for Veh-treated animals, suggesting that pain response was not affected by the compound treatments. Nevertheless, MORs have been shown to be involved in memory formation, particularly, in the context of memory formation associated with opiate drug abuse, by regulating GABAergic inputs and facilitating neuronal excitatory activity through the hippocampal CA1 area.<a onclick="showRef(event, 'ref89'); return false;" href="javascript:void(0);" class="ref ref89">(89)</a> Therefore, the agonist (or antagonist) activity of the compounds at MORs and synergy of MOR and CB<sub>2</sub>R activities on memory and neuroprotection is—at least in principle—possible. Indeed, the compounds tested exhibit a remarkably high in vivo efficacy, with sub-mg/kg active doses as compared with their low micromolar affinities in vitro on CB<sub>2</sub>Rs or MORs. Their precise PK/PD profiles and any possible synergy between pharmacological targets should be examined to confirm that the compounds exhibit a very unique and interesting pharmacological activity.</div><figure id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0011.jpeg" id="gr11" class="inline-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of the compounds on Aß<sub>25–35</sub>-induced learning impairments in mice: spontaneous alternation performance (upper panels) and passive avoidance response (lower panels). Mice received Aβ<sub>25–35</sub> (9 nmol, i.c.v.) or vehicle solution (3 μL, i.c.v.) on day 1 and then compound (a, b) <b>3a</b>, (c, d) <b>3d</b>, (e, f) <b>3e</b>, (g, h) <b>4a</b>, or (i, j) <b>8</b> in the 0.1–3 mg/kg, i.p. dose range, o.d. between day 1 to 7. Mice were then tested for (a, c, e, g, and i) spontaneous alternation on day 8 and (b, d, f, h, and j) passive avoidance on days 9 and 10. Data show means ± SEM (upper panels) or median and interquartile range (lower panels). ANOVA: <i>F</i><sub>(4,79)</sub> = 3.05, <i>p</i> < 0.05, <i>n</i> = 12–18 in (a); <i>F</i><sub>(4,62)</sub> = 3.77, <i>p</i> > 0.01, <i>n</i> = 11–15 in (c); <i>F</i><sub>(4,64)</sub> = 3.85, <i>p</i> < 0.01, <i>n</i> = 10–15 in (e); <i>F</i><sub>(4,67)</sub> = 3.14, <i>p</i> < 0.05, <i>n</i> = 11–17 in (g); <i>F</i><sub>(4,50)</sub> = 5.40, <i>p</i> < 0.01, <i>n</i> = 8–12 in (i). Kruskal–Wallis ANOVA: <i>H</i> = 9.87, <i>p</i> < 0.05, <i>n</i> = 12–15 in (b); <i>H</i> = 17.4, <i>p</i> < 0.01, <i>n</i> = 11–14 in (d); <i>H</i> = 21.9, <i>p</i> < 0.001, <i>n</i> = 12–13 in (f); <i>H</i> = 13.9, <i>p</i> < 0.01, <i>n</i> = 12–17 in (h); <i>H</i> = 11.8, <i>p</i> < 0.05, <i>n</i> = 12–15 in (j). Post hoc: *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001 vs (V + V)-treated group; <sup>#</sup><i>p</i> < 0.05, <sup>##</sup><i>p</i> < 0.01, and <sup>###</sup><i>p</i> < 0.001 vs (V + Aß<sub>25–35</sub>)-treated group; Dunnett’s (upper panels) or Dunn’s test (lower panels).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></div><div id="sec3_9" class="NLM_sec NLM_sec_level_2"><div id="ac_i19" class="anchor-spacer"></div><h3 class="article-section__title" id="_i19"> Liver Histology</h3><div class="NLM_p last">Livers of mice treated with the high dose (3 mg/kg) were dissected out on day 12, after the behavioral experiments, post-fixed in buffered formalin 4%, and cut into 2 mm slices. At least two-thirds of the parenchyma was embedded, including all macroscopically visible abnormalities. The material underwent standardized dehydration and paraffin embedding as well as hematoxylin–eosin staining after well-established routine protocols. All slides were assessed by the same pathologist, completely blinded to the treatment protocols. The assessment included all typical liver changes seen with drug toxicity: Necrosis was reported focal, segmental, diffuse, or zonal in percentages and divided between fresh and long-standing necrosis. Steatosis was reported as macro- or microvesicular, given in percentages, as diffuse or zonal (lobular zones I–III). Fibrosis was assessed according to stages I to IV after Batts and Ludwig.<a onclick="showRef(event, 'ref90'); return false;" href="javascript:void(0);" class="ref ref90">(90)</a> Inflammation is reported semiquantitatively in a four-tiered system 0–3 and divided into portal and/or lobular. Cholestasis was also reported in a four-tiered system 0–3 specified to intrahepatocytic or canalicular. Cell ballooning was also stated in percentage. After the assessment, the findings were realigned with the treating groups. Microvesicular steatosis was present in all groups, including controls (6/10) showing the highest ratio in group <b>3d</b> (6/6) and the lowest in group <b>4a</b> (2/9). Necrosis was differentiated into fresh necrosis and older necrosis. The fresh necrosis in these specimen was completed without reaction, only hours old. It was seen in all groups, including controls. The highest ratio was observed in the Aß/V group (11/12) and group <b>3d</b> (5/6) with nearly all specimen affected. Older necrosis was reported in two specimen only, both in group Aß/V. Other findings, such as discrete lobular inflammation, were seen only in a single specimen, not related to treatment groups. The results suggest drug-independent reasons for steatosis and fresh necrosis because they were also found in the control groups in a high percentage. One possible cause of the observed liver damage could be the high level of DMSO used for compound injection.<a onclick="showRef(event, 'ref91'); return false;" href="javascript:void(0);" class="ref ref91">(91)</a> No hepatotoxic relation to compound treatment could be established. Further experiments for long-time toxicity must be performed.</div></div></div><div id="sec4" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i20">Conclusions</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_84223" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_84223" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div class="NLM_p">In the current study, sets of hybrid compounds combining tacrine <b>1</b> as ChE inhibitor and the hCB<sub>2</sub>R agonist <b>2</b> were designed and synthesized using different molecular attachment points in the benzimidazole core, different spacer lengths, and structures. The newly synthesized compounds were first evaluated in a series of experiments to confirm activity on AD-relevant targets, namely, AChE, BChE, and hCB<sub>2</sub>R. The hybrid compounds showed higher inhibition of ChEs compared to <b>1</b>. To follow this up, a kinetic study was performed. The study showed a mixed-type inhibition by compounds tested and suggests binding to a second site in ChE leading to higher inhibition. While <b>1</b> has no effect on Aβ aggregation when assayed at 1/1 ratio, all hybrids tested had an effect. Above all, <b>3e</b> showed a pronounced inhibition of self- and AChE-induced Aβ aggregation. Radioligand binding studies on hCB<sub>2</sub>R showed a lower affinity from the nanomolar range of <b>2</b> to the single-digit micromolar range for the hybrids. Hybrids <b>3e</b> and <b>4c</b>, representative for the two different sets, were investigated by a cAMP-regulated gene expression experiment, which showed they maintained their agonist behavior at the hCB<sub>2</sub>R. To investigate the effectiveness, microglial activity was investigated. Therefore, different M1 and M2 markers were quantified. Despite the significantly lower affinity for the hCB<sub>2</sub>R compared to <b>2</b>, the compounds showed an immunomodulatory effect similar to the parent molecule <b>2</b>. The concept of incorporating a disulfide into the linker to introduce neuroprotection was investigated in a HT22 cell assay. Both tested compounds, <b>8</b> and the sulfur-free analogue <b>3e</b>, showed neuroprotection against glutamate-induced oxidative stress. Due to the promising in vitro profile, several compounds were tested in vivo and showed pronounced effects on short- and long-term memory, proving their ability to cross the BBB. Keeping the hepatotoxicity of <b>1</b> in mind, liver histology of high dose-treated animals (3 mg/kg) was carried out (<a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">Table <a class="ref showTableEvent internalNav" data-ID="tbl2" href="#tbl2">2</a></a>). In first-line experiments, the tested hybrids showed no hepatotoxicity effect, but this must be further investigated. The high in vivo efficacy of the compounds should be emphasized, which is significantly higher in particular for the compounds <b>3e</b> and <b>8</b> (0.1 mg/kg), than for the parent molecules <b>1</b> and <b>2</b>, which were investigated in our previous work.<a onclick="showRef(event, 'ref48 ref87'); return false;" href="javascript:void(0);" class="ref ref48 ref87">(48,87)</a> Due to the significantly lower dosage compared to <b>1</b>, a lower liver-damaging side effect of the novel hybrids in a potential clinical application might be assumed. We consider these data also of interest for other drug discovery efforts with regard to tacrine-containing experimental therapeutics as well as hybrid molecules with higher molar mass aiming at CNS activity.</div><div class="NLM_table-wrap" id="tbl2"><div class="hlFld-FigureCaption"><div class="NLM_caption" id=""><div class="title2">Table 2. Results of the Liver Histology Performed with High Dose (3 mg/kg)-Treated Mice</div></div></div><div class="scrollable-table-wrap"><table class="table "><colgroup><col align="left" /></col><col align="char" char="/" /></col><col align="left" /></col><col align="char" char="−" /></col><col align="char" char="/" /></col><col align="left" /></col><col align="char" char="−" /></col></colgroup><thead><tr valign="top" class="colsep0"><th class="rowsep1 colsep0" colspan="4" align="center">microvesicular steatosis</th><th class="rowsep1 colsep0" colspan="3" align="center" char="/">necrosis</th></tr><tr valign="top" class="colsep0"><th class="colsep0 rowsep0" align="center">treatment</th><th class="colsep0 rowsep0" align="center" char="/">positive/specimen</th><th class="colsep0 rowsep0" align="center">% of specimen</th><th class="colsep0 rowsep0" align="center" char="−">reported area %</th><th class="colsep0 rowsep0" align="center" char="/">positive/specimen</th><th class="colsep0 rowsep0" align="center">% of specimen</th><th class="colsep0 rowsep0" align="center" char="−">reported area %</th></tr></thead><tbody><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">V/V</td><td class="colsep0 rowsep0" align="char" char="/">6/10</td><td class="colsep0 rowsep0" align="left">60</td><td class="colsep0 rowsep0" align="char" char="−">30–40</td><td class="colsep0 rowsep0" align="char" char="/">5/10</td><td class="colsep0 rowsep0" align="left">50</td><td class="colsep0 rowsep0" align="char" char="−">2–30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aß/V</td><td class="colsep0 rowsep0" align="char" char="/">7/10</td><td class="colsep0 rowsep0" align="left">58</td><td class="colsep0 rowsep0" align="char" char="−">10–30</td><td class="colsep0 rowsep0" align="char" char="/">11/12</td><td class="colsep0 rowsep0" align="left">91</td><td class="colsep0 rowsep0" align="char" char="−">1–30</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aß/<b>3a</b> (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="/">8/12</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="char" char="−">5–30</td><td class="colsep0 rowsep0" align="char" char="/">8/12</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="char" char="−">2–50</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aß/<b>3d</b> (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="/">6/6</td><td class="colsep0 rowsep0" align="left">100</td><td class="colsep0 rowsep0" align="char" char="−">3–45</td><td class="colsep0 rowsep0" align="char" char="/">5/6</td><td class="colsep0 rowsep0" align="left">83</td><td class="colsep0 rowsep0" align="char" char="−">5–15</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aß/<b>4a</b> (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="/">2/9</td><td class="colsep0 rowsep0" align="left">22</td><td class="colsep0 rowsep0" align="char" char="−">10–30</td><td class="colsep0 rowsep0" align="char" char="/">6/9</td><td class="colsep0 rowsep0" align="left">66</td><td class="colsep0 rowsep0" align="char" char="−">5–10</td></tr><tr valign="top" class="colsep0"><td class="colsep0 rowsep0" align="left">Aß/<b>8</b> (3 mg/kg)</td><td class="colsep0 rowsep0" align="char" char="/">8/11</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="char" char="−">20–40</td><td class="colsep0 rowsep0" align="char" char="/">8/11</td><td class="colsep0 rowsep0" align="left">72</td><td class="colsep0 rowsep0" align="char" char="−">5–50</td></tr></tbody></table></div></div></div><div id="sec5" class="NLM_sec NLM_sec_level_1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i22">Experimental Section</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_33008" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_33008" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><div id="sec5_1" class="NLM_sec NLM_sec_level_2"><div id="ac_i23" class="anchor-spacer"></div><h3 class="article-section__title" id="_i23"> Chemistry</h3><div id="sec5_1_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i24" class="anchor-spacer"></div><h4 class="article-section__title" id="_i24"> General Information</h4><div id="sec5_1_1_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i25" class="anchor-spacer"></div><h5 class="article-section__title" id="_i25"> Reagents and Solvents</h5><div class="NLM_p last">All reagents were used without further purification and bought from common commercial suppliers. For anhydrous reaction conditions, THF was dried prior to use by refluxing over sodium slices with benzophenone as an indicator under an argon atmosphere.</div></div><div id="sec5_1_1_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i26" class="anchor-spacer"></div><h5 class="article-section__title" id="_i26"> Thin-Layer Chromatography (TLC)</h5><div class="NLM_p last">To monitor reaction progress, thin-layer chromatography (precoated plates with silica gel, from Machery-Nagel: ALUGRAM Xtra SIL G/UV<sub>254</sub>) was carried out. The spots were visualized by UV light (254 and 366 nm), by staining in the iodine chamber, orby using spray reagents (Ehrlich’s reagent: primary amines turn red). The eluent systems are indicated in volume (v) ratios of the respective solvents (v/v).</div></div><div id="sec5_1_1_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i27" class="anchor-spacer"></div><h5 class="article-section__title" id="_i27"> Preparative Thin-Layer Chromatography</h5><div class="NLM_p last">Silica gel (Merck KGaA: Silica gel 60 GF<sub>254</sub>) was mixed with water. Glass plates were coated evenly with the mixture and dried at room temperature. The compound was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and applied to the starting line in small drops. The plate was then transferred to a preparative TLC chamber with the mobile phase. After successful separation, the plate was dried, and the product was detected under UV light (254 and 366 nm), scraped off, and then extracted with MeOH.</div></div><div id="sec5_1_1_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i28" class="anchor-spacer"></div><h5 class="article-section__title" id="_i28"> Column Chromatography</h5><div class="NLM_p last">Silica gel (particle size, 0.063–0.2 mm; Merck) was used for column chromatography. The eluent systems are indicated in volume (v) ratios of the respective solvents (v/v). Column chromatography was also performed using an Interchim Puri Flash 430 (Ultra Performance Flash Purification) instrument (Montluçon, France) connected to an Interchim Flash ELSD. Used columns were Silica 25 g (30 μm) (Interchim, Montluçon, France).</div></div><div id="sec5_1_1_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i29" class="anchor-spacer"></div><h5 class="article-section__title" id="_i29"> Nuclear Magnetic Resonance Spectroscopy (NMR)</h5><div class="NLM_p last">Measurements of NMR spectra were performed on a Bruker Advance 400 (<sup>1</sup>H NMR: 400 MHz; <sup>13</sup>C NMR: 101 MHz). <sup>1</sup>H and <sup>13</sup>C NMR spectra were calibrated with the hydrogen signal of the respective solvent as the internal standard. In this work, CDCl<sub>3</sub>, CD<sub>3</sub>OD, and D<sub>2</sub>O were used as solvents (<sup>1</sup>H: CDCl<sub>3</sub>, 7.26 ppm; <sup>1</sup>H: CD<sub>3</sub>OD, 3.31 ppm; <sup>1</sup>H: D<sub>2</sub>O, 4.79 ppm; <sup>13</sup>C: CDCl<sub>3</sub>, 77.16 ppm; <sup>13</sup>C: CD<sub>3</sub>OD, 49.0 ppm). <i>J</i> is the coupling constant in hertz (s<sup>–1</sup>). The abbreviations of the indicated signal diversities were s = singlet, d = doublet, t = triplet, q = quartet, and m = multiplet.</div></div><div id="sec5_1_1_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i30" class="anchor-spacer"></div><h5 class="article-section__title" id="_i30"> Liquid Chromatography/Mass Spectrometry (LC/MS)</h5><div class="NLM_p">Measurements for verification and purity of the compounds were performed by LC/MS (from Shimadzu), comprising a DGU-20A3R controller, pump LC-20AB, degasser DGU-20A, and SPD-20A UV/Vis detector. ESI ionization was accomplished by an LCMS-2020 single quadrupol mass spectrometer. As a stationary phase, for analytical purpose, a Synergi 4U fusion-RP 80 Å (150 × 4.6 mm) column and for preparative purpose, a Synergi 4U fusion-RP 80 Å (250 × 10.0 mm) were used. As a mobile phase, a gradient of MeOH/water (both containing 0.1% formic acid) (phase A/phase B) was used. The compounds were dissolved in MeOH and filtered through syringe filters.</div><div class="NLM_p">The parameters for the methods are given as follows: flow rate, 1.0 mL/min; UV detection, 254 nm; scan range, 100–800 <i>m</i>/<i>z</i>; gradient: A, H<sub>2</sub>O (0.1% CF<sub>3</sub>COOH) and B, MeOH (0.1% CF<sub>3</sub>COOH); 0–8 min 5% → 90% B, 8–13 min 90% B, 13–14 min 90% → 10% B, and 14–18 min 10% → 5% B.</div><div class="NLM_p last">Compounds were only used for biological evaluation if the purity was ≥95%.</div></div></div><div id="sec5_1_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i31" class="anchor-spacer"></div><h4 class="article-section__title" id="_i31"> General Procedures</h4><div id="sec5_1_2_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i32" class="anchor-spacer"></div><h5 class="article-section__title" id="_i32"> General Procedure I for Nucleophilic Substitution of Aryl Chloride by a Diamine (for Compounds <b>12a</b>–<b>g)</b></h5><div class="NLM_p last">The chloride compound <b>11</b> was dissolved in hexanol, and the corresponding diamine was added. The mixture was stirred for 24 h under reflux conditions under an argon atmosphere. The solvent was evaporated under high vacuum using an evaporator. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and extracted with water. The organic layer was dried over anhydrous MgSO<sub>4</sub>, and the solvent was removed in vacuo.</div></div><div id="sec5_1_2_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i33" class="anchor-spacer"></div><h5 class="article-section__title" id="_i33"> General Procedure II for Aromatic Substitution of Fluoride by Amines (for Compounds <b>17a</b>–<b>f</b> and <b>20</b>)</h5><div class="NLM_p last">The respective fluoride compound and the respective amine were dissolved in THF, and then NEt<sub>3</sub> was added. The mixture was stirred at room temperature overnight. The solvent was then removed in vacuo, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with water. The organic layers were combined and dried over anhydrous MgSO<sub>4</sub>, and the solvent was removed in vacuo.</div></div><div id="sec5_1_2_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i34" class="anchor-spacer"></div><h5 class="article-section__title" id="_i34"> General Procedure III for Reduction of an Aromatic Nitro Moiety with Stannous Chloride Dihydrate (for Compounds <b>18a</b>–<b>f</b>)</h5><div class="NLM_p last">The respective nitro compound was dissolved in ethanol, and SnCl<sub>2</sub>·2H<sub>2</sub>O was added. The mixture was stirred under reflux conditions under an argon atmosphere for 5 h. Then, the mixture was basified with NH<sub>3(aq)</sub> (25%), and the precipitate was filtered off by suction. The filtrate was concentrated in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with 1M NaOH. The organic layers were combined and dried over anhydrous MgSO<sub>4</sub>, and the solvent was removed in vacuo. The product was directly used in the next reaction, without further purification, and just characterized by mass spectrometry.</div></div><div id="sec5_1_2_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i35" class="anchor-spacer"></div><h5 class="article-section__title" id="_i35"> General Procedure IV for Amide Formation with HBTU-Activated Ester (for Compounds <b>19a</b>–<b>f</b> and <b>22</b>)</h5><div class="NLM_p last">The respective acid was dissolved in DMF then NEt<sub>3</sub>, and HBTU was added. This mixture was added to a solution of the respective amine in DMF. The mixture was stirred overnight at room temperature, and the solvent was then removed in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with a saturated NaHCO<sub>3</sub> solution. The organic layers were combined and dried over anhydrous MgSO<sub>4</sub>, and the solvent was removed in vacuo.</div></div><div id="sec5_1_2_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i36" class="anchor-spacer"></div><h5 class="article-section__title" id="_i36"> General Procedure V for Ring Closure to Benzimidazole (for Compounds <b>3a</b>–<b>e</b>, <b>6</b>, and <b>23</b>)</h5><div class="NLM_p last">The respective amide was dissolved in glacial acetic acid. The mixture was stirred depending on the reaction progress for 2–6 h under reflux conditions and was then concentrated in vacuo. The residue was basified with NH<sub>3(aq)</sub> (25%) and extracted with CH<sub>2</sub>Cl<sub>2</sub>. The organic layers were combined, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo.</div></div></div><div id="sec5_1_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i37" class="anchor-spacer"></div><h4 class="article-section__title" id="_i37"> Synthesis</h4><div id="sec5_1_3_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i38" class="anchor-spacer"></div><h5 class="article-section__title" id="_i38"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>3a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide <b>19a</b> (258 mg, 0.43 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>3a</b> (210 mg, 0.36 mmol, 84%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86 (d, <i>J</i> = 8.2 Hz, 1H), 7.70 (s, 1H), 7.57 (d, <i>J</i> = 8.3 Hz, 1H), 7.51–7.45 (m, 1H), 7.24–7.15 (m, 2H), 7.11 (d, <i>J</i> = 8.3 Hz, 1H), 6.90 (d, <i>J</i> = 8.6 Hz, 2H), 6.66–6.61 (m, 2H), 4.13 (t, <i>J</i> = 6.6 Hz, 2H), 4.04 (s, 2H), 3.88 (s, 1H), 3.82 (q, <i>J</i> = 7.0 Hz, 2H), 3.56–3.23 (m, 6H), 2.96 (t, <i>J</i> = 6.4 Hz, 2H), 2.31 (t, <i>J</i> = 6.3 Hz, 2H), 1.83–1.75 (m, 2H), 1.74–1.66 (m, 2H), 1.27 (t, <i>J</i> = 7.0 Hz, 3H), 1.15 (s, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.7, 158.8, 158.2, 154.9, 149.2, 147.2, 142.2, 135.9, 131.6, 129.4, 128.9, 128.7, 127.7, 124.6, 122.0, 121.7, 120.6, 118.0, 117.9, 114.9, 109.5, 63.5, 47.3, 44.5, 34.0, 33.8, 24.8, 22.9, 22.7, 14.9, 14.2 ppm. ESI: <i>m/z</i> calcd for C<sub>36</sub>H<sub>42</sub>N<sub>5</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 576.33; found, 576.25; retention time, 7.90 min; HPLC purity, 97%.</div></div><div id="sec5_1_3_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i39" class="anchor-spacer"></div><h5 class="article-section__title" id="_i39"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>3b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide <b>19b</b> (104 mg, 0.17 mmol). The crude product was purified by preparative thin-layer chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>3b</b> (23 mg, 39.0 μmol, 23%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.16 (d, <i>J</i> = 7.8 Hz, 1H), 8.06 (d, <i>J</i> = 8.0 Hz, 1H), 7.74 (s, 1H), 7.56–7.49 (m, 2H), 7.27–7.22 (m, 2H),7.15 (d, <i>J</i> = 7.9 Hz, 2H), 6.62 (d, <i>J</i> = 8.3 Hz, 2H), 4.43 (s, 2H), 4.00–3.92 (m, 2H), 3.77 (q, <i>J</i> = 6.9 Hz, 2H), 3.57–3.48 (m, 2H), 3.40–3.13 (m, 4H), 3.08–3.03 (m, 2H), 2.59–2.51 (m, 2H), 2.20–2.12 (m, 2H), 1.75–1.71 (m, 4H), 1.29–1.17 (m, 8H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.0, 158.4, 156.7, 154.2, 151.0, 145.9, 142.3, 134.2, 132.2, 129.8, 128.4, 128.1, 127.5, 124.5, 122.4, 121.8, 119.7, 117.7, 115.9, 115.0, 111.7, 63.5, 46.0, 42.8, 33.9, 32.0, 29.8, 24.8, 22.4, 22.1, 14.9, 14.2 ppm. ESI: <i>m/z</i> calcd for C<sub>37</sub>H<sub>45</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 295.68; found, 295.60; retention time, 7.82 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i40" class="anchor-spacer"></div><h5 class="article-section__title" id="_i40"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>3c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide <b>19c</b> (166 mg, 0.27 mmol). The crude product was purified by column chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>3c</b> (46 mg, 76.2 μmol, 28%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.90 (d, <i>J</i> = 8.3 Hz, 1H), 7.82 (d, <i>J</i> = 8.3 Hz, 1H), 7.75 (s, 1H), 7.55 (t, <i>J</i> = 11.1, 4.0 Hz, 1H), 7.34 (t, <i>J</i> = 7.3 Hz, 1H), 7.29–7.26 (m, 1H), 7.18 (d, <i>J</i> = 8.3 Hz, 1H), 7.09 (d, <i>J</i> = 8.6 Hz, 2H), 6.76 (d, <i>J</i> = 8.6 Hz, 2H), 4.20 (s, 2H), 3.97 (t, <i>J</i> = 7.1 Hz, 2H), 3.87 (q, <i>J</i> = 7.0 Hz, 2H), 3.64–3.36 (m, 4H), 3.30 (t, <i>J</i> = 6.7 Hz, 2H), 3.05 (t, <i>J</i> = 5.8 Hz, 2H), 2.62 (t, <i>J</i> = 5.7 Hz, 2H), 1.92–1.83 (m, 4H), 1.61–1.49 (m, 4H), 1.30 (t, <i>J</i> = 7.0 Hz, 3H), 1.26–1.19 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.8, 158.7, 157.2, 154.5, 150.3, 147.5, 142.2, 135.9, 131.3, 129.5, 128.9, 128.5, 127.9, 124.1, 122.5, 121.5, 120.6, 117.8, 116.9, 115.9, 109.5, 63.5, 48.7, 43.9, 33.9, 29.8, 28.9, 27.0, 25.0, 23.1, 22.9, 14.8, 14.2 ppm. ESI: <i>m/z</i> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 302.69; found, 302.65; retention time, 7.92 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i41" class="anchor-spacer"></div><h5 class="article-section__title" id="_i41"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>3d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide <b>19d</b> (346 mg, 0.47 mmol). The crude product was purified by column chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>3d</b> (22 mg, 35.6 μmol, 51%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.05–7.98 (m, 2H), 7.72 (s, 1H), 7.56 (t, <i>J</i> = 7.6 Hz, 1H), 7.33 (t, <i>J</i> = 7.7 Hz, 1H), 7.25–7.19 (m, 2H), 7.11 (d, <i>J</i> = 8.5 Hz, 2H), 6.78 (d, <i>J</i> = 8.5 Hz, 2H), 4.22 (s, 2H), 3.98 (t, <i>J</i> = 7.2 Hz, 2H), 3.92 (q, <i>J</i> = 7.0 Hz, 2H), 3.61 (t, <i>J</i> = 7.1 Hz, 2H), 3.56–3.32 (m, 4H), 3.06–3.01 (m, 2H), 2.55–2.49 (m, 2H), 1.83–1.75 (m, 4H), 1.67–1.52 (m, 4H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.28–1.13 (m, 8H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.0, 158.2, 154.7, 154.7, 153.4, 142.1, 141.1, 135.9, 131.1, 131.1, 129.6, 128.0, 124.7, 123.9, 122.7, 121.4, 117.6, 117.3, 115.0, 112.4, 109.7, 63.6, 48.1, 44.0, 33.8, 31.1, 26.7, 29.2, 24.5, 24.2, 22.3, 21.3, 14.8, 14.1 ppm. ESI: <i>m/z</i> calcd for C<sub>39</sub>H<sub>49</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 309.70; found, 309.65; retention time, 8.07 min; HPLC purity, 99%.</div></div><div id="sec5_1_3_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i42" class="anchor-spacer"></div><h5 class="article-section__title" id="_i42"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>3e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide <b>19e</b> (142 mg, 0.22 mmol). The crude product was purified by preparative thin-layer chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>3e</b> (70 mg, 0.11 mmol, 50%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.96–7.90 (m, 2H), 7.75 (s, 1H), 7.55 (t, <i>J</i> = 8.1, Hz, 1H), 7.33 (t, <i>J</i> = 9.2 Hz 1H), 7.30–7.27 (m, 1H), 7.25–7.22 (m, 1H), 7.11 (d, <i>J</i> = 8.6 Hz, 2H), 6.79 (d, <i>J</i> = 8.6 Hz, 2H), 4.23 (s, 2H), 3.98–3.90 (m, 4H), 3.61–3.33 (m, 6H), 3.09–3.03 (m, 2H), 2.70–2.64 (m, 2H), 1.92–1.86 (m, 4H), 1.59–1.47 (m, 4H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H), 1.30–1.13 (m, 10H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.9, 158.2, 154.5, 151.1, 146.9, 142.19, 136.0, 131.2, 129.6, 128.7, 128.3, 128.1, 125.4, 123.9, 122.9, 121.5, 120.1, 117.7, 155.8, 115.0, 109.6, 63.6, 49.3, 44.1, 33.9, 33.7, 31.6, 29.5, 26.8, 26.7, 24.9, 23.1, 22.7, 14.9, 14.3 ppm. ESI: <i>m/z</i> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 316.70; found, 316.90; retention time, 8.27 min; HPLC purity, 95%.</div></div><div id="sec5_1_3_6" class="NLM_sec NLM_sec_level_4"><div id="ac_i43" class="anchor-spacer"></div><h5 class="article-section__title" id="_i43"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>4a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (271 mg, 0.74 mmol), <i>N</i><sup>1</sup>-(1,2,3,4-tetrahydroacridin-9-yl)ethane-1,2-diamine <b>12a</b> (179 mg, 0.74 mmol), HBTU (281 mg, 0.74 mmol), and NEt<sub>3</sub> (145 μL, 1.05 mmol). The crude product was purified by preparative thin-layer chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>4a</b> (35.0 mg, 59.3 μmol, 8%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.24 (s, 1H), 8.13 (d, <i>J</i> = 8.7 Hz, 1H), 7.84 (d, <i>J</i> = 8.5 Hz, 1H), 7.62 (d, <i>J</i> = 8.6 Hz, 1H), 7.44 (t, <i>J</i> = 7.7 Hz, 1H), 7.34 (d, <i>J</i> = 8.5 Hz, 1H), 7.30–7.24 (m, 2H), 7.06 (d, <i>J</i> = 8.4 Hz, 2H), 6.70 (d, <i>J</i> = 8.4 Hz, 2H), 4.21 (s, 2H), 4.04–3.99 (m, 4H), 3.92–3.83 (m, 4H), 2.83–2.79 (m, 2H), 2.69–2.62 (m, 2H), 1.85–1.71 (m, <i>J</i> = 25.6, 5.6 Hz, 4H), 1.63–1.52 (m, 1H), 1.44–1.39 (m, 2H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 0.90 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.8, 158.2, 155.3, 155.0, 152.3, 147.8, 142.1, 138.0, 130.6, 129.7, 128.5, 127.5, 125.5, 124.7, 122.1, 120.0, 118.7, 117.1, 115.1, 114.9, 109.8, 63.6, 44.7, 42.5, 40.6, 38.3, 33.7, 31.5, 29.8, 26.3, 24.2, 22.5, 21.3, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>37</sub>H<sub>45</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>: 295.68; found: 295.75; retention time: 8.96 min; HPLC purity, 96%.</div></div><div id="sec5_1_3_7" class="NLM_sec NLM_sec_level_4"><div id="ac_i44" class="anchor-spacer"></div><h5 class="article-section__title" id="_i44"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>4b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (370 mg, 1.01 mmol), <i>N</i><sup>1</sup>-(1,2,3,4-tetrahydroacridin-9-yl)propane-1,3-diamine <b>12b</b> (200 mg, 0.78 mmol), HBTU (326 mg, 1.33 mmol), and NEt<sub>3</sub> (184 μL, 1.33 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>4b</b> (67.0 mg, 0.11 mmol, 14%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.37 (s, 1H), 8.24 (d, <i>J</i> = 8.7 Hz, 1H), 8.20 (d, <i>J</i> = 8.4 Hz, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 1H), 7.54 (t, <i>J</i> = 7.7 Hz, 1H), 7.35 (t, <i>J</i> = 7.8 Hz, 1H), 7.25 (d, <i>J</i> = 10.0 Hz, 1H), 7.08 (d, <i>J</i> = 8.4 Hz, 2H), 6.76 (d, <i>J</i> = 8.4 Hz, 2H), 4.19 (s, 2H), 3.97–3.88 (m, 6H), 3.71–3.65 (m, 2H), 3.14–3.09 (m, 2H), 2.75 (t, <i>J</i> = 5.8 Hz, 2H), 2.07–2.00 (m, 2H), 1.85–1.74 (m, 4H), 1.57–1.48 (m, 1H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.33–1.24 (m, 2H), 0.87 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.4, 158.2, 155.5, 155.0, 152.0, 148.3, 142.3, 137.7, 131.6 129.6, 128.1, 127.8, 125.0, 124.2, 122.2, 119.1, 117.8, 116.6, 115.6, 114.9, 109.4, 63.6, 44.3, 42.8, 38.2, 36.2, 36.7, 33.8, 31.2, 29.3, 26.2, 24.6, 22.5, 21.1, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>38</sub>H<sub>47</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 302.69; found, 302.75; retention time, 8.82 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_8" class="NLM_sec NLM_sec_level_4"><div id="ac_i45" class="anchor-spacer"></div><h5 class="article-section__title" id="_i45"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>4c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (286 mg, 0.78 mmol), <i>N</i><sup>1</sup>-(1,2,3,4-tetrahydroacridin-9-yl)butane-1,4-diamine <b>12c</b> (161 mg, 0.60 mmol), HBTU (250 mg, 0.66 mmol), and NEt<sub>3</sub> (141 μL, 1.02 mmol). The crude product was purified by preparative thin-layer chromatography (10:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>4c</b> (38.0 mg, 0.62 mmol, 10%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.26 (s, 1H), 8.18 (d, <i>J</i> = 8.7 Hz, 1H), 8.07 (d, <i>J</i> = 8.4 Hz, 1H), 7.86 (d, <i>J</i> = 8.5, 1H), 7.51 (t, <i>J</i> = 7.6, 1H), 7.32 (t, <i>J</i> = 7.6 Hz, 1H), 7.23 (d, <i>J</i> = 8.5 Hz, 1H), 7.06 (d, <i>J</i> = 8.6 Hz, 2H), 6.72 (d, <i>J</i> = 8.4 Hz, 2H), 4.18 (s, 2H), 3.96–3.88 (m, 6H), 3.56–3.49 (m, 2H), 3.03 (t, <i>J</i> = 5.9 Hz, 2H), 2.60 (t, <i>J</i> = 5.7 Hz, 2H), 1.96–1.88 (m, 2H), 1.81–1.70 (m, 6H), 1.56–1.48 (m, 1H), 1.34 (t, <i>J</i> = 7.0 Hz, 3H), 1.31–1.23 (m, 2H), 0.86 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.4, 158.2, 155.8, 154.9, 153.2, 142.9, 142.1, 137.5, 132.2, 129.6, 128.6, 127.7, 125.1, 124.7, 122.1, 120.5, 118.6, 116.5, 116.0, 114.9, 109.4, 63.6, 47.9, 42.8, 39.3, 38.3, 33.7, 29.8, 28.6, 28.1, 26.8, 26.2, 23.9, 22.4, 20.8, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>39</sub>H<sub>49</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 309.70; found, 309.70; retention time, 8.77 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_9" class="NLM_sec NLM_sec_level_4"><div id="ac_i46" class="anchor-spacer"></div><h5 class="article-section__title" id="_i46"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>4d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (286 mg, 0.78 mmol), <i>N</i><sup>1</sup>-(1,2,3,4-tetrahydroacridin-9-yl)pentane-1,5-diamine <b>12d</b> (170 mg, 0.60 mmol), HBTU (250 mg, 0.66 mmol), and NEt<sub>3</sub> (141 μL, 1.02 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>4d</b> (57.0 mg, 0.32 mmol, 15%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.15 (d, <i>J</i> = 8.7 Hz, 1H), 8.04 (s, 1H), 7.85 (d, <i>J</i> = 8.5, 1H), 7.82–7.77 (m, 1H), 7.60 (t, <i>J</i> = 7.3 Hz, 1H), 7.40–7.34 (m, 2H), 7.08 (d, <i>J</i> = 8.1 Hz, 2H), 6.67 (d, <i>J</i> = 7.0 Hz, 2H), 4.28 (s, 2H), 4.10–4.04 (m, 2H), 3.91–3.84 (m, 4H), 3.49–3.45 (m, 2H), 2.89–2.85 (m, 2H), 2.43–2.38 (m, 2H), 1.90–1.85 (m, 2H), 1.65–1.58 (m, 2H), 1.60–1.56 (m, 4H), 1.46–1.43 (m, 1H), 1.32 (t, <i>J</i> = 7.0 Hz, 4H), 1.26–1.25 (m, 5H), 0.94 (d, <i>J</i> = 6.8 Hz, 6H) ppm.<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.5, 158.2, 155.5, 154.2, 153.6, 143.3, 142.3, 137.4, 130.7, 129.8, 128.5, 127.4, 125.2, 124.2, 122.5, 119.7, 118.0, 117.3, 115.8, 114.9, 109.9, 63.6, 47.5, 43.0, 39.2, 38.3, 33.1, 29.8, 29.0, 28.2, 27.9, 26.8, 26.3, 23.6, 22.5, 20.4, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 316.70; found, 316.75; retention time, 8.82 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_10" class="NLM_sec NLM_sec_level_4"><div id="ac_i47" class="anchor-spacer"></div><h5 class="article-section__title" id="_i47"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>4e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (114 mg, 0.31 mmol), <i>N</i><sup>1</sup>-(1,2,3,4-tetrahydroacridin-9-yl)hexane-1,6-diamine <b>12e</b> (92.2 mg, 0.31 mmol), HBTU (118 mg, 0.31 mmol), and NEt<sub>3</sub> (65.1 μL, 0.47 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>4e</b> (40.0 mg, 61.9 μmol, 20%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.11 (s, 1H), 8.05 (d, <i>J</i> = 8.2 Hz, 1H), 7.78–7.75 (m, 2H), 7.55–7.50 (m, 1H), 7.37–7.32 (m, 1H), 7.29–7.26 (m, 1H), 7.08 (d, <i>J</i> = 8.8 Hz, 2H), 6.74 (d, <i>J</i> = 8.8 Hz, 2H), 4.21 (s, 2H), 4.02–3.86 (m, 6H), 3.64 (t, <i>J</i> = 6.6 Hz, 2H), 3.47–3.40 (m, 2H), 2.62 (t, <i>J</i> = 5.7 Hz, 2H), 1.87–1.80 (m, 4H), 1.75–1.68 (m, 2H), 1.65–1.59 (m, 2H), 1.56–1.51 (m, 1H), 1.42–1.32 (m, 9H), 0.88 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.3, 158.2, 155.2, 154.7, 153.4, 143.3, 142.2, 137.5, 130.5, 129.6, 128.9, 127.7, 124.4, 124.0, 122.0, 118,1, 118.0, 117,0, 115,1, 114,9, 109.6, 63.6, 48.9, 42.8, 42.5, 39.9, 38.2, 36.6, 33.8, 31.3, 31.1, 29.5, 26.4, 26.2, 24.1, 22.4, 21.8, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>41</sub>H<sub>53</sub>N<sub>5</sub>O<sub>2</sub> [M + 2H]<sup>2+</sup>, 323.71; found, 323.80; retention time, 8.94 min; HPLC purity, 95%.</div></div><div id="sec5_1_3_11" class="NLM_sec NLM_sec_level_4"><div id="ac_i48" class="anchor-spacer"></div><h5 class="article-section__title" id="_i48"> 2-(4-Ethoxybenzyl)-<i>N</i>-ethyl-1-isopentyl-<i>N</i>-(4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>5</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (23.7 mg, 64.6 μmol), <i>N</i><sup>1</sup>-ethyl-<i>N</i><sup>4</sup>-(1,2,3,4-tetrahydroacridin-9-yl)butane-1,4-diamine <b>14</b> (16.0 mg, 53.8 μmol), HBTU (24.5 mg, 64.6 μmol), and NEt<sub>3</sub> (14.9 μL, 0.11 mmol). The solvent was removed in vacuo, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with NaHCO<sub>3(aq)</sub>. The crude product was purified by preparative TLC (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)). The product <b>5</b> (21 mg, 32.5 μmol, 60%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.89 (d, <i>J</i> = 8.1 Hz, 1H), 7.75–7.73 (s, 1H), 7.56–7.51 (m, 1H), 7.36–7.30 (m, 1H), 7.27–7.23 (m, 3H), 7.14 (d, <i>J</i> = 8.6 Hz, 2H), 6.82 (d, <i>J</i> = 8.6 Hz, 2H), 4.24 (s, 2H), 4.02–3.95 (m, 4H), 3.58–3.42 (m, 4H), 3.08–3.03 (m, 2H), 2.77–2.69 (m, 2H), 1.94–1.88 (m, 4H), 1.83–1.65 (m, 6H), 1.59–1.51 (m, 1H), 1.41–1.35 (m, 6H), 1.29–1.23 (m, 2H), 0.90 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.4, 158.2, 155.4, 154.8, 153.7, 142.2, 142.2, 137.5, 130.5, 129.6, 128.9, 127.9, 125.0, 124.0, 121.3, 119.9, 117.8, 116.9, 115.2, 115.0, 109.7, 63.6, 52.4, 48.0, 44.1, 42.8, 41.1, 38.3, 33.9, 30.5, 28.3, 26.3, 24.2, 22.5, 22.3, 21.2, 14.9, 14.2. ppm. ESI: <i>m/z</i> calcd for C<sub>41</sub>H<sub>52</sub>N<sub>5</sub>O<sub>2</sub> [M + 1H]<sup>1+</sup>, 646.41; found, 646.25; retention time 8.94 min; HPLC purity, 99%<i>.</i></div></div><div id="sec5_1_3_12" class="NLM_sec NLM_sec_level_4"><div id="ac_i49" class="anchor-spacer"></div><h5 class="article-section__title" id="_i49"> 2-(4-Ethoxybenzyl)-<i>N</i>,<i>N</i>-diethyl-1-(2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>6</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3-(2-(4-ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide <b>19f</b> (398 mg, 0.58 mmol). The crude product was purified by column chromatography (CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%) 16:1:0.1), and product <b>6</b> (220 mg, 33.1 mmol, 57%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.95–7.89 (m, 2H), 7.68 (s, 1H), 7.50 (t, <i>J</i> = 6.9 Hz, 1H), 7.31–7.27 (m, 1H), 7.22 (d, <i>J</i> = 8.3, 1H), 7.07 (d, <i>J</i> = 8.4 Hz, 2H), 6.73 (d, <i>J</i> = 8.4 Hz, 2H), 4.25 (s, 2H), 4.13 (t, <i>J</i> = 5.4 Hz, 2H), 3.90 (q, <i>J</i> = 7.0 Hz, 2H), 3.58 (t, <i>J</i> = 5.1 Hz, 2H), 3.51 (t, <i>J</i> = 5.4 Hz, 2H), 3.46–3.41 (m, 4H), 3.54–3.32 (m, 4H), 3.39–3.35 (m, 2H), 3.02 (t, <i>J</i> = 6.0 Hz, 2H), 2.62 (t, <i>J</i> = 5.9 Hz, 2H), 1.86–1.75 (m, 4H), 1.31 (t, <i>J</i> = 7.0 Hz, 3H), 1.21–1.06 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.7, 158.0, 157.1, 155.3, 151.6, 145.5, 142.0, 135.1, 131.1, 129.5, 129.1, 127.9, 126.9, 124.1, 123.0, 122.2, 119.7, 117.4, 116.4, 114.8, 109.8, 70.8, 70.3, 69.4, 63.4, 48.2, 47.9, 44.1, 33.5, 32.6, 24.4, 22.7, 22.3, 14.8, 14.1 ppm. ESI: <i>m/z</i> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>5</sub>O<sub>4</sub> [M + 2H]<sup>2+</sup>, 332.70; found, 332.70; retention time, 7.89 min; HPLC purity, 99%.</div></div><div id="sec5_1_3_13" class="NLM_sec NLM_sec_level_4"><div id="ac_i50" class="anchor-spacer"></div><h5 class="article-section__title" id="_i50"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>7</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (40 mg, 0.11 mmol), <i>N</i>-(2-(2-(2-aminoethoxy)ethoxy)ethyl)-1,2,3,4-tetrahydroacridin-9-amine <b>12f</b> (36.2 mg, 0.11 mmol), HBTU (41.7 mg, 0.11 mmol), and NEt<sub>3</sub> (23.6 μL, 0.17 mmol). The crude product was purified by column chromatography (16:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>7</b> (33.0 mg 48.7 μmol, 44%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.08 (s, 1H), 8.00 (d, <i>J</i> = 8.1 Hz, 1H), 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.72 (d, <i>J</i> = 8.5, 1H), 7.56–7.52 (m, 1H), 7.32 (t, <i>J</i> = 8.0, 1H), 7.15 (d, <i>J</i> = 8.5 Hz, 1H), 7.08 (d, <i>J</i> = 8.6 Hz, 2H), 6.76 (d, <i>J</i> = 8.7 Hz, 2H), 4.17 (s, 2H), 3.95–3.90 (m, 4H), 3.85–3.81 (m, 2H), 3.72–3.67 (m, 10H), 3.02–2.98 (m, 2H), 2.58 (t, <i>J</i> = 7.8 Hz, 2H), 1.85–1.78 (m, 4H), 1.56–1.49 (m, 1H), 1.35 (t, <i>J</i> = 7.0 Hz, 3H), 1.30–1.27 (m, 2H), 0.86 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.0, 158.2, 155.2, 154.95, 153.3, 143.0, 142.1, 137.5, 130.5, 129.7, 128.5, 127.7, 124.6, 123.7, 122.1, 118.4, 117.9, 117.0, 114.7, 114.9, 109.5, 70.4, 70.3, 70.0, 69.9, 63.6, 48.1, 42.8, 39.8, 38.2, 33.8, 31.2, 29.8, 26.2, 23.9, 22.4, 21.8, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>41</sub>H<sub>53</sub>N<sub>5</sub>O<sub>4</sub> [M + 2H]<sup>2+</sup>, 339.80; found, 339.70; retention time, 8.75 min; HPLC purity, 98%.</div></div><div id="sec5_1_3_14" class="NLM_sec NLM_sec_level_4"><div id="ac_i51" class="anchor-spacer"></div><h5 class="article-section__title" id="_i51"> 2-(4-Ethoxybenzyl)-1-isopentyl-<i>N</i>-(2-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)disulfaneyl)ethyl)-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxamide (<b>8</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic acid <b>24</b> (48 mg, 0.13 mmol), <i>N</i>-(2-((2-aminoethyl)disulfaneyl)ethyl)-1,2,3,4-tetrahydroacridin-9-amine (35 mg, 0.11 mmol), HBTU (49 mg, 0.13 mmol), and NEt<sub>3</sub> (26 μL, 0.19 mmol). The crude product was purified by preparative thin-layer chromatography (18:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>8</b> (35 mg, 51.4 μmol, 47%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 8.15 (d, <i>J</i> = 1.3 Hz, 1H), 8.00–7.96 (m, 1H), 7.84 (dd, <i>J</i> = 8.5, 0.8 Hz, 1H), 7.77 (dd, <i>J</i> = 8.5, 1.6 Hz, 1H), 7.53–7.50 (m, 1H), 7.35–7.32 (m, 1H), 7.29–7.25 (m, 1H), 7.13–7.08 (m, 2H), 6.86 (t, <i>J</i> = 5.8 Hz, 1H), 6.80–6.76 (m, 2H), 4.23 (s, 2H), 4.01–3.92 (m, 4H), 3.89–3.82 (m, 2H), 3.75 (q, <i>J</i> = 6.3 Hz, 2H), 3.04–2.96 (m, 2H), 2.95–2.86 (m, 4H), 2.71 (s, 2H), 1.86 (t, <i>J</i> = 2.8 Hz, 4H), 1.62–1.50 (m, 1H), 1.42–1.33 (m, 5H), 0.88 (d, <i>J</i> = 5.3 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.3, 158.2, 157.4, 155.3, 151.2, 145.8, 142.3, 137.7, 129.6, 129.4, 128.4, 127.7, 127.1, 124.4, 123.1, 122.1, 119.9, 118.2, 116.6, 115.0, 109.6, 63.6, 46.9, 42.9, 39.0, 38.9, 38.2, 37.9, 33.8, 33.0, 26.3, 24.8, 22.8, 22.5, 14.9 ppm. ESI: <i>m/z</i> calcd for C<sub>39</sub>H<sub>49</sub>N<sub>5</sub>O<sub>2</sub>S<sub>2</sub> [M + 2H]<sup>2+</sup>, 341.66; found, 341.70; retention time, 9.38 min; HPLC purity, 96%.</div></div><div id="sec5_1_3_15" class="NLM_sec NLM_sec_level_4"><div id="ac_i52" class="anchor-spacer"></div><h5 class="article-section__title" id="_i52"> 9-Chloro-1,2,3,4-tetrahydroacridine (<b>11</b>)</h5><div class="NLM_p last">2-Aminobenzoic acid <b>9</b> (1.00 g, 7.29 mmol) and cyclohexanone <b>10</b> (883 μL, 8.53 mmol) were combined in a flask and cooled down to 0 °C. Then, POCl<sub>3</sub> (8.00 mL) was slowly added. Afterward, the mixture was stirred for 3 h under reflux conditions and then concentrated to a slurry in vacuo. The slurry was dissolved in ethyl acetate and neutralized with aqueous sodium hydroxide. The mixture was extracted with ethyl acetate. The organic layers were combined and dried over anhydrous MgSO<sub>4</sub>, and the solvent was removed in vacuo. The crude product was purified by recrystallization from acetone. The product <b>11</b> (988 mg, 4.54 mmol, 62%) was obtained as a brown solid. mp = 66 °C<i>.</i><sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.17 (d, <i>J</i> = 8.4, 1H), 7.98 (d, <i>J</i> = 8.5 Hz, 1H), 7.69–7.63 (m, 1H), 7.56–7.50 (m, 1H), 3.13 (t, <i>J</i> = 5.6 Hz, 2H), 3.03 (t, <i>J</i> = 6.4 Hz, 2H), 1.97–1.93 (m, 4H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 159.4, 146.2, 141.8, 129.4, 128.9, 128.3, 126.6, 125.4, 123.7, 33.9, 27.5, 22.6, 21.5 ppm. ESI: <i>m/z</i> calcd for C<sub>13</sub>H<sub>13</sub>ClN [M + H]<sup>+</sup>, 218.07; found, 218.00; retention time, 9.97 min.</div></div><div id="sec5_1_3_16" class="NLM_sec NLM_sec_level_4"><div id="ac_i53" class="anchor-spacer"></div><h5 class="article-section__title" id="_i53"> <i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)ethane-1,2-diamine (<b>12a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (800 mg, 3.67 mmol) and ethane-1,2-diamine (1.23 mL, 18.35 mmol). The product <b>12a</b> (557 mg, 2.31 mmol, 63%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.85 (d, <i>J</i> = 8.5 Hz, 1H), 7.48 (t, <i>J</i> = 10.0, 5.1 Hz, 1H), 7.26 (t, 1H), 4.75 (s, 1H), 3.43–3.36 (m, 2H), 3.03–2.97 (m, 2H), 2.89–2.81 (m, 2H), 2.72–2.65 (m, 2H), 1.86–1.80 (m, 4H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 157.5, 149.9, 146.4, 127.7, 127.2, 122.6, 121.8, 119.5, 115.5, 50.0, 41.4, 33.0, 23.8, 22.0, 21.8 ppm. ESI: <i>m/z</i> calcd for C<sub>15</sub>H<sub>20</sub>N<sub>3</sub> [M + H]<sup>+</sup>, 242.17; found, 242.10; retention time, 4.09 min.</div></div><div id="sec5_1_3_17" class="NLM_sec NLM_sec_level_4"><div id="ac_i54" class="anchor-spacer"></div><h5 class="article-section__title" id="_i54"> <i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)propane-1,3-diamine (<b>12b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (600 mg, 2.76 mmol) and propane-1,3-diamine (1.15 mL, 13.8 mmol). The product <b>12b</b> (530 mg, 1.97 mmol, 80%) was obtained as a brown oil (417 mg, 1.63 mmol, 59%). <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.87 (m, 1H), 7.83–7.79 (m, 1H), 7.46–7.39 (m, 1H), 7.24–7.19 (1 H), 3.48 (t, <i>J</i> = 6.7 Hz, 2H), 3.01 (t, <i>J</i> = 6.1 Hz, 2H), 2.89 (t, <i>J</i> = 6.2 Hz, 2H), 2.60 (t, <i>J</i> = 5.9 Hz, 2H), 1.85–1.76 (m, 4H), 1.85–1.76 (m, 2H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 157.3, 149.9, 146.3, 127.6, 127.2, 122.6, 121.9, 119.1, 114.8, 47.0, 39.4, 33.1, 26.4, 24.1, 22.1, 21.8 ppm. ESI: <i>m/z</i> calcd for C<sub>16</sub>H<sub>22</sub>N<sub>3</sub> [M + H]<sup>+</sup>, 256.18; found, 256.10; retention time, 4.26 min.</div></div><div id="sec5_1_3_18" class="NLM_sec NLM_sec_level_4"><div id="ac_i55" class="anchor-spacer"></div><h5 class="article-section__title" id="_i55"> <i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)butane-1,4-diamine (<b>12c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (535 mg, 2.45 mmol) and butane-1,4-diamine (1.08 g, 12.3 mmol). The product <b>12c</b> (530 mg, 1.97 mmol, 80%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.99–7.92 (m, 2H), 7.57–7.52 (m, 1H), 7.36–7.31 (m, 1H), 3.53 (t, <i>J</i> = 7.1 Hz, 2H), 3.07 (t, <i>J</i> = 6.3 Hz, 2H), 2.76 (t, <i>J</i> = 6.9 Hz, 2H), 2.71 (t, <i>J</i> = 6.2 Hz, 2H), 1.93–1.88 (m, 4H), 1.76–1.68 (m, 2H), 1.61–1.52 (m, 2H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 157.9, 151.1, 146.7, 128.6, 128.1, 123.7, 122.9, 119.9, 115.6, 49.29, 41.72, 33.56, 30.76, 29.06, 24.82, 22.98, 22.61 ppm. ESI: <i>m/z</i> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub> [M + H]<sup>+</sup>, 270.20; found, 270.10; retention time, 4.26 min.</div></div><div id="sec5_1_3_19" class="NLM_sec NLM_sec_level_4"><div id="ac_i56" class="anchor-spacer"></div><h5 class="article-section__title" id="_i56"> <i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)pentane-1,5-diamine (<b>12d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (600 mg, 2.76 mmol) and pentane-1,5-diamine (1.62 mL, 13.8 mmol). The product <b>12d</b> (427 mg, 1.51 mmol, 55%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.09 (d, <i>J</i> = 8.4 Hz, 1H), 7.91–7.86 (m, 1H), 7.62–7.56 (m, 1H), 7.30–7.24 (m, 1H), 3.41 (t, <i>J</i> = 7.0 Hz, 2H), 3.07–3.03 (m, 2H), 3.02–2.98 (m, 2H), 2.96–2.89 (m, 2H), 2.66–2.60 (m, 4H), 1.62–1.39 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.5, 150.6, 146.6, 128.6, 128.2, 123.5, 122.7, 120.3, 115.9, 49.3, 41.9, 33.2, 32.8, 31.7, 27.4, 24.8, 23.0, 22.6 ppm. ESI: <i>m/z</i> calcd for C<sub>18</sub>H<sub>26</sub>N<sub>3</sub> [M + H]<sup>+</sup>, 284.21; found, 284.15; retention time, 4.66 min.</div></div><div id="sec5_1_3_20" class="NLM_sec NLM_sec_level_4"><div id="ac_i57" class="anchor-spacer"></div><h5 class="article-section__title" id="_i57"> <i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)hexane-1,6-diamine (<b>12e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (500 mg, 2.30 mmol) and hexane-1,6-diamine (1.50 mL, 11.5 mmol). The product <b>12e</b> was obtained as a brown oil (343 mg, 1.15 mmol, 50%).<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.94 (d, <i>J</i> = 8.4 Hz, 1H), 7.89 (d, <i>J</i> = 8.4 Hz, 1H), 7.53 (t, <i>J</i> = 6.8 Hz, 1H), 7.32 (t, <i>J</i> = 6.8 Hz, 1H), 3.47 (t, <i>J</i> = 7.2 Hz, 2H), 3.04 (t, <i>J</i> = 6.5 Hz, 2H), 2.72–2.65 (m, 4H), 1.92–1.88 (m, 4H), 1.69–1.60 (m, 2H), 1.46–1.35 (m, 6H) ppm.<sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.8, 151.0, 147.74, 129.0, 128.8, 124.1, 123.3, 120.6, 116.2, 49.9, 42.5, 34.4, 34.0, 32.2, 27.3, 27.1, 25.2, 23.4, 23.2 ppm. ESI: <i>m/z</i> calcd for C<sub>19</sub>H<sub>28</sub>N<sub>3</sub> [M + 2H]<sup>2+</sup>, 149.62; found, 149.65; retention time, 5.38 min.</div></div><div id="sec5_1_3_21" class="NLM_sec NLM_sec_level_4"><div id="ac_i58" class="anchor-spacer"></div><h5 class="article-section__title" id="_i58"> <i>N</i>-(2-(2-(2-Aminoethoxy)ethoxy)ethyl)-1,2,3,4-tetrahydroacridin-9-amine (<b>12f</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure I using 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (600 mg, 2.76 mg) and 2,2′-(ethane-1,2-diylbis(oxy))bis(ethan-1-amine) (2.00 mL, 13.8 mmol). The product <b>12f</b> (864 mg, 2.62 mmol, 95%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ = 7.95 (d, <i>J</i> = 8.5 Hz, 1H), 7.89 (d, <i>J</i> = 8.5 Hz, 1H), 7.58–7.59 (m, 1H), 7.37–75.30 (m, 1H), 3.67–3.56 (m, 8H), 3.50 (t, <i>J</i> = 5.2 Hz, 2H), 3.05 (t, <i>J</i> = 6.0 Hz, 2H), 2.88–2.84 (m, 2H), 2.76 (t, <i>J</i> = 5.7 Hz, 2H), 1.94–1.86 (m, 4H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 158.7, 150.4, 147.5, 128.8, 128.2, 123.8, 122.7, 120.8, 117.5, 73.6, 70.5, 70.3, 70.3, 48.6, 41.8, 24.7, 23.1, 22.9, 22.6 ppm. ESI: <i>m/z</i> calcd for C<sub>19</sub>H<sub>28</sub>N<sub>3</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 330.22; found, 330.05; retention time, 4.60 min.</div></div><div id="sec5_1_3_22" class="NLM_sec NLM_sec_level_4"><div id="ac_i59" class="anchor-spacer"></div><h5 class="article-section__title" id="_i59"> <i>N</i>-(2-((2-Aminoethyl)disulfaneyl)ethyl)-1,2,3,4-tetrahydroacridin-9-amine (<b>12g</b>)</h5><div class="NLM_p last">2,2′-Dithiobis(ethylamine)dihydrochloride (608 mg, 2.70 mmol) was suspended in hexanol, and NEt<sub>3</sub> (1.49 mL, 10.8 mmol) was added. The reaction vessel was closed and stirred for 30 min at 160 °C. Then, 9-chloro-1,2,3,4-tetrahydroacridine <b>11</b> (117 mg, 0.54 mg) was added, and the mixture was stirred for further 12 h at 160 °C. The solvent was removed under high vacuum at 60 °C. The crude product was purified using RP flash chromatography to yield <b>12g</b> (80 mg, 0.33 mmol, 44%) as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, MeOD): δ 8.44 (d, <i>J</i> = 8.7 Hz, 1H), 7.88–7.86 (m, 2H), 7.65–7.61 (m, 1H), 4.33 (t, <i>J</i> = 6.6 Hz, 2H), 3.34–3.29 (m, 2H), 3.24 (t, <i>J</i> = 6.6 Hz, 2H), 3.08 (t, <i>J</i> = 5.3 Hz, 2H), 3.03 (t, <i>J</i> = 6.9 Hz, 2H), 2.79 (t, <i>J</i> = 5.7 Hz, 2H), 2.02–1.94 (m, 4H) ppm. <sup>13</sup>C NMR (101 MHz, MeOD): δ = 156.8, 151.0, 138.2, 132.8, 125.3, 124.9, 118.9, 115.9, 112.3, 46.29, 38.0, 36.7, 33.7, 28.1, 23.9, 21.6, 20.4 ppm. ESI: <i>m/z</i> calcd for C<sub>17</sub>H<sub>24</sub>N<sub>3</sub>S<sub>2</sub> [M + H]<sup>+</sup>, 334.14; found, 334.00; retention time, 5.31 min.</div></div><div id="sec5_1_3_23" class="NLM_sec NLM_sec_level_4"><div id="ac_i60" class="anchor-spacer"></div><h5 class="article-section__title" id="_i60"> <i>N</i>-(4-((1,2,3,4-Tetrahydroacridin-9-yl)amino)butyl)acetamide (<b>13</b>)</h5><div class="NLM_p last"><i>N</i><sup>1</sup>-(1,2,3,4-Tetrahydroacridin-9-yl)butane-1,4-diamine <b>12c</b> (51.0 mg, 0.19 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub>, and acetic acid anhydride (359 μL, 3.80 mmol) was added at room temperature. After stirring for 5 min, the mixture was basified by washing with a saturated NaHCO<sub>3</sub> solution. The organic layer was dried over anhydrous MgSO<sub>4</sub> and concentrated in vacuo. The product <b>13</b> (59.2 mg, 0.19 mmol, quant.) was obtained as a pale yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.13–8.10 (m, 1H), 7.95–7.91 (m, 1H), 7.53–7.48 (m, 1H), 7.34–7.30 (m, 1H), 3.79 (t, <i>J</i> = 7.1 Hz, 2H), 3.26 (q, <i>J</i> = 6.5 Hz, 2H), 2.99 (t, <i>J</i> = 6.0 Hz, 2H), 2.55 (t, <i>J</i> = 5.7 Hz, 2H), 1.84–1.75 (m, 6H), 1.66–1.59 (m, 2H), 1.23 (s, 3H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.2, 155.11 151.7, 139.3, 131.6, 124.7, 124.3, 120.8, 116.2, 111.3, 47.8, 38.7, 28.5, 28.1, 26.5, 24.1, 23.1, 22.0, 20.8 ppm. ESI: <i>m/z</i> calcd for C<sub>19</sub>H<sub>26</sub>N<sub>3</sub>O [M + H]<sup>+</sup>, 312.21; found, 312.05; retention time, 6.58 min.</div></div><div id="sec5_1_3_24" class="NLM_sec NLM_sec_level_4"><div id="ac_i61" class="anchor-spacer"></div><h5 class="article-section__title" id="_i61"> <i>N</i><sup>1</sup>-Ethyl-<i>N</i><sup>4</sup>-(1,2,3,4-tetrahydroacridin-9-yl)butane-1,4-diamine (<b>14</b>)</h5><div class="NLM_p last"><i>N</i>-(4-((1,2,3,4-Tetrahydroacridin-9-yl)amino)butyl)acetamide <b>13</b> (218 mg, 0.70 mmol) was dissolved in dry THF. LiAlH<sub>4</sub> (133 mg, 3.50 mmol) was added, the mixture was stirred for 48 h under reflux conditions, and then NH<sub>3(aq)</sub> (25%) was carefully added to the mixture on ice. The mixture was concentrated in vacuo, dissolved in ethyl acetate, and washed with a mixture of water/NH<sub>3(aq)</sub> (25%) (1:1). The combined organic layers were dried over anhydrous MgSO<sub>4</sub> and concentrated in vacuo. The crude product was purified by column chromatography (4:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)). The product <b>14</b> (144 mg, 0.48 mmol, 69%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.98–7.90 (m, 2H), 7.56–7.51 (m, 1H), 7.35–7.29 (m, 1H), 3.52 (t, <i>J</i> = 6.8 Hz, 2H), 3.07–3.03 (m, 2H), 2.72–2.65 (m, 6H), 1.92–1.86 (m, 4H), 1.76–1.61(m, 4H), 1.14 (t, <i>J</i> = 7.2 Hz, 3H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ = 157.8, 151.2, 146.6, 128.7, 127.9, 123.8, 123.0, 119.9, 115.6, 49.2, 49.0, 44.0, 33.5, 29.3, 27.1, 24.8, 23.0, 22.6, 14.7 ppm. ESI: <i>m/z</i> calcd for C<sub>19</sub>H<sub>28</sub>N<sub>3</sub> [M + 2H]<sup>2+</sup>, 149.62; found, 149.65; retention time, 4.77 min.</div></div><div id="sec5_1_3_25" class="NLM_sec NLM_sec_level_4"><div id="ac_i62" class="anchor-spacer"></div><h5 class="article-section__title" id="_i62"> <i>N</i>,<i>N</i>-Diethyl-4-fluoro-3-nitrobenzamide (<b>16</b>)</h5><div class="NLM_p last">4-Fluoro-3-nitrobenzoic acid <b>15</b> (1.00 g, 5.4 mmol) was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and cooled down to 0 °C. A catalytic amount of <i>N</i>,<i>N</i>-dimethylformamide was added, and oxalylchloride (2.31 mL, 27.01 mmol) was added dropwise. The mixture was stirred for 10 min at 0 °C, allowed to come to room temperature, and then stirred again for 1 h. The mixture was then evaporated, and the residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and cooled down to 0 °C. Then, a mixture of HNEt<sub>2</sub> (621 μL, 1.1 mmol) and NEt<sub>3</sub> (2.24 mL, 16.2 mmol) in CH<sub>2</sub>Cl<sub>2</sub> was slowly added to the cold mixture. After stirring for 3 h at room temperature, the mixture was washed with water. The combined organic layers were dried over anhydrous MgSO<sub>4</sub> and concentrated in vacuo. The product <b>16</b> (918 mg, 3.82 mmol, 71%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.11 (d, <i>J</i> = 7.0 Hz, 1H), 7.66–7.70 (m, 1 H), 7.35 (d, <i>J</i> = 10.4 Hz, 1H), 3.65–3.18 (m, 4H), 1.30–1.11 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.5, 156.8, 154.1, 136.9, 133.8, 124.4, 118.8, 43.4, 14.0 ppm. ESI: <i>m/z</i> calcd for C<sub>11</sub>H<sub>14</sub>FN<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 241.10; found, 241.10.</div></div><div id="sec5_1_3_26" class="NLM_sec NLM_sec_level_4"><div id="ac_i63" class="anchor-spacer"></div><h5 class="article-section__title" id="_i63"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide (<b>17a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (351 mg, 1.46 mmol), <b>12a</b> (388 mg, 1.61 mmol), and NEt<sub>3</sub> (304 μL, 2.19 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)). The product <b>17a</b> (475 mg, 1.03 mmol, 71%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.27 (t, <i>J</i> = 5.2 Hz, 1H), 8.24 (d, <i>J</i> = 1.8 Hz, 1H), 7.91 (t, <i>J</i> = 8.5 Hz, 2H), 7.53 (t, <i>J</i> = 7.6 Hz, 1H), 7.46 (d, <i>J</i> = 8.8 Hz, 1H), 7.33 (t, <i>J</i> = 7.6 Hz, 1H), 6.76 (d, <i>J</i> = 8.8 Hz, 1H), 4.27 (s, 1H), 3.77–3.70 (m, 2H), 3.55–3.48 (m, 2H), 3.46–3.32 (m, 4H), 3.04 (t, <i>J</i> = 6.0 Hz, 2H), 2.71 (t, <i>J</i> = 5.8 Hz, 2H), 1.91–1.81 (m, 4H), 1.18 (t, <i>J</i> = 7.0 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.2, 158.9, 149.5, 147.3, 145.5, 135.1, 131.3, 128.9, 128.6, 125.7, 124.5, 124.4, 122.2, 120.8, 118.2, 113.8, 47.4, 43.6, 34.0, 25.0, 22.9, 22.7 ppm. ESI: <i>m/z</i> calcd for C<sub>26</sub>H<sub>33</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 462.57; found, 462.15; retention time, 7.718 min.</div></div><div id="sec5_1_3_27" class="NLM_sec NLM_sec_level_4"><div id="ac_i64" class="anchor-spacer"></div><h5 class="article-section__title" id="_i64"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide (<b>17b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (173 mg, 0.72 mmol), <b>12b</b> (165 mg, 0.65 mmol), and NEt<sub>3</sub> (136 μL, 0.98 mmol). The crude product was purified by flash chromatography (gradient CH<sub>2</sub>Cl<sub>2</sub>, MeOH), and the product <b>17b</b> (110 mg, 0.23 mmol, 36%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.23 (d, <i>J</i> = 2.0 Hz, 1H), 8.16 (t, <i>J</i> = 5.1 Hz, 1H), 7.89 (d, <i>J</i> = 8.4, 2H), 7.54–7.50 (m, 1H), 7.49–7.45 (m, 1H), 7.33–7.27 (m, 1H), 6.74 (d, <i>J</i> = 8.9 Hz, 1H), 3.60 (t, <i>J</i> = 6.9 Hz, 2H), 3.49–3.30 (m, 6H), 3.03 (t, <i>J</i> = 5.3 Hz, 2H), 2.68 (t, <i>J</i> = 5.5 Hz, 2H), 2.09–1.98 (m, 2H), 1.90–1.81 (m, 4H), 1.18 (t, <i>J</i> = 7.1 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ = 169.9, 154.6, 151.6, 145.9, 143.1, 135.8, 130.3, 129.1, 128.6, 124.2, 124.8, 123.5, 122.6, 119.0, 115.5, 113.8, 52.9, 42.6, 41.6, 34.7, 26.9, 24.5, 22.4, 22.0, 13.3 ppm. ESI: <i>m/z</i> calcd for C<sub>27</sub>H<sub>34</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 476.26; found, 476.15; retention time, 7.83 min.</div></div><div id="sec5_1_3_28" class="NLM_sec NLM_sec_level_4"><div id="ac_i65" class="anchor-spacer"></div><h5 class="article-section__title" id="_i65"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide (<b>17c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (430 mg, 1.79 mmol), <b>12c</b> (439 mg, 1.63 mmol), and NEt<sub>3</sub> (340 μL, 2.45 mmol). The crude product was purified by flash chromatography (gradient CH<sub>2</sub>Cl<sub>2</sub>, MeOH), and the product <b>17c</b> (212 mg, 0.43 mmol, 26%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.16 (t, <i>J</i> = 4.9 Hz, 1H), 7.96–7.92 (m, 2H), 7.58–7.51 (m, 2H), 7.37–7.32 (m, 1H), 6.81 (d, <i>J</i> = 8.9 Hz, 1H), 3.57 (t, <i>J</i> = 6.2 Hz, 2H), 3.45–3.33 (m, 6H), 3.09–3.05 (m, 2H), 2.72–2.67 (m, 2H), 1.92–1.86 (m, 4H), 1.85–1.79 (m, 4H), 1.20 (t, <i>J</i> = 7.1 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.4, 154.4, 151.0, 146.6, 145.8, 135.4, 131.0, 128.9, 128.1, 125.8, 124.2, 124.1, 122.8, 120.0, 116.1, 113.9, 53.6, 48.9, 42.9, 33.5, 29.3, 26.5, 25.0, 23.0, 22.7, 13.8 ppm. ESI: <i>m/z</i> calcd for C<sub>28</sub>H<sub>36</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 490.28; found, 490.15; retention time, 8.04 min.</div></div><div id="sec5_1_3_29" class="NLM_sec NLM_sec_level_4"><div id="ac_i66" class="anchor-spacer"></div><h5 class="article-section__title" id="_i66"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide (<b>17d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (221 mg, 0.92 mmol), <b>12d</b> (237 mg, 0.84 mmol), and NEt<sub>3</sub> (173 μL, 1.26 mmol). The crude product was purified by flash chromatography (gradient CH<sub>2</sub>Cl<sub>2</sub>, MeOH), and the product <b>17d</b> (160 mg, 0.32 mmol, 38%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.21 (d, <i>J</i> = 2.0 Hz, 1H), 8.13–8.05 (m, 3H), 7.56–7.51 (m, 1H), 7.50–7.46 (m, 1H), 7.35–7.30 (m, 1H), 6.81 (d, <i>J</i> = 8.9 Hz, 1H), 3.72 (t, <i>J</i> = 7.2 Hz, 2H), 3.45–3.35 (m, 3H), 3.33–3.27 (m, 2H), 3.12–3.07 (m, 2H), 2.67–2.63 (m, 2H), 1.87–1.79 (m, 6H), 1.77–1.70 (m, 2H), 1.58–1.50 (m, 2H), 1.17 (t, <i>J</i> = 7.1 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.4, 154.6, 153.3, 145.8, 142.7, 135.2, 130.7, 130.4, 125.7, 124.5, 124.3, 123.8, 123.7, 118.0, 114.0, 113.5, 53.1, 48.5, 42.9, 31.1, 30.0, 28.6, 24.6, 24.3, 22.5, 21.7, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>29</sub>H<sub>38</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 504.30; found, 504.15; retention time, 8.36 min.</div></div><div id="sec5_1_3_30" class="NLM_sec NLM_sec_level_4"><div id="ac_i67" class="anchor-spacer"></div><h5 class="article-section__title" id="_i67"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide (<b>17e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (341 mg, 1.42 mmol), <b>12e</b> (458 mg, 1.56 mmol), and NEt<sub>3</sub> (297 μL, 2.13 mmol). The product <b>17e</b> (230 mg, 0.44 mmol, 31%) was obtained as a brown oil and used in the next reaction step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.55 (d, <i>J</i> = 8.4 Hz, 1H), 8.26 (d, <i>J</i> = 2.0 Hz, 1H), 8.18–8.13 (m, 2H), 7.73–7.67 (m, 1H), 7.57–7.52 (m, 1H), 7.48–7.42 (m, 1H), 6.86 (d, <i>J</i> = 8.9 Hz, 1H), 3.94 (t, <i>J</i> = 7.0 Hz, 2H), 3.51–3.37 (m, 4H), 3.36–3.29 (m, 4H), 2.60 (t, <i>J</i> = 6.2 Hz, 2H), 1.91–1.83 (m, 4H), 1.69–1.58 (m, 4H), 1.57–1.53 (m, 4H), 1.21 (t, <i>J</i> = 7.1 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 168.5, 155.45, 152.0, 146.0, 142.04 135.4, 129.52, 129.2, 125.4, 124.9, 123.7, 123.2, 121.6, 118.7, 114.0, 113.6, 53.1, 48.2, 43.0, 31.3, 31.2, 28.8, 26.8, 26.6, 26.3, 23.8, 20.8, 13.8 ppm. ESI: <i>m/z</i> calcd for C<sub>30</sub>H<sub>40</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 518.31; found, 518.40; retention time, 8.55 min.</div></div><div id="sec5_1_3_31" class="NLM_sec NLM_sec_level_4"><div id="ac_i68" class="anchor-spacer"></div><h5 class="article-section__title" id="_i68"> <i>N</i>,<i>N</i>-Diethyl-3-nitro-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide (<b>17f</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure II using <i>N</i>,<i>N</i>-diethyl-4-fluoro-3-nitrobenzamide <b>16</b> (475 mg, 1.98 mmol), <b>12f</b> (718 mg, 2.18 mmol), and NEt<sub>3</sub> (410 μL, 2.97 mmol). The crude product was purified by flash chromatography (gradient CH<sub>2</sub>Cl<sub>2</sub>/MeOH), and product <b>17f</b> (575 mg, 1.05 mmol, 53%) was obtained as a brown oil and used in the next reaction step without further purification. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.41–8.35 (m, 2H), 8.22 (d, <i>J</i> = 2.0 Hz, 1H), 8.11–8.07 (m, 1H), 7.66–7.60 (m, 1H), 7.56–7.52 (m, 1H), 7.42–7.37 (m, 1H), 6.86 (d, <i>J</i> = 8.9 Hz, 1H), 4.01–3.95 (m, 2H), 3.83–3.73 (m, 4H), 3.75–3.70 (m, 4H), 3.52–3.48 (m, 2H), 3.47–3.35 (m, 4H), 3.27–3.22 (m, 2H), 2.68–2.63 (m, 2H), 1.90–1.83 (m, 4H), 1.20 (t, <i>J</i> = 7.1 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 169.3, 154.30, 151.4, 145.8, 143.1, 135.4, 131.1, 125.7, 125.0, 124.3, 124.2, 123.6, 121.3, 117.6, 116.0, 114.1, 70.9, 70.5, 70.0, 69.0, 52.7, 48.1, 42.8, 30.1, 23.9, 22.4, 21.4, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>30</sub>H<sub>40</sub>N<sub>5</sub>O<sub>5</sub> [M + H]<sup>+</sup>, 550.30; found, 550.25; retention time, 8.05 min.</div></div><div id="sec5_1_3_32" class="NLM_sec NLM_sec_level_4"><div id="ac_i69" class="anchor-spacer"></div><h5 class="article-section__title" id="_i69"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide (<b>18a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide <b>17a</b> (475 mg, 1.03 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (1.44 g, 6.39 mmol). The product <b>18a</b> (325 mg, 0.75 mmol, 73%) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>26</sub>H<sub>35</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 432.28; found, 432.30; retention time, 7.534 min.</div></div><div id="sec5_1_3_33" class="NLM_sec NLM_sec_level_4"><div id="ac_i70" class="anchor-spacer"></div><h5 class="article-section__title" id="_i70"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide (<b>18b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide <b>17b</b> (110 mg, 0.23 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (323 mg, 1.43 mmol). The product <b>18b</b> (89.1 mg, 0.20 mmol, 87%) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>27</sub>H<sub>36</sub>N<sub>5</sub>O [M + H]<sup>+</sup>, 223.65; found, 223.65; retention time, 7.84 min.</div></div><div id="sec5_1_3_34" class="NLM_sec NLM_sec_level_4"><div id="ac_i71" class="anchor-spacer"></div><h5 class="article-section__title" id="_i71"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide (<b>18c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide <b>17c</b> (212 mg, 0.43 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (602 mg, 2.67 mmol). The product <b>18c</b> (154 mg, 0.34 mmol, 79%) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>28</sub>H<sub>38</sub>N<sub>5</sub>O [M + 2H]<sup>2+</sup>, 230.66; found, 230.60; retention time, 7.17 min.</div></div><div id="sec5_1_3_35" class="NLM_sec NLM_sec_level_4"><div id="ac_i72" class="anchor-spacer"></div><h5 class="article-section__title" id="_i72"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide (<b>18d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide <b>17d</b> (236 mg, 0.47 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (657 mg, 2.91 mmol). The product <b>18d</b> (222 mg, 0.47 mmol, quant.) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>29</sub>H<sub>40</sub>N<sub>5</sub>O [M + 2H]<sup>2+</sup>, 237.67; found, 237.65; retention time, 7.73 min.</div></div><div id="sec5_1_3_36" class="NLM_sec NLM_sec_level_4"><div id="ac_i73" class="anchor-spacer"></div><h5 class="article-section__title" id="_i73"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide (<b>18e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide <b>17e</b> (230 mg, 0.44 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (616 mg, 2.73 mmol). The product <b>18e</b> (140 mg, 0.29 mmol, 66%) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>30</sub>H<sub>42</sub>N<sub>5</sub>O [M + 2H]<sup>2+</sup>, 244.68; found, 244.65; retention time, 7.93 min.</div></div><div id="sec5_1_3_37" class="NLM_sec NLM_sec_level_4"><div id="ac_i74" class="anchor-spacer"></div><h5 class="article-section__title" id="_i74"> 3-Amino-<i>N</i>,<i>N</i>-diethyl-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide (<b>18f</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure III using <i>N</i>,<i>N</i>-diethyl-3-nitro-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide <b>17f</b> (575 mg, 1.05 mmol) and SnCl<sub>2</sub>·2H<sub>2</sub>O (1.47 g, 8.51 mmol). The product <b>18f</b> (290 mg, 0.56 mmol, 53%) was obtained as a colorless oil and directly used for the next reaction without purification. ESI: <i>m/z</i> calcd for C<sub>30</sub>H<sub>42</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>, 260.67; found, 260.60; retention time, 7.50 min.</div></div><div id="sec5_1_3_38" class="NLM_sec NLM_sec_level_4"><div id="ac_i75" class="anchor-spacer"></div><h5 class="article-section__title" id="_i75"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide (<b>19a</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethyl)amino)benzamide <b>18a</b> (325 mg, 0.75 mmol), 2-(4-ethoxyphenyl)acetic acid (30 mg, 0.83 mmol), HBTU (313 mg, 0.83 mmol), and triethylamine (156 μL, 1.13 mmol). The product <b>19a</b> (258 mg, 0.43 mmol, 57%) was obtained as an orange/brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.72 (s, 1H), 7.97 (d, <i>J</i> = 8.5 Hz, 1H), 7.89 (d, <i>J</i> = 8.4 Hz, 1H), 7.52 (t, <i>J</i> = 7.6 Hz, 1H), 7.32 (t, <i>J</i> = 7.6 Hz, 1H), 7.23 (d, <i>J</i> = 8.5 Hz, 2H), 7.15 (d, <i>J</i> = 1.4 Hz, 1H), 7.00 (dd, <i>J</i> = 8.3, 1.4 Hz, 1H), 6.74 (d, <i>J</i> = 8.5 Hz, 2H), 6.46 (d, <i>J</i> = 8.4 Hz, 1H), 4.73 (s, 1H), 4.64 (t, <i>J</i> = 5.3 Hz, 1H), 3.85 (q, <i>J</i> = 7.0 Hz, 2H), 3.66–3.59 (m, 4H), 3.39 (s, 4H), 3.26–3.18 (m, 2H), 3.01 (t, <i>J</i> = 6.1 Hz, 2H), 2.63 (t, <i>J</i> = 6.0 Hz, 2H), 1.89–1.75 (m, 4H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.15 (s, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.7, 171.1, 158.1, 157.9, 150.9, 146.5, 143.2, 130.2, 128.7, 127.8, 127.2, 125.3, 125.2, 124.7, 124.0, 123.8, 122.9, 120.2, 116.9, 114.7, 111.1, 63.4, 47.6, 44.3, 42.9, 33.5, 24.8, 22.9 , 22.6, 14.8 ppm. ESI: <i>m/z</i> calcd for C<sub>36</sub>H<sub>45</sub>N<sub>5</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 594.78; found, 594.25; retention time, 8.101 min.</div></div><div id="sec5_1_3_39" class="NLM_sec NLM_sec_level_4"><div id="ac_i76" class="anchor-spacer"></div><h5 class="article-section__title" id="_i76"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide (<b>19b</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((3-((1,2,3,4-tetrahydroacridin-9-yl)amino)propyl)amino)benzamide <b>18b</b> (154 mg, 0.34 mmol), 2-(4-ethoxyphenyl)acetic acid (136 mg, 0.37 mmol), HBTU (140 mg, 0.37 mmol), and triethylamine (70.6 μL, 0.51 mmol). The product <b>19b</b> (104 mg, 0.17 mmol, 50%) was obtained as an orange/brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.07 (s, 1H), 8.02 (d, <i>J</i> = 9.5 Hz, 1H), 7.59–7.55 (m, 1H), 7.47–7.44 (m, 1H), 7.29–7.28 (m, 1H), 7.24 (d, <i>J</i> = 8.4 Hz, 2H), 7.05–7.02 (m, 1H), 6.76–6.74 (m, 2H), 6.56–6.52 (m, 1H), 3.92–3.83 (m, 4H), 3.73 (s, 2H), 3.42–3.36 (m, 4H), 3.22–3.15 (m, 2H), 2.73–2.68 (m, 2H), 2.43–2.36 (m, 2H), 2.03–1.97 (m, 2H), 1.71–1.65 (m, 4H), 1.32 (t, <i>J</i> = 7.0 Hz, 3H), 1.20–1.09 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.1, 171.9, 162.7, 157.2, 151.9, 146.6, 143.5, 130.6, 129.4, 127.3, 126.7, 125.8, 124.7, 124.6, 123.0, 121.1, 119.5, 118.5, 115.5, 114.8, 111.0, 63.5, 46.1, 42.8, 42.5, 39.4, 29.8, 29.5, 24.8, 22.4, 22.1, 14.9, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>37</sub>H<sub>47</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>, 304.69; found, 304.70; retention time, 8.23 min.</div></div><div id="sec5_1_3_40" class="NLM_sec NLM_sec_level_4"><div id="ac_i77" class="anchor-spacer"></div><h5 class="article-section__title" id="_i77"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide (<b>19c</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((4-((1,2,3,4-tetrahydroacridin-9-yl)amino)butyl)amino)benzamide <b>18c</b> (139 mg, 0.30 mmol), 2-(4-ethoxyphenyl)acetic acid (121 mg, 0.33 mmol), HBTU (125 mg, 0.33 mmol), and triethylamine (62.3 μL, 0.45 mmol). The product <b>19c</b> (166 mg, 0.27 mmol, 90%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.97 (s, 1H), 7.79–7.77 (m, 1H), 7.53–7.50 (m, 1H), 7.34–7.31 (m, 1H), 7.24 (d, <i>J</i> = 8.6 Hz, 2H), 7.17–7.14 (m, 1H), 7.06–7.02 (m, 1H), 6.81 (d, <i>J</i> = 8.6 Hz, 2H), 6.50–6.46 (m, 1H), 4.03–3.91 (m, 4H), 3.64 (s, 2H), 3.42–3.31 (m, 4H), 3.05–3.00 (m, 2H), 2.94–2.90 (m, 2H), 2.63–2.57 (m, 2H), 1.87–1.80 (m, 4H), 1.73–1.56 (m, 4H), 1.33 (t, <i>J</i> = 7.0 Hz, 3H), 1.19–1.11 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.7, 171.4, 162.1, 158.4, 152.4, 144.7, 143.8, 130.5, 129.8, 127.2, 126.9, 125.9, 124.9, 124.3, 123.6, 121.9, 119.5, 118.9, 115.7, 115.1, 111.1, 63.6, 48.9, 47.2, 44.4, 43.1, 32.2, 28.7, 26.3, 24.7, 22.7, 22.2, 14.9, 13.6 ppm. ESI: <i>m/z</i> calcd for C<sub>38</sub>H<sub>49</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>, 311.69; found, 311.70; retention time, 8.39 min.</div></div><div id="sec5_1_3_41" class="NLM_sec NLM_sec_level_4"><div id="ac_i78" class="anchor-spacer"></div><h5 class="article-section__title" id="_i78"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide (<b>19d</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((5-((1,2,3,4-tetrahydroacridin-9-yl)amino)pentyl)amino)benzamide <b>19d</b> (222 mg, 0.47 mmol), 2-(4-ethoxyphenyl)acetic acid (191 mg, 0.52 mmol), HBTU (197 mg, 0.52 mmol), and triethylamine (98.4 μL, 0.71 mmol). The product <b>19d</b> (299 mg, 0.47 mmol, quant.) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.11 (d, <i>J</i> = 8.7 Hz, 1H), 7.59–7.56 (m, 2H), 7.43–7.36 (m, 2H), 7.27–7.25 (m, 2H), 6.92–6.87 (m, 1H), 6.79 (d, <i>J</i> = 8.6 Hz, 2H), 6.33 (d, <i>J</i> = 8.5 Hz, 1H), 3.95 (q, <i>J</i> = 14.0, 7.0 Hz, 2H), 3.86–3.82 (m, 2H), 3.69 (s, 2H), 3.46–3.37 (m, 4H), 3.00–2.95 (m, 2H), 2.69–2.64 (m, 2H), 2.50–2.45 (m, 2H), 1.80–1.72 (m, 6H), 1.69–1.63 (m, 2H), 1.37–1.33 (m, 5H), 1.30–1.21 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.8, 171.2, 161.4, 157.6, 153.1, 146.7, 143.7, 130.5, 129.5, 127.3, 126.7, 125.8. 124.8, 124.5, 123.5, 122.2, 119.6, 118.8, 115.7, 114.9, 111.3, 63.6, 48.6, 47.4, 45.1, 43.2, 30.2, 29.9, 28.4, 28.2, 23.56, 22.2, 22.1, 14.9, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>39</sub>H<sub>51</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>, 318.70; found, 318.65; retention time, 8.75 min.</div></div><div id="sec5_1_3_42" class="NLM_sec NLM_sec_level_4"><div id="ac_i79" class="anchor-spacer"></div><h5 class="article-section__title" id="_i79"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide (<b>19e</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((6-((1,2,3,4-tetrahydroacridin-9-yl)amino)hexyl)amino)benzamide <b>18e</b> (140 mg, 0.29 mmol), 2-(4-ethoxyphenyl)acetic acid (52.3 mg, 0.29 mmol), HBTU (133 mg, 0.35 mmol), and triethylamine (61.0 μL, 0.44 mmol). The product <b>19e</b> (142 mg, 0.22 mmol, 76%) was obtained as a brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.56 (s, 1H), 8.15 (d, <i>J</i> = 8.7 Hz, 1H), 7.88 (d, <i>J</i> = 8.4 Hz, 1H), 7.53 (t, <i>J</i> = 7.2 Hz, 1H), 7.35 (t, <i>J</i> = 8.0 Hz, 1H), 7.25 (d, <i>J</i> = 8.6 Hz 2H), 7.04–7.00 (m, 1H), 6.75 (d, <i>J</i> = 8.6 Hz, 2H), 6.48–6.44 (m, 1H), 3.92 (q, <i>J</i> = 7.0 Hz, 2H), 3.81 (m, 2H), 3.71 (s, 2H), 3.49–3.32 (m, 4H), 2.96–2.91 (m, 2H), 2.88–2.83 (m, 2H), 2.54–2.49 (m, 2H), 1.80–1.68 (m, 6H), 1.54–1.47 (m, 2H), 1.37–1.31 (m, 4H), 1.25 (t, <i>J</i> = 7.3 Hz, 3H), 1.14–1.09 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 172.0, 170.8, 162.7, 158.1, 156.0, 150.5, 144.07, 130.4, 129.4, 127.6, 127.0, 125.8, 125.1, 124.9, 123.8, 122.6, 119.9, 119.0, 115.7, 114.7, 111.3, 63.5, 48.1, 46.3, 45.2, 43.2, 31.5, 30.3, 28.6, 28.3, 26.2, 25.9, 21.8, 20.7, 14.9, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>40</sub>H<sub>53</sub>N<sub>5</sub>O<sub>3</sub> [M + 2H]<sup>2+</sup>, 325.70; found: 325.75; retention time: 8.76 min.</div></div><div id="sec5_1_3_43" class="NLM_sec NLM_sec_level_4"><div id="ac_i80" class="anchor-spacer"></div><h5 class="article-section__title" id="_i80"> 3-(2-(4-Ethoxyphenyl)acetamido)-<i>N</i>,<i>N</i>-diethyl-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide (<b>19f</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure IV using 3-amino-<i>N</i>,<i>N</i>-diethyl-4-((2-(2-(2-((1,2,3,4-tetrahydroacridin-9-yl)amino)ethoxy)ethoxy)ethyl)amino)benzamide <b>18f</b> (290 mg, 0.56 mmol), 2-(4-ethoxyphenyl)acetic acid (122 mg, 0.62 mmol), HBTU (235 mg, 0.62 mmol), and triethylamine (116 μL, 0.84 mmol). The product <b>19f</b> (398 mg, 0.58 mmol, quant.) was obtained as a brown oil.<sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.03–7.96 (m, 2H), 7.87 (d, <i>J</i> = 8.3 Hz, 1H), 7.51 (t, <i>J</i> = 8.0 Hz, 1H), 7.31 (t, <i>J</i> = 7.2 Hz 1H), 7.20 (d, <i>J</i> = 8.6 Hz, 2H), 7.07–7.03 (m, <i>J</i> = 8.4, 1.9 Hz, 1H), 6.81 (d, <i>J</i> = 8.6 Hz, 2H), 6.56–6.52 (m, 1H), 3.99–3.92 (m, 2H), 3.71–3.67 (m, 2H), 3.63–3.56 (m, 10H), 3.42–3.31 (m, 4H), 3.17 (t, <i>J</i> = 5.3 Hz, 2H), 2.99–2.94 (m, 2H), 2.67–2.62 (m, 2H), 1.84–1.76 (m, 4H), 1.36 (t, <i>J</i> = 7.2 Hz, 3H), 1.14–1.09 (m, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 171.5, 170.9, 158.3, 156.6, 152.1, 144.9, 143.4, 130.5, 129.5, 127.0, 126.4, 125.7, 124.6, 124.3, 123.5, 123.3, 119.5, 118.7, 115.9, 115.0, 111.6, 70.4, 70.3, 70.2, 69.6, 63.5, 53.5, 48.3, 45.8, 43.5, 29.8, 24.4, 22.8, 22.3, 14.9, 13.7 ppm. ESI: <i>m/z</i> calcd for C<sub>40</sub>H<sub>51</sub>N<sub>5</sub>O<sub>5</sub> [M + 2H]<sup>2+</sup>, 341.70; found, 341.70; retention time, 8.34 min.</div></div><div id="sec5_1_3_44" class="NLM_sec NLM_sec_level_4"><div id="ac_i81" class="anchor-spacer"></div><h5 class="article-section__title" id="_i81"> Ethyl 4-(Isopentylamino)-3-nitrobenzoate (<b>20</b>)</h5><div class="NLM_p last">4-Fluoro-3-nitrobenzoic acid <b>15</b> (1.00 g, 5.40 mmol) was dissolved in ethanol, and a cat. amount (few drops) of H<sub>2</sub>SO<sub>4</sub> (95–97%) was added. After stirring overnight under reflux conditions, the mixture was basified with triethylamine, and 3-methylbutan-1-amine (691 μL, 5.94 mmol) was added. After stirring under reflux conditions overnight, the mixture was concentrated in vacuo. The residue was dissolved in CH<sub>2</sub>Cl<sub>2</sub> and washed with 1 M HCl<sub>(aq)</sub> and NaHCO<sub>3</sub> solution. The organic layers were combined, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. The product <b>20</b> (1.46 g, 5.22 mmol, 97%) was obtained as a yellow oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.88–8.85 (m, 1H), 8.31 (s, 1H), 8.07–8.03 (m, 1H), 6.88–6.83 (m, 1H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 3.39–3.33 (m, 2H), 1.83–1.72 (m, 1H), 1.65 (q, <i>J</i> = 7.1 Hz, 2H), 1.38 (t, <i>J</i> = 7.1 Hz, 3H), 0.99 (d, <i>J</i> = 6.7 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 165.3, 147.9, 136.5, 131.3, 129.6, 117.5, 113.6, 61.1, 41.6, 37.8, 26.1, 22.6, 14.5 ppm. ESI: <i>m/z</i> calcd for C<sub>14</sub>H<sub>21</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 281.15; found, 281.00; retention time, 11.85 min.</div></div><div id="sec5_1_3_45" class="NLM_sec NLM_sec_level_4"><div id="ac_i82" class="anchor-spacer"></div><h5 class="article-section__title" id="_i82"> Ethyl 3-Amino-4-(isopentylamino)benzoate (<b>21</b>)</h5><div class="NLM_p last">Ethyl 4-(isopentylamino)-3-nitrobenzoate <b>20</b> (1.46 g, 5.22 mmol) was dissolved in MeOH and a cat. amount of Pd/C (10%) was added. The mixture was stirred under a hydrogen atmosphere (8 bar) at room temperature for 3 h. The clear mixture was filtered off by suction over Celite. The combined organic layers were dried over anhydrous MgSO<sub>4</sub> and concentrated in vacuo, and product <b>36</b> (1.31 g, 5.22 mmol, quant.) was obtained as a colorless oil. The product was directly used for the next reaction step without further purification. ESI: <i>m/z</i> calcd for C<sub>14</sub>H<sub>23</sub>N<sub>2</sub>O<sub>2</sub> [M + H]<sup>+</sup>, 251.18; found, 251.05; retention time, 10.34 min.</div></div><div id="sec5_1_3_46" class="NLM_sec NLM_sec_level_4"><div id="ac_i83" class="anchor-spacer"></div><h5 class="article-section__title" id="_i83"> Ethyl 3-(2-(4-Ethoxyphenyl)acetamido)-4-(isopentylamino)benzoate (<b>22</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using 3 ethyl 3-amino-4-(isopentylamino)benzoate <b>21</b> (1.31 g, 5.22 mmol), 2-(4-ethoxyphenyl)acetic acid (1.03 g, 5.74 mmol), HBTU (2.18 g, 5.74 mmol), and NEt<sub>3</sub> (1.08 mL, 7.83 mmol). The product <b>22</b> (2.15 g, 5.22 mmol, quant.) was obtained as an orange/brown oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 7.86–7.82 (m, 1H), 7.73–7.71 (m, 1H), 7.32–7.29 (m, 2H), 6.97–6.94 (m, 2H), 6.65 (d, <i>J</i> = 8.7 Hz, 1H), 4.32 (q, <i>J</i> = 7.1 Hz, 2H), 4.17 (q, <i>J</i> = 7.1 Hz, 2H), 3.74 (s, 2H), 3.14–3.08 (m, 2H), 1.70–1.65 (m, 1H), 1.50–1.40 (m, 5H), 1.37 (t, <i>J</i> = 7.1 Hz, 3H), 0.96 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 170.8, 158.6, 147.2, 130.5, 130.2, 130.1, 127.8, 126.5, 121.5, 118.4, 115.4, 114.6, 63.7, 60.5, 41.8, 38.8, 38.3, 26.1, 22.7, 14.9, 14.6 ppm. ESI: <i>m/z</i> calcd for C<sub>24</sub>H<sub>33</sub>N<sub>2</sub>O<sub>4</sub> [M + H]<sup>+</sup>, 413.24; found, 413.10; retention time, 11.04 min.</div></div><div id="sec5_1_3_47" class="NLM_sec NLM_sec_level_4"><div id="ac_i84" class="anchor-spacer"></div><h5 class="article-section__title" id="_i84"> Ethyl 2-(4-Ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylate (<b>23</b>)</h5><div class="NLM_p last">The reaction was carried out according to general procedure V using ethyl 3-(2-(4-ethoxyphenyl)acetamido)-4-(isopentylamino)benzoate <b>22</b> (2.15 g, 5.22 mmol). The crude product was purified by column chromatography (20:1:0.1 CH<sub>2</sub>Cl<sub>2</sub>/MeOH/NH<sub>3(aq)</sub> (25%)), and product <b>23</b> (1.67 g, 4.23 mmol, 81%) was obtained as a purple oil. <sup>1</sup>H NMR (400 MHz, CDCl<sub>3</sub>): δ 8.44 (s, 1H), 7.95–7.91 (m, 1H), 7.21 (d, <i>J</i> = 8.4 Hz, 1H), 7.10 (d, <i>J</i> = 8.8 Hz, 2H), 6.78 (d, <i>J</i> = 8.8 Hz, 2H), 4.35 (q, <i>J</i> = 7.1 Hz, 2H), 4.20 (s, 2H), 3.96–3.89 (m, 4H), 1.56–1.46 (m, 1H), 1.39–1.28 (m, 8H), 0.85 (d, <i>J</i> = 6.8 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, CDCl<sub>3</sub>): δ 167.2, 158.1, 155.1, 142.2, 138.5, 129.5, 127.7, 124.4, 123.8, 121.7, 114.9, 108.9, 63.4, 60.7, 42.7, 38.0, 33.8, 26.1, 22.3, 14.7, 14.4 ppm. ESI: <i>m/z</i> calcd for C<sub>24</sub>H<sub>31</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 395.23; found, 395.15; retention time, 11.11 min.</div></div><div id="sec5_1_3_48" class="NLM_sec NLM_sec_level_4"><div id="ac_i85" class="anchor-spacer"></div><h5 class="article-section__title" id="_i85"> 2-(4-Ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylic Acid (<b>24</b>)</h5><div class="NLM_p last">Ethyl 2-(4-ethoxybenzyl)-1-isopentyl-1<i>H</i>-benzo[<i>d</i>]imidazole-5-carboxylate <b>23</b> (250 mg, 0.63 mmol) was dissolved in THF, and lithium hydroxide (150 mg, 0.63 mmol) in water was added. After 48 h of harsh stirring under reflux conditions, the mixture was concentrated in vacuo, and the residue was acidified with 2 M HCl<sub>(aq)</sub>. Then, CH<sub>2</sub>Cl<sub>2</sub> was added, and the organic layer was washed with water. The organic layers were combined, dried over anhydrous MgSO<sub>4</sub>, and concentrated in vacuo. Product <b>24</b> (231 mg, 0.63 mmol, quant.) was obtained as a purple oil. <sup>1</sup>H NMR (400 MHz, D<sub>2</sub>O): δ 8.10–8.07 (m, 1H), 7.80–7.75 (m, <i>J</i> = 9.9 Hz, 1H), 7.29 (d, <i>J</i> = 8.5 Hz, 1H), 7.06 (d, <i>J</i> = 8.5 Hz, 2H), 6.78 (d, <i>J</i> = 8.3 Hz, 2H), 4.10 (s, 2H), 3.94–3.88 (m, 2H), 3.86–3.80 (m, 2H), 1.36–1.27 (m, 1H), 1.21 (t, <i>J</i> = 6.9 Hz, 3H), 1.08–1.01 (m, 2H), 0.66 (d, <i>J</i> = 6.6 Hz, 6H) ppm. <sup>13</sup>C NMR (101 MHz, DMSO): δ 167.6, 166.2, 158.4, 135.7, 132.8, 130.6, 128.0, 126.5, 125.3, 125.2, 117.2, 115.5, 63.7, 43.8, 37.1, 31.1, 25.8, 22.2, 14.8 ppm. ESI: <i>m/z</i> calcd for C<sub>22</sub>H<sub>27</sub>N<sub>2</sub>O<sub>3</sub> [M + H]<sup>+</sup>, 367.20; found, 367.15; retention time, 10.13 min.</div></div></div></div><div id="sec5_2" class="NLM_sec NLM_sec_level_2"><div id="ac_i86" class="anchor-spacer"></div><h3 class="article-section__title" id="_i86"> Pharmacology</h3><div id="sec5_2_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i87" class="anchor-spacer"></div><h4 class="article-section__title" id="_i87"> Inhibition of hBChE</h4><div class="NLM_p last">BChE (E.C. 3.1.1.8, from humans) was kindly provided by Oksana Lockridge from the University of Nebraska Medical Center. 5,5′-Dithiobis(2-nitrobenzoic acid) and ATC iodide were obtained from Fluka Analytical, and tacrine hydrochloride was purchased from Sigma-Aldrich. Inhibitory activities were evaluated using Ellman’s method.<sup>64</sup> The stock solutions of the test compounds were prepared in ethanol (33.3 mM) and diluted to the desired concentrations. For the testing, 50 μL of 5,5′-dithiobis(2-nitrobenzoic acid) and 50 μL of enzyme were added to 1.5 mL of the buffer. After 50 μL of the test compound was added, the mixture was incubated for 4.5 min. Afterward, 10 μL of acetylthiocholine iodide was added, and the mixture was allowed to incubate for further 2.5 min. Enzyme activity was then observed via UV (λ = 412 nm). IC<sub>50</sub> values were determined graphically from inhibition curves using Pad Prism 5.0 software. Experiments were carried out three times independently.</div></div><div id="sec5_2_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i88" class="anchor-spacer"></div><h4 class="article-section__title" id="_i88"> Inhibition of hAChE and hBChE</h4><div class="NLM_p last">The hAChE inhibitory activity was evaluated spectrophotometrically at 37 °C by Ellman’s method.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> AChE stock solution was prepared by dissolving recombinant hAChE lyophilized powder (Sigma, Italy) in 0.1 M phosphate buffer (pH = 8.0) containing Triton X-100 0.1%. The stock solution of BChE from human serum (Sigma, Italy) was prepared by dissolving the lyophilized powder in an aqueous solution of gelatin 0.1%. Stock solutions of inhibitors (1 or 2 mM) were prepared in methanol. The assay solution consisted of a 0.1 M phosphate buffer at pH 8.0, with the addition of 340 μM 5,5′-dithiobis(2-nitrobenzoic acid), 0.02 unit/mL hAChE or hBChE, and 550 μM substrate (acetylthiocholine iodide or butyrylthiocholine iodide for AchE or BchE, respectively). Fifty microliter aliquots of increasing concentration of the tested compound were added to the assay solution and preincubated for 20 min at 37 °C with the enzyme. Upon addition of the substrate, the increase in absorbance at 412 nm was monitored for 3 min. Assays were carried out with a blank containing all components except the enzyme to account for the nonenzymatic reaction. The reaction rates were compared, and the percent inhibition was calculated. IC<sub>50</sub> values were determined graphically from inhibition curves using GraphPad Prism 4.03 software. Experiments were carried out three times independently.</div></div><div id="sec5_2_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i89" class="anchor-spacer"></div><h4 class="article-section__title" id="_i89"> Investigation of Inhibitory Constants and Mode of Inhibition toward hAChE</h4><div class="NLM_p last">To assess the mechanism of action and inhibitory constant reciprocal plots of 1/<i>V</i> versus 1/[S] were constructed using relatively low concentrations of substrate (ACTh, 0.111–0.554 mM). The evaluation of the enzyme activity was carried out by Ellman’s method.<a onclick="showRef(event, 'ref64'); return false;" href="javascript:void(0);" class="ref ref64">(64)</a> The plots were assessed by a weighted least square analysis that assumed the variance of <i>V</i> to be a constant percentage of <i>V</i> for the entire data set. The mechanism of inhibition was assessed by comparing the overlaid Lineweaver–Burk plots with the theoretical trends for competitive, mixed-type, and noncompetitive inhibition. To determine the inhibition constant <i>K</i><sub>i</sub>, slopes of reciprocal plots were replotted against the concentration of the tested inhibitor (<b>3e</b>, range 0–100 nM; <b>4b</b>, range 0–7.5 nM; <b>8</b>, range 0–25.0 nM), and <i>K</i><sub>i</sub> was determined as the intersect on the negative <i>x</i> axis. The <i>K</i><sub class="stack">i</sub><sup class="stack">′</sup> (dissociation constant for the enzyme–substrate–inhibitor complex) value was determined by plotting the apparent 1/<i>V</i><sub>max</sub> versus inhibitor concentration.<a onclick="showRef(event, 'ref92'); return false;" href="javascript:void(0);" class="ref ref92">(92)</a> Data analysis was performed using GraphPad Prism 4.03 software. Experiments were carried out three times independently.</div></div><div id="sec5_2_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i90" class="anchor-spacer"></div><h4 class="article-section__title" id="_i90"> Inhibition of AChE-Induced Aβ<sub>40</sub> Aggregation<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a></h4><div class="NLM_p last">Aβ<sub>40</sub>, supplied as trifluoroacetate salt, was purchased from Bachem AG (Switzerland). Aβ<sub>40</sub> (2 mg mL<sup>–1</sup>) was dissolved in 1,1,1,3,3,3-hexafluoro-2-propanol (HFIP), lyophilized, and redissolved in DMSO to achieve a 2.3 mM stock solution. Stock solutions of tested inhibitors were prepared in methanol (2.0 mM) and diluted in the assay buffer. Aliquots of Aβ<sub>40</sub> peptide (2 μL) were incubated for 24 h at room temperature in 0.215 M sodium phosphate buffer (pH 8.0) at a final concentration of 230 μM. For co-incubation experiment aliquots (16 μL) of hAChE solution (final concentration, 2.30 μM; Aβ/AChE molar ratio, 100:1) and hAChE in the presence of 2 μL of the tested inhibitor (final inhibitor concentration, 100 μM) in 0.215 M sodium phosphate buffer solution (pH 8.0) were added. Blanks containing Aβ<sub>40</sub> alone, hAChE alone, and Aβ<sub>40</sub> plus tested inhibitors in 0.215 M sodium phosphate buffer (pH 8.0) were also prepared. The final volume of each sample was 20 μL. To quantify amyloid fibril formation, the thioflavin T fluorescence method was then applied.<sup>93</sup> The fluorescence intensities related to fibril formation were monitored for 300 s at λ<sub>em</sub> = 490 nm (λ<sub>exc</sub> = 446 nm). Fluorescence intensities of samples without and with an inhibitor were compared, and percent inhibition was calculated.<a onclick="showRef(event, 'ref65'); return false;" href="javascript:void(0);" class="ref ref65">(65)</a> The experiment was carried out two times independently, and each was performed in duplicate.</div></div><div id="sec5_2_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i91" class="anchor-spacer"></div><h4 class="article-section__title" id="_i91"> Inhibition of Aβ<sub>42</sub> Self-Aggregation</h4><div class="NLM_p last">As reported in a previously published protocol,<a onclick="showRef(event, 'ref68'); return false;" href="javascript:void(0);" class="ref ref68">(68)</a> HFIP-pretreated Aβ<sub>42</sub> samples (Bachem AG, Switzerland) were solubilized with a CH<sub>3</sub>CN/0.3 mM Na<sub>2</sub>CO<sub>3</sub>/250 mM NaOH (48.4:48.4:3.2) mixture to obtain a 500 μM stock solution. Experiments were performed by diluting (final Aβ concentration, 50 μM) and incubating the peptide in 10 mM phosphate buffer (pH = 8.0) containing 10 mM NaCl, at 30 °C for 24 h with and without an inhibitor (50 μM, Aβ/inhibitor = 1:1). Blanks containing the tested inhibitors were also prepared. Each assay was run in duplicate. To quantify amyloid fibril formation, the thioflavin T fluorescence method was used.<a onclick="showRef(event, 'ref93'); return false;" href="javascript:void(0);" class="ref ref93">(93)</a> After incubation, samples were diluted to a final volume of 2.0 mL with 50 mM glycine–NaOH buffer (pH 8.5) containing 1.5 μM thioflavin T. A 300 s time scan of the fluorescence intensity was carried out (λ<sub>exc</sub> = 446 nm; λ<sub>em</sub> = 490 nm, FP-6200 fluorometer, Jasco Europe), and values at the plateau were averaged after subtracting the background fluorescence of 1.5 μM thioflavin T solution. The fluorescence intensities obtained in the absence and in the presence of tested inhibitors were compared, and the percent inhibition due to the presence of the inhibitor was calculated by the following formula: 100 – (IF<sub>i</sub>/IF<sub>o</sub> × 100), where IF<sub>i</sub> and IF<sub>o</sub> are the fluorescence intensities obtained for Aβ<sub>42</sub> in the presence and in the absence of inhibitor, respectively. The experiment was carried out two times independently, and each was performed in duplicate.</div></div><div id="sec5_2_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i92" class="anchor-spacer"></div><h4 class="article-section__title" id="_i92"> Radioligand Binding Studies on hCB<sub>2</sub>R and hCB<sub>1</sub>R and Efficacy</h4><div id="sec5_2_6_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i93" class="anchor-spacer"></div><h5 class="article-section__title" id="_i93"> HEK hCB<sub>2</sub>R Cell Line</h5><div class="NLM_p last">Human embryonic kidney cells (HEK) stably expressing the hCB<sub>2</sub>R were grown in Dulbecco’s modified Eagle’s medium containing high glucose supplemented with 8% fetal calf serum and 25 μg/mL zeocin in a 37 °C incubator in the presence of 5% CO<sub>2</sub>. Cells were passaged twice a week.</div></div><div id="sec5_2_6_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i94" class="anchor-spacer"></div><h5 class="article-section__title" id="_i94"> CHO hCB<sub>1</sub>R Cell Line</h5><div class="NLM_p last">Chinese hamster ovary cells (CHO) stably expressing the hCB<sub>1</sub>R were grown in Ham’s F-12 Nutrient Mix supplemented with 8% fetal calf serum and 400 μg/mL geneticin in a 37 °C incubator in the presence of 5% CO<sub>2</sub>. Cells were passaged twice a week.</div></div><div id="sec5_2_6_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i95" class="anchor-spacer"></div><h5 class="article-section__title" id="_i95"> U266 Cell Line</h5><div class="NLM_p last">The U266 cell line was purchased from ATCC (LGC Standards, Milan, IT). Cell authentication was performed by IST (Genova, Italy). Cells were cultured in an RPMI 1640 medium (Lonza, Milan, IT) supplemented with 10% fetal bovine serum (FBS), 2 mM <span class="smallcaps smallerCapital">l</span>-glutamine, 100 IU/mL penicillin, 100 μg/mL ampicillin/streptomycin, 1 mM sodium pyruvate and grown at 37 °C with 5% CO<sub>2</sub> and 95% humidity.</div></div><div id="sec5_2_6_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i96" class="anchor-spacer"></div><h5 class="article-section__title" id="_i96"> Cell Thawing</h5><div class="NLM_p last">Cells were removed from liquid nitrogen stocks and warmed up in a 37 °C water bath. Then, the cells were resuspended in 10 mL of DMEM (high glucose) and 8–10% FCS. The suspension was centrifuged for 5 min at 1000 rpm, and the supernatant was discarded. The pellet was resuspended in 10 mL of DMEM (high glucose) with 2.5 μL (25 μg/mL) of zeocin and 8–10% FCS. The suspension was transferred into a tissue culture flask and then placed in an incubator (37 °C, 5% CO<sub>2</sub>, humid). The medium was changed on the following day.</div></div><div id="sec5_2_6_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i97" class="anchor-spacer"></div><h5 class="article-section__title" id="_i97"> Cell Passaging</h5><div class="NLM_p last">The passaging rate was determined by examining the cells under the light microscope. The medium was discarded, and cells were washed gently by adding 5 mL of PBS. The PBS was discarded, and 3 mL of Trypsin/EDTA was added. The flask was placed in the incubator for 5 min. After incubation, 7 mL of DMEM (high glucose) with 8–10% FCS was added. The cells were washed down and transferred into a falcon tube. The tube was centrifuged for 5 min at 1000 rpm. The supernatant was discarded, and 5–10 mL of DMEM (high glucose) with zeocin (25 μg/mL) and 8–10% FCS was added. The cell suspension was divided into aliquots according to the passaging rate of the cells. Cells were passaged twice a week.</div></div></div><div id="sec5_2_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i98" class="anchor-spacer"></div><h4 class="article-section__title" id="_i98"> Binding Studies</h4><div id="sec5_2_7_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i99" class="anchor-spacer"></div><h5 class="article-section__title" id="_i99"> Membrane Preparation</h5><div class="NLM_p last">The cells were passaged according to their passaging rate (1:8) and plated on petri dishes 3 days before preparation. The preparation itself was carried out on ice. The medium was dispensed, and the cells were washed with 5 mL of PBS. Then, 3.5 mL of preparation buffer (50 mM Tris, 1 mM MgCl<sub>2</sub>·6H<sub>2</sub>O, 1 mM EDTA, pH 7.4) were added. The cells were scrubbed from the surface, and the cell suspensions were combined. The combined suspension was treated two times for 10 s with an ultraturrax. The cell lysate was then centrifuged for 10 min at 3200 rpm at 4 °C. The supernatant was transferred to ultracentrifugation tubes and centrifugated for 50 min at 37,000 rpm at 4 °C. The supernatant was discarded, and the pellet was resuspended in binding buffer (50 mM Tris, 5 mM MgCl<sub>2</sub>·6 H<sub>2</sub>O, 2.5 mM EDTA, pH 7.4). The protein concentration of the pellet was determined using the Bradford assay (according to vendor’s description). The suspension was passaged, and the aliquots were shock-frosted in liquid nitrogen and stored at −80 °C until further use.</div></div><div id="sec5_2_7_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i100" class="anchor-spacer"></div><h5 class="article-section__title" id="_i100"> Radioligand Binding Assay</h5><div class="NLM_p last">SR-144,528 (inverse agonist for hCB<sub>2</sub>R) was purchased from Santa Cruz Biotechnology Inc. Unlabeled CP 55,940 (agonist for hCB<sub>2</sub>R and hCB<sub>1</sub>R) was obtained from Sigma-Aldrich Life Science. Radioactive labeled [<sup>3</sup>H]CP 55,940 was acquired by Hartmann Analytic GmbH. Rimonabant (inverse agonist for hCB<sub>1</sub>R) was obtained by an in-house synthesis. Saturation assays were carried out similar to Murkherjee et al.<a onclick="showRef(event, 'ref94'); return false;" href="javascript:void(0);" class="ref ref94">(94)</a> to determine the <i>K</i><sub>D</sub> value of the membrane samples. Saturation assays were carried out using eight concentrations of [<sup>3</sup>H]CP 55,940, ranging from 0.088 to 4.4 nM. Reactions were started by adding 8 μg membrane per well of a 96 well Multiscreen filter plate (Millipore) containing the radioligand in assay buffer (50 mM Tris-HCl, pH 7.4; 5 mM MgCl<sub>2</sub>·6 H<sub>2</sub>O; 2.5 mM EDTA; 2 mg/mL BSA). After incubating for 3 h at RT, the reaction was stopped by vacuum filtration, and each well was washed four times with 100 μL of cold binding buffer (50 mM Tris-HCl, pH 7.4; 5 mM MgCl<sub>2</sub>·6 H<sub>2</sub>O; 2.5 mM EDTA). The filter plate was dried at 40 °C. The activity was measured in a Microbeta Trilux counter (Wallac) using an IRGA Safe plus-scintillation cocktail (PerkinElmer). Competition assays were performed with 5–11 concentrations of replacing ligands (0.1 nM–0.4 mM) and 0.44 nM [<sup>3</sup>H]CP 55,940. Nonspecific binding was determined using 10 μM <b>2</b> for hCB<sub>2</sub>R and 10 μM rimonabant for hCB<sub>1</sub>R.</div></div><div id="sec5_2_7_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i101" class="anchor-spacer"></div><h5 class="article-section__title" id="_i101"> Statistical Analysis</h5><div class="NLM_p last">To determine the IC<sub>50</sub> values, statistical evaluations and sigmoidal dose–response curve fittings were performed using GraphPad Prism 5 software applying nonlinear regression and one site fit logIC<sub>50</sub> as curve fitting functions. <i>K</i><sub>i</sub> values were determined according to the Cheng–Prusoff equation when the displacement of [<sup>3</sup>H]CP 55,940 was higher than 60% at 100 μM test compound concentration<span class="NLM_disp-formula" id="ueq1"><img class="imgWithoutFigViewer " src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_m001.gif" alt="" id="_i102" /></img></span>with [L*] as radioligand concentration (0.44 nM), and the <i>K</i><sub>i</sub> value was calculated for at least two individual experiments. <i>K</i><sub>D</sub> values and standard errors were determined for <u class="uu">h</u>CB<sub>2</sub>R <i>K</i><sub>D</sub>(hCB<sub>2</sub>R) = 4.16 ± 3.04 and for CB<sub>1</sub>R <i>K</i><sub>D</sub>(hCB<sub>1</sub>R) = 2.24 ± 1.15.</div></div></div><div id="sec5_2_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i103" class="anchor-spacer"></div><h4 class="article-section__title" id="_i103"> hCB<sub>2</sub>R Efficacy</h4><div id="sec5_2_8_1" class="NLM_sec NLM_sec_level_4"><div id="ac_i104" class="anchor-spacer"></div><h5 class="article-section__title" id="_i104"> MTT Assay</h5><div class="NLM_p last">The U266 cell line (4 × 104 cells/mL) was plated on 96-well plates to a final volume of 100 μL/ well. After incubating for 1 day, compounds or vehicles were added at different concentrations. Six replicates were used for each treatment. At the indicated time point, cell viability was assessed by adding 0.8 mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) (Sigma-Aldrich) to the medium. After 3 h, the plates were centrifuged, the supernatant was discarded, and the pellet was solubilized with 100 μL/well DMSO. The absorbance of the samples against a background control (medium alone) was measured at 570 nm using an ELISA reader microliter plate (BioTek Instruments, Winooski, VT, USA). For some experiments, 1 h of preincubation with Forskolin or AM630 was performed. Each sample was evaluated in six wells and in two independent experiments.</div></div><div id="sec5_2_8_2" class="NLM_sec NLM_sec_level_4"><div id="ac_i105" class="anchor-spacer"></div><h5 class="article-section__title" id="_i105"> cAMP Assay</h5><div class="NLM_p last">U266 cells (1 × 10<sup>6</sup>/mL ) were plated in 24-well plates and treated with the appropriate compounds for 2 h. After treatment, the cells were processed for the detection of cAMP levels, using the cAMP assay kit (Enzo Life Sciences, Farmingdale, NY, USA) in accordance to the manufacturer’s protocol. U266 cells were treated with Forskolin (10 μM), AM630 (25 μM), or compound (50 μM) for 2 h. For combination treatments, U266 cells were preincubated with AM630 (25 μM) for 30 min before adding the compounds. The concentration of cAMP was calculated by measuring the absorbance at 450 nm with an ELISA reader. Each compound was evaluated in duplicate and in two independent assays. cAMP levels were stated as pmol/mg protein.</div></div><div id="sec5_2_8_3" class="NLM_sec NLM_sec_level_4"><div id="ac_i106" class="anchor-spacer"></div><h5 class="article-section__title" id="_i106"> RNA Extraction and qRT-PCR</h5><div class="NLM_p last">Total RNA from treated and vehicle U266 cells was extracted using the RNeasy Mini Kit (Qiagen) at the appropriate time points, and cDNA was synthesized using the High-Capacity cDNA Archive Kit (Applied Biosystems, Foster City, PA) according to the manufacturer’s instructions. Quantitative real-time polymerase chain reactions (qRT-PCR) for MIF, STAT-3, and GAPDH were performed using the iQ5 multicolor real-time PCR detection system (Bio-Rad, Hercules, CA). The PCR reaction was performed with SYBR Green qPCR mastermix (Qiagen) using 500 ng of cDNA for the reaction, following the amplification protocol indicated by the manufacturer’s instruction. All samples were tested in triplicates in the same plate, GAPDH levels were used to normalize mRNA contents, and target gene levels were calculated by the 2<sup>–ΔΔCT</sup> method. cDNA from Forskolin-treated cells was used as CREB-induced MIF and STAT-3 as a positive control. cDNA from MD-48-treated cells was used for CB<sub>2</sub> agonist MIF and STAT-3 gene expression control. cDNA from AM630-treated cells was used for antagonist/inverse agonist CB<sub>2</sub> MIF and STAT-3 expression control. Each sample was evaluated in triplicate and in three different experiments.</div></div><div id="sec5_2_8_4" class="NLM_sec NLM_sec_level_4"><div id="ac_i107" class="anchor-spacer"></div><h5 class="article-section__title" id="_i107"> Statistical Analysis</h5><div class="NLM_p last">The statistical significance for MTT and qRT-PCR assays was determined using the analysis of variance (ANOVA) test. The calculation of IC<sub>50</sub> was performed by a nonlinear fit of log-dose versus response, using GraphPad Prism 5.01 software. cAMP concentration was calculated utilizing a four-parameter logistic (4PL) curve fitting program.</div></div><div id="sec5_2_8_5" class="NLM_sec NLM_sec_level_4"><div id="ac_i108" class="anchor-spacer"></div><h5 class="article-section__title" id="_i108"> Calcium Mobilization Assay</h5><div class="NLM_p last">Compounds were tested using a fluorescence-based assay. Briefly, CHO-K1 cells were engineered to either co-express hCB<sub>1</sub>R and G<sub>αq16</sub> or hCB<sub>2</sub>R and G<sub>αq16</sub>. Activation of the receptor therefore leads to mobilization of intracellular calcium. Cells were seeded out in 96-well plates and incubated overnight. The next day, cells were loaded with the fluorescent dye calcein-4 AM. Calcium flux was monitored using an automated plate reader (FlexStation, Molecular Devices). Statistical analysis was performed using GraphPad Prism 5 software.</div></div></div></div><div id="sec5_3" class="NLM_sec NLM_sec_level_2"><div id="ac_i109" class="anchor-spacer"></div><h3 class="article-section__title" id="_i109"> Effects on Microglia</h3><div id="sec5_3_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i110" class="anchor-spacer"></div><h4 class="article-section__title" id="_i110"> Cell Cultures</h4><div class="NLM_p last">Mouse N9 microglial cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM) supplemented with 10% heat-inactivated fetal bovine serum (FBS), 1% penicillin/streptomycin, and 2 mM glutamine (all cell cultures’ reagents were from Aurogene Srl, Rome, Italy). At confluence, after a short wash with sterile PBS, microglia were trypsinized for 5 min at 37 ° C, and trypsin was inactivated with a complete DMEM medium. Detached cells were then collected, centrifuged for 5 min at 300<i>g</i>, and resuspended to be counted. For experiments, microglial cells were plated at the density of 2.5 × 10<sup>5</sup> in a 35 mm Ø dish and exposed to 100 ng/mL lipopolysaccharide (LPS), in the presence or absence of increasing concentrations of the compound to be tested. After 24 h of treatment, microglial conditioned media were collected and partly used for nitrite measurement, partly filtered through 0.22 μm filters, concentrated using Microcon YM-3 (Millipore, Billerica, MA), and resuspended in 12 μL of 4× loading buffer (0.2 M Tris-HCl, pH 6.8; 8% sodium dodecyl sulfate; 40% glycerol; 0.4% bromophenol blue, and 0.4 M dithiothreitol; Sigma-Aldrich) for Western blot analysis. In parallel, microglial cells were collected in 2× loading buffer (LB; 50 μL per dish) for Western blot analysis.</div></div><div id="sec5_3_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i111" class="anchor-spacer"></div><h4 class="article-section__title" id="_i111"> Western Blotting</h4><div class="NLM_p last">Concentrated microglial conditioned media and cell samples were briefly sonicated and loaded into 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE; Bio-Rad). After electrophoresis and transfer onto nitrocellulose membranes (GE Healthcare, Milano, Italy), membranes were blocked for 1 h in blocking solution PBS–0.1% Tween-20 (Sigma-Aldrich), 4% nonfat dry milk (Bio-Rad) and incubated overnight at 4 °C with primary antibodies in PBS–0.1% Tween-20. Primary antibodies used were rabbit anti-iNOS, rabbit anti-IL1β, rabbit anti-TREM2, and rabbit anti-TGFβ2, and mouse anti-GAPDH (all 1:1000 dilution except for anti-GAPDH used 1:20,000 dilution, all from Santa Cruz Biotechnology). Membranes were then incubated with specific secondary antibodies conjugated to horseradish peroxidase (goat anti-rabbit and goat anti-mouse, both at 1:2000 dilution and from Santa Cruz) for 90 min at room temperature in PBS–0.1% Tween-20. Labeled proteins were visualized by using the Clarity Western ECL substrate (Bio-Rad) and detected using Bio-Rad Image Lab software with a ChemiDoc MP imaging system (Bio-Rad).</div></div><div id="sec5_3_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i112" class="anchor-spacer"></div><h4 class="article-section__title" id="_i112"> Nitrite Assay</h4><div class="NLM_p last">Accumulation of nitrite in microglial conditioned media was measured by a colorimetric assay based on the Griess reaction. A nitrate standard curve was performed with NaNO<sub>2</sub> at known concentrations. Sulfanilamide (5 mM; Sigma-Aldrich) was added to the culture medium and the standard curve. Sulfanilamide reacts with nitrite under acidic conditions to form a diazonium cation, which subsequently couples to <i>N</i>-1-naphthyl-ethylenediamine dihydrochloride (NEDA, 40 mM; Sigma-Aldrich) to produce a colored azo dye. After 15 min of incubation at room temperature in the dark, absorbance was read at 540 nm with a multiplate spectrophotometric reader (Bio-Rad Laboratories Srl, Segrate, Milano, Italy).</div></div><div id="sec5_3_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i113" class="anchor-spacer"></div><h4 class="article-section__title" id="_i113"> Statistical Analysis</h4><div class="NLM_p last">All quantitative data are presented as means ± SE from at least three independent experiments. Statistical significance between different treatments was calculated using GraphPad Prism 6 software applying one-way analysis of variance (ANOVA) followed by post hoc comparison through Bonferroni’s test. A value of <i>p</i> < 0.05 was considered statistically significant.</div></div></div><div id="sec5_4" class="NLM_sec NLM_sec_level_2"><div id="ac_i114" class="anchor-spacer"></div><h3 class="article-section__title" id="_i114"> Neuroprotection on HT-22 Cells</h3><div id="sec5_4_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i115" class="anchor-spacer"></div><h4 class="article-section__title" id="_i115"> Cell Culture</h4><div class="NLM_p last">HT-22 cells were grown in Dulbecco’s modified Eagle’s medium (DMEM, Sigma-Aldrich, Munich, Germany) supplemented with 10% (v/v) heat-inactivated fetal calf serum (FCS) and 1% (v/v) penicillin/streptomycin. Cells were passaged every 2 days and incubated at 37 °C with 5% CO<sub>2</sub> in a humidified incubator. Compounds were dissolved in DMSO, (Sigma-Aldrich, Munich, Germany) and diluted with medium. Generally, 80% confluent cells were seeded with 5000 cells per well into sterile 96-well plates and were incubated for 24 h.</div></div><div id="sec5_4_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i116" class="anchor-spacer"></div><h4 class="article-section__title" id="_i116"> Neurotoxicity</h4><div class="NLM_p last">For the neurotoxicity assay, the previous medium was discarded, and different concentrations of the compound were added to the wells. DMSO (0.5%) in DMEM served as control. Cells were incubated for 24 h. After incubation, an MTT assay was performed.</div></div><div id="sec5_4_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i117" class="anchor-spacer"></div><h4 class="article-section__title" id="_i117"> Neuroprotection</h4><div class="NLM_p last">For neuroprotection, 5 mM glutamate (monosodium-<span class="smallcaps smallerCapital">l</span>-glutamate, Sigma-Aldrich, Munich, Germany) was co-incubated with different concentrations of respective compounds for 24 h. Quercetin (25 μM, Sigma-Aldrich, Munich, Germany) served as a positive control. After 24 h of incubation, an MTT assay was performed.</div></div><div id="sec5_4_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i118" class="anchor-spacer"></div><h4 class="article-section__title" id="_i118"> MTT Assay</h4><div class="NLM_p last">Cell viability was determined using the 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT, Sigma-Aldrich, Munich, Germany) assay. MTT solution (4 mg/mL in PBS) was diluted 1:10 with medium and added to the wells after removal of the previous medium. Cells were incubated for 3 h when the supernatant was removed and lysis buffer (10% SDS) was applied. The next day, absorbance at 560 nm was determined with a multiwell plate photometer (Tecan, SpectraMax 250).</div></div><div id="sec5_4_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i119" class="anchor-spacer"></div><h4 class="article-section__title" id="_i119"> Statistical Analysis</h4><div class="NLM_p last">Results are presented as percentage to untreated control cells. Data are expressed as means ± SD of three different independent experiments, and each was performed in sextuplicate. Analysis was accomplished using GraphPad Prism 5 software applying one-way ANOVA followed by Dunnett’s multiple comparison post-test. Levels of significance: *<i>p</i> < 0.05; **<i>p</i> < 0.01; ***<i>p</i> < 0.001.</div></div></div><div id="sec5_5" class="NLM_sec NLM_sec_level_2"><div id="ac_i120" class="anchor-spacer"></div><h3 class="article-section__title" id="_i120"> In Vivo Studies</h3><div id="sec5_5_1" class="NLM_sec NLM_sec_level_3"><div id="ac_i121" class="anchor-spacer"></div><h4 class="article-section__title" id="_i121"> Aim of the Study</h4><div class="NLM_p last">To test five compounds <b>3a</b>, <b>3d</b>, <b>3e</b>, <b>4a</b>, and <b>6</b> as protectant drugs in the in vivo mouse model of Alzheimer’s disease induced by intracerebroventricular (i.c.v.) injection of oligomerized Aβ<sub>25–35</sub> peptide. Each compound was injected intraperitoneally (i.p.) o.d. between day 1 and 7, as summarized in <a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">Supplementary Figure 4</a>. The peptide was injected on day 1, and behavioral examination was performed between days 8 and 10. All animals were then sacrificed on day 11 and their brain stored at −80 °C awaiting further biochemical analyses. In addition, the livers of high dose-treated animals (3 mg/kg) were removed and fixed in formaldehyde solution.</div></div><div id="sec5_5_2" class="NLM_sec NLM_sec_level_3"><div id="ac_i122" class="anchor-spacer"></div><h4 class="article-section__title" id="_i122"> Animals</h4><div class="NLM_p last">Male Swiss mice, 6 weeks old and weighing 30–35 g, from Janvier (Saint-Berthevin, France), were kept for housing, and experiments took place within the animal facility building of the University of Montpellier (CECEMA, Office of Veterinary Services agreement #B-34-172-23). Animals were housed in groups with access to food and water ad libitum, except during behavioral experiments. They were kept in a temperature and humidity-controlled animal facility on a 12 h/12 h light/dark cycle (lights off at 07:00 p.m.). All animal procedures were conducted in strict adherence to the European Union directive of September 22, 2010 (2010/63/UE) and authorized (file #1485-15034) by the National Ethic Committee (Paris, France).</div></div><div id="sec5_5_3" class="NLM_sec NLM_sec_level_3"><div id="ac_i123" class="anchor-spacer"></div><h4 class="article-section__title" id="_i123"> Drug Preparation</h4><div class="NLM_p last">Compounds were weighed and solubilized in pure DMSO, and a stock solution at 2 mg/mL was prepared in DMSO/ddH<sub>2</sub>O. The percentage of DMSO in ddH<sub>2</sub>O for 3 mg/kg dose was 30%. Stock solution in DMSO was stored for 1 week at +4 °C, and the injection solutions were made fresh daily. Vehicle solutions used for control groups were DMSO 30% in H<sub>2</sub>O.</div></div><div id="sec5_5_4" class="NLM_sec NLM_sec_level_3"><div id="ac_i124" class="anchor-spacer"></div><h4 class="article-section__title" id="_i124"> Amyloid Peptide Preparation and Injection</h4><div class="NLM_p last">Mice were anesthetized with isoflurane 2.5% and were injected i.c.v. with Aβ<sub>25–35</sub> peptide (9 nmol/mouse) or vehicle solution (distilled water), in a final volume of 3 μL/mouse, according to the previously described method.<a onclick="showRef(event, 'ref87 ref95 ref96 ref97 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref87 ref95 ref96 ref97 ref98 ref99">(87,95−99)</a> Homogeneous oligomeric preparation of Aβ<sub>25–35</sub> peptide was performed by incubation for 4 days at 37 °C according to Maurice et al.<a onclick="showRef(event, 'ref87'); return false;" href="javascript:void(0);" class="ref ref87">(87)</a> Since it is well established that vehicle solution similar as a control scrambled Aβ<sub>25–35</sub> peptide failed to induce toxicity and therefore affect learning abilities, vehicle-treated animals served as controls.<a onclick="showRef(event, 'ref87 ref95 ref96 ref97 ref98 ref99 ref100'); return false;" href="javascript:void(0);" class="ref ref87 ref95 ref96 ref97 ref98 ref99 ref100">(87,95−100)</a></div></div><div id="sec5_5_5" class="NLM_sec NLM_sec_level_3"><div id="ac_i125" class="anchor-spacer"></div><h4 class="article-section__title" id="_i125"> Spontaneous Alternation Performances</h4><div class="NLM_p last">On day 8, all animals were tested for spontaneous alternation performance in the Y maze, an index of spatial working memory. The Y maze is made of gray polyvinyl chloride. Each arm is 40 cm long, 13 cm high, 3 cm wide at the bottom, 10 cm wide at the top, and converging at an equal angle. Each mouse will be placed at the end of one arm and allowed to move freely through the maze during an 8 min session. The series of arm entries, including possible returns into the same arm, was checked visually. An alternation was defined as entries into all three arms on consecutive occasions. The number of maximum alternations is, therefore, the total number of arm entries minus two, and the percentage of alternation was calculated as (actual alternations/maximum alternations) × 100. Parameters included the percentage of alternation (memory index) and the total number of arm entries (exploration index).<a onclick="showRef(event, 'ref87 ref95 ref96 ref98 ref99'); return false;" href="javascript:void(0);" class="ref ref87 ref95 ref96 ref98 ref99">(87,95,96,98,99)</a> Animals that shown an extreme behavior (alternation percentage of <20% or >90% or number of arm entries <10) were discarded from the calculation. In this study, 11 animals were discarded accordingly (3.2% attrition).</div></div><div id="sec5_5_6" class="NLM_sec NLM_sec_level_3"><div id="ac_i126" class="anchor-spacer"></div><h4 class="article-section__title" id="_i126"> Passive Avoidance Test</h4><div class="NLM_p last">On days 9 and 10, a passive avoidance test was performed. The apparatus is a two-compartment (15 × 20 × 15 cm high) box with one compartment illuminated with white polyvinyl chloride walls and the other darkened with black polyvinyl chloride walls and a grid floor. A guillotine door separates each compartment. A 60 W lamp positioned 40 cm above the apparatus lights up the white compartment during the experiment. Scrambled foot shocks (0.3 mA for 3 s) were delivered to the grid floor using a shock generator scrambler (Lafayette Instruments, Lafayette, USA). The guillotine door was initially closed during the training session. During the training session, on day 9, each mouse was placed into the white compartment. After 5 s, the door was raised. When the mouse entered the darkened compartment and placed all its paws on the grid floor, the door was closed, and the foot shock was delivered for 3 s. The step-through latency, that is, the latency spent to enter the darkened compartment, and the number of vocalizations was recorded. The retention test was carried out 24 h after training, on day 10. Each mouse was placed again into the white compartment. After 5 s, the door was raised. The step-through and escape latencies (corresponding to the re-exit from the darkened compartment) were recorded up to 300 s. Animals that show all latencies during the training and retention session lower than 10 s are considered as failing to respond to the procedure and were discarded from the calculations. In this study, nine animals were discarded accordingly (2.6% attrition).</div></div><div id="sec5_5_7" class="NLM_sec NLM_sec_level_3"><div id="ac_i127" class="anchor-spacer"></div><h4 class="article-section__title" id="_i127"> Sacrifice and Brain and Liver Sampling</h4><div class="NLM_p last">On day 11, all animals were sacrificed, their brains dissected out to isolate the hippocampus and cortex. Samples were frozen in liquid nitrogen and stored at −80 °C awaiting further analysis. For treated with the high dose (3 mg/kg) of compounds, the livers were also dissected out, post-fixed in formalin, and kept at 4 °C.</div></div><div id="sec5_5_8" class="NLM_sec NLM_sec_level_3"><div id="ac_i128" class="anchor-spacer"></div><h4 class="article-section__title" id="_i128"> Statistical Analyses</h4><div class="NLM_p last">All values, except passive avoidance latencies, were expressed as means ± SEM. Statistical analyses were performed on the different conditions using one-way ANOVA (<i>F</i> value), followed by Dunnett’s post hoc multiple comparison test. Passive avoidance latencies do not follow a Gaussian distribution since upper cutoff times are set. They were therefore analyzed using a Kruskal–Wallis nonparametric ANOVA (<i>H</i> value), followed by Dunn’s multiple comparison test. <i>p</i> < 0.05 was considered as statistically significant.</div></div></div></div><div class="NLM_back"><div class="article_supporting-info" id="notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i129"><a href="/doi/suppl/10.1021/acs.jmedchem.9b00623" class="ext-link">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_77684" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_77684" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a href="/" class="ext-link">ACS Publications website</a> at DOI: <a href="/doi/abs/10.1021/acs.jmedchem.9b00623" class="ext-link">10.1021/acs.jmedchem.9b00623</a>.<ul class="NLM_list-list_type-label" id="silist"><li><p class="inline">RP-HPLC chromatograms of the lead compounds (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf" class="ext-link">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (<a href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_002.csv" class="ext-link">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf">jm9b00623_si_001.pdf (794.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_002.csv">jm9b00623_si_002.csv (4.25 kb)</a></li></ul></div></div></div><div class="testing" data-doi="10.1021/acs.jmedchem.9b00623" data-url="https://widgets.figshare.com/static/figshare.js" id="figshare-widget"></div><div class="TermsAndConditionsDropzone3" data-pb-dropzone="TermsAndConditionsDropzone3"><div data-widget-def="UX3HTMLWidget" data-widget-id="85b54935-30e9-4058-a6d2-0b40fb754a85" class="mb-4">
        



        
            <h2 class="">
                Terms & Conditions
            </h2>
        
        <p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system: <a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div><div class="authorInformationSection"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="authorInformationSection">Author Information</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_13173" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_13173" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><ul><li><span class="author-information-subsection-header">Corresponding Author</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Decker</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-6773-6245" title="Orcid link">http://orcid.org/0000-0002-6773-6245</a>; 
    </span><span class="author-email">
                Email: <a href="/cdn-cgi/l/email-protection#84e9ede7ece5e1e8aae0e1e7efe1f6c4f1eaeda9f3f1e1f6fee6f1f6e3aae0e1"><span class="__cf_email__" data-cfemail="f895919b90999d94d69c9d9b939d8ab88d9691d58f8d9d8a829a8d8a9fd69c9d">[email protected]</span></a></span></div></li></ul></li><li><span class="author-information-subsection-header">Authors</span><ul><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Scheiner</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Dominik Dolles</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sandra Gunesch</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Matthias Hoffmann</span> - <span class="hlFld-Affiliation affiliation">Pharmaceutical
and Medicinal Chemistry, Institute of Pharmacy and Food Chemistry, Julius Maximilian University of Würzburg, Am Hubland, 97074 Würzburg, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Massimo Nabissi</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Oliviero Marinelli</span> - <span class="hlFld-Affiliation affiliation">School
of Pharmacy, University of Camerino, Via Madonna delle Carceri 9, 62032 Camerino, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Marina Naldi</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro 6, 40126 Bologna, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Manuela Bartolini</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, Via Belmeloro 6, 40126 Bologna, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Sabrina Petralla</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, Via Selmi 3, 40126 Bologna, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Eleonora Poeta</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, Via Selmi 3, 40126 Bologna, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Barbara Monti</span> - <span class="hlFld-Affiliation affiliation">Department
of Pharmacy and Biotechnology, University
of Bologna, Via Selmi 3, 40126 Bologna, Italy</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Christina Falkeis</span> - <span class="hlFld-Affiliation affiliation">Pathology,
Clinical Center Bayreuth, Preuschwitzer Straße 101, 95445 Bayreuth, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Michael Vieth</span> - <span class="hlFld-Affiliation affiliation">Pathology,
Clinical Center Bayreuth, Preuschwitzer Straße 101, 95445 Bayreuth, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Harald Hübner</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany</span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Peter Gmeiner</span> - <span class="hlFld-Affiliation affiliation">Medicinal
Chemistry, Department of Chemistry and Pharmacy, Friedrich-Alexander University Erlangen-Nürnberg, Schuhstraße 19, 91052 Erlangen, Germany</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0002-4127-197X" title="Orcid link">http://orcid.org/0000-0002-4127-197X</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Rangan Maitra</span> - <span class="hlFld-Affiliation affiliation">Center
for Drug Discovery, Research Triangle Institute, Research Triangle Park, North Carolina 27709, United States</span>; 
    <span class="author-orcid"><img src="/products/achs/releasedAssets/images/orchid.png" alt="Orcid" /></img><a href="http://orcid.org/0000-0001-6663-6800" title="Orcid link">http://orcid.org/0000-0001-6663-6800</a></span></div></li><li><div class="authorItemInformation"><span class="hlFld-ContribAuthor strong">Tangui Maurice</span> - <span class="hlFld-Affiliation affiliation">MMDN, University of Montpellier, INSERM,
EPHE, UMR-S1198, 34095 Montpellier, France</span></div></li></ul></li><li><span class="author-information-subsection-header">Author Contributions</span><p>Synthesis of the target compounds was performed by M.S. and D.D. Inhibitory, kinetic studies on hAChE and Aß aggregation were performed by M.O., M.N., and M.B. Inhibitory potency on hBChE and hAChE was performed by S.G. and M.H., radioligand binding studies on CBRs by M.S., and CB2R efficacy by cAMP-regulated gene expression by M.N. The calcium mobilization assay on CBRs was performed by R.M. and neuroprotection and neurotoxicity experiments by S.G. and M.S. Microglia effects were investigated by S.P., E.P., and B.M., and in vivo experiments were performed by M.S. and T.M. and liver histology by C.F. and M.V. Finally, MOR binding studies were performed by H.H. and P.G. All authors contributed to writing the manuscript and read and approved the final version.</p></li><li><span class="author-information-subsection-header">Funding</span><p>M.D. acknowledges the German Research Council (Deutsche Forschungsgemeinschaft (DFG) DFG DE 1546/6-3 and M.D. and T.M. also acknowledge support from Campus France (PHC Procope) and the German Academic Exchange Service (DAAD) with funds of the Federal Ministry of Education and Research (BMBF). The Italian Ministry of Education, Universities and Research (MIUR) is acknowledged for financial support. M.H. acknowledges the German Academic Scholarship Foundation (“Studienstiftung des deutschen Volkes”) for a Ph.D. fellowship and the Elite Network of Bavaria (International Doctoral program “Receptor Dynamics”) for support.</p></li><li><span class="author-information-subsection-header">Notes</span><div class="authorInformation_notesSection">The authors declare no competing financial interest.<br /></br></div></li></ul></div><div class="ack" id="ack1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i131">Acknowledgments</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_40768" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_40768" class="dropBlock__holder"></div></div></div></div></div><hr /></hr><p class="last">We thank O. Lockridge (University of Nebraska Medical Center) for providing human BChE. We thank S. Kachler and Professor K.-N. Klotz (Institute of Pharmacology and Toxicology, University of Würzburg) for technical support and workspace for radioligand binding studies. Mrs. Nicola Arveda’s technical assistance is acknowledged for the assays involving hAChE.</p></div><table summary="" class="NLM_def-list" id="dl1"><tr><td colspan="2" class="NLM_title">Abbreviations</td></tr><tr><td class="NLM_term">Aβ</td><td class="NLM_def"><p class="first last">amyloid-beta</p></td></tr><tr><td class="NLM_term">ACh</td><td class="NLM_def"><p class="first last">acetylcholine</p></td></tr><tr><td class="NLM_term">AChE</td><td class="NLM_def"><p class="first last">acetylcholinesterase</p></td></tr><tr><td class="NLM_term">ACth</td><td class="NLM_def"><p class="first last">acetylthiocholine</p></td></tr><tr><td class="NLM_term">AD</td><td class="NLM_def"><p class="first last">Alzheimer’s disease</p></td></tr><tr><td class="NLM_term">ANOVA</td><td class="NLM_def"><p class="first last">analysis of variance</p></td></tr><tr><td class="NLM_term">APP</td><td class="NLM_def"><p class="first last">amyloid precursor protein</p></td></tr><tr><td class="NLM_term">BBB</td><td class="NLM_def"><p class="first last">blood–brain-barrier</p></td></tr><tr><td class="NLM_term">BChE</td><td class="NLM_def"><p class="first last">butyrylcholinesterase</p></td></tr><tr><td class="NLM_term">cAMP</td><td class="NLM_def"><p class="first last">cyclic adenosine monophosphate</p></td></tr><tr><td class="NLM_term">CAS</td><td class="NLM_def"><p class="first last">catalytic active site</p></td></tr><tr><td class="NLM_term">ChE</td><td class="NLM_def"><p class="first last">cholinesterase</p></td></tr><tr><td class="NLM_term">CHO</td><td class="NLM_def"><p class="first last">Chinese hamster ovary</p></td></tr><tr><td class="NLM_term">CNS</td><td class="NLM_def"><p class="first last">central nervous system</p></td></tr><tr><td class="NLM_term">Cpd</td><td class="NLM_def"><p class="first last">compound</p></td></tr><tr><td class="NLM_term">CRE</td><td class="NLM_def"><p class="first last">cAMP response element</p></td></tr><tr><td class="NLM_term">CREB</td><td class="NLM_def"><p class="first last">cAMP response element-binding protein</p></td></tr><tr><td class="NLM_term">DMSO</td><td class="NLM_def"><p class="first last">dimethyl sulfoxide</p></td></tr><tr><td class="NLM_term">FSK</td><td class="NLM_def"><p class="first last">forskolin</p></td></tr><tr><td class="NLM_term">GAPDH</td><td class="NLM_def"><p class="first last">glycerinaldehyde-3-phosphat-dehydrogenase</p></td></tr><tr><td class="NLM_term">GTP<sub>ϒ</sub>S</td><td class="NLM_def"><p class="first last">guanosine 5′[ϒ-thio]triphosphate</p></td></tr><tr><td class="NLM_term">HBTU</td><td class="NLM_def"><p class="first last">2-(1<i>H</i>-benzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexafluorophosphate</p></td></tr><tr><td class="NLM_term">hCB<sub>1/2</sub>R</td><td class="NLM_def"><p class="first last">human cannabinoid receptor 1/2</p></td></tr><tr><td class="NLM_term">HEK</td><td class="NLM_def"><p class="first last">human embryotic kidney</p></td></tr><tr><td class="NLM_term">i.c.v.</td><td class="NLM_def"><p class="first last">intracerebroventricular</p></td></tr><tr><td class="NLM_term">Il1β</td><td class="NLM_def"><p class="first last">interleukin 1 beta</p></td></tr><tr><td class="NLM_term">iNOS</td><td class="NLM_def"><p class="first last">inducible nitric oxide synthase</p></td></tr><tr><td class="NLM_term">i.p..</td><td class="NLM_def"><p class="first last">intraperitoneal</p></td></tr><tr><td class="NLM_term">LPS</td><td class="NLM_def"><p class="first last">lipopolysaccharide</p></td></tr><tr><td class="NLM_term">MIF</td><td class="NLM_def"><p class="first last">macrophage migration inhibitory factor</p></td></tr><tr><td class="NLM_term">MTT</td><td class="NLM_def"><p class="first last">3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide</p></td></tr><tr><td class="NLM_term">NMDA</td><td class="NLM_def"><p class="first last"><i>N</i>-methyl-<span class="smallcaps smallerCapital">d</span>-aspartate;</p></td></tr><tr><td class="NLM_term">MOR</td><td class="NLM_def"><p class="first last">μ-opioid receptor</p></td></tr><tr><td class="NLM_term">PAS</td><td class="NLM_def"><p class="first last">peripheral anionic site</p></td></tr><tr><td class="NLM_term">PEG</td><td class="NLM_def"><p class="first last">polyethylene glycol</p></td></tr><tr><td class="NLM_term">ROS</td><td class="NLM_def"><p class="first last">reactive oxygen species</p></td></tr><tr><td class="NLM_term">(q)RT/PCR</td><td class="NLM_def"><p class="first last">(quantitative) reverse transcription polymerase chain reaction</p></td></tr><tr><td class="NLM_term">SAR</td><td class="NLM_def"><p class="first last">structure–activity relationship</p></td></tr><tr><td class="NLM_term">SD</td><td class="NLM_def"><p class="first last">standard deviation</p></td></tr><tr><td class="NLM_term">SR</td><td class="NLM_def"><p class="first last">scavenger receptor</p></td></tr><tr><td class="NLM_term">STAT-3</td><td class="NLM_def"><p class="first last">signal transducer and activator of transcription</p></td></tr><tr><td class="NLM_term">ST-PA</td><td class="NLM_def"><p class="first last">step-through passive avoidance</p></td></tr><tr><td class="NLM_term">TGFβ2</td><td class="NLM_def"><p class="first last">transforming growth factor beta-2</p></td></tr><tr><td class="NLM_term">THC</td><td class="NLM_def"><p class="first last">tetrahydrocannabinol</p></td></tr><tr><td class="NLM_term">THF</td><td class="NLM_def"><p class="first last">tetrahydrofuran</p></td></tr><tr><td class="NLM_term">TNF</td><td class="NLM_def"><p class="first last">tumor necrosis factor</p></td></tr><tr><td class="NLM_term">TREM2</td><td class="NLM_def"><p class="first last">triggering receptor expressed on myeloid cells 2</p></td></tr><tr><td class="NLM_term">V or VEI</td><td class="NLM_def"><p class="first last">vehicle</p></td></tr><tr><td class="NLM_term">YMT</td><td class="NLM_def"><p class="first last">Y-maze test</p></td></tr></table><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_05607" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_05607" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="references-count">
            This article references 100 other publications.
        </p><ol id="references" class="useLabel"><li id="ref1"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref1'); return false;" data-citation="" class="refNumLink">1</a></strong><div class="NLM_citation" id="cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C.</span></span> <i>World Alzheimer report 2018</i>; <span class="NLM_publisher-name">ADI</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">48</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1-48&author=C.+Patterson&title=World+Alzheimer+report+2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DC.%26btitle%3DWorld%2520Alzheimer%2520report%25202018%26pub%3DADI%26date%3D2018%26spage%3D1%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref2"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref2'); return false;" data-citation="" class="refNumLink">2</a></strong><div class="NLM_citation" id="cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zemek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drtinova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.914168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1517%2F14740338.2014.914168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24845946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=759-774&author=F.+Zemekauthor=L.+Drtinovaauthor=E.+Nepovimovaauthor=V.+Sepsovaauthor=J.+Korabecnyauthor=J.+Klimesauthor=K.+Kuca&title=Outcomes+of+Alzheimer%E2%80%99s+disease+therapy+with+acetylcholinesterase+inhibitors+and+memantine&doi=10.1517%2F14740338.2014.914168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine</span></div><div class="casAuthors">Zemek, Filip; Drtinova, Lucie; Nepovimova, Eugenie; Sepsova, Vendula; Korabecny, Jan; Klimes, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-774</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing no. of people and countries.  Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike.  Moreover, no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point.  An increasing no. of novel approaches have been tested in numerous clin. trials, but none of them has proved safe and effective for treating AD.  Areas covered: This review summarizes all currently available compds. (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concg. on clin. aspects such as the mechanisms of action, pharmacokinetics, pharmacodynamics and clin. trials.  This review also considers the mechanisms and side effects to provide perspective on current treatment options.  Expert opinion: Novel approaches in the treatment of AD are being intensively tested, but so far without any major success.  Patients diagnosed with AD still mostly benefit from four compds. to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCHTA-GByu7Vg90H21EOLACvtfcHk0lh9iA865qzyFg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D&md5=5dfa0e4ee53453755456895458e49a29</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.914168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.914168%26sid%3Dliteratum%253Aachs%26aulast%3DZemek%26aufirst%3DF.%26aulast%3DDrtinova%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DKlimes%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DOutcomes%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%2520with%2520acetylcholinesterase%2520inhibitors%2520and%2520memantine%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D759%26epage%3D774%26doi%3D10.1517%2F14740338.2014.914168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref3"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref3'); return false;" data-citation="" class="refNumLink">3</a></strong><div class="NLM_citation" id="cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glenner, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. W.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(84)80190-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0006-291X%2884%2980190-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=6375662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL2cXitVOntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1984&pages=885-890&author=G.+G.+Glennerauthor=C.+W.+Wong&title=Alzheimer%E2%80%99s+disease%3A+initial+report+of+the+purification+and+characterization+of+a+novel+cerebrovascular+amyloid+protein&doi=10.1016%2FS0006-291X%2884%2980190-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease:  initial report of the purification and characterization of a novel cerebrovascular amyloid protein</span></div><div class="casAuthors">Glenner, George G.; Wong, Caine W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">885-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A purified protein derived from the twisted β-pleated sheet fibrils in cerebrovascular amyloidosis assocd. with Alzheimer's disease was isolated by Sephadex G-100 column chromatog. with 5 M guanidine-HCl in 1 N acetic acid and by HPLC.  Partial amino acid sequence anal. and a computer search reveals this protein to have nohomol. with any protein sequenced thus far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqimb5yE9JMLrVg90H21EOLACvtfcHk0lgdlUVfUAj6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXitVOntLw%253D&md5=e30caf2b0d9c41ee223b53ffe7a690dd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2884%2980190-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252884%252980190-4%26sid%3Dliteratum%253Aachs%26aulast%3DGlenner%26aufirst%3DG.%2BG.%26aulast%3DWong%26aufirst%3DC.%2BW.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520initial%2520report%2520of%2520the%2520purification%2520and%2520characterization%2520of%2520a%2520novel%2520cerebrovascular%2520amyloid%2520protein%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1984%26volume%3D120%26spage%3D885%26epage%3D890%26doi%3D10.1016%2FS0006-291X%2884%2980190-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref4"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref4'); return false;" data-citation="" class="refNumLink">4</a></strong><div class="NLM_citation" id="cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4913</span>– <span class="NLM_lpage">4917</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.13.4913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.83.13.4913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=3088567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=4913-4917&author=I.+Grundke-Iqbalauthor=K.+Iqbalauthor=Y.+C.+Tungauthor=M.+Quinlanauthor=H.+M.+Wisniewskiauthor=L.+I.+Binder&title=Abnormal+phosphorylation+of+the+microtubule-associated+protein+%CF%84+%28tau%29+in+Alzheimer+cytoskeletal+pathology&doi=10.1073%2Fpnas.83.13.4913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span></div><div class="casAuthors">Grundke-Iqbal, Inge; Iqbal, Khalid; Tung, Yunn Chyn; Quinlan, Maureen; Wisniewski, Henryk M.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4913-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A monoclonal antibody to the microtubule-assocd. protein τ (tau) labeled some neurofibrillary tangles and plaque neurites, the 2 major locations of paired-helical filaments (PHF), in Alzheimer disease brain.  The antibody also labeled isolated PHF that had been repeatedly washed with SDS.  Dephosphorylation of the tissue sections with alk. phosphatase prior to immunolabeling dramatically increased the no. of tangles and plaques recognized by the antibody.  The plaque core amyloid was not stained in either dephosphorylated or nondephosphorylated tissue sections.  On immunoblots PHF polypeptides were labeled readily only when dephosphorylated.  In contrast, a com. available monoclonal antibody to a phosphorylated epitope of neurofilaments that labeled the tangles and the plaque neurites in tissue did not label any PHF polypeptides on immunoblots.  The PHF polypeptides, labeled with the monoclonal antibody to τ, electrophoresed with those polypeptides recognized by antibodies to isolated PHF.  The antibody to τ labeled microtubules from normal human brains assembled in vitro but identically treated Alzheimer brain prepns. had to be dephosphorylated to be completely recognized by this antibody.  These findings suggest that τ in Alzheimer brain is an abnormally phosphorylated protein component of PHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcyxbsq2aXprVg90H21EOLACvtfcHk0lgdlUVfUAj6CA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D&md5=3ac88b7002e26c53c54e71a3a91471ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.13.4913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.13.4913%26sid%3Dliteratum%253Aachs%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DY.%2BC.%26aulast%3DQuinlan%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DH.%2BM.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DAbnormal%2520phosphorylation%2520of%2520the%2520microtubule-associated%2520protein%2520%25CF%2584%2520%2528tau%2529%2520in%2520Alzheimer%2520cytoskeletal%2520pathology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D4913%26epage%3D4917%26doi%3D10.1073%2Fpnas.83.13.4913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref5"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref5'); return false;" data-citation="" class="refNumLink">5</a></strong><div class="NLM_citation" id="cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2012.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.pneurobio.2012.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22459297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BC38rgs1GgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=38-51&author=I.+Ferrer&title=Defining+Alzheimer+as+a+common+age-related+neurodegenerative+process+not+inevitably+leading+to+dementia&doi=10.1016%2Fj.pneurobio.2012.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia</span></div><div class="casAuthors">Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the description by Alois Alzheimer, more than 50 years have passed during which senile dementia and pre-senile dementia have been considered Alzheimer disease (AD) on the basis of their common neuropathological and clinical manifestations.  AD now covers pre-senile dementia, senile dementia, mild cognitive impairment and pre-clinical AD, all of them within the context of AD-related pathology.  However, there is still a gray area between normal aging with AD-related pathology and AD.  Here it is proposed that Alzheimer (or alzheimer) is an age-related neurodegenerative process distinguished from normal aging by the presence of senile plaques and neurofibrillary tangles.  Alzheimer affects about 80% of individuals aged 65 years but dementia only occurs in a small percentage of individuals at this age; prevalence of dementia in Alzheimer increases to 25% in individuals aged 80 years.  The concepts derived from the β-amyloid hypothesis support β-amyloid as a conductor in the pathogenesis of familial AD and as a prodding factor in sporadic AD.  Moreover, seeding of β-amyloid and truncated tau explains incorporation, enhancement and perpetuation of AD-related changes.  Therefore, the earliest Alzheimer changes confined to selected regions are the first grounds and the main risk factor for developing dementia.  The term Alzheimer embraces this assumption and likens its meaning to other degenerative biological processes, such as atherosclerosis, that may eventually progress to disease.  In this context, the first stages of Alzheimer should be considered as primary targets of therapeutic intervention in order to prevent progression to diseased states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8RZSMq5h6HMAKB7Fa-xrUfW6udTcc2eZhf3R5kkb6ULntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgs1GgtA%253D%253D&md5=60276ba23f11747b14a35ea1e18c45bf</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2012.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2012.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DDefining%2520Alzheimer%2520as%2520a%2520common%2520age-related%2520neurodegenerative%2520process%2520not%2520inevitably%2520leading%2520to%2520dementia%26jtitle%3DProg.%2520Neurobiol.%26date%3D2012%26volume%3D97%26spage%3D38%26epage%3D51%26doi%3D10.1016%2Fj.pneurobio.2012.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref6"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref6'); return false;" data-citation="" class="refNumLink">6</a></strong><div class="NLM_citation" id="cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutzendler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.-B.</span></span> <span> </span><span class="NLM_article-title">Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1181</span>, <span class="refDoi"> DOI: 10.1038/nn1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnn1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15475950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1181&author=J.+Tsaiauthor=J.+Grutzendlerauthor=K.+Duffauthor=W.-B.+Gan&title=Fibrillar+amyloid+deposition+leads+to+local+synaptic+abnormalities+and+breakage+of+neuronal+branches&doi=10.1038%2Fnn1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches</span></div><div class="casAuthors">Tsai, Julia; Grutzendler, Jaime; Duff, Karen; Gan, Wen-Biao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1181-1183</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amyloid plaques are a hallmark of Alzheimer disease, but their importance in its pathogenesis is controversial.  By neuronal labeling and transcranial two-photon imaging, we show in a transgenic mouse model of Alzheimer disease that dendrites passing through or near fibrillar amyloid deposits undergo spine loss and shaft atrophy, and nearby axons develop large varicosities, together leading to neurite breakage and large-scale, permanent disruption of neuronal connections.  Thus, fibrillar amyloid deposition is more detrimental to neuronal circuitry than previously thought, underscoring the importance of prevention and early clearance of plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE4pZtUunDnbVg90H21EOLACvtfcHk0lhnhcN8gIWgYA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7o%253D&md5=5c8f894f6b8246f784d70f836a9b7a5a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnn1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1335%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DGrutzendler%26aufirst%3DJ.%26aulast%3DDuff%26aufirst%3DK.%26aulast%3DGan%26aufirst%3DW.-B.%26atitle%3DFibrillar%2520amyloid%2520deposition%2520leads%2520to%2520local%2520synaptic%2520abnormalities%2520and%2520breakage%2520of%2520neuronal%2520branches%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26spage%3D1181%26doi%3D10.1038%2Fnn1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref7"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref7'); return false;" data-citation="" class="refNumLink">7</a></strong><div class="NLM_citation" id="cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Isla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Growdon, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span> <span> </span><span class="NLM_article-title">Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1002/ana.410410106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fana.410410106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9005861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK2s7lvVGjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=17-24&author=T.+G%C3%B3mez-Islaauthor=R.+Hollisterauthor=H.+Westauthor=S.+Muiauthor=J.+H.+Growdonauthor=R.+C.+Petersenauthor=J.+E.+Parisiauthor=B.+T.+Hyman&title=Neuronal+loss+correlates+with+but+exceeds+neurofibrillary+tangles+in+Alzheimer%E2%80%99s+disease&doi=10.1002%2Fana.410410106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease</span></div><div class="casAuthors">Gomez-Isla T; Hollister R; West H; Mui S; Growdon J H; Petersen R C; Parisi J E; Hyman B T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-24</span>
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    </div><div class="casAbstract">To assess the relationship between dementia, neuronal loss, and neuropathological findings in Alzheimer's disease (AD), we counted the number of neurons, senile plaques, and neurofibrillary tangles in a high-order association cortex.  We studied the superior temporal sulcus of 34 individuals with AD and 17 nondemented control subjects, using statistically unbiased, stereological counting techniques.  The number of superior temporal sulcus neurons in nondemented control subjects was stable across the sixth to ninth decades.  In AD, more than 50% of the neurons were lost.  Both neuronal loss and neurofibrillary tangles increased in parallel with the duration and severity of illness, but the amount of neuronal loss exceeded by manyfold the amount of neurofibrillary tangles accumulated.  In contrast to the correlation between neurofibrillary tangles and neuronal loss, the number of senile plaques and the percentage of the superior temporal sulcus that was covered by Abeta (amyloid burden) were not related to neuronal loss, number of neurofibrillary tangles, or duration of disease.  Neither the amount nor the rate of neuronal loss in the superior temporal sulcus in AD correlated with apolipoprotein E genotype.  These data suggest that neuronal loss in association areas such as the superior temporal sulcus contributes directly to cognitive impairment in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRb4pZx19FriEh5eUSa2oe_fW6udTcc2eZeNI_OhAQH77ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7lvVGjsw%253D%253D&md5=77d2cb983d20b2a7cfe60426e4f55a50</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fana.410410106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410410106%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Isla%26aufirst%3DT.%26aulast%3DHollister%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DMui%26aufirst%3DS.%26aulast%3DGrowdon%26aufirst%3DJ.%2BH.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DParisi%26aufirst%3DJ.%2BE.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26atitle%3DNeuronal%2520loss%2520correlates%2520with%2520but%2520exceeds%2520neurofibrillary%2520tangles%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D1997%26volume%3D41%26spage%3D17%26epage%3D24%26doi%3D10.1002%2Fana.410410106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref8"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref8'); return false;" data-citation="" class="refNumLink">8</a></strong><div class="NLM_citation" id="cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loo, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittemore, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walencewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotman, C. W.</span></span> <span> </span><span class="NLM_article-title">Apoptosis is induced by beta-amyloid in cultured central nervous system neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">7951</span>– <span class="NLM_lpage">7955</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.17.7951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.90.17.7951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8367446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXmtVWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=7951-7955&author=D.+T.+Looauthor=A.+Copaniauthor=C.+J.+Pikeauthor=E.+R.+Whittemoreauthor=A.+J.+Walencewiczauthor=C.+W.+Cotman&title=Apoptosis+is+induced+by+beta-amyloid+in+cultured+central+nervous+system+neurons&doi=10.1073%2Fpnas.90.17.7951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis is induced by β-amyloid in cultured central nervous system neurons</span></div><div class="casAuthors">Loo, Deryk T.; Copani, Agata; Pike, Christian J.; Whittemore, Edward R.; Walencewicz, Andrea J.; Cotman, Carl W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7951-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanism responsible for the neurodegeneration in Alzheimer disease is not known; however, accumulating evidence suggests that β-amyloid peptide (AβP) contributes to this degeneration.  The authors now report that synthetic AβPs trigger the degeneration of cultured neurons through activation of an apoptotic pathway.  Neurons treated with AβPs exhibit morphol. and biochem. characteristics of apoptosis, including membrane blebbing, compaction of nuclear chromatin, and internucleosomal DNA fragmentation.  Aurintricarboxylic acid, an inhibitor of nucleases, prevents DNA fragmentation and delays cell death.  Thus, apoptosis may play a role in the neuronal loss assocd. with Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEKn2IOaIiabVg90H21EOLACvtfcHk0lhzcD9M3OeKzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtVWis7Y%253D&md5=4301e766187b57f18c951b9acd00f0c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.17.7951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.17.7951%26sid%3Dliteratum%253Aachs%26aulast%3DLoo%26aufirst%3DD.%2BT.%26aulast%3DCopani%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DC.%2BJ.%26aulast%3DWhittemore%26aufirst%3DE.%2BR.%26aulast%3DWalencewicz%26aufirst%3DA.%2BJ.%26aulast%3DCotman%26aufirst%3DC.%2BW.%26atitle%3DApoptosis%2520is%2520induced%2520by%2520beta-amyloid%2520in%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D7951%26epage%3D7955%26doi%3D10.1073%2Fpnas.90.17.7951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref9"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref9'); return false;" data-citation="" class="refNumLink">9</a></strong><div class="NLM_citation" id="cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadesus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, G.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress signalling in Alzheimer’s disease</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1000</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2004.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.brainres.2004.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15053949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1000&publication_year=2004&pages=32-39&author=X.+Zhuauthor=A.+K.+Rainaauthor=H.+G.+Leeauthor=G.+Casadesusauthor=M.+A.+Smithauthor=G.+Perry&title=Oxidative+stress+signalling+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.brainres.2004.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress signalling in Alzheimer's disease</span></div><div class="casAuthors">Zhu, Xiongwei; Raina, Arun K.; Lee, Hyoung-gon; Casadesus, Gemma; Smith, Mark A.; Perry, George</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1000</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">32-39</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Multiple lines of evidence demonstrate that oxidative stress is an early event in Alzheimer's disease (AD), occurring prior to cytopathol., and therefore may play a key pathogenic role in the disease.  Indeed, that oxidative mechanisms are involved in the cell loss and other neuropathol. assocd. with AD is evidenced by the large no. of metabolic signs of oxidative stress as well as by markers of oxidative damage.  However, what is intriguing is that oxidative damage decreases with disease progression, such that levels of markers of rapidly formed oxidative damage, which are initially elevated, decrease as the disease progresses to advanced AD.  This finding, along with the compensatory upregulation of antioxidant enzymes found in vulnerable neurons in AD, indicates that reactive oxygen species (ROS) not only cause damage to cellular structures but also provoke cellular responses.  Mammalian cells respond to extracellular stimuli by transmitting intracellular instructions by signal transduction cascades to coordinate appropriate responses.  Therefore, not surprisingly stress-activated protein kinase (SAPK) pathways, pathways that are activated by oxidative stress, are extensively activated during AD.  In this paper, we review the evidence of oxidative stress and compensatory responses that occur in AD with a particular focus on the roles and mechanism of activation of SAPK pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-8SJNlzlJLVg90H21EOLACvtfcHk0lhzcD9M3OeKzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisF2htrw%253D&md5=61808b21e4fd8dcee6fce30637b51425</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2004.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2004.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DRaina%26aufirst%3DA.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DCasadesus%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DPerry%26aufirst%3DG.%26atitle%3DOxidative%2520stress%2520signalling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBrain%2520Res.%26date%3D2004%26volume%3D1000%26spage%3D32%26epage%3D39%26doi%3D10.1016%2Fj.brainres.2004.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref10"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref10'); return false;" data-citation="" class="refNumLink">10</a></strong><div class="NLM_citation" id="cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1038/nrn960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12415294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotleqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=862-872&author=F.+M.+LaFerla&title=Calcium+dyshomeostasis+and+intracellular+signalling+in+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnrn960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease</span></div><div class="casAuthors">LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">862-872</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Calcium modulates many neural processes, including synaptic plasticity and apoptosis.  Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of Alzheimer's disease.  Increased intracellular calcium elicits the characteristic lesions of this disorder, including the accumulation of amyloid-β, the hyperphosphorylation of TAU and neuronal death.  Conversely, neurodegeneration that is induced by amyloid-β or TAU is probably mediated by changes in calcium homeostasis.  Disruption of calcium regulation in the endoplasmic reticulum mediates the most significant signal-transduction cascades that are assocd. with Alzheimer's disease.  Moreover, mutations that cause familial Alzheimer's disease have been linked to intracellular calcium signaling pathways.  Destabilization of calcium signaling seems to be central to the pathogenesis of Alzheimer's disease, and targeting this process might be therapeutically beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rDohVx62LrVg90H21EOLACvtfcHk0lhzcD9M3OeKzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotleqtr8%253D&md5=1894cb967d1b2902fa54b4fab9d29145</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrn960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn960%26sid%3Dliteratum%253Aachs%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DCalcium%2520dyshomeostasis%2520and%2520intracellular%2520signalling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2002%26volume%3D3%26spage%3D862%26epage%3D872%26doi%3D10.1038%2Fnrn960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref11"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref11'); return false;" data-citation="" class="refNumLink">11</a></strong><div class="NLM_citation" id="cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelenboom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebich, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frautschy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, W. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landreth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lue, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Banion, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasinetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tooyoma, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Muiswinkel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerhuis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyniak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss-Coray, T.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Alzheimer’s disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/S0197-4580(00)00124-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0197-4580%2800%2900124-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10858586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVSmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=383-421&author=H.+Akiyamaauthor=S.+Bargerauthor=S.+Barnumauthor=B.+Bradtauthor=J.+Bauerauthor=G.+M.+Coleauthor=N.+R.+Cooperauthor=P.+Eikelenboomauthor=M.+Emmerlingauthor=B.+L.+Fiebichauthor=C.+E.+Finchauthor=S.+Frautschyauthor=W.+S.+T.+Griffinauthor=H.+Hampelauthor=M.+Hullauthor=G.+Landrethauthor=L.-F.+Lueauthor=R.+Mrakauthor=I.+R.+Mackenzieauthor=P.+L.+McGeerauthor=M.+B.+O%E2%80%99Banionauthor=J.+Pachterauthor=G.+Pasinettiauthor=C.+Plata-Salamanauthor=J.+Rogersauthor=R.+Rydelauthor=Y.+Shenauthor=W.+Streitauthor=R.+Strohmeyerauthor=I.+Tooyomaauthor=F.+L.+Van+Muiswinkelauthor=R.+Veerhuisauthor=D.+Walkerauthor=S.+Websterauthor=B.+Wegrzyniakauthor=G.+Wenkauthor=T.+Wyss-Coray&title=Inflammation+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0197-4580%2800%2900124-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Alzheimer's disease</span></div><div class="casAuthors">Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S. T.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.-F.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-421</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review, with 636 refs.  Inflammation clearly occurs in pathol. vulnerable regions of the Alzheimer's disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses.  In the periphery, degenerating tissue and the deposition of highly insol. abnormal materials are classical stimulants of inflammation.  Likewise, in the AD brain damaged neurons and neurites and highly insol. amyloid β peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation.  Because these stimuli are discrete, microlocalized, and present from early preclin. to terminal stages of AD, local upregulation of complement, cytokines, acute-phase reactants, and other inflammatory mediators is also discrete, microlocalized, and chronic.  Cumulated over many years, direct and bystander damage from AD inflammatory mechanisms is likely to exacerbate the very pathogenic processes that gave rise to it.  Thus, animal models and clin. studies, although still in their infancy, strongly suggest that AD inflammation contributes to AD pathogenesis.  By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72c3W8HExubVg90H21EOLACvtfcHk0lgZDMJJAdvWqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVSmt74%253D&md5=409a0ca2920ef2cba12474cb7d05f4aa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0197-4580%2800%2900124-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-4580%252800%252900124-X%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DBarger%26aufirst%3DS.%26aulast%3DBarnum%26aufirst%3DS.%26aulast%3DBradt%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DG.%2BM.%26aulast%3DCooper%26aufirst%3DN.%2BR.%26aulast%3DEikelenboom%26aufirst%3DP.%26aulast%3DEmmerling%26aufirst%3DM.%26aulast%3DFiebich%26aufirst%3DB.%2BL.%26aulast%3DFinch%26aufirst%3DC.%2BE.%26aulast%3DFrautschy%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DW.%2BS.%2BT.%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DHull%26aufirst%3DM.%26aulast%3DLandreth%26aufirst%3DG.%26aulast%3DLue%26aufirst%3DL.-F.%26aulast%3DMrak%26aufirst%3DR.%26aulast%3DMackenzie%26aufirst%3DI.%2BR.%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DO%25E2%2580%2599Banion%26aufirst%3DM.%2BB.%26aulast%3DPachter%26aufirst%3DJ.%26aulast%3DPasinetti%26aufirst%3DG.%26aulast%3DPlata-Salaman%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DRydel%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStreit%26aufirst%3DW.%26aulast%3DStrohmeyer%26aufirst%3DR.%26aulast%3DTooyoma%26aufirst%3DI.%26aulast%3DVan%2BMuiswinkel%26aufirst%3DF.%2BL.%26aulast%3DVeerhuis%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWebster%26aufirst%3DS.%26aulast%3DWegrzyniak%26aufirst%3DB.%26aulast%3DWenk%26aufirst%3DG.%26aulast%3DWyss-Coray%26aufirst%3DT.%26atitle%3DInflammation%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2000%26volume%3D21%26spage%3D383%26epage%3D421%26doi%3D10.1016%2FS0197-4580%2800%2900124-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref12"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref12'); return false;" data-citation="" class="refNumLink">12</a></strong><div class="NLM_citation" id="cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss-Coray, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucke, L.</span></span> <span> </span><span class="NLM_article-title">Inflammation in neurodegenerative disease—a double-edged sword</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(02)00794-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0896-6273%2802%2900794-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12165466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt12isrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=419-432&author=T.+Wyss-Corayauthor=L.+Mucke&title=Inflammation+in+neurodegenerative+disease%E2%80%94a+double-edged+sword&doi=10.1016%2FS0896-6273%2802%2900794-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in neurodegenerative disease-a double-edged sword</span></div><div class="casAuthors">Wyss-Coray, Tony; Mucke, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">419-432</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Inflammation is a defense reaction against diverse insults, designed to remove noxious agents and to inhibit their detrimental effects.  It consists of a dazzling array of mol. and cellular mechanisms and an intricate network of controls to keep them in check.  In neurodegenerative diseases, inflammation may be triggered by the accumulation of proteins with abnormal conformations or by signals emanating from injured neurons.  Given the multiple functions of many inflammatory factors, it has been difficult to pinpoint their roles in specific (patho)physiol. situations.  Studies of genetically modified mice and of mol. pathways in activated glia are beginning to shed light on this issue.  Altered expression of different inflammatory factors can either promote or counteract neurodegenerative processes.  Since many inflammatory responses are beneficial, directing and instructing the inflammatory machinery may be a better therapeutic objective than suppressing it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopCpnZhmVqr7Vg90H21EOLACvtfcHk0lgZDMJJAdvWqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt12isrs%253D&md5=4d3562f56df8c1ab8d8e794d9821dea6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2802%2900794-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252802%252900794-8%26sid%3Dliteratum%253Aachs%26aulast%3DWyss-Coray%26aufirst%3DT.%26aulast%3DMucke%26aufirst%3DL.%26atitle%3DInflammation%2520in%2520neurodegenerative%2520disease%25E2%2580%2594a%2520double-edged%2520sword%26jtitle%3DNeuron%26date%3D2002%26volume%3D35%26spage%3D419%26epage%3D432%26doi%3D10.1016%2FS0896-6273%2802%2900794-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref13"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref13'); return false;" data-citation="" class="refNumLink">13</a></strong><div class="NLM_citation" id="cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barger, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, A. D.</span></span> <span> </span><span class="NLM_article-title">Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1038/42257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F42257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9278049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2sXlslagsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=1997&pages=878-881&author=S.+W.+Bargerauthor=A.+D.+Harmon&title=Microglial+activation+by+Alzheimer+amyloid+precursor+protein+and+modulation+by+apolipoprotein+E&doi=10.1038%2F42257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E</span></div><div class="casAuthors">Barger, Steven W.; Harmon, Ashley D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">6645</span>),
    <span class="NLM_cas:pages">878-881</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A role for β-amyloid precursor protein (β-APP) in the development of Alzheimer's disease has been indicated by genetics, and many conditions in which β-APP is raised have been assocd. with an increased risk of Alzheimer's disease or an Alzheimer's-like pathol.  Inflammatory events may also contribute to Alzheimer's disease.  Here the authors investigate whether a secreted deriv. of β-APP (sAPP-α) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage.  The authors found that treatment with sAPP-α increased markers of activation in microglia and enhanced their prodn. of neurotoxins.  The ability of sAPP-α to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not E4, a variant assocd. with an increased risk for Alzheimer's.  A product of amyloidogenic β-APP processing (sAPP-β) also activated microglia.  Because sAPP-β is deficient in the neuroprotective activity shown by sAPP-α, the results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that det. neuronal viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfT_4zAisRYLVg90H21EOLACvtfcHk0lgZDMJJAdvWqw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlslagsrY%253D&md5=db2c2a17c66253192067a297f6f7da1a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2F42257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42257%26sid%3Dliteratum%253Aachs%26aulast%3DBarger%26aufirst%3DS.%2BW.%26aulast%3DHarmon%26aufirst%3DA.%2BD.%26atitle%3DMicroglial%2520activation%2520by%2520Alzheimer%2520amyloid%2520precursor%2520protein%2520and%2520modulation%2520by%2520apolipoprotein%2520E%26jtitle%3DNature%26date%3D1997%26volume%3D388%26spage%3D878%26epage%3D881%26doi%3D10.1038%2F42257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref14"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref14'); return false;" data-citation="" class="refNumLink">14</a></strong><div class="NLM_citation" id="cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassatella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szendrei, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otvos, L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span> <span> </span><span class="NLM_article-title">Activation of microglial cells by β-amyloid protein and interferon-γ</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1038/374647a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F374647a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7715705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2MXltVOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=647-650&author=L.+Medaauthor=M.+A.+Cassatellaauthor=G.+I.+Szendreiauthor=L.+Otvosauthor=P.+Baronauthor=M.+Villalbaauthor=D.+Ferrariauthor=F.+Rossi&title=Activation+of+microglial+cells+by+%CE%B2-amyloid+protein+and+interferon-%CE%B3&doi=10.1038%2F374647a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of microglial cells by β-amyloid protein and interferon-γ</span></div><div class="casAuthors">Meda, Lucia; Cassatella, Marc A.; Szendrei, Gyorgyi I.; Otvos, Laszlo, Jr.; Baron, Pierluigi; Villalba, Martin; Ferrari, Davide; Rossi, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6523</span>),
    <span class="NLM_cas:pages">647-50</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Alzheimer's disease is the most common cause of progressive intellectual failure.  The lesions that develop, called senile plaques, are extracellular deposits principally composed of insol. aggregates of β-amyloid protein (Aβ), infiltrated by reactive microglia and astrocytes.  Although Aβ, and a portion of it, the fragment 25-35 [Aβ(25-35)], have been shown to exert a direct toxic effect on neurons, the role of microglia in such neuronal injury remains unclear.  Here the authors report a synergistic effect between Aβ and interferon-γ (IFN-γ) in triggering the prodn. of reactive nitrogen intermediates and tumor-necrosis factor-α (TNF-α) from microglia.  Furthermore, using co-culture expts., the authors show that activation of microglia with IFN-γ and Aβ leads to neuronal cell injury in vitro.  Thus, Aβ and IFN-γ activate microglia to produce reactive nitrogen intermediates and TNF-α, and this may have a role in the pathogenesis of neuronal degeneration obsd. in aging and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnk_Q78NWIiLVg90H21EOLACvtfcHk0litAuGhBMfCFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVOhsLs%253D&md5=5396aa76c1b554bc9a015f33508ec1d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F374647a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374647a0%26sid%3Dliteratum%253Aachs%26aulast%3DMeda%26aufirst%3DL.%26aulast%3DCassatella%26aufirst%3DM.%2BA.%26aulast%3DSzendrei%26aufirst%3DG.%2BI.%26aulast%3DOtvos%26aufirst%3DL.%26aulast%3DBaron%26aufirst%3DP.%26aulast%3DVillalba%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DF.%26atitle%3DActivation%2520of%2520microglial%2520cells%2520by%2520%25CE%25B2-amyloid%2520protein%2520and%2520interferon-%25CE%25B3%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D647%26epage%3D650%26doi%3D10.1038%2F374647a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref15"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref15'); return false;" data-citation="" class="refNumLink">15</a></strong><div class="NLM_citation" id="cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shie, F.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, H.-J.</span></span> <span> </span><span class="NLM_article-title">Mechanism mediating oligomeric Aβ clearance by naïve primary microglia</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2011.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.nbd.2011.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21220023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVGlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=221-230&author=C.-N.+Yangauthor=Y.-J.+Shiaoauthor=F.-S.+Shieauthor=B.-S.+Guoauthor=P.-H.+Chenauthor=C.-Y.+Choauthor=Y.-J.+Chenauthor=F.-L.+Huangauthor=H.-J.+Tsay&title=Mechanism+mediating+oligomeric+A%CE%B2+clearance+by+na%C3%AFve+primary+microglia&doi=10.1016%2Fj.nbd.2011.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism mediating oligomeric Aβ clearance by naive primary microglia</span></div><div class="casAuthors">Yang, Cheng-Ning; Shiao, Young-Ji; Shie, Feng-Shiun; Guo, Bo-Shen; Chen, Pei-Hao; Cho, Chi-Yuan; Chen, Yi-Jen; Huang, Fong-Lee; Tsay, Huey-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The accumulation of sol. oligomeric amyloid-β peptide (oAβ) proceeds the formation of senile plaques and contributes to synaptic and memory deficits in Alzheimer's disease (AD).  The mechanism of mediating microglial oAβ [n.61472]clearance remains unclear and thought to occur via scavenger receptors (SRs) in microglia.  SRs respond to their ligands in a subtype-specific manner.  Therefore, we sought to identify the specific subtypes of SRs that mediate oAβ [n.61472]internalization and proteases that degrade oAβ [n.61472]species in naive primary microglia.  The component of oAβ species were characterized by western blot anal., anal. ultracentrifugation anal., and at. force microscopy.  The oAβ species remained sol. in the medium and microglial lysates during incubation at 37 °C.  SR-A, but not CD36, mediated oAβ internalization in microglia as suggested by the use of subtype-specific neutralizing antibodies and small interfering RNAs (siRNAs).  Immunopptn. anal. showed that oAβ [n.61472]interacted with SR-A on the plasma membrane.  After internalization, over 40% of oAβ vesicles were trafficked toward lysosomes and degraded by cysteine proteases, including cathepsin B. The inhibitors of proteasome, neprilysin, matrix metalloproteinases, and insulin degrading enzyme failed to protect internalized oAβ from degrdn.  Our study suggests that SR-A and lysosomal cathepsin B are crit. in microglial oAβ [n.61472]clearance, providing insight into how microglia are involved in the clearance of oAβ and their roles in the early stages of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv13L-K12jmbVg90H21EOLACvtfcHk0litAuGhBMfCFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVGlt7Y%253D&md5=bbee6e78e700a8db7f3ff6b5b0422cae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2011.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2011.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.-N.%26aulast%3DShiao%26aufirst%3DY.-J.%26aulast%3DShie%26aufirst%3DF.-S.%26aulast%3DGuo%26aufirst%3DB.-S.%26aulast%3DChen%26aufirst%3DP.-H.%26aulast%3DCho%26aufirst%3DC.-Y.%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DHuang%26aufirst%3DF.-L.%26aulast%3DTsay%26aufirst%3DH.-J.%26atitle%3DMechanism%2520mediating%2520oligomeric%2520A%25CE%25B2%2520clearance%2520by%2520na%25C3%25AFve%2520primary%2520microglia%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D42%26spage%3D221%26epage%3D230%26doi%3D10.1016%2Fj.nbd.2011.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref16"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref16'); return false;" data-citation="" class="refNumLink">16</a></strong><div class="NLM_citation" id="cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">136</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2305-5839.2015.03.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.3978%2Fj.issn.2305-5839.2015.03.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26207229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFequrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=136&author=W.-Y.+Wangauthor=M.-S.+Tanauthor=J.-T.+Yuauthor=L.+Tan&title=Role+of+pro-inflammatory+cytokines+released+from+microglia+in+Alzheimer%E2%80%99s+disease&doi=10.3978%2Fj.issn.2305-5839.2015.03.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease</span></div><div class="casAuthors">Wang, Wen-Ying; Tan, Meng-Shan; Yu, Jin-Tai; Tan, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">136/1-136/15</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is characterized by the formation of extracellular amyloid plaques (or senile plaques) and intracellular neurofibrillary tangles.  However, increasing evidences demonstrated that neuroinflammatory changes, including chronic microgliosis are key pathol. components of AD.  Microglia, the resident immune cells of the brain, is constantly survey the microenvironment under physiol. conditions.  In AD, deposition of β-amyliod (Aβ) peptide initiates a spectrum of cerebral neuroinflammation mediated by activating microglia.  Activated microglia may play a potentially detrimental role by eliciting the expression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) influencing the surrounding brain tissue.  Emerging studies have demonstrated that up-regulation of pro-inflammatory cytokines play multiple roles in both neurodegeneration and neuroprotection.  Understanding the pro-inflammatory cytokines signaling pathways involved in the regulation of AD is crucial to the development of strategies for therapy.  This review will discuss the mechanisms and important role of pro-inflammatory cytokines in the pathogenesis of AD, and the ongoing drug targeting pro-inflammatory cytokine for therapeutic modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydEyb_SUzbbVg90H21EOLACvtfcHk0litAuGhBMfCFw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFequrk%253D&md5=21894d5d8de838c4137bfc5ebcd35218</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2305-5839.2015.03.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2305-5839.2015.03.49%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.-Y.%26aulast%3DTan%26aufirst%3DM.-S.%26aulast%3DYu%26aufirst%3DJ.-T.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DRole%2520of%2520pro-inflammatory%2520cytokines%2520released%2520from%2520microglia%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26spage%3D136%26doi%3D10.3978%2Fj.issn.2305-5839.2015.03.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref17"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref17'); return false;" data-citation="" class="refNumLink">17</a></strong><div class="NLM_citation" id="cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Multiple functions of endocannabinoid signaling in the brain</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1146/annurev-neuro-062111-150420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1146%2Fannurev-neuro-062111-150420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22524785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFegsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=529-558&author=I.+Katonaauthor=T.+F.+Freund&title=Multiple+functions+of+endocannabinoid+signaling+in+the+brain&doi=10.1146%2Fannurev-neuro-062111-150420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple functions of endocannabinoid signaling in the brain</span></div><div class="casAuthors">Katona, Istvan; Freund, Tamas F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">529-558</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Despite being regarded as a hippie science for decades, cannabinoid research has finally found its well-deserved position in mainstream neuroscience.  A series of groundbreaking discoveries revealed that endocannabinoid mols. are as widespread and important as conventional neurotransmitters such as glutamate or GABA, yet they act in profoundly unconventional ways.  We aim to illustrate how uncovering the mol., anatomical, and physiol. characteristics of endocannabinoid signaling has revealed new mechanistic insights into several fundamental phenomena in synaptic physiol.  First, we summarize unexpected advances in the mol. complexity of biogenesis and inactivation of the two endocannabinoids, anandamide and 2-arachidonoylglycerol.  Then, we show how these new metabolic routes are integrated into well-known intracellular signaling pathways.  These endocannabinoid-producing signalosomes operate in phasic and tonic modes, thereby differentially governing homeostatic, short-term, and long-term synaptic plasticity throughout the brain.  Finally, we discuss how cell type- and synapse-specific refinement of endocannabinoid signaling may explain the characteristic behavioral effects of cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcaMxJBq__27Vg90H21EOLACvtfcHk0lj1zHssyxNbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFegsbjE&md5=4a150010c171ef8d4a7f8e201ff0f554</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-neuro-062111-150420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-neuro-062111-150420%26sid%3Dliteratum%253Aachs%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DMultiple%2520functions%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2012%26volume%3D35%26spage%3D529%26epage%3D558%26doi%3D10.1146%2Fannurev-neuro-062111-150420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref18"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref18'); return false;" data-citation="" class="refNumLink">18</a></strong><div class="NLM_citation" id="cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and the brain</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1146/annurev-psych-113011-143739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1146%2Fannurev-psych-113011-143739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22804774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=21-47&author=R.+Mechoulamauthor=L.+A.+Parker&title=The+endocannabinoid+system+and+the+brain&doi=10.1146%2Fannurev-psych-113011-143739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and the brain</span></div><div class="casAuthors">Mechoulam Raphael; Parker Linda A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 years later.  The cannabinoid system affects both central nervous system (CNS) and peripheral processes.  In this review, we have tried to summarize research--with an emphasis on recent publications--on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory.  The effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.  Recently, numerous endocannabinoid-like compounds have been identified in the brain.  Only a few have been investigated for their CNS activity, and future investigations on their action may throw light on a wide spectrum of brain functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHFfYzzaa6fbBItaL1WaVAfW6udTcc2ebBB-vwNiglTbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D&md5=01c8b675ee9970bde0cb96d5e1b8a553</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-113011-143739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-113011-143739%26sid%3Dliteratum%253Aachs%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2013%26volume%3D64%26spage%3D21%26epage%3D47%26doi%3D10.1146%2Fannurev-psych-113011-143739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref19"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref19'); return false;" data-citation="" class="refNumLink">19</a></strong><div class="NLM_citation" id="cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system in guarding against fear, anxiety and stress</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1038/nrn4036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn4036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26585799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=705-718&author=B.+Lutzauthor=G.+Marsicanoauthor=R.+Maldonadoauthor=C.+J.+Hillard&title=The+endocannabinoid+system+in+guarding+against+fear%2C+anxiety+and+stress&doi=10.1038%2Fnrn4036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system in guarding against fear, anxiety and stress</span></div><div class="casAuthors">Lutz, Beat; Marsicano, Giovanni; Maldonado, Rafael; Hillard, Cecilia J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">705-718</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiol. and behavioral outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signaling seems to det. the value of fear-evoking stimuli and to tune appropriate behavioral responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signaling can lead to psychiatric disorders.  An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioral maladaptation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKFcVfg5ub7Vg90H21EOLACvtfcHk0lj1zHssyxNbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtb%252FI&md5=320dde506b7f434721cde79316af972d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrn4036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4036%26sid%3Dliteratum%253Aachs%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520endocannabinoid%2520system%2520in%2520guarding%2520against%2520fear%252C%2520anxiety%2520and%2520stress%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D705%26epage%3D718%26doi%3D10.1038%2Fnrn4036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref20"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref20'); return false;" data-citation="" class="refNumLink">20</a></strong><div class="NLM_citation" id="cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameri, A.</span></span> <span> </span><span class="NLM_article-title">The effects of cannabinoids on the brain</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(98)00087-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0301-0082%2898%2900087-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10368032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=315-348&author=A.+Ameri&title=The+effects+of+cannabinoids+on+the+brain&doi=10.1016%2FS0301-0082%2898%2900087-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of cannabinoids on the brain</span></div><div class="casAuthors">Ameri, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-348</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with many refs.  Cannabinoids have a long history of consumption for recreational and medical reasons.  The primary active constituent of the hemp plant Cannabis sativa is Δ9-tetrahydrocannabinol (Δ9-THC).  In humans, psychoactive cannabinoids produce euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concn. and impairment of memory.  The cognitive deficiencies seem to persist after withdrawal.  The toxicity of marijuana has been underestimated for a long time, since recent findings revealed Δ9-THC-induced cell death with shrinkage of neurons and DNA fragmentation in the hippocampus.  The acute effects of cannabinoids as well as the development of tolerance are mediated by G protein-coupled cannabinoid receptors.  The CB1 receptor and its splice variant CB1A, are found predominantly in the brain with highest densities in the hippocampus, cerebellum and striatum.  The CB2 receptor is found predominantly in the spleen and in hemopoietic cells and has only 44% overall nucleotide sequence identity with the CB1 receptor.  The existence of this receptor provided the mol. basis for the immunosuppressive actions of marijuana.  The CB1 receptor mediates inhibition of adenylate cyclase, inhibition of N- and P/Q-type calcium channels, stimulation of potassium channels, and activation of mitogen-activated protein kinase.  The CB2 receptor mediates inhibition of adenylate cyclase and activation of mitogen-activated protein kinase.  The discovery of endogenous cannabinoid receptor ligands, anandamide (N-arachidonylethanolamine) and 2-arachidonylglycerol made the notion of a central cannabinoid neuromodulatory system plausible.  Anandamide is released from neurons upon depolarization through a mechanism that requires calcium-dependent cleavage from a phospholipid precursor in neuronal membranes.  The release of anandamide is followed by rapid uptake into the plasma and hydrolysis by fatty-acid amidohydrolase.  The psychoactive cannabinoids increase the activity of dopaminergic neurons in the ventral tegmental area-mesolimbic pathway.  Since these dopaminergic circuits are known to play a pivotal role in mediating the reinforcing (rewarding) effects of the most drugs of abuse, the enhanced dopaminergic drive elicited by the cannabinoids is thought to underlie the reinforcing and abuse properties of marijuana.  Thus, cannabinoids share a final common neuronal action with other major drugs of abuse such as morphine, ethanol and nicotine in producing facilitation of the mesolimbic dopamine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPcJ7-vQg37Vg90H21EOLACvtfcHk0lj1zHssyxNbRg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D&md5=7ffe2ffb3c7604a4795f59aa240d260a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900087-2%26sid%3Dliteratum%253Aachs%26aulast%3DAmeri%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520cannabinoids%2520on%2520the%2520brain%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D58%26spage%3D315%26epage%3D348%26doi%3D10.1016%2FS0301-0082%2898%2900087-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref21"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref21'); return false;" data-citation="" class="refNumLink">21</a></strong><div class="NLM_citation" id="cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Shaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abu-Shaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0ljdrKj3lKWmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbu-Shaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref22"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref22'); return false;" data-citation="" class="refNumLink">22</a></strong><div class="NLM_citation" id="cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Sickle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouihate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1126/science.1115740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1126%2Fscience.1115740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16224028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=329-332&author=M.+D.+Van%0ASickleauthor=M.+Duncanauthor=P.+J.+Kingsleyauthor=A.+Mouihateauthor=P.+Urbaniauthor=K.+Mackieauthor=N.+Stellaauthor=A.+Makriyannisauthor=D.+Piomelliauthor=J.+S.+Davisonauthor=L.+J.+Marnettauthor=V.+Di+Marzoauthor=Q.+J.+Pittmanauthor=K.+D.+Patelauthor=K.+A.+Sharkey&title=Identification+and+functional+characterization+of+brainstem+cannabinoid+CB2+receptors&doi=10.1126%2Fscience.1115740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span></div><div class="casAuthors">Van Sickle, Marja D.; Duncan, Marnie; Kingsley, Philip J.; Mouihate, Abdeslam; Urbani, Paolo; Mackie, Ken; Stella, Nephi; Makriyannis, Alexandros; Piomelli, Daniele; Davison, Joseph S.; Marnett, Lawrence J.; Di Marzo, Vincenzo; Pittman, Quentin J.; Patel, Kamala D.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5746</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial.  The authors report the expression of CB2 receptor mRNA and protein localization on brainstem neurons.  These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors.  CB2 receptors represent an alternative site of action of endocannabinoids that opens the possibility of nonpsychotropic therapeutic interventions using enhanced endocannabinoid levels in localized brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWgg6LDIT0bVg90H21EOLACvtfcHk0ljdrKj3lKWmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL&md5=ab457ab0bd1b8e30ea927a1e61366323</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.1115740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1115740%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSickle%26aufirst%3DM.%2BD.%26aulast%3DDuncan%26aufirst%3DM.%26aulast%3DKingsley%26aufirst%3DP.%2BJ.%26aulast%3DMouihate%26aufirst%3DA.%26aulast%3DUrbani%26aufirst%3DP.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStella%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%2BS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPittman%26aufirst%3DQ.%2BJ.%26aulast%3DPatel%26aufirst%3DK.%2BD.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520brainstem%2520cannabinoid%2520CB2%2520receptors%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D329%26epage%3D332%26doi%3D10.1126%2Fscience.1115740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref23"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref23'); return false;" data-citation="" class="refNumLink">23</a></strong><div class="NLM_citation" id="cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajardo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolón, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/syn.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fsyn.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15266552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Gns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=208-213&author=E.+N%C3%BA%C3%B1ezauthor=C.+Benitoauthor=M.+R.+Pazosauthor=A.+Barbachanoauthor=O.+Fajardoauthor=S.+Gonz%C3%A1lezauthor=R.+M.+Tol%C3%B3nauthor=J.+Romero&title=Cannabinoid+CB2+receptors+are+expressed+by+perivascular+microglial+cells+in+the+human+brain%3A+an+immunohistochemical+study&doi=10.1002%2Fsyn.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study</span></div><div class="casAuthors">Nunez, Estefania; Benito, Cristina; Pazos, M. Ruth; Barbachano, Antonio; Fajardo, Otto; Gonzalez, Sara; Tolon, Rosa M.; Romero, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-213</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Two types of cannabinoid receptors have been characterized so far, CB1 and CB2.  While CB1 receptors are present both in the central nervous system and in the periphery, CB2 receptors showed an almost exclusive distribution within the immune system.  We now report that CB2 receptors are present in a specific microglial cell type of the human cerebellum.  Thus, we have performed immunohistochem. anal. of tissue sections of white matter areas of the human cerebellum and detected the presence of CB2 receptors in perivascular microglial cells.  These findings match with the well-known immunomodulatory role of CB2 receptors and open new perspectives on the possible role that these receptors may play in pathophysiol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoQ0hprkbR1bVg90H21EOLACvtfcHk0ljdrKj3lKWmzQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Gns7w%253D&md5=38e2351802dff05a21b3d2e51169ec38</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20050%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DBarbachano%26aufirst%3DA.%26aulast%3DFajardo%26aufirst%3DO.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DTol%25C3%25B3n%26aufirst%3DR.%2BM.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520are%2520expressed%2520by%2520perivascular%2520microglial%2520cells%2520in%2520the%2520human%2520brain%253A%2520an%2520immunohistochemical%2520study%26jtitle%3DSynapse%26date%3D2004%26volume%3D53%26spage%3D208%26epage%3D213%26doi%3D10.1002%2Fsyn.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref24"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref24'); return false;" data-citation="" class="refNumLink">24</a></strong><div class="NLM_citation" id="cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grünblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monoranu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arzberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggendorf, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span> <span> </span><span class="NLM_article-title">Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.3233/JAD-2007-12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.3233%2FJAD-2007-12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=18198416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=291-311&author=E.+Gr%C3%BCnblattauthor=N.+Zanderauthor=J.+Bartlauthor=L.+Jieauthor=C.+M.+Monoranuauthor=T.+Arzbergerauthor=R.+Ravidauthor=W.+Roggendorfauthor=M.+Gerlachauthor=P.+Riederer&title=Comparison+analysis+of+gene+expression+patterns+between+sporadic+Alzheimer%E2%80%99s+and+Parkinson%E2%80%99s+disease&doi=10.3233%2FJAD-2007-12402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease</span></div><div class="casAuthors">Gruenblatt, Edna; Zander, Nicole; Bartl, Jasmin; Jie, Li; Monoranu, Camelia-Maria; Arzberger, Thomas; Ravid, Rivka; Roggendorf, Wolfgang; Gerlach, Manfred; Riederer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">291-311</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Sporadic Alzheimer's (AD) and Parkinson's disease (PD) are late-onset neurodegenerative diseases with tremendous impact on lives of affected individuals.  There is a great probability of developing concurrent Parkinsonism in AD and vice-versa than would be predicted by independent prevalence of each disease.  We hypothesize that in sporadic AD as well as PD a combination of environmental effects and gene expression may affect specific brain areas leading to neurodegeneration.  We profiled gene expression of AD compared to PD and age matched controls post-mortem in the hippocampus, the gyrus-frontalis-medius (Gfm) and the cerebellum using Gene-Chip microarray (Affymetrix) and quant.-real-time-RT-PCR.  Twelve genes altered in similar manner in AD and PD, while four genes showed differential expression profiles between AD and PD in different brain regions (cannabinoid-receptor-2, Histone-cluster-1-H3e, nicotinic-cholinergic-receptor-α6 and β-site-APP-cleaving enzyme-1).  Knowledge of selective gene expression profile can lead to better understanding of disease pathol. and development of specific diagnosis and effective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt2Fj086--37Vg90H21EOLACvtfcHk0lie3MDNJqcoyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFKjtA%253D%253D&md5=ca706394d8bc3649b7d316e42abd33f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-2007-12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2007-12402%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCnblatt%26aufirst%3DE.%26aulast%3DZander%26aufirst%3DN.%26aulast%3DBartl%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DL.%26aulast%3DMonoranu%26aufirst%3DC.%2BM.%26aulast%3DArzberger%26aufirst%3DT.%26aulast%3DRavid%26aufirst%3DR.%26aulast%3DRoggendorf%26aufirst%3DW.%26aulast%3DGerlach%26aufirst%3DM.%26aulast%3DRiederer%26aufirst%3DP.%26atitle%3DComparison%2520analysis%2520of%2520gene%2520expression%2520patterns%2520between%2520sporadic%2520Alzheimer%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2007%26volume%3D12%26spage%3D291%26epage%3D311%26doi%3D10.3233%2FJAD-2007-12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref25"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref25'); return false;" data-citation="" class="refNumLink">25</a></strong><div class="NLM_citation" id="cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolón, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rábano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">11136</span>– <span class="NLM_lpage">11141</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.23-35-11136.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1523%2FJNEUROSCI.23-35-11136.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=14657172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvV2gtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=11136-11141&author=C.+Benitoauthor=E.+N%C3%BA%C3%B1ezauthor=R.+M.+Tol%C3%B3nauthor=E.+J.+Carrierauthor=A.+R%C3%A1banoauthor=C.+J.+Hillardauthor=J.+Romero&title=Cannabinoid+CB2+receptors+and+fatty+acid+amide+hydrolase+are+selectively+overexpressed+in+neuritic+plaque-associated+glia+in+Alzheimer%E2%80%99s+disease+brains&doi=10.1523%2FJNEUROSCI.23-35-11136.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains</span></div><div class="casAuthors">Benito, Cristina; Nunez, Estefania; Tolon, Rosa M.; Carrier, Erica J.; Rabano, Alberto; Hillard, Cecilia J.; Romero, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11136-11141</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endocannabinoid system is still poorly understood.  Recently, the basic elements that constitute it, i.e., membrane receptors, endogenous ligands, and mechanisms for termination of the signaling process, have been partially characterized.  There is a considerable lack of information, however, concerning the distribution, concn., and function of those components in the human body, particularly during pathol. events.  We have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid CB1 and CB2 receptors, in postmortem brains from patients with Alzheimer's disease.  Using specific polyclonal antibodies, we have performed immunohistochem. anal. in hippocampus and entorhinal cortex sections from brains of Alzheimer's disease patients.  Our results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-assocd. astrocytes and microglia, resp., whereas the expression of CB1 receptors remains unchanged.  In addn., the hydrolase activity seems to be elevated in the plaques and surrounding areas.  Thus, some elements of the endocannabinoid system may be postulated as possible modulators of the inflammatory response assocd. with this neurodegenerative process and as possible targets for new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8Gm8V3n8jrVg90H21EOLACvtfcHk0lie3MDNJqcoyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvV2gtbw%253D&md5=c324980efac10a672fc425ef376694f1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-35-11136.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-35-11136.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DTol%25C3%25B3n%26aufirst%3DR.%2BM.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DR%25C3%25A1bano%26aufirst%3DA.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520and%2520fatty%2520acid%2520amide%2520hydrolase%2520are%2520selectively%2520overexpressed%2520in%2520neuritic%2520plaque-associated%2520glia%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D11136%26epage%3D11141%26doi%3D10.1523%2FJNEUROSCI.23-35-11136.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref26"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref26'); return false;" data-citation="" class="refNumLink">26</a></strong><div class="NLM_citation" id="cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Type-2 cannabinoid receptors in neurodegeneration</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.phrs.2016.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=27450295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=721-730&author=T.+Bisognoauthor=S.+Oddiauthor=A.+Piccoliauthor=D.+Fazioauthor=M.+Maccarrone&title=Type-2+cannabinoid+receptors+in+neurodegeneration&doi=10.1016%2Fj.phrs.2016.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Type-2 cannabinoid receptors in neurodegeneration</span></div><div class="casAuthors">Bisogno, Tiziana; Oddi, Sergio; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">721-730</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on its wide expression in immune cells, type-2 cannabinoid (CB2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function.  However, their recent identification in mammalian brain areas, as well as in distinct neuronal cells, has opened the way to a re-consideration of CB2 signaling in the context of brain pathophysiol., synaptic plasticity and neuroprotection.  To date, accumulated evidence from several independent preclin. studies has offered new perspectives on the possible involvement of CB2 signaling in brain and spinal cord traumatic injury, as well as in the most relevant neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and Huntington's chorea.  Here, we will review available information on CB2 in these disease conditions, along with data that support also its therapeutic potential to treat them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDLv1Yh2dX27Vg90H21EOLACvtfcHk0lie3MDNJqcoyw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr7F&md5=b880502073163ef08a7af918544a7dd1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DOddi%26aufirst%3DS.%26aulast%3DPiccoli%26aufirst%3DA.%26aulast%3DFazio%26aufirst%3DD.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DType-2%2520cannabinoid%2520receptors%2520in%2520neurodegeneration%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D721%26epage%3D730%26doi%3D10.1016%2Fj.phrs.2016.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref27"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref27'); return false;" data-citation="" class="refNumLink">27</a></strong><div class="NLM_citation" id="cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obregon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shytle, R. D.</span></span> <span> </span><span class="NLM_article-title">Stimulation of cannabinoid receptor 2 (CB 2) suppresses microglial activation</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-2-29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1186%2F1742-2094-2-29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16343349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FlvFWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=29&author=J.+Ehrhartauthor=D.+Obregonauthor=T.+Moriauthor=H.+Houauthor=N.+Sunauthor=Y.+Baiauthor=T.+Kleinauthor=F.+Fernandezauthor=J.+Tanauthor=R.+D.+Shytle&title=Stimulation+of+cannabinoid+receptor+2+%28CB+2%29+suppresses+microglial+activation&doi=10.1186%2F1742-2094-2-29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation</span></div><div class="casAuthors">Ehrhart Jared; Obregon Demian; Mori Takashi; Hou Huayan; Sun Nan; Bai Yun; Klein Thomas; Fernandez Francisco; Tan Jun; Shytle R Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activated microglial cells have been implicated in a number of neurodegenerative disorders, including Alzheimer's disease (AD), multiple sclerosis (MS), and HIV dementia.  It is well known that inflammatory mediators such as nitric oxide (NO), cytokines, and chemokines play an important role in microglial cell-associated neuron cell damage.  Our previous studies have shown that CD40 signaling is involved in pathological activation of microglial cells.  Many data reveal that cannabinoids mediate suppression of inflammation in vitro and in vivo through stimulation of cannabinoid receptor 2 (CB2).  METHODS:  In this study, we investigated the effects of a cannabinoid agonist on CD40 expression and function by cultured microglial cells activated by IFN-gamma using RT-PCR, Western immunoblotting, flow cytometry, and anti-CB2 small interfering RNA (siRNA) analyses.  Furthermore, we examined if the stimulation of CB2 could modulate the capacity of microglial cells to phagocytise Abeta1-42 peptide using a phagocytosis assay.  RESULTS:  We found that the selective stimulation of cannabinoid receptor CB2 by JWH-015 suppressed IFN-gamma-induced CD40 expression.  In addition, this CB2 agonist markedly inhibited IFN-gamma-induced phosphorylation of JAK/STAT1.  Further, this stimulation was also able to suppress microglial TNF-alpha and nitric oxide production induced either by IFN-gamma or Abeta peptide challenge in the presence of CD40 ligation.  Finally, we showed that CB2 activation by JWH-015 markedly attenuated CD40-mediated inhibition of microglial phagocytosis of Abeta1-42 peptide.  Taken together, these results provide mechanistic insight into beneficial effects provided by cannabinoid receptor CB2 modulation in neurodegenerative diseases, particularly AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwpZCNS5cmhmhHGZei4OW9fW6udTcc2eavFCGyQzAbQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FlvFWnsA%253D%253D&md5=516f5264a60d5aa11675107dbd0e8879</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-2-29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-2-29%26sid%3Dliteratum%253Aachs%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DObregon%26aufirst%3DD.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DFernandez%26aufirst%3DF.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DShytle%26aufirst%3DR.%2BD.%26atitle%3DStimulation%2520of%2520cannabinoid%2520receptor%25202%2520%2528CB%25202%2529%2520suppresses%2520microglial%2520activation%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2005%26volume%3D2%26spage%3D29%26doi%3D10.1186%2F1742-2094-2-29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref28"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref28'); return false;" data-citation="" class="refNumLink">28</a></strong><div class="NLM_citation" id="cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Holgado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, N. J.</span></span> <span> </span><span class="NLM_article-title">Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/jnr.10165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fjnr.10165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11891798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFCgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=829-836&author=F.+Molina-Holgadoauthor=E.+Molina-Holgadoauthor=C.+Guazaauthor=N.+J.+Rothwell&title=Role+of+CB1+and+CB2+receptors+in+the+inhibitory+effects+of+cannabinoids+on+lipopolysaccharide-induced+nitric+oxide+release+in+astrocyte+cultures&doi=10.1002%2Fjnr.10165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures</span></div><div class="casAuthors">Molina-Holgado, Francisco; Molina-Holgado, Eduardo; Guaza, Carmen; Rothwell, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">829-836</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the role of the central cannabinoid receptor (CB1) in mediating the actions of the endogenous cannabinoid agonist anandamide and the synthetic cannabinoid CP-55940.  Activation of primary mouse astrocyte cultures by exposure to bacterial lipopolysaccharide (LPS) caused a marked (approx. tenfold) increase in nitric oxide (NO) release.  Coincubation with the cannabinoid agonists anandamide or CP-55940 markedly inhibited release of NO (-12% to -55%).  This effect was abolished by SR-141716A (1 μM), a CB1 receptor antagonist.  SR-141716A alone also significantly increased NO release in response to LPS, suggesting that endogenous cannabinoids modify inflammatory responses.  In contrast, coincubation with the CB2 receptor antagonist SR-144528 (1 μM) abolished the inhibitory effects of the endogenous cannabinoid anandamide on LPS-induced NO release, although this may reflect nonspecific effects of this ligand or cannabinoid actions through atypical receptors of anandamide.  We also showed that endogenous or synthetic cannabinoids inhibit LPS-induced inducible NO synthase expression (mRNA and protein) in astrocyte cultures.  These results indicate that CB1 receptors may promote antiinflammatory responses in astrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_NRvXnWJg7Vg90H21EOLACvtfcHk0lgeo9P-s81_mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFCgtLo%253D&md5=4a2e3e4f6d36a78359f79549e6ee4214</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjnr.10165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.10165%26sid%3Dliteratum%253Aachs%26aulast%3DMolina-Holgado%26aufirst%3DF.%26aulast%3DMolina-Holgado%26aufirst%3DE.%26aulast%3DGuaza%26aufirst%3DC.%26aulast%3DRothwell%26aufirst%3DN.%2BJ.%26atitle%3DRole%2520of%2520CB1%2520and%2520CB2%2520receptors%2520in%2520the%2520inhibitory%2520effects%2520of%2520cannabinoids%2520on%2520lipopolysaccharide-induced%2520nitric%2520oxide%2520release%2520in%2520astrocyte%2520cultures%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2002%26volume%3D67%26spage%3D829%26epage%3D836%26doi%3D10.1002%2Fjnr.10165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref29"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref29'); return false;" data-citation="" class="refNumLink">29</a></strong><div class="NLM_citation" id="cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokensgard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. K.</span></span> <span> </span><span class="NLM_article-title">Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1002/glia.20108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fglia.20108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15390091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsF2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=211-219&author=W.+S.+Shengauthor=S.+Huauthor=X.+Minauthor=G.+A.+Cabralauthor=J.+R.+Lokensgardauthor=P.+K.+Peterson&title=Synthetic+cannabinoid+WIN55%2C+212-2+inhibits+generation+of+inflammatory+mediators+by+IL-1%CE%B2-stimulated+human+astrocytes&doi=10.1002%2Fglia.20108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes</span></div><div class="casAuthors">Sheng Wen S; Hu Shuxian; Min Xinan; Cabral Guy A; Lokensgard James R; Peterson Phillip K</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-9</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Activated glial cells have been implicated in the neuropathogenesis of many infectious and inflammatory diseases of the brain.  A number of inflammatory mediators have been proposed to play a role in glial cell-related brain damage; e.g., free radicals such as nitric oxide (NO), cytokines, and chemokines.  Our laboratory has been interested in the effect of psychoactive drugs and their derivatives on the production of these mediators.  Cannabinoids have been shown to possess immunomodulatory as well as psychoactive properties.  We previously have shown that interleukin (IL)-1beta-stimulated human astrocytes, but not microglia, produce NO.  In this study, we investigated the effects of the synthetic cannabinoid WIN55,212-2 on the production of several key inflammatory mediators by human fetal astrocytes activated by IL-1beta.  Expression of the cannabinoid receptors CB1 and CB2 was detected on human astrocytes.  WIN55,212-2 (10(-5) M) potently inhibited inducible NO synthase (iNOS) and corresponding NO production by IL-1beta-stimulated astrocytes.  The CB1 and CB2 receptor-specific antagonists SR141716A and SR144528, respectively, partially blocked this suppressive effect.  In addition, treatment of astrocytes with WIN55,212-2 downregulated in a concentration-dependent manner IL-1beta-induced tumor necrosis factor (TNF)-alpha release.  Treatment with WIN55,212-2 also inhibited production of the chemokines CXCL10, CCL2 and CCL5 by IL-1beta-activated astrocytes.  These findings indicate that WIN55,212-2 inhibits the production of inflammatory mediators by IL-1beta-stimulated human astrocytes and suggest that comparable agents may have therapeutic potential for the management of brain inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTisPFlwsWFEUGy1nwu7K2mfW6udTcc2eavFCGyQzAbQ7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsF2ksQ%253D%253D&md5=cc98950a8387f6ce90b2c707dc8e15e2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fglia.20108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20108%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DW.%2BS.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DLokensgard%26aufirst%3DJ.%2BR.%26aulast%3DPeterson%26aufirst%3DP.%2BK.%26atitle%3DSynthetic%2520cannabinoid%2520WIN55%252C%2520212-2%2520inhibits%2520generation%2520of%2520inflammatory%2520mediators%2520by%2520IL-1%25CE%25B2-stimulated%2520human%2520astrocytes%26jtitle%3DGlia%26date%3D2005%26volume%3D49%26spage%3D211%26epage%3D219%26doi%3D10.1002%2Fglia.20108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref30"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref30'); return false;" data-citation="" class="refNumLink">30</a></strong><div class="NLM_citation" id="cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, M.</span></span> <span> </span><span class="NLM_article-title">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.neurobiolaging.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22795792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=791-804&author=J.+Wuauthor=B.+Bieauthor=H.+Yangauthor=J.+J.+Xuauthor=D.+L.+Brownauthor=M.+Naguib&title=Activation+of+the+CB2+receptor+system+reverses+amyloid-induced+memory+deficiency&doi=10.1016%2Fj.neurobiolaging.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span></div><div class="casAuthors">Wu, Jiang; Bie, Bihua; Yang, Hui; Xu, Jijun J.; Brown, David L.; Naguib, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cannabinoid type 2 (CB2) agonists are neuroprotective and appear to play modulatory roles in neurodegenerative processes in Alzheimer's disease.  We have studied the effect of 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7)-a novel selective CB2 agonist that lacks psychoactivity-on ameliorating the neuroinflammatory process, synaptic dysfunction, and cognitive impairment induced by bilateral microinjection of amyloid-β (Aβ)1-40 fibrils into the hippocampal CA1 area of rats.  In rats injected with Aβ1-40 fibrils, compared with the administration of i.p. saline for 14 days, treatment with 15 mg/kg of i.p. MDA7 daily for 14 days (1) ameliorated the expression of CD11b (microglia marker) and glial fibrillary acidic protein (astrocyte marker), (2) decreased the secretion of interleukin-1β, (3) decreased the upsurge of CB2 receptors, (4) promoted Aβ clearance, and (5) restored synaptic plasticity, cognition, and memory.  Our findings suggest that MDA7 is an innovative therapeutic approach for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekBBhIM0ej7Vg90H21EOLACvtfcHk0lgeo9P-s81_mQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO&md5=ee0c45a830bc6f4d2236ccfcee75b2ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBie%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DNaguib%26aufirst%3DM.%26atitle%3DActivation%2520of%2520the%2520CB2%2520receptor%2520system%2520reverses%2520amyloid-induced%2520memory%2520deficiency%26jtitle%3DNeurobiol.%2520Aging%26date%3D2013%26volume%3D34%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.neurobiolaging.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref31"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref31'); return false;" data-citation="" class="refNumLink">31</a></strong><div class="NLM_citation" id="cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Moreno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spuch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innamorato, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ceballos, M. L.</span></span> <span> </span><span class="NLM_article-title">Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-9-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1186%2F1742-2094-9-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22212381" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1-15&author=A.+M.+Mart%C3%ADn-Morenoauthor=B.+Breraauthor=C.+Spuchauthor=E.+Carroauthor=L.+Garc%C3%ADa-Garc%C3%ADaauthor=M.+Delgadoauthor=M.+A.+Pozoauthor=N.+G.+Innamoratoauthor=A.+Cuadradoauthor=M.+L.+de+Ceballos&title=Prolonged+oral+cannabinoid+administration+prevents+neuroinflammation%2C+lowers+%CE%B2-amyloid+levels+and+improves+cognitive+performance+in+Tg+APP+2576+mice&doi=10.1186%2F1742-2094-9-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-9-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-9-8%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-Moreno%26aufirst%3DA.%2BM.%26aulast%3DBrera%26aufirst%3DB.%26aulast%3DSpuch%26aufirst%3DC.%26aulast%3DCarro%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DL.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DPozo%26aufirst%3DM.%2BA.%26aulast%3DInnamorato%26aufirst%3DN.%2BG.%26aulast%3DCuadrado%26aufirst%3DA.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26atitle%3DProlonged%2520oral%2520cannabinoid%2520administration%2520prevents%2520neuroinflammation%252C%2520lowers%2520%25CE%25B2-amyloid%2520levels%2520and%2520improves%2520cognitive%2520performance%2520in%2520Tg%2520APP%25202576%2520mice%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2012%26volume%3D9%26spage%3D1%26epage%3D15%26doi%3D10.1186%2F1742-2094-9-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref32"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref32'); return false;" data-citation="" class="refNumLink">32</a></strong><div class="NLM_citation" id="cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingtdeux, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marambaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Abramo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.2119/molmed.2013.00140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2119%2Fmolmed.2013.00140" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=29-36&author=J.+Koppelauthor=V.+Vingtdeuxauthor=P.+Marambaudauthor=C.+d%E2%80%99Abramoauthor=H.+Jimenezauthor=M.+Stauberauthor=R.+Friedmanauthor=P.+Davies&title=CB2+receptor+deficiency+increases+amyloid+pathology+and+alters+tau+processing+in+a+transgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.2119%2Fmolmed.2013.00140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2013.00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2013.00140%26sid%3Dliteratum%253Aachs%26aulast%3DKoppel%26aufirst%3DJ.%26aulast%3DVingtdeux%26aufirst%3DV.%26aulast%3DMarambaud%26aufirst%3DP.%26aulast%3Dd%25E2%2580%2599Abramo%26aufirst%3DC.%26aulast%3DJimenez%26aufirst%3DH.%26aulast%3DStauber%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DCB2%2520receptor%2520deficiency%2520increases%2520amyloid%2520pathology%2520and%2520alters%2520tau%2520processing%2520in%2520a%2520transgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D29%26epage%3D36%26doi%3D10.2119%2Fmolmed.2013.00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref33"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref33'); return false;" data-citation="" class="refNumLink">33</a></strong><div class="NLM_citation" id="cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A. J. F.</span></span> <span> </span><span class="NLM_article-title">Selective loss of central cholinergic neurons in Alzheimer’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(76)91936-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0140-6736%2876%2991936-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1976&pages=1403&author=P.+Daviesauthor=A.+J.+F.+Maloney&title=Selective+loss+of+central+cholinergic+neurons+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2876%2991936-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2876%2991936-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252876%252991936-X%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DA.%2BJ.%2BF.%26atitle%3DSelective%2520loss%2520of%2520central%2520cholinergic%2520neurons%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D1976%26volume%3D308%26spage%3D1403%26doi%3D10.1016%2FS0140-6736%2876%2991936-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref34"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref34'); return false;" data-citation="" class="refNumLink">34</a></strong><div class="NLM_citation" id="cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arendt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigl, V.</span></span> <span> </span><span class="NLM_article-title">Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development—a study of molecular forms</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1016/0197-0186(92)90189-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0197-0186%2892%2990189-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1303164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXltVag" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1992&pages=381-396&author=T.+Arendtauthor=M.+K.+Br%C3%BCcknerauthor=M.+Langeauthor=V.+Bigl&title=Changes+in+acetylcholinesterase+and+butyrylcholinesterase+in+Alzheimer%E2%80%99s+disease+resemble+embryonic+development%E2%80%94a+study+of+molecular+forms&doi=10.1016%2F0197-0186%2892%2990189-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development. A study of molecular forms.</span></div><div class="casAuthors">Arendt, Thomas; Bruckner, Martina K.; Lange, Matthias; Bigl, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">381-96</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    </div><div class="casAbstract">The pattern of mol. forms of acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) sepd. by d. gradient centrifugation was investigated in the brain and cerebrospinal fluid in Alzheimer's disease (AD), in human embryonic brain and in rat brain after exptl. cholinergic deafferentation of the cerebral cortex.  While a selective loss of the AChE G4 form was a rather const. finding in AD, a small but significant increase of G1 for both AchE and BChE was found in the most severely affected cases.  Both in normal human brain and in AD a significant relationship could be established between the AChE G4/G1 ratio in different brain regions and the activity of choline acetyltransferase (ChAT).  A similar decrease of the AChE G4 form as obsd. in AD can be induced in rat by exptl. cholinergic deafferentation of the cerebral cortex.  The increase in G1 of both AChE and BChE in different brain regions in AD is quant. related to the local d. of neuritic plaques which are histochem. reactive for both enzymes.  In human embryonic brain, a high abundance of G1 and a low G4/G1 ratio for both AChE and BChE was found resembling the pattern obsd. in AD.  Furthermore, both in embryonic brain and in AD AChE shows no substrate inhibition which is a const. feature of the enzymes in the adult human brain.  It is concluded that the degeneration of the cholinergic cortical afferentation in AD as reflected by a decrease of AChE G4 is accompanied by the process of a neuritic sprouting response involved in plaque formation which is probably assocd. with the expression of a developmental form of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfFdAst2WU6rVg90H21EOLACvtfcHk0lhftNVXwpJNTQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltVag&md5=a4aa253e74ab647685abf2ec939aa8f9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0197-0186%2892%2990189-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0197-0186%252892%252990189-X%26sid%3Dliteratum%253Aachs%26aulast%3DArendt%26aufirst%3DT.%26aulast%3DBr%25C3%25BCckner%26aufirst%3DM.%2BK.%26aulast%3DLange%26aufirst%3DM.%26aulast%3DBigl%26aufirst%3DV.%26atitle%3DChanges%2520in%2520acetylcholinesterase%2520and%2520butyrylcholinesterase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520resemble%2520embryonic%2520development%25E2%2580%2594a%2520study%2520of%2520molecular%2520forms%26jtitle%3DNeurochem.%2520Int.%26date%3D1992%26volume%3D21%26spage%3D381%26epage%3D396%26doi%3D10.1016%2F0197-0186%2892%2990189-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref35"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref35'); return false;" data-citation="" class="refNumLink">35</a></strong><div class="NLM_citation" id="cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, D. K.</span></span> <span> </span><span class="NLM_article-title">A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1185/03007990152673800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1185%2F03007990152673800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11900310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=159-165&author=N.+H.+Greigauthor=T.+Utsukiauthor=Q.+S.+Yuauthor=X.+Zhuauthor=H.+W.+Hollowayauthor=T.+Perryauthor=B.+Leeauthor=D.+K.+Ingramauthor=D.+K.+Lahiri&title=A+new+therapeutic+target+in+Alzheimer%E2%80%99s+disease+treatment%3A+attention+to+butyrylcholinesterase&doi=10.1185%2F03007990152673800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase</span></div><div class="casAuthors">Greig, Nigel H.; Utsuki, Tada; Yu, Qian-sheng; Zhu, Xiaoxiang; Holloway, Harold W.; Perry, TracyAnn; Lee, Bong; Ingram, Donald K.; Lahiri, Debomoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">LibraPharm Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterized by widespread loss of central cholinergic function.  The only symptomatic treatment proven effective to date is the use of cholinesterase (ChE) inhibitors to augment surviving cholinergic activity.  ChE inhibitors act on the enzymes that hydrolyze acetylcholine (ACh) following synaptic release.  In the healthy brain, acetylcholinesterase (AChE) predominates (80%) and butyrylcholinesterase (BuChE) is considered to play a minor role in regulating brain ACh levels.  In the AD brain, BuChE activity rises while AChE activity remains unchanged or declines.  Therefore both enzymes are likely to have involvement in regulating ACh levels and represent legitimate therapeutic targets to ameliorate the cholinergic deficit.  The two enzymes differ in location, substrate specificity and kinetics.  Recent evidence suggests that BuChE may also have a role in the etiol. and progression of AD beyond regulation of synaptic ACh levels.  Exptl. evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.  The development of specific BuChE inhibitors and the continued use of ChE inhibitors with the ability to inhibit BuChE in addn. to AChE should lead to improved clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4MokwgwULbVg90H21EOLACvtfcHk0liBOEAqFR9EOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslSnug%253D%253D&md5=bf6513e8d8d7edd39f6b95342a238128</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1185%2F03007990152673800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007990152673800%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DUtsuki%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DPerry%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DIngram%26aufirst%3DD.%2BK.%26aulast%3DLahiri%26aufirst%3DD.%2BK.%26atitle%3DA%2520new%2520therapeutic%2520target%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%253A%2520attention%2520to%2520butyrylcholinesterase%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2001%26volume%3D17%26spage%3D159%26epage%3D165%26doi%3D10.1185%2F03007990152673800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref36"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref36'); return false;" data-citation="" class="refNumLink">36</a></strong><div class="NLM_citation" id="cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">Cholinergic function and Alzheimer’s disease</span>. <i>Int. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S5</span>, <span class="refDoi"> DOI: 10.1002/gps.935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fgps.935" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=S1-S5&author=E.+Giacobini&title=Cholinergic+function+and+Alzheimer%E2%80%99s+disease&doi=10.1002%2Fgps.935"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fgps.935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.935%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DCholinergic%2520function%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D18%26spage%3DS1%26epage%3DS5%26doi%3D10.1002%2Fgps.935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref37"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref37'); return false;" data-citation="" class="refNumLink">37</a></strong><div class="NLM_citation" id="cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span> <span> </span><span class="NLM_article-title">Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on</span>. <i>Curr. Ther. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/S0011-393X(03)00059-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0011-393X%2803%2900059-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24944370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=216-235&author=G.+T.+Grossberg&title=Cholinesterase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+getting+on+and+staying+on&doi=10.1016%2FS0011-393X%2803%2900059-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinesterase inhibitors for the treatment of alzheimer's disease: Getting on and staying on</span></div><div class="casAuthors">Grossberg, George T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Therapeutic Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">216-235</span>CODEN:
                <span class="NLM_cas:coden">CTCEA9</span>;
        ISSN:<span class="NLM_cas:issn">0011-393X</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine.  In addn. to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.  The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacol. differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clin. practice.  Using published literature collected over time by the author, a review was conducted, focusing on the pharmacol. and clin. data of donepezil, galantamine, and rivastigmine.  All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large.  These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit.  To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clin. practice, consisting of a "start low, go slow" procedure with a min. of 4 wk between dose increases.  After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).  Cholinesterase inhibitors provide symptomatic benefit in AD across key symptom domains.  Factors influencing the safety, tolerability, and efficacy of these agents in clin. practice include ChE enzymes inhibited, brain and.  Brain-region ChE selectivity, and metab. route.  Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj8qRzCpybb7Vg90H21EOLACvtfcHk0liBOEAqFR9EOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlKntbw%253D&md5=0c4d3b44d7d1cbf29b85c7b6f75598f5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0011-393X%2803%2900059-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0011-393X%252803%252900059-6%26sid%3Dliteratum%253Aachs%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26atitle%3DCholinesterase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520getting%2520on%2520and%2520staying%2520on%26jtitle%3DCurr.%2520Ther.%2520Res.%26date%3D2003%26volume%3D64%26spage%3D216%26epage%3D235%26doi%3D10.1016%2FS0011-393X%2803%2900059-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref38"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref38'); return false;" data-citation="" class="refNumLink">38</a></strong><div class="NLM_citation" id="cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darvesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geula, C.</span></span> <span> </span><span class="NLM_article-title">Neurobiology of butyrylcholinesterase</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1038/nrn1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn1035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12563284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=131-138&author=S.+Darveshauthor=D.+A.+Hopkinsauthor=C.+Geula&title=Neurobiology+of+butyrylcholinesterase&doi=10.1038%2Fnrn1035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Neurobiology of butyrylcholinesterase</span></div><div class="casAuthors">Darvesh, Sultan; Hopkins, David A.; Geula, Changiz</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-138</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Butyrylcholinesterase is a serine hydrolase related to acetylcholinesterase that catalyzes the hydrolysis of esters of choline, including acetylcholine.  Butyrylcholinesterase has unique enzymic properties and is widely distributed in the nervous system, pointing to its possible involvement in neural function.  Here, we summarize the biochem. properties of butyrylcholinesterase and review the evidence that this enzyme has important roles in cholinergic neurotransmission and could be involved in other nervous system functions and in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf8WbhaQUqP7Vg90H21EOLACvtfcHk0liBOEAqFR9EOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12hsg%253D%253D&md5=aeb5008a2c61e5feb48506f835899519</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrn1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1035%26sid%3Dliteratum%253Aachs%26aulast%3DDarvesh%26aufirst%3DS.%26aulast%3DHopkins%26aufirst%3DD.%2BA.%26aulast%3DGeula%26aufirst%3DC.%26atitle%3DNeurobiology%2520of%2520butyrylcholinesterase%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D131%26epage%3D138%26doi%3D10.1038%2Fnrn1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref39"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref39'); return false;" data-citation="" class="refNumLink">39</a></strong><div class="NLM_citation" id="cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duysen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span> <span> </span><span class="NLM_article-title">Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0306-4522%2801%2900613-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11934471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XisV2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=627-639&author=M.+M.+Mesulamauthor=A.+Guillozetauthor=P.+Shawauthor=A.+Leveyauthor=E.+Duysenauthor=O.+Lockridge&title=Acetylcholinesterase+knockouts+establish+central+cholinergic+pathways+and+can+use+butyrylcholinesterase+to+hydrolyze+acetylcholine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine</span></div><div class="casAuthors">Mesulam, M.-M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-639</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Acetylcholinesterase is one of the most prominent constituents of central cholinergic pathways.  It terminates the synaptic action of acetylcholine through hydrolysis and yields the choline moiety that is necessary for transmitter recycling.  Despite these pivotal relationships, mice nullizygous for acetylcholinesterase established all principal anatomical components of central cholinergic pathways.  No compensatory increase in the distribution of butyrylcholinesterase was detected.  However, both the wild-type and nullizygous mice showed that butyrylcholinesterase enzyme activity extended to all parts of the brain receiving cholinergic innervation and that it could hydrolyze the acetylcholine surrogate acetylthiocholine.  As opposed to acetylcholinesterase which was mostly of neuronal origin, butyrylcholinesterase appeared to be mostly of glial origin.  These expts. lead to the unexpected conclusion that acetylcholinesterase is not necessary for the establishment of cholinergic pathways.  They also show that butyrylcholinesterase can potentially substitute for acetylcholinesterase and that this enzyme is likely to play a constitutive (rather than just back-up) role in the hydrolysis of acetylcholine in the normal brain.  The inhibition of butyrylcholinesterase may therefore provide a desirable feature of cholinergic therapies, including those aimed at treating Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaarm2WZSE07Vg90H21EOLACvtfcHk0lg43Wch5E_5EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisV2hsrw%253D&md5=ca2117183dd41ebd26e137a65404e805</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2801%2900613-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252801%252900613-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesulam%26aufirst%3DM.%2BM.%26aulast%3DGuillozet%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DLevey%26aufirst%3DA.%26aulast%3DDuysen%26aufirst%3DE.%26aulast%3DLockridge%26aufirst%3DO.%26atitle%3DAcetylcholinesterase%2520knockouts%2520establish%2520central%2520cholinergic%2520pathways%2520and%2520can%2520use%2520butyrylcholinesterase%2520to%2520hydrolyze%2520acetylcholine%26jtitle%3DNeuroscience%26date%3D2002%26volume%3D110%26spage%3D627%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref40"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref40'); return false;" data-citation="" class="refNumLink">40</a></strong><div class="NLM_citation" id="cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nordberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darreh-Shori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somogyi, M.</span></span> <span> </span><span class="NLM_article-title">A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease</span>. <i>Prim. Care Companion CNS Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.4088/PCC.12r01412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.4088%2FPCC.12r01412" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1-30&author=A.+Nordbergauthor=C.+Ballardauthor=R.+Bullockauthor=T.+Darreh-Shoriauthor=M.+Somogyi&title=A+review+of+butyrylcholinesterase+as+a+therapeutic+target+in+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.4088%2FPCC.12r01412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.4088%2FPCC.12r01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.12r01412%26sid%3Dliteratum%253Aachs%26aulast%3DNordberg%26aufirst%3DA.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DR.%26aulast%3DDarreh-Shori%26aufirst%3DT.%26aulast%3DSomogyi%26aufirst%3DM.%26atitle%3DA%2520review%2520of%2520butyrylcholinesterase%2520as%2520a%2520therapeutic%2520target%2520in%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DPrim.%2520Care%2520Companion%2520CNS%2520Disord.%26date%3D2013%26volume%3D15%26spage%3D1%26epage%3D30%26doi%3D10.4088%2FPCC.12r01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref41"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref41'); return false;" data-citation="" class="refNumLink">41</a></strong><div class="NLM_citation" id="cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiewert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duysen, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J.</span></span> <span> </span><span class="NLM_article-title">Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04347.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1111%2Fj.1471-4159.2006.04347.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17212694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Grs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=1421-1429&author=J.+Hartmannauthor=C.+Kiewertauthor=E.+G.+Duysenauthor=O.+Lockridgeauthor=N.+H.+Greigauthor=J.+Klein&title=Excessive+hippocampal+acetylcholine+levels+in+acetylcholinesterase-deficient+mice+are+moderated+by+butyrylcholinesterase+activity&doi=10.1111%2Fj.1471-4159.2006.04347.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity</span></div><div class="casAuthors">Hartmann, Joachim; Kiewert, Cornelia; Duysen, Ellen G.; Lockridge, Oksana; Greig, Nigel H.; Klein, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Central cholinergic systems are involved in a plethora of brain functions and are severely and selectively damaged in neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies.  Cholinergic dysfunction is treated with inhibitors of acetylcholinesterase (AChE) while the role of butyrylcholinesterase (BChE) for brain cholinergic function is unclear.  We have used in vivo microdialysis to investigate the regulation of hippocampal acetylcholine (ACh) levels in mice that are devoid of AChE (AChE-/- mice).  Extracellular ACh levels in the hippocampus were 60-fold elevated in AChE-/- mice compared with wild-type (AChE+/+) animals.  In AChE-/- mice, calcium-free conditions reduced hippocampal ACh levels by 50%, and infusion of tetrodotoxin by more than 90%, indicating continuous ACh release.  Infusion of a selective AChE inhibitor (BW284c51) caused a dose-dependent, up to 16-fold increase of extracellular ACh levels in AChE+/+ mice but did not change ACh levels in AChE-/- mice.  In contrast, infusion of a selective inhibitor of BChE (bambuterol) caused up to fivefold elevation of ACh levels in AChE-/- mice, but was without effect in AChE+/+ animals.  These results were corroborated with two other specific inhibitors of AChE and BChE, tolserine and bis-norcymserine, resp.  We conclude that lack of AChE causes dramatically increased levels of extracellular ACh in the brain.  Importantly, in the absence of AChE, the levels of extracellular ACh in the brain are controlled by the activity of BChE.  These results point to a potential usefulness of BChE inhibitors in the treatment of central cholinergic dysfunction in which brain AChE activity is typically reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosHAJAnTb_b7Vg90H21EOLACvtfcHk0lg43Wch5E_5EA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Grs7g%253D&md5=95d7181c01f859a8b03bfdfed31be6ad</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04347.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04347.x%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DJ.%26aulast%3DKiewert%26aufirst%3DC.%26aulast%3DDuysen%26aufirst%3DE.%2BG.%26aulast%3DLockridge%26aufirst%3DO.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DKlein%26aufirst%3DJ.%26atitle%3DExcessive%2520hippocampal%2520acetylcholine%2520levels%2520in%2520acetylcholinesterase-deficient%2520mice%2520are%2520moderated%2520by%2520butyrylcholinesterase%2520activity%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D100%26spage%3D1421%26epage%3D1429%26doi%3D10.1111%2Fj.1471-4159.2006.04347.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref42"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref42'); return false;" data-citation="" class="refNumLink">42</a></strong><div class="NLM_citation" id="cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa-Hibi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussaoui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span> <span> </span><span class="NLM_article-title">Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2011.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bbr.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21820013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKjurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2011&pages=222-229&author=Y.+Furukawa-Hibiauthor=T.+Alkamauthor=A.+Nittaauthor=A.+Matsuyamaauthor=H.+Mizoguchiauthor=K.+Suzukiauthor=S.+Moussaouiauthor=Q.+S.+Yuauthor=N.+H.+Greigauthor=T.+Nagaiauthor=K.+Yamada&title=Butyrylcholinesterase+inhibitors+ameliorate+cognitive+dysfunction+induced+by+amyloid-%CE%B2+peptide+in+mice&doi=10.1016%2Fj.bbr.2011.07.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice</span></div><div class="casAuthors">Furukawa-Hibi, Yoko; Alkam, Tursun; Nitta, Atsumi; Matsuyama, Akihiro; Mizoguchi, Hiroyuki; Suzuki, Kazuhiko; Moussaoui, Saliha; Yu, Qian-Sheng; Greig, Nigel H.; Nagai, Taku; Yamada, Kiyofumi</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-229</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cholinesterase inhibitor, rivastigmine, ameliorates cognitive dysfunction and is approved for the treatment of Alzheimer's disease (AD).  Rivastigmine is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE); however, the impact of BuChE inhibition on cognitive dysfunction remains to be detd.  We compared the effects of a selective BuChE inhibitor, N1-phenethyl-norcymserine (PEC), rivastigmine and donepezil (an AChE-selective inhibitor) on cognitive dysfunction induced by amyloid-β peptide (Aβ1-40) in mice.  Five-week-old imprinting control region (ICR) mice were injected intracerebroventricularly (i.c.v.) with either Aβ1-40 or the control peptide Aβ40-1 on Day 0, and their recognition memory was analyzed by a novel object recognition test.  Treatment with donepezil (1.0 mg/kg), rivastigmine (0.03, 0.1, 0.3 mg/kg) or PEC (1.0, 3.0 mg/kg) 20 min prior to, or immediately after the acquisition session (Day 4) ameliorated the Aβ1-40 induced memory impairment, indicating a beneficial effect on memory acquisition and consolidation.  In contrast, none of the investigated drugs proved effective when administrated before the retention session (Day 5).  Repeated daily administration of donepezil, rivastigmine or PEC, on Days 0-3 inclusively, ameliorated the cognitive dysfunction in Aβ1-40 challenged mice.  Consistent with the reversal of memory impairments, donepezil, rivastigmine or PEC treatment significantly reduced Aβ1-40 induced tyrosine nitration of hippocampal proteins, a marker of oxidative damage.  These results indicate that BuChE inhibition, as well as AChE inhibition, is a viable therapeutic strategy for cognitive dysfunction in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWrQS5R61AGbVg90H21EOLACvtfcHk0lgG5hAFT7bcWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKjurrE&md5=e1d7203ed15e8b829e505a41c8c0e7ff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DFurukawa-Hibi%26aufirst%3DY.%26aulast%3DAlkam%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DMatsuyama%26aufirst%3DA.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMoussaoui%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26atitle%3DButyrylcholinesterase%2520inhibitors%2520ameliorate%2520cognitive%2520dysfunction%2520induced%2520by%2520amyloid-%25CE%25B2%2520peptide%2520in%2520mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D225%26spage%3D222%26epage%3D229%26doi%3D10.1016%2Fj.bbr.2011.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref43"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref43'); return false;" data-citation="" class="refNumLink">43</a></strong><div class="NLM_citation" id="cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepeu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamczarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambamurti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, D. K.</span></span> <span> </span><span class="NLM_article-title">Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">17213</span>– <span class="NLM_lpage">17218</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508575102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.0508575102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16275899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yksLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=17213-17218&author=N.+H.+Greigauthor=T.+Utsukiauthor=D.+K.+Ingramauthor=Y.+Wangauthor=G.+Pepeuauthor=C.+Scaliauthor=Q.+S.+Yuauthor=J.+Mamczarzauthor=H.+W.+Hollowayauthor=T.+Giordanoauthor=D.+Chenauthor=K.+Furukawaauthor=K.+Sambamurtiauthor=A.+Brossiauthor=D.+K.+Lahiri&title=Selective+butyrylcholinesterase+inhibition+elevates+brain+acetylcholine%2C+augments+learning+and+lowers+Alzheimer+%CE%B2-amyloid+peptide+in+rodent&doi=10.1073%2Fpnas.0508575102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent</span></div><div class="casAuthors">Greig, Nigel H.; Utsuki, Tadanobu; Ingram, Donald K.; Wang, Yue; Pepeu, Giancarlo; Scali, Carla; Yu, Qian-Sheng; Mamczarz, Jacek; Holloway, Harold W.; Giordano, Tony; Chen, DeMao; Furukawa, Katsutoshi; Sambamurti, Kumar; Brossi, Arnold; Lahiri, Debomoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17213-17218</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Like acetylcholinesterase, butyrylcholinesterase (BChE) inactivates the neurotransmitter acetylcholine (ACh) and is hence a viable therapeutic target in Alzheimer's disease, which is characterized by a cholinergic deficit.  Potent, reversible, and brain-targeted BChE inhibitors (cymserine analogs) were developed based on binding domain structures to help elucidate the role of this enzyme in the central nervous system.  In rats, cymserine analogs caused long-term inhibition of brain BChE and elevated extracellular ACh levels, without inhibitory effects on acetylcholinesterase.  In rat brain slices, selective BChE inhibition augmented long-term potentiation.  These compds. also improved the cognitive performance (maze navigation) of aged rats.  In cultured human SK-N-SH neuroblastoma cells, intra- and extracellular β-amyloid precursor protein, and secreted β-amyloid peptide levels were reduced without affecting cell viability.  Treatment of transgenic mice that overexpressed human mutant amyloid precursor protein also resulted in lower β-amyloid peptide brain levels than controls.  Selective, reversible inhibition of brain BChE may represent a treatment for Alzheimer's disease, improving cognition and modulating neuropathol. markers of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI6ACIUUc5wrVg90H21EOLACvtfcHk0lgG5hAFT7bcWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yksLfE&md5=a4ac89f6186f77125545c667f9efbe21</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508575102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508575102%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DUtsuki%26aufirst%3DT.%26aulast%3DIngram%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPepeu%26aufirst%3DG.%26aulast%3DScali%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DMamczarz%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DGiordano%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFurukawa%26aufirst%3DK.%26aulast%3DSambamurti%26aufirst%3DK.%26aulast%3DBrossi%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DD.%2BK.%26atitle%3DSelective%2520butyrylcholinesterase%2520inhibition%2520elevates%2520brain%2520acetylcholine%252C%2520augments%2520learning%2520and%2520lowers%2520Alzheimer%2520%25CE%25B2-amyloid%2520peptide%2520in%2520rodent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2005%26volume%3D102%26spage%3D17213%26epage%3D17218%26doi%3D10.1073%2Fpnas.0508575102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref44"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref44'); return false;" data-citation="" class="refNumLink">44</a></strong><div class="NLM_citation" id="cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strehaiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siméon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span> <span> </span><span class="NLM_article-title">Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2015.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bbr.2015.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26306824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2016&pages=351-360&author=T.+Mauriceauthor=M.+Strehaianoauthor=N.+Sim%C3%A9onauthor=C.+Bertrandauthor=A.+Chatonnet&title=Learning+performances+and+vulnerability+to+amyloid+toxicity+in+the+butyrylcholinesterase+knockout+mouse&doi=10.1016%2Fj.bbr.2015.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse</span></div><div class="casAuthors">Maurice, Tangui; Strehaiano, Manon; Simeon, Nathalie; Bertrand, Christelle; Chatonnet, Arnaud</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Butyrylcholinesterase (BChE) is an important enzyme for detoxication and metab. of ester compds.  It also hydrolyzes the neurotransmitter acetylcholine (ACh) in pathol. conditions and may play a role in Alzheimer's disease (AD).  We here compared the learning ability and vulnerability to Aβ toxicity in male and female BChE knockout (KO) mice and their 129 Sv wild-type (Wt) controls.  Animals tested for place learning in the water-maze showed increased acquisition slopes and presence in the training quadrant during the probe test.  An increased passive avoidance response was also obsd. for males.  BChE KO mice therefore showed enhanced learning ability in spatial and non-spatial memory tests.  Intracerebroventricular (ICV) injection of increasing doses of amyloid-β[25-35] (Aβ25-35) peptide oligomers resulted, in Wt mice, in learning and memory deficits, oxidative stress and decrease in ACh hippocampal content.  In BChE KO mice, the Aβ25-35-induced deficit in place learning was attenuated in males and blocked in females.  No change in lipid peroxidn. or ACh levels was obsd. after Aβ25-35 treatment in male or female BChE KO mice.  These data showed that the genetic invalidation of BChE in mice augmented learning capacities and lowered the vulnerability to Aβ toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3M4M6LenzrVg90H21EOLACvtfcHk0lgG5hAFT7bcWA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOqt7bP&md5=1b8f7885ee358acacce167f61ea2599c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2015.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2015.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DStrehaiano%26aufirst%3DM.%26aulast%3DSim%25C3%25A9on%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DC.%26aulast%3DChatonnet%26aufirst%3DA.%26atitle%3DLearning%2520performances%2520and%2520vulnerability%2520to%2520amyloid%2520toxicity%2520in%2520the%2520butyrylcholinesterase%2520knockout%2520mouse%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D296%26spage%3D351%26epage%3D360%26doi%3D10.1016%2Fj.bbr.2015.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref45"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref45'); return false;" data-citation="" class="refNumLink">45</a></strong><div class="NLM_citation" id="cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lhzNKiA6DHjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref46"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref46'); return false;" data-citation="" class="refNumLink">46</a></strong><div class="NLM_citation" id="cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lhzNKiA6DHjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref47"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref47'); return false;" data-citation="" class="refNumLink">47</a></strong><div class="NLM_citation" id="cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span>; <span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Dual-acting compounds acting as receptor ligands and enzyme inhibitors</span>. In  <i>Design of hybrid molecules for drug development</i>, <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FB978-0-08-101011-2.00005-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=137-165&author=D.+Dolles&author=M.+Decker&title=Design+of+hybrid+molecules+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-101011-2.00005-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-101011-2.00005-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26atitle%3DDual-acting%2520compounds%2520acting%2520as%2520receptor%2520ligands%2520and%2520enzyme%2520inhibitors%26btitle%3DDesign%2520of%2520hybrid%2520molecules%2520for%2520drug%2520development%26pub%3DElsevier%26date%3D2017%26spage%3D137%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref48"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref48'); return false;" data-citation="" class="refNumLink">48</a></strong><div class="NLM_citation" id="cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+M%C3%B6llerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure%E2%80%93activity+relationships+and+computational+investigations+into+the+development+of+potent+and+balanced+dual-acting+butyrylcholinesterase+inhibitors+and+human+cannabinoid+receptor+2+ligands+with+pro-cognitive+in+vivo+profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span></div><div class="casAuthors">Dolles, Dominik; Hoffmann, Matthias; Gunesch, Sandra; Marinelli, Oliviero; Moeller, Jan; Santoni, Giorgio; Chatonnet, Arnaud; Lohse, Martin J.; Wittmann, Hans-Joachim; Strasser, Andrea; Nabissi, Massimo; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1646-1663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB2R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease.  The authors merged pharmacophores for both targets into small benzimidazole-based mols., investigated SARs, and identified several dual-acting ligands with a balanced affinity/inhibitory activity and an excellent selectivity over both hCB1R and hAChE.  A homol. model for the hCB2R was developed based on the hCB1R crystal structure and used for mol. dynamics studies to investigate binding modes.  In vitro studies proved hCB2R agonism.  Unwanted μ-opioid receptor affinity could be designed out.  One well-balanced dual-acting and selective hBChE inhibitor/hCB2R agonist showed superior in vivo activity over the lead CB2 agonist with regards to cognition improvement.  The data shows the possibility to combine a small mol. with selective and balanced GPCR-activity/enzyme inhibition and in vivo activity for the therapy of AD and may help to rationalize the development of other dual-acting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgCAoLm6nAVbVg90H21EOLACvtfcHk0lhzNKiA6DHjHw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D&md5=49e8e68c2c9a023b872e2522fad6e78c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DM%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520and%2520computational%2520investigations%2520into%2520the%2520development%2520of%2520potent%2520and%2520balanced%2520dual-acting%2520butyrylcholinesterase%2520inhibitors%2520and%2520human%2520cannabinoid%2520receptor%25202%2520ligands%2520with%2520pro-cognitive%2520in%2520vivo%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref49"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref49'); return false;" data-citation="" class="refNumLink">49</a></strong><div class="NLM_citation" id="cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R. M.</span></span> <span> </span><span class="NLM_article-title">Tacrine: a pharmacological review</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/0301-0082(91)90002-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0301-0082%2891%2990002-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1714613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1Kiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1991&pages=257-277&author=S.+E.+Freemanauthor=R.+M.+Dawson&title=Tacrine%3A+a+pharmacological+review&doi=10.1016%2F0301-0082%2891%2990002-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine:  a pharmacological review</span></div><div class="casAuthors">Freeman, Shirley E.; Dawson, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-77</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    </div><div class="casAbstract">A review with 162 refs. on tacrine interactions with morphine, with drugs that block the myoneural junction, with glycolate psychotomimetic drugs, with cholinesterases, with muscarinic receptors, with ion channels, with the release and uptake of neurotransmitters, and use as an antidote against nerve agent poisoning and in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNNQE5N9GzjrVg90H21EOLACvtfcHk0lgeeh3VfLbUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1Kiurs%253D&md5=ee92496e1f6b19b773798a17b0af44a0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0301-0082%2891%2990002-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0301-0082%252891%252990002-I%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DS.%2BE.%26aulast%3DDawson%26aufirst%3DR.%2BM.%26atitle%3DTacrine%253A%2520a%2520pharmacological%2520review%26jtitle%3DProg.%2520Neurobiol.%26date%3D1991%26volume%3D36%26spage%3D257%26epage%3D277%26doi%3D10.1016%2F0301-0082%2891%2990002-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref50"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref50'); return false;" data-citation="" class="refNumLink">50</a></strong><div class="NLM_citation" id="cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summers, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majovski, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachiki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, A.</span></span> <span> </span><span class="NLM_article-title">Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1056/NEJM198611133152001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1056%2FNEJM198611133152001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=2430180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaL2s%252FjvFahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=1986&pages=1241-1245&author=W.+K.+Summersauthor=L.+V.+Majovskiauthor=G.+M.+Marshauthor=K.+Tachikiauthor=A.+Kling&title=Oral+tetrahydroaminoacridine+in+long-term+treatment+of+senile+dementia%2C+Alzheimer+type&doi=10.1056%2FNEJM198611133152001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type</span></div><div class="casAuthors">Summers W K; Majovski L V; Marsh G M; Tachiki K; Kling A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1241-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study.  In the nonblinded first phase of the study, significant improvement occurred in subjects who received the drug, as compared with their pretreatment status, on the global assessment (P = 0.001), the Orientation Test (P = 0.001), and the more sophisticated Names Learning Test (P = 0.001).  During the second phase, the subjects served as their own controls in a double-blind, placebo-controlled, cross-over study in which the order of administration of the drug and placebo was randomly assigned.  Among the 14 subjects completing Phase II, THA treatment produced significantly better results than placebo on the global assessment (P = 0.003), the Orientation Test (P = 0.004), the Alzheimer's Deficit Scale (P = 0.003), and the Names Learning Test (P = 0.001).  Twelve subjects have entered Phase III, which involves long-term administration of oral THA.  The average duration of treatment in these subjects at present is 12.6 months; symptomatic improvements have occurred, and no serious side effects attributable to THA have been observed.  These encouraging initial results suggest that THA may be at least temporarily useful in the long-term palliative treatment of patients with Alzheimer's disease.  We stress that further observations will be required before a clear assessment of the role of this agent can be made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMwVWLd0gLpp6t8nS6Nc3fW6udTcc2ebp2i7oYkvbHrntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FjvFahsA%253D%253D&md5=cdb2761ff58c436d8e12d9a9ab219ccd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1056%2FNEJM198611133152001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198611133152001%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DW.%2BK.%26aulast%3DMajovski%26aufirst%3DL.%2BV.%26aulast%3DMarsh%26aufirst%3DG.%2BM.%26aulast%3DTachiki%26aufirst%3DK.%26aulast%3DKling%26aufirst%3DA.%26atitle%3DOral%2520tetrahydroaminoacridine%2520in%2520long-term%2520treatment%2520of%2520senile%2520dementia%252C%2520Alzheimer%2520type%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1986%26volume%3D315%26spage%3D1241%26epage%3D1245%26doi%3D10.1056%2FNEJM198611133152001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref51"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref51'); return false;" data-citation="" class="refNumLink">51</a></strong><div class="NLM_citation" id="cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracon, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. W.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03510370044030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1001%2Fjama.1994.03510370044030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8139084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Gjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1994&pages=992-998&author=P.+B.+Watkinsauthor=H.+J.+Zimmermanauthor=M.+J.+Knappauthor=S.+I.+Graconauthor=K.+W.+Lewis&title=Hepatotoxic+effects+of+tacrine+administration+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1001%2Fjama.1994.03510370044030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">hepatotoxic effects of tacrine administration in patients with Alzheimer's disease</span></div><div class="casAuthors">Watkins, Paul B.; Zimmerman, Hyman J.; Knapp, Margaret J.; Gracon, Stephen I.; Lewis, Karen W.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">992-8</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">The study was undertaken to characterize the hepatic effects of tacrine treatment in patients with Alzheimer's disease.  Controlled trials of tacrine therapy were designed consisting of two blinded, parallel group trials; three blinded, enrichment-design trials; and their resp. open-label extensions.  Multicenter clin. trials were performed in the United States, France, and Canada.  A total of 2446 men and women at least 50 yr of age with a diagnosis of probable Alzheimer's disease of mild to moderate severity and in good health without significant hepatic, cardiovascular, or renal disease were examd.  Tacrine vs. placebo was administered, with weekly measurement of serum hepatic enzymes.  Incidence, max. severity, and timing of event for serum alanine aminotransferase (ALT) elevation were monitored.  Among the 2446 patients who received tacrine in clin. trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%).  The elevated ALT levels were generally asymptomatic and occurred more frequently in women than men.  The mean time from initiation of tacrine treatment to first ALT level greater than three times the ULN was 50 days, and 90% of all initial ALT levels greater than three times the ULN occurred during the first 12 wk of treatment.  Of 145 patients who discontinued tacrine treatment because of an ALT level greater than three times the ULN and were rechallenged, 127 (88%) were able to resume long-term therapy with the drug.  In all instances, discontinuing tacrine completely reversed elevations in ALT levels, and no deaths related to hepatotoxicity occurred.  These data suggest that the potential for serious hepatic toxicity can be reduced through careful monitoring of ALT levels in patients who may benefit from tacrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGFf98reQra7Vg90H21EOLACvtfcHk0lgeeh3VfLbUUQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Gjs7c%253D&md5=6b7f1c1f770d8974d2d4cbfb2954469b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03510370044030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03510370044030%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DZimmerman%26aufirst%3DH.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%2BJ.%26aulast%3DGracon%26aufirst%3DS.%2BI.%26aulast%3DLewis%26aufirst%3DK.%2BW.%26atitle%3DHepatotoxic%2520effects%2520of%2520tacrine%2520administration%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJAMA%26date%3D1994%26volume%3D271%26spage%3D992%26epage%3D998%26doi%3D10.1001%2Fjama.1994.03510370044030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref52"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref52'); return false;" data-citation="" class="refNumLink">52</a></strong><div class="NLM_citation" id="cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">H. Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span> <span> </span><span class="NLM_article-title">Tacrine-based multifunctional agents in Alzheimer’s disease: an old story in continuous development</span>. <i>Curr. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3546</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170309123920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F0929867324666170309123920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28294041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3522-3546&author=A.+Milelliauthor=A.+De+Simoneauthor=N.+Ticchiauthor=H.+H.+Chenauthor=N.+Betariauthor=V.+Andrisanoauthor=V.+Tumiatti&title=Tacrine-based+multifunctional+agents+in+Alzheimer%E2%80%99s+disease%3A+an+old+story+in+continuous+development&doi=10.2174%2F0929867324666170309123920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development.bdintg.</span></div><div class="casAuthors">Milelli, Andrea; De Simone, Angela; Ticchi, Nicole; Chen, Huan H.; Betari, Nibal; Andrisano, Vincenza; Tumiatti, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3522-3546</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The design of multifunctional agents represents one of the most active research field in medicinal chem.  In particular, tacrine, a well known Acetylcholinesterase inhibitor, is one of the most used starting point to develop multifunctional ligands and hundreds of papers report about these new agents.  This is the third review of a series concerning tacrine based multifunctional ligands; in particular, in the present, we will summarize and discuss the most intriguing examples of tacrine-based multifunctional agents published since 2013 until 2016. </P><P> Methods: We analyzed the bibliog. databases for peer-reviewed publications concerning tacrine-based multifunctional agents possessing biol. actions that go beyond the simple "cholinergic" blockage.  These papers have been subdivided according to their biol. activities.  Since this is the third review of a series, we took into considerations only the papers appeared since 2013 until 2016.  Results: In this review, we have analyzed more than 33 papers.  All the reported compds. retain good inhibitory activity towards acetyl- and butyryl-cholinesterase.  The other biol. activities concern mostly inhibition of a. β-amyloid aggregation, b. β-secretase, c. monoamino oxidases, modulation of β; and ROS and metal chelation.  Conclusion: The anal. of the current literature reported in this review confirm the importance of tacrine as scaffold to develop multifunctional agents potentially usefull to contrast Alzheimer's disease.  Furthermore, the compds. herein reported showed very intriguing biol. activities that could be used as starting point to develop new compds. even more interesting and, hopefully, clin. usefull to contrast Alzheimer's Disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZimowwL4q_7Vg90H21EOLACvtfcHk0li7T4SiSfDQSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM&md5=2a6f856526a08139bca151c647733f95</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170309123920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170309123920%26sid%3Dliteratum%253Aachs%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DTicchi%26aufirst%3DN.%26aulast%3DH.%2BChen%26aufirst%3DH.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DTumiatti%26aufirst%3DV.%26atitle%3DTacrine-based%2520multifunctional%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520old%2520story%2520in%2520continuous%2520development%26jtitle%3DCurr.%2520Med.%2520Chem%26date%3D2017%26volume%3D24%26spage%3D3522%26epage%3D3546%26doi%3D10.2174%2F0929867324666170309123920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref53"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref53'); return false;" data-citation="" class="refNumLink">53</a></strong><div class="NLM_citation" id="cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic agents in Alzheimer’s disease through a multi-target directed ligands strategy: Recent progress based on tacrine core</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3000</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170717114944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F1568026617666170717114944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28714419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3000-3016&author=H.+Linauthor=Q.+Liauthor=K.+Guauthor=J.+Zhuauthor=X.+Jiangauthor=Y.+Chenauthor=H.+Sun&title=Therapeutic+agents+in+Alzheimer%E2%80%99s+disease+through+a+multi-target+directed+ligands+strategy%3A+Recent+progress+based+on+tacrine+core&doi=10.2174%2F1568026617666170717114944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Agents in Alzheimer';s Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core</span></div><div class="casAuthors">Lin, Hongzhi; Li, Qi; Gu, Kai; Zhu, Jie; Jiang, Xueyang; Chen, Yao; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3000-3016</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's Disease (AD) is one of the most common forms of dementia in elderly people.  To date, efficacious therapeutic agent for the treatment of AD is still very limited, so it has long been a challenging and attractive task to discover new anti-AD drugs.  Considering the multifactorial nature of AD, recently, the concept of Multi-Target-Directed Ligands (MTDLs) has emerged as a new strategy for designing therapeutic agents on AD.  MTDLs are believed to exert their effects through simultaneously affecting multiple targets which contribute to etiol. of AD.  Therefore, MTDLs are considered to be more efficacious than mono-target agents.  Tacrine is the first drug approved by Food and Drug Administration (FDA).  Although the clin. use of tacrine is restricted because of its hepatotoxicity, the high Ligand Efficiency (LE) of this compd. makes it an ideal component for designing MTDLs.  This article provides an update review of the advances on the development of MTDLs based on tacrine.  Case studies are carefully selected to show the detailed strategy on medicinal modification of Tacrine-Based MTDLs.  Finally, several concerns and opinions on designing new MTDLs are discussed as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpCkartJK5bVg90H21EOLACvtfcHk0li7T4SiSfDQSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtLrL&md5=41ddb7b2d2fc697b92c72b174039f512</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170717114944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170717114944%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520through%2520a%2520multi-target%2520directed%2520ligands%2520strategy%253A%2520Recent%2520progress%2520based%2520on%2520tacrine%2520core%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D3000%26epage%3D3016%26doi%3D10.2174%2F1568026617666170717114944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref54"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref54'); return false;" data-citation="" class="refNumLink">54</a></strong><div class="NLM_citation" id="cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Tacrine-silibinin codrug shows neuro-and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5231</span>– <span class="NLM_lpage">5242</span>, <span class="refDoi"> DOI: 10.1021/jm300246n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300246n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5231-5242&author=X.+Chenauthor=K.+Zengerauthor=A.+Luppauthor=B.+Klingauthor=J.+Heilmannauthor=C.+Fleckauthor=B.+Krausauthor=M.+Decker&title=Tacrine-silibinin+codrug+shows+neuro-and+hepatoprotective+effects+in+vitro+and+pro-cognitive+and+hepatoprotective+effects+in+vivo&doi=10.1021%2Fjm300246n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-Silibinin Codrug Shows Neuro- and Hepatoprotective Effects in Vitro and Pro-Cognitive and Hepatoprotective Effects in Vivo</span></div><div class="casAuthors">Chen, Xinyu; Zenger, Katharina; Lupp, Amelie; Kling, Beata; Heilmann, Joerg; Fleck, Christian; Kraus, Birgit; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5231-5242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A codrug of the anti-Alzheimer drug tacrine and the natural product silibinin was synthesized.  The codrug's biol. and pharmacol. properties were compared to an equimolar mixt. of the components.  The compd. showed potent acetyl- and butyrylcholinesterase inhibition.  In a cellular hepatotoxicity model, analyzing the influence on viability and mitochondria of hepatic stellate cells (HSC), the toxicity of the codrug was markedly reduced in comparison to that of tacrine.  Using a neuronal cell line (HT-22), a neuroprotective effect against glutamate-induced toxicity could be obsd. that was absent for the 1:1 mixt. of components.  In subsequent in vivo expts. in rats, in contrast to the effects seen after tacrine treatment, after administration of the codrug, no hepatotoxicity and no induction of the cytochrome P 450 system were noticed.  In a scopolamine-induced cognitive impairment model using Wistar rats, the codrug was as potent as tacrine in reversing memory dysfunction.  The tacrine-silibinin codrug shows high AChE and BChE inhibition, neuroprotective effects, lacks tacrine's hepatotoxicity in vitro and in vivo, and shows the same pro-cognitive effects in vivo as tacrine, being superior to the phys. mixt. of tacrine and silibinin in all these regards.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7cNXF3vJ0LrVg90H21EOLACvtfcHk0li7T4SiSfDQSA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVertb0%253D&md5=e3bc1878607eba40b8253c40c017a2a4</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300246n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300246n%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZenger%26aufirst%3DK.%26aulast%3DLupp%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DB.%26aulast%3DHeilmann%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DKraus%26aufirst%3DB.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DTacrine-silibinin%2520codrug%2520shows%2520neuro-and%2520hepatoprotective%2520effects%2520in%2520vitro%2520and%2520pro-cognitive%2520and%2520hepatoprotective%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5231%26epage%3D5242%26doi%3D10.1021%2Fjm300246n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref55"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref55'); return false;" data-citation="" class="refNumLink">55</a></strong><div class="NLM_citation" id="cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEneny-King, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edginton, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. P. N.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 binding studies of novel tacrine derivatives: predicting the risk of hepatotoxicity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmcl.2017.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28400237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2443-2449&author=A.+McEneny-Kingauthor=W.+Osmanauthor=A.+N.+Edgintonauthor=P.+P.+N.+Rao&title=Cytochrome+P450+binding+studies+of+novel+tacrine+derivatives%3A+predicting+the+risk+of+hepatotoxicity&doi=10.1016%2Fj.bmcl.2017.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity</span></div><div class="casAuthors">McEneny-King, Alanna; Osman, Wesseem; Edginton, Andrea N.; Rao, Praveen P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2443-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 1,2,3,4-tetrahydroacridine deriv. tacrine was the first drug approved to treat Alzheimer's disease (AD).  It is known to act as a potent cholinesterase inhibitor.  However, tacrine was removed from the market due to its hepatotoxicity concerns as it undergoes metab. to toxic quinonemethide species through the cytochrome P 450 enzyme CYP1A2.  Despite these challenges, tacrine serves as a useful template in the development of novel multitargeting anti-AD agents.  In this regard, the authors sought to evaluate the risk of hepatotoxicity in a series of C9 substituted tacrine derivs. that exhibit cholinesterase inhibition properties.  The hepatotoxic potential of tacrine derivs. was evaluated using recombinant cytochrome (CYP) P 450 CYP1A2 and CYP3A4 enzymes.  Mol. docking studies were conducted to predict their binding modes and potential risk of forming hepatotoxic metabolites.  Tacrine derivs. compd. I (N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine) and II (6-chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine) which possess a C9 3,4-dimethoxybenzylamino substituent exhibited weak binding to CYP1A2 enzyme (I, IC50 = 33.0 μM; II, IC50 = 8.5 μM) compared to tacrine (CYP1A2 IC50 = 1.5 μM).  Modeling studies show that the presence of a bulky 3,4-dimethoxybenzylamino C9 substituent prevents the orientation of the 1,2,3,4-tetrahydroacridine ring close to the heme-iron center of CYP1A2 thereby reducing the risk of forming hepatotoxic species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWER0-gNWyrVg90H21EOLACvtfcHk0lizd525vXWwJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCksbs%253D&md5=ac187061c1082f8c072b7dc165d26dff</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcEneny-King%26aufirst%3DA.%26aulast%3DOsman%26aufirst%3DW.%26aulast%3DEdginton%26aufirst%3DA.%2BN.%26aulast%3DRao%26aufirst%3DP.%2BP.%2BN.%26atitle%3DCytochrome%2520P450%2520binding%2520studies%2520of%2520novel%2520tacrine%2520derivatives%253A%2520predicting%2520the%2520risk%2520of%2520hepatotoxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2443%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2017.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref56"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref56'); return false;" data-citation="" class="refNumLink">56</a></strong><div class="NLM_citation" id="cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span> <span> </span><span class="NLM_article-title">In-vitro stability and metabolism of a tacrine–silibinin codrug</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1111/jphp.12070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1111%2Fjphp.12070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24236987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslygsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1765-1772&author=K.+Zengerauthor=X.+Chenauthor=M.+Deckerauthor=B.+Kraus&title=In-vitro+stability+and+metabolism+of+a+tacrine%E2%80%93silibinin+codrug&doi=10.1111%2Fjphp.12070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro stability and metabolism of a tacrine-silibinin codrug</span></div><div class="casAuthors">Zenger, Katharina; Chen, Xinyu; Decker, Michael; Kraus, Birgit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1765-1772</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Objectives : A tacrine-silibinin codrug showed promising results in pharmacol. and toxicity testing, superior to an equimolar mixt. of tacrine and silibinin.  The aim of this study was to get more information about its stability, possible degrdn. products, metabolites, and esp. its active principle in vitro and in vivo.  Methods : The stability of the codrug was analyzed under in-vitro assay conditions.  Addnl., its metab. was investigated using pooled human liver microsomes.  Metabolites were identified via liq. chromatog.-high resoln. electrospray ionization mass spectrometry.  Furthermore, the influence of one of the main cleavage products, tacrine hemi succinamide, on viability and mitochondria of hepatic stellate cells was analyzed.  Key findings : The codrug remained stable in culture medium (Dulbecco's modified Eagle's medium) over an incubation period of 24 h, whereas exposition to microsomal enzymes led to rapid cleavage of the ester bond to form silibinin and a tacrine hemi succinamide.  In addn., glucuronidated metabolites of both silibinin and the codrug were detected.  For the tacrine hemi succinamide, no effects were obsd. with regard to cell viability and mitochondrial impairment.  Conclusions : This study helps understand and interpret previous results concerning the effects and the absence of toxicity of the tacrine-silibinin codrug and supplies important information for further identification of the active principles of the codrug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ7t-8hcwXHLVg90H21EOLACvtfcHk0lizd525vXWwJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslygsr%252FI&md5=f98932a3201cdacb70f8f4e6551e298b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjphp.12070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.12070%26sid%3Dliteratum%253Aachs%26aulast%3DZenger%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DM.%26aulast%3DKraus%26aufirst%3DB.%26atitle%3DIn-vitro%2520stability%2520and%2520metabolism%2520of%2520a%2520tacrine%25E2%2580%2593silibinin%2520codrug%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D1765%26epage%3D1772%26doi%3D10.1111%2Fjphp.12070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref57"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref57'); return false;" data-citation="" class="refNumLink">57</a></strong><div class="NLM_citation" id="cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodzic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salois, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span> <span> </span><span class="NLM_article-title">Novel benzimidazole derivatives as selective CB<sub>2</sub> agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3695</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmcl.2008.05.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=18522867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3695-3700&author=D.+Pag%C3%A9author=E.+Balauxauthor=L.+Boisvertauthor=Z.+Liuauthor=C.+Milburnauthor=M.+Tremblayauthor=Z.+Weiauthor=S.+Wooauthor=X.+Luoauthor=Y.-X.+Chengauthor=H.+Yangauthor=S.+Srivastavaauthor=F.+Zhouauthor=W.+Brownauthor=M.+Tomaszewskiauthor=C.+Walpoleauthor=L.+Hodzicauthor=S.+St-Ongeauthor=C.+Godboutauthor=D.+Saloisauthor=K.+Payza&title=Novel+benzimidazole+derivatives+as+selective+CB2+agonists&doi=10.1016%2Fj.bmcl.2008.05.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzimidazole derivatives as selective CB2 agonists</span></div><div class="casAuthors">Page, Daniel; Balaux, Elise; Boisvert, Luc; Liu, Ziping; Milburn, Claire; Tremblay, Maxime; Wei, Zhongyong; Woo, Simon; Luo, Xuehong; Cheng, Yun-Xing; Yang, Hua; Srivastava, Sanjay; Zhou, Fei; Brown, William; Tomaszewski, Miroslaw; Walpole, Christopher; Hodzic, Leila; St-Onge, Stephane; Godbout, Claude; Salois, Dominic; Payza, Keymal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3695-3700</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prepn. and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety, e.g., I, are reported.  They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies.  They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbeiXe1I0Yg7Vg90H21EOLACvtfcHk0lizd525vXWwJA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D&md5=fa9e0921054b0d9f26044a1feb82a604</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.073%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A9%26aufirst%3DD.%26aulast%3DBalaux%26aufirst%3DE.%26aulast%3DBoisvert%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMilburn%26aufirst%3DC.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DW.%26aulast%3DTomaszewski%26aufirst%3DM.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DHodzic%26aufirst%3DL.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DPayza%26aufirst%3DK.%26atitle%3DNovel%2520benzimidazole%2520derivatives%2520as%2520selective%2520CB2%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3695%26epage%3D3700%26doi%3D10.1016%2Fj.bmcl.2008.05.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref58"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref58'); return false;" data-citation="" class="refNumLink">58</a></strong><div class="NLM_citation" id="cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatzky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Aminobenzimidazoles and structural isomers as templates for dual-acting butyrylcholinesterase inhibitors and hCB2R ligands to combat neurodegenerative disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcmdc.201500418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26548365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1270-1283&author=D.+Dollesauthor=M.+Nimczickauthor=M.+Scheinerauthor=J.+Ramlerauthor=P.+Stadtm%C3%BCllerauthor=E.+Sawatzkyauthor=A.+Drakopoulosauthor=C.+Sotrifferauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Decker&title=Aminobenzimidazoles+and+structural+isomers+as+templates+for+dual-acting+butyrylcholinesterase+inhibitors+and+hCB2R+ligands+to+combat+neurodegenerative+disorders&doi=10.1002%2Fcmdc.201500418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders</span></div><div class="casAuthors">Dolles, Dominik; Nimczick, Martin; Scheiner, Matthias; Ramler, Jacqueline; Stadtmueller, Patricia; Sawatzky, Edgar; Drakopoulos, Antonios; Sotriffer, Christoph; Wittmann, Hans-Joachim; Strasser, Andrea; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1270-1283</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for resp. dual-acting compds.  The design, synthesis, and pharmacol. evaluation of various derivs. led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1 and AChE, resp.  Computational studies of the first- and second-generation lead structures by applying mol. dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization.  Dual-acting compds. with "balanced" affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiol. impairment occurring in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2lcUsRAXJ7Vg90H21EOLACvtfcHk0lgiBxofEecJ7g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI&md5=dcd6f52f38134002413bd3d975ee9da3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500418%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DRamler%26aufirst%3DJ.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DP.%26aulast%3DSawatzky%26aufirst%3DE.%26aulast%3DDrakopoulos%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DAminobenzimidazoles%2520and%2520structural%2520isomers%2520as%2520templates%2520for%2520dual-acting%2520butyrylcholinesterase%2520inhibitors%2520and%2520hCB2R%2520ligands%2520to%2520combat%2520neurodegenerative%2520disorders%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1270%26epage%3D1283%26doi%3D10.1002%2Fcmdc.201500418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref59"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref59'); return false;" data-citation="" class="refNumLink">59</a></strong><div class="NLM_citation" id="cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">The first photochromic affinity switch for the human cannabinoid receptor 2</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1700032</span>, <span class="refDoi"> DOI: 10.1002/adtp.201700032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fadtp.201700032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=1700032&author=D.+Dollesauthor=A.+Strasserauthor=H.+J.+Wittmannauthor=O.+Marinelliauthor=M.+Nabissiauthor=R.+G.+Pertweeauthor=M.+Decker&title=The+first+photochromic+affinity+switch+for+the+human+cannabinoid+receptor+2&doi=10.1002%2Fadtp.201700032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201700032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201700032%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DWittmann%26aufirst%3DH.%2BJ.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DThe%2520first%2520photochromic%2520affinity%2520switch%2520for%2520the%2520human%2520cannabinoid%2520receptor%25202%26jtitle%3DAdv.%2520Ther.%26date%3D2018%26volume%3D1%26spage%3D1700032%26doi%3D10.1002%2Fadtp.201700032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref60"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref60'); return false;" data-citation="" class="refNumLink">60</a></strong><div class="NLM_citation" id="cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3938</span>– <span class="NLM_lpage">3946</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2014.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24984935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOntrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3938-3946&author=M.+Nimczickauthor=D.+Pempauthor=F.+H.+Darrasauthor=X.+Chenauthor=J.+Heilmannauthor=M.+Decker&title=Synthesis+and+biological+evaluation+of+bivalent+cannabinoid+receptor+ligands+based+on+hCB2R+selective+benzimidazoles+reveal+unexpected+intrinsic+properties&doi=10.1016%2Fj.bmc.2014.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties</span></div><div class="casAuthors">Nimczick, Martin; Pemp, Daniela; Darras, Fouad H.; Chen, Xinyu; Heilmann, Joerg; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3938-3946</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design of bivalent ligands targeting G protein-coupled receptors (GPCRs) often leads to the development of new, highly selective and potent compds.  To date, no bivalent ligands for the human cannabinoid receptor type 2 (hCB2R) of the endocannabinoid system (ECS) are described.  Therefore, two sets of homobivalent ligands contg. as parent structure the hCB2R selective agonist I and coupled at different attachment positions were synthesized.  Changes of the parent structure at these positions have a crucial effect on the potency and efficacy of the ligands.  However, the authors discovered that bivalency has an influence on the effect at both cannabinoid receptors.  Moreover, the authors found out that the spacer length and the attachment position altered the efficacy of the bivalent ligands at the receptors by turning agonists into antagonists and inverse agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKDa1voY3HeLVg90H21EOLACvtfcHk0liFgcA_2q_rKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOntrbE&md5=1496bd99dbd6dd60d77fb5d24153ae17</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DPemp%26aufirst%3DD.%26aulast%3DDarras%26aufirst%3DF.%2BH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHeilmann%26aufirst%3DJ.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520bivalent%2520cannabinoid%2520receptor%2520ligands%2520based%2520on%2520hCB2R%2520selective%2520benzimidazoles%2520reveal%2520unexpected%2520intrinsic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3938%26epage%3D3946%26doi%3D10.1016%2Fj.bmc.2014.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref61"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref61'); return false;" data-citation="" class="refNumLink">61</a></strong><div class="NLM_citation" id="cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, G.</span></span> <span> </span><span class="NLM_article-title">Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998-2018)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2019.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=30744931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVWlt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=895-930&author=P.+Mishraauthor=A.+Kumarauthor=G.+Panda&title=Anti-cholinesterase+hybrids+as+multi-target-directed+ligands+against+Alzheimer%E2%80%99s+disease+%281998-2018%29&doi=10.1016%2Fj.bmc.2019.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018)</span></div><div class="casAuthors">Mishra, Pankaj; Kumar, Amit; Panda, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">895-930</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a genetically complex, progressive and irreversible neurodegenerative disorder of the brain which involves multiple assocd. etiol. targets.  The complex pathogenesis of AD gave rise to multi-target-directed ligands (MTDLs) principle to combat this dreaded disease.  Within this approach, the design and synthesis of hybrids prevailed greatly because of their capability to simultaneously target the intertwined pathogenesis components of the disease.  The hybrids include pharmacophoric hybridization of two or more established chem. scaffolds endowed with the desired pharmacol. properties into a single moiety.  In AD, the primary foundation of medication therapy and drug design strategies includes the inhibition of cholinesterase (ChE) enzymes.  Hence the development of ChE inhibition based hybrids is the central choice of AD medicinal chem. research.  To illustrate the progress of ChE inhibition based hybrids and novel targets, we reviewed the medicinal chem. and pharmacol. properties of the multi-target mols. published since 1998-Dec. 2018.  We hope that this article will allow the readers to easily follow the evolution of this prominent medicinal chem. approach to develop a more efficient inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6n_9YGJjsrVg90H21EOLACvtfcHk0liFgcA_2q_rKA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVWlt7g%253D&md5=5941878ce58266e56b041f4d239d2b63</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPanda%26aufirst%3DG.%26atitle%3DAnti-cholinesterase%2520hybrids%2520as%2520multi-target-directed%2520ligands%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520%25281998-2018%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D895%26epage%3D930%26doi%3D10.1016%2Fj.bmc.2019.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref62"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref62'); return false;" data-citation="" class="refNumLink">62</a></strong><div class="NLM_citation" id="cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeloni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrelia, S.</span></span> <span> </span><span class="NLM_article-title">Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.neuropharm.2011.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22032870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=997-1003&author=A.+Minariniauthor=A.+Milelliauthor=V.+Tumiattiauthor=M.+Rosiniauthor=E.+Simoniauthor=M.+L.+Bolognesiauthor=V.+Andrisanoauthor=M.+Bartoliniauthor=E.+Motoriauthor=C.+Angeloniauthor=S.+Hrelia&title=Cystamine-tacrine+dimer%3A+a+new+multi-target-directed+ligand+as+potential+therapeutic+agent+for+Alzheimer%E2%80%99s+disease+treatment&doi=10.1016%2Fj.neuropharm.2011.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment</span></div><div class="casAuthors">Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">997-1003</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia, clin. characterized by loss of memory and progressive deficits in different cognitive domains.  An emerging disease-modifying approach to face the multifactorial nature of AD may be represented by the development of Multi-Target Directed Ligands (MTDLs), i.e., single compds. which may simultaneously modulate different targets involved in the neurodegenerative AD cascade.  The structure of tacrine, an acetylcholinesterase (AChE) inhibitor (AChEI), has been widely used as scaffold to provide new MTDLs.  In particular, its homodimer bis(7)tacrine represents an interesting lead compd. to design novel MTDLs.  Thus, in the search of new rationally designed MTDLs against AD, we replaced the heptamethylene linker of bis(7)tacrine with the structure of cystamine, leading to cystamine-tacrine dimer.  In this study we demonstrated that the cystamine-tacrine dimer is endowed with a lower toxicity in comparison to bis(7)tacrine, it is able to inhibit AChE, butyrylcholinesterase (BChE), self- and AChE-induced beta-amyloid aggregation in the same range of the ref. compd. and exerts a neuroprotective action on SH-SY5Y cell line against H2O2-induced oxidative injury.  The investigation of the mechanism of neuroprotection showed that the cystamine-tacrine dimer acts by activating kinase 1 and 2 (ERK1/2) and Akt/protein kinase B (PKB) pathways.  This article is part of a Special Issue entitled Post-Traumatic Stress Disorder'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMDhDTA4-1CrVg90H21EOLACvtfcHk0lg_MB1G608f2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrsb0%253D&md5=7e5f7b53dc8268218a4edc78e7dc48d8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DSimoni%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DMotori%26aufirst%3DE.%26aulast%3DAngeloni%26aufirst%3DC.%26aulast%3DHrelia%26aufirst%3DS.%26atitle%3DCystamine-tacrine%2520dimer%253A%2520a%2520new%2520multi-target-directed%2520ligand%2520as%2520potential%2520therapeutic%2520agent%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D997%26epage%3D1003%26doi%3D10.1016%2Fj.neuropharm.2011.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref63"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref63'); return false;" data-citation="" class="refNumLink">63</a></strong><div class="NLM_citation" id="cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.-H.</span></span> <span> </span><span class="NLM_article-title">Homodimeric tacrine congeners as acetylcholinesterase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2277</span>– <span class="NLM_lpage">2282</span>, <span class="refDoi"> DOI: 10.1021/jm010308g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010308g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFagsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2277-2282&author=M.-K.+Huauthor=L.-J.+Wuauthor=G.+Hsiaoauthor=M.-H.+Yen&title=Homodimeric+tacrine+congeners+as+acetylcholinesterase+inhibitors&doi=10.1021%2Fjm010308g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors</span></div><div class="casAuthors">Wu, Li-Ju; Hsiao, George; Yen, Mao-Hsiung; Hu, Ming-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2277-2282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the search for highly selective and potent derivs. of tacrine, a no. of homodimeric tacrine congeners were synthesized and conducted for their effects on rat acetylcholinesterase (AChE) and human butyrylcholinesterase (BChE) inhibitions.  Heptylene-linked bis-(6-chloro)tacrine I [R = Cl, X = (CH2)m, Y = CH, Z = (CH2)n, m = 2, n = 7] was found up to 3000- and 3-fold more potent in inhibiting rat AChE than tacrine and the unsubstituted bis-tacrine I [R = H, X = (CH2)m, Y = CH, Z = (CH2)n, m = 2, n = 7] (II), resp.  Changes in the size of the carbocyclic ring of the dimeric tacrine reduced both the selectivity and the potency of AChE inhibition as compared to II.  Inserting an aza into the tacrine nucleus as the desired isosteres I [R = H, X = (CH2)m, Y = N, Z = (CH2)n, m = 2, n = 6-8] resulted in moderate potency but tended to be detrimental to selectivity.  The pronounced enhancement of AChE inhibition potency and AChE/BChE selectivity was achieved with incorporation of a halogen at the 6-position of homodimeric tacrines.  The assay results of I (R = H, F, Cl, Y = CH, N, m = 1-3, n = 6-8) also provided evidence that the 7-methylene tether tended to be optimal to AChE inhibition potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7H3dDhmCpn7Vg90H21EOLACvtfcHk0lg_MB1G608f2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFagsL4%253D&md5=ed4e5a530df14b1402d6cc129c2c47c0</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm010308g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010308g%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.-K.%26aulast%3DWu%26aufirst%3DL.-J.%26aulast%3DHsiao%26aufirst%3DG.%26aulast%3DYen%26aufirst%3DM.-H.%26atitle%3DHomodimeric%2520tacrine%2520congeners%2520as%2520acetylcholinesterase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2277%26epage%3D2282%26doi%3D10.1021%2Fjm010308g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref64"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref64'); return false;" data-citation="" class="refNumLink">64</a></strong><div class="NLM_citation" id="cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Featherstone, R. M.</span></span> <span> </span><span class="NLM_article-title">A new and rapid colorimetric determination of acetylcholinesterase activity</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(61)90145-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-2952%2861%2990145-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=13726518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaF3MXht1Gns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1961&pages=88-95&author=G.+L.+Ellmanauthor=K.+D.+Courtneyauthor=V.+Andresauthor=R.+M.+Featherstone&title=A+new+and+rapid+colorimetric+determination+of+acetylcholinesterase+activity&doi=10.1016%2F0006-2952%2861%2990145-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A new and rapid colorimetric determination of acetylcholinesterase activity</span></div><div class="casAuthors">Ellman, George L.; Courtney, K. Diane; Andres, Valentino, Jr.; Featherstone, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A photometric method for detg. acetylcholinesterase activity of tissue exts., homogenates, cell suspensions, etc. was described.  The enzyme activity of acetylcholinesterase was measured by following the increase of yellow color produced from thiocholine when it reacts with dithiobisnitrobenzoate ion, based on the reactions: acetylthiocholine (enzyme.rdblhar.) thioeholine + acetate.  Thiocholine + dithiobisnitrobenzoate .rdblhar. yellow color.  The method was used to study the enzyme in human erythrocytes and homogenates of rat brain, kidney, lungs, liver, and muscle tissue.  Hydrolysis rates [(moles/l./min.) × 10-6/g. tissue] by these homogenates of tissues on acetylthiocholine were 10.31, 0.28, 1.63, 1.07, and 1.82, and on butyrylthiocholine were 0.31, 0.21, 0.54, 0.65, and 0.12, resp.  Data obtained with acetylthiocholine as substrate were similar to those with acetylcholine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq21LY6gwNKrVg90H21EOLACvtfcHk0lg_MB1G608f2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXht1Gns7o%253D&md5=46f891b7e338036a7c7d4333b82b6874</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2861%2990145-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252861%252990145-9%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DG.%2BL.%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DAndres%26aufirst%3DV.%26aulast%3DFeatherstone%26aufirst%3DR.%2BM.%26atitle%3DA%2520new%2520and%2520rapid%2520colorimetric%2520determination%2520of%2520acetylcholinesterase%2520activity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1961%26volume%3D7%26spage%3D88%26epage%3D95%26doi%3D10.1016%2F0006-2952%2861%2990145-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref65"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref65'); return false;" data-citation="" class="refNumLink">65</a></strong><div class="NLM_citation" id="cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavrini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span> <span> </span><span class="NLM_article-title">β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(02)01514-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0006-2952%2802%2901514-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12527333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2003&pages=407-416&author=M.+Bartoliniauthor=C.+Bertucciauthor=V.+Cavriniauthor=V.+Andrisano&title=%CE%B2-Amyloid+aggregation+induced+by+human+acetylcholinesterase%3A+inhibition+studies&doi=10.1016%2FS0006-2952%2802%2901514-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies</span></div><div class="casAuthors">Bartolini, Manuela; Bertucci, Carlo; Cavrini, Vanni; Andrisano, Vincenza</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-416</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The aggregation of β-amyloid (1-40) (Aβ) induced by human recombinant acetylcholinesterase (HuAChE) was studied by means of CD (CD) and by thioflavin T fluorescence spectroscopy.  Aβ was incubated alone and with HuAChE.  The kinetic of fibrils formation was followed for 48 h.  The increasing β-conformation content induced by HuAChE, preliminary to the formation of Aβ fibrils, was detd. by CD.  This phenomenon was found to be related to the thioflavin T emission of fluorescence at 490 nm.  Incubation expts. were performed in the presence of known AChE inhibitors (physostigmine, edrophonium, decamethonium, propidium) and drugs used for Alzheimer's disease (AD) (tacrine, donepezil), to test their capability of preventing the HuAChE-induced Aβ aggregation.  The non-competitive or mixed mode of AChE inhibition was confirmed to be an essential feature.  At 100 μM propidium, decamethonium, donepezil and physostigmine were found to inhibit the HuAChE-induced Aβ aggregation by 82, 25, 22 and 30%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2eDGIBesVCbVg90H21EOLACvtfcHk0lg_MB1G608f2w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVKitA%253D%253D&md5=51d1021e8be93014f0b15a61db241392</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2802%2901514-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252802%252901514-9%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DCavrini%26aufirst%3DV.%26aulast%3DAndrisano%26aufirst%3DV.%26atitle%3D%25CE%25B2-Amyloid%2520aggregation%2520induced%2520by%2520human%2520acetylcholinesterase%253A%2520inhibition%2520studies%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D65%26spage%3D407%26epage%3D416%26doi%3D10.1016%2FS0006-2952%2802%2901514-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref66"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref66'); return false;" data-citation="" class="refNumLink">66</a></strong><div class="NLM_citation" id="cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4377</span>– <span class="NLM_lpage">4387</span>, <span class="refDoi"> DOI: 10.2174/138161206778792985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F138161206778792985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17105433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GntrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4377-4387&author=A.+Castroauthor=A.+Martinez&title=Targeting+beta-amyloid+pathogenesis+through+acetylcholinesterase+inhibitors&doi=10.2174%2F138161206778792985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors</span></div><div class="casAuthors">Castro, Ana; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4377-4387</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although the hallmarks of neurodegeneration in Alzheimer's brains are well known, one of the current difficulties is related to the lack of solid evidence about the ultimate factors that give rise to the pathogenesis of this disease, creating a great challenge for the definition of efficient treatments for Alzheimer's disease (AD).  Current therapeutic option for AD patients is the use of acetylcholinesterase (AChE) inhibitors, which gives only a symptomatic relief.  However, recent studies show a long-lasting effect in a certain percentage of patients.  In fact, there is accumulating evidence that an AChE has secondary non-cholinergic functions including the processing and deposition of β-amyloid (Aβ).  AChE could play a role in the Aβ metab. and during an early step in the development of the senile plaque, as revealed by the finding that AChE accelerates Aβ deposition.  Considering the non-classical AChE functions, their relationships with AD hallmarks, and the putative role of peripheral anionic site in all these functions, the dual binding site AChE inhibitors may acquire importance for AD treatment.  On the other hand, the interference of AChE inhibitors with Aβ processing is not a general rule for this class of compds. with the involvement of other features such as chem. structure and/or genetic regulation.  This review highlights the collection of several compds. with an outstanding profile against AChE-induced amyloid aggregation and potent AChE inhibitory activity, indicating the possibility of targeting Aβ through the inhibition of AChE and reveals the emergence of a new generation of AChE inhibitors aiming to be excellent candidate drugs for the future cure of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrisn7G_dIHxrVg90H21EOLACvtfcHk0lirbTksfrOKvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GntrbI&md5=fd41eca56c6433d9ee6a3989908ff2c5</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2174%2F138161206778792985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206778792985%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DTargeting%2520beta-amyloid%2520pathogenesis%2520through%2520acetylcholinesterase%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D4377%26epage%3D4387%26doi%3D10.2174%2F138161206778792985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref67"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref67'); return false;" data-citation="" class="refNumLink">67</a></strong><div class="NLM_citation" id="cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zha, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaresi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span> <span> </span><span class="NLM_article-title">Novel tacrine–benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, biological evaluation, and X-ray crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=114-131&author=X.+Zhaauthor=D.+Lambaauthor=L.+Zhangauthor=Y.+Louauthor=C.+Xuauthor=D.+Kangauthor=L.+Chenauthor=Y.+Xuauthor=L.+Zhangauthor=A.+De+Simoneauthor=S.+Samezauthor=A.+Persaresiauthor=J.+Stojanauthor=M.+G.+Lopezauthor=J.+Egeaauthor=V.+Andrisanoauthor=M.+Bartolini&title=Novel+tacrine%E2%80%93benzofuran+hybrids+as+potent+multitarget-directed+ligands+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+X-ray+crystallography&doi=10.1021%2Facs.jmedchem.5b01119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography</span></div><div class="casAuthors">Zha, Xiaoming; Lamba, Doriano; Zhang, Lili; Lou, Yinghan; Xu, Changxu; Kang, Di; Chen, Li; Xu, Yungen; Zhang, Luyong; De Simone, Angela; Samez, Sarah; Pesaresi, Alessandro; Stojan, Jure; Lopez, Manuela G.; Egea, Javier; Andrisano, Vincenza; Bartolini, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twenty-six new tacrine-benzofuran hybrids, I [R = H, OMe, X = (CH2)m, Y= (CH2)n, m = 1-3, n = 6, 7], II [R = H, OMe, X = CH2, Y = (CH2)6; R = OMe, X = (CH2)2, Y = (CH2)6; R = H, X = (CH2)m, m = 1, 2, Y = (CH2)7; R = H, X = (CH2)2, Y = (CH2)7; R = OMe, X = (CH2)3, Y = (CH2)7] and III [R = H, OMe, X = CH2, Y = (CH2)6; R = OMe, X = (CH2)m, m = 2, 3, Y = (CH2)6; R = H, X = (CH2)m, m = 1-3, Y = (CH2)7; R = OMe, X = (CH2)3, Y = (CH2)7] were designed, synthesized, and evaluated in vitro on key mol. targets for Alzheimer's disease.  Most hybrids exhibited good inhibitory activities on cholinesterases and β-amyloid self-aggregation.  Selected compds. displayed significant inhibition of human β-secretase-1 (hBACE-1).  Among the 26 hybrids, II [R = H, X = (CH2)2, Y = (CH2)7] (IV) showed the most interesting profile as a subnanomolar selective inhibitor of human acetylcholinesterase (hAChE) (IC50 = 0.86 nM) and a good inhibitor of both β-amyloid aggregation (hAChE- and self-induced, 61.3% and 58.4%, resp.) and hBACE-1 activity (IC50 = 1.35 μM).  Kinetic studies showed that IV acted as a slow, tight-binding, mixed-type inhibitor, while X-ray crystallog. studies highlighted the ability of IV to induce large-scale structural changes in the active-site gorge of Torpedo californica AChE (TcAChE), with significant implications for structure-based drug design.  In vivo studies confirmed that IV significantly ameliorates performances of scopolamine-treated ICR mice.  Finally, IV administration did not exhibit significant hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowdWlshOsJO7Vg90H21EOLACvtfcHk0lirbTksfrOKvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr%252FJ&md5=809e7be0412644a990920590f8a31125</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01119%26sid%3Dliteratum%253Aachs%26aulast%3DZha%26aufirst%3DX.%26aulast%3DLamba%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DSamez%26aufirst%3DS.%26aulast%3DPersaresi%26aufirst%3DA.%26aulast%3DStojan%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DM.%2BG.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DBartolini%26aufirst%3DM.%26atitle%3DNovel%2520tacrine%25E2%2580%2593benzofuran%2520hybrids%2520as%2520potent%2520multitarget-directed%2520ligands%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520X-ray%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D114%26epage%3D131%26doi%3D10.1021%2Facs.jmedchem.5b01119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref68"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref68'); return false;" data-citation="" class="refNumLink">68</a></strong><div class="NLM_citation" id="cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span> <span> </span><span class="NLM_article-title">Insight into the kinetic of amyloid β (1–42) peptide self-aggregation: elucidation of inhibitors’ mechanism of action</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2152</span>– <span class="NLM_lpage">2161</span>, <span class="refDoi"> DOI: 10.1002/cbic.200700427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcbic.200700427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17939148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=2152-2161&author=M.+Bartoliniauthor=C.+Bertucciauthor=M.+L.+Bolognesiauthor=A.+Cavalliauthor=C.+Melchiorreauthor=V.+Andrisano&title=Insight+into+the+kinetic+of+amyloid+%CE%B2+%281%E2%80%9342%29+peptide+self-aggregation%3A+elucidation+of+inhibitors%E2%80%99+mechanism+of+action&doi=10.1002%2Fcbic.200700427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the kinetic of amyloid β (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action</span></div><div class="casAuthors">Bartolini, Manuela; Bertucci, Carlo; Bolognesi, Maria Laura; Cavalli, Andrea; Melchiorre, Carlo; Andrisano, Vincenza</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2152-2161</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The initial transition of amyloid β (1-42) (Aβ42) sol. monomers/small oligomers from unordered/α-helix to a β-sheet-rich conformation represents a suitable target to design new potent inhibitors and to obtain effective therapeutics for Alzheimer's disease.  Under optimized conditions, this reliable and reproducible CD kinetic study showed a 3-step sigmoid profile that was characterized by a lag phase (prevailing unordered/α-helix conformation), an exponential growth phase (increasing β-sheet secondary structure) and a plateau phase (prevailing β-sheet secondary structure).  This kinetic anal. brought insight into the inhibitors' mechanism of action.  In fact, an increase in the duration of the lag phase can be related to the formation of an inhibitor-Aβ complex, in which the non-amyloidogenic conformation is stabilized.  When the exponential rate is affected exclusively, such as in the case of Congo red and tetracycline, then the inhibitor affinity might be higher for the pleated β-sheet structure.  Finally, by adding the inhibitor at the end of the exponential phase, the sol. protofibrils can be disrupted and the Aβ amyloidogenic structure can revert into monomers/small oligomers.  Congo red and tetracycline preferentially bind to amyloid in the β-sheet conformation because both decreased the slope of the exponential growth, even if to a different extent, whereas no effect was obsd. for tacrine and galantamine.  Some very preliminary indications can be derived about the structural requirements for binding to nonamyloidogenic or β-sheet amyloid secondary structure for the development of potent antiaggregating agents.  On these premises, memoquin, a multifunctional mol. that was designed to become a drug candidate for the treatment of Alzheimer's disease, was investigated under the reported CD assay and its anti-amyloidogenic mechanism of action was elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9pwqFx_yuLVg90H21EOLACvtfcHk0lirbTksfrOKvw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValu73F&md5=f7e4f04aeba478f5c7da03dcce6d1553</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200700427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200700427%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DC.%26aulast%3DAndrisano%26aufirst%3DV.%26atitle%3DInsight%2520into%2520the%2520kinetic%2520of%2520amyloid%2520%25CE%25B2%2520%25281%25E2%2580%259342%2529%2520peptide%2520self-aggregation%253A%2520elucidation%2520of%2520inhibitors%25E2%2580%2599%2520mechanism%2520of%2520action%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D2152%26epage%3D2161%26doi%3D10.1002%2Fcbic.200700427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref69"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref69'); return false;" data-citation="" class="refNumLink">69</a></strong><div class="NLM_citation" id="cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Stuivenberg, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, H. K. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolfs, T. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keizer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wals, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Looff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verveer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1838</span>, <span class="refDoi"> DOI: 10.1021/jm040843r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1823-1838&author=J.+H.+M.+Langeauthor=H.+H.+van+Stuivenbergauthor=H.+K.+A.+C.+Coolenauthor=T.+J.+P.+Adolfsauthor=A.+C.+McCrearyauthor=H.+G.+Keizerauthor=H.+C.+Walsauthor=W.+Veermanauthor=A.+J.+M.+Borstauthor=W.+de+Looffauthor=P.+C.+Verveerauthor=C.+G.+Kruse&title=Bioisosteric+replacements+of+the+pyrazole+moiety+of+rimonabant%3A+synthesis%2C+biological+properties%2C+and+molecular+modeling+investigations+of+thiazoles%2C+triazoles%2C+and+imidazoles+as+potent+and+selective+CB1+cannabinoid+receptor+antagonists&doi=10.1021%2Fjm040843r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; van Stuivenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1823-1838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant.  A no. of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays.  The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class.  Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model.  Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant.  A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16SsR1EEEVbVg90H21EOLACvtfcHk0lgxZPvzOoWgxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D&md5=c3b80380a273d7f69a33c812a45e0154</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm040843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040843r%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%2BA.%2BC.%26aulast%3DAdolfs%26aufirst%3DT.%2BJ.%2BP.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3DWals%26aufirst%3DH.%2BC.%26aulast%3DVeerman%26aufirst%3DW.%26aulast%3DBorst%26aufirst%3DA.%2BJ.%2BM.%26aulast%3Dde%2BLooff%26aufirst%3DW.%26aulast%3DVerveer%26aufirst%3DP.%2BC.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DBioisosteric%2520replacements%2520of%2520the%2520pyrazole%2520moiety%2520of%2520rimonabant%253A%2520synthesis%252C%2520biological%2520properties%252C%2520and%2520molecular%2520modeling%2520investigations%2520of%2520thiazoles%252C%2520triazoles%252C%2520and%2520imidazoles%2520as%2520potent%2520and%2520selective%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1823%26epage%3D1838%26doi%3D10.1021%2Fjm040843r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref70"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref70'); return false;" data-citation="" class="refNumLink">70</a></strong><div class="NLM_citation" id="cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyers, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensink, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0707568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17994110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlajsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=390-401&author=B.+B.+Yaoauthor=G.+C.+Hsiehauthor=J.+M.+Frostauthor=Y.+Fanauthor=T.+R.+Garrisonauthor=A.+V.+Dazaauthor=G.+K.+Graysonauthor=C.+Z.+Zhuauthor=M.+Paiauthor=P.+Chandranauthor=A.+K.+Salyersauthor=E.+J.+Wensinkauthor=P.+Honoreauthor=J.+P.+Sullivanauthor=M.+J.+Dartauthor=M.+D.+Meyer&title=In+vitro+and+in+vivo+characterization+of+A-796260%3A+a+selective+cannabinoid+CB2+receptor+agonist+exhibiting+analgesic+activity+in+rodent+pain+models&doi=10.1038%2Fsj.bjp.0707568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models</span></div><div class="casAuthors">Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Selective cannabinoid CB2 receptor agonists have demonstrated analgesic activity across multiple preclin. pain models.  AM1241 is an indole deriv. that exhibits high affinity and selectivity for the CB2 binding site and broad spectrum analgesic activity in rodent models, but is not an antagonist of CB2 in vitro functional assays.  Addnl., its analgesic effects are -opioid receptor-dependent.  Herein, we describe the in vitro and in vivo pharmacol. properties of A-796260, a novel CB2 agonist.  Exptl. approach: A-796260 was characterized in radioligand binding and in vitro functional assays at rat and human CB1 and CB2 receptors.  The behavioral profile of A-796260 was assessed in models of inflammatory, post-operative, neuropathic, and osteoarthritic (OA) pain, as well as its effects on motor activity.  The receptor specificity was confirmed using selective CB1, CB2, and -opioid receptor antagonists.  A-796260 exhibited high affinity and agonist efficacy at human and rat CB2 receptors, and was selective for the CB2 vs CB1 subtype.  Efficacy in models of inflammatory, post-operative, neuropathic and OA pain was demonstrated, and these activities were selectively blocked by CB2, but not CB1, or -opioid receptor-selective antagonists.  Efficacy was achieved at doses that had no significant effects on motor activity.  These results further confirm the therapeutic potential of CB2 receptor-selective agonists for the treatment of pain.  In addn., they demonstrate that A-796260 may be a useful new pharmacol. compd. for further studying CB2 receptor pharmacol. and for evaluating its role in the modulation of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRpbBOoGZg27Vg90H21EOLACvtfcHk0lgxZPvzOoWgxA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlajsbs%253D&md5=c4d06d34da40f688a17aa15fffe03c64</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707568%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DFrost%26aufirst%3DJ.%2BM.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DSalyers%26aufirst%3DA.%2BK.%26aulast%3DWensink%26aufirst%3DE.%2BJ.%26aulast%3DHonore%26aufirst%3DP.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520A-796260%253A%2520a%2520selective%2520cannabinoid%2520CB2%2520receptor%2520agonist%2520exhibiting%2520analgesic%2520activity%2520in%2520rodent%2520pain%2520models%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D390%26epage%3D401%26doi%3D10.1038%2Fsj.bjp.0707568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref71"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref71'); return false;" data-citation="" class="refNumLink">71</a></strong><div class="NLM_citation" id="cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcmdc.201500041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=25820617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1alu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=773-786&author=M.+Nimczickauthor=M.+Decker&title=New+approaches+in+the+design+and+development+of+cannabinoid+receptor+ligands%3A+multifunctional+and+bivalent+compounds&doi=10.1002%2Fcmdc.201500041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds</span></div><div class="casAuthors">Nimczick, Martin; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-786</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the identification of the endocannabinoid system, two G protein-coupled receptors (GPCRs) of this complex system were identified and characterized: cannabinoid receptors type 1 (CB1R) and type 2 (CB2R).  In addn. to orthosteric and subsequently allosteric ligands, new strategies have been used to target CBRs.  Bivalent ligands and multifunctional ligands acting at diverse biol. targets have been designed, synthesized, and characterized for both CBRs.  Due to their altered receptor binding and pharmacol. profiles, they are interesting tools to explore CBR functions and their interactions with other physiol. systems.  Moreover, this approach may bear therapeutic advantages in the therapy of CBR-related disorders, esp. multifactorial diseases.  Promising prospects include anorectics with fewer side effects, analgesics with decreased tolerance, and therapeutics with multiple pharmacol. activities for the treatment of cancer, inflammation, multiple sclerosis, Huntington's and Alzheimer's diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO0S1iWc8qP7Vg90H21EOLACvtfcHk0ljjYbcIMx-fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1alu7s%253D&md5=48866ef33207c0dcb703225d1e2e577e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500041%26sid%3Dliteratum%253Aachs%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DNew%2520approaches%2520in%2520the%2520design%2520and%2520development%2520of%2520cannabinoid%2520receptor%2520ligands%253A%2520multifunctional%2520and%2520bivalent%2520compounds%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D773%26epage%3D786%26doi%3D10.1002%2Fcmdc.201500041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref72"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref72'); return false;" data-citation="" class="refNumLink">72</a></strong><div class="NLM_citation" id="cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devane, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+cannabinoid+receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0ljjYbcIMx-fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref73"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref73'); return false;" data-citation="" class="refNumLink">73</a></strong><div class="NLM_citation" id="cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockie, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0702351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10188977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=665-672&author=R.+A.+Rossauthor=H.+C.+Brockieauthor=L.+A.+Stevensonauthor=V.+L.+Murphyauthor=F.+Templetonauthor=A.+Makriyannisauthor=R.+G.+Pertwee&title=Agonist-inverse+agonist+characterization+at+CB1+and+CB2+cannabinoid+receptors+of+L759633%2C+L759656+and+AM630&doi=10.1038%2Fsj.bjp.0702351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630</span></div><div class="casAuthors">Ross, Ruth A.; Brockie, Heather C.; Stevenson, Lesley A.; Murphy, Vicki L.; Templeton, Fiona; Makriyannis, Alexandros; Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">We have tested our prediction that AM630 is a CB2 cannabinoid receptor ligand and also investigated whether L759633 and L759656, are CB2 receptor agonists.  Binding assays with membranes from CHO cells stably transfected with human CB1 or CB2 receptors using [3H]-CP55940, confirmed the CB2-selectivity of L759633 and L759656 (CB2/CB1 affinity ratios = 163 and 414 resp.) and showed AM630 to have a Ki at CB2 receptors of 31.2 nM and a CB2/CB1 affinity ratio of 165.  In CB2-transfected cells, L759633 and L759656 were potent inhibitors of forskolin-stimulated cAMP prodn., with EC50 values of 8.1 and 3.1 nM resp. and CB1/CB2 EC50 ratios of > 1000 and > 3000 resp.  AM630 inhibited [35S]-GTPγS binding to CB2 receptor membranes (EC50 = 76.6 nM), enhanced forskolin-stimulated cAMP prodn. in CB2-transfected cells (5.2 fold by 1 μM), and antagonized the inhibition of forskolin-stimulated cAMP prodn. in this cell line induced by CP55940.  In CB1-transfected cells, forskolin-stimulated cAMP prodn. was significantly inhibited by AM630 (22.6% at 1 μM and 45.9% at 10 μM) and by L759633 at 10 μM (48%) but not 1 μM.  L759656 (10 μM) was not inhibitory.  AM630 also produced a slight decrease in the mean inhibitory effect of CP55940 on cAMP prodn. which was not statistically significant.  We conclude that AM630 is a CB2-selective ligand that behaves as an inverse agonist at CB2 receptors and as a weak partial agonist at CB1 receptors.  L759633 and L759656 are both potent CB2-selective agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSFP_3NFRGm7Vg90H21EOLACvtfcHk0ljjYbcIMx-fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWit78%253D&md5=6d0f811a461a91ebef93f45605fd3b11</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702351%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DBrockie%26aufirst%3DH.%2BC.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DMurphy%26aufirst%3DV.%2BL.%26aulast%3DTempleton%26aufirst%3DF.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DAgonist-inverse%2520agonist%2520characterization%2520at%2520CB1%2520and%2520CB2%2520cannabinoid%2520receptors%2520of%2520L759633%252C%2520L759656%2520and%2520AM630%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D665%26epage%3D672%26doi%3D10.1038%2Fsj.bjp.0702351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref74"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref74'); return false;" data-citation="" class="refNumLink">74</a></strong><div class="NLM_citation" id="cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span> <span> </span><span class="NLM_article-title">cAMP detection methods in HTS: selecting the best from the rest</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1038/nrd1306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrd1306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15040577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFegtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=125-135&author=C.+Williams&title=cAMP+detection+methods+in+HTS%3A+selecting+the+best+from+the+rest&doi=10.1038%2Fnrd1306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP detection methods in HTS: selecting the best from the rest</span></div><div class="casAuthors">Williams, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The no. of technologies that enable high-throughput functional screening of G-protein-coupled receptors has expanded markedly over the past 5 yr.  Consequently, choosing the most appropriate technol. can be a daunting task, particularly for Gi- or Gs-coupled receptors.  The most common systems for cAMP detection are reviewed, highlighting the practical and theor. aspects that are important in their application to high-throughput screening.  Current technologies can do the job, but it is likely that the future may require development of technologies that provide even greater biol. information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCj3Y5Nf5rVg90H21EOLACvtfcHk0ljjYbcIMx-fqg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFegtw%253D%253D&md5=521d70b04daba0ec620c2f72130a5458</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrd1306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1306%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DC.%26atitle%3DcAMP%2520detection%2520methods%2520in%2520HTS%253A%2520selecting%2520the%2520best%2520from%2520the%2520rest%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2004%26volume%3D3%26spage%3D125%26epage%3D135%26doi%3D10.1038%2Fnrd1306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref75"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref75'); return false;" data-citation="" class="refNumLink">75</a></strong><div class="NLM_citation" id="cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chautard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicod, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pralong, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, R. C.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3′, 5′-monophosphate responsive element-binding protein CREB in pituitary cells</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1210/mend.12.5.0109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1210%2Fmend.12.5.0109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9605932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=698-705&author=G.+Waeberauthor=N.+Thompsonauthor=T.+Chautardauthor=M.+Steinmannauthor=P.+Nicodauthor=F.+P.+Pralongauthor=T.+Calandraauthor=R.+C.+Gaillard&title=Transcriptional+activation+of+the+macrophage+migration-inhibitory+factor+gene+by+the+corticotropin-releasing+factor+is+mediated+by+the+cyclic+adenosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+responsive+element-binding+protein+CREB+in+pituitary+cells&doi=10.1210%2Fmend.12.5.0109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3',5'-monophosphate responsive element-binding protein CREB in pituitary cells</span></div><div class="casAuthors">Waeber, Gerard; Thompson, Nancy; Chautard, Thierry; Steinmann, Myriam; Nicod, Pascal; Pralong, Francois P.; Calandra, Thierry; Gaillard, Rolf C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">698-705</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Macrophage migration-inhibitory factor (MIF) has recently been identified as a pituitary hormone that functions as a counterregulatory modulator of glucocorticoid action within the immune system.  In the anterior pituitary gland, MIF is expressed in TSH- and ACTH-producing cells, and its secretion is induced by CRF.  To investigate MIF function and regulation within pituitary cells, we initiated the characterization of the MIF 5'-regulatory region of the gene.  The -1033 to +63 bp of the murine MIF promoter was cloned 5' to a luciferase reporter gene and transiently transfected into freshly isolated rat anterior pituitary cells.  This construct drove high basal transcriptional activity that was further enhanced after stimulation with CRF or with an activator of adenylate cyclase.  These transcriptional effects were assocd. with a concomitant rise in ACTH secretion in the transfected cells and by an increase in MIF gene expression as assessed by Northern blot anal.  A cAMP-responsive element (CRE) was identified within the MIF promoter region which, once mutated, abolished the cAMP responsiveness of the gene.  Using this newly identified CRE, DNA-binding activity was detected by gel retardation assay in nuclear exts. prepd. from isolated anterior pituitary cells and AtT-20 corticotroph tumor cells.  Supershift expts. using antibodies against the CRE-binding protein CREB, together with competition assays and the use of recombinant CREB, allowed the detection of CREB-binding activity with the identified MIF CRE.  These data demonstrate that CREB is the mediator of the CRF-induced MIF gene transcription in pituitary cells through an identified CRE in the proximal region of the MIF promoter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4ctiJbpNnCrVg90H21EOLACvtfcHk0lhFvLr7tfwDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSgs78%253D&md5=770f5d527647a365076307134c26dd73</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1210%2Fmend.12.5.0109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.12.5.0109%26sid%3Dliteratum%253Aachs%26aulast%3DWaeber%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%26aulast%3DChautard%26aufirst%3DT.%26aulast%3DSteinmann%26aufirst%3DM.%26aulast%3DNicod%26aufirst%3DP.%26aulast%3DPralong%26aufirst%3DF.%2BP.%26aulast%3DCalandra%26aufirst%3DT.%26aulast%3DGaillard%26aufirst%3DR.%2BC.%26atitle%3DTranscriptional%2520activation%2520of%2520the%2520macrophage%2520migration-inhibitory%2520factor%2520gene%2520by%2520the%2520corticotropin-releasing%2520factor%2520is%2520mediated%2520by%2520the%2520cyclic%2520adenosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520responsive%2520element-binding%2520protein%2520CREB%2520in%2520pituitary%2520cells%26jtitle%3DMol.%2520Endocrinol.%26date%3D1998%26volume%3D12%26spage%3D698%26epage%3D705%26doi%3D10.1210%2Fmend.12.5.0109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref76"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref76'); return false;" data-citation="" class="refNumLink">76</a></strong><div class="NLM_citation" id="cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, K.</span></span> <span> </span><span class="NLM_article-title">Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells</span>. <i>Biochim. Biophys. Acta Gene Struct. Expr.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1493</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/S0167-4781(00)00168-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0167-4781%2800%2900168-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10978511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1Sns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1493&publication_year=2000&pages=91-100&author=K.+Katoauthor=M.+Nomotoauthor=H.+Izumiauthor=T.+Iseauthor=S.+Nakanoauthor=Y.+Nihoauthor=K.+Kohno&title=Structure+and+functional+analysis+of+the+human+STAT3+gene+promoter%3A+alteration+of+chromatin+structure+as+a+possible+mechanism+for+the+upregulation+in+cisplatin-resistant+cells&doi=10.1016%2FS0167-4781%2800%2900168-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells</span></div><div class="casAuthors">Kato, K.; Nomoto, M.; Izumi, H.; Ise, T.; Nakano, S.; Niho, Y.; Kohno, K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Structure and Expression</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1493</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">BBGSD5</span>;
        ISSN:<span class="NLM_cas:issn">0167-4781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is involved in the signal transduction activated by various cytokines and growth factors.  We found that the STAT3 gene is overexpressed in cisplatin-resistant cells.  We isolated a genomic fragment contg. the 5'-portion of the human STAT3 gene using a bubble PCR method.  Using the bubble PCR product as a probe, one genomic clone was isolated.  The nucleotide sequence of the first exon and the 1800 base pairs (bps) preceding it was detd.  The promoter region of the human STAT3 gene is highly homologous to the corresponding region of the mouse STAT3 gene; several potential factor binding sites such as CRE/ATF, SBE, and GC boxes are also well conserved between human and mouse.  A transient expression assay using the luciferase reporter gene showed that the sequence from -403 to +102 possesses maximal promoter activity, and transcription of the STAT3 gene was significantly higher in cisplatin-resistant cells than in parental cisplatin-sensitive cells.  Deletion of the region between -261 and -167 resulted in significant loss of promoter activity in both parental and cisplatin-resistant cells.  In vivo footprint anal. revealed several protein bindings; however, no significant differences were obsd. between drug-sensitive and drug-resistant cells.  MNase digestion revealed that several open or active nucleosomes were only detected in cisplatin-resistant cells.  These results suggest that STAT3 promoter function in a highly structured chromatin environment requires a complex interaction of several transcriptional factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvgaeUQnDp7Vg90H21EOLACvtfcHk0lhFvLr7tfwDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1Sns7g%253D&md5=211aad8e6a379cb222e310918699f7a0</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0167-4781%2800%2900168-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4781%252800%252900168-8%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DK.%26aulast%3DNomoto%26aufirst%3DM.%26aulast%3DIzumi%26aufirst%3DH.%26aulast%3DIse%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DNiho%26aufirst%3DY.%26aulast%3DKohno%26aufirst%3DK.%26atitle%3DStructure%2520and%2520functional%2520analysis%2520of%2520the%2520human%2520STAT3%2520gene%2520promoter%253A%2520alteration%2520of%2520chromatin%2520structure%2520as%2520a%2520possible%2520mechanism%2520for%2520the%2520upregulation%2520in%2520cisplatin-resistant%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%2520Gene%2520Struct.%2520Expr.%26date%3D2000%26volume%3D1493%26spage%3D91%26epage%3D100%26doi%3D10.1016%2FS0167-4781%2800%2900168-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref77"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref77'); return false;" data-citation="" class="refNumLink">77</a></strong><div class="NLM_citation" id="cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonavida, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis</span>. <i>Clin. Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12538484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Ortw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=316-326&author=S.+Alasauthor=B.+Bonavida&title=Inhibition+of+constitutive+STAT3+activity+sensitizes+resistant+non-Hodgkin%E2%80%99s+lymphoma+and+multiple+myeloma+to+chemotherapeutic+drug-mediated+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis</span></div><div class="casAuthors">Alas, Steve; Bonavida, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-326</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hematopoietic malignancies have been shown to depend on cytokine growth factor autocrine/paracrine loops for growth and differentiation.  This results in the constitutive activation of cytokine-mediated transcription factors like signal transducer and activators of transcription (STAT) 3 in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).  Recent evidence demonstrates that cytokines also contribute to a drug-resistant phenotype in many tumor cell types.  We hypothesized that inhibitors of the STAT3 pathway would sensitize drug-resistant and endogenous cytokine-dependent NHL and MM tumor cells to the cytotoxic effects of chemotherapeutic drugs.  We examd. an AIDS-related NHL cell line, 2F7, known to be dependent on interleukin (IL)-10 for survival and an MM cell line, U266, known to be dependent on IL-6 for survival.  IL-10 and IL-6 signal the cells through the activation of Janus kinase (JAK)1 and JAK2, resp.  Thus, we investigated the effect of two chem. STAT3 pathway inhibitors, namely, piceatannol (JAK1/STAT3 inhibitor) and tyrphostin AG490 (JAK2/STAT3 inhibitor), on the tumor cells for sensitization to therapeutic drugs.  We demonstrate by phosphoprotein immunoblotting anal. and electrophoretic mobility shift anal. that piceatannol and AG490 inhibit the constitutive activity of STAT3 in 2F7 and U266, resp.  Furthermore, piceatannol and AG490 sensitize 2F7 and U266 cells, resp., to apoptosis by a range of therapeutic drugs including cisplatin, fludarabine, Adriamycin, and vinblastine.  The specificity of the inhibitors was corroborated in expts. showing that piceatannol had no effect on U266 and, likewise, AG490 has no effect on 2F7.  The sensitization obsd. by these inhibitors correlated with the inhibition of Bcl-2 expression in 2F7 and Bcl-xL expression in U266.  Altogether, these results demonstrate that STAT3 pathway inhibitors are a novel class of chemotherapeutic sensitizing agents capable of reversing the drug-resistant phenotype of cytokine-dependent tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA8FrtRMRcL7Vg90H21EOLACvtfcHk0lhFvLr7tfwDAw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Ortw%253D%253D&md5=a8429459592fc28b78075df1baff89bf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlas%26aufirst%3DS.%26aulast%3DBonavida%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520constitutive%2520STAT3%2520activity%2520sensitizes%2520resistant%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520and%2520multiple%2520myeloma%2520to%2520chemotherapeutic%2520drug-mediated%2520apoptosis%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2003%26volume%3D9%26spage%3D316%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref78"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref78'); return false;" data-citation="" class="refNumLink">78</a></strong><div class="NLM_citation" id="cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Q.</span></span> <span> </span><span class="NLM_article-title">Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">djw131</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1093%2Fjnci%2Fdjw131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djw131&author=Y.+Zhengauthor=Q.+Wangauthor=T.+Liauthor=J.+Qianauthor=Y.+Luauthor=Y.+Liauthor=E.+Biauthor=F.+Reuauthor=Y.+Qinauthor=J.+Drazbaauthor=E.+Hsiauthor=J.+Yangauthor=Z.+Caiauthor=Q.+Yi&title=Role+of+myeloma-derived+MIF+in+myeloma+cell+adhesion+to+bone+marrow+and+chemotherapy+response&doi=10.1093%2Fjnci%2Fdjw131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw131%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DE.%26aulast%3DReu%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DDrazba%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DQ.%26atitle%3DRole%2520of%2520myeloma-derived%2520MIF%2520in%2520myeloma%2520cell%2520adhesion%2520to%2520bone%2520marrow%2520and%2520chemotherapy%2520response%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26spage%3Ddjw131%26doi%3D10.1093%2Fjnci%2Fdjw131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref79"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref79'); return false;" data-citation="" class="refNumLink">79</a></strong><div class="NLM_citation" id="cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2016.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26827137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1063-1070&author=A.+Fulpauthor=Y.+Zhangauthor=K.+Bortoffauthor=H.+Seltzmanauthor=R.+Snyderauthor=R.+Wietheauthor=G.+Amatoauthor=R.+Maitra&title=Pyrazole+antagonists+of+the+CB1+receptor+with+reduced+brain+penetration&doi=10.1016%2Fj.bmc.2016.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span></div><div class="casAuthors">Fulp, Alan; Zhang, Yanan; Bortoff, Katherine; Seltzman, Herbert; Snyder, Rodney; Wiethe, Robert; Amato, George; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1063-1070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 1 cannabinoid receptor (CB1) antagonists might be useful for treating obesity, liver disease, metabolic syndrome, and dyslipidemias.  Unfortunately, inhibition of CB1 in the central nervous system (CNS) produces adverse effects, including depression, anxiety and suicidal ideation in some patients, which led to withdrawal of the pyrazole inverse agonist rimonabant (SR141716A) from European markets.  Efforts are underway to produce peripherally selective CB1 antagonists to circumvent CNS-assocd. adverse effects.  In this study, novel analogs of rimonabant (1) were explored in which the 1-aminopiperidine group was switched to a 4-aminopiperidine, attached at the 4-amino position (5).  The piperidine nitrogen was functionalized with carbamates, amides, and sulfonamides, providing compds. that are potent inverse agonists of hCB1 with good selectivity for hCB1 over hCB2.  Select compds. were further studied using in vitro models of brain penetration, oral absorption and metabolic stability.  Several compds. were identified with predicted minimal brain penetration and good metabolic stability.  In vivo pharmacokinetic testing revealed that inverse agonist I is orally bioavailable and has vastly reduced brain penetration compared to rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQF0R_5pD887Vg90H21EOLACvtfcHk0lhCW_2hYMtJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D&md5=6cf6e50b077db6b1767f2397e3a5e017</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DWiethe%26aufirst%3DR.%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPyrazole%2520antagonists%2520of%2520the%2520CB1%2520receptor%2520with%2520reduced%2520brain%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1063%26epage%3D1070%26doi%3D10.1016%2Fj.bmc.2016.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref80"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref80'); return false;" data-citation="" class="refNumLink">80</a></strong><div class="NLM_citation" id="cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulpuri, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, I.</span></span> <span> </span><span class="NLM_article-title">Peripherally selective cannabinoid 1 receptor (CB1R) agonists for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7525</span>– <span class="NLM_lpage">7543</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7525-7543&author=H.+H.+Seltzmanauthor=C.+Shinerauthor=E.+E.+Hirtauthor=A.+F.+Gilliamauthor=B.+F.+Thomasauthor=R.+Maitraauthor=R.+Snyderauthor=S.+L.+Blackauthor=P.+R.+Patelauthor=Y.+Mulpuriauthor=I.+Spigelman&title=Peripherally+selective+cannabinoid+1+receptor+%28CB1R%29+agonists+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Facs.jmedchem.6b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Seltzman, Herbert H.; Shiner, Craig; Hirt, Erin E.; Gilliam, Anne F.; Thomas, Brian F.; Maitra, Rangan; Snyder, Rod; Black, Sherry L.; Patel, Purvi R.; Mulpuri, Yatendra; Spigelman, Igor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7525-7543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alleviation of neuropathic pain by cannabinoids is limited by their central nervous system (CNS) side effects.  Indole and indene compds. were engineered for high hCB1R affinity, peripheral selectivity, metabolic stability, and in vivo efficacy.  An epithelial cell line assay identified candidates with <1% blood-brain barrier penetration for testing in a rat neuropathy induced by unilateral sciatic nerve entrapment (SNE).  The SNE-induced mech. allodynia was reversibly suppressed, partially or completely, after i.p. or oral administration of several indenes.  At doses that relieve neuropathy symptoms, the indenes completely lacked, while the brain-permeant CB1R agonist HU-210 (1) exhibited strong CNS side effects, in catalepsy, hypothermia, and motor incoordination assays.  Pharmacokinetic findings of ∼0.001 cerebrospinal fluid:plasma ratio further supported limited CNS penetration.  Pretreatment with selective CB1R or CB2R blockers suggested mainly CB1R contribution to an indene's anti-allodynic effects.  Therefore, this class of CB1R agonists holds promise as a viable treatment for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2b16dl7mj8LVg90H21EOLACvtfcHk0lhCW_2hYMtJ8Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrF&md5=34e913618d61c632bfb90f390af7142e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00516%26sid%3Dliteratum%253Aachs%26aulast%3DSeltzman%26aufirst%3DH.%2BH.%26aulast%3DShiner%26aufirst%3DC.%26aulast%3DHirt%26aufirst%3DE.%2BE.%26aulast%3DGilliam%26aufirst%3DA.%2BF.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DMulpuri%26aufirst%3DY.%26aulast%3DSpigelman%26aufirst%3DI.%26atitle%3DPeripherally%2520selective%2520cannabinoid%25201%2520receptor%2520%2528CB1R%2529%2520agonists%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7525%26epage%3D7543%26doi%3D10.1021%2Facs.jmedchem.6b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref81"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref81'); return false;" data-citation="" class="refNumLink">81</a></strong><div class="NLM_citation" id="cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaté, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejmech.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=29407994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=93-107&author=S.+Schrammauthor=G.+Huangauthor=S.+Guneschauthor=F.+Langauthor=J.+Roaauthor=P.+H%C3%B6ggerauthor=R.+Sabat%C3%A9author=P.+Maherauthor=M.+Decker&title=Regioselective+synthesis+of+7-O-esters+of+the+flavonolignan+silibinin+and+SARs+lead+to+compounds+with+overadditive+neuroprotective+effects&doi=10.1016%2Fj.ejmech.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects</span></div><div class="casAuthors">Schramm, Simon; Huang, Guozheng; Gunesch, Sandra; Lang, Florian; Roa, Judit; Hoegger, Petra; Sabate, Raimon; Maher, Pamela; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-107</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of neuroprotective hybrid compds. was synthesized by conjugation of the flavonolignan silibinin with natural phenolic acids, such as ferulic, cinnamic and syringic acid.  Selective 7-O-esterification without protection groups was achieved by applying the resp. acyl chlorides.  Sixteen compds. were obtained and SARs were established by evaluating antioxidative properties in the physicochem. FRAP assay, as well as in a cell-based neuroprotection assay using murine hippocampal HT-22 cells.  Despite weak activities in the FRAP assay, esters of the α,β-unsatd. acids showed pronounced overadditive effects at low concns. greatly exceeding the effects of equimolar mixts. of silibinin and the resp. acids in the neuroprotection assay.  Cinnamic and ferulic acid esters I and II also showed overadditive effects regarding inhibition of microglial activation, PC12 cell differentiation, in vitro ischemia as well as anti-aggregating abilities against Aβ42 peptide and τ protein.  Remarkably, the esters of ferulic acid with silybin A and silybin B showed a moderate but significant difference in both neuroprotection and in their anti-aggregating capacities.  The results demonstrate that non-toxic natural antioxidants can be regioselectively connected as esters with medium-term stability exhibiting very pronounced overadditive effects in a portfolio of biol. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb6hOBfuLx97Vg90H21EOLACvtfcHk0lhl1xjqnBN-Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehs7Y%253D&md5=a0472a18235e9d724ea4b2667be6863f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DRoa%26aufirst%3DJ.%26aulast%3DH%25C3%25B6gger%26aufirst%3DP.%26aulast%3DSabat%25C3%25A9%26aufirst%3DR.%26aulast%3DMaher%26aufirst%3DP.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DRegioselective%2520synthesis%2520of%25207-O-esters%2520of%2520the%2520flavonolignan%2520silibinin%2520and%2520SARs%2520lead%2520to%2520compounds%2520with%2520overadditive%2520neuroprotective%2520effects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D93%26epage%3D107%26doi%3D10.1016%2Fj.ejmech.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref82"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref82'); return false;" data-citation="" class="refNumLink">82</a></strong><div class="NLM_citation" id="cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saedtler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Investigations into neuroprotectivity, stability, and water solubility of 7-O-cinnamoylsilibinin, its hemisuccinate and dehydro derivatives</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1800206</span>, <span class="refDoi"> DOI: 10.1002/ardp.201800206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fardp.201800206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&pages=1800206&author=S.+Schrammauthor=S.+Guneschauthor=F.+Langauthor=M.+Saedtlerauthor=L.+Meinelauthor=P.+H%C3%B6ggerauthor=M.+Decker&title=Investigations+into+neuroprotectivity%2C+stability%2C+and+water+solubility+of+7-O-cinnamoylsilibinin%2C+its+hemisuccinate+and+dehydro+derivatives&doi=10.1002%2Fardp.201800206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fardp.201800206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201800206%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DS.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DSaedtler%26aufirst%3DM.%26aulast%3DMeinel%26aufirst%3DL.%26aulast%3DH%25C3%25B6gger%26aufirst%3DP.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DInvestigations%2520into%2520neuroprotectivity%252C%2520stability%252C%2520and%2520water%2520solubility%2520of%25207-O-cinnamoylsilibinin%252C%2520its%2520hemisuccinate%2520and%2520dehydro%2520derivatives%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26spage%3D1800206%26doi%3D10.1002%2Fardp.201800206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref83"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref83'); return false;" data-citation="" class="refNumLink">83</a></strong><div class="NLM_citation" id="cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>652</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(94)90334-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-8993%2894%2990334-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7953717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Ogsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=1994&pages=169-173&author=J.+B.+Davisauthor=P.+Maher&title=Protein+kinase+C+activation+inhibits+glutamate-induced+cytotoxicity+in+a+neuronal+cell+line&doi=10.1016%2F0006-8993%2894%2990334-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line</span></div><div class="casAuthors">Davis, John B.; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-73</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">A neuronal cell line, HT-22, is sensitive to glutamate cytotoxicity via a non-receptor mediated oxidative pathway. 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, blocks this glutamate-induced cell death.  Down-regulation of protein kinase C eliminates the protection against glutamate cytotoxicity afforded by TPA.  The data suggest that protein kinase C activation blocks an early step in the cytotoxic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zoz4lIRjcbVg90H21EOLACvtfcHk0lhl1xjqnBN-Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Ogsbk%253D&md5=7e914f0eba8082ec6dbed0b6c8f0c444</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2894%2990334-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252894%252990334-4%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DProtein%2520kinase%2520C%2520activation%2520inhibits%2520glutamate-induced%2520cytotoxicity%2520in%2520a%2520neuronal%2520cell%2520line%26jtitle%3DBrain%2520Res.%26date%3D1994%26volume%3D652%26spage%3D169%26epage%3D173%26doi%3D10.1016%2F0006-8993%2894%2990334-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref84"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref84'); return false;" data-citation="" class="refNumLink">84</a></strong><div class="NLM_citation" id="cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaar, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span> <span> </span><span class="NLM_article-title">Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(89)90043-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0896-6273%2889%2990043-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=2576375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3cXltV2ksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1989&pages=1547-1558&author=T.+H.+Murphyauthor=M.+Miyamotoauthor=A.+Sastreauthor=R.+L.+Schnaarauthor=J.+T.+Coyle&title=Glutamate+toxicity+in+a+neuronal+cell+line+involves+inhibition+of+cystine+transport+leading+to+oxidative+stress&doi=10.1016%2F0896-6273%2889%2990043-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress</span></div><div class="casAuthors">Murphy, Timothy H.; Miyamoto, Masaomi; Sastre, Antonio; Schnaar, Ronald L.; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1547-58</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">Glutamate binds to both excitatory neurotransmitter binding sites and a Cl--dependent, quisqualate- and cystine-inhibited transport site on brain neurons.  The neuroblastoma-primary retina hybrid cells (N18-RE-105) are susceptible to glutamate-induced cytotoxicity.  The Cl--dependent transport site to which glutamate and quisqualate (but not kainate or NMDA) bind has a high affinity for cystine than for glutamate.  Lowering cystine concns. in the cell culture medium results in cytotoxicity similar to that induced by glutamate addn. in its morphol., kinetics, and Ca2+ dependence.  Glutamate-induced cytotoxicity is directly proportional to its ability to inhibit cystine uptake.  Exposure to glutamate (or lowered cystine) causes a decrease in glutathione levels and an accumulation of intracellular peroxides.  Like N18-RE-105 cells, primary rat hippocampal neurons (but not glia) in culture degenerate in medium with lowered cystine concn.  Thus, glutamate-induced cytotoxicity in N18-RE-105 cells is due to inhibition of cystine uptake, resulting in lowered glutathione levels leading to oxidative stress and cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKGHs5RF0MXbVg90H21EOLACvtfcHk0lhl1xjqnBN-Qw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltV2ksrg%253D&md5=af2faf651f0807f7c54e147915b91a9d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2889%2990043-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252889%252990043-3%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DT.%2BH.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DSastre%26aufirst%3DA.%26aulast%3DSchnaar%26aufirst%3DR.%2BL.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DGlutamate%2520toxicity%2520in%2520a%2520neuronal%2520cell%2520line%2520involves%2520inhibition%2520of%2520cystine%2520transport%2520leading%2520to%2520oxidative%2520stress%26jtitle%3DNeuron%26date%3D1989%26volume%3D2%26spage%3D1547%26epage%3D1558%26doi%3D10.1016%2F0896-6273%2889%2990043-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref85"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref85'); return false;" data-citation="" class="refNumLink">85</a></strong><div class="NLM_citation" id="cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1998.71010095.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1046%2Fj.1471-4159.1998.71010095.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9648855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1cXktFams7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1998&pages=95-105&author=S.+Tanauthor=M.+Woodauthor=P.+Maher&title=Oxidative+stress+induces+a+form+of+programmed+cell+death+with+characteristics+of+both+apoptosis+and+necrosis+in+neuronal+cells&doi=10.1046%2Fj.1471-4159.1998.71010095.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells</span></div><div class="casAuthors">Tan, Shirlee; Wood, Malcolm; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Oxidative stress is implicated in a no. of neurol. disorders including stroke, Parkinson's disease, and Alzheimer's disease.  To study the effects of oxidative stress on neuronal cells, the authors have used an immortalized mouse hippocampal cell line (HT-22) that is particularly sensitive to glutamate.  In these cells, glutamate competes for cystine uptake, leading to a redn. in glutathione and, ultimately, cell death.  As it has been reported that protein kinase C activation inhibits glutamate toxicity in these cells and is also assocd. with the inhibition of apoptosis in other cell types, the authors asked if glutamate toxicity was via apoptosis.  Morphol., glutamate-treated cells underwent plasma membrane blebbing and cell shrinkage, but no DNA fragmentation was obsd.  At the ultrastructural level, there was damage to mitochondria and other organelles although the nuclei remained intact.  Protein and RNA synthesis inhibitors as well as certain protease inhibitors protected the cells from glutamate toxicity.  Both the macromol. synthesis inhibitors and the protease inhibitors had to be added relatively soon after the addn. of glutamate, suggesting that protein synthesis and protease activation are early and distinct steps in the cell death pathway.  Thus, the oxidative stress brought about by treatment with glutamate initiates a series of events that lead to a form of cell death distinct from either necrosis or apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpplvJv3Oe3UrVg90H21EOLACvtfcHk0lgoluTMS5dm9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFams7g%253D&md5=3e292281baa963ef7da1ae54ac6eb423</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1998.71010095.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1998.71010095.x%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DOxidative%2520stress%2520induces%2520a%2520form%2520of%2520programmed%2520cell%2520death%2520with%2520characteristics%2520of%2520both%2520apoptosis%2520and%2520necrosis%2520in%2520neuronal%2520cells%26jtitle%3DJ.%2520Neurochem.%26date%3D1998%26volume%3D71%26spage%3D95%26epage%3D105%26doi%3D10.1046%2Fj.1471-4159.1998.71010095.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref86"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref86'); return false;" data-citation="" class="refNumLink">86</a></strong><div class="NLM_citation" id="cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Oxytosis: a novel form of programmed cell death</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.2174/1568026013394741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F1568026013394741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11895126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1aitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=497-506&author=S.+Tanauthor=D.+Schubertauthor=P.+Maher&title=Oxytosis%3A+a+novel+form+of+programmed+cell+death&doi=10.2174%2F1568026013394741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytosis: a novel form of programmed cell death</span></div><div class="casAuthors">Tan, Shirlee; Schubert, David; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Extensive nerve cell death occurs during the development of the central nervous system as well as in episodes of trauma and in neurodegenerative disease.  The mechanistic details of how these cells die are poorly understood.  Here we describe a unique oxidative stress-induced programmed cell death pathway called oxytosis, and outline pharmacol. approaches which interfere with its execution.  Oxidative glutamate toxicity, in which exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to a depletion of glutathione, is used as an example of oxytosis.  It is shown that there is a sequential requirement for de novo macromol. synthesis, lipoxygenase activation, reactive oxygen species prodn., and the opening of cGMP-gated channels which allow the influx of extracellular calcium.  The translation initiation factor eIF2α plays a central role in this pathway by regulating the levels of glutathione.  Finally, examples are given in which the redn. in glutathione, the prodn. of reactive oxygen species, and calcium influx can be exptl. manipulated to prevent cell death.  The reviewed data suggest that oxytosis may be involved in nerve cell death assocd. with nervous system trauma and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq70jHZZ6C5Y7Vg90H21EOLACvtfcHk0lgoluTMS5dm9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1aitrc%253D&md5=7fc6a76e10947ab5224d5c3c7d37979e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2174%2F1568026013394741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026013394741%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DSchubert%26aufirst%3DD.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DOxytosis%253A%2520a%2520novel%2520form%2520of%2520programmed%2520cell%2520death%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2001%26volume%3D1%26spage%3D497%26epage%3D506%26doi%3D10.2174%2F1568026013394741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref87"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref87'); return false;" data-citation="" class="refNumLink">87</a></strong><div class="NLM_citation" id="cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, A.</span></span> <span> </span><span class="NLM_article-title">Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>706</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(95)01032-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-8993%2895%2901032-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8822355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK28Xns1yitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=706&publication_year=1996&pages=181-193&author=T.+Mauriceauthor=B.+P.+Lockhartauthor=A.+Privat&title=Amnesia+induced+in+mice+by+centrally+administered+%CE%B2-amyloid+peptides+involves+cholinergic+dysfunction&doi=10.1016%2F0006-8993%2895%2901032-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction</span></div><div class="casAuthors">Maurice, Tangui; Lockhart, Brian P.; Privat, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">706</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-93</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Substantial evidences suggest that the increased cerebral deposition, and neurotoxic action of the β-amyloid peptide, the major constituent of senile plaques, may represent the underlying cause of the cognitive deficits obsd. in Alzheimer's disease.  Herein, the authors attempted to verify this hypothesis by inducing a potential Alzheimer's-type amnesia after direct intracerebroventricular administration of aggregated β25-35-amyloid peptide in mice.  In this aim, amnesic capacities were evaluated after 6 to 13 days, using spontaneous alternation in the Y-maze, step-down type passive avoidance and place learning in a water-maze.  Pre-training administration of aggregated β25-35 peptide induced dose-dependent decreases in both alternation behavior and passive avoidance, at doses of 3 and 9 nmol/mouse.  A reduced but still significant impairment was obsd. when the peptide was not aggregated, or 'aged', by preincubation for 4 days at 37°.  The β1-28 peptide, at 3 nmol/mouse, also induced a marked decrease in step-down latency.  Post-training, but not pre-retention, administration of β25-35 peptide also significantly impaired learning.  The beneficial effects of cholinergic agents on β25-35-induced amnesia was examd. using the cholinesterase inhibitor tacrine (THA, 1.3 and 4.3 μmol/kg i.p.) and the nicotinic receptor agonist (-)-nicotine (NIC, 0.06 and 0.2 μmol/kg i.p.).  Both drugs induced a dose-dependent abrogation of the β25-35-induced decreases in alternation behavior and passive avoidance.  Furthermore, THA, at 1.3 μmol/kg, and NIC, at 0.2 μmol/kg, also reversed the β25-35-induced impairment of place learning and retention in the water-maze.  Histol. examn. of Cresyl violet-stained brain sections indicated a moderate but significant cell loss within the frontoparietal cortex and the hippocampal formation of mice treated with aged β25-35 peptide (9 nmol).  Examn. of Congo red-stained sections in the same animals demonstrated the presence of numerous amyloid deposits throughout these brain areas.  These results confirm that the deposition of β-amyloid peptide in the brain is in some way related to impairment of learning and cholinergic degeneration and suggest that the [25-35] fragment of the β-amyloid protein, sufficient to induce neuronal death in cultures, also induces an Alzheimer's-type amnesia in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsjUgNl1iVLVg90H21EOLACvtfcHk0lgoluTMS5dm9g"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1yitQ%253D%253D&md5=5a0465719e2a405fcc1c6aae31ad0367</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2895%2901032-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252895%252901032-7%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DPrivat%26aufirst%3DA.%26atitle%3DAmnesia%2520induced%2520in%2520mice%2520by%2520centrally%2520administered%2520%25CE%25B2-amyloid%2520peptides%2520involves%2520cholinergic%2520dysfunction%26jtitle%3DBrain%2520Res.%26date%3D1996%26volume%3D706%26spage%3D181%26epage%3D193%26doi%3D10.1016%2F0006-8993%2895%2901032-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref88"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref88'); return false;" data-citation="" class="refNumLink">88</a></strong><div class="NLM_citation" id="cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Blockade of Tau hyperphosphorylation and Aβ 1–42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ 1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnpp.2013.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=23493042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1706-1723&author=V.+Lahmyauthor=J.+Meunierauthor=S.+Malmstr%C3%B6mauthor=G.+Naertauthor=L.+Givaloisauthor=S.+H.+Kimauthor=V.+Villardauthor=A.+Vamvakidesauthor=T.+Maurice&title=Blockade+of+Tau+hyperphosphorylation+and+A%CE%B2+1%E2%80%9342+generation+by+the+aminotetrahydrofuran+derivative+ANAVEX2-73%2C+a+mixed+muscarinic+and+%CF%83+1+receptor+agonist%2C+in+a+nontransgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpp.2013.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Lahmy, Valentine; Meunier, Johann; Malmstroem, Susanna; Naert, Gaelle; Givalois, Laurent; Kim, Seung Hyun; Villard, Vanessa; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1723</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The main objective of the present study was to establish whether the mixed σ1/muscarinic ligand ANAVEX2-73, shown to be neuroprotective in Alzheimer's disease (AD) models in vivo and currently in clin. phase I/IIa, could have the ability to reduce the appearance of hyperphosphorylated Tau and amyloid-β1-42 (Aβ1-42) in the Aβ25-35 mouse model of AD.  We therefore first confirmed that Aβ25-35 injection induced hyperphosphorylation of Tau protein, by showing that it rapidly decreased Akt activity and activated glycogen synthase kinase-3β (GSK-3β) in the mouse hippocampus.  Second, we showed that the kinase activation, and resulting Tau alteration, directly contributed to the amyloid toxicity, as co-administration of the selective GSK-3β inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole blocked both Tau phosphorylation and Aβ25-35-induced memory impairments.  Third, we analyzed the ANAVEX2-73 effect on Tau phosphorylation and activation of the related kinase pathways (Akt and GSK-3β).  And fourth, we also addressed the impact of the drug on Aβ25-35-induced Aβ1-42 seeding and obsd. that the compd. significantly blocked the increase in Aβ1-42 and C99 levels in the hippocampus, suggesting that it may alleviate amyloid load in AD models.  The comparison with PRE-084, a selective and ref. σ1 receptor agonist, and xanomeline, a muscarinic ligand presenting similar profile as ANAVEX2-73 on M1 and M2 subtypes, confirmed that both muscarinic and σ1 targets are involved in the ANAVEX2-73 effects.  The drug, acting synergistically on both targets, but with moderate affinity, presents a promising pharmacol. profile.  Neuropsychopharmacol. (2013) 38, 1706-1723; doi:10.1038/npp.2013.70; published online 3 Apr. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Ullin5U0GbVg90H21EOLACvtfcHk0lhCNmOXUoOBuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP&md5=84921702de85f5bc6152b178915adb44</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.70%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DBlockade%2520of%2520Tau%2520hyperphosphorylation%2520and%2520A%25CE%25B2%25201%25E2%2580%259342%2520generation%2520by%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX2-73%252C%2520a%2520mixed%2520muscarinic%2520and%2520%25CF%2583%25201%2520receptor%2520agonist%252C%2520in%2520a%2520nontransgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1706%26epage%3D1723%26doi%3D10.1038%2Fnpp.2013.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref89"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref89'); return false;" data-citation="" class="refNumLink">89</a></strong><div class="NLM_citation" id="cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McQuiston, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggau, P.</span></span> <span> </span><span class="NLM_article-title">Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1152/jn.01150.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1152%2Fjn.01150.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12750411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVelu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2003&pages=1936-1948&author=A.+R.+McQuistonauthor=P.+Saggau&title=Mu-opioid+receptors+facilitate+the+propagation+of+excitatory+activity+in+rat+hippocampal+area+CA1+by+disinhibition+of+all+anatomical+layers&doi=10.1152%2Fjn.01150.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers</span></div><div class="casAuthors">McQuiston, A. Rory; Saggau, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1936-1948</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Hippocampal μ-opioid receptors (MORs) have been implicated in memory formation assocd. with opiate drug abuse.  MORs modulate hippocampal synaptic plasticity acutely, when chronically activated, and during drug withdrawal.  At the network level, MORs increase excitability in area CA1 by disinhibiting pyramidal cells.  The precise inhibitory interneuron subtypes affected by MOR activation are unknown; however, not all subtypes are inhibited, and specific interneuron subtypes have been shown to preferentially express MORs.  Here the authors investigate, using voltage-sensitive dye imaging in brain slices, the effect of MOR activation on the patterns of inhibition and on the propagation of excitatory activity in rat hippocampal CA1.  MOR activation augments excitatory activity evoked by stimulating inputs in stratum oriens [i.e., Schaffer collateral and commissural pathway (SCC) and antidromic], stratum radiatum (i.e., SCC), and stratum lacunosum-mol. (SLM; i.e., perforant path and thalamus).  The augmented excitatory activity is further facilitated as it propagates through the CA1 network.  This was obsd. as a proportionately larger increase in amplitudes of excitatory activity at sites distal from where the activity was evoked.  This facilitation was obsd. for excitatory activity propagating from all three stimulation sites.  The augmentation and facilitation were prevented by GABAA receptor antagonists (bicuculline, 30 μM), but not by GABAB receptor antagonists (CGP 55845, 10 μM).  Furthermore, MOR activation inhibited IPSPs in all layers of area CA1.  These findings suggest that MOR-induced suppression of GABA release onto GABAA receptors augments all inputs to CA1 pyramidal cells and facilitates the propagation of excitatory activity through the network of area CA1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75MF7f_zyT7Vg90H21EOLACvtfcHk0lhCNmOXUoOBuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVelu7Y%253D&md5=3e058205251e582bcbd83d0f3ceaad19</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1152%2Fjn.01150.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.01150.2002%26sid%3Dliteratum%253Aachs%26aulast%3DMcQuiston%26aufirst%3DA.%2BR.%26aulast%3DSaggau%26aufirst%3DP.%26atitle%3DMu-opioid%2520receptors%2520facilitate%2520the%2520propagation%2520of%2520excitatory%2520activity%2520in%2520rat%2520hippocampal%2520area%2520CA1%2520by%2520disinhibition%2520of%2520all%2520anatomical%2520layers%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2003%26volume%3D90%26spage%3D1936%26epage%3D1948%26doi%3D10.1152%2Fjn.01150.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref90"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref90'); return false;" data-citation="" class="refNumLink">90</a></strong><div class="NLM_citation" id="cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batts, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, J.</span></span> <span> </span><span class="NLM_article-title">An update on terminology and reporting</span>. <i>Am. J. Surg. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1097/00000478-199512000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1097%2F00000478-199512000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7503362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK28%252FotlKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1995&pages=1409-1417&author=K.+P.+Battsauthor=J.+Ludwig&title=An+update+on+terminology+and+reporting&doi=10.1097%2F00000478-199512000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic hepatitis. An update on terminology and reporting</span></div><div class="casAuthors">Batts K P; Ludwig J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-17</span>
        ISSN:<span class="NLM_cas:issn">0147-5185</span>.
    </div><div class="casAbstract">The terms chronic active hepatitis (CAH), chronic persistent hepatitis (CpH), and chronic lobular hepatitis (CLH) have become obsolete, and their use without further specifications should be discontinued.  This recommendation has become necessary because these names have changed from descriptive terms, intended for grading, to terms that are used either as morphologic diagnoses or disease designations or both, depending on individual preferences.  Because this practice has caused serious misunderstandings, many authors and two international groups have recommended the use of a clear etiologic terminology.  For the reporting practice of pathologists, we recommend that the pathologist routinely sign out biopsy samples with features of chronic hepatitis by indicating etiology, grade, and stage.  An example would be autoimmune hepatitis, severe, stage 3.  The stage in this case would indicate the presence of well-developed septal fibrosis but no nodular regeneration.  Obviously, for the etiologic diagnosis, morphologic findings must be integrated with clinical and laboratory data.  If this information is not available, clear morphologic diagnoses should be reported.  Thus, instead of CPH, the diagnosis should be portal hepatitis, cause undetermined.  This reporting practice eliminates ambiguous terminology and avoids the risk of inappropriate treatment as might occur, for example, when a term such as CAH is used to describe Wilson's disease and is misunderstood to mean autoimmune hepatitis.  For a transitional period and to facilitate relearning, the terms CAH, CPH, and CLH can be reported in parentheses behind the etiologic diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdtB05sEuTX9yzdcP07UmufW6udTcc2ebuyzCUbNhgHLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FotlKkug%253D%253D&md5=cc7f13cfcf5709d820c4cf408e576190</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2F00000478-199512000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000478-199512000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DBatts%26aufirst%3DK.%2BP.%26aulast%3DLudwig%26aufirst%3DJ.%26atitle%3DAn%2520update%2520on%2520terminology%2520and%2520reporting%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D1995%26volume%3D19%26spage%3D1409%26epage%3D1417%26doi%3D10.1097%2F00000478-199512000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref91"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref91'); return false;" data-citation="" class="refNumLink">91</a></strong><div class="NLM_citation" id="cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, P.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of dimethylformamide and dimethylsulfoxide at and above the levels used in some aflatoxin studies</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7354621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL3cXht1aqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1980&pages=257-262&author=T.+Mathewauthor=R.+Karunanithyauthor=M.+Yeeauthor=P.+Natarajan&title=Hepatotoxicity+of+dimethylformamide+and+dimethylsulfoxide+at+and+above+the+levels+used+in+some+aflatoxin+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of dimethylformamide and dimethyl sulfoxide at and above the levels used in some aflatoxin studies</span></div><div class="casAuthors">Mathew, T.; Karunanithy, R.; Yee, M. H.; Natarajan, P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-62</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">Rats were treated with a single i.p. injection of DMF  [68-12-2] or DMSO  [67-68-5].  The doses of DMF administered were 0.6, 0.9, and 1.2 mL/kg, and those of DMSO were 1.2, 2.4, 3.6, and 4.8 mL/kg.  The animals were sacrificed at 24, 48, 72, and 120 h following administration of each dose.  The liver was investigated in all cases.  Treatment with DMF at 0.6 mL/kg caused some histol. lesions of the liver which became well defined at 0.9 and 1.2 mL/kg causing severe central phlebitis with centrilobular coagulative necrosis of the cells assocd. with a heavy inflammatory infiltrate.  Maximal liver lesions occurred at 48 h and started to regress after 72 h.  However, cellular atypism became a consistent finding after this inflammatory phase.  DMSO-treated animals showed minimal histol. lesions of the liver at 1.2 and 2.4 mL/kg.  Higher doses caused fatty infiltration with a predominantly periportal distribution.  It tended to produce its maximal effect in 12 h which then regressed rapidly after 24 h.  The development of histol. lesions in the liver even at 0.6 mL/kg suggested that DMF was not a suitable solvent for aflatoxin studies, and hence the results obtained from such studies need cautious interpretation.  DMSO appeared to be an ideal alternative for toxicol. studies at a much higher dose level compared to DMF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1GhpeIUvWj7Vg90H21EOLACvtfcHk0lhCNmOXUoOBuw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXht1aqsrw%253D&md5=287c7ca6860471cdcc66fdcc07da7009</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DT.%26aulast%3DKarunanithy%26aufirst%3DR.%26aulast%3DYee%26aufirst%3DM.%26aulast%3DNatarajan%26aufirst%3DP.%26atitle%3DHepatotoxicity%2520of%2520dimethylformamide%2520and%2520dimethylsulfoxide%2520at%2520and%2520above%2520the%2520levels%2520used%2520in%2520some%2520aflatoxin%2520studies%26jtitle%3DLab.%2520Invest.%26date%3D1980%26volume%3D42%26spage%3D257%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref92"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref92'); return false;" data-citation="" class="refNumLink">92</a></strong><div class="NLM_citation" id="cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <i>The organic chemistry of enzyme-catalyzed reactions</i>. <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+B.+Silverman&title=The+organic+chemistry+of+enzyme-catalyzed+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26btitle%3DThe%2520organic%2520chemistry%2520of%2520enzyme-catalyzed%2520reactions%26pub%3DAcademic%2520Press%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref93"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref93'); return false;" data-citation="" class="refNumLink">93</a></strong><div class="NLM_citation" id="cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naiki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakakuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of amyloid fibril polymerization in vitro</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1906561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK3Mzgtl2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=104-110&author=H.+Naikiauthor=K.+Higuchiauthor=K.+Nakakukiauthor=T.+Takeda&title=Kinetic+analysis+of+amyloid+fibril+polymerization+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic analysis of amyloid fibril polymerization in vitro</span></div><div class="casAuthors">Naiki H; Higuchi K; Nakakuki K; Takeda T</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-10</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">We investigated the polymerization kinetics of murine senile amyloid fibrils (fASSAM) in vitro.  When sonicated murine senile amyloid fibrils was incubated with its constituent monomer protein, the extension of amyloid fibrils was observed in an electron microscopic analysis.  Quantitative fluorometric analysis with thioflavine T (Naiki H, Higuchi K, Hosokawa M, Takeda T: Anal Biochem 177:244, 1989) revealed that (a) extension of amyloid fibrils occurred by a pseudo-first-order exponential increase in the fluorescence of thioflavine T; (b) the rate of extension was maximal around pH 7.5, and was inhibited with the increase in KCl or NaCl concentration in the reaction mixture; (c) the rate of polymerization was proportional to the product of the murine senile amyloid fibrils number concentration and the constituent monomer protein concentration; (d) the net rate of extension was the sum of the rates of polymerization and depolymerization with the equilibrium association constant K of 5 x 10(7) M-1.  These results show that amyloid fibril formation can apparently be explained by a first-order kinetic model: that is, extension of amyloid fibrils proceeds by consecutive association of precursor proteins onto the ends of existing fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzqvddojADZ77NkxioyDXTfW6udTcc2eZPo8HzdA9VVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3Mzgtl2mtw%253D%253D&md5=f0bf34063b451a94204b8205d8a9f00e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaiki%26aufirst%3DH.%26aulast%3DHiguchi%26aufirst%3DK.%26aulast%3DNakakuki%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DT.%26atitle%3DKinetic%2520analysis%2520of%2520amyloid%2520fibril%2520polymerization%2520in%2520vitro%26jtitle%3DLab.%2520Invest.%26date%3D1991%26volume%3D65%26spage%3D104%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref94"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref94'); return false;" data-citation="" class="refNumLink">94</a></strong><div class="NLM_citation" id="cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span> <span> </span><span class="NLM_article-title">Species comparison and pharmacological characterization of rat and human CB<sub>2</sub> cannabinoid receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2004.09.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejphar.2004.09.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15556131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2004&pages=1-9&author=S.+Mukherjeeauthor=M.+Adamsauthor=K.+Whiteakerauthor=A.+Dazaauthor=K.+Kageauthor=S.+Cassarauthor=M.+Meyerauthor=B.+B.+Yao&title=Species+comparison+and+pharmacological+characterization+of+rat+and+human+CB2+cannabinoid+receptors&doi=10.1016%2Fj.ejphar.2004.09.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors</span></div><div class="casAuthors">Mukherjee, Sutapa; Adams, Monique; Whiteaker, Kristi; Daza, Anthony; Kage, Karen; Cassar, Steven; Meyer, Michael; Yao, Betty Bei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmacol. effects of cannabinoid ligands are thought to be mediated through cannabinoid CB1 and CB2 receptor subtypes.  Sequence anal. revealed that rat and human cannabinoid CB2 receptors are divergent and share 81% amino acid homol.  Pharmacol. anal. of the possible species differences between rat and human cannabinoid CB2 receptors was performed using radioligand binding and functional assays.  Pronounced species selectivity at the rat cannabinoid CB2 receptor (50- to 140-fold) was obsd. with AM-1710 (3-(1,1-Dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo[c]chromen-6-one) and AM-1714 (3-(1,1-Dimethyl-heptyl)-1-9-dihydroxy-benzo[c]chromen-6-one).  In contrast, JWH-015 ((2-Methyl-1-propyl-1H-indol-3-yl)-naphthalen-1-yl-methanone) was 3- to 10-fold selective at the human cannabinoid CB2 receptor.  Endocannabinoid ligands were more human receptor selective.  Cannabinoid CB2 receptor antagonist, AM-630 ((6-Iodo-2-methyl-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(4-methoxy-phenyl)-methanone) was more potent at the rat receptor in radioligand binding and functional assays than that of the human receptor.  The findings of the pharmacol. differences between the human and rat cannabinoid CB2 receptors in this study provide crit. information for characterizing cannabinoid ligands in in vivo rodent models for drug discovery purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxt0gttmCZzLVg90H21EOLACvtfcHk0ljxhKCeezePKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLnL&md5=cd966d58f39b09919f824eb61b150196</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.09.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.09.058%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DK.%26aulast%3DDaza%26aufirst%3DA.%26aulast%3DKage%26aufirst%3DK.%26aulast%3DCassar%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26atitle%3DSpecies%2520comparison%2520and%2520pharmacological%2520characterization%2520of%2520rat%2520and%2520human%2520CB2%2520cannabinoid%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D505%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.ejphar.2004.09.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref95"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref95'); return false;" data-citation="" class="refNumLink">95</a></strong><div class="NLM_citation" id="cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, A.</span></span> <span> </span><span class="NLM_article-title">Sigma1 (σ1) receptor agonists and neurosteroids attenuate β25–35-amyloid peptide-induced amnesia in mice through a common mechanism</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(97)00405-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0306-4522%2897%2900405-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9460750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK1c7it1SrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=413-428&author=T.+Mauriceauthor=T.-P.+Suauthor=A.+Privat&title=Sigma1+%28%CF%831%29+receptor+agonists+and+neurosteroids+attenuate+%CE%B225%E2%80%9335-amyloid+peptide-induced+amnesia+in+mice+through+a+common+mechanism&doi=10.1016%2FS0306-4522%2897%2900405-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism</span></div><div class="casAuthors">Maurice T; Su T P; Privat A</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-28</span>
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    </div><div class="casAbstract">The sigma1 (sigma 1) receptor agonists exert potent anti-amnesic effects, as they apparently block the learning impairments either induced by the muscarinic receptor antagonist scopolamine, the N-methyl-D-aspartate receptor antagonist dizocilpine or inherently due to the age-related deficits in senescence-accelerated mice.  We recently described the amnesia induced by the beta-amyloid-related peptide beta 25-35, administered centrally in an aggregated form, in mice.  The deficits were sensitive to cholinomimetics or to N-methyl-D-aspartate/glycine modulatory site agonists.  Herein, we examined the effects of sigma 1 receptor ligands on the beta 25-35 peptide-induced amnesia.  The effects of neuro(active) steroids, which interact in vitro and in vivo with sigma 1 receptors were examined in parallel.  Mnesic capacity was evaluated seven days after administration of aggregated beta 25-35 peptide (3 nmol), using spontaneous alternation in the Y-maze for spatial short-term memory, or after 14 days, using the step-down type passive avoidance test for long-term memory.  The sigma 1 receptor agonists (+)-pentazocine, PRE-084, or SA4503 attenuated, in a dose-dependent and bell-shaped manner, the beta 25-35 peptide-induced deficits on both tests.  These effects were antagonized by haloperidol or BMY-14802, confirming the sigma 1 receptor pharmacology.  Pregnenolone, dehydroepiandrosterone, and their sulphate esters, but not progesterone, also dose-dependently attenuated the beta 25-35 peptide-induced deficits.  Progesterone blocked the beneficial effects of each other neurosteroid, behaving as an antagonist.  Furthermore, haloperidol blocked the effects induced by neurosteroids, whereas progesterone antagonized the effects of the non-steroidal sigma 1 receptor agonists, showing a clear crossed pharmacology of different drug classes.  These results demonstrate that: (i) the anti-amnesic effect of sigma 1 receptor agonists may be of therapeutic relevance in pathological states affecting the cholinergic and/or glutamatergic systems, such as in pathological aging; (ii) neurosteroids play an important role in learning processes and may collectively constitute a therapeutic target; (iii) the interaction between sigma 1 systems and neurosteroids appears indeed of behavioural relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk2M14yVWgsSA3UY9EwTNrfW6udTcc2eZPo8HzdA9VVLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7it1SrsA%253D%253D&md5=b32d89a65019b0a50a3667b8626c60fa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2897%2900405-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252897%252900405-3%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DPrivat%26aufirst%3DA.%26atitle%3DSigma1%2520%2528%25CF%25831%2529%2520receptor%2520agonists%2520and%2520neurosteroids%2520attenuate%2520%25CE%25B225%25E2%2580%259335-amyloid%2520peptide-induced%2520amnesia%2520in%2520mice%2520through%2520a%2520common%2520mechanism%26jtitle%3DNeuroscience%26date%3D1998%26volume%3D83%26spage%3D413%26epage%3D428%26doi%3D10.1016%2FS0306-4522%2897%2900405-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref96"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref96'); return false;" data-citation="" class="refNumLink">96</a></strong><div class="NLM_citation" id="cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ieni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0706927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17057756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12gsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=998-1012&author=J.+Meunierauthor=J.+Ieniauthor=T.+Maurice&title=The+anti-amnesic+and+neuroprotective+effects+of+donepezil+against+amyloid+beta25-35+peptide-induced+toxicity+in+mice+involve+an+interaction+with+the+sigma1+receptor&doi=10.1038%2Fsj.bjp.0706927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-amnesic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor</span></div><div class="casAuthors">Meunier, J.; Ieni, J.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">998-1012</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: The acetylcholinesterase inhibitor, donepezil, is also a high affinity σ1 receptor agonist.  We examd. the involvement of σ1 receptors in its anti-amnesic and neuroprotective properties against amyloid β25-35 peptide-induced toxicity in mice.  Exptl. approach:Mice were given an intracerebroventricular (i.c.v.) injection of Aβ25-35 peptide (9 nmol) 7-9 days before being tested for spontaneous alternation and passive avoidance.  Hippocampal lipid peroxidn. was measured 7 days after Aβ25-35 injection to evaluate oxidative stress.  Donepezil, the σ1 agonist PRE-084 or the cholinesterase (ChE) inhibitors tacrine, rivastigmine and galantamine were administered either 20 min before behavioral sessions to check their anti-amnesic effects, or 20 min before Aβ25-35 injection, or 24 h after Aβ25-35 injection and then once daily before behavioral sessions, to check their pre- and post-i.c.v. neuroprotective activity, resp.  Key results: All the drugs tested were anti-amnesic, but only the effects of PRE-084 and donepezil were prevented by the σ1 antagonist BD1047.  Only PRE-084 and donepezil showed neuroprotection when administered pre i.c.v.; they blocked lipid peroxidn. and learning deficits, effects inhibited by BD1047.  Post i.c.v., PRE-084 and donepezil showed complete neuroprotection whereas the other ChE inhibitors showed partial effects.  BD1047 blocked these effects of PRE-084, attenuated those of donepezil, but did not affect the partial effects of the other ChE inhibitors.Conclusions and implications.  The potent anti-amnesic and neuroprotective effects of donepezil against Aβ25-35-induced toxicity involve both its cholinergic and σ1 agonistic properties.  This dual action may explain its sustained activity compared to other ChE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnuVPGFVAubVg90H21EOLACvtfcHk0liZu2Zi-IorWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12gsLvN&md5=74e469485771b149a04d178a1890da79</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706927%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DIeni%26aufirst%3DJ.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DThe%2520anti-amnesic%2520and%2520neuroprotective%2520effects%2520of%2520donepezil%2520against%2520amyloid%2520beta25-35%2520peptide-induced%2520toxicity%2520in%2520mice%2520involve%2520an%2520interaction%2520with%2520the%2520sigma1%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D998%26epage%3D1012%26doi%3D10.1038%2Fsj.bjp.0706927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref97"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref97'); return false;" data-citation="" class="refNumLink">97</a></strong><div class="NLM_citation" id="cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl) sulfonyl](2, 5-difluorophenyl) amino] ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1–42 seeding and short-term memory deficits in the Aβ25–35 mouse model of Alzheimer’s disease</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>698</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejphar.2012.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=23123349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslaqu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=698&publication_year=2013&pages=193-199&author=J.+Meunierauthor=V.+Villardauthor=L.+Givaloisauthor=T.+Maurice&title=The+%CE%B3-secretase+inhibitor+2-%5B%281R%29-1-%5B%284-chlorophenyl%29+sulfonyl%5D%282%2C+5-difluorophenyl%29+amino%5D+ethyl-5-fluorobenzenebutanoic+acid+%28BMS-299897%29+alleviates+A%CE%B21%E2%80%9342+seeding+and+short-term+memory+deficits+in+the+A%CE%B225%E2%80%9335+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejphar.2012.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease</span></div><div class="casAuthors">Meunier, Johann; Villard, Vanessa; Givalois, Laurent; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">698</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">193-199</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease pathomimetic toxicity could be induced in mice within one week after the intracerebroventricular (i.c.v.) injection of an aggregated prepn. of the highly toxic and endogenous amyloid-β fragment Aβ25-35.  It was recently reported that Aβ25-35 also provokes a modification of APP processing with accumulation of endogenous Aβ1-42.  We here analyzed whether a γ-secretase inhibitor, BMS-299897, attenuated this Aβ25-35-induced Aβ1-42 seeding and toxicity.  The compd. was administered at 0.1-1 nmol/mouse, concomitantly with Aβ25-35 (9 nmol) in male Swiss mice.  After one week, the contents in Aβ1-42 and Aβ1-40, and the levels in lipid peroxidn. were analyzed in the mouse hippocampus.  Mice were submitted to spontaneous alternation, passive avoidance and object recognition to analyze their short- and long-term memory abilities.  Aβ25-35 increased Aβ1-42 content (+240%) but failed to affect Aβ1-40.  BMS-299897 blocked the increase in Aβ1-42 content and decreased Aβ1-40 levels significantly.  The compd. did not affect Aβ25-35-induced increase in hippocampal lipid peroxidn.  Behaviorally, BMS-299897 blocked the Aβ25-35-induced deficits in spontaneous alternation or novel object recognition, using a 1 h intertrial time interval.  BMS-299896 failed to affect the passive avoidance impairments or novel object recognition, using a 24 h intertrial time interval.  These results confirmed that Aβ25-35 injection provoked an accumulation in endogenous Aβ1-42, an effect blocked by γ-secretase inhibition.  This Aβ1-42 accumulation marginally contributed to the toxicity or long-term memory deficits.  However, since the seeded Aβ1-42 affected short-term memory, the rapid Aβ25-35 injection Alzheimer's disease model could be used to screen the activity of new secretase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-qM5cWq1c9rVg90H21EOLACvtfcHk0liZu2Zi-IorWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslaqu77J&md5=0cdaf0d189845ae408aa5dbcca379cf5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DThe%2520%25CE%25B3-secretase%2520inhibitor%25202-%255B%25281R%2529-1-%255B%25284-chlorophenyl%2529%2520sulfonyl%255D%25282%252C%25205-difluorophenyl%2529%2520amino%255D%2520ethyl-5-fluorobenzenebutanoic%2520acid%2520%2528BMS-299897%2529%2520alleviates%2520A%25CE%25B21%25E2%2580%259342%2520seeding%2520and%2520short-term%2520memory%2520deficits%2520in%2520the%2520A%25CE%25B225%25E2%2580%259335%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D698%26spage%3D193%26epage%3D199%26doi%3D10.1016%2Fj.ejphar.2012.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref98"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref98'); return false;" data-citation="" class="refNumLink">98</a></strong><div class="NLM_citation" id="cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid β 25–35-induced toxicity in mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnpp.2008.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=19052542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFagurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1552-1566&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=T.+Alkamauthor=A.+Nittaauthor=K.+Yamadaauthor=T.+Nabeshimaauthor=A.+Vamvakidesauthor=T.+Maurice&title=Antiamnesic+and+neuroprotective+effects+of+the+aminotetrahydrofuran+derivative+ANAVEX1-41+against+amyloid+%CE%B2+25%E2%80%9335-induced+toxicity+in+mice&doi=10.1038%2Fnpp.2008.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid β25-35-Induced Toxicity in Mice</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Alkam, Tursun; Nitta, Atsumi; Yamada, Kiyofumi; Nabeshima, Toshitaka; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1552-1566</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The antiamnesic and neuroprotective activities of the new aminotetrahydrofuran deriv. tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride (ANAVEX1-41), a nonselective muscarinic receptor ligand and σ1 protein activator, were examd. in mice injected intracerebroventricularly with amyloid β25-35 (Aβ25-35) peptide (9 nmol).  Aβ25-35 impaired significantly spontaneous alternation performance, a spatial working memory, and passive avoidance response.  When ANAVEX1-41 (1-1000 μg/kg i.p.) was administered 7 days after Aβ25-35, ie, 20 min before the behavioral tests, it significantly reversed the Aβ25-35-induced deficits, the most active doses being in the 3-100 μg/kg range.  When the compd. was preadministered 20 min before Aβ25-35, ie, 7 days before the tests, it prevented the learning impairments at 30-100 μg/kg.  Morphol. anal. of corticolimbic structures showed that Aβ25-35 induced a significant cell loss in the CA1 pyramidal cell layer of the hippocampus that was prevented by ANAVEX1-41 (100 μg/kg).  Increased no. of glial fibrillary acidic protein immunopos. cells in the retrosplenial cortex or throughout the hippocampus revealed an Aβ25-35-induced inflammation that was prevented by ANAVEX1-41.  The drug also prevented the parameters of Aβ25-35-induced oxidative stress measured in hippocampus exts., ie, the increases in lipid peroxidn. and protein nitration.  ANAVEX1-41, however, failed to prevent Aβ25-35-induced caspase-9 expression.  The compd. also blocked the Aβ25-35-induced caspase-3 expression, a marker of apoptosis.  Both the muscarinic antagonist scopolamine and the σ1 protein inactivator BD1047 prevented the beneficial effects of ANAVEX1-41 (30 or 100 μg/kg) against Aβ25-35-induced learning impairments, suggesting that muscarinic and σ1 targets are involved in the drug effect.  A synergic effect could indeed account for the very low active doses measured in vivo.  These data outline the therapeutic potential of ANAVEX1-41 as a neuroprotective agent in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0XFhD0QttH7Vg90H21EOLACvtfcHk0liZu2Zi-IorWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFagurs%253D&md5=6ee3c75c6065592454fe6b00ebc5bdab</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.212%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DAlkam%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DNabeshima%26aufirst%3DT.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAntiamnesic%2520and%2520neuroprotective%2520effects%2520of%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX1-41%2520against%2520amyloid%2520%25CE%25B2%252025%25E2%2580%259335-induced%2520toxicity%2520in%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1552%26epage%3D1566%26doi%3D10.1038%2Fnpp.2008.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref99"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref99'); return false;" data-citation="" class="refNumLink">99</a></strong><div class="NLM_citation" id="cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma<sub>1</sub> (σ<sub>1</sub>) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1177/0269881110379286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1177%2F0269881110379286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=20829307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1101-1117&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=A.+Vamvakidesauthor=T.+Maurice&title=Anti-amnesic+and+neuroprotective+potentials+of+the+mixed+muscarinic+receptor%2Fsigma1+%28%CF%831%29+ligand+ANAVEX2-73%2C+a+novel+aminotetrahydrofuran+derivative&doi=10.1177%2F0269881110379286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1101-1117</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) binds to muscarinic acetylcholine and sigma1 (σ1) receptors with affinities in the low micromolar range.  We characterized its anti-amnesic and neuroprotective potentials in pharmacol. and pathol. amnesia models.  Spatial working memory was evaluated using spontaneous alternation in the Y-maze and non-spatial memory using passive avoidance procedures.  ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments.  ANAVEX2-73 (300 μg/kg) also reversed the learning deficits in mice injected with Aβ25-35 peptide, a non-transgenic Alzheimer's disease model.  When the drug was injected simultaneously with Aβ25-35, 7 days before the tests, it blocked the appearance of learning impairments.  This protective activity was confirmed since ANAVEX2-73 blocked the Aβ25-35-induced oxidative stress in the hippocampus.  This effect was differentially sensitive to the muscarinic receptor antagonist scopolamine or the σ1 protein antagonist BD1047, confirming the mixed muscarinic/σ1 pharmacol. action.  Finally, its unique demethyl metabolite, ANAVEX19-144, was also effective and ANAVEX2-73 presented a longer duration of action, effective 12 h before Aβ25-35, than its related compd. ANAVEX1-41.  The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ1 activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVEQ6V9EfObVg90H21EOLACvtfcHk0lh2tmcHMH3xkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF&md5=4a9ed81d07ba7a7e11b72385f60d941f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1177%2F0269881110379286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110379286%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAnti-amnesic%2520and%2520neuroprotective%2520potentials%2520of%2520the%2520mixed%2520muscarinic%2520receptor%252Fsigma1%2520%2528%25CF%25831%2529%2520ligand%2520ANAVEX2-73%252C%2520a%2520novel%2520aminotetrahydrofuran%2520derivative%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2011%26volume%3D25%26spage%3D1101%26epage%3D1117%26doi%3D10.1177%2F0269881110379286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="ref100"><div class="reference"><strong class="refLabel"><a href="javascript:void(0);" onclick="showRef(event, 'ref100'); return false;" data-citation="" class="refNumLink">100</a></strong><div class="NLM_citation" id="cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zussy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brureau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ixart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span> <span> </span><span class="NLM_article-title">Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2011.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ajpath.2011.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21703413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2011&pages=315-334&author=C.+Zussyauthor=A.+Brureauauthor=B.+Delairauthor=S.+Marchalauthor=E.+Kellerauthor=G.+Ixartauthor=G.+Naertauthor=J.+Meunierauthor=N.+Chevallierauthor=T.+Mauriceauthor=L.+Givalois&title=Time-course+and+regional+analyses+of+the+physiopathological+changes+induced+after+cerebral+injection+of+an+amyloid+%CE%B2+fragment+in+rats&doi=10.1016%2Fj.ajpath.2011.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats</span></div><div class="casAuthors">Zussy, Charleine; Brureau, Anthony; Delair, Brice; Marchal, Stephane; Keller, Emeline; Ixart, Guy; Naert, Gaelle; Meunier, Johann; Chevallier, Nathalie; Maurice, Tangui; Givalois, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">315-334</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative pathol. characterized by the presence of senile plaques and neurofibrillary tangles, accompanied by synaptic and neuronal loss.  The major component of senile plaques is an amyloid β protein (Aβ) formed by pathol. processing of the Aβ precursor protein.  We assessed the time-course and regional effects of a single intracerebroventricular injection of aggregated Aβ fragment 25-35 (Aβ25-35) in rats.  Using a combined biochem., behavioral, and morphol. approach, we analyzed the peptide effects after 1, 2, and 3 wk in the hippocampus, cortex, amygdala, and hypothalamus.  The scrambled Aβ25-35 peptide was used as neg. control.  The aggregated forms of Aβ peptides were first characterized using electron microscopy, IR spectroscopy, and Congo Red staining.  Intracerebroventricular injection of Aβ25-35 decreased body wt., induced short- and long-term memory impairments, increased endocrine stress, cerebral oxidative and cellular stress, neuroinflammation, and neuroprotective reactions, and modified endogenous amyloid processing, with specific time-course and regional responses.  Moreover, Aβ25-35, the presence of which was shown in the different brain structures and over 3 wk, provoked a rapid glial activation, acetylcholine homeostasis perturbation, and hippocampal morphol. alterations.  In conclusion, the acute intracerebroventricular Aβ25-35 injection induced substantial central modifications in rats, highly reminiscent of the human physiopathol., that could contribute to physiol. and cognitive deficits obsd. in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSrf9_FMhbsbVg90H21EOLACvtfcHk0lh2tmcHMH3xkg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVKks7g%253D&md5=a73269e690a9e6b92f2e8ccd4513830a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2011.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2011.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DZussy%26aufirst%3DC.%26aulast%3DBrureau%26aufirst%3DA.%26aulast%3DDelair%26aufirst%3DB.%26aulast%3DMarchal%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DIxart%26aufirst%3DG.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DGivalois%26aufirst%3DL.%26atitle%3DTime-course%2520and%2520regional%2520analyses%2520of%2520the%2520physiopathological%2520changes%2520induced%2520after%2520cerebral%2520injection%2520of%2520an%2520amyloid%2520%25CE%25B2%2520fragment%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D179%26spage%3D315%26epage%3D334%26doi%3D10.1016%2Fj.ajpath.2011.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></div><script data-cfasync="false" src="/cdn-cgi/scripts/5c5dd728/cloudflare-static/email-decode.min.js"></script><script type="text/javascript">window.refViewer={'ref1':['cit1'],'ref2':['cit2'],'ref3':['cit3'],'ref4':['cit4'],'ref5':['cit5'],'ref6':['cit6'],'ref7':['cit7'],'ref8':['cit8'],'ref9':['cit9'],'ref10':['cit10'],'ref11':['cit11'],'ref12':['cit12'],'ref13':['cit13'],'ref14':['cit14'],'ref15':['cit15'],'ref16':['cit16'],'ref17':['cit17'],'ref18':['cit18'],'ref19':['cit19'],'ref20':['cit20'],'ref21':['cit21'],'ref22':['cit22'],'ref23':['cit23'],'ref24':['cit24'],'ref25':['cit25'],'ref26':['cit26'],'ref27':['cit27'],'ref28':['cit28'],'ref29':['cit29'],'ref30':['cit30'],'ref31':['cit31'],'ref32':['cit32'],'ref33':['cit33'],'ref34':['cit34'],'ref35':['cit35'],'ref36':['cit36'],'ref37':['cit37'],'ref38':['cit38'],'ref39':['cit39'],'ref40':['cit40'],'ref41':['cit41'],'ref42':['cit42'],'ref43':['cit43'],'ref44':['cit44'],'ref45':['cit45'],'ref46':['cit46'],'ref47':['cit47'],'ref48':['cit48'],'ref49':['cit49'],'ref50':['cit50'],'ref51':['cit51'],'ref52':['cit52'],'ref53':['cit53'],'ref54':['cit54'],'ref55':['cit55'],'ref56':['cit56'],'ref57':['cit57'],'ref58':['cit58'],'ref59':['cit59'],'ref60':['cit60'],'ref61':['cit61'],'ref62':['cit62'],'ref63':['cit63'],'ref64':['cit64'],'ref65':['cit65'],'ref66':['cit66'],'ref67':['cit67'],'ref68':['cit68'],'ref69':['cit69'],'ref70':['cit70'],'ref71':['cit71'],'ref72':['cit72'],'ref73':['cit73'],'ref74':['cit74'],'ref75':['cit75'],'ref76':['cit76'],'ref77':['cit77'],'ref78':['cit78'],'ref79':['cit79'],'ref80':['cit80'],'ref81':['cit81'],'ref82':['cit82'],'ref83':['cit83'],'ref84':['cit84'],'ref85':['cit85'],'ref86':['cit86'],'ref87':['cit87'],'ref88':['cit88'],'ref89':['cit89'],'ref90':['cit90'],'ref91':['cit91'],'ref92':['cit92'],'ref93':['cit93'],'ref94':['cit94'],'ref95':['cit95'],'ref96':['cit96'],'ref97':['cit97'],'ref98':['cit98'],'ref99':['cit99'],'ref100':['cit100']}</script><div class="articleCitedByDropzone" data-pb-dropzone="articleCitedByDropzone"><div class="cited-by"><div class="article_content-header cited-content_header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="citeThis">Cited By</h2></div></div></div><hr/></hr><div class="cited-by__content"><div class="cited-content hlFld-Abstract"><p>This article is cited by 17 publications.</p><ol class="cited-content_cbyCitation"><li><span class="cited-content_cbyCitation_article-contributors">Matthias Scheiner, Matthias Hoffmann, Feng He, Eleonora Poeta, Arnaud Chatonnet, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Selective Pseudo-irreversible Butyrylcholinesterase Inhibitors Transferring Antioxidant Moieties to the Enzyme Show Pronounced Neuroprotective Efficacy In Vitro and In Vivo in an Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (13)
                                     , 9302-9320. <a href="https://doi.org/10.1021/acs.jmedchem.1c00534" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.1c00534</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.1c00534&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.1c00534%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DSelective%252BPseudo-irreversible%252BButyrylcholinesterase%252BInhibitors%252BTransferring%252BAntioxidant%252BMoieties%252Bto%252Bthe%252BEnzyme%252BShow%252BPronounced%252BNeuroprotective%252BEfficacy%252BIn%252BVitro%252Band%252BIn%252BVivo%252Bin%252Ban%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DScheiner%26aufirst%3DMatthias%26date%3D2021%26date%3D2021%26date%3D2021%26date%3D23032021%26date%3D21062021%26volume%3D64%26issue%3D13%26spage%3D9302%26epage%3D9320" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Feng He, C. James Chou, Matthias Scheiner, Eleonora Poeta, Natalia Yuan Chen, Sandra Gunesch, Matthias Hoffmann, Christoph Sotriffer, Barbara Monti, Tangui Maurice, <span class="NLM_string-name hlFld-ContribAuthor">Michael Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Melatonin- and Ferulic Acid-Based HDAC6 Selective Inhibitors Exhibit Pronounced Immunomodulatory Effects In Vitro and Neuroprotective Effects in a Pharmacological Alzheimer’s Disease Mouse Model. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (7)
                                     , 3794-3812. <a href="https://doi.org/10.1021/acs.jmedchem.0c01940" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01940</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01940&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01940%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DMelatonin-%252Band%252BFerulic%252BAcid-Based%252BHDAC6%252BSelective%252BInhibitors%252BExhibit%252BPronounced%252BImmunomodulatory%252BEffects%252BIn%252BVitro%252Band%252BNeuroprotective%252BEffects%252Bin%252Ba%252BPharmacological%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BMouse%252BModel%26aulast%3DHe%26aufirst%3DFeng%26date%3D2021%26date%3D2021%26date%3D2020%26date%3D09112020%26date%3D26032021%26volume%3D64%26issue%3D7%26spage%3D3794%26epage%3D3812" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Elisabet Viayna, Nicolas Coquelle, Monika Cieslikiewicz-Bouet, Pedro Cisternas, Carolina A. Oliva, Elena Sánchez-López, Miren Ettcheto, Manuela Bartolini, Angela De Simone, Mattia Ricchini, Marisa Rendina, Mégane Pons, Omidreza Firuzi, Belén Pérez, Luciano Saso, Vincenza Andrisano, Florian Nachon, Xavier Brazzolotto, Maria Luisa García, Antoni Camins, Israel Silman, Ludovic Jean, Nibaldo C. Inestrosa, Jacques-Philippe Colletier, Pierre-Yves Renard, <span class="NLM_string-name hlFld-ContribAuthor">Diego Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of a Potent Dual Inhibitor of Acetylcholinesterase and Butyrylcholinesterase with Antioxidant Activity that Alleviates Alzheimer-like Pathology in Old APP/PS1 Mice. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>64 </em>
                                    (1)
                                     , 812-839. <a href="https://doi.org/10.1021/acs.jmedchem.0c01775" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01775</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01775&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01775%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Ba%252BPotent%252BDual%252BInhibitor%252Bof%252BAcetylcholinesterase%252Band%252BButyrylcholinesterase%252Bwith%252BAntioxidant%252BActivity%252Bthat%252BAlleviates%252BAlzheimer-like%252BPathology%252Bin%252BOld%252BAPP%25252FPS1%252BMice%26aulast%3DViayna%26aufirst%3DElisabet%26date%3D2021%26date%3D2020%26date%3D2020%26date%3D09102020%26date%3D28122020%26volume%3D64%26issue%3D1%26spage%3D812%26epage%3D839" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">Giuseppe Felice Mangiatordi, Francesca Intranuovo, Pietro Delre, Francesca Serena Abatematteo, Carmen Abate, Mauro Niso, Teresa Maria Creanza, Nicola Ancona, Angela Stefanachi, <span class="NLM_string-name hlFld-ContribAuthor">Marialessandra Contino</span>. </span><span class="cited-content_cbyCitation_article-title">Cannabinoid Receptor Subtype 2 (CB2R) in a Multitarget Approach: Perspective of an Innovative Strategy in Cancer and Neurodegeneration. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (23)
                                     , 14448-14469. <a href="https://doi.org/10.1021/acs.jmedchem.0c01357" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c01357</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c01357&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c01357%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCannabinoid%252BReceptor%252BSubtype%252B2%252B%252528CB2R%252529%252Bin%252Ba%252BMultitarget%252BApproach%25253A%252BPerspective%252Bof%252Ban%252BInnovative%252BStrategy%252Bin%252BCancer%252Band%252BNeurodegeneration%26aulast%3DMangiatordi%26aufirst%3DGiuseppe%2BFelice%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D03082020%26date%3D23102020%26volume%3D63%26issue%3D23%26spage%3D14448%26epage%3D14469" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors">F. Javier Pérez-Areales, María Garrido, Ester Aso, Manuela Bartolini, Angela De Simone, Alba Espargaró, Tiziana Ginex, Raimon Sabate, Belén Pérez, Vincenza Andrisano, Dolors Puigoriol-Illamola, Mercè Pallàs, F. Javier Luque, María Isabel Loza, José Brea, Isidro Ferrer, Francisco Ciruela, Angel Messeguer, <span class="NLM_string-name hlFld-ContribAuthor">Diego Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Centrally Active Multitarget Anti-Alzheimer Agents Derived from the Antioxidant Lead CR-6. </span><span class="cited-content_cbyCitation_journal-name">Journal of Medicinal Chemistry</span><span> <strong>2020,</strong> <em>63 </em>
                                    (17)
                                     , 9360-9390. <a href="https://doi.org/10.1021/acs.jmedchem.0c00528" title="DOI URL">https://doi.org/10.1021/acs.jmedchem.0c00528</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1021/acs.jmedchem.0c00528&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1021%2Facs.jmedchem.0c00528%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Medicinal%2520Chemistry%26atitle%3DCentrally%252BActive%252BMultitarget%252BAnti-Alzheimer%252BAgents%252BDerived%252Bfrom%252Bthe%252BAntioxidant%252BLead%252BCR-6%26aulast%3DP%25C3%25A9rez-Areales%26aufirst%3DF.%2BJavier%26date%3D2020%26date%3D2020%26date%3D2020%26date%3D31032020%26date%3D11082020%26date%3D24072020%26volume%3D63%26issue%3D17%26spage%3D9360%26epage%3D9390" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shulin  Wan</span>, <span class="hlFld-ContribAuthor ">Shuai  Xia</span>, <span class="hlFld-ContribAuthor ">Jerry  Medford</span>, <span class="hlFld-ContribAuthor ">Emma  Durocher</span>, <span class="hlFld-ContribAuthor ">Tessa E.  Steenwinkel</span>, <span class="hlFld-ContribAuthor ">Lexi  Rule</span>, <span class="hlFld-ContribAuthor ">Yibin  Zhang</span>, <span class="hlFld-ContribAuthor ">Rudy L.  Luck</span>, <span class="hlFld-ContribAuthor ">Thomas  Werner</span>, <span class="hlFld-ContribAuthor ">Haiying  Liu</span>. </span><span class="cited-content_cbyCitation_article-title">A ratiometric near-infrared fluorescent probe based on a novel reactive cyanine platform for mitochondrial pH detection. </span><span class="cited-content_cbyCitation_journal-name">Journal of Materials Chemistry B</span><span> <strong>2021,</strong> <em>9 </em>
                                    (25)
                                     , 5150-5161. <a href="https://doi.org/10.1039/D1TB00643F" title="DOI URL">https://doi.org/10.1039/D1TB00643F</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1039/D1TB00643F&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1039%2FD1TB00643F%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Materials%2520Chemistry%2520B%26atitle%3DA%252Bratiometric%252Bnear-infrared%252Bfluorescent%252Bprobe%252Bbased%252Bon%252Ba%252Bnovel%252Breactive%252Bcyanine%252Bplatform%252Bfor%252Bmitochondrial%252BpH%252Bdetection%26aulast%3DWan%26aufirst%3DShulin%26date%3D2021%26date%3D2021%26volume%3D9%26issue%3D25%26spage%3D5150%26epage%3D5161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Giulia  Abate</span>, <span class="hlFld-ContribAuthor ">Daniela  Uberti</span>, <span class="hlFld-ContribAuthor ">Simone  Tambaro</span>. </span><span class="cited-content_cbyCitation_article-title">Potential and Limits of Cannabinoids in Alzheimer’s Disease Therapy. </span><span class="cited-content_cbyCitation_journal-name">Biology</span><span> <strong>2021,</strong> <em>10 </em>
                                    (6)
                                     , 542. <a href="https://doi.org/10.3390/biology10060542" title="DOI URL">https://doi.org/10.3390/biology10060542</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/biology10060542&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fbiology10060542%26sid%3Dliteratum%253Aachs%26jtitle%3DBiology%26atitle%3DPotential%252Band%252BLimits%252Bof%252BCannabinoids%252Bin%252BAlzheimer%2525E2%252580%252599s%252BDisease%252BTherapy%26aulast%3DAbate%26aufirst%3DGiulia%26date%3D2021%26date%3D2021%26volume%3D10%26issue%3D6%26spage%3D542" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Anna  Pasieka</span>, <span class="hlFld-ContribAuthor ">Dawid  Panek</span>, <span class="hlFld-ContribAuthor ">Jakub  Jończyk</span>, <span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Natalia  Szałaj</span>, <span class="hlFld-ContribAuthor ">Gniewomir  Latacz</span>, <span class="hlFld-ContribAuthor ">Julia  Tabor</span>, <span class="hlFld-ContribAuthor ">Eva  Mezeiova</span>, <span class="hlFld-ContribAuthor ">Fabien  Chantegreil</span>, <span class="hlFld-ContribAuthor ">José  Dias</span>, <span class="hlFld-ContribAuthor ">Damijan  Knez</span>, <span class="hlFld-ContribAuthor ">Junfeng  Lu</span>, <span class="hlFld-ContribAuthor ">Rongbiao  Pi</span>, <span class="hlFld-ContribAuthor ">Jan  Korabecny</span>, <span class="hlFld-ContribAuthor ">Xavier  Brazzolotto</span>, <span class="hlFld-ContribAuthor ">Stanislav  Gobec</span>, <span class="hlFld-ContribAuthor ">Georg  Höfner</span>, <span class="hlFld-ContribAuthor ">Klaus  Wanner</span>, <span class="hlFld-ContribAuthor ">Anna  Więckowska</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>. </span><span class="cited-content_cbyCitation_article-title">Discovery of multifunctional anti-Alzheimer’s agents with a unique mechanism of action including inhibition of the enzyme butyrylcholinesterase and γ-aminobutyric acid transporters. </span><span class="cited-content_cbyCitation_journal-name">European Journal of Medicinal Chemistry</span><span> <strong>2021,</strong> <em>218 </em>, 113397. <a href="https://doi.org/10.1016/j.ejmech.2021.113397" title="DOI URL">https://doi.org/10.1016/j.ejmech.2021.113397</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.ejmech.2021.113397&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.ejmech.2021.113397%26sid%3Dliteratum%253Aachs%26jtitle%3DEuropean%2520Journal%2520of%2520Medicinal%2520Chemistry%26atitle%3DDiscovery%252Bof%252Bmultifunctional%252Banti-Alzheimer%2525E2%252580%252599s%252Bagents%252Bwith%252Ba%252Bunique%252Bmechanism%252Bof%252Baction%252Bincluding%252Binhibition%252Bof%252Bthe%252Benzyme%252Bbutyrylcholinesterase%252Band%252B%2525CE%2525B3-aminobutyric%252Bacid%252Btransporters%26aulast%3DPasieka%26aufirst%3DAnna%26date%3D2021%26volume%3D218%26spage%3D113397" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Hofmann</span>, <span class="hlFld-ContribAuthor ">Tiziana  Ginex</span>, <span class="hlFld-ContribAuthor ">Alba  Espargaró</span>, <span class="hlFld-ContribAuthor ">Matthias  Scheiner</span>, <span class="hlFld-ContribAuthor ">Sandra  Gunesch</span>, <span class="hlFld-ContribAuthor ">Marc  Aragó</span>, <span class="hlFld-ContribAuthor ">Christian  Stigloher</span>, <span class="hlFld-ContribAuthor ">Raimon  Sabaté</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Azobioisosteres of Curcumin with Pronounced Activity against Amyloid Aggregation, Intracellular Oxidative Stress, and Neuroinflammation. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2021,</strong> <em>27 </em>
                                    (19)
                                     , 6015-6027. <a href="https://doi.org/10.1002/chem.202005263" title="DOI URL">https://doi.org/10.1002/chem.202005263</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202005263&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202005263%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DAzobioisosteres%252Bof%252BCurcumin%252Bwith%252BPronounced%252BActivity%252Bagainst%252BAmyloid%252BAggregation%25252C%252BIntracellular%252BOxidative%252BStress%25252C%252Band%252BNeuroinflammation%26aulast%3DHofmann%26aufirst%3DJulian%26date%3D2021%26date%3D2021%26volume%3D27%26issue%3D19%26spage%3D6015%26epage%3D6027" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Shuaishuai  Xing</span>, <span class="hlFld-ContribAuthor ">Qi  Li</span>, <span class="hlFld-ContribAuthor ">Baichen  Xiong</span>, <span class="hlFld-ContribAuthor ">Yao  Chen</span>, <span class="hlFld-ContribAuthor ">Feng  Feng</span>, <span class="hlFld-ContribAuthor ">Wenyuan  Liu</span>, <span class="hlFld-ContribAuthor ">Haopeng  Sun</span>. </span><span class="cited-content_cbyCitation_article-title">Structure and therapeutic uses of butyrylcholinesterase: Application in detoxification, Alzheimer's disease, and fat metabolism. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2021,</strong> <em>41 </em>
                                    (2)
                                     , 858-901. <a href="https://doi.org/10.1002/med.21745" title="DOI URL">https://doi.org/10.1002/med.21745</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21745&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21745%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DStructure%252Band%252Btherapeutic%252Buses%252Bof%252Bbutyrylcholinesterase%25253A%252BApplication%252Bin%252Bdetoxification%25252C%252BAlzheimer%252527s%252Bdisease%25252C%252Band%252Bfat%252Bmetabolism%26aulast%3DXing%26aufirst%3DShuaishuai%26date%3D2021%26date%3D2020%26volume%3D41%26issue%3D2%26spage%3D858%26epage%3D901" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Matthias  Scheiner</span>, <span class="hlFld-ContribAuthor ">Alexandra  Sink</span>, <span class="hlFld-ContribAuthor ">Philipp  Spatz</span>, <span class="hlFld-ContribAuthor ">Erik  Endres</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Photopharmacology on Acetylcholinesterase: Novel Photoswitchable Inhibitors with Improved Pharmacological Profiles. </span><span class="cited-content_cbyCitation_journal-name">ChemPhotoChem</span><span> <strong>2021,</strong> <em>5 </em>
                                    (2)
                                     , 149-159. <a href="https://doi.org/10.1002/cptc.202000119" title="DOI URL">https://doi.org/10.1002/cptc.202000119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/cptc.202000119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fcptc.202000119%26sid%3Dliteratum%253Aachs%26jtitle%3DChemPhotoChem%26atitle%3DPhotopharmacology%252Bon%252BAcetylcholinesterase%25253A%252BNovel%252BPhotoswitchable%252BInhibitors%252Bwith%252BImproved%252BPharmacological%252BProfiles%26aulast%3DScheiner%26aufirst%3DMatthias%26date%3D2021%26date%3D2020%26volume%3D5%26issue%3D2%26spage%3D149%26epage%3D159" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Hongguang  Ma</span>, <span class="hlFld-ContribAuthor ">Boshi  Huang</span>, <span class="hlFld-ContribAuthor ">Yan  Zhang</span>. </span><span class="cited-content_cbyCitation_article-title">Recent advances in multitarget-directed ligands targeting G-protein-coupled receptors. </span><span class="cited-content_cbyCitation_journal-name">Drug Discovery Today</span><span> <strong>2020,</strong> <em>25 </em>
                                    (9)
                                     , 1682-1692. <a href="https://doi.org/10.1016/j.drudis.2020.07.004" title="DOI URL">https://doi.org/10.1016/j.drudis.2020.07.004</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1016/j.drudis.2020.07.004&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1016%2Fj.drudis.2020.07.004%26sid%3Dliteratum%253Aachs%26jtitle%3DDrug%2520Discovery%2520Today%26atitle%3DRecent%252Badvances%252Bin%252Bmultitarget-directed%252Bligands%252Btargeting%252BG-protein-coupled%252Breceptors%26aulast%3DMa%26aufirst%3DHongguang%26date%3D2020%26volume%3D25%26issue%3D9%26spage%3D1682%26epage%3D1692" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Vijay  Kumar</span>, <span class="hlFld-ContribAuthor ">Bhupinder  Kumar</span>, <span class="hlFld-ContribAuthor ">Ashish  Ranjan Dwivedi</span>, <span class="hlFld-ContribAuthor ">Devashish  Mehta</span>, <span class="hlFld-ContribAuthor ">Naveen  Kumar</span>, <span class="hlFld-ContribAuthor ">Beenu  Bajaj</span>, <span class="hlFld-ContribAuthor ">Tania  Arora</span>, <span class="hlFld-ContribAuthor ">Vikash  Prashar</span>, <span class="hlFld-ContribAuthor ">Jyoti  Parkash</span>, <span class="hlFld-ContribAuthor ">Vinod  Kumar</span>. </span><span class="cited-content_cbyCitation_article-title">Design, Synthesis and Evaluation of
              O
              ‐Pentyne Substituted Diphenylpyrimidines as Monoamine Oxidase and Acetylcholinesterase Inhibitors. </span><span class="cited-content_cbyCitation_journal-name">ChemistrySelect</span><span> <strong>2020,</strong> <em>5 </em>
                                    (27)
                                     , 8021-8032. <a href="https://doi.org/10.1002/slct.202002425" title="DOI URL">https://doi.org/10.1002/slct.202002425</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/slct.202002425&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fslct.202002425%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistrySelect%26atitle%3DDesign%25252C%252BSynthesis%252Band%252BEvaluation%252Bof%252BO%252B%2525E2%252580%252590Pentyne%252BSubstituted%252BDiphenylpyrimidines%252Bas%252BMonoamine%252BOxidase%252Band%252BAcetylcholinesterase%252BInhibitors%26aulast%3DKumar%26aufirst%3DVijay%26date%3D2020%26date%3D2020%26volume%3D5%26issue%3D27%26spage%3D8021%26epage%3D8032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Claudia  Albertini</span>, <span class="hlFld-ContribAuthor ">Alessandra  Salerno</span>, <span class="hlFld-ContribAuthor ">Pedro  Sena Murteira Pinheiro</span>, <span class="hlFld-ContribAuthor ">Maria L.  Bolognesi</span>. </span><span class="cited-content_cbyCitation_article-title">From combinations to multitarget‐directed ligands: A continuum in Alzheimer's disease polypharmacology. </span><span class="cited-content_cbyCitation_journal-name">Medicinal Research Reviews</span><span> <strong>2020,</strong> <em>10 </em><a href="https://doi.org/10.1002/med.21699" title="DOI URL">https://doi.org/10.1002/med.21699</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/med.21699&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fmed.21699%26sid%3Dliteratum%253Aachs%26jtitle%3DMedicinal%2520Research%2520Reviews%26atitle%3DFrom%252Bcombinations%252Bto%252Bmultitarget%2525E2%252580%252590directed%252Bligands%25253A%252BA%252Bcontinuum%252Bin%252BAlzheimer%252527s%252Bdisease%252Bpolypharmacology%26aulast%3DAlbertini%26aufirst%3DClaudia%26date%3D2020%26date%3D2020%26volume%3D10" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Julian  Hofmann</span>, <span class="hlFld-ContribAuthor ">Shaimaa  Fayez</span>, <span class="hlFld-ContribAuthor ">Matthias  Scheiner</span>, <span class="hlFld-ContribAuthor ">Matthias  Hoffmann</span>, <span class="hlFld-ContribAuthor ">Sabrina  Oerter</span>, <span class="hlFld-ContribAuthor ">Antje  Appelt‐Menzel</span>, <span class="hlFld-ContribAuthor ">Pamela  Maher</span>, <span class="hlFld-ContribAuthor ">Tangui  Maurice</span>, <span class="hlFld-ContribAuthor ">Gerhard  Bringmann</span>, <span class="hlFld-ContribAuthor ">Michael  Decker</span>. </span><span class="cited-content_cbyCitation_article-title">Sterubin: Enantioresolution and Configurational Stability, Enantiomeric Purity in Nature, and Neuroprotective Activity in Vitro and in Vivo. </span><span class="cited-content_cbyCitation_journal-name">Chemistry – A European Journal</span><span> <strong>2020,</strong> <em>26 </em>
                                    (32)
                                     , 7299-7308. <a href="https://doi.org/10.1002/chem.202001264" title="DOI URL">https://doi.org/10.1002/chem.202001264</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1002/chem.202001264&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1002%2Fchem.202001264%26sid%3Dliteratum%253Aachs%26jtitle%3DChemistry%2520%25E2%2580%2593%2520A%2520European%2520Journal%26atitle%3DSterubin%25253A%252BEnantioresolution%252Band%252BConfigurational%252BStability%25252C%252BEnantiomeric%252BPurity%252Bin%252BNature%25252C%252Band%252BNeuroprotective%252BActivity%252Bin%252BVitro%252Band%252Bin%252BVivo%26aulast%3DHofmann%26aufirst%3DJulian%26date%3D2020%26date%3D2020%26volume%3D26%26issue%3D32%26spage%3D7299%26epage%3D7308" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Jean Jacques  Vanden Eynde</span>, <span class="hlFld-ContribAuthor ">Arduino A.  Mangoni</span>, <span class="hlFld-ContribAuthor ">Jarkko  Rautio</span>, <span class="hlFld-ContribAuthor ">Jérôme  Leprince</span>, <span class="hlFld-ContribAuthor ">Yasu-Taka  Azuma</span>, <span class="hlFld-ContribAuthor ">Alfonso T.  García-Sosa</span>, <span class="hlFld-ContribAuthor ">Christopher  Hulme</span>, <span class="hlFld-ContribAuthor ">Josef  Jampilek</span>, <span class="hlFld-ContribAuthor ">Rafik  Karaman</span>, <span class="hlFld-ContribAuthor ">Wei  Li</span>, <span class="hlFld-ContribAuthor ">Paula A. C.  Gomes</span>, <span class="hlFld-ContribAuthor ">Dimitra  Hadjipavlou-Litina</span>, <span class="hlFld-ContribAuthor ">Raffaele  Capasso</span>, <span class="hlFld-ContribAuthor ">Athina  Geronikaki</span>, <span class="hlFld-ContribAuthor ">Laura  Cerchia</span>, <span class="hlFld-ContribAuthor ">Jean-Marc  Sabatier</span>, <span class="hlFld-ContribAuthor ">Rino  Ragno</span>, <span class="hlFld-ContribAuthor ">Tiziano  Tuccinardi</span>, <span class="hlFld-ContribAuthor ">Andrea  Trabocchi</span>, <span class="hlFld-ContribAuthor ">Jean-Yves  Winum</span>, <span class="hlFld-ContribAuthor ">F. Javier  Luque</span>, <span class="hlFld-ContribAuthor ">Katalin  Prokai-Tatrai</span>, <span class="hlFld-ContribAuthor ">Mariana  Spetea</span>, <span class="hlFld-ContribAuthor ">Michael  Gütschow</span>, <span class="hlFld-ContribAuthor ">Ivan  Kosalec</span>, <span class="hlFld-ContribAuthor ">Catherine  Guillou</span>, <span class="hlFld-ContribAuthor ">M. Helena  Vasconcelos</span>, <span class="hlFld-ContribAuthor ">George  Kokotos</span>, <span class="hlFld-ContribAuthor ">Giulio  Rastelli</span>, <span class="hlFld-ContribAuthor ">Maria Emília  de Sousa</span>, <span class="hlFld-ContribAuthor ">Clementina  Manera</span>, <span class="hlFld-ContribAuthor ">Sandra  Gemma</span>, <span class="hlFld-ContribAuthor ">Stefano  Mangani</span>, <span class="hlFld-ContribAuthor ">Carlo  Siciliano</span>, <span class="hlFld-ContribAuthor ">Stefania  Galdiero</span>, <span class="hlFld-ContribAuthor ">Hong  Liu</span>, <span class="hlFld-ContribAuthor ">Peter J. H.  Scott</span>, <span class="hlFld-ContribAuthor ">Cristóbal  de los Ríos</span>, <span class="hlFld-ContribAuthor ">Luigi A.  Agrofoglio</span>, <span class="hlFld-ContribAuthor ">Simona  Collina</span>, <span class="hlFld-ContribAuthor ">Rita C.  Guedes</span>, <span class="hlFld-ContribAuthor ">Diego  Muñoz-Torrero</span>. </span><span class="cited-content_cbyCitation_article-title">Breakthroughs in Medicinal Chemistry: New Targets and Mechanisms, New Drugs, New Hopes–6. </span><span class="cited-content_cbyCitation_journal-name">Molecules</span><span> <strong>2020,</strong> <em>25 </em>
                                    (1)
                                     , 119. <a href="https://doi.org/10.3390/molecules25010119" title="DOI URL">https://doi.org/10.3390/molecules25010119</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.3390/molecules25010119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.3390%2Fmolecules25010119%26sid%3Dliteratum%253Aachs%26jtitle%3DMolecules%26atitle%3DBreakthroughs%252Bin%252BMedicinal%252BChemistry%25253A%252BNew%252BTargets%252Band%252BMechanisms%25252C%252BNew%252BDrugs%25252C%252BNew%252BHopes%2525E2%252580%2525936%26aulast%3DVanden%2BEynde%26aufirst%3DJean%2BJacques%26date%3D2020%26date%3D2019%26volume%3D25%26issue%3D1%26spage%3D119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li><li><span class="cited-content_cbyCitation_article-contributors"><span class="hlFld-ContribAuthor ">Natalia  Szałaj</span>, <span class="hlFld-ContribAuthor ">Justyna  Godyń</span>, <span class="hlFld-ContribAuthor ">Jakub  Jończyk</span>, <span class="hlFld-ContribAuthor ">Anna  Pasieka</span>, <span class="hlFld-ContribAuthor ">Dawid  Panek</span>, <span class="hlFld-ContribAuthor ">Tomasz  Wichur</span>, <span class="hlFld-ContribAuthor ">Krzysztof  Więckowski</span>, <span class="hlFld-ContribAuthor ">Paula  Zaręba</span>, <span class="hlFld-ContribAuthor ">Marek  Bajda</span>, <span class="hlFld-ContribAuthor ">Anja  Pislar</span>, <span class="hlFld-ContribAuthor ">Barbara  Malawska</span>, <span class="hlFld-ContribAuthor ">Raimon  Sabate</span>, <span class="hlFld-ContribAuthor ">Anna  Więckowska</span>. </span><span class="cited-content_cbyCitation_article-title">Multidirectional
              in vitro
              and
              in cellulo
              studies as a tool for identification of multi-target-directed ligands aiming at symptoms and causes of Alzheimer’s disease. </span><span class="cited-content_cbyCitation_journal-name">Journal of Enzyme Inhibition and Medicinal Chemistry</span><span> <strong>2020,</strong> <em>35 </em>
                                    (1)
                                     , 1944-1952. <a href="https://doi.org/10.1080/14756366.2020.1835882" title="DOI URL">https://doi.org/10.1080/14756366.2020.1835882</a></span><span class="deliverFormatsLinks"><a href="/servlet/linkout?suffix=&amp;dbid=16384&amp;doi=10.1080/14756366.2020.1835882&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dcitedby%26id%3Ddoi%3A10.1080%2F14756366.2020.1835882%26sid%3Dliteratum%253Aachs%26jtitle%3DJournal%2520of%2520Enzyme%2520Inhibition%2520and%2520Medicinal%2520Chemistry%26atitle%3DMultidirectional%252Bin%2525C2%2525A0vitro%252Band%252Bin%252Bcellulo%252Bstudies%252Bas%252Ba%252Btool%252Bfor%252Bidentification%252Bof%252Bmulti-target-directed%252Bligands%252Baiming%252Bat%252Bsymptoms%252Band%252Bcauses%252Bof%252BAlzheimer%2525E2%252580%252599s%252Bdisease%26aulast%3DSza%25C5%2582aj%26aufirst%3DNatalia%26date%3D2020%26date%3D2020%26volume%3D35%26issue%3D1%26spage%3D1944%26epage%3D1952" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></span></li></ol></div></div></div></div></div><div class="article_content-right" id="article_content-right" tabindex="0"><div class="tab tab--flex"><div class="tab__close"><i class="icon-close" tabindex="0" aria-label="close the sidebar."></i></div><ul role="tablist" class="rlist tab__nav"><li role="presentation" class="active"><a id="pane-m1con" href="#pane-m1" aria-controls="pane-m1" role="tab" data-toggle="tab" title="Figures" aria-selected="true" class="active empty" aria-label="Figures"><i class="icon-image"></i><span>Figures</span></a></li><li role="presentation"><a id="pane-m2con" href="#pane-m2" aria-controls="pane-m2" role="tab" data-toggle="tab" title="References" aria-selected="false" class="empty"><i class="icon-link"></i><span>References</span></a></li><li role="presentation"><a id="pane-m3con" href="#pane-m3" aria-controls="pane-m3" role="tab" data-toggle="tab" title="Support Info" aria-selected="false" class="empty tab__nav-suppInfo"><i class="icon-supporting-info"></i><span>Support Info</span></a></li></ul><div class="paneContainer"><ul class="rlist tab__content"><li id="pane-m1" aria-labelledby="pane-m1" class="tab__pane tab__pane-figures active empty"><figure data-id="_i1" data-index="0" class="article__inlineFigure"><h2 class="fig-label">Abstract</h2><img class="rightTab-fig internalNav" src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0016.gif" alt="" id="tgr1" /></img><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0016.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=_i1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig1" data-index="1" class="article__inlineFigure"><h2 class="fig-label">Figure 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0001.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0001.jpeg" id="rightTab-gr1" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 1. Tacrine <b>1</b> and selective hCB<sub>2</sub>R agonist <b>2</b>.<a onclick="showRef(event, 'ref58'); return false;" href="javascript:void(0);" class="ref ref58">(58)</a></p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0001.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig1"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig2" data-index="2" class="article__inlineFigure"><h2 class="fig-label">Figure 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0002.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0002.jpeg" id="rightTab-gr2" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 2. Designed hybrids <b>3a</b>–<b>e</b> and <b>4a</b>–<b>e</b> used to investigate the optimal spacer length and the attachment point.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0002.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig2"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig3" data-index="3" class="article__inlineFigure"><h2 class="fig-label">Figure 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0003.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0003.jpeg" id="rightTab-gr3" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 3. Designed hybrids <b>5</b>–<b>8</b>.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0003.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig3"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="sch1" data-index="4" class="article__inlineFigure"><h2 class="fig-label">Scheme 1</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0012.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0012.jpeg" id="rightTab-gr12" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 1. Synthesis of Tacrine-Amine Intermediates <b>12a</b>–<b>g</b> and <b>14</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0012.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch1"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) POCl<sub>3</sub>, reflux; (b) respective diamine, hexanol, reflux; (c) Ac<sub>2</sub>O, r.t.; (d) LiAlH<sub>4</sub>, THF, reflux.</p></p></figure><figure data-id="sch2" data-index="5" class="article__inlineFigure"><h2 class="fig-label">Scheme 2</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0013.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0013.jpeg" id="rightTab-gr13" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 2. Synthesis of Hybrids <b>3a</b>–<b>e</b> and <b>6</b><sup>a</sup></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0013.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch2"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) HNEt<sub>2</sub>, cat. DMF, (COCl)<sub>2</sub>, CH<sub>2</sub>Cl<sub>2</sub> at 0 °C → r.t.; (b) respective amines <b>12a</b>–<b>f</b>, THF, NEt<sub>3</sub>, r.t.; (c) SnCl<sub>2</sub>·2H<sub>2</sub>O, EtOH, reflux; (d) 2-(4-ethoxyphenyl)acetic acid, HBTU, NEt<sub>3</sub>, DMF, r.t.; (e) AcOH, reflux.</p></p></figure><figure data-id="sch3" data-index="6" class="article__inlineFigure"><h2 class="fig-label">Scheme 3</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0014.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0014.jpeg" id="rightTab-gr14" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><div class="title2">Scheme 3. Synthesis of Hybrids <b>4a</b>–<b>e</b>, <b>5</b>, <b>7</b>, and <b>8</b><i><sup>a</sup></i></div></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0014.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=sch3"><span>Download MS PowerPoint Slide</span></a></div></div><p class="last"><p class="last"><span class="fn-label"><sup>a</sup></span>Reagents and conditions: (a) (I) cat. H<sub>2</sub>SO<sub>4</sub> (97%), EtOH, reflux; (II) NEt<sub>3</sub> 3-methylbutan-1-amine, r.t.; (b) cat. Pd/C (10%), MeOH, H<sub>2</sub> atm, 8 bar, r.t.; (c) 2-(4-ethoxyphenyl)acetic acid, HBTU, NEt<sub>3</sub>, DMF, r.t.; (d) AcOH, reflux; (e) LiOH, H<sub>2</sub>O, reflux; (f) respective amines <b>12a</b>–<b>g</b>, <b>14</b>, HBTU, NEt<sub>3</sub>, DMF, r.t.</p></p></figure><figure data-id="fig4" data-index="7" class="article__inlineFigure"><h2 class="fig-label">Figure 4</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0004.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0004.jpeg" id="rightTab-gr4" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 4. Plot of pIC<sub>50</sub> values toward hBChE against pIC<sub>50</sub> values toward hAChE of all hybrids.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0004.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig4"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig5" data-index="8" class="article__inlineFigure"><h2 class="fig-label">Figure 5</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0005.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0005.jpeg" id="rightTab-gr5" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 5. Kinetic study on the mechanism of hAChE inhibition by <b>3e</b>, <b>4b</b>, and <b>8</b>. Lineweaver–Burk reciprocal plots of hAChE initial velocity at increasing substrate (acetylthiocholine, ACth) concentration in the absence of the inhibitor (control) and the presence of increasing concentrations of the inhibitor are shown. Values are the means of at least three independent determinations.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0005.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig5"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig6" data-index="9" class="article__inlineFigure"><h2 class="fig-label">Figure 6</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0006.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0006.jpeg" id="rightTab-gr6" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 6. AChE-mediated and self-induced Aβ aggregation. Footnote a denotes inhibition of Aβ<sub>42</sub> self-aggregation investigated by the thioflavin T fluorescence assay. Assays were carried out in the presence of 50 μM inhibitor and 50 μM Aβ<sub>42</sub> ([I] = [Aβ<sub>42</sub>]). Values are expressed as means ± SEM of two independent experiments, and each was performed in duplicate. Footnote b denotes % inhibition of hAChE-induced Aβ<sub>40</sub> aggregation at [I] = 100 μM. The Aβ<sub>40</sub>/hAChE ratio was equal to 100:1. Values are expressed as means ± SEM of two independent experiments, and each was performed in duplicate.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0006.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig6"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig7" data-index="10" class="article__inlineFigure"><h2 class="fig-label">Figure 7</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0007.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0007.jpeg" id="rightTab-gr7" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 7. Test compounds (<b>2</b>, <b>3e</b>, and <b>4c</b>) reduce MIF and STAT-3 gene expression. U266 cells were treated with hybrid compounds (50 μM), FSK (10 μM), or AM630 (25 μM) for 2 h. In a combined experiment (AM630 plus test compounds), U266 cells were preincubated with AM630 for 30 min. Before adding the test compounds, MIF and STAT-3 mRNA levels were determined by qRT-PCR. GAPDH was used for normalization. Data are expressed as relative fold with respect to vehicle-treated cells used as the control. Values are means of at least two independent experiments, and each was performed in duplicate. Data are expressed as means ± SD *<i>p</i> < 0.01 vs untreated; # vs AM630.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0007.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig7"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig8" data-index="11" class="article__inlineFigure"><h2 class="fig-label">Figure 8</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0008.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0008.jpeg" id="rightTab-gr8" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 8. Calcium mobilization assay in CHO-K1 cells overexpressing hCB<sub>1</sub> or hCB<sub>2</sub> and G<sub>αq16.</sub> Compounds were tested in each cell type as described under <a class="ref internalNav" href="#sec5" aria-label="Experimental Section">Experimental Section</a>. Agonism was noted in cells expressing hCB<sub>2</sub> (left) but not in cells expressing hCB<sub>1</sub> (right). The synthetic full agonist CP 55,040 served as a comparator and positive control. No significant signal was noted in vehicle control cells.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0008.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig8"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig9" data-index="12" class="article__inlineFigure"><h2 class="fig-label">Figure 9</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0009.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0009.jpeg" id="rightTab-gr9" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 9. Effect of compounds <b>2</b>, <b>3e</b>, and <b>4a</b> on microglial activation in N9 cells previously activated by LPS (100 ng/mL). IL1β release and expression of iNOS, TREM2, and TGFβ2 were tested through Western blot analysis after 24 h of treatment with LPS in the presence of increasing concentrations (1, 2.5, and 5 μM) of compounds (A) <b>2</b>, (B) <b>3e</b>, and (C) <b>4a</b>, respectively, and (G–R) quantified through densitometry. NO release was evaluated through the Griess reaction in media conditioned for 24 h by microglial cells treated by LPS in the presence of compounds (D) <b>2</b>, (E) <b>3e</b>, and (F) <b>4a</b>, showing an increase in NO release in media conditioned by LPS-treated cells that are reduced by the co-treatment with the compounds, with the strongest effect of compound <b>2</b>. Both (G–I) IL1β release and (J–L) iNOS expression, which are markers of M1 neurotoxic microglia, strongly increase in LPS-treated cells but significantly decrease in cells co-treated with compounds (G, J) <b>2</b>, (H, K) <b>3e</b>, and (I, L) <b>4a</b> in a dose-dependent way, while the expression of the M2 microglial markers (M–O) TREM2 and (P–R) TGFβ2 is not reduced by co-treatment with the compounds. All quantitative data are presented as means ± SEM from at least three independent experiments. Statistical significance between different treatments was calculated by using one-way analysis of variance (ANOVA) followed by post hoc comparison through Bonferroni’s test. *<i>p</i> < 0.05; **<i>p</i> < 0.01 compare to control; <sup>#</sup><i>p</i> < 0.05; <sup>##</sup><i>p</i> < 0.01 compare to LPS.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0009.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig9"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig10" data-index="13" class="article__inlineFigure"><h2 class="fig-label">Figure 10</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0010.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0010.jpeg" id="rightTab-gr10" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 10. Compounds <b>4e</b> and <b>8</b> were studied on neuronal HT-22 cells for (A) neurotoxicity effects and (B, C) neuroprotection against glutamate-induced oxidative stress at 1–25 μM. Results of the modified MTT test are presented as means ± SD of three independent experiments, each performed in sextuplicate, and refer to untreated control cells, which were set as 100% values. Statistical analysis was achieved by applying one-way ANOVA followed by Dunnett’s multiple comparison post-test. Levels of significance: *<i>p</i> < 0.005; **<i>p</i> < 0.01; ***<i>p</i> < 0.001. Treated cells were compared to (A) untreated cells and (B) cells treated with glutamate only.</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0010.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig10"><span>Download MS PowerPoint Slide</span></a></div></div></figure><figure data-id="fig11" data-index="14" class="article__inlineFigure"><h2 class="fig-label">Figure 11</h2><img src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/medium/jm9b00623_0011.gif" alt="" data-lg-src="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0011.jpeg" id="rightTab-gr11" class="rightTab-fig internalNav" /></img><figcaption><div class="hlFld-FigureCaption caption"><p class="first last">Figure 11. Effect of the compounds on Aß<sub>25–35</sub>-induced learning impairments in mice: spontaneous alternation performance (upper panels) and passive avoidance response (lower panels). Mice received Aβ<sub>25–35</sub> (9 nmol, i.c.v.) or vehicle solution (3 μL, i.c.v.) on day 1 and then compound (a, b) <b>3a</b>, (c, d) <b>3d</b>, (e, f) <b>3e</b>, (g, h) <b>4a</b>, or (i, j) <b>8</b> in the 0.1–3 mg/kg, i.p. dose range, o.d. between day 1 to 7. Mice were then tested for (a, c, e, g, and i) spontaneous alternation on day 8 and (b, d, f, h, and j) passive avoidance on days 9 and 10. Data show means ± SEM (upper panels) or median and interquartile range (lower panels). ANOVA: <i>F</i><sub>(4,79)</sub> = 3.05, <i>p</i> < 0.05, <i>n</i> = 12–18 in (a); <i>F</i><sub>(4,62)</sub> = 3.77, <i>p</i> > 0.01, <i>n</i> = 11–15 in (c); <i>F</i><sub>(4,64)</sub> = 3.85, <i>p</i> < 0.01, <i>n</i> = 10–15 in (e); <i>F</i><sub>(4,67)</sub> = 3.14, <i>p</i> < 0.05, <i>n</i> = 11–17 in (g); <i>F</i><sub>(4,50)</sub> = 5.40, <i>p</i> < 0.01, <i>n</i> = 8–12 in (i). Kruskal–Wallis ANOVA: <i>H</i> = 9.87, <i>p</i> < 0.05, <i>n</i> = 12–15 in (b); <i>H</i> = 17.4, <i>p</i> < 0.01, <i>n</i> = 11–14 in (d); <i>H</i> = 21.9, <i>p</i> < 0.001, <i>n</i> = 12–13 in (f); <i>H</i> = 13.9, <i>p</i> < 0.01, <i>n</i> = 12–17 in (h); <i>H</i> = 11.8, <i>p</i> < 0.05, <i>n</i> = 12–15 in (j). Post hoc: *<i>p</i> < 0.05, **<i>p</i> < 0.01, and ***<i>p</i> < 0.001 vs (V + V)-treated group; <sup>#</sup><i>p</i> < 0.05, <sup>##</sup><i>p</i> < 0.01, and <sup>###</sup><i>p</i> < 0.001 vs (V + Aß<sub>25–35</sub>)-treated group; Dunnett’s (upper panels) or Dunn’s test (lower panels).</p></div></figcaption><div class="figure-bottom-links"><div class="download-hi-res-img"><a title="High Resolution Image" href="/na101/home/literatum/publisher/achs/journals/content/jmcmar/2019/jmcmar.2019.62.issue-20/acs.jmedchem.9b00623/20191018/images/large/jm9b00623_0011.jpeg"><span>High Resolution Image</span></a></div><div class="download-ppt"><a title="Download MS PowerPoint Slide" href="/action/downloadFigures?doi=10.1021/acs.jmedchem.9b00623&amp;id=fig11"><span>Download MS PowerPoint Slide</span></a></div></div></figure></li><li id="pane-m2" aria-labelledby="pane-m2" class="tab__pane tab__pane-references empty"><div class="refs-header-label"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-_i133">References</h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a href="#" data-db-target-for="sectionsDB_37728" class="" data-db-switch="icon-angle-up"><span>Jump To</span><i class="icon-angle-down"></i></a><div data-db-target-of="sectionsDB_37728" class="dropBlock__holder"></div></div></div></div></div><hr /></hr></div><p class="rightTab-references-count">
            This article references 100 other publications.
        </p><ol id="rightTab-references" class="useLabel"><li id="rightTab-ref1"><div class="reference"><strong class="refLabel"><a href="#ref1" class="rightTabRefNumLink">1</a></strong><div class="NLM_citation" id="rightTab-cit1"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Patterson, C.</span></span> <i>World Alzheimer report 2018</i>; <span class="NLM_publisher-name">ADI</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2018</span>; pp  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">48</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2018&pages=1-48&author=C.+Patterson&title=World+Alzheimer+report+2018"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit1&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DPatterson%26aufirst%3DC.%26btitle%3DWorld%2520Alzheimer%2520report%25202018%26pub%3DADI%26date%3D2018%26spage%3D1%26epage%3D48" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref2"><div class="reference"><strong class="refLabel"><a href="#ref2" class="rightTabRefNumLink">2</a></strong><div class="NLM_citation" id="rightTab-cit2"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zemek, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drtinova, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nepovimova, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sepsova, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Korabecny, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klimes, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kuca, K.</span></span> <span> </span><span class="NLM_article-title">Outcomes of Alzheimer’s disease therapy with acetylcholinesterase inhibitors and memantine</span>. <i>Expert Opin. Drug Saf.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>13</i></span>,  <span class="NLM_fpage">759</span>– <span class="NLM_lpage">774</span>, <span class="refDoi"> DOI: 10.1517/14740338.2014.914168</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1517%2F14740338.2014.914168" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24845946" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref2/cit2&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=13&publication_year=2014&pages=759-774&author=F.+Zemekauthor=L.+Drtinovaauthor=E.+Nepovimovaauthor=V.+Sepsovaauthor=J.+Korabecnyauthor=J.+Klimesauthor=K.+Kuca&title=Outcomes+of+Alzheimer%E2%80%99s+disease+therapy+with+acetylcholinesterase+inhibitors+and+memantine&doi=10.1517%2F14740338.2014.914168"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit2R"><div class="casContent"><span class="casTitleNuber">2</span><div class="casTitle"><span class="NLM_cas:atitle">Outcomes of Alzheimer's disease therapy with acetylcholinesterase inhibitors and memantine</span></div><div class="casAuthors">Zemek, Filip; Drtinova, Lucie; Nepovimova, Eugenie; Sepsova, Vendula; Korabecny, Jan; Klimes, Jiri; Kuca, Kamil</div><div class="citationInfo"><span class="NLM_cas:title">Expert Opinion on Drug Safety</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">13</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">759-774</span>CODEN:
                <span class="NLM_cas:coden">EODSA9</span>;
        ISSN:<span class="NLM_cas:issn">1474-0338</span>.
    
            (<span class="NLM_cas:orgname">Informa Healthcare</span>)
        </div><div class="casAbstract">A review.  Introduction: Alzheimer's disease (AD) is a world-wide health problem with implications for an increasing no. of people and countries.  Populations suffering from AD financially strain the healthcare budgets of rich and poor countries alike.  Moreover, no effective treatment is available and current drugs merely slow the progression of cognitive function deterioration and overall health status toward an inevitable end point.  An increasing no. of novel approaches have been tested in numerous clin. trials, but none of them has proved safe and effective for treating AD.  Areas covered: This review summarizes all currently available compds. (donepezil, rivastigmine, galantamine, memantine) for the management of AD, concg. on clin. aspects such as the mechanisms of action, pharmacokinetics, pharmacodynamics and clin. trials.  This review also considers the mechanisms and side effects to provide perspective on current treatment options.  Expert opinion: Novel approaches in the treatment of AD are being intensively tested, but so far without any major success.  Patients diagnosed with AD still mostly benefit from four compds. to significantly improve cognition functions and overall health and help manage other symptoms or even prolong the symptom-free period.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGomCHTA-GByu7Vg90H21EOLACvtfcHk0ljLUUpGbZLnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXosVOrt70%253D&md5=5dfa0e4ee53453755456895458e49a29</span></div><a href="/servlet/linkout?suffix=cit2&amp;dbid=16384&amp;doi=10.1517%2F14740338.2014.914168&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1517%252F14740338.2014.914168%26sid%3Dliteratum%253Aachs%26aulast%3DZemek%26aufirst%3DF.%26aulast%3DDrtinova%26aufirst%3DL.%26aulast%3DNepovimova%26aufirst%3DE.%26aulast%3DSepsova%26aufirst%3DV.%26aulast%3DKorabecny%26aufirst%3DJ.%26aulast%3DKlimes%26aufirst%3DJ.%26aulast%3DKuca%26aufirst%3DK.%26atitle%3DOutcomes%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%2520therapy%2520with%2520acetylcholinesterase%2520inhibitors%2520and%2520memantine%26jtitle%3DExpert%2520Opin.%2520Drug%2520Saf.%26date%3D2014%26volume%3D13%26spage%3D759%26epage%3D774%26doi%3D10.1517%2F14740338.2014.914168" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref3"><div class="reference"><strong class="refLabel"><a href="#ref3" class="rightTabRefNumLink">3</a></strong><div class="NLM_citation" id="rightTab-cit3"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Glenner, G. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wong, C. W.</span></span> <span> </span><span class="NLM_article-title">Alzheimer’s disease: initial report of the purification and characterization of a novel cerebrovascular amyloid protein</span>. <i>Biochem. Biophys. Res. Commun.</i> <span class="NLM_year" style="font-weight: bold;">1984</span>,  <span class="NLM_volume"><i>120</i></span>,  <span class="NLM_fpage">885</span>– <span class="NLM_lpage">890</span>, <span class="refDoi"> DOI: 10.1016/S0006-291X(84)80190-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0006-291X%2884%2980190-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=6375662" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref3/cit3&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL2cXitVOntLw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=120&publication_year=1984&pages=885-890&author=G.+G.+Glennerauthor=C.+W.+Wong&title=Alzheimer%E2%80%99s+disease%3A+initial+report+of+the+purification+and+characterization+of+a+novel+cerebrovascular+amyloid+protein&doi=10.1016%2FS0006-291X%2884%2980190-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit3R"><div class="casContent"><span class="casTitleNuber">3</span><div class="casTitle"><span class="NLM_cas:atitle">Alzheimer's disease:  initial report of the purification and characterization of a novel cerebrovascular amyloid protein</span></div><div class="casAuthors">Glenner, George G.; Wong, Caine W.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical and Biophysical Research Communications</span>
        (<span class="NLM_cas:date">1984</span>),
    <span class="NLM_cas:volume">120</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">885-90</span>CODEN:
                <span class="NLM_cas:coden">BBRCA9</span>;
        ISSN:<span class="NLM_cas:issn">0006-291X</span>.
    </div><div class="casAbstract">A purified protein derived from the twisted β-pleated sheet fibrils in cerebrovascular amyloidosis assocd. with Alzheimer's disease was isolated by Sephadex G-100 column chromatog. with 5 M guanidine-HCl in 1 N acetic acid and by HPLC.  Partial amino acid sequence anal. and a computer search reveals this protein to have nohomol. with any protein sequenced thus far.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqimb5yE9JMLrVg90H21EOLACvtfcHk0ljLUUpGbZLnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL2cXitVOntLw%253D&md5=e30caf2b0d9c41ee223b53ffe7a690dd</span></div><a href="/servlet/linkout?suffix=cit3&amp;dbid=16384&amp;doi=10.1016%2FS0006-291X%2884%2980190-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-291X%252884%252980190-4%26sid%3Dliteratum%253Aachs%26aulast%3DGlenner%26aufirst%3DG.%2BG.%26aulast%3DWong%26aufirst%3DC.%2BW.%26atitle%3DAlzheimer%25E2%2580%2599s%2520disease%253A%2520initial%2520report%2520of%2520the%2520purification%2520and%2520characterization%2520of%2520a%2520novel%2520cerebrovascular%2520amyloid%2520protein%26jtitle%3DBiochem.%2520Biophys.%2520Res.%2520Commun.%26date%3D1984%26volume%3D120%26spage%3D885%26epage%3D890%26doi%3D10.1016%2FS0006-291X%2884%2980190-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref4"><div class="reference"><strong class="refLabel"><a href="#ref4" class="rightTabRefNumLink">4</a></strong><div class="NLM_citation" id="rightTab-cit4"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grundke-Iqbal, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Iqbal, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tung, Y. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Quinlan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wisniewski, H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Binder, L. I.</span></span> <span> </span><span class="NLM_article-title">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span>. <i>Proc. Natl. Acad. Sci. U. S. A.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">4913</span>– <span class="NLM_lpage">4917</span>, <span class="refDoi"> DOI: 10.1073/pnas.83.13.4913</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.83.13.4913" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=3088567" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref4/cit4&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1986&pages=4913-4917&author=I.+Grundke-Iqbalauthor=K.+Iqbalauthor=Y.+C.+Tungauthor=M.+Quinlanauthor=H.+M.+Wisniewskiauthor=L.+I.+Binder&title=Abnormal+phosphorylation+of+the+microtubule-associated+protein+%CF%84+%28tau%29+in+Alzheimer+cytoskeletal+pathology&doi=10.1073%2Fpnas.83.13.4913"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit4R"><div class="casContent"><span class="casTitleNuber">4</span><div class="casTitle"><span class="NLM_cas:atitle">Abnormal phosphorylation of the microtubule-associated protein τ (tau) in Alzheimer cytoskeletal pathology</span></div><div class="casAuthors">Grundke-Iqbal, Inge; Iqbal, Khalid; Tung, Yunn Chyn; Quinlan, Maureen; Wisniewski, Henryk M.; Binder, Lester I.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">4913-17</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">A monoclonal antibody to the microtubule-assocd. protein τ (tau) labeled some neurofibrillary tangles and plaque neurites, the 2 major locations of paired-helical filaments (PHF), in Alzheimer disease brain.  The antibody also labeled isolated PHF that had been repeatedly washed with SDS.  Dephosphorylation of the tissue sections with alk. phosphatase prior to immunolabeling dramatically increased the no. of tangles and plaques recognized by the antibody.  The plaque core amyloid was not stained in either dephosphorylated or nondephosphorylated tissue sections.  On immunoblots PHF polypeptides were labeled readily only when dephosphorylated.  In contrast, a com. available monoclonal antibody to a phosphorylated epitope of neurofilaments that labeled the tangles and the plaque neurites in tissue did not label any PHF polypeptides on immunoblots.  The PHF polypeptides, labeled with the monoclonal antibody to τ, electrophoresed with those polypeptides recognized by antibodies to isolated PHF.  The antibody to τ labeled microtubules from normal human brains assembled in vitro but identically treated Alzheimer brain prepns. had to be dephosphorylated to be completely recognized by this antibody.  These findings suggest that τ in Alzheimer brain is an abnormally phosphorylated protein component of PHF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcyxbsq2aXprVg90H21EOLACvtfcHk0ljLUUpGbZLnWw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL28XksFyqtrg%253D&md5=3ac88b7002e26c53c54e71a3a91471ba</span></div><a href="/servlet/linkout?suffix=cit4&amp;dbid=16384&amp;doi=10.1073%2Fpnas.83.13.4913&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.83.13.4913%26sid%3Dliteratum%253Aachs%26aulast%3DGrundke-Iqbal%26aufirst%3DI.%26aulast%3DIqbal%26aufirst%3DK.%26aulast%3DTung%26aufirst%3DY.%2BC.%26aulast%3DQuinlan%26aufirst%3DM.%26aulast%3DWisniewski%26aufirst%3DH.%2BM.%26aulast%3DBinder%26aufirst%3DL.%2BI.%26atitle%3DAbnormal%2520phosphorylation%2520of%2520the%2520microtubule-associated%2520protein%2520%25CF%2584%2520%2528tau%2529%2520in%2520Alzheimer%2520cytoskeletal%2520pathology%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.%2520S.%2520A.%26date%3D1986%26volume%3D83%26spage%3D4913%26epage%3D4917%26doi%3D10.1073%2Fpnas.83.13.4913" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref5"><div class="reference"><strong class="refLabel"><a href="#ref5" class="rightTabRefNumLink">5</a></strong><div class="NLM_citation" id="rightTab-cit5"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ferrer, I.</span></span> <span> </span><span class="NLM_article-title">Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>97</i></span>,  <span class="NLM_fpage">38</span>– <span class="NLM_lpage">51</span>, <span class="refDoi"> DOI: 10.1016/j.pneurobio.2012.03.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.pneurobio.2012.03.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22459297" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref5/cit5&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BC38rgs1GgtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=97&publication_year=2012&pages=38-51&author=I.+Ferrer&title=Defining+Alzheimer+as+a+common+age-related+neurodegenerative+process+not+inevitably+leading+to+dementia&doi=10.1016%2Fj.pneurobio.2012.03.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit5R"><div class="casContent"><span class="casTitleNuber">5</span><div class="casTitle"><span class="NLM_cas:atitle">Defining Alzheimer as a common age-related neurodegenerative process not inevitably leading to dementia</span></div><div class="casAuthors">Ferrer Isidro</div><div class="citationInfo"><span class="NLM_cas:title">Progress in neurobiology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">97</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">38-51</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">Since the description by Alois Alzheimer, more than 50 years have passed during which senile dementia and pre-senile dementia have been considered Alzheimer disease (AD) on the basis of their common neuropathological and clinical manifestations.  AD now covers pre-senile dementia, senile dementia, mild cognitive impairment and pre-clinical AD, all of them within the context of AD-related pathology.  However, there is still a gray area between normal aging with AD-related pathology and AD.  Here it is proposed that Alzheimer (or alzheimer) is an age-related neurodegenerative process distinguished from normal aging by the presence of senile plaques and neurofibrillary tangles.  Alzheimer affects about 80% of individuals aged 65 years but dementia only occurs in a small percentage of individuals at this age; prevalence of dementia in Alzheimer increases to 25% in individuals aged 80 years.  The concepts derived from the β-amyloid hypothesis support β-amyloid as a conductor in the pathogenesis of familial AD and as a prodding factor in sporadic AD.  Moreover, seeding of β-amyloid and truncated tau explains incorporation, enhancement and perpetuation of AD-related changes.  Therefore, the earliest Alzheimer changes confined to selected regions are the first grounds and the main risk factor for developing dementia.  The term Alzheimer embraces this assumption and likens its meaning to other degenerative biological processes, such as atherosclerosis, that may eventually progress to disease.  In this context, the first stages of Alzheimer should be considered as primary targets of therapeutic intervention in order to prevent progression to diseased states.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcT8RZSMq5h6HMAKB7Fa-xrUfW6udTcc2eZoYXu2SQz387ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38rgs1GgtA%253D%253D&md5=60276ba23f11747b14a35ea1e18c45bf</span></div><a href="/servlet/linkout?suffix=cit5&amp;dbid=16384&amp;doi=10.1016%2Fj.pneurobio.2012.03.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.pneurobio.2012.03.005%26sid%3Dliteratum%253Aachs%26aulast%3DFerrer%26aufirst%3DI.%26atitle%3DDefining%2520Alzheimer%2520as%2520a%2520common%2520age-related%2520neurodegenerative%2520process%2520not%2520inevitably%2520leading%2520to%2520dementia%26jtitle%3DProg.%2520Neurobiol.%26date%3D2012%26volume%3D97%26spage%3D38%26epage%3D51%26doi%3D10.1016%2Fj.pneurobio.2012.03.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref6"><div class="reference"><strong class="refLabel"><a href="#ref6" class="rightTabRefNumLink">6</a></strong><div class="NLM_citation" id="rightTab-cit6"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tsai, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grutzendler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gan, W.-B.</span></span> <span> </span><span class="NLM_article-title">Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches</span>. <i>Nat. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">1181</span>, <span class="refDoi"> DOI: 10.1038/nn1335</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnn1335" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15475950" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref6/cit6&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXovFamu7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=2004&pages=1181&author=J.+Tsaiauthor=J.+Grutzendlerauthor=K.+Duffauthor=W.-B.+Gan&title=Fibrillar+amyloid+deposition+leads+to+local+synaptic+abnormalities+and+breakage+of+neuronal+branches&doi=10.1038%2Fnn1335"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit6R"><div class="casContent"><span class="casTitleNuber">6</span><div class="casTitle"><span class="NLM_cas:atitle">Fibrillar amyloid deposition leads to local synaptic abnormalities and breakage of neuronal branches</span></div><div class="casAuthors">Tsai, Julia; Grutzendler, Jaime; Duff, Karen; Gan, Wen-Biao</div><div class="citationInfo"><span class="NLM_cas:title">Nature Neuroscience</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">1181-1183</span>CODEN:
                <span class="NLM_cas:coden">NANEFN</span>;
        ISSN:<span class="NLM_cas:issn">1097-6256</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Amyloid plaques are a hallmark of Alzheimer disease, but their importance in its pathogenesis is controversial.  By neuronal labeling and transcranial two-photon imaging, we show in a transgenic mouse model of Alzheimer disease that dendrites passing through or near fibrillar amyloid deposits undergo spine loss and shaft atrophy, and nearby axons develop large varicosities, together leading to neurite breakage and large-scale, permanent disruption of neuronal connections.  Thus, fibrillar amyloid deposition is more detrimental to neuronal circuitry than previously thought, underscoring the importance of prevention and early clearance of plaques.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqE4pZtUunDnbVg90H21EOLACvtfcHk0lihMsOEbsGXfg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXovFamu7o%253D&md5=5c8f894f6b8246f784d70f836a9b7a5a</span></div><a href="/servlet/linkout?suffix=cit6&amp;dbid=16384&amp;doi=10.1038%2Fnn1335&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnn1335%26sid%3Dliteratum%253Aachs%26aulast%3DTsai%26aufirst%3DJ.%26aulast%3DGrutzendler%26aufirst%3DJ.%26aulast%3DDuff%26aufirst%3DK.%26aulast%3DGan%26aufirst%3DW.-B.%26atitle%3DFibrillar%2520amyloid%2520deposition%2520leads%2520to%2520local%2520synaptic%2520abnormalities%2520and%2520breakage%2520of%2520neuronal%2520branches%26jtitle%3DNat.%2520Neurosci.%26date%3D2004%26volume%3D7%26spage%3D1181%26doi%3D10.1038%2Fnn1335" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref7"><div class="reference"><strong class="refLabel"><a href="#ref7" class="rightTabRefNumLink">7</a></strong><div class="NLM_citation" id="rightTab-cit7"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Gómez-Isla, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hollister, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">West, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Growdon, J. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Petersen, R. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parisi, J. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hyman, B. T.</span></span> <span> </span><span class="NLM_article-title">Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer’s disease</span>. <i>Ann. Neurol.</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>41</i></span>,  <span class="NLM_fpage">17</span>– <span class="NLM_lpage">24</span>, <span class="refDoi"> DOI: 10.1002/ana.410410106</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fana.410410106" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9005861" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref7/cit7&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK2s7lvVGjsw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=41&publication_year=1997&pages=17-24&author=T.+G%C3%B3mez-Islaauthor=R.+Hollisterauthor=H.+Westauthor=S.+Muiauthor=J.+H.+Growdonauthor=R.+C.+Petersenauthor=J.+E.+Parisiauthor=B.+T.+Hyman&title=Neuronal+loss+correlates+with+but+exceeds+neurofibrillary+tangles+in+Alzheimer%E2%80%99s+disease&doi=10.1002%2Fana.410410106"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit7R"><div class="casContent"><span class="casTitleNuber">7</span><div class="casTitle"><span class="NLM_cas:atitle">Neuronal loss correlates with but exceeds neurofibrillary tangles in Alzheimer's disease</span></div><div class="casAuthors">Gomez-Isla T; Hollister R; West H; Mui S; Growdon J H; Petersen R C; Parisi J E; Hyman B T</div><div class="citationInfo"><span class="NLM_cas:title">Annals of neurology</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">41</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">17-24</span>
        ISSN:<span class="NLM_cas:issn">0364-5134</span>.
    </div><div class="casAbstract">To assess the relationship between dementia, neuronal loss, and neuropathological findings in Alzheimer's disease (AD), we counted the number of neurons, senile plaques, and neurofibrillary tangles in a high-order association cortex.  We studied the superior temporal sulcus of 34 individuals with AD and 17 nondemented control subjects, using statistically unbiased, stereological counting techniques.  The number of superior temporal sulcus neurons in nondemented control subjects was stable across the sixth to ninth decades.  In AD, more than 50% of the neurons were lost.  Both neuronal loss and neurofibrillary tangles increased in parallel with the duration and severity of illness, but the amount of neuronal loss exceeded by manyfold the amount of neurofibrillary tangles accumulated.  In contrast to the correlation between neurofibrillary tangles and neuronal loss, the number of senile plaques and the percentage of the superior temporal sulcus that was covered by Abeta (amyloid burden) were not related to neuronal loss, number of neurofibrillary tangles, or duration of disease.  Neither the amount nor the rate of neuronal loss in the superior temporal sulcus in AD correlated with apolipoprotein E genotype.  These data suggest that neuronal loss in association areas such as the superior temporal sulcus contributes directly to cognitive impairment in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcRb4pZx19FriEh5eUSa2oe_fW6udTcc2eZoYXu2SQz387ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK2s7lvVGjsw%253D%253D&md5=77d2cb983d20b2a7cfe60426e4f55a50</span></div><a href="/servlet/linkout?suffix=cit7&amp;dbid=16384&amp;doi=10.1002%2Fana.410410106&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fana.410410106%26sid%3Dliteratum%253Aachs%26aulast%3DG%25C3%25B3mez-Isla%26aufirst%3DT.%26aulast%3DHollister%26aufirst%3DR.%26aulast%3DWest%26aufirst%3DH.%26aulast%3DMui%26aufirst%3DS.%26aulast%3DGrowdon%26aufirst%3DJ.%2BH.%26aulast%3DPetersen%26aufirst%3DR.%2BC.%26aulast%3DParisi%26aufirst%3DJ.%2BE.%26aulast%3DHyman%26aufirst%3DB.%2BT.%26atitle%3DNeuronal%2520loss%2520correlates%2520with%2520but%2520exceeds%2520neurofibrillary%2520tangles%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Neurol.%26date%3D1997%26volume%3D41%26spage%3D17%26epage%3D24%26doi%3D10.1002%2Fana.410410106" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref8"><div class="reference"><strong class="refLabel"><a href="#ref8" class="rightTabRefNumLink">8</a></strong><div class="NLM_citation" id="rightTab-cit8"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Loo, D. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Copani, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pike, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whittemore, E. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walencewicz, A. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cotman, C. W.</span></span> <span> </span><span class="NLM_article-title">Apoptosis is induced by beta-amyloid in cultured central nervous system neurons</span>. <i>Proc. Natl. Acad. Sci. U.S.A.</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">7951</span>– <span class="NLM_lpage">7955</span>, <span class="refDoi"> DOI: 10.1073/pnas.90.17.7951</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.90.17.7951" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8367446" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref8/cit8&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXmtVWis7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=1993&pages=7951-7955&author=D.+T.+Looauthor=A.+Copaniauthor=C.+J.+Pikeauthor=E.+R.+Whittemoreauthor=A.+J.+Walencewiczauthor=C.+W.+Cotman&title=Apoptosis+is+induced+by+beta-amyloid+in+cultured+central+nervous+system+neurons&doi=10.1073%2Fpnas.90.17.7951"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit8R"><div class="casContent"><span class="casTitleNuber">8</span><div class="casTitle"><span class="NLM_cas:atitle">Apoptosis is induced by β-amyloid in cultured central nervous system neurons</span></div><div class="casAuthors">Loo, Deryk T.; Copani, Agata; Pike, Christian J.; Whittemore, Edward R.; Walencewicz, Andrea J.; Cotman, Carl W.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">7951-5</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    </div><div class="casAbstract">The mol. mechanism responsible for the neurodegeneration in Alzheimer disease is not known; however, accumulating evidence suggests that β-amyloid peptide (AβP) contributes to this degeneration.  The authors now report that synthetic AβPs trigger the degeneration of cultured neurons through activation of an apoptotic pathway.  Neurons treated with AβPs exhibit morphol. and biochem. characteristics of apoptosis, including membrane blebbing, compaction of nuclear chromatin, and internucleosomal DNA fragmentation.  Aurintricarboxylic acid, an inhibitor of nucleases, prevents DNA fragmentation and delays cell death.  Thus, apoptosis may play a role in the neuronal loss assocd. with Alzheimer disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoEKn2IOaIiabVg90H21EOLACvtfcHk0ljQXE4z1hUJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmtVWis7Y%253D&md5=4301e766187b57f18c951b9acd00f0c5</span></div><a href="/servlet/linkout?suffix=cit8&amp;dbid=16384&amp;doi=10.1073%2Fpnas.90.17.7951&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.90.17.7951%26sid%3Dliteratum%253Aachs%26aulast%3DLoo%26aufirst%3DD.%2BT.%26aulast%3DCopani%26aufirst%3DA.%26aulast%3DPike%26aufirst%3DC.%2BJ.%26aulast%3DWhittemore%26aufirst%3DE.%2BR.%26aulast%3DWalencewicz%26aufirst%3DA.%2BJ.%26aulast%3DCotman%26aufirst%3DC.%2BW.%26atitle%3DApoptosis%2520is%2520induced%2520by%2520beta-amyloid%2520in%2520cultured%2520central%2520nervous%2520system%2520neurons%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%2520U.S.A.%26date%3D1993%26volume%3D90%26spage%3D7951%26epage%3D7955%26doi%3D10.1073%2Fpnas.90.17.7951" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref9"><div class="reference"><strong class="refLabel"><a href="#ref9" class="rightTabRefNumLink">9</a></strong><div class="NLM_citation" id="rightTab-cit9"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Raina, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casadesus, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Smith, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, G.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress signalling in Alzheimer’s disease</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>1000</i></span>,  <span class="NLM_fpage">32</span>– <span class="NLM_lpage">39</span>, <span class="refDoi"> DOI: 10.1016/j.brainres.2004.01.012</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.brainres.2004.01.012" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15053949" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref9/cit9&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXisF2htrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1000&publication_year=2004&pages=32-39&author=X.+Zhuauthor=A.+K.+Rainaauthor=H.+G.+Leeauthor=G.+Casadesusauthor=M.+A.+Smithauthor=G.+Perry&title=Oxidative+stress+signalling+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.brainres.2004.01.012"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit9R"><div class="casContent"><span class="casTitleNuber">9</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress signalling in Alzheimer's disease</span></div><div class="casAuthors">Zhu, Xiongwei; Raina, Arun K.; Lee, Hyoung-gon; Casadesus, Gemma; Smith, Mark A.; Perry, George</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">1000</span>
        (<span class="NLM_cas:issue">1,2</span>),
    <span class="NLM_cas:pages">32-39</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science B.V.</span>)
        </div><div class="casAbstract">A review.  Multiple lines of evidence demonstrate that oxidative stress is an early event in Alzheimer's disease (AD), occurring prior to cytopathol., and therefore may play a key pathogenic role in the disease.  Indeed, that oxidative mechanisms are involved in the cell loss and other neuropathol. assocd. with AD is evidenced by the large no. of metabolic signs of oxidative stress as well as by markers of oxidative damage.  However, what is intriguing is that oxidative damage decreases with disease progression, such that levels of markers of rapidly formed oxidative damage, which are initially elevated, decrease as the disease progresses to advanced AD.  This finding, along with the compensatory upregulation of antioxidant enzymes found in vulnerable neurons in AD, indicates that reactive oxygen species (ROS) not only cause damage to cellular structures but also provoke cellular responses.  Mammalian cells respond to extracellular stimuli by transmitting intracellular instructions by signal transduction cascades to coordinate appropriate responses.  Therefore, not surprisingly stress-activated protein kinase (SAPK) pathways, pathways that are activated by oxidative stress, are extensively activated during AD.  In this paper, we review the evidence of oxidative stress and compensatory responses that occur in AD with a particular focus on the roles and mechanism of activation of SAPK pathways.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrM-8SJNlzlJLVg90H21EOLACvtfcHk0ljQXE4z1hUJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXisF2htrw%253D&md5=61808b21e4fd8dcee6fce30637b51425</span></div><a href="/servlet/linkout?suffix=cit9&amp;dbid=16384&amp;doi=10.1016%2Fj.brainres.2004.01.012&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.brainres.2004.01.012%26sid%3Dliteratum%253Aachs%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DRaina%26aufirst%3DA.%2BK.%26aulast%3DLee%26aufirst%3DH.%2BG.%26aulast%3DCasadesus%26aufirst%3DG.%26aulast%3DSmith%26aufirst%3DM.%2BA.%26aulast%3DPerry%26aufirst%3DG.%26atitle%3DOxidative%2520stress%2520signalling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DBrain%2520Res.%26date%3D2004%26volume%3D1000%26spage%3D32%26epage%3D39%26doi%3D10.1016%2Fj.brainres.2004.01.012" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref10"><div class="reference"><strong class="refLabel"><a href="#ref10" class="rightTabRefNumLink">10</a></strong><div class="NLM_citation" id="rightTab-cit10"><span><span class="NLM_contrib-group"><span class="NLM_string-name">LaFerla, F. M.</span></span> <span> </span><span class="NLM_article-title">Calcium dyshomeostasis and intracellular signalling in Alzheimer’s disease</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">862</span>– <span class="NLM_lpage">872</span>, <span class="refDoi"> DOI: 10.1038/nrn960</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn960" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12415294" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref10/cit10&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38Xotleqtr8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2002&pages=862-872&author=F.+M.+LaFerla&title=Calcium+dyshomeostasis+and+intracellular+signalling+in+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnrn960"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit10R"><div class="casContent"><span class="casTitleNuber">10</span><div class="casTitle"><span class="NLM_cas:atitle">Calcium dyshomeostasis and intracellular signaling in Alzheimer's disease</span></div><div class="casAuthors">LaFerla, Frank M.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">862-872</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Calcium modulates many neural processes, including synaptic plasticity and apoptosis.  Dysregulation of intracellular calcium signaling has been implicated in the pathogenesis of Alzheimer's disease.  Increased intracellular calcium elicits the characteristic lesions of this disorder, including the accumulation of amyloid-β, the hyperphosphorylation of TAU and neuronal death.  Conversely, neurodegeneration that is induced by amyloid-β or TAU is probably mediated by changes in calcium homeostasis.  Disruption of calcium regulation in the endoplasmic reticulum mediates the most significant signal-transduction cascades that are assocd. with Alzheimer's disease.  Moreover, mutations that cause familial Alzheimer's disease have been linked to intracellular calcium signaling pathways.  Destabilization of calcium signaling seems to be central to the pathogenesis of Alzheimer's disease, and targeting this process might be therapeutically beneficial.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq6rDohVx62LrVg90H21EOLACvtfcHk0ljQXE4z1hUJbg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xotleqtr8%253D&md5=1894cb967d1b2902fa54b4fab9d29145</span></div><a href="/servlet/linkout?suffix=cit10&amp;dbid=16384&amp;doi=10.1038%2Fnrn960&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn960%26sid%3Dliteratum%253Aachs%26aulast%3DLaFerla%26aufirst%3DF.%2BM.%26atitle%3DCalcium%2520dyshomeostasis%2520and%2520intracellular%2520signalling%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2002%26volume%3D3%26spage%3D862%26epage%3D872%26doi%3D10.1038%2Fnrn960" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref11"><div class="reference"><strong class="refLabel"><a href="#ref11" class="rightTabRefNumLink">11</a></strong><div class="NLM_citation" id="rightTab-cit11"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Akiyama, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barger, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barnum, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bradt, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bauer, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cole, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cooper, N. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Eikelenboom, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Emmerling, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fiebich, B. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Finch, C. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frautschy, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Griffin, W. S. T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hampel, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hull, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Landreth, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lue, L.-F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mrak, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackenzie, I. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McGeer, P. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">O’Banion, M. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pachter, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pasinetti, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Plata-Salaman, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rogers, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rydel, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Streit, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strohmeyer, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tooyoma, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Van Muiswinkel, F. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerhuis, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walker, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Webster, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wegrzyniak, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wenk, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wyss-Coray, T.</span></span> <span> </span><span class="NLM_article-title">Inflammation and Alzheimer’s disease</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">383</span>– <span class="NLM_lpage">421</span>, <span class="refDoi"> DOI: 10.1016/S0197-4580(00)00124-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0197-4580%2800%2900124-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10858586" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref11/cit11&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3cXktVSmt74%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=2000&pages=383-421&author=H.+Akiyamaauthor=S.+Bargerauthor=S.+Barnumauthor=B.+Bradtauthor=J.+Bauerauthor=G.+M.+Coleauthor=N.+R.+Cooperauthor=P.+Eikelenboomauthor=M.+Emmerlingauthor=B.+L.+Fiebichauthor=C.+E.+Finchauthor=S.+Frautschyauthor=W.+S.+T.+Griffinauthor=H.+Hampelauthor=M.+Hullauthor=G.+Landrethauthor=L.-F.+Lueauthor=R.+Mrakauthor=I.+R.+Mackenzieauthor=P.+L.+McGeerauthor=M.+B.+O%E2%80%99Banionauthor=J.+Pachterauthor=G.+Pasinettiauthor=C.+Plata-Salamanauthor=J.+Rogersauthor=R.+Rydelauthor=Y.+Shenauthor=W.+Streitauthor=R.+Strohmeyerauthor=I.+Tooyomaauthor=F.+L.+Van+Muiswinkelauthor=R.+Veerhuisauthor=D.+Walkerauthor=S.+Websterauthor=B.+Wegrzyniakauthor=G.+Wenkauthor=T.+Wyss-Coray&title=Inflammation+and+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0197-4580%2800%2900124-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit11R"><div class="casContent"><span class="casTitleNuber">11</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation and Alzheimer's disease</span></div><div class="casAuthors">Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G. M.; Cooper, N. R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B. L.; Finch, C. E.; Frautschy, S.; Griffin, W. S. T.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.-F.; Mrak, R.; Mackenzie, I. R.; McGeer, P. L.; O'Banion, M. K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F. L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T.</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">383-421</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">A review, with 636 refs.  Inflammation clearly occurs in pathol. vulnerable regions of the Alzheimer's disease (AD) brain, and it does so with the full complexity of local peripheral inflammatory responses.  In the periphery, degenerating tissue and the deposition of highly insol. abnormal materials are classical stimulants of inflammation.  Likewise, in the AD brain damaged neurons and neurites and highly insol. amyloid β peptide deposits and neurofibrillary tangles provide obvious stimuli for inflammation.  Because these stimuli are discrete, microlocalized, and present from early preclin. to terminal stages of AD, local upregulation of complement, cytokines, acute-phase reactants, and other inflammatory mediators is also discrete, microlocalized, and chronic.  Cumulated over many years, direct and bystander damage from AD inflammatory mechanisms is likely to exacerbate the very pathogenic processes that gave rise to it.  Thus, animal models and clin. studies, although still in their infancy, strongly suggest that AD inflammation contributes to AD pathogenesis.  By better understanding AD inflammatory and immunoregulatory processes, it should be possible to develop anti-inflammatory approaches that may not cure AD but will likely help slow the progression or delay the onset of this devastating disorder.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr72c3W8HExubVg90H21EOLACvtfcHk0liB9jf-R-6ovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXktVSmt74%253D&md5=409a0ca2920ef2cba12474cb7d05f4aa</span></div><a href="/servlet/linkout?suffix=cit11&amp;dbid=16384&amp;doi=10.1016%2FS0197-4580%2800%2900124-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0197-4580%252800%252900124-X%26sid%3Dliteratum%253Aachs%26aulast%3DAkiyama%26aufirst%3DH.%26aulast%3DBarger%26aufirst%3DS.%26aulast%3DBarnum%26aufirst%3DS.%26aulast%3DBradt%26aufirst%3DB.%26aulast%3DBauer%26aufirst%3DJ.%26aulast%3DCole%26aufirst%3DG.%2BM.%26aulast%3DCooper%26aufirst%3DN.%2BR.%26aulast%3DEikelenboom%26aufirst%3DP.%26aulast%3DEmmerling%26aufirst%3DM.%26aulast%3DFiebich%26aufirst%3DB.%2BL.%26aulast%3DFinch%26aufirst%3DC.%2BE.%26aulast%3DFrautschy%26aufirst%3DS.%26aulast%3DGriffin%26aufirst%3DW.%2BS.%2BT.%26aulast%3DHampel%26aufirst%3DH.%26aulast%3DHull%26aufirst%3DM.%26aulast%3DLandreth%26aufirst%3DG.%26aulast%3DLue%26aufirst%3DL.-F.%26aulast%3DMrak%26aufirst%3DR.%26aulast%3DMackenzie%26aufirst%3DI.%2BR.%26aulast%3DMcGeer%26aufirst%3DP.%2BL.%26aulast%3DO%25E2%2580%2599Banion%26aufirst%3DM.%2BB.%26aulast%3DPachter%26aufirst%3DJ.%26aulast%3DPasinetti%26aufirst%3DG.%26aulast%3DPlata-Salaman%26aufirst%3DC.%26aulast%3DRogers%26aufirst%3DJ.%26aulast%3DRydel%26aufirst%3DR.%26aulast%3DShen%26aufirst%3DY.%26aulast%3DStreit%26aufirst%3DW.%26aulast%3DStrohmeyer%26aufirst%3DR.%26aulast%3DTooyoma%26aufirst%3DI.%26aulast%3DVan%2BMuiswinkel%26aufirst%3DF.%2BL.%26aulast%3DVeerhuis%26aufirst%3DR.%26aulast%3DWalker%26aufirst%3DD.%26aulast%3DWebster%26aufirst%3DS.%26aulast%3DWegrzyniak%26aufirst%3DB.%26aulast%3DWenk%26aufirst%3DG.%26aulast%3DWyss-Coray%26aufirst%3DT.%26atitle%3DInflammation%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeurobiol.%2520Aging%26date%3D2000%26volume%3D21%26spage%3D383%26epage%3D421%26doi%3D10.1016%2FS0197-4580%2800%2900124-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref12"><div class="reference"><strong class="refLabel"><a href="#ref12" class="rightTabRefNumLink">12</a></strong><div class="NLM_citation" id="rightTab-cit12"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wyss-Coray, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mucke, L.</span></span> <span> </span><span class="NLM_article-title">Inflammation in neurodegenerative disease—a double-edged sword</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">419</span>– <span class="NLM_lpage">432</span>, <span class="refDoi"> DOI: 10.1016/S0896-6273(02)00794-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0896-6273%2802%2900794-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12165466" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref12/cit12&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38Xmt12isrs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2002&pages=419-432&author=T.+Wyss-Corayauthor=L.+Mucke&title=Inflammation+in+neurodegenerative+disease%E2%80%94a+double-edged+sword&doi=10.1016%2FS0896-6273%2802%2900794-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit12R"><div class="casContent"><span class="casTitleNuber">12</span><div class="casTitle"><span class="NLM_cas:atitle">Inflammation in neurodegenerative disease-a double-edged sword</span></div><div class="casAuthors">Wyss-Coray, Tony; Mucke, Lennart</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">419-432</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    
            (<span class="NLM_cas:orgname">Cell Press</span>)
        </div><div class="casAbstract">A review.  Inflammation is a defense reaction against diverse insults, designed to remove noxious agents and to inhibit their detrimental effects.  It consists of a dazzling array of mol. and cellular mechanisms and an intricate network of controls to keep them in check.  In neurodegenerative diseases, inflammation may be triggered by the accumulation of proteins with abnormal conformations or by signals emanating from injured neurons.  Given the multiple functions of many inflammatory factors, it has been difficult to pinpoint their roles in specific (patho)physiol. situations.  Studies of genetically modified mice and of mol. pathways in activated glia are beginning to shed light on this issue.  Altered expression of different inflammatory factors can either promote or counteract neurodegenerative processes.  Since many inflammatory responses are beneficial, directing and instructing the inflammatory machinery may be a better therapeutic objective than suppressing it.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGopCpnZhmVqr7Vg90H21EOLACvtfcHk0liB9jf-R-6ovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38Xmt12isrs%253D&md5=4d3562f56df8c1ab8d8e794d9821dea6</span></div><a href="/servlet/linkout?suffix=cit12&amp;dbid=16384&amp;doi=10.1016%2FS0896-6273%2802%2900794-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0896-6273%252802%252900794-8%26sid%3Dliteratum%253Aachs%26aulast%3DWyss-Coray%26aufirst%3DT.%26aulast%3DMucke%26aufirst%3DL.%26atitle%3DInflammation%2520in%2520neurodegenerative%2520disease%25E2%2580%2594a%2520double-edged%2520sword%26jtitle%3DNeuron%26date%3D2002%26volume%3D35%26spage%3D419%26epage%3D432%26doi%3D10.1016%2FS0896-6273%2802%2900794-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref13"><div class="reference"><strong class="refLabel"><a href="#ref13" class="rightTabRefNumLink">13</a></strong><div class="NLM_citation" id="rightTab-cit13"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Barger, S. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Harmon, A. D.</span></span> <span> </span><span class="NLM_article-title">Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1997</span>,  <span class="NLM_volume"><i>388</i></span>,  <span class="NLM_fpage">878</span>– <span class="NLM_lpage">881</span>, <span class="refDoi"> DOI: 10.1038/42257</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F42257" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9278049" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref13/cit13&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2sXlslagsrY%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=388&publication_year=1997&pages=878-881&author=S.+W.+Bargerauthor=A.+D.+Harmon&title=Microglial+activation+by+Alzheimer+amyloid+precursor+protein+and+modulation+by+apolipoprotein+E&doi=10.1038%2F42257"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit13R"><div class="casContent"><span class="casTitleNuber">13</span><div class="casTitle"><span class="NLM_cas:atitle">Microglial activation by Alzheimer amyloid precursor protein and modulation by apolipoprotein E</span></div><div class="casAuthors">Barger, Steven W.; Harmon, Ashley D.</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1997</span>),
    <span class="NLM_cas:volume">388</span>
        (<span class="NLM_cas:issue">6645</span>),
    <span class="NLM_cas:pages">878-881</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">A role for β-amyloid precursor protein (β-APP) in the development of Alzheimer's disease has been indicated by genetics, and many conditions in which β-APP is raised have been assocd. with an increased risk of Alzheimer's disease or an Alzheimer's-like pathol.  Inflammatory events may also contribute to Alzheimer's disease.  Here the authors investigate whether a secreted deriv. of β-APP (sAPP-α) can induce inflammatory reactions in microglia, which are brain cells of monocytic lineage.  The authors found that treatment with sAPP-α increased markers of activation in microglia and enhanced their prodn. of neurotoxins.  The ability of sAPP-α to activate microglia was blocked by prior incubation of the protein with apolipoprotein E3 but not E4, a variant assocd. with an increased risk for Alzheimer's.  A product of amyloidogenic β-APP processing (sAPP-β) also activated microglia.  Because sAPP-β is deficient in the neuroprotective activity shown by sAPP-α, the results indicate that increased amyloidogenic processing could adversely affect the balance of sAPP activities that det. neuronal viability.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpfT_4zAisRYLVg90H21EOLACvtfcHk0liB9jf-R-6ovQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2sXlslagsrY%253D&md5=db2c2a17c66253192067a297f6f7da1a</span></div><a href="/servlet/linkout?suffix=cit13&amp;dbid=16384&amp;doi=10.1038%2F42257&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F42257%26sid%3Dliteratum%253Aachs%26aulast%3DBarger%26aufirst%3DS.%2BW.%26aulast%3DHarmon%26aufirst%3DA.%2BD.%26atitle%3DMicroglial%2520activation%2520by%2520Alzheimer%2520amyloid%2520precursor%2520protein%2520and%2520modulation%2520by%2520apolipoprotein%2520E%26jtitle%3DNature%26date%3D1997%26volume%3D388%26spage%3D878%26epage%3D881%26doi%3D10.1038%2F42257" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref14"><div class="reference"><strong class="refLabel"><a href="#ref14" class="rightTabRefNumLink">14</a></strong><div class="NLM_citation" id="rightTab-cit14"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meda, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassatella, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Szendrei, G. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Otvos, L.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Baron, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villalba, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ferrari, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rossi, F.</span></span> <span> </span><span class="NLM_article-title">Activation of microglial cells by β-amyloid protein and interferon-γ</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>374</i></span>,  <span class="NLM_fpage">647</span>– <span class="NLM_lpage">650</span>, <span class="refDoi"> DOI: 10.1038/374647a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F374647a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7715705" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref14/cit14&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2MXltVOhsLs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=374&publication_year=1995&pages=647-650&author=L.+Medaauthor=M.+A.+Cassatellaauthor=G.+I.+Szendreiauthor=L.+Otvosauthor=P.+Baronauthor=M.+Villalbaauthor=D.+Ferrariauthor=F.+Rossi&title=Activation+of+microglial+cells+by+%CE%B2-amyloid+protein+and+interferon-%CE%B3&doi=10.1038%2F374647a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit14R"><div class="casContent"><span class="casTitleNuber">14</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of microglial cells by β-amyloid protein and interferon-γ</span></div><div class="casAuthors">Meda, Lucia; Cassatella, Marc A.; Szendrei, Gyorgyi I.; Otvos, Laszlo, Jr.; Baron, Pierluigi; Villalba, Martin; Ferrari, Davide; Rossi, Filippo</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London)</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">374</span>
        (<span class="NLM_cas:issue">6523</span>),
    <span class="NLM_cas:pages">647-50</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    
            (<span class="NLM_cas:orgname">Macmillan Magazines</span>)
        </div><div class="casAbstract">Alzheimer's disease is the most common cause of progressive intellectual failure.  The lesions that develop, called senile plaques, are extracellular deposits principally composed of insol. aggregates of β-amyloid protein (Aβ), infiltrated by reactive microglia and astrocytes.  Although Aβ, and a portion of it, the fragment 25-35 [Aβ(25-35)], have been shown to exert a direct toxic effect on neurons, the role of microglia in such neuronal injury remains unclear.  Here the authors report a synergistic effect between Aβ and interferon-γ (IFN-γ) in triggering the prodn. of reactive nitrogen intermediates and tumor-necrosis factor-α (TNF-α) from microglia.  Furthermore, using co-culture expts., the authors show that activation of microglia with IFN-γ and Aβ leads to neuronal cell injury in vitro.  Thus, Aβ and IFN-γ activate microglia to produce reactive nitrogen intermediates and TNF-α, and this may have a role in the pathogenesis of neuronal degeneration obsd. in aging and Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqnk_Q78NWIiLVg90H21EOLACvtfcHk0lhydNwaF2pN-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2MXltVOhsLs%253D&md5=5396aa76c1b554bc9a015f33508ec1d3</span></div><a href="/servlet/linkout?suffix=cit14&amp;dbid=16384&amp;doi=10.1038%2F374647a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F374647a0%26sid%3Dliteratum%253Aachs%26aulast%3DMeda%26aufirst%3DL.%26aulast%3DCassatella%26aufirst%3DM.%2BA.%26aulast%3DSzendrei%26aufirst%3DG.%2BI.%26aulast%3DOtvos%26aufirst%3DL.%26aulast%3DBaron%26aufirst%3DP.%26aulast%3DVillalba%26aufirst%3DM.%26aulast%3DFerrari%26aufirst%3DD.%26aulast%3DRossi%26aufirst%3DF.%26atitle%3DActivation%2520of%2520microglial%2520cells%2520by%2520%25CE%25B2-amyloid%2520protein%2520and%2520interferon-%25CE%25B3%26jtitle%3DNature%26date%3D1995%26volume%3D374%26spage%3D647%26epage%3D650%26doi%3D10.1038%2F374647a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref15"><div class="reference"><strong class="refLabel"><a href="#ref15" class="rightTabRefNumLink">15</a></strong><div class="NLM_citation" id="rightTab-cit15"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yang, C.-N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiao, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shie, F.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guo, B.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, P.-H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cho, C.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, F.-L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tsay, H.-J.</span></span> <span> </span><span class="NLM_article-title">Mechanism mediating oligomeric Aβ clearance by naïve primary microglia</span>. <i>Neurobiol. Dis.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">221</span>– <span class="NLM_lpage">230</span>, <span class="refDoi"> DOI: 10.1016/j.nbd.2011.01.005</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.nbd.2011.01.005" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21220023" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref15/cit15&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXkvVGlt7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=2011&pages=221-230&author=C.-N.+Yangauthor=Y.-J.+Shiaoauthor=F.-S.+Shieauthor=B.-S.+Guoauthor=P.-H.+Chenauthor=C.-Y.+Choauthor=Y.-J.+Chenauthor=F.-L.+Huangauthor=H.-J.+Tsay&title=Mechanism+mediating+oligomeric+A%CE%B2+clearance+by+na%C3%AFve+primary+microglia&doi=10.1016%2Fj.nbd.2011.01.005"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit15R"><div class="casContent"><span class="casTitleNuber">15</span><div class="casTitle"><span class="NLM_cas:atitle">Mechanism mediating oligomeric Aβ clearance by naive primary microglia</span></div><div class="casAuthors">Yang, Cheng-Ning; Shiao, Young-Ji; Shie, Feng-Shiun; Guo, Bo-Shen; Chen, Pei-Hao; Cho, Chi-Yuan; Chen, Yi-Jen; Huang, Fong-Lee; Tsay, Huey-Jen</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Disease</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">221-230</span>CODEN:
                <span class="NLM_cas:coden">NUDIEM</span>;
        ISSN:<span class="NLM_cas:issn">0969-9961</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The accumulation of sol. oligomeric amyloid-β peptide (oAβ) proceeds the formation of senile plaques and contributes to synaptic and memory deficits in Alzheimer's disease (AD).  The mechanism of mediating microglial oAβ [n.61472]clearance remains unclear and thought to occur via scavenger receptors (SRs) in microglia.  SRs respond to their ligands in a subtype-specific manner.  Therefore, we sought to identify the specific subtypes of SRs that mediate oAβ [n.61472]internalization and proteases that degrade oAβ [n.61472]species in naive primary microglia.  The component of oAβ species were characterized by western blot anal., anal. ultracentrifugation anal., and at. force microscopy.  The oAβ species remained sol. in the medium and microglial lysates during incubation at 37 °C.  SR-A, but not CD36, mediated oAβ internalization in microglia as suggested by the use of subtype-specific neutralizing antibodies and small interfering RNAs (siRNAs).  Immunopptn. anal. showed that oAβ [n.61472]interacted with SR-A on the plasma membrane.  After internalization, over 40% of oAβ vesicles were trafficked toward lysosomes and degraded by cysteine proteases, including cathepsin B. The inhibitors of proteasome, neprilysin, matrix metalloproteinases, and insulin degrading enzyme failed to protect internalized oAβ from degrdn.  Our study suggests that SR-A and lysosomal cathepsin B are crit. in microglial oAβ [n.61472]clearance, providing insight into how microglia are involved in the clearance of oAβ and their roles in the early stages of AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpv13L-K12jmbVg90H21EOLACvtfcHk0lhydNwaF2pN-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXkvVGlt7Y%253D&md5=bbee6e78e700a8db7f3ff6b5b0422cae</span></div><a href="/servlet/linkout?suffix=cit15&amp;dbid=16384&amp;doi=10.1016%2Fj.nbd.2011.01.005&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.nbd.2011.01.005%26sid%3Dliteratum%253Aachs%26aulast%3DYang%26aufirst%3DC.-N.%26aulast%3DShiao%26aufirst%3DY.-J.%26aulast%3DShie%26aufirst%3DF.-S.%26aulast%3DGuo%26aufirst%3DB.-S.%26aulast%3DChen%26aufirst%3DP.-H.%26aulast%3DCho%26aufirst%3DC.-Y.%26aulast%3DChen%26aufirst%3DY.-J.%26aulast%3DHuang%26aufirst%3DF.-L.%26aulast%3DTsay%26aufirst%3DH.-J.%26atitle%3DMechanism%2520mediating%2520oligomeric%2520A%25CE%25B2%2520clearance%2520by%2520na%25C3%25AFve%2520primary%2520microglia%26jtitle%3DNeurobiol.%2520Dis.%26date%3D2011%26volume%3D42%26spage%3D221%26epage%3D230%26doi%3D10.1016%2Fj.nbd.2011.01.005" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref16"><div class="reference"><strong class="refLabel"><a href="#ref16" class="rightTabRefNumLink">16</a></strong><div class="NLM_citation" id="rightTab-cit16"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wang, W.-Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, M.-S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, J.-T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, L.</span></span> <span> </span><span class="NLM_article-title">Role of pro-inflammatory cytokines released from microglia in Alzheimer’s disease</span>. <i>Ann. Transl. Med.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">136</span>, <span class="refDoi"> DOI: 10.3978/j.issn.2305-5839.2015.03.49</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.3978%2Fj.issn.2305-5839.2015.03.49" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26207229" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref16/cit16&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XnsFequrk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2015&pages=136&author=W.-Y.+Wangauthor=M.-S.+Tanauthor=J.-T.+Yuauthor=L.+Tan&title=Role+of+pro-inflammatory+cytokines+released+from+microglia+in+Alzheimer%E2%80%99s+disease&doi=10.3978%2Fj.issn.2305-5839.2015.03.49"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit16R"><div class="casContent"><span class="casTitleNuber">16</span><div class="casTitle"><span class="NLM_cas:atitle">Role of pro-inflammatory cytokines released from microglia in Alzheimer's disease</span></div><div class="casAuthors">Wang, Wen-Ying; Tan, Meng-Shan; Yu, Jin-Tai; Tan, Lan</div><div class="citationInfo"><span class="NLM_cas:title">Annals of Translational Medicine</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">10</span>),
    <span class="NLM_cas:pages">136/1-136/15</span>CODEN:
                <span class="NLM_cas:coden">ATMNDX</span>;
        ISSN:<span class="NLM_cas:issn">2305-5847</span>.
    
            (<span class="NLM_cas:orgname">AME Publishing Co.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the brain, which is characterized by the formation of extracellular amyloid plaques (or senile plaques) and intracellular neurofibrillary tangles.  However, increasing evidences demonstrated that neuroinflammatory changes, including chronic microgliosis are key pathol. components of AD.  Microglia, the resident immune cells of the brain, is constantly survey the microenvironment under physiol. conditions.  In AD, deposition of β-amyliod (Aβ) peptide initiates a spectrum of cerebral neuroinflammation mediated by activating microglia.  Activated microglia may play a potentially detrimental role by eliciting the expression of pro-inflammatory cytokines such as interleukin (IL)-1β, IL-6, and tumor necrosis factor-α (TNF-α) influencing the surrounding brain tissue.  Emerging studies have demonstrated that up-regulation of pro-inflammatory cytokines play multiple roles in both neurodegeneration and neuroprotection.  Understanding the pro-inflammatory cytokines signaling pathways involved in the regulation of AD is crucial to the development of strategies for therapy.  This review will discuss the mechanisms and important role of pro-inflammatory cytokines in the pathogenesis of AD, and the ongoing drug targeting pro-inflammatory cytokine for therapeutic modulation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrydEyb_SUzbbVg90H21EOLACvtfcHk0lhydNwaF2pN-Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XnsFequrk%253D&md5=21894d5d8de838c4137bfc5ebcd35218</span></div><a href="/servlet/linkout?suffix=cit16&amp;dbid=16384&amp;doi=10.3978%2Fj.issn.2305-5839.2015.03.49&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3978%252Fj.issn.2305-5839.2015.03.49%26sid%3Dliteratum%253Aachs%26aulast%3DWang%26aufirst%3DW.-Y.%26aulast%3DTan%26aufirst%3DM.-S.%26aulast%3DYu%26aufirst%3DJ.-T.%26aulast%3DTan%26aufirst%3DL.%26atitle%3DRole%2520of%2520pro-inflammatory%2520cytokines%2520released%2520from%2520microglia%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DAnn.%2520Transl.%2520Med.%26date%3D2015%26volume%3D3%26spage%3D136%26doi%3D10.3978%2Fj.issn.2305-5839.2015.03.49" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref17"><div class="reference"><strong class="refLabel"><a href="#ref17" class="rightTabRefNumLink">17</a></strong><div class="NLM_citation" id="rightTab-cit17"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Katona, I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Freund, T. F.</span></span> <span> </span><span class="NLM_article-title">Multiple functions of endocannabinoid signaling in the brain</span>. <i>Annu. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>35</i></span>,  <span class="NLM_fpage">529</span>– <span class="NLM_lpage">558</span>, <span class="refDoi"> DOI: 10.1146/annurev-neuro-062111-150420</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1146%2Fannurev-neuro-062111-150420" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22524785" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref17/cit17&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFegsbjE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=35&publication_year=2012&pages=529-558&author=I.+Katonaauthor=T.+F.+Freund&title=Multiple+functions+of+endocannabinoid+signaling+in+the+brain&doi=10.1146%2Fannurev-neuro-062111-150420"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit17R"><div class="casContent"><span class="casTitleNuber">17</span><div class="casTitle"><span class="NLM_cas:atitle">Multiple functions of endocannabinoid signaling in the brain</span></div><div class="casAuthors">Katona, Istvan; Freund, Tamas F.</div><div class="citationInfo"><span class="NLM_cas:title">Annual Review of Neuroscience</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">35</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">529-558</span>CODEN:
                <span class="NLM_cas:coden">ARNSD5</span>;
        ISSN:<span class="NLM_cas:issn">0147-006X</span>.
    
            (<span class="NLM_cas:orgname">Annual Reviews Inc.</span>)
        </div><div class="casAbstract">A review.  Despite being regarded as a hippie science for decades, cannabinoid research has finally found its well-deserved position in mainstream neuroscience.  A series of groundbreaking discoveries revealed that endocannabinoid mols. are as widespread and important as conventional neurotransmitters such as glutamate or GABA, yet they act in profoundly unconventional ways.  We aim to illustrate how uncovering the mol., anatomical, and physiol. characteristics of endocannabinoid signaling has revealed new mechanistic insights into several fundamental phenomena in synaptic physiol.  First, we summarize unexpected advances in the mol. complexity of biogenesis and inactivation of the two endocannabinoids, anandamide and 2-arachidonoylglycerol.  Then, we show how these new metabolic routes are integrated into well-known intracellular signaling pathways.  These endocannabinoid-producing signalosomes operate in phasic and tonic modes, thereby differentially governing homeostatic, short-term, and long-term synaptic plasticity throughout the brain.  Finally, we discuss how cell type- and synapse-specific refinement of endocannabinoid signaling may explain the characteristic behavioral effects of cannabinoids.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqcaMxJBq__27Vg90H21EOLACvtfcHk0ljcI9H2GqpEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFegsbjE&md5=4a150010c171ef8d4a7f8e201ff0f554</span></div><a href="/servlet/linkout?suffix=cit17&amp;dbid=16384&amp;doi=10.1146%2Fannurev-neuro-062111-150420&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-neuro-062111-150420%26sid%3Dliteratum%253Aachs%26aulast%3DKatona%26aufirst%3DI.%26aulast%3DFreund%26aufirst%3DT.%2BF.%26atitle%3DMultiple%2520functions%2520of%2520endocannabinoid%2520signaling%2520in%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Neurosci.%26date%3D2012%26volume%3D35%26spage%3D529%26epage%3D558%26doi%3D10.1146%2Fannurev-neuro-062111-150420" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref18"><div class="reference"><strong class="refLabel"><a href="#ref18" class="rightTabRefNumLink">18</a></strong><div class="NLM_citation" id="rightTab-cit18"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Parker, L. A.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system and the brain</span>. <i>Annu. Rev. Psychol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">21</span>– <span class="NLM_lpage">47</span>, <span class="refDoi"> DOI: 10.1146/annurev-psych-113011-143739</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1146%2Fannurev-psych-113011-143739" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22804774" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref18/cit18&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2013&pages=21-47&author=R.+Mechoulamauthor=L.+A.+Parker&title=The+endocannabinoid+system+and+the+brain&doi=10.1146%2Fannurev-psych-113011-143739"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit18R"><div class="casContent"><span class="casTitleNuber">18</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system and the brain</span></div><div class="casAuthors">Mechoulam Raphael; Parker Linda A</div><div class="citationInfo"><span class="NLM_cas:title">Annual review of psychology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">21-47</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">The psychoactive constituent in cannabis, Δ(9)-tetrahydrocannabinol (THC), was isolated in the mid-1960s, but the cannabinoid receptors, CB1 and CB2, and the major endogenous cannabinoids (anandamide and 2-arachidonoyl glycerol) were identified only 20 to 25 years later.  The cannabinoid system affects both central nervous system (CNS) and peripheral processes.  In this review, we have tried to summarize research--with an emphasis on recent publications--on the actions of the endocannabinoid system on anxiety, depression, neurogenesis, reward, cognition, learning, and memory.  The effects are at times biphasic--lower doses causing effects opposite to those seen at high doses.  Recently, numerous endocannabinoid-like compounds have been identified in the brain.  Only a few have been investigated for their CNS activity, and future investigations on their action may throw light on a wide spectrum of brain functions.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQHFfYzzaa6fbBItaL1WaVAfW6udTcc2eYbueLHfoxYFbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BC38fgs1yntg%253D%253D&md5=01c8b675ee9970bde0cb96d5e1b8a553</span></div><a href="/servlet/linkout?suffix=cit18&amp;dbid=16384&amp;doi=10.1146%2Fannurev-psych-113011-143739&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1146%252Fannurev-psych-113011-143739%26sid%3Dliteratum%253Aachs%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DParker%26aufirst%3DL.%2BA.%26atitle%3DThe%2520endocannabinoid%2520system%2520and%2520the%2520brain%26jtitle%3DAnnu.%2520Rev.%2520Psychol.%26date%3D2013%26volume%3D64%26spage%3D21%26epage%3D47%26doi%3D10.1146%2Fannurev-psych-113011-143739" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref19"><div class="reference"><strong class="refLabel"><a href="#ref19" class="rightTabRefNumLink">19</a></strong><div class="NLM_citation" id="rightTab-cit19"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lutz, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsicano, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maldonado, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span> <span> </span><span class="NLM_article-title">The endocannabinoid system in guarding against fear, anxiety and stress</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>16</i></span>,  <span class="NLM_fpage">705</span>– <span class="NLM_lpage">718</span>, <span class="refDoi"> DOI: 10.1038/nrn4036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn4036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26585799" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref19/cit19&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtb%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=16&publication_year=2015&pages=705-718&author=B.+Lutzauthor=G.+Marsicanoauthor=R.+Maldonadoauthor=C.+J.+Hillard&title=The+endocannabinoid+system+in+guarding+against+fear%2C+anxiety+and+stress&doi=10.1038%2Fnrn4036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit19R"><div class="casContent"><span class="casTitleNuber">19</span><div class="casTitle"><span class="NLM_cas:atitle">The endocannabinoid system in guarding against fear, anxiety and stress</span></div><div class="casAuthors">Lutz, Beat; Marsicano, Giovanni; Maldonado, Rafael; Hillard, Cecilia J.</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">16</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">705-718</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The endocannabinoid (eCB) system has emerged as a central integrator linking the perception of external and internal stimuli to distinct neurophysiol. and behavioral outcomes (such as fear reaction, anxiety and stress-coping), thus allowing an organism to adapt to its changing environment. eCB signaling seems to det. the value of fear-evoking stimuli and to tune appropriate behavioral responses, which are essential for the organism's long-term viability, homeostasis and stress resilience; and dysregulation of eCB signaling can lead to psychiatric disorders.  An understanding of the underlying neural cell populations and cellular processes enables the development of therapeutic strategies to mitigate behavioral maladaptation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpBKFcVfg5ub7Vg90H21EOLACvtfcHk0ljcI9H2GqpEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvVOgtb%252FI&md5=320dde506b7f434721cde79316af972d</span></div><a href="/servlet/linkout?suffix=cit19&amp;dbid=16384&amp;doi=10.1038%2Fnrn4036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn4036%26sid%3Dliteratum%253Aachs%26aulast%3DLutz%26aufirst%3DB.%26aulast%3DMarsicano%26aufirst%3DG.%26aulast%3DMaldonado%26aufirst%3DR.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26atitle%3DThe%2520endocannabinoid%2520system%2520in%2520guarding%2520against%2520fear%252C%2520anxiety%2520and%2520stress%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2015%26volume%3D16%26spage%3D705%26epage%3D718%26doi%3D10.1038%2Fnrn4036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref20"><div class="reference"><strong class="refLabel"><a href="#ref20" class="rightTabRefNumLink">20</a></strong><div class="NLM_citation" id="rightTab-cit20"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ameri, A.</span></span> <span> </span><span class="NLM_article-title">The effects of cannabinoids on the brain</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>58</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">348</span>, <span class="refDoi"> DOI: 10.1016/S0301-0082(98)00087-2</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0301-0082%2898%2900087-2" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10368032" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref20/cit20&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=58&publication_year=1999&pages=315-348&author=A.+Ameri&title=The+effects+of+cannabinoids+on+the+brain&doi=10.1016%2FS0301-0082%2898%2900087-2"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit20R"><div class="casContent"><span class="casTitleNuber">20</span><div class="casTitle"><span class="NLM_cas:atitle">The effects of cannabinoids on the brain</span></div><div class="casAuthors">Ameri, Angela</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford)</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">58</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">315-348</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">A review with many refs.  Cannabinoids have a long history of consumption for recreational and medical reasons.  The primary active constituent of the hemp plant Cannabis sativa is Δ9-tetrahydrocannabinol (Δ9-THC).  In humans, psychoactive cannabinoids produce euphoria, enhancement of sensory perception, tachycardia, antinociception, difficulties in concn. and impairment of memory.  The cognitive deficiencies seem to persist after withdrawal.  The toxicity of marijuana has been underestimated for a long time, since recent findings revealed Δ9-THC-induced cell death with shrinkage of neurons and DNA fragmentation in the hippocampus.  The acute effects of cannabinoids as well as the development of tolerance are mediated by G protein-coupled cannabinoid receptors.  The CB1 receptor and its splice variant CB1A, are found predominantly in the brain with highest densities in the hippocampus, cerebellum and striatum.  The CB2 receptor is found predominantly in the spleen and in hemopoietic cells and has only 44% overall nucleotide sequence identity with the CB1 receptor.  The existence of this receptor provided the mol. basis for the immunosuppressive actions of marijuana.  The CB1 receptor mediates inhibition of adenylate cyclase, inhibition of N- and P/Q-type calcium channels, stimulation of potassium channels, and activation of mitogen-activated protein kinase.  The CB2 receptor mediates inhibition of adenylate cyclase and activation of mitogen-activated protein kinase.  The discovery of endogenous cannabinoid receptor ligands, anandamide (N-arachidonylethanolamine) and 2-arachidonylglycerol made the notion of a central cannabinoid neuromodulatory system plausible.  Anandamide is released from neurons upon depolarization through a mechanism that requires calcium-dependent cleavage from a phospholipid precursor in neuronal membranes.  The release of anandamide is followed by rapid uptake into the plasma and hydrolysis by fatty-acid amidohydrolase.  The psychoactive cannabinoids increase the activity of dopaminergic neurons in the ventral tegmental area-mesolimbic pathway.  Since these dopaminergic circuits are known to play a pivotal role in mediating the reinforcing (rewarding) effects of the most drugs of abuse, the enhanced dopaminergic drive elicited by the cannabinoids is thought to underlie the reinforcing and abuse properties of marijuana.  Thus, cannabinoids share a final common neuronal action with other major drugs of abuse such as morphine, ethanol and nicotine in producing facilitation of the mesolimbic dopamine system.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpdPcJ7-vQg37Vg90H21EOLACvtfcHk0ljcI9H2GqpEdw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXjs1ejs7c%253D&md5=7ffe2ffb3c7604a4795f59aa240d260a</span></div><a href="/servlet/linkout?suffix=cit20&amp;dbid=16384&amp;doi=10.1016%2FS0301-0082%2898%2900087-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0301-0082%252898%252900087-2%26sid%3Dliteratum%253Aachs%26aulast%3DAmeri%26aufirst%3DA.%26atitle%3DThe%2520effects%2520of%2520cannabinoids%2520on%2520the%2520brain%26jtitle%3DProg.%2520Neurobiol.%26date%3D1999%26volume%3D58%26spage%3D315%26epage%3D348%26doi%3D10.1016%2FS0301-0082%2898%2900087-2" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref21"><div class="reference"><strong class="refLabel"><a href="#ref21" class="rightTabRefNumLink">21</a></strong><div class="NLM_citation" id="rightTab-cit21"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Munro, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, K. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Abu-Shaar, M.</span></span> <span> </span><span class="NLM_article-title">Molecular characterization of a peripheral receptor for cannabinoids</span>. <i>Nature</i> <span class="NLM_year" style="font-weight: bold;">1993</span>,  <span class="NLM_volume"><i>365</i></span>,  <span class="NLM_fpage">61</span>– <span class="NLM_lpage">65</span>, <span class="refDoi"> DOI: 10.1038/365061a0</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2F365061a0" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7689702" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref21/cit21&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=365&publication_year=1993&pages=61-65&author=S.+Munroauthor=K.+L.+Thomasauthor=M.+Abu-Shaar&title=Molecular+characterization+of+a+peripheral+receptor+for+cannabinoids&doi=10.1038%2F365061a0"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit21R"><div class="casContent"><span class="casTitleNuber">21</span><div class="casTitle"><span class="NLM_cas:atitle">Molecular characterization of a peripheral receptor for cannabinoids</span></div><div class="casAuthors">Munro, Sean; Thomas, Kerrie L.; Abu-Shaar, Muna</div><div class="citationInfo"><span class="NLM_cas:title">Nature (London, United Kingdom)</span>
        (<span class="NLM_cas:date">1993</span>),
    <span class="NLM_cas:volume">365</span>
        (<span class="NLM_cas:issue">6441</span>),
    <span class="NLM_cas:pages">61-5</span>CODEN:
                <span class="NLM_cas:coden">NATUAS</span>;
        ISSN:<span class="NLM_cas:issn">0028-0836</span>.
    </div><div class="casAbstract">The major active ingredient of marijuana, Δ9-tetrahydrocannabinol (Δ-THC), has been used as a psychoactive agent for thousands of years.  Marijuana, and Δ9-THC, also exert a wide range of other effects including analgesia, anti-inflammation, immunosuppression, anticonvulsion, alleviation of intraocular pressure in glaucoma, and attenuation of vomiting.  The clin. application of cannabinoids has, however, been limited by their psychoactive effects, and this has led to interest in the biochem. bases of their action.  Progress stemmed initially from the synthesis of potent derivs. of Δ9-THC4,5, and more recently from the cloning of a gene encoding a G-protein-coupled receptor for cannabinoids.  This receptor is expressed in the brain but not in the periphery, except for a low level in testes.  It has been proposed that the nonpsychoactive effects of cannabinoids are either mediated centrally or through direct interaction with other, non-receptor proteins.  Here the authors report the cloning of a receptor for cannabinoids that is not expressed in the brain but rather in macrophages in the marginal zone of spleen.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoHsq4vy1XH17Vg90H21EOLACvtfcHk0liP_FATrdaO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXmsVWiurk%253D&md5=476435b57bd0f24483e2f24b813cc32f</span></div><a href="/servlet/linkout?suffix=cit21&amp;dbid=16384&amp;doi=10.1038%2F365061a0&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252F365061a0%26sid%3Dliteratum%253Aachs%26aulast%3DMunro%26aufirst%3DS.%26aulast%3DThomas%26aufirst%3DK.%2BL.%26aulast%3DAbu-Shaar%26aufirst%3DM.%26atitle%3DMolecular%2520characterization%2520of%2520a%2520peripheral%2520receptor%2520for%2520cannabinoids%26jtitle%3DNature%26date%3D1993%26volume%3D365%26spage%3D61%26epage%3D65%26doi%3D10.1038%2F365061a0" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref22"><div class="reference"><strong class="refLabel"><a href="#ref22" class="rightTabRefNumLink">22</a></strong><div class="NLM_citation" id="rightTab-cit22"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Van
Sickle, M. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duncan, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kingsley, P. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mouihate, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Urbani, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stella, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piomelli, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davison, J. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marnett, L. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Di Marzo, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pittman, Q. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sharkey, K. A.</span></span> <span> </span><span class="NLM_article-title">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span>. <i>Science</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>310</i></span>,  <span class="NLM_fpage">329</span>– <span class="NLM_lpage">332</span>, <span class="refDoi"> DOI: 10.1126/science.1115740</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1126%2Fscience.1115740" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16224028" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref22/cit22&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=310&publication_year=2005&pages=329-332&author=M.+D.+Van%0ASickleauthor=M.+Duncanauthor=P.+J.+Kingsleyauthor=A.+Mouihateauthor=P.+Urbaniauthor=K.+Mackieauthor=N.+Stellaauthor=A.+Makriyannisauthor=D.+Piomelliauthor=J.+S.+Davisonauthor=L.+J.+Marnettauthor=V.+Di+Marzoauthor=Q.+J.+Pittmanauthor=K.+D.+Patelauthor=K.+A.+Sharkey&title=Identification+and+functional+characterization+of+brainstem+cannabinoid+CB2+receptors&doi=10.1126%2Fscience.1115740"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit22R"><div class="casContent"><span class="casTitleNuber">22</span><div class="casTitle"><span class="NLM_cas:atitle">Identification and functional characterization of brainstem cannabinoid CB2 receptors</span></div><div class="casAuthors">Van Sickle, Marja D.; Duncan, Marnie; Kingsley, Philip J.; Mouihate, Abdeslam; Urbani, Paolo; Mackie, Ken; Stella, Nephi; Makriyannis, Alexandros; Piomelli, Daniele; Davison, Joseph S.; Marnett, Lawrence J.; Di Marzo, Vincenzo; Pittman, Quentin J.; Patel, Kamala D.; Sharkey, Keith A.</div><div class="citationInfo"><span class="NLM_cas:title">Science (Washington, DC, United States)</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">310</span>
        (<span class="NLM_cas:issue">5746</span>),
    <span class="NLM_cas:pages">329-332</span>CODEN:
                <span class="NLM_cas:coden">SCIEAS</span>;
        ISSN:<span class="NLM_cas:issn">0036-8075</span>.
    
            (<span class="NLM_cas:orgname">American Association for the Advancement of Science</span>)
        </div><div class="casAbstract">The presence and function of CB2 receptors in central nervous system (CNS) neurons are controversial.  The authors report the expression of CB2 receptor mRNA and protein localization on brainstem neurons.  These functional CB2 receptors in the brainstem were activated by a CB2 receptor agonist, 2-arachidonoylglycerol, and by elevated endogenous levels of endocannabinoids, which also act at CB1 receptors.  CB2 receptors represent an alternative site of action of endocannabinoids that opens the possibility of nonpsychotropic therapeutic interventions using enhanced endocannabinoid levels in localized brain areas.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGriWgg6LDIT0bVg90H21EOLACvtfcHk0liP_FATrdaO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtV2hurvL&md5=ab457ab0bd1b8e30ea927a1e61366323</span></div><a href="/servlet/linkout?suffix=cit22&amp;dbid=16384&amp;doi=10.1126%2Fscience.1115740&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1126%252Fscience.1115740%26sid%3Dliteratum%253Aachs%26aulast%3DVan%2BSickle%26aufirst%3DM.%2BD.%26aulast%3DDuncan%26aufirst%3DM.%26aulast%3DKingsley%26aufirst%3DP.%2BJ.%26aulast%3DMouihate%26aufirst%3DA.%26aulast%3DUrbani%26aufirst%3DP.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DStella%26aufirst%3DN.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPiomelli%26aufirst%3DD.%26aulast%3DDavison%26aufirst%3DJ.%2BS.%26aulast%3DMarnett%26aufirst%3DL.%2BJ.%26aulast%3DDi%2BMarzo%26aufirst%3DV.%26aulast%3DPittman%26aufirst%3DQ.%2BJ.%26aulast%3DPatel%26aufirst%3DK.%2BD.%26aulast%3DSharkey%26aufirst%3DK.%2BA.%26atitle%3DIdentification%2520and%2520functional%2520characterization%2520of%2520brainstem%2520cannabinoid%2520CB2%2520receptors%26jtitle%3DScience%26date%3D2005%26volume%3D310%26spage%3D329%26epage%3D332%26doi%3D10.1126%2Fscience.1115740" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref23"><div class="reference"><strong class="refLabel"><a href="#ref23" class="rightTabRefNumLink">23</a></strong><div class="NLM_citation" id="rightTab-cit23"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pazos, M. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barbachano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fajardo, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">González, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolón, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: an immunohistochemical study</span>. <i>Synapse</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>53</i></span>,  <span class="NLM_fpage">208</span>– <span class="NLM_lpage">213</span>, <span class="refDoi"> DOI: 10.1002/syn.20050</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fsyn.20050" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15266552" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref23/cit23&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXms1Gns7w%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=53&publication_year=2004&pages=208-213&author=E.+N%C3%BA%C3%B1ezauthor=C.+Benitoauthor=M.+R.+Pazosauthor=A.+Barbachanoauthor=O.+Fajardoauthor=S.+Gonz%C3%A1lezauthor=R.+M.+Tol%C3%B3nauthor=J.+Romero&title=Cannabinoid+CB2+receptors+are+expressed+by+perivascular+microglial+cells+in+the+human+brain%3A+an+immunohistochemical+study&doi=10.1002%2Fsyn.20050"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit23R"><div class="casContent"><span class="casTitleNuber">23</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors are expressed by perivascular microglial cells in the human brain: An immunohistochemical study</span></div><div class="casAuthors">Nunez, Estefania; Benito, Cristina; Pazos, M. Ruth; Barbachano, Antonio; Fajardo, Otto; Gonzalez, Sara; Tolon, Rosa M.; Romero, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Synapse (New York, NY, United States)</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">53</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">208-213</span>CODEN:
                <span class="NLM_cas:coden">SYNAET</span>;
        ISSN:<span class="NLM_cas:issn">0887-4476</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">Two types of cannabinoid receptors have been characterized so far, CB1 and CB2.  While CB1 receptors are present both in the central nervous system and in the periphery, CB2 receptors showed an almost exclusive distribution within the immune system.  We now report that CB2 receptors are present in a specific microglial cell type of the human cerebellum.  Thus, we have performed immunohistochem. anal. of tissue sections of white matter areas of the human cerebellum and detected the presence of CB2 receptors in perivascular microglial cells.  These findings match with the well-known immunomodulatory role of CB2 receptors and open new perspectives on the possible role that these receptors may play in pathophysiol. events.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqoQ0hprkbR1bVg90H21EOLACvtfcHk0liP_FATrdaO6Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXms1Gns7w%253D&md5=38e2351802dff05a21b3d2e51169ec38</span></div><a href="/servlet/linkout?suffix=cit23&amp;dbid=16384&amp;doi=10.1002%2Fsyn.20050&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fsyn.20050%26sid%3Dliteratum%253Aachs%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DPazos%26aufirst%3DM.%2BR.%26aulast%3DBarbachano%26aufirst%3DA.%26aulast%3DFajardo%26aufirst%3DO.%26aulast%3DGonz%25C3%25A1lez%26aufirst%3DS.%26aulast%3DTol%25C3%25B3n%26aufirst%3DR.%2BM.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520are%2520expressed%2520by%2520perivascular%2520microglial%2520cells%2520in%2520the%2520human%2520brain%253A%2520an%2520immunohistochemical%2520study%26jtitle%3DSynapse%26date%3D2004%26volume%3D53%26spage%3D208%26epage%3D213%26doi%3D10.1002%2Fsyn.20050" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref24"><div class="reference"><strong class="refLabel"><a href="#ref24" class="rightTabRefNumLink">24</a></strong><div class="NLM_citation" id="rightTab-cit24"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grünblatt, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zander, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartl, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jie, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Monoranu, C. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Arzberger, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ravid, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roggendorf, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gerlach, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Riederer, P.</span></span> <span> </span><span class="NLM_article-title">Comparison analysis of gene expression patterns between sporadic Alzheimer’s and Parkinson’s disease</span>. <i>J. Alzheimer’s Dis.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">291</span>– <span class="NLM_lpage">311</span>, <span class="refDoi"> DOI: 10.3233/JAD-2007-12402</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.3233%2FJAD-2007-12402" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=18198416" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref24/cit24&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXisFKjtA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2007&pages=291-311&author=E.+Gr%C3%BCnblattauthor=N.+Zanderauthor=J.+Bartlauthor=L.+Jieauthor=C.+M.+Monoranuauthor=T.+Arzbergerauthor=R.+Ravidauthor=W.+Roggendorfauthor=M.+Gerlachauthor=P.+Riederer&title=Comparison+analysis+of+gene+expression+patterns+between+sporadic+Alzheimer%E2%80%99s+and+Parkinson%E2%80%99s+disease&doi=10.3233%2FJAD-2007-12402"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit24R"><div class="casContent"><span class="casTitleNuber">24</span><div class="casTitle"><span class="NLM_cas:atitle">Comparison Analysis of Gene Expression Patterns between Sporadic Alzheimer's and Parkinson's Disease</span></div><div class="casAuthors">Gruenblatt, Edna; Zander, Nicole; Bartl, Jasmin; Jie, Li; Monoranu, Camelia-Maria; Arzberger, Thomas; Ravid, Rivka; Roggendorf, Wolfgang; Gerlach, Manfred; Riederer, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Alzheimer's Disease</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">291-311</span>CODEN:
                <span class="NLM_cas:coden">JADIF9</span>;
        ISSN:<span class="NLM_cas:issn">1387-2877</span>.
    
            (<span class="NLM_cas:orgname">IOS Press</span>)
        </div><div class="casAbstract">Sporadic Alzheimer's (AD) and Parkinson's disease (PD) are late-onset neurodegenerative diseases with tremendous impact on lives of affected individuals.  There is a great probability of developing concurrent Parkinsonism in AD and vice-versa than would be predicted by independent prevalence of each disease.  We hypothesize that in sporadic AD as well as PD a combination of environmental effects and gene expression may affect specific brain areas leading to neurodegeneration.  We profiled gene expression of AD compared to PD and age matched controls post-mortem in the hippocampus, the gyrus-frontalis-medius (Gfm) and the cerebellum using Gene-Chip microarray (Affymetrix) and quant.-real-time-RT-PCR.  Twelve genes altered in similar manner in AD and PD, while four genes showed differential expression profiles between AD and PD in different brain regions (cannabinoid-receptor-2, Histone-cluster-1-H3e, nicotinic-cholinergic-receptor-α6 and β-site-APP-cleaving enzyme-1).  Knowledge of selective gene expression profile can lead to better understanding of disease pathol. and development of specific diagnosis and effective therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpt2Fj086--37Vg90H21EOLACvtfcHk0lg6p4hHdHCDjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXisFKjtA%253D%253D&md5=ca706394d8bc3649b7d316e42abd33f1</span></div><a href="/servlet/linkout?suffix=cit24&amp;dbid=16384&amp;doi=10.3233%2FJAD-2007-12402&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.3233%252FJAD-2007-12402%26sid%3Dliteratum%253Aachs%26aulast%3DGr%25C3%25BCnblatt%26aufirst%3DE.%26aulast%3DZander%26aufirst%3DN.%26aulast%3DBartl%26aufirst%3DJ.%26aulast%3DJie%26aufirst%3DL.%26aulast%3DMonoranu%26aufirst%3DC.%2BM.%26aulast%3DArzberger%26aufirst%3DT.%26aulast%3DRavid%26aufirst%3DR.%26aulast%3DRoggendorf%26aufirst%3DW.%26aulast%3DGerlach%26aufirst%3DM.%26aulast%3DRiederer%26aufirst%3DP.%26atitle%3DComparison%2520analysis%2520of%2520gene%2520expression%2520patterns%2520between%2520sporadic%2520Alzheimer%25E2%2580%2599s%2520and%2520Parkinson%25E2%2580%2599s%2520disease%26jtitle%3DJ.%2520Alzheimer%25E2%2580%2599s%2520Dis.%26date%3D2007%26volume%3D12%26spage%3D291%26epage%3D311%26doi%3D10.3233%2FJAD-2007-12402" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref25"><div class="reference"><strong class="refLabel"><a href="#ref25" class="rightTabRefNumLink">25</a></strong><div class="NLM_citation" id="rightTab-cit25"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Benito, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Núñez, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tolón, R. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carrier, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rábano, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hillard, C. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Romero, J.</span></span> <span> </span><span class="NLM_article-title">Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer’s disease brains</span>. <i>J. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>23</i></span>,  <span class="NLM_fpage">11136</span>– <span class="NLM_lpage">11141</span>, <span class="refDoi"> DOI: 10.1523/JNEUROSCI.23-35-11136.2003</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1523%2FJNEUROSCI.23-35-11136.2003" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=14657172" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref25/cit25&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXpvV2gtbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=23&publication_year=2003&pages=11136-11141&author=C.+Benitoauthor=E.+N%C3%BA%C3%B1ezauthor=R.+M.+Tol%C3%B3nauthor=E.+J.+Carrierauthor=A.+R%C3%A1banoauthor=C.+J.+Hillardauthor=J.+Romero&title=Cannabinoid+CB2+receptors+and+fatty+acid+amide+hydrolase+are+selectively+overexpressed+in+neuritic+plaque-associated+glia+in+Alzheimer%E2%80%99s+disease+brains&doi=10.1523%2FJNEUROSCI.23-35-11136.2003"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit25R"><div class="casContent"><span class="casTitleNuber">25</span><div class="casTitle"><span class="NLM_cas:atitle">Cannabinoid CB2 receptors and fatty acid amide hydrolase are selectively overexpressed in neuritic plaque-associated glia in Alzheimer's disease brains</span></div><div class="casAuthors">Benito, Cristina; Nunez, Estefania; Tolon, Rosa M.; Carrier, Erica J.; Rabano, Alberto; Hillard, Cecilia J.; Romero, Julian</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">23</span>
        (<span class="NLM_cas:issue">35</span>),
    <span class="NLM_cas:pages">11136-11141</span>CODEN:
                <span class="NLM_cas:coden">JNRSDS</span>;
        ISSN:<span class="NLM_cas:issn">0270-6474</span>.
    
            (<span class="NLM_cas:orgname">Society for Neuroscience</span>)
        </div><div class="casAbstract">The endocannabinoid system is still poorly understood.  Recently, the basic elements that constitute it, i.e., membrane receptors, endogenous ligands, and mechanisms for termination of the signaling process, have been partially characterized.  There is a considerable lack of information, however, concerning the distribution, concn., and function of those components in the human body, particularly during pathol. events.  We have studied the status of some of the components of the endocannabinoid system, fatty acid amide hydrolase and cannabinoid CB1 and CB2 receptors, in postmortem brains from patients with Alzheimer's disease.  Using specific polyclonal antibodies, we have performed immunohistochem. anal. in hippocampus and entorhinal cortex sections from brains of Alzheimer's disease patients.  Our results show that both fatty acid amide hydrolase and cannabinoid CB2 receptors are abundantly and selectively expressed in neuritic plaque-assocd. astrocytes and microglia, resp., whereas the expression of CB1 receptors remains unchanged.  In addn., the hydrolase activity seems to be elevated in the plaques and surrounding areas.  Thus, some elements of the endocannabinoid system may be postulated as possible modulators of the inflammatory response assocd. with this neurodegenerative process and as possible targets for new therapeutic approaches.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ8Gm8V3n8jrVg90H21EOLACvtfcHk0lg6p4hHdHCDjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXpvV2gtbw%253D&md5=c324980efac10a672fc425ef376694f1</span></div><a href="/servlet/linkout?suffix=cit25&amp;dbid=16384&amp;doi=10.1523%2FJNEUROSCI.23-35-11136.2003&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1523%252FJNEUROSCI.23-35-11136.2003%26sid%3Dliteratum%253Aachs%26aulast%3DBenito%26aufirst%3DC.%26aulast%3DN%25C3%25BA%25C3%25B1ez%26aufirst%3DE.%26aulast%3DTol%25C3%25B3n%26aufirst%3DR.%2BM.%26aulast%3DCarrier%26aufirst%3DE.%2BJ.%26aulast%3DR%25C3%25A1bano%26aufirst%3DA.%26aulast%3DHillard%26aufirst%3DC.%2BJ.%26aulast%3DRomero%26aufirst%3DJ.%26atitle%3DCannabinoid%2520CB2%2520receptors%2520and%2520fatty%2520acid%2520amide%2520hydrolase%2520are%2520selectively%2520overexpressed%2520in%2520neuritic%2520plaque-associated%2520glia%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520brains%26jtitle%3DJ.%2520Neurosci.%26date%3D2003%26volume%3D23%26spage%3D11136%26epage%3D11141%26doi%3D10.1523%2FJNEUROSCI.23-35-11136.2003" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref26"><div class="reference"><strong class="refLabel"><a href="#ref26" class="rightTabRefNumLink">26</a></strong><div class="NLM_citation" id="rightTab-cit26"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bisogno, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Oddi, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Piccoli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fazio, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maccarrone, M.</span></span> <span> </span><span class="NLM_article-title">Type-2 cannabinoid receptors in neurodegeneration</span>. <i>Pharmacol. Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>111</i></span>,  <span class="NLM_fpage">721</span>– <span class="NLM_lpage">730</span>, <span class="refDoi"> DOI: 10.1016/j.phrs.2016.07.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.phrs.2016.07.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=27450295" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref26/cit26&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr7F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=111&publication_year=2016&pages=721-730&author=T.+Bisognoauthor=S.+Oddiauthor=A.+Piccoliauthor=D.+Fazioauthor=M.+Maccarrone&title=Type-2+cannabinoid+receptors+in+neurodegeneration&doi=10.1016%2Fj.phrs.2016.07.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit26R"><div class="casContent"><span class="casTitleNuber">26</span><div class="casTitle"><span class="NLM_cas:atitle">Type-2 cannabinoid receptors in neurodegeneration</span></div><div class="casAuthors">Bisogno, Tiziana; Oddi, Sergio; Piccoli, Alessandra; Fazio, Domenico; Maccarrone, Mauro</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">111</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">721-730</span>CODEN:
                <span class="NLM_cas:coden">PHMREP</span>;
        ISSN:<span class="NLM_cas:issn">1043-6618</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">Based on its wide expression in immune cells, type-2 cannabinoid (CB2) receptors were traditionally thought to act as "peripheral receptors" with an almost exclusively immunomodulatory function.  However, their recent identification in mammalian brain areas, as well as in distinct neuronal cells, has opened the way to a re-consideration of CB2 signaling in the context of brain pathophysiol., synaptic plasticity and neuroprotection.  To date, accumulated evidence from several independent preclin. studies has offered new perspectives on the possible involvement of CB2 signaling in brain and spinal cord traumatic injury, as well as in the most relevant neurodegenerative disorders like Alzheimer's disease, Parkinson's disease and Huntington's chorea.  Here, we will review available information on CB2 in these disease conditions, along with data that support also its therapeutic potential to treat them.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoDLv1Yh2dX27Vg90H21EOLACvtfcHk0lg6p4hHdHCDjw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhtlWnsr7F&md5=b880502073163ef08a7af918544a7dd1</span></div><a href="/servlet/linkout?suffix=cit26&amp;dbid=16384&amp;doi=10.1016%2Fj.phrs.2016.07.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.phrs.2016.07.021%26sid%3Dliteratum%253Aachs%26aulast%3DBisogno%26aufirst%3DT.%26aulast%3DOddi%26aufirst%3DS.%26aulast%3DPiccoli%26aufirst%3DA.%26aulast%3DFazio%26aufirst%3DD.%26aulast%3DMaccarrone%26aufirst%3DM.%26atitle%3DType-2%2520cannabinoid%2520receptors%2520in%2520neurodegeneration%26jtitle%3DPharmacol.%2520Res.%26date%3D2016%26volume%3D111%26spage%3D721%26epage%3D730%26doi%3D10.1016%2Fj.phrs.2016.07.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref27"><div class="reference"><strong class="refLabel"><a href="#ref27" class="rightTabRefNumLink">27</a></strong><div class="NLM_citation" id="rightTab-cit27"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ehrhart, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Obregon, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hou, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bai, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fernandez, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shytle, R. D.</span></span> <span> </span><span class="NLM_article-title">Stimulation of cannabinoid receptor 2 (CB 2) suppresses microglial activation</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">29</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-2-29</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1186%2F1742-2094-2-29" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16343349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref27/cit27&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BD28%252FlvFWnsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=2005&pages=29&author=J.+Ehrhartauthor=D.+Obregonauthor=T.+Moriauthor=H.+Houauthor=N.+Sunauthor=Y.+Baiauthor=T.+Kleinauthor=F.+Fernandezauthor=J.+Tanauthor=R.+D.+Shytle&title=Stimulation+of+cannabinoid+receptor+2+%28CB+2%29+suppresses+microglial+activation&doi=10.1186%2F1742-2094-2-29"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit27R"><div class="casContent"><span class="casTitleNuber">27</span><div class="casTitle"><span class="NLM_cas:atitle">Stimulation of cannabinoid receptor 2 (CB2) suppresses microglial activation</span></div><div class="casAuthors">Ehrhart Jared; Obregon Demian; Mori Takashi; Hou Huayan; Sun Nan; Bai Yun; Klein Thomas; Fernandez Francisco; Tan Jun; Shytle R Douglas</div><div class="citationInfo"><span class="NLM_cas:title">Journal of neuroinflammation</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">29</span>
        ISSN:<span class="NLM_cas:issn"></span>.
    </div><div class="casAbstract">BACKGROUND:  Activated microglial cells have been implicated in a number of neurodegenerative disorders, including Alzheimer's disease (AD), multiple sclerosis (MS), and HIV dementia.  It is well known that inflammatory mediators such as nitric oxide (NO), cytokines, and chemokines play an important role in microglial cell-associated neuron cell damage.  Our previous studies have shown that CD40 signaling is involved in pathological activation of microglial cells.  Many data reveal that cannabinoids mediate suppression of inflammation in vitro and in vivo through stimulation of cannabinoid receptor 2 (CB2).  METHODS:  In this study, we investigated the effects of a cannabinoid agonist on CD40 expression and function by cultured microglial cells activated by IFN-gamma using RT-PCR, Western immunoblotting, flow cytometry, and anti-CB2 small interfering RNA (siRNA) analyses.  Furthermore, we examined if the stimulation of CB2 could modulate the capacity of microglial cells to phagocytise Abeta1-42 peptide using a phagocytosis assay.  RESULTS:  We found that the selective stimulation of cannabinoid receptor CB2 by JWH-015 suppressed IFN-gamma-induced CD40 expression.  In addition, this CB2 agonist markedly inhibited IFN-gamma-induced phosphorylation of JAK/STAT1.  Further, this stimulation was also able to suppress microglial TNF-alpha and nitric oxide production induced either by IFN-gamma or Abeta peptide challenge in the presence of CD40 ligation.  Finally, we showed that CB2 activation by JWH-015 markedly attenuated CD40-mediated inhibition of microglial phagocytosis of Abeta1-42 peptide.  Taken together, these results provide mechanistic insight into beneficial effects provided by cannabinoid receptor CB2 modulation in neurodegenerative diseases, particularly AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTwpZCNS5cmhmhHGZei4OW9fW6udTcc2eZTAaPIcVVJcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD28%252FlvFWnsA%253D%253D&md5=516f5264a60d5aa11675107dbd0e8879</span></div><a href="/servlet/linkout?suffix=cit27&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-2-29&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-2-29%26sid%3Dliteratum%253Aachs%26aulast%3DEhrhart%26aufirst%3DJ.%26aulast%3DObregon%26aufirst%3DD.%26aulast%3DMori%26aufirst%3DT.%26aulast%3DHou%26aufirst%3DH.%26aulast%3DSun%26aufirst%3DN.%26aulast%3DBai%26aufirst%3DY.%26aulast%3DKlein%26aufirst%3DT.%26aulast%3DFernandez%26aufirst%3DF.%26aulast%3DTan%26aufirst%3DJ.%26aulast%3DShytle%26aufirst%3DR.%2BD.%26atitle%3DStimulation%2520of%2520cannabinoid%2520receptor%25202%2520%2528CB%25202%2529%2520suppresses%2520microglial%2520activation%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2005%26volume%3D2%26spage%3D29%26doi%3D10.1186%2F1742-2094-2-29" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref28"><div class="reference"><strong class="refLabel"><a href="#ref28" class="rightTabRefNumLink">28</a></strong><div class="NLM_citation" id="rightTab-cit28"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Holgado, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Molina-Holgado, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guaza, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rothwell, N. J.</span></span> <span> </span><span class="NLM_article-title">Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures</span>. <i>J. Neurosci. Res.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>67</i></span>,  <span class="NLM_fpage">829</span>– <span class="NLM_lpage">836</span>, <span class="refDoi"> DOI: 10.1002/jnr.10165</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fjnr.10165" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11891798" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref28/cit28&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XitFCgtLo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=67&publication_year=2002&pages=829-836&author=F.+Molina-Holgadoauthor=E.+Molina-Holgadoauthor=C.+Guazaauthor=N.+J.+Rothwell&title=Role+of+CB1+and+CB2+receptors+in+the+inhibitory+effects+of+cannabinoids+on+lipopolysaccharide-induced+nitric+oxide+release+in+astrocyte+cultures&doi=10.1002%2Fjnr.10165"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit28R"><div class="casContent"><span class="casTitleNuber">28</span><div class="casTitle"><span class="NLM_cas:atitle">Role of CB1 and CB2 receptors in the inhibitory effects of cannabinoids on lipopolysaccharide-induced nitric oxide release in astrocyte cultures</span></div><div class="casAuthors">Molina-Holgado, Francisco; Molina-Holgado, Eduardo; Guaza, Carmen; Rothwell, Nancy J.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neuroscience Research</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">67</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">829-836</span>CODEN:
                <span class="NLM_cas:coden">JNREDK</span>;
        ISSN:<span class="NLM_cas:issn">0360-4012</span>.
    
            (<span class="NLM_cas:orgname">Wiley-Liss, Inc.</span>)
        </div><div class="casAbstract">The purpose of this study was to investigate the role of the central cannabinoid receptor (CB1) in mediating the actions of the endogenous cannabinoid agonist anandamide and the synthetic cannabinoid CP-55940.  Activation of primary mouse astrocyte cultures by exposure to bacterial lipopolysaccharide (LPS) caused a marked (approx. tenfold) increase in nitric oxide (NO) release.  Coincubation with the cannabinoid agonists anandamide or CP-55940 markedly inhibited release of NO (-12% to -55%).  This effect was abolished by SR-141716A (1 μM), a CB1 receptor antagonist.  SR-141716A alone also significantly increased NO release in response to LPS, suggesting that endogenous cannabinoids modify inflammatory responses.  In contrast, coincubation with the CB2 receptor antagonist SR-144528 (1 μM) abolished the inhibitory effects of the endogenous cannabinoid anandamide on LPS-induced NO release, although this may reflect nonspecific effects of this ligand or cannabinoid actions through atypical receptors of anandamide.  We also showed that endogenous or synthetic cannabinoids inhibit LPS-induced inducible NO synthase expression (mRNA and protein) in astrocyte cultures.  These results indicate that CB1 receptors may promote antiinflammatory responses in astrocytes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGob_NRvXnWJg7Vg90H21EOLACvtfcHk0liVccspQS9Pzg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XitFCgtLo%253D&md5=4a2e3e4f6d36a78359f79549e6ee4214</span></div><a href="/servlet/linkout?suffix=cit28&amp;dbid=16384&amp;doi=10.1002%2Fjnr.10165&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fjnr.10165%26sid%3Dliteratum%253Aachs%26aulast%3DMolina-Holgado%26aufirst%3DF.%26aulast%3DMolina-Holgado%26aufirst%3DE.%26aulast%3DGuaza%26aufirst%3DC.%26aulast%3DRothwell%26aufirst%3DN.%2BJ.%26atitle%3DRole%2520of%2520CB1%2520and%2520CB2%2520receptors%2520in%2520the%2520inhibitory%2520effects%2520of%2520cannabinoids%2520on%2520lipopolysaccharide-induced%2520nitric%2520oxide%2520release%2520in%2520astrocyte%2520cultures%26jtitle%3DJ.%2520Neurosci.%2520Res.%26date%3D2002%26volume%3D67%26spage%3D829%26epage%3D836%26doi%3D10.1002%2Fjnr.10165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref29"><div class="reference"><strong class="refLabel"><a href="#ref29" class="rightTabRefNumLink">29</a></strong><div class="NLM_citation" id="rightTab-cit29"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Sheng, W. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hu, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Min, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lokensgard, J. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Peterson, P. K.</span></span> <span> </span><span class="NLM_article-title">Synthetic cannabinoid WIN55, 212-2 inhibits generation of inflammatory mediators by IL-1β-stimulated human astrocytes</span>. <i>Glia</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>49</i></span>,  <span class="NLM_fpage">211</span>– <span class="NLM_lpage">219</span>, <span class="refDoi"> DOI: 10.1002/glia.20108</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fglia.20108" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15390091" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref29/cit29&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADC%252BD2crpsF2ksQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=49&publication_year=2005&pages=211-219&author=W.+S.+Shengauthor=S.+Huauthor=X.+Minauthor=G.+A.+Cabralauthor=J.+R.+Lokensgardauthor=P.+K.+Peterson&title=Synthetic+cannabinoid+WIN55%2C+212-2+inhibits+generation+of+inflammatory+mediators+by+IL-1%CE%B2-stimulated+human+astrocytes&doi=10.1002%2Fglia.20108"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit29R"><div class="casContent"><span class="casTitleNuber">29</span><div class="casTitle"><span class="NLM_cas:atitle">Synthetic cannabinoid WIN55,212-2 inhibits generation of inflammatory mediators by IL-1beta-stimulated human astrocytes</span></div><div class="casAuthors">Sheng Wen S; Hu Shuxian; Min Xinan; Cabral Guy A; Lokensgard James R; Peterson Phillip K</div><div class="citationInfo"><span class="NLM_cas:title">Glia</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">49</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">211-9</span>
        ISSN:<span class="NLM_cas:issn">0894-1491</span>.
    </div><div class="casAbstract">Activated glial cells have been implicated in the neuropathogenesis of many infectious and inflammatory diseases of the brain.  A number of inflammatory mediators have been proposed to play a role in glial cell-related brain damage; e.g., free radicals such as nitric oxide (NO), cytokines, and chemokines.  Our laboratory has been interested in the effect of psychoactive drugs and their derivatives on the production of these mediators.  Cannabinoids have been shown to possess immunomodulatory as well as psychoactive properties.  We previously have shown that interleukin (IL)-1beta-stimulated human astrocytes, but not microglia, produce NO.  In this study, we investigated the effects of the synthetic cannabinoid WIN55,212-2 on the production of several key inflammatory mediators by human fetal astrocytes activated by IL-1beta.  Expression of the cannabinoid receptors CB1 and CB2 was detected on human astrocytes.  WIN55,212-2 (10(-5) M) potently inhibited inducible NO synthase (iNOS) and corresponding NO production by IL-1beta-stimulated astrocytes.  The CB1 and CB2 receptor-specific antagonists SR141716A and SR144528, respectively, partially blocked this suppressive effect.  In addition, treatment of astrocytes with WIN55,212-2 downregulated in a concentration-dependent manner IL-1beta-induced tumor necrosis factor (TNF)-alpha release.  Treatment with WIN55,212-2 also inhibited production of the chemokines CXCL10, CCL2 and CCL5 by IL-1beta-activated astrocytes.  These findings indicate that WIN55,212-2 inhibits the production of inflammatory mediators by IL-1beta-stimulated human astrocytes and suggest that comparable agents may have therapeutic potential for the management of brain inflammation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTisPFlwsWFEUGy1nwu7K2mfW6udTcc2eZTAaPIcVVJcLntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADC%252BD2crpsF2ksQ%253D%253D&md5=cc98950a8387f6ce90b2c707dc8e15e2</span></div><a href="/servlet/linkout?suffix=cit29&amp;dbid=16384&amp;doi=10.1002%2Fglia.20108&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fglia.20108%26sid%3Dliteratum%253Aachs%26aulast%3DSheng%26aufirst%3DW.%2BS.%26aulast%3DHu%26aufirst%3DS.%26aulast%3DMin%26aufirst%3DX.%26aulast%3DCabral%26aufirst%3DG.%2BA.%26aulast%3DLokensgard%26aufirst%3DJ.%2BR.%26aulast%3DPeterson%26aufirst%3DP.%2BK.%26atitle%3DSynthetic%2520cannabinoid%2520WIN55%252C%2520212-2%2520inhibits%2520generation%2520of%2520inflammatory%2520mediators%2520by%2520IL-1%25CE%25B2-stimulated%2520human%2520astrocytes%26jtitle%3DGlia%26date%3D2005%26volume%3D49%26spage%3D211%26epage%3D219%26doi%3D10.1002%2Fglia.20108" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref30"><div class="reference"><strong class="refLabel"><a href="#ref30" class="rightTabRefNumLink">30</a></strong><div class="NLM_citation" id="rightTab-cit30"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Wu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bie, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, J. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, D. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naguib, M.</span></span> <span> </span><span class="NLM_article-title">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span>. <i>Neurobiol. Aging</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">791</span>– <span class="NLM_lpage">804</span>, <span class="refDoi"> DOI: 10.1016/j.neurobiolaging.2012.06.011</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.neurobiolaging.2012.06.011" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22795792" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref30/cit30&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2013&pages=791-804&author=J.+Wuauthor=B.+Bieauthor=H.+Yangauthor=J.+J.+Xuauthor=D.+L.+Brownauthor=M.+Naguib&title=Activation+of+the+CB2+receptor+system+reverses+amyloid-induced+memory+deficiency&doi=10.1016%2Fj.neurobiolaging.2012.06.011"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit30R"><div class="casContent"><span class="casTitleNuber">30</span><div class="casTitle"><span class="NLM_cas:atitle">Activation of the CB2 receptor system reverses amyloid-induced memory deficiency</span></div><div class="casAuthors">Wu, Jiang; Bie, Bihua; Yang, Hui; Xu, Jijun J.; Brown, David L.; Naguib, Mohamed</div><div class="citationInfo"><span class="NLM_cas:title">Neurobiology of Aging</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">791-804</span>CODEN:
                <span class="NLM_cas:coden">NEAGDO</span>;
        ISSN:<span class="NLM_cas:issn">0197-4580</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Cannabinoid type 2 (CB2) agonists are neuroprotective and appear to play modulatory roles in neurodegenerative processes in Alzheimer's disease.  We have studied the effect of 1-((3-benzyl-3-methyl-2,3-dihydro-1-benzofuran-6-yl) carbonyl) piperidine (MDA7)-a novel selective CB2 agonist that lacks psychoactivity-on ameliorating the neuroinflammatory process, synaptic dysfunction, and cognitive impairment induced by bilateral microinjection of amyloid-β (Aβ)1-40 fibrils into the hippocampal CA1 area of rats.  In rats injected with Aβ1-40 fibrils, compared with the administration of i.p. saline for 14 days, treatment with 15 mg/kg of i.p. MDA7 daily for 14 days (1) ameliorated the expression of CD11b (microglia marker) and glial fibrillary acidic protein (astrocyte marker), (2) decreased the secretion of interleukin-1β, (3) decreased the upsurge of CB2 receptors, (4) promoted Aβ clearance, and (5) restored synaptic plasticity, cognition, and memory.  Our findings suggest that MDA7 is an innovative therapeutic approach for the treatment of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqekBBhIM0ej7Vg90H21EOLACvtfcHk0lhwGONDakNT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtVektLnO&md5=ee0c45a830bc6f4d2236ccfcee75b2ad</span></div><a href="/servlet/linkout?suffix=cit30&amp;dbid=16384&amp;doi=10.1016%2Fj.neurobiolaging.2012.06.011&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neurobiolaging.2012.06.011%26sid%3Dliteratum%253Aachs%26aulast%3DWu%26aufirst%3DJ.%26aulast%3DBie%26aufirst%3DB.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DXu%26aufirst%3DJ.%2BJ.%26aulast%3DBrown%26aufirst%3DD.%2BL.%26aulast%3DNaguib%26aufirst%3DM.%26atitle%3DActivation%2520of%2520the%2520CB2%2520receptor%2520system%2520reverses%2520amyloid-induced%2520memory%2520deficiency%26jtitle%3DNeurobiol.%2520Aging%26date%3D2013%26volume%3D34%26spage%3D791%26epage%3D804%26doi%3D10.1016%2Fj.neurobiolaging.2012.06.011" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref31"><div class="reference"><strong class="refLabel"><a href="#ref31" class="rightTabRefNumLink">31</a></strong><div class="NLM_citation" id="rightTab-cit31"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Martín-Moreno, A. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brera, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spuch, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Carro, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">García-García, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delgado, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pozo, M. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Innamorato, N. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cuadrado, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Ceballos, M. L.</span></span> <span> </span><span class="NLM_article-title">Prolonged oral cannabinoid administration prevents neuroinflammation, lowers β-amyloid levels and improves cognitive performance in Tg APP 2576 mice</span>. <i>J. Neuroinflammation</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">15</span>, <span class="refDoi"> DOI: 10.1186/1742-2094-9-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1186%2F1742-2094-9-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref31/cit31&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22212381" title="">PubMed</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2012&pages=1-15&author=A.+M.+Mart%C3%ADn-Morenoauthor=B.+Breraauthor=C.+Spuchauthor=E.+Carroauthor=L.+Garc%C3%ADa-Garc%C3%ADaauthor=M.+Delgadoauthor=M.+A.+Pozoauthor=N.+G.+Innamoratoauthor=A.+Cuadradoauthor=M.+L.+de+Ceballos&title=Prolonged+oral+cannabinoid+administration+prevents+neuroinflammation%2C+lowers+%CE%B2-amyloid+levels+and+improves+cognitive+performance+in+Tg+APP+2576+mice&doi=10.1186%2F1742-2094-9-8"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit31&amp;dbid=16384&amp;doi=10.1186%2F1742-2094-9-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1186%252F1742-2094-9-8%26sid%3Dliteratum%253Aachs%26aulast%3DMart%25C3%25ADn-Moreno%26aufirst%3DA.%2BM.%26aulast%3DBrera%26aufirst%3DB.%26aulast%3DSpuch%26aufirst%3DC.%26aulast%3DCarro%26aufirst%3DE.%26aulast%3DGarc%25C3%25ADa-Garc%25C3%25ADa%26aufirst%3DL.%26aulast%3DDelgado%26aufirst%3DM.%26aulast%3DPozo%26aufirst%3DM.%2BA.%26aulast%3DInnamorato%26aufirst%3DN.%2BG.%26aulast%3DCuadrado%26aufirst%3DA.%26aulast%3Dde%2BCeballos%26aufirst%3DM.%2BL.%26atitle%3DProlonged%2520oral%2520cannabinoid%2520administration%2520prevents%2520neuroinflammation%252C%2520lowers%2520%25CE%25B2-amyloid%2520levels%2520and%2520improves%2520cognitive%2520performance%2520in%2520Tg%2520APP%25202576%2520mice%26jtitle%3DJ.%2520Neuroinflammation%26date%3D2012%26volume%3D9%26spage%3D1%26epage%3D15%26doi%3D10.1186%2F1742-2094-9-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref32"><div class="reference"><strong class="refLabel"><a href="#ref32" class="rightTabRefNumLink">32</a></strong><div class="NLM_citation" id="rightTab-cit32"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Koppel, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vingtdeux, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marambaud, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">d’Abramo, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jimenez, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stauber, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Friedman, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span> <span> </span><span class="NLM_article-title">CB2 receptor deficiency increases amyloid pathology and alters tau processing in a transgenic mouse model of Alzheimer’s disease</span>. <i>Mol. Med.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">29</span>– <span class="NLM_lpage">36</span>, <span class="refDoi"> DOI: 10.2119/molmed.2013.00140</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref32/cit32&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2119%2Fmolmed.2013.00140" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=2013&pages=29-36&author=J.+Koppelauthor=V.+Vingtdeuxauthor=P.+Marambaudauthor=C.+d%E2%80%99Abramoauthor=H.+Jimenezauthor=M.+Stauberauthor=R.+Friedmanauthor=P.+Davies&title=CB2+receptor+deficiency+increases+amyloid+pathology+and+alters+tau+processing+in+a+transgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.2119%2Fmolmed.2013.00140"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit32&amp;dbid=16384&amp;doi=10.2119%2Fmolmed.2013.00140&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2119%252Fmolmed.2013.00140%26sid%3Dliteratum%253Aachs%26aulast%3DKoppel%26aufirst%3DJ.%26aulast%3DVingtdeux%26aufirst%3DV.%26aulast%3DMarambaud%26aufirst%3DP.%26aulast%3Dd%25E2%2580%2599Abramo%26aufirst%3DC.%26aulast%3DJimenez%26aufirst%3DH.%26aulast%3DStauber%26aufirst%3DM.%26aulast%3DFriedman%26aufirst%3DR.%26aulast%3DDavies%26aufirst%3DP.%26atitle%3DCB2%2520receptor%2520deficiency%2520increases%2520amyloid%2520pathology%2520and%2520alters%2520tau%2520processing%2520in%2520a%2520transgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DMol.%2520Med.%26date%3D2013%26volume%3D19%26spage%3D29%26epage%3D36%26doi%3D10.2119%2Fmolmed.2013.00140" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref33"><div class="reference"><strong class="refLabel"><a href="#ref33" class="rightTabRefNumLink">33</a></strong><div class="NLM_citation" id="rightTab-cit33"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davies, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maloney, A. J. F.</span></span> <span> </span><span class="NLM_article-title">Selective loss of central cholinergic neurons in Alzheimer’s disease</span>. <i>Lancet</i> <span class="NLM_year" style="font-weight: bold;">1976</span>,  <span class="NLM_volume"><i>308</i></span>,  <span class="NLM_fpage">1403</span>, <span class="refDoi"> DOI: 10.1016/S0140-6736(76)91936-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref33/cit33&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0140-6736%2876%2991936-X" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=308&publication_year=1976&pages=1403&author=P.+Daviesauthor=A.+J.+F.+Maloney&title=Selective+loss+of+central+cholinergic+neurons+in+Alzheimer%E2%80%99s+disease&doi=10.1016%2FS0140-6736%2876%2991936-X"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit33&amp;dbid=16384&amp;doi=10.1016%2FS0140-6736%2876%2991936-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0140-6736%252876%252991936-X%26sid%3Dliteratum%253Aachs%26aulast%3DDavies%26aufirst%3DP.%26aulast%3DMaloney%26aufirst%3DA.%2BJ.%2BF.%26atitle%3DSelective%2520loss%2520of%2520central%2520cholinergic%2520neurons%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DLancet%26date%3D1976%26volume%3D308%26spage%3D1403%26doi%3D10.1016%2FS0140-6736%2876%2991936-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref34"><div class="reference"><strong class="refLabel"><a href="#ref34" class="rightTabRefNumLink">34</a></strong><div class="NLM_citation" id="rightTab-cit34"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Arendt, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brückner, M. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lange, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bigl, V.</span></span> <span> </span><span class="NLM_article-title">Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer’s disease resemble embryonic development—a study of molecular forms</span>. <i>Neurochem. Int.</i> <span class="NLM_year" style="font-weight: bold;">1992</span>,  <span class="NLM_volume"><i>21</i></span>,  <span class="NLM_fpage">381</span>– <span class="NLM_lpage">396</span>, <span class="refDoi"> DOI: 10.1016/0197-0186(92)90189-X</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0197-0186%2892%2990189-X" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1303164" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref34/cit34&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3sXltVag" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=21&publication_year=1992&pages=381-396&author=T.+Arendtauthor=M.+K.+Br%C3%BCcknerauthor=M.+Langeauthor=V.+Bigl&title=Changes+in+acetylcholinesterase+and+butyrylcholinesterase+in+Alzheimer%E2%80%99s+disease+resemble+embryonic+development%E2%80%94a+study+of+molecular+forms&doi=10.1016%2F0197-0186%2892%2990189-X"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit34R"><div class="casContent"><span class="casTitleNuber">34</span><div class="casTitle"><span class="NLM_cas:atitle">Changes in acetylcholinesterase and butyrylcholinesterase in Alzheimer's disease resemble embryonic development. A study of molecular forms.</span></div><div class="casAuthors">Arendt, Thomas; Bruckner, Martina K.; Lange, Matthias; Bigl, Volker</div><div class="citationInfo"><span class="NLM_cas:title">Neurochemistry International</span>
        (<span class="NLM_cas:date">1992</span>),
    <span class="NLM_cas:volume">21</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">381-96</span>CODEN:
                <span class="NLM_cas:coden">NEUIDS</span>;
        ISSN:<span class="NLM_cas:issn">0197-0186</span>.
    </div><div class="casAbstract">The pattern of mol. forms of acetylcholinesterase (AChE, EC 3.1.1.7) and butyrylcholinesterase (BChE, EC 3.1.1.8) sepd. by d. gradient centrifugation was investigated in the brain and cerebrospinal fluid in Alzheimer's disease (AD), in human embryonic brain and in rat brain after exptl. cholinergic deafferentation of the cerebral cortex.  While a selective loss of the AChE G4 form was a rather const. finding in AD, a small but significant increase of G1 for both AchE and BChE was found in the most severely affected cases.  Both in normal human brain and in AD a significant relationship could be established between the AChE G4/G1 ratio in different brain regions and the activity of choline acetyltransferase (ChAT).  A similar decrease of the AChE G4 form as obsd. in AD can be induced in rat by exptl. cholinergic deafferentation of the cerebral cortex.  The increase in G1 of both AChE and BChE in different brain regions in AD is quant. related to the local d. of neuritic plaques which are histochem. reactive for both enzymes.  In human embryonic brain, a high abundance of G1 and a low G4/G1 ratio for both AChE and BChE was found resembling the pattern obsd. in AD.  Furthermore, both in embryonic brain and in AD AChE shows no substrate inhibition which is a const. feature of the enzymes in the adult human brain.  It is concluded that the degeneration of the cholinergic cortical afferentation in AD as reflected by a decrease of AChE G4 is accompanied by the process of a neuritic sprouting response involved in plaque formation which is probably assocd. with the expression of a developmental form of the enzyme.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqfFdAst2WU6rVg90H21EOLACvtfcHk0lhwGONDakNT1w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3sXltVag&md5=a4aa253e74ab647685abf2ec939aa8f9</span></div><a href="/servlet/linkout?suffix=cit34&amp;dbid=16384&amp;doi=10.1016%2F0197-0186%2892%2990189-X&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0197-0186%252892%252990189-X%26sid%3Dliteratum%253Aachs%26aulast%3DArendt%26aufirst%3DT.%26aulast%3DBr%25C3%25BCckner%26aufirst%3DM.%2BK.%26aulast%3DLange%26aufirst%3DM.%26aulast%3DBigl%26aufirst%3DV.%26atitle%3DChanges%2520in%2520acetylcholinesterase%2520and%2520butyrylcholinesterase%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520resemble%2520embryonic%2520development%25E2%2580%2594a%2520study%2520of%2520molecular%2520forms%26jtitle%3DNeurochem.%2520Int.%26date%3D1992%26volume%3D21%26spage%3D381%26epage%3D396%26doi%3D10.1016%2F0197-0186%2892%2990189-X" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref35"><div class="reference"><strong class="refLabel"><a href="#ref35" class="rightTabRefNumLink">35</a></strong><div class="NLM_citation" id="rightTab-cit35"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Perry, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lee, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, D. K.</span></span> <span> </span><span class="NLM_article-title">A new therapeutic target in Alzheimer’s disease treatment: attention to butyrylcholinesterase</span>. <i>Curr. Med. Res. Opin.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">159</span>– <span class="NLM_lpage">165</span>, <span class="refDoi"> DOI: 10.1185/03007990152673800</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1185%2F03007990152673800" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11900310" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref35/cit35&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XkslSnug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2001&pages=159-165&author=N.+H.+Greigauthor=T.+Utsukiauthor=Q.+S.+Yuauthor=X.+Zhuauthor=H.+W.+Hollowayauthor=T.+Perryauthor=B.+Leeauthor=D.+K.+Ingramauthor=D.+K.+Lahiri&title=A+new+therapeutic+target+in+Alzheimer%E2%80%99s+disease+treatment%3A+attention+to+butyrylcholinesterase&doi=10.1185%2F03007990152673800"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit35R"><div class="casContent"><span class="casTitleNuber">35</span><div class="casTitle"><span class="NLM_cas:atitle">A new therapeutic target in Alzheimer's disease treatment: Attention to butyrylcholinesterase</span></div><div class="casAuthors">Greig, Nigel H.; Utsuki, Tada; Yu, Qian-sheng; Zhu, Xiaoxiang; Holloway, Harold W.; Perry, TracyAnn; Lee, Bong; Ingram, Donald K.; Lahiri, Debomoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Current Medical Research and Opinion</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">159-165</span>CODEN:
                <span class="NLM_cas:coden">CMROCX</span>;
        ISSN:<span class="NLM_cas:issn">0300-7995</span>.
    
            (<span class="NLM_cas:orgname">LibraPharm Ltd.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a progressive neurodegenerative disorder of the elderly, characterized by widespread loss of central cholinergic function.  The only symptomatic treatment proven effective to date is the use of cholinesterase (ChE) inhibitors to augment surviving cholinergic activity.  ChE inhibitors act on the enzymes that hydrolyze acetylcholine (ACh) following synaptic release.  In the healthy brain, acetylcholinesterase (AChE) predominates (80%) and butyrylcholinesterase (BuChE) is considered to play a minor role in regulating brain ACh levels.  In the AD brain, BuChE activity rises while AChE activity remains unchanged or declines.  Therefore both enzymes are likely to have involvement in regulating ACh levels and represent legitimate therapeutic targets to ameliorate the cholinergic deficit.  The two enzymes differ in location, substrate specificity and kinetics.  Recent evidence suggests that BuChE may also have a role in the etiol. and progression of AD beyond regulation of synaptic ACh levels.  Exptl. evidence from the use of agents with enhanced selectivity for BuChE (cymserine, MF-8622) and ChE inhibitors such as rivastigmine, which have a dual inhibitory action on both AChE and BuChE, indicate potential therapeutic benefits of inhibiting both AChE and BuChE in AD and related dementias.  The development of specific BuChE inhibitors and the continued use of ChE inhibitors with the ability to inhibit BuChE in addn. to AChE should lead to improved clin. outcomes.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq4MokwgwULbVg90H21EOLACvtfcHk0liDMjXup0CgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XkslSnug%253D%253D&md5=bf6513e8d8d7edd39f6b95342a238128</span></div><a href="/servlet/linkout?suffix=cit35&amp;dbid=16384&amp;doi=10.1185%2F03007990152673800&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1185%252F03007990152673800%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DUtsuki%26aufirst%3DT.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DZhu%26aufirst%3DX.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DPerry%26aufirst%3DT.%26aulast%3DLee%26aufirst%3DB.%26aulast%3DIngram%26aufirst%3DD.%2BK.%26aulast%3DLahiri%26aufirst%3DD.%2BK.%26atitle%3DA%2520new%2520therapeutic%2520target%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%253A%2520attention%2520to%2520butyrylcholinesterase%26jtitle%3DCurr.%2520Med.%2520Res.%2520Opin.%26date%3D2001%26volume%3D17%26spage%3D159%26epage%3D165%26doi%3D10.1185%2F03007990152673800" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref36"><div class="reference"><strong class="refLabel"><a href="#ref36" class="rightTabRefNumLink">36</a></strong><div class="NLM_citation" id="rightTab-cit36"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Giacobini, E.</span></span> <span> </span><span class="NLM_article-title">Cholinergic function and Alzheimer’s disease</span>. <i>Int. J. Psychiatry</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">S1</span>– <span class="NLM_lpage">S5</span>, <span class="refDoi"> DOI: 10.1002/gps.935</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref36/cit36&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fgps.935" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2003&pages=S1-S5&author=E.+Giacobini&title=Cholinergic+function+and+Alzheimer%E2%80%99s+disease&doi=10.1002%2Fgps.935"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit36&amp;dbid=16384&amp;doi=10.1002%2Fgps.935&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fgps.935%26sid%3Dliteratum%253Aachs%26aulast%3DGiacobini%26aufirst%3DE.%26atitle%3DCholinergic%2520function%2520and%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DInt.%2520J.%2520Psychiatry%26date%3D2003%26volume%3D18%26spage%3DS1%26epage%3DS5%26doi%3D10.1002%2Fgps.935" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref37"><div class="reference"><strong class="refLabel"><a href="#ref37" class="rightTabRefNumLink">37</a></strong><div class="NLM_citation" id="rightTab-cit37"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Grossberg, G. T.</span></span> <span> </span><span class="NLM_article-title">Cholinesterase inhibitors for the treatment of Alzheimer’s disease: getting on and staying on</span>. <i>Curr. Ther. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>64</i></span>,  <span class="NLM_fpage">216</span>– <span class="NLM_lpage">235</span>, <span class="refDoi"> DOI: 10.1016/S0011-393X(03)00059-6</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0011-393X%2803%2900059-6" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24944370" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref37/cit37&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXltlKntbw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=64&publication_year=2003&pages=216-235&author=G.+T.+Grossberg&title=Cholinesterase+inhibitors+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+getting+on+and+staying+on&doi=10.1016%2FS0011-393X%2803%2900059-6"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit37R"><div class="casContent"><span class="casTitleNuber">37</span><div class="casTitle"><span class="NLM_cas:atitle">Cholinesterase inhibitors for the treatment of alzheimer's disease: Getting on and staying on</span></div><div class="casAuthors">Grossberg, George T.</div><div class="citationInfo"><span class="NLM_cas:title">Current Therapeutic Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">64</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">216-235</span>CODEN:
                <span class="NLM_cas:coden">CTCEA9</span>;
        ISSN:<span class="NLM_cas:issn">0011-393X</span>.
    
            (<span class="NLM_cas:orgname">Excerpta Medica, Inc.</span>)
        </div><div class="casAbstract">A review.  Cholinesterase (ChE) inhibitors currently used in the treatment of Alzheimer's disease (AD) are the acetylcholinesterase (AChE)-selective inhibitors, donepezil and galantamine, and the dual AChE and butyrylcholinesterase (BuChE) inhibitor, rivastigmine.  In addn. to differences in selectivity for AChE and BuChE, ChE inhibitors also differ in pharmacokinetic and pharmacodynamic properties, and these differences could significantly impact on safety, tolerability, and efficacy.  The aim of this article was to provide an overview of the ChE inhibitors widely used in AD, focusing on key pharmacol. differences among agents and how these may translate into important differences in safety, tolerability, and efficacy in clin. practice.  Using published literature collected over time by the author, a review was conducted, focusing on the pharmacol. and clin. data of donepezil, galantamine, and rivastigmine.  All ChE inhibitors have the potential to induce centrally mediated cholinergic adverse events (AEs), such as nausea and vomiting, if the dose is increased too rapidly or in increments that are too large.  These AEs, which are most likely to occur during the "getting on," or dose-escalation, phase of treatment, may result in patients discontinuing treatment early without achieving optimum therapeutic benefit.  To reduce the incidence of these AEs, a slow dose-escalation schedule has been established in clin. practice, consisting of a "start low, go slow" procedure with a min. of 4 wk between dose increases.  After "getting on" treatment, maintaining treatment in the long term, or "staying on," may be achieved with good safety, tolerability, and sustained symptomatic efficacy across the key symptom domains (activities of daily living, behavior, and cognition).  Cholinesterase inhibitors provide symptomatic benefit in AD across key symptom domains.  Factors influencing the safety, tolerability, and efficacy of these agents in clin. practice include ChE enzymes inhibited, brain and.  Brain-region ChE selectivity, and metab. route.  Class-specific cholinergic AEs can be minimized using slow, flexible dose escalation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrj8qRzCpybb7Vg90H21EOLACvtfcHk0liDMjXup0CgBQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXltlKntbw%253D&md5=0c4d3b44d7d1cbf29b85c7b6f75598f5</span></div><a href="/servlet/linkout?suffix=cit37&amp;dbid=16384&amp;doi=10.1016%2FS0011-393X%2803%2900059-6&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0011-393X%252803%252900059-6%26sid%3Dliteratum%253Aachs%26aulast%3DGrossberg%26aufirst%3DG.%2BT.%26atitle%3DCholinesterase%2520inhibitors%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520getting%2520on%2520and%2520staying%2520on%26jtitle%3DCurr.%2520Ther.%2520Res.%26date%3D2003%26volume%3D64%26spage%3D216%26epage%3D235%26doi%3D10.1016%2FS0011-393X%2803%2900059-6" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref38"><div class="reference"><strong class="refLabel"><a href="#ref38" class="rightTabRefNumLink">38</a></strong><div class="NLM_citation" id="rightTab-cit38"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Darvesh, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hopkins, D. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Geula, C.</span></span> <span> </span><span class="NLM_article-title">Neurobiology of butyrylcholinesterase</span>. <i>Nat. Rev. Neurosci.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>4</i></span>,  <span class="NLM_fpage">131</span>– <span class="NLM_lpage">138</span>, <span class="refDoi"> DOI: 10.1038/nrn1035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrn1035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12563284" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref38/cit38&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXot12hsg%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=4&publication_year=2003&pages=131-138&author=S.+Darveshauthor=D.+A.+Hopkinsauthor=C.+Geula&title=Neurobiology+of+butyrylcholinesterase&doi=10.1038%2Fnrn1035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit38R"><div class="casContent"><span class="casTitleNuber">38</span><div class="casTitle"><span class="NLM_cas:atitle">Neurobiology of butyrylcholinesterase</span></div><div class="casAuthors">Darvesh, Sultan; Hopkins, David A.; Geula, Changiz</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Neuroscience</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">4</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">131-138</span>CODEN:
                <span class="NLM_cas:coden">NRNAAN</span>;
        ISSN:<span class="NLM_cas:issn">1471-003X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  Butyrylcholinesterase is a serine hydrolase related to acetylcholinesterase that catalyzes the hydrolysis of esters of choline, including acetylcholine.  Butyrylcholinesterase has unique enzymic properties and is widely distributed in the nervous system, pointing to its possible involvement in neural function.  Here, we summarize the biochem. properties of butyrylcholinesterase and review the evidence that this enzyme has important roles in cholinergic neurotransmission and could be involved in other nervous system functions and in neurodegenerative diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrf8WbhaQUqP7Vg90H21EOLACvtfcHk0ljY1NXplAW2oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXot12hsg%253D%253D&md5=aeb5008a2c61e5feb48506f835899519</span></div><a href="/servlet/linkout?suffix=cit38&amp;dbid=16384&amp;doi=10.1038%2Fnrn1035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrn1035%26sid%3Dliteratum%253Aachs%26aulast%3DDarvesh%26aufirst%3DS.%26aulast%3DHopkins%26aufirst%3DD.%2BA.%26aulast%3DGeula%26aufirst%3DC.%26atitle%3DNeurobiology%2520of%2520butyrylcholinesterase%26jtitle%3DNat.%2520Rev.%2520Neurosci.%26date%3D2003%26volume%3D4%26spage%3D131%26epage%3D138%26doi%3D10.1038%2Fnrn1035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref39"><div class="reference"><strong class="refLabel"><a href="#ref39" class="rightTabRefNumLink">39</a></strong><div class="NLM_citation" id="rightTab-cit39"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mesulam, M. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Guillozet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shaw, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Levey, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duysen, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span> <span> </span><span class="NLM_article-title">Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>110</i></span>,  <span class="NLM_fpage">627</span>– <span class="NLM_lpage">639</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0306-4522%2801%2900613-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11934471" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref39/cit39&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XisV2hsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=110&publication_year=2002&pages=627-639&author=M.+M.+Mesulamauthor=A.+Guillozetauthor=P.+Shawauthor=A.+Leveyauthor=E.+Duysenauthor=O.+Lockridge&title=Acetylcholinesterase+knockouts+establish+central+cholinergic+pathways+and+can+use+butyrylcholinesterase+to+hydrolyze+acetylcholine"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit39R"><div class="casContent"><span class="casTitleNuber">39</span><div class="casTitle"><span class="NLM_cas:atitle">Acetylcholinesterase knockouts establish central cholinergic pathways and can use butyrylcholinesterase to hydrolyze acetylcholine</span></div><div class="casAuthors">Mesulam, M.-M.; Guillozet, A.; Shaw, P.; Levey, A.; Duysen, E. G.; Lockridge, O.</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">110</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">627-639</span>CODEN:
                <span class="NLM_cas:coden">NRSCDN</span>;
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Ltd.</span>)
        </div><div class="casAbstract">Acetylcholinesterase is one of the most prominent constituents of central cholinergic pathways.  It terminates the synaptic action of acetylcholine through hydrolysis and yields the choline moiety that is necessary for transmitter recycling.  Despite these pivotal relationships, mice nullizygous for acetylcholinesterase established all principal anatomical components of central cholinergic pathways.  No compensatory increase in the distribution of butyrylcholinesterase was detected.  However, both the wild-type and nullizygous mice showed that butyrylcholinesterase enzyme activity extended to all parts of the brain receiving cholinergic innervation and that it could hydrolyze the acetylcholine surrogate acetylthiocholine.  As opposed to acetylcholinesterase which was mostly of neuronal origin, butyrylcholinesterase appeared to be mostly of glial origin.  These expts. lead to the unexpected conclusion that acetylcholinesterase is not necessary for the establishment of cholinergic pathways.  They also show that butyrylcholinesterase can potentially substitute for acetylcholinesterase and that this enzyme is likely to play a constitutive (rather than just back-up) role in the hydrolysis of acetylcholine in the normal brain.  The inhibition of butyrylcholinesterase may therefore provide a desirable feature of cholinergic therapies, including those aimed at treating Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqaarm2WZSE07Vg90H21EOLACvtfcHk0ljY1NXplAW2oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XisV2hsrw%253D&md5=ca2117183dd41ebd26e137a65404e805</span></div><a href="/servlet/linkout?suffix=cit39&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2801%2900613-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252801%252900613-3%26sid%3Dliteratum%253Aachs%26aulast%3DMesulam%26aufirst%3DM.%2BM.%26aulast%3DGuillozet%26aufirst%3DA.%26aulast%3DShaw%26aufirst%3DP.%26aulast%3DLevey%26aufirst%3DA.%26aulast%3DDuysen%26aufirst%3DE.%26aulast%3DLockridge%26aufirst%3DO.%26atitle%3DAcetylcholinesterase%2520knockouts%2520establish%2520central%2520cholinergic%2520pathways%2520and%2520can%2520use%2520butyrylcholinesterase%2520to%2520hydrolyze%2520acetylcholine%26jtitle%3DNeuroscience%26date%3D2002%26volume%3D110%26spage%3D627%26epage%3D639" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref40"><div class="reference"><strong class="refLabel"><a href="#ref40" class="rightTabRefNumLink">40</a></strong><div class="NLM_citation" id="rightTab-cit40"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nordberg, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ballard, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bullock, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darreh-Shori, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Somogyi, M.</span></span> <span> </span><span class="NLM_article-title">A review of butyrylcholinesterase as a therapeutic target in the treatment of Alzheimer’s disease</span>. <i>Prim. Care Companion CNS Disord.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>15</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">30</span>, <span class="refDoi"> DOI: 10.4088/PCC.12r01412</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref40/cit40&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.4088%2FPCC.12r01412" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=15&publication_year=2013&pages=1-30&author=A.+Nordbergauthor=C.+Ballardauthor=R.+Bullockauthor=T.+Darreh-Shoriauthor=M.+Somogyi&title=A+review+of+butyrylcholinesterase+as+a+therapeutic+target+in+the+treatment+of+Alzheimer%E2%80%99s+disease&doi=10.4088%2FPCC.12r01412"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit40&amp;dbid=16384&amp;doi=10.4088%2FPCC.12r01412&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.4088%252FPCC.12r01412%26sid%3Dliteratum%253Aachs%26aulast%3DNordberg%26aufirst%3DA.%26aulast%3DBallard%26aufirst%3DC.%26aulast%3DBullock%26aufirst%3DR.%26aulast%3DDarreh-Shori%26aufirst%3DT.%26aulast%3DSomogyi%26aufirst%3DM.%26atitle%3DA%2520review%2520of%2520butyrylcholinesterase%2520as%2520a%2520therapeutic%2520target%2520in%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DPrim.%2520Care%2520Companion%2520CNS%2520Disord.%26date%3D2013%26volume%3D15%26spage%3D1%26epage%3D30%26doi%3D10.4088%2FPCC.12r01412" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref41"><div class="reference"><strong class="refLabel"><a href="#ref41" class="rightTabRefNumLink">41</a></strong><div class="NLM_citation" id="rightTab-cit41"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hartmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kiewert, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Duysen, E. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockridge, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Klein, J.</span></span> <span> </span><span class="NLM_article-title">Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>100</i></span>,  <span class="NLM_fpage">1421</span>– <span class="NLM_lpage">1429</span>, <span class="refDoi"> DOI: 10.1111/j.1471-4159.2006.04347.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1111%2Fj.1471-4159.2006.04347.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17212694" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref41/cit41&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2sXjt1Grs7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=100&publication_year=2007&pages=1421-1429&author=J.+Hartmannauthor=C.+Kiewertauthor=E.+G.+Duysenauthor=O.+Lockridgeauthor=N.+H.+Greigauthor=J.+Klein&title=Excessive+hippocampal+acetylcholine+levels+in+acetylcholinesterase-deficient+mice+are+moderated+by+butyrylcholinesterase+activity&doi=10.1111%2Fj.1471-4159.2006.04347.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit41R"><div class="casContent"><span class="casTitleNuber">41</span><div class="casTitle"><span class="NLM_cas:atitle">Excessive hippocampal acetylcholine levels in acetylcholinesterase-deficient mice are moderated by butyrylcholinesterase activity</span></div><div class="casAuthors">Hartmann, Joachim; Kiewert, Cornelia; Duysen, Ellen G.; Lockridge, Oksana; Greig, Nigel H.; Klein, Jochen</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">100</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1421-1429</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Blackwell Publishing Ltd.</span>)
        </div><div class="casAbstract">Central cholinergic systems are involved in a plethora of brain functions and are severely and selectively damaged in neurodegenerative diseases such as Alzheimer's disease and dementia with Lewy bodies.  Cholinergic dysfunction is treated with inhibitors of acetylcholinesterase (AChE) while the role of butyrylcholinesterase (BChE) for brain cholinergic function is unclear.  We have used in vivo microdialysis to investigate the regulation of hippocampal acetylcholine (ACh) levels in mice that are devoid of AChE (AChE-/- mice).  Extracellular ACh levels in the hippocampus were 60-fold elevated in AChE-/- mice compared with wild-type (AChE+/+) animals.  In AChE-/- mice, calcium-free conditions reduced hippocampal ACh levels by 50%, and infusion of tetrodotoxin by more than 90%, indicating continuous ACh release.  Infusion of a selective AChE inhibitor (BW284c51) caused a dose-dependent, up to 16-fold increase of extracellular ACh levels in AChE+/+ mice but did not change ACh levels in AChE-/- mice.  In contrast, infusion of a selective inhibitor of BChE (bambuterol) caused up to fivefold elevation of ACh levels in AChE-/- mice, but was without effect in AChE+/+ animals.  These results were corroborated with two other specific inhibitors of AChE and BChE, tolserine and bis-norcymserine, resp.  We conclude that lack of AChE causes dramatically increased levels of extracellular ACh in the brain.  Importantly, in the absence of AChE, the levels of extracellular ACh in the brain are controlled by the activity of BChE.  These results point to a potential usefulness of BChE inhibitors in the treatment of central cholinergic dysfunction in which brain AChE activity is typically reduced.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGosHAJAnTb_b7Vg90H21EOLACvtfcHk0ljY1NXplAW2oA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXjt1Grs7g%253D&md5=95d7181c01f859a8b03bfdfed31be6ad</span></div><a href="/servlet/linkout?suffix=cit41&amp;dbid=16384&amp;doi=10.1111%2Fj.1471-4159.2006.04347.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fj.1471-4159.2006.04347.x%26sid%3Dliteratum%253Aachs%26aulast%3DHartmann%26aufirst%3DJ.%26aulast%3DKiewert%26aufirst%3DC.%26aulast%3DDuysen%26aufirst%3DE.%2BG.%26aulast%3DLockridge%26aufirst%3DO.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DKlein%26aufirst%3DJ.%26atitle%3DExcessive%2520hippocampal%2520acetylcholine%2520levels%2520in%2520acetylcholinesterase-deficient%2520mice%2520are%2520moderated%2520by%2520butyrylcholinesterase%2520activity%26jtitle%3DJ.%2520Neurochem.%26date%3D2007%26volume%3D100%26spage%3D1421%26epage%3D1429%26doi%3D10.1111%2Fj.1471-4159.2006.04347.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref42"><div class="reference"><strong class="refLabel"><a href="#ref42" class="rightTabRefNumLink">42</a></strong><div class="NLM_citation" id="rightTab-cit42"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa-Hibi, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Matsuyama, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mizoguchi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Suzuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Moussaoui, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nagai, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span> <span> </span><span class="NLM_article-title">Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>225</i></span>,  <span class="NLM_fpage">222</span>– <span class="NLM_lpage">229</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2011.07.035</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bbr.2011.07.035" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21820013" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref42/cit42&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXhtFKjurrE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=225&publication_year=2011&pages=222-229&author=Y.+Furukawa-Hibiauthor=T.+Alkamauthor=A.+Nittaauthor=A.+Matsuyamaauthor=H.+Mizoguchiauthor=K.+Suzukiauthor=S.+Moussaouiauthor=Q.+S.+Yuauthor=N.+H.+Greigauthor=T.+Nagaiauthor=K.+Yamada&title=Butyrylcholinesterase+inhibitors+ameliorate+cognitive+dysfunction+induced+by+amyloid-%CE%B2+peptide+in+mice&doi=10.1016%2Fj.bbr.2011.07.035"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit42R"><div class="casContent"><span class="casTitleNuber">42</span><div class="casTitle"><span class="NLM_cas:atitle">Butyrylcholinesterase inhibitors ameliorate cognitive dysfunction induced by amyloid-β peptide in mice</span></div><div class="casAuthors">Furukawa-Hibi, Yoko; Alkam, Tursun; Nitta, Atsumi; Matsuyama, Akihiro; Mizoguchi, Hiroyuki; Suzuki, Kazuhiko; Moussaoui, Saliha; Yu, Qian-Sheng; Greig, Nigel H.; Nagai, Taku; Yamada, Kiyofumi</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">225</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">222-229</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The cholinesterase inhibitor, rivastigmine, ameliorates cognitive dysfunction and is approved for the treatment of Alzheimer's disease (AD).  Rivastigmine is a dual inhibitor of acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE); however, the impact of BuChE inhibition on cognitive dysfunction remains to be detd.  We compared the effects of a selective BuChE inhibitor, N1-phenethyl-norcymserine (PEC), rivastigmine and donepezil (an AChE-selective inhibitor) on cognitive dysfunction induced by amyloid-β peptide (Aβ1-40) in mice.  Five-week-old imprinting control region (ICR) mice were injected intracerebroventricularly (i.c.v.) with either Aβ1-40 or the control peptide Aβ40-1 on Day 0, and their recognition memory was analyzed by a novel object recognition test.  Treatment with donepezil (1.0 mg/kg), rivastigmine (0.03, 0.1, 0.3 mg/kg) or PEC (1.0, 3.0 mg/kg) 20 min prior to, or immediately after the acquisition session (Day 4) ameliorated the Aβ1-40 induced memory impairment, indicating a beneficial effect on memory acquisition and consolidation.  In contrast, none of the investigated drugs proved effective when administrated before the retention session (Day 5).  Repeated daily administration of donepezil, rivastigmine or PEC, on Days 0-3 inclusively, ameliorated the cognitive dysfunction in Aβ1-40 challenged mice.  Consistent with the reversal of memory impairments, donepezil, rivastigmine or PEC treatment significantly reduced Aβ1-40 induced tyrosine nitration of hippocampal proteins, a marker of oxidative damage.  These results indicate that BuChE inhibition, as well as AChE inhibition, is a viable therapeutic strategy for cognitive dysfunction in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqWrQS5R61AGbVg90H21EOLACvtfcHk0lhMo9wLxruNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXhtFKjurrE&md5=e1d7203ed15e8b829e505a41c8c0e7ff</span></div><a href="/servlet/linkout?suffix=cit42&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2011.07.035&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2011.07.035%26sid%3Dliteratum%253Aachs%26aulast%3DFurukawa-Hibi%26aufirst%3DY.%26aulast%3DAlkam%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DMatsuyama%26aufirst%3DA.%26aulast%3DMizoguchi%26aufirst%3DH.%26aulast%3DSuzuki%26aufirst%3DK.%26aulast%3DMoussaoui%26aufirst%3DS.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DNagai%26aufirst%3DT.%26aulast%3DYamada%26aufirst%3DK.%26atitle%3DButyrylcholinesterase%2520inhibitors%2520ameliorate%2520cognitive%2520dysfunction%2520induced%2520by%2520amyloid-%25CE%25B2%2520peptide%2520in%2520mice%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2011%26volume%3D225%26spage%3D222%26epage%3D229%26doi%3D10.1016%2Fj.bbr.2011.07.035" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref43"><div class="reference"><strong class="refLabel"><a href="#ref43" class="rightTabRefNumLink">43</a></strong><div class="NLM_citation" id="rightTab-cit43"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Greig, N. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Utsuki, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ingram, D. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pepeu, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scali, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yu, Q. S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mamczarz, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Holloway, H. W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Giordano, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Furukawa, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sambamurti, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brossi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lahiri, D. K.</span></span> <span> </span><span class="NLM_article-title">Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent</span>. <i>Proc. Natl. Acad. Sci.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>102</i></span>,  <span class="NLM_fpage">17213</span>– <span class="NLM_lpage">17218</span>, <span class="refDoi"> DOI: 10.1073/pnas.0508575102</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1073%2Fpnas.0508575102" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=16275899" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref43/cit43&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXht1yksLfE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=102&publication_year=2005&pages=17213-17218&author=N.+H.+Greigauthor=T.+Utsukiauthor=D.+K.+Ingramauthor=Y.+Wangauthor=G.+Pepeuauthor=C.+Scaliauthor=Q.+S.+Yuauthor=J.+Mamczarzauthor=H.+W.+Hollowayauthor=T.+Giordanoauthor=D.+Chenauthor=K.+Furukawaauthor=K.+Sambamurtiauthor=A.+Brossiauthor=D.+K.+Lahiri&title=Selective+butyrylcholinesterase+inhibition+elevates+brain+acetylcholine%2C+augments+learning+and+lowers+Alzheimer+%CE%B2-amyloid+peptide+in+rodent&doi=10.1073%2Fpnas.0508575102"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit43R"><div class="casContent"><span class="casTitleNuber">43</span><div class="casTitle"><span class="NLM_cas:atitle">Selective butyrylcholinesterase inhibition elevates brain acetylcholine, augments learning and lowers Alzheimer β-amyloid peptide in rodent</span></div><div class="casAuthors">Greig, Nigel H.; Utsuki, Tadanobu; Ingram, Donald K.; Wang, Yue; Pepeu, Giancarlo; Scali, Carla; Yu, Qian-Sheng; Mamczarz, Jacek; Holloway, Harold W.; Giordano, Tony; Chen, DeMao; Furukawa, Katsutoshi; Sambamurti, Kumar; Brossi, Arnold; Lahiri, Debomoy K.</div><div class="citationInfo"><span class="NLM_cas:title">Proceedings of the National Academy of Sciences of the United States of America</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">102</span>
        (<span class="NLM_cas:issue">47</span>),
    <span class="NLM_cas:pages">17213-17218</span>CODEN:
                <span class="NLM_cas:coden">PNASA6</span>;
        ISSN:<span class="NLM_cas:issn">0027-8424</span>.
    
            (<span class="NLM_cas:orgname">National Academy of Sciences</span>)
        </div><div class="casAbstract">Like acetylcholinesterase, butyrylcholinesterase (BChE) inactivates the neurotransmitter acetylcholine (ACh) and is hence a viable therapeutic target in Alzheimer's disease, which is characterized by a cholinergic deficit.  Potent, reversible, and brain-targeted BChE inhibitors (cymserine analogs) were developed based on binding domain structures to help elucidate the role of this enzyme in the central nervous system.  In rats, cymserine analogs caused long-term inhibition of brain BChE and elevated extracellular ACh levels, without inhibitory effects on acetylcholinesterase.  In rat brain slices, selective BChE inhibition augmented long-term potentiation.  These compds. also improved the cognitive performance (maze navigation) of aged rats.  In cultured human SK-N-SH neuroblastoma cells, intra- and extracellular β-amyloid precursor protein, and secreted β-amyloid peptide levels were reduced without affecting cell viability.  Treatment of transgenic mice that overexpressed human mutant amyloid precursor protein also resulted in lower β-amyloid peptide brain levels than controls.  Selective, reversible inhibition of brain BChE may represent a treatment for Alzheimer's disease, improving cognition and modulating neuropathol. markers of the disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrI6ACIUUc5wrVg90H21EOLACvtfcHk0lhMo9wLxruNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXht1yksLfE&md5=a4ac89f6186f77125545c667f9efbe21</span></div><a href="/servlet/linkout?suffix=cit43&amp;dbid=16384&amp;doi=10.1073%2Fpnas.0508575102&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1073%252Fpnas.0508575102%26sid%3Dliteratum%253Aachs%26aulast%3DGreig%26aufirst%3DN.%2BH.%26aulast%3DUtsuki%26aufirst%3DT.%26aulast%3DIngram%26aufirst%3DD.%2BK.%26aulast%3DWang%26aufirst%3DY.%26aulast%3DPepeu%26aufirst%3DG.%26aulast%3DScali%26aufirst%3DC.%26aulast%3DYu%26aufirst%3DQ.%2BS.%26aulast%3DMamczarz%26aufirst%3DJ.%26aulast%3DHolloway%26aufirst%3DH.%2BW.%26aulast%3DGiordano%26aufirst%3DT.%26aulast%3DChen%26aufirst%3DD.%26aulast%3DFurukawa%26aufirst%3DK.%26aulast%3DSambamurti%26aufirst%3DK.%26aulast%3DBrossi%26aufirst%3DA.%26aulast%3DLahiri%26aufirst%3DD.%2BK.%26atitle%3DSelective%2520butyrylcholinesterase%2520inhibition%2520elevates%2520brain%2520acetylcholine%252C%2520augments%2520learning%2520and%2520lowers%2520Alzheimer%2520%25CE%25B2-amyloid%2520peptide%2520in%2520rodent%26jtitle%3DProc.%2520Natl.%2520Acad.%2520Sci.%26date%3D2005%26volume%3D102%26spage%3D17213%26epage%3D17218%26doi%3D10.1073%2Fpnas.0508575102" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref44"><div class="reference"><strong class="refLabel"><a href="#ref44" class="rightTabRefNumLink">44</a></strong><div class="NLM_citation" id="rightTab-cit44"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strehaiano, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Siméon, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertrand, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span> <span> </span><span class="NLM_article-title">Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse</span>. <i>Behav. Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>296</i></span>,  <span class="NLM_fpage">351</span>– <span class="NLM_lpage">360</span>, <span class="refDoi"> DOI: 10.1016/j.bbr.2015.08.026</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bbr.2015.08.026" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26306824" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref44/cit44&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhsVOqt7bP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=296&publication_year=2016&pages=351-360&author=T.+Mauriceauthor=M.+Strehaianoauthor=N.+Sim%C3%A9onauthor=C.+Bertrandauthor=A.+Chatonnet&title=Learning+performances+and+vulnerability+to+amyloid+toxicity+in+the+butyrylcholinesterase+knockout+mouse&doi=10.1016%2Fj.bbr.2015.08.026"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit44R"><div class="casContent"><span class="casTitleNuber">44</span><div class="casTitle"><span class="NLM_cas:atitle">Learning performances and vulnerability to amyloid toxicity in the butyrylcholinesterase knockout mouse</span></div><div class="casAuthors">Maurice, Tangui; Strehaiano, Manon; Simeon, Nathalie; Bertrand, Christelle; Chatonnet, Arnaud</div><div class="citationInfo"><span class="NLM_cas:title">Behavioural Brain Research</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">296</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">351-360</span>CODEN:
                <span class="NLM_cas:coden">BBREDI</span>;
        ISSN:<span class="NLM_cas:issn">0166-4328</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Butyrylcholinesterase (BChE) is an important enzyme for detoxication and metab. of ester compds.  It also hydrolyzes the neurotransmitter acetylcholine (ACh) in pathol. conditions and may play a role in Alzheimer's disease (AD).  We here compared the learning ability and vulnerability to Aβ toxicity in male and female BChE knockout (KO) mice and their 129 Sv wild-type (Wt) controls.  Animals tested for place learning in the water-maze showed increased acquisition slopes and presence in the training quadrant during the probe test.  An increased passive avoidance response was also obsd. for males.  BChE KO mice therefore showed enhanced learning ability in spatial and non-spatial memory tests.  Intracerebroventricular (ICV) injection of increasing doses of amyloid-β[25-35] (Aβ25-35) peptide oligomers resulted, in Wt mice, in learning and memory deficits, oxidative stress and decrease in ACh hippocampal content.  In BChE KO mice, the Aβ25-35-induced deficit in place learning was attenuated in males and blocked in females.  No change in lipid peroxidn. or ACh levels was obsd. after Aβ25-35 treatment in male or female BChE KO mice.  These data showed that the genetic invalidation of BChE in mice augmented learning capacities and lowered the vulnerability to Aβ toxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpV3M4M6LenzrVg90H21EOLACvtfcHk0lhMo9wLxruNDQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhsVOqt7bP&md5=1b8f7885ee358acacce167f61ea2599c</span></div><a href="/servlet/linkout?suffix=cit44&amp;dbid=16384&amp;doi=10.1016%2Fj.bbr.2015.08.026&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bbr.2015.08.026%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DStrehaiano%26aufirst%3DM.%26aulast%3DSim%25C3%25A9on%26aufirst%3DN.%26aulast%3DBertrand%26aufirst%3DC.%26aulast%3DChatonnet%26aufirst%3DA.%26atitle%3DLearning%2520performances%2520and%2520vulnerability%2520to%2520amyloid%2520toxicity%2520in%2520the%2520butyrylcholinesterase%2520knockout%2520mouse%26jtitle%3DBehav.%2520Brain%2520Res.%26date%3D2016%26volume%3D296%26spage%3D351%26epage%3D360%26doi%3D10.1016%2Fj.bbr.2015.08.026" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref45"><div class="reference"><strong class="refLabel"><a href="#ref45" class="rightTabRefNumLink">45</a></strong><div class="NLM_citation" id="rightTab-cit45"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Morphy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rankovic, Z.</span></span> <span> </span><span class="NLM_article-title">Designed multiple ligands. An emerging drug discovery paradigm</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">6523</span>– <span class="NLM_lpage">6543</span>, <span class="refDoi"> DOI: 10.1021/jm058225d</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm058225d" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref45/cit45&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=6523-6543&author=R.+Morphyauthor=Z.+Rankovic&title=Designed+multiple+ligands.+An+emerging+drug+discovery+paradigm&doi=10.1021%2Fjm058225d"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit45R"><div class="casContent"><span class="casTitleNuber">45</span><div class="casTitle"><span class="NLM_cas:atitle">Designed Multiple Ligands.</span></div><div class="casAuthors">Morphy, Richard; Rankovic, Zoran</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">21</span>),
    <span class="NLM_cas:pages">6523-6543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A review.  The review discusses main areas in designed multiple ligands (DMLs) discovery that include 5HT transporter-based DMLs for depression, dopamine D2-receptor based DMLs for schizophrenia, histamine H1 receptor-based DMLs for allergies, DMLs targeting the angiotensin system for hypertension, nonsteroidal anti-inflammatory drugs, and PPAR-based DMLs for metabolic disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrgouWcjsiKgbVg90H21EOLACvtfcHk0lg5U1HLQKgluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2MXhtVeisr%252FL&md5=00e3bf5a521fc91996ce95bb379a0b5c</span></div><a href="/servlet/linkout?suffix=cit45&amp;dbid=16384&amp;doi=10.1021%2Fjm058225d&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm058225d%26sid%3Dliteratum%253Aachs%26aulast%3DMorphy%26aufirst%3DR.%26aulast%3DRankovic%26aufirst%3DZ.%26atitle%3DDesigned%2520multiple%2520ligands.%2520An%2520emerging%2520drug%2520discovery%2520paradigm%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D6523%26epage%3D6543%26doi%3D10.1021%2Fjm058225d" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref46"><div class="reference"><strong class="refLabel"><a href="#ref46" class="rightTabRefNumLink">46</a></strong><div class="NLM_citation" id="rightTab-cit46"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Proschak, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stark, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Merk, D.</span></span> <span> </span><span class="NLM_article-title">Polypharmacology by design: a medicinal chemist’s perspective on multitargeting compounds</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">420</span>– <span class="NLM_lpage">444</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.8b00760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.8b00760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref46/cit46&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2019&pages=420-444&author=E.+Proschakauthor=H.+Starkauthor=D.+Merk&title=Polypharmacology+by+design%3A+a+medicinal+chemist%E2%80%99s+perspective+on+multitargeting+compounds&doi=10.1021%2Facs.jmedchem.8b00760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit46R"><div class="casContent"><span class="casTitleNuber">46</span><div class="casTitle"><span class="NLM_cas:atitle">Polypharmacology by Design: A Medicinal Chemist's Perspective on Multitargeting Compounds</span></div><div class="casAuthors">Proschak, Ewgenij; Stark, Holger; Merk, Daniel</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">420-444</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Multitargeting compds. comprising activity on more than a single biol. target have gained remarkable relevance in drug discovery owing to the complexity of multifactorial diseases such as cancer, inflammation, or the metabolic syndrome.  Polypharmacol. drug profiles can produce additive or synergistic effects while reducing side effects and significantly contribute to the high therapeutic success of indispensable drugs such as aspirin.  While their identification has long been the result of serendipity, medicinal chem. now tends to design polypharmacol.  Modern in vitro pharmacol. methods and chem. probes allow a systematic search for rational target combinations and recent innovations in computational technologies, crystallog., or fragment-based design equip multitarget compd. development with valuable tools.  In this Perspective, we analyze the relevance of multiple ligands in drug discovery and the versatile toolbox to design polypharmacol.  We conclude that despite some characteristic challenges remaining unresolved, designed polypharmacol. holds enormous potential to secure future therapeutic innovation.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpOEwJSxWw3vbVg90H21EOLACvtfcHk0lg5U1HLQKgluA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXhtlKms7fE&md5=6dc4b8e1c4777372396626140a302663</span></div><a href="/servlet/linkout?suffix=cit46&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.8b00760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.8b00760%26sid%3Dliteratum%253Aachs%26aulast%3DProschak%26aufirst%3DE.%26aulast%3DStark%26aufirst%3DH.%26aulast%3DMerk%26aufirst%3DD.%26atitle%3DPolypharmacology%2520by%2520design%253A%2520a%2520medicinal%2520chemist%25E2%2580%2599s%2520perspective%2520on%2520multitargeting%2520compounds%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2019%26volume%3D62%26spage%3D420%26epage%3D444%26doi%3D10.1021%2Facs.jmedchem.8b00760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref47"><div class="reference"><strong class="refLabel"><a href="#ref47" class="rightTabRefNumLink">47</a></strong><div class="NLM_citation" id="rightTab-cit47"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span>; <span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Dual-acting compounds acting as receptor ligands and enzyme inhibitors</span>. In  <i>Design of hybrid molecules for drug development</i>, <span class="NLM_publisher-name">Elsevier</span>: <span class="NLM_publisher-loc">Amsterdam</span>, <span class="NLM_year">2017</span>; pp  <span class="NLM_fpage">137</span>– <span class="NLM_lpage">165</span>.</span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref47/cit47&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FB978-0-08-101011-2.00005-2" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2017&pages=137-165&author=D.+Dolles&author=M.+Decker&title=Design+of+hybrid+molecules+for+drug+development"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit47&amp;dbid=16384&amp;doi=10.1016%2FB978-0-08-101011-2.00005-2&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26id%3Ddoi%3A10.1016%252FB978-0-08-101011-2.00005-2%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26atitle%3DDual-acting%2520compounds%2520acting%2520as%2520receptor%2520ligands%2520and%2520enzyme%2520inhibitors%26btitle%3DDesign%2520of%2520hybrid%2520molecules%2520for%2520drug%2520development%26pub%3DElsevier%26date%3D2017%26spage%3D137%26epage%3D165" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref48"><div class="reference"><strong class="refLabel"><a href="#ref48" class="rightTabRefNumLink">48</a></strong><div class="NLM_citation" id="rightTab-cit48"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hoffmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Möller, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Santoni, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chatonnet, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lohse, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Structure–activity relationships and computational investigations into the development of potent and balanced dual-acting butyrylcholinesterase inhibitors and human cannabinoid receptor 2 ligands with pro-cognitive in vivo profiles</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>61</i></span>,  <span class="NLM_fpage">1646</span>– <span class="NLM_lpage">1663</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.7b01760</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.7b01760" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref48/cit48&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=61&publication_year=2018&pages=1646-1663&author=D.+Dollesauthor=M.+Hoffmannauthor=S.+Guneschauthor=O.+Marinelliauthor=J.+M%C3%B6llerauthor=G.+Santoniauthor=A.+Chatonnetauthor=M.+J.+Lohseauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Nabissiauthor=T.+Mauriceauthor=M.+Decker&title=Structure%E2%80%93activity+relationships+and+computational+investigations+into+the+development+of+potent+and+balanced+dual-acting+butyrylcholinesterase+inhibitors+and+human+cannabinoid+receptor+2+ligands+with+pro-cognitive+in+vivo+profiles&doi=10.1021%2Facs.jmedchem.7b01760"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit48R"><div class="casContent"><span class="casTitleNuber">48</span><div class="casTitle"><span class="NLM_cas:atitle">Structure-Activity Relationships and Computational Investigations into the Development of Potent and Balanced Dual-Acting Butyrylcholinesterase Inhibitors and Human Cannabinoid Receptor 2 Ligands with Pro-Cognitive in Vivo Profiles</span></div><div class="casAuthors">Dolles, Dominik; Hoffmann, Matthias; Gunesch, Sandra; Marinelli, Oliviero; Moeller, Jan; Santoni, Giorgio; Chatonnet, Arnaud; Lohse, Martin J.; Wittmann, Hans-Joachim; Strasser, Andrea; Nabissi, Massimo; Maurice, Tangui; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">61</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">1646-1663</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">The enzyme butyrylcholinesterase (BChE) and the human cannabinoid receptor 2 (hCB2R) represent promising targets for pharmacotherapy in the later stages of Alzheimer's disease.  The authors merged pharmacophores for both targets into small benzimidazole-based mols., investigated SARs, and identified several dual-acting ligands with a balanced affinity/inhibitory activity and an excellent selectivity over both hCB1R and hAChE.  A homol. model for the hCB2R was developed based on the hCB1R crystal structure and used for mol. dynamics studies to investigate binding modes.  In vitro studies proved hCB2R agonism.  Unwanted μ-opioid receptor affinity could be designed out.  One well-balanced dual-acting and selective hBChE inhibitor/hCB2R agonist showed superior in vivo activity over the lead CB2 agonist with regards to cognition improvement.  The data shows the possibility to combine a small mol. with selective and balanced GPCR-activity/enzyme inhibition and in vivo activity for the therapy of AD and may help to rationalize the development of other dual-acting ligands.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqgCAoLm6nAVbVg90H21EOLACvtfcHk0ljVlaZ4vNmtEw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXit1Sqsbo%253D&md5=49e8e68c2c9a023b872e2522fad6e78c</span></div><a href="/servlet/linkout?suffix=cit48&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.7b01760&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.7b01760%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DHoffmann%26aufirst%3DM.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DM%25C3%25B6ller%26aufirst%3DJ.%26aulast%3DSantoni%26aufirst%3DG.%26aulast%3DChatonnet%26aufirst%3DA.%26aulast%3DLohse%26aufirst%3DM.%2BJ.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DStructure%25E2%2580%2593activity%2520relationships%2520and%2520computational%2520investigations%2520into%2520the%2520development%2520of%2520potent%2520and%2520balanced%2520dual-acting%2520butyrylcholinesterase%2520inhibitors%2520and%2520human%2520cannabinoid%2520receptor%25202%2520ligands%2520with%2520pro-cognitive%2520in%2520vivo%2520profiles%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2018%26volume%3D61%26spage%3D1646%26epage%3D1663%26doi%3D10.1021%2Facs.jmedchem.7b01760" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref49"><div class="reference"><strong class="refLabel"><a href="#ref49" class="rightTabRefNumLink">49</a></strong><div class="NLM_citation" id="rightTab-cit49"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Freeman, S. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dawson, R. M.</span></span> <span> </span><span class="NLM_article-title">Tacrine: a pharmacological review</span>. <i>Prog. Neurobiol.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>36</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">277</span>, <span class="refDoi"> DOI: 10.1016/0301-0082(91)90002-I</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0301-0082%2891%2990002-I" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1714613" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref49/cit49&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3MXlt1Kiurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=36&publication_year=1991&pages=257-277&author=S.+E.+Freemanauthor=R.+M.+Dawson&title=Tacrine%3A+a+pharmacological+review&doi=10.1016%2F0301-0082%2891%2990002-I"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit49R"><div class="casContent"><span class="casTitleNuber">49</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine:  a pharmacological review</span></div><div class="casAuthors">Freeman, Shirley E.; Dawson, R. M.</div><div class="citationInfo"><span class="NLM_cas:title">Progress in Neurobiology (Oxford, United Kingdom)</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">36</span>
        (<span class="NLM_cas:issue">4</span>),
    <span class="NLM_cas:pages">257-77</span>CODEN:
                <span class="NLM_cas:coden">PGNBA5</span>;
        ISSN:<span class="NLM_cas:issn">0301-0082</span>.
    </div><div class="casAbstract">A review with 162 refs. on tacrine interactions with morphine, with drugs that block the myoneural junction, with glycolate psychotomimetic drugs, with cholinesterases, with muscarinic receptors, with ion channels, with the release and uptake of neurotransmitters, and use as an antidote against nerve agent poisoning and in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrNNQE5N9GzjrVg90H21EOLACvtfcHk0lgAEpWURP3X_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3MXlt1Kiurs%253D&md5=ee92496e1f6b19b773798a17b0af44a0</span></div><a href="/servlet/linkout?suffix=cit49&amp;dbid=16384&amp;doi=10.1016%2F0301-0082%2891%2990002-I&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0301-0082%252891%252990002-I%26sid%3Dliteratum%253Aachs%26aulast%3DFreeman%26aufirst%3DS.%2BE.%26aulast%3DDawson%26aufirst%3DR.%2BM.%26atitle%3DTacrine%253A%2520a%2520pharmacological%2520review%26jtitle%3DProg.%2520Neurobiol.%26date%3D1991%26volume%3D36%26spage%3D257%26epage%3D277%26doi%3D10.1016%2F0301-0082%2891%2990002-I" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref50"><div class="reference"><strong class="refLabel"><a href="#ref50" class="rightTabRefNumLink">50</a></strong><div class="NLM_citation" id="rightTab-cit50"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Summers, W. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Majovski, L. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marsh, G. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tachiki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, A.</span></span> <span> </span><span class="NLM_article-title">Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type</span>. <i>N. Engl. J. Med.</i> <span class="NLM_year" style="font-weight: bold;">1986</span>,  <span class="NLM_volume"><i>315</i></span>,  <span class="NLM_fpage">1241</span>– <span class="NLM_lpage">1245</span>, <span class="refDoi"> DOI: 10.1056/NEJM198611133152001</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1056%2FNEJM198611133152001" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=2430180" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref50/cit50&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaL2s%252FjvFahsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=315&publication_year=1986&pages=1241-1245&author=W.+K.+Summersauthor=L.+V.+Majovskiauthor=G.+M.+Marshauthor=K.+Tachikiauthor=A.+Kling&title=Oral+tetrahydroaminoacridine+in+long-term+treatment+of+senile+dementia%2C+Alzheimer+type&doi=10.1056%2FNEJM198611133152001"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit50R"><div class="casContent"><span class="casTitleNuber">50</span><div class="casTitle"><span class="NLM_cas:atitle">Oral tetrahydroaminoacridine in long-term treatment of senile dementia, Alzheimer type</span></div><div class="casAuthors">Summers W K; Majovski L V; Marsh G M; Tachiki K; Kling A</div><div class="citationInfo"><span class="NLM_cas:title">The New England journal of medicine</span>
        (<span class="NLM_cas:date">1986</span>),
    <span class="NLM_cas:volume">315</span>
        (<span class="NLM_cas:issue">20</span>),
    <span class="NLM_cas:pages">1241-5</span>
        ISSN:<span class="NLM_cas:issn">0028-4793</span>.
    </div><div class="casAbstract">We treated 17 patients who had moderate to severe Alzheimer's disease with oral tetrahydroaminoacridine (THA), a centrally active anticholinesterase, in a three-phase study.  In the nonblinded first phase of the study, significant improvement occurred in subjects who received the drug, as compared with their pretreatment status, on the global assessment (P = 0.001), the Orientation Test (P = 0.001), and the more sophisticated Names Learning Test (P = 0.001).  During the second phase, the subjects served as their own controls in a double-blind, placebo-controlled, cross-over study in which the order of administration of the drug and placebo was randomly assigned.  Among the 14 subjects completing Phase II, THA treatment produced significantly better results than placebo on the global assessment (P = 0.003), the Orientation Test (P = 0.004), the Alzheimer's Deficit Scale (P = 0.003), and the Names Learning Test (P = 0.001).  Twelve subjects have entered Phase III, which involves long-term administration of oral THA.  The average duration of treatment in these subjects at present is 12.6 months; symptomatic improvements have occurred, and no serious side effects attributable to THA have been observed.  These encouraging initial results suggest that THA may be at least temporarily useful in the long-term palliative treatment of patients with Alzheimer's disease.  We stress that further observations will be required before a clear assessment of the role of this agent can be made.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQXMwVWLd0gLpp6t8nS6Nc3fW6udTcc2ea6W4qh5k32G7ntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaL2s%252FjvFahsA%253D%253D&md5=cdb2761ff58c436d8e12d9a9ab219ccd</span></div><a href="/servlet/linkout?suffix=cit50&amp;dbid=16384&amp;doi=10.1056%2FNEJM198611133152001&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1056%252FNEJM198611133152001%26sid%3Dliteratum%253Aachs%26aulast%3DSummers%26aufirst%3DW.%2BK.%26aulast%3DMajovski%26aufirst%3DL.%2BV.%26aulast%3DMarsh%26aufirst%3DG.%2BM.%26aulast%3DTachiki%26aufirst%3DK.%26aulast%3DKling%26aufirst%3DA.%26atitle%3DOral%2520tetrahydroaminoacridine%2520in%2520long-term%2520treatment%2520of%2520senile%2520dementia%252C%2520Alzheimer%2520type%26jtitle%3DN.%2520Engl.%2520J.%2520Med.%26date%3D1986%26volume%3D315%26spage%3D1241%26epage%3D1245%26doi%3D10.1056%2FNEJM198611133152001" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref51"><div class="reference"><strong class="refLabel"><a href="#ref51" class="rightTabRefNumLink">51</a></strong><div class="NLM_citation" id="rightTab-cit51"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Watkins, P. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zimmerman, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Knapp, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gracon, S. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lewis, K. W.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxic effects of tacrine administration in patients with Alzheimer’s disease</span>. <i>JAMA</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>271</i></span>,  <span class="NLM_fpage">992</span>– <span class="NLM_lpage">998</span>, <span class="refDoi"> DOI: 10.1001/jama.1994.03510370044030</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1001%2Fjama.1994.03510370044030" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8139084" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref51/cit51&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Gjs7c%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=271&publication_year=1994&pages=992-998&author=P.+B.+Watkinsauthor=H.+J.+Zimmermanauthor=M.+J.+Knappauthor=S.+I.+Graconauthor=K.+W.+Lewis&title=Hepatotoxic+effects+of+tacrine+administration+in+patients+with+Alzheimer%E2%80%99s+disease&doi=10.1001%2Fjama.1994.03510370044030"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit51R"><div class="casContent"><span class="casTitleNuber">51</span><div class="casTitle"><span class="NLM_cas:atitle">hepatotoxic effects of tacrine administration in patients with Alzheimer's disease</span></div><div class="casAuthors">Watkins, Paul B.; Zimmerman, Hyman J.; Knapp, Margaret J.; Gracon, Stephen I.; Lewis, Karen W.</div><div class="citationInfo"><span class="NLM_cas:title">JAMA, the Journal of the American Medical Association</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">271</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">992-8</span>CODEN:
                <span class="NLM_cas:coden">JAMAAP</span>;
        ISSN:<span class="NLM_cas:issn">0098-7484</span>.
    </div><div class="casAbstract">The study was undertaken to characterize the hepatic effects of tacrine treatment in patients with Alzheimer's disease.  Controlled trials of tacrine therapy were designed consisting of two blinded, parallel group trials; three blinded, enrichment-design trials; and their resp. open-label extensions.  Multicenter clin. trials were performed in the United States, France, and Canada.  A total of 2446 men and women at least 50 yr of age with a diagnosis of probable Alzheimer's disease of mild to moderate severity and in good health without significant hepatic, cardiovascular, or renal disease were examd.  Tacrine vs. placebo was administered, with weekly measurement of serum hepatic enzymes.  Incidence, max. severity, and timing of event for serum alanine aminotransferase (ALT) elevation were monitored.  Among the 2446 patients who received tacrine in clin. trials, ALT levels greater than the upper limit of normal (ULN) occurred on at least one occasion in 1203 patients (49%), ALT levels greater than three times the ULN occurred in 621 patients (25%), and ALT levels greater than 20 times the ULN occurred in 40 patients (2%).  The elevated ALT levels were generally asymptomatic and occurred more frequently in women than men.  The mean time from initiation of tacrine treatment to first ALT level greater than three times the ULN was 50 days, and 90% of all initial ALT levels greater than three times the ULN occurred during the first 12 wk of treatment.  Of 145 patients who discontinued tacrine treatment because of an ALT level greater than three times the ULN and were rechallenged, 127 (88%) were able to resume long-term therapy with the drug.  In all instances, discontinuing tacrine completely reversed elevations in ALT levels, and no deaths related to hepatotoxicity occurred.  These data suggest that the potential for serious hepatic toxicity can be reduced through careful monitoring of ALT levels in patients who may benefit from tacrine therapy.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpGFf98reQra7Vg90H21EOLACvtfcHk0lgAEpWURP3X_Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Gjs7c%253D&md5=6b7f1c1f770d8974d2d4cbfb2954469b</span></div><a href="/servlet/linkout?suffix=cit51&amp;dbid=16384&amp;doi=10.1001%2Fjama.1994.03510370044030&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1001%252Fjama.1994.03510370044030%26sid%3Dliteratum%253Aachs%26aulast%3DWatkins%26aufirst%3DP.%2BB.%26aulast%3DZimmerman%26aufirst%3DH.%2BJ.%26aulast%3DKnapp%26aufirst%3DM.%2BJ.%26aulast%3DGracon%26aufirst%3DS.%2BI.%26aulast%3DLewis%26aufirst%3DK.%2BW.%26atitle%3DHepatotoxic%2520effects%2520of%2520tacrine%2520administration%2520in%2520patients%2520with%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DJAMA%26date%3D1994%26volume%3D271%26spage%3D992%26epage%3D998%26doi%3D10.1001%2Fjama.1994.03510370044030" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref52"><div class="reference"><strong class="refLabel"><a href="#ref52" class="rightTabRefNumLink">52</a></strong><div class="NLM_citation" id="rightTab-cit52"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ticchi, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">H. Chen, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Betari, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span> <span> </span><span class="NLM_article-title">Tacrine-based multifunctional agents in Alzheimer’s disease: an old story in continuous development</span>. <i>Curr. Med. Chem</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">3522</span>– <span class="NLM_lpage">3546</span>, <span class="refDoi"> DOI: 10.2174/0929867324666170309123920</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F0929867324666170309123920" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28294041" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref52/cit52&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2017&pages=3522-3546&author=A.+Milelliauthor=A.+De+Simoneauthor=N.+Ticchiauthor=H.+H.+Chenauthor=N.+Betariauthor=V.+Andrisanoauthor=V.+Tumiatti&title=Tacrine-based+multifunctional+agents+in+Alzheimer%E2%80%99s+disease%3A+an+old+story+in+continuous+development&doi=10.2174%2F0929867324666170309123920"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit52R"><div class="casContent"><span class="casTitleNuber">52</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-based Multifunctional Agents in Alzheimer's Disease: An Old Story in Continuous Development.bdintg.</span></div><div class="casAuthors">Milelli, Andrea; De Simone, Angela; Ticchi, Nicole; Chen, Huan H.; Betari, Nibal; Andrisano, Vincenza; Tumiatti, Vincenzo</div><div class="citationInfo"><span class="NLM_cas:title">Current Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">32</span>),
    <span class="NLM_cas:pages">3522-3546</span>CODEN:
                <span class="NLM_cas:coden">CMCHE7</span>;
        ISSN:<span class="NLM_cas:issn">0929-8673</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Background: The design of multifunctional agents represents one of the most active research field in medicinal chem.  In particular, tacrine, a well known Acetylcholinesterase inhibitor, is one of the most used starting point to develop multifunctional ligands and hundreds of papers report about these new agents.  This is the third review of a series concerning tacrine based multifunctional ligands; in particular, in the present, we will summarize and discuss the most intriguing examples of tacrine-based multifunctional agents published since 2013 until 2016. </P><P> Methods: We analyzed the bibliog. databases for peer-reviewed publications concerning tacrine-based multifunctional agents possessing biol. actions that go beyond the simple "cholinergic" blockage.  These papers have been subdivided according to their biol. activities.  Since this is the third review of a series, we took into considerations only the papers appeared since 2013 until 2016.  Results: In this review, we have analyzed more than 33 papers.  All the reported compds. retain good inhibitory activity towards acetyl- and butyryl-cholinesterase.  The other biol. activities concern mostly inhibition of a. β-amyloid aggregation, b. β-secretase, c. monoamino oxidases, modulation of β; and ROS and metal chelation.  Conclusion: The anal. of the current literature reported in this review confirm the importance of tacrine as scaffold to develop multifunctional agents potentially usefull to contrast Alzheimer's disease.  Furthermore, the compds. herein reported showed very intriguing biol. activities that could be used as starting point to develop new compds. even more interesting and, hopefully, clin. usefull to contrast Alzheimer's Disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrZimowwL4q_7Vg90H21EOLACvtfcHk0ljJ9K8X57gVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhslGgtrnM&md5=2a6f856526a08139bca151c647733f95</span></div><a href="/servlet/linkout?suffix=cit52&amp;dbid=16384&amp;doi=10.2174%2F0929867324666170309123920&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F0929867324666170309123920%26sid%3Dliteratum%253Aachs%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DTicchi%26aufirst%3DN.%26aulast%3DH.%2BChen%26aufirst%3DH.%26aulast%3DBetari%26aufirst%3DN.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DTumiatti%26aufirst%3DV.%26atitle%3DTacrine-based%2520multifunctional%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520an%2520old%2520story%2520in%2520continuous%2520development%26jtitle%3DCurr.%2520Med.%2520Chem%26date%3D2017%26volume%3D24%26spage%3D3522%26epage%3D3546%26doi%3D10.2174%2F0929867324666170309123920" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref53"><div class="reference"><strong class="refLabel"><a href="#ref53" class="rightTabRefNumLink">53</a></strong><div class="NLM_citation" id="rightTab-cit53"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lin, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gu, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Jiang, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sun, H.</span></span> <span> </span><span class="NLM_article-title">Therapeutic agents in Alzheimer’s disease through a multi-target directed ligands strategy: Recent progress based on tacrine core</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>17</i></span>,  <span class="NLM_fpage">3000</span>– <span class="NLM_lpage">3016</span>, <span class="refDoi"> DOI: 10.2174/1568026617666170717114944</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F1568026617666170717114944" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28714419" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref53/cit53&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXhvValtLrL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=17&publication_year=2017&pages=3000-3016&author=H.+Linauthor=Q.+Liauthor=K.+Guauthor=J.+Zhuauthor=X.+Jiangauthor=Y.+Chenauthor=H.+Sun&title=Therapeutic+agents+in+Alzheimer%E2%80%99s+disease+through+a+multi-target+directed+ligands+strategy%3A+Recent+progress+based+on+tacrine+core&doi=10.2174%2F1568026617666170717114944"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit53R"><div class="casContent"><span class="casTitleNuber">53</span><div class="casTitle"><span class="NLM_cas:atitle">Therapeutic Agents in Alzheimer';s Disease Through a Multi-targetdirected Ligands Strategy: Recent Progress Based on Tacrine Core</span></div><div class="casAuthors">Lin, Hongzhi; Li, Qi; Gu, Kai; Zhu, Jie; Jiang, Xueyang; Chen, Yao; Sun, Haopeng</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Sharjah, United Arab Emirates)</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">17</span>
        (<span class="NLM_cas:issue">27</span>),
    <span class="NLM_cas:pages">3000-3016</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">Alzheimer's Disease (AD) is one of the most common forms of dementia in elderly people.  To date, efficacious therapeutic agent for the treatment of AD is still very limited, so it has long been a challenging and attractive task to discover new anti-AD drugs.  Considering the multifactorial nature of AD, recently, the concept of Multi-Target-Directed Ligands (MTDLs) has emerged as a new strategy for designing therapeutic agents on AD.  MTDLs are believed to exert their effects through simultaneously affecting multiple targets which contribute to etiol. of AD.  Therefore, MTDLs are considered to be more efficacious than mono-target agents.  Tacrine is the first drug approved by Food and Drug Administration (FDA).  Although the clin. use of tacrine is restricted because of its hepatotoxicity, the high Ligand Efficiency (LE) of this compd. makes it an ideal component for designing MTDLs.  This article provides an update review of the advances on the development of MTDLs based on tacrine.  Case studies are carefully selected to show the detailed strategy on medicinal modification of Tacrine-Based MTDLs.  Finally, several concerns and opinions on designing new MTDLs are discussed as well.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoZpCkartJK5bVg90H21EOLACvtfcHk0ljJ9K8X57gVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXhvValtLrL&md5=41ddb7b2d2fc697b92c72b174039f512</span></div><a href="/servlet/linkout?suffix=cit53&amp;dbid=16384&amp;doi=10.2174%2F1568026617666170717114944&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026617666170717114944%26sid%3Dliteratum%253Aachs%26aulast%3DLin%26aufirst%3DH.%26aulast%3DLi%26aufirst%3DQ.%26aulast%3DGu%26aufirst%3DK.%26aulast%3DZhu%26aufirst%3DJ.%26aulast%3DJiang%26aufirst%3DX.%26aulast%3DChen%26aufirst%3DY.%26aulast%3DSun%26aufirst%3DH.%26atitle%3DTherapeutic%2520agents%2520in%2520Alzheimer%25E2%2580%2599s%2520disease%2520through%2520a%2520multi-target%2520directed%2520ligands%2520strategy%253A%2520Recent%2520progress%2520based%2520on%2520tacrine%2520core%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2017%26volume%3D17%26spage%3D3000%26epage%3D3016%26doi%3D10.2174%2F1568026617666170717114944" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref54"><div class="reference"><strong class="refLabel"><a href="#ref54" class="rightTabRefNumLink">54</a></strong><div class="NLM_citation" id="rightTab-cit54"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zenger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lupp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kling, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fleck, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Tacrine-silibinin codrug shows neuro-and hepatoprotective effects in vitro and pro-cognitive and hepatoprotective effects in vivo</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>55</i></span>,  <span class="NLM_fpage">5231</span>– <span class="NLM_lpage">5242</span>, <span class="refDoi"> DOI: 10.1021/jm300246n</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm300246n" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref54/cit54&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XnsVertb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=55&publication_year=2012&pages=5231-5242&author=X.+Chenauthor=K.+Zengerauthor=A.+Luppauthor=B.+Klingauthor=J.+Heilmannauthor=C.+Fleckauthor=B.+Krausauthor=M.+Decker&title=Tacrine-silibinin+codrug+shows+neuro-and+hepatoprotective+effects+in+vitro+and+pro-cognitive+and+hepatoprotective+effects+in+vivo&doi=10.1021%2Fjm300246n"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit54R"><div class="casContent"><span class="casTitleNuber">54</span><div class="casTitle"><span class="NLM_cas:atitle">Tacrine-Silibinin Codrug Shows Neuro- and Hepatoprotective Effects in Vitro and Pro-Cognitive and Hepatoprotective Effects in Vivo</span></div><div class="casAuthors">Chen, Xinyu; Zenger, Katharina; Lupp, Amelie; Kling, Beata; Heilmann, Joerg; Fleck, Christian; Kraus, Birgit; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">55</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">5231-5242</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">A codrug of the anti-Alzheimer drug tacrine and the natural product silibinin was synthesized.  The codrug's biol. and pharmacol. properties were compared to an equimolar mixt. of the components.  The compd. showed potent acetyl- and butyrylcholinesterase inhibition.  In a cellular hepatotoxicity model, analyzing the influence on viability and mitochondria of hepatic stellate cells (HSC), the toxicity of the codrug was markedly reduced in comparison to that of tacrine.  Using a neuronal cell line (HT-22), a neuroprotective effect against glutamate-induced toxicity could be obsd. that was absent for the 1:1 mixt. of components.  In subsequent in vivo expts. in rats, in contrast to the effects seen after tacrine treatment, after administration of the codrug, no hepatotoxicity and no induction of the cytochrome P 450 system were noticed.  In a scopolamine-induced cognitive impairment model using Wistar rats, the codrug was as potent as tacrine in reversing memory dysfunction.  The tacrine-silibinin codrug shows high AChE and BChE inhibition, neuroprotective effects, lacks tacrine's hepatotoxicity in vitro and in vivo, and shows the same pro-cognitive effects in vivo as tacrine, being superior to the phys. mixt. of tacrine and silibinin in all these regards.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo7cNXF3vJ0LrVg90H21EOLACvtfcHk0ljJ9K8X57gVKg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XnsVertb0%253D&md5=e3bc1878607eba40b8253c40c017a2a4</span></div><a href="/servlet/linkout?suffix=cit54&amp;dbid=16384&amp;doi=10.1021%2Fjm300246n&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm300246n%26sid%3Dliteratum%253Aachs%26aulast%3DChen%26aufirst%3DX.%26aulast%3DZenger%26aufirst%3DK.%26aulast%3DLupp%26aufirst%3DA.%26aulast%3DKling%26aufirst%3DB.%26aulast%3DHeilmann%26aufirst%3DJ.%26aulast%3DFleck%26aufirst%3DC.%26aulast%3DKraus%26aufirst%3DB.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DTacrine-silibinin%2520codrug%2520shows%2520neuro-and%2520hepatoprotective%2520effects%2520in%2520vitro%2520and%2520pro-cognitive%2520and%2520hepatoprotective%2520effects%2520in%2520vivo%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2012%26volume%3D55%26spage%3D5231%26epage%3D5242%26doi%3D10.1021%2Fjm300246n" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref55"><div class="reference"><strong class="refLabel"><a href="#ref55" class="rightTabRefNumLink">55</a></strong><div class="NLM_citation" id="rightTab-cit55"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McEneny-King, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Osman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Edginton, A. N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rao, P. P. N.</span></span> <span> </span><span class="NLM_article-title">Cytochrome P450 binding studies of novel tacrine derivatives: predicting the risk of hepatotoxicity</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2017</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">2443</span>– <span class="NLM_lpage">2449</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2017.04.006</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmcl.2017.04.006" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=28400237" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref55/cit55&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2sXlvVCksbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2017&pages=2443-2449&author=A.+McEneny-Kingauthor=W.+Osmanauthor=A.+N.+Edgintonauthor=P.+P.+N.+Rao&title=Cytochrome+P450+binding+studies+of+novel+tacrine+derivatives%3A+predicting+the+risk+of+hepatotoxicity&doi=10.1016%2Fj.bmcl.2017.04.006"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit55R"><div class="casContent"><span class="casTitleNuber">55</span><div class="casTitle"><span class="NLM_cas:atitle">Cytochrome P450 binding studies of novel tacrine derivatives: Predicting the risk of hepatotoxicity</span></div><div class="casAuthors">McEneny-King, Alanna; Osman, Wesseem; Edginton, Andrea N.; Rao, Praveen P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2017</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2443-2449</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The 1,2,3,4-tetrahydroacridine deriv. tacrine was the first drug approved to treat Alzheimer's disease (AD).  It is known to act as a potent cholinesterase inhibitor.  However, tacrine was removed from the market due to its hepatotoxicity concerns as it undergoes metab. to toxic quinonemethide species through the cytochrome P 450 enzyme CYP1A2.  Despite these challenges, tacrine serves as a useful template in the development of novel multitargeting anti-AD agents.  In this regard, the authors sought to evaluate the risk of hepatotoxicity in a series of C9 substituted tacrine derivs. that exhibit cholinesterase inhibition properties.  The hepatotoxic potential of tacrine derivs. was evaluated using recombinant cytochrome (CYP) P 450 CYP1A2 and CYP3A4 enzymes.  Mol. docking studies were conducted to predict their binding modes and potential risk of forming hepatotoxic metabolites.  Tacrine derivs. compd. I (N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine) and II (6-chloro-N-(3,4-dimethoxybenzyl)-1,2,3,4-tetrahydroacridin-9-amine) which possess a C9 3,4-dimethoxybenzylamino substituent exhibited weak binding to CYP1A2 enzyme (I, IC50 = 33.0 μM; II, IC50 = 8.5 μM) compared to tacrine (CYP1A2 IC50 = 1.5 μM).  Modeling studies show that the presence of a bulky 3,4-dimethoxybenzylamino C9 substituent prevents the orientation of the 1,2,3,4-tetrahydroacridine ring close to the heme-iron center of CYP1A2 thereby reducing the risk of forming hepatotoxic species.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpbWER0-gNWyrVg90H21EOLACvtfcHk0ljkBuVBn3JK7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2sXlvVCksbs%253D&md5=ac187061c1082f8c072b7dc165d26dff</span></div><a href="/servlet/linkout?suffix=cit55&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2017.04.006&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2017.04.006%26sid%3Dliteratum%253Aachs%26aulast%3DMcEneny-King%26aufirst%3DA.%26aulast%3DOsman%26aufirst%3DW.%26aulast%3DEdginton%26aufirst%3DA.%2BN.%26aulast%3DRao%26aufirst%3DP.%2BP.%2BN.%26atitle%3DCytochrome%2520P450%2520binding%2520studies%2520of%2520novel%2520tacrine%2520derivatives%253A%2520predicting%2520the%2520risk%2520of%2520hepatotoxicity%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2017%26volume%3D27%26spage%3D2443%26epage%3D2449%26doi%3D10.1016%2Fj.bmcl.2017.04.006" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref56"><div class="reference"><strong class="refLabel"><a href="#ref56" class="rightTabRefNumLink">56</a></strong><div class="NLM_citation" id="rightTab-cit56"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zenger, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kraus, B.</span></span> <span> </span><span class="NLM_article-title">In-vitro stability and metabolism of a tacrine–silibinin codrug</span>. <i>J. Pharm. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">1765</span>– <span class="NLM_lpage">1772</span>, <span class="refDoi"> DOI: 10.1111/jphp.12070</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1111%2Fjphp.12070" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24236987" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref56/cit56&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhslygsr%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2013&pages=1765-1772&author=K.+Zengerauthor=X.+Chenauthor=M.+Deckerauthor=B.+Kraus&title=In-vitro+stability+and+metabolism+of+a+tacrine%E2%80%93silibinin+codrug&doi=10.1111%2Fjphp.12070"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit56R"><div class="casContent"><span class="casTitleNuber">56</span><div class="casTitle"><span class="NLM_cas:atitle">In-vitro stability and metabolism of a tacrine-silibinin codrug</span></div><div class="casAuthors">Zenger, Katharina; Chen, Xinyu; Decker, Michael; Kraus, Birgit</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Pharmacy and Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1765-1772</span>CODEN:
                <span class="NLM_cas:coden">JPPMAB</span>;
        ISSN:<span class="NLM_cas:issn">0022-3573</span>.
    
            (<span class="NLM_cas:orgname">John Wiley & Sons Ltd.</span>)
        </div><div class="casAbstract">Objectives : A tacrine-silibinin codrug showed promising results in pharmacol. and toxicity testing, superior to an equimolar mixt. of tacrine and silibinin.  The aim of this study was to get more information about its stability, possible degrdn. products, metabolites, and esp. its active principle in vitro and in vivo.  Methods : The stability of the codrug was analyzed under in-vitro assay conditions.  Addnl., its metab. was investigated using pooled human liver microsomes.  Metabolites were identified via liq. chromatog.-high resoln. electrospray ionization mass spectrometry.  Furthermore, the influence of one of the main cleavage products, tacrine hemi succinamide, on viability and mitochondria of hepatic stellate cells was analyzed.  Key findings : The codrug remained stable in culture medium (Dulbecco's modified Eagle's medium) over an incubation period of 24 h, whereas exposition to microsomal enzymes led to rapid cleavage of the ester bond to form silibinin and a tacrine hemi succinamide.  In addn., glucuronidated metabolites of both silibinin and the codrug were detected.  For the tacrine hemi succinamide, no effects were obsd. with regard to cell viability and mitochondrial impairment.  Conclusions : This study helps understand and interpret previous results concerning the effects and the absence of toxicity of the tacrine-silibinin codrug and supplies important information for further identification of the active principles of the codrug in vivo.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpZ7t-8hcwXHLVg90H21EOLACvtfcHk0ljkBuVBn3JK7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhslygsr%252FI&md5=f98932a3201cdacb70f8f4e6551e298b</span></div><a href="/servlet/linkout?suffix=cit56&amp;dbid=16384&amp;doi=10.1111%2Fjphp.12070&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1111%252Fjphp.12070%26sid%3Dliteratum%253Aachs%26aulast%3DZenger%26aufirst%3DK.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DDecker%26aufirst%3DM.%26aulast%3DKraus%26aufirst%3DB.%26atitle%3DIn-vitro%2520stability%2520and%2520metabolism%2520of%2520a%2520tacrine%25E2%2580%2593silibinin%2520codrug%26jtitle%3DJ.%2520Pharm.%2520Pharmacol.%26date%3D2013%26volume%3D65%26spage%3D1765%26epage%3D1772%26doi%3D10.1111%2Fjphp.12070" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref57"><div class="reference"><strong class="refLabel"><a href="#ref57" class="rightTabRefNumLink">57</a></strong><div class="NLM_citation" id="rightTab-cit57"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Pagé, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Balaux, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Boisvert, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Liu, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milburn, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tremblay, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wei, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Woo, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Luo, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cheng, Y.-X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Srivastava, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhou, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brown, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tomaszewski, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Walpole, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hodzic, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">St-Onge, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Godbout, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salois, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Payza, K.</span></span> <span> </span><span class="NLM_article-title">Novel benzimidazole derivatives as selective CB<sub>2</sub> agonists</span>. <i>Bioorg. Med. Chem. Lett.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>18</i></span>,  <span class="NLM_fpage">3695</span>– <span class="NLM_lpage">3700</span>, <span class="refDoi"> DOI: 10.1016/j.bmcl.2008.05.073</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmcl.2008.05.073" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=18522867" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref57/cit57&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=18&publication_year=2008&pages=3695-3700&author=D.+Pag%C3%A9author=E.+Balauxauthor=L.+Boisvertauthor=Z.+Liuauthor=C.+Milburnauthor=M.+Tremblayauthor=Z.+Weiauthor=S.+Wooauthor=X.+Luoauthor=Y.-X.+Chengauthor=H.+Yangauthor=S.+Srivastavaauthor=F.+Zhouauthor=W.+Brownauthor=M.+Tomaszewskiauthor=C.+Walpoleauthor=L.+Hodzicauthor=S.+St-Ongeauthor=C.+Godboutauthor=D.+Saloisauthor=K.+Payza&title=Novel+benzimidazole+derivatives+as+selective+CB2+agonists&doi=10.1016%2Fj.bmcl.2008.05.073"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit57R"><div class="casContent"><span class="casTitleNuber">57</span><div class="casTitle"><span class="NLM_cas:atitle">Novel benzimidazole derivatives as selective CB2 agonists</span></div><div class="casAuthors">Page, Daniel; Balaux, Elise; Boisvert, Luc; Liu, Ziping; Milburn, Claire; Tremblay, Maxime; Wei, Zhongyong; Woo, Simon; Luo, Xuehong; Cheng, Yun-Xing; Yang, Hua; Srivastava, Sanjay; Zhou, Fei; Brown, William; Tomaszewski, Miroslaw; Walpole, Christopher; Hodzic, Leila; St-Onge, Stephane; Godbout, Claude; Salois, Dominic; Payza, Keymal</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry Letters</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">18</span>
        (<span class="NLM_cas:issue">13</span>),
    <span class="NLM_cas:pages">3695-3700</span>CODEN:
                <span class="NLM_cas:coden">BMCLE8</span>;
        ISSN:<span class="NLM_cas:issn">0960-894X</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Ltd.</span>)
        </div><div class="casAbstract">The prepn. and evaluation of a novel class of CB2 agonists based on a benzimidazole moiety, e.g., I, are reported.  They showed binding affinities up to 1 nM towards the CB2 receptor with partial to full agonist potencies.  They also demonstrated good to excellent selectivity (>1000-fold) over the CB1 receptor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqbeiXe1I0Yg7Vg90H21EOLACvtfcHk0ljkBuVBn3JK7w"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXnt1Ohurs%253D&md5=fa9e0921054b0d9f26044a1feb82a604</span></div><a href="/servlet/linkout?suffix=cit57&amp;dbid=16384&amp;doi=10.1016%2Fj.bmcl.2008.05.073&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmcl.2008.05.073%26sid%3Dliteratum%253Aachs%26aulast%3DPag%25C3%25A9%26aufirst%3DD.%26aulast%3DBalaux%26aufirst%3DE.%26aulast%3DBoisvert%26aufirst%3DL.%26aulast%3DLiu%26aufirst%3DZ.%26aulast%3DMilburn%26aufirst%3DC.%26aulast%3DTremblay%26aufirst%3DM.%26aulast%3DWei%26aufirst%3DZ.%26aulast%3DWoo%26aufirst%3DS.%26aulast%3DLuo%26aufirst%3DX.%26aulast%3DCheng%26aufirst%3DY.-X.%26aulast%3DYang%26aufirst%3DH.%26aulast%3DSrivastava%26aufirst%3DS.%26aulast%3DZhou%26aufirst%3DF.%26aulast%3DBrown%26aufirst%3DW.%26aulast%3DTomaszewski%26aufirst%3DM.%26aulast%3DWalpole%26aufirst%3DC.%26aulast%3DHodzic%26aufirst%3DL.%26aulast%3DSt-Onge%26aufirst%3DS.%26aulast%3DGodbout%26aufirst%3DC.%26aulast%3DSalois%26aufirst%3DD.%26aulast%3DPayza%26aufirst%3DK.%26atitle%3DNovel%2520benzimidazole%2520derivatives%2520as%2520selective%2520CB2%2520agonists%26jtitle%3DBioorg.%2520Med.%2520Chem.%2520Lett.%26date%3D2008%26volume%3D18%26spage%3D3695%26epage%3D3700%26doi%3D10.1016%2Fj.bmcl.2008.05.073" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref58"><div class="reference"><strong class="refLabel"><a href="#ref58" class="rightTabRefNumLink">58</a></strong><div class="NLM_citation" id="rightTab-cit58"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Scheiner, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ramler, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stadtmüller, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sawatzky, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drakopoulos, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sotriffer, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Aminobenzimidazoles and structural isomers as templates for dual-acting butyrylcholinesterase inhibitors and hCB2R ligands to combat neurodegenerative disorders</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>11</i></span>,  <span class="NLM_fpage">1270</span>– <span class="NLM_lpage">1283</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500418</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcmdc.201500418" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26548365" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref58/cit58&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=11&publication_year=2016&pages=1270-1283&author=D.+Dollesauthor=M.+Nimczickauthor=M.+Scheinerauthor=J.+Ramlerauthor=P.+Stadtm%C3%BCllerauthor=E.+Sawatzkyauthor=A.+Drakopoulosauthor=C.+Sotrifferauthor=H.-J.+Wittmannauthor=A.+Strasserauthor=M.+Decker&title=Aminobenzimidazoles+and+structural+isomers+as+templates+for+dual-acting+butyrylcholinesterase+inhibitors+and+hCB2R+ligands+to+combat+neurodegenerative+disorders&doi=10.1002%2Fcmdc.201500418"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit58R"><div class="casContent"><span class="casTitleNuber">58</span><div class="casTitle"><span class="NLM_cas:atitle">Aminobenzimidazoles and Structural Isomers as Templates for Dual-Acting Butyrylcholinesterase Inhibitors and hCB2R Ligands To Combat Neurodegenerative Disorders</span></div><div class="casAuthors">Dolles, Dominik; Nimczick, Martin; Scheiner, Matthias; Ramler, Jacqueline; Stadtmueller, Patricia; Sawatzky, Edgar; Drakopoulos, Antonios; Sotriffer, Christoph; Wittmann, Hans-Joachim; Strasser, Andrea; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">11</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1270-1283</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A pharmacophore model for butyrylcholinesterase (BChE) inhibitors was applied to a human cannabinoid subtype 2 receptor (hCB2R) agonist and verified it as a first-generation lead for resp. dual-acting compds.  The design, synthesis, and pharmacol. evaluation of various derivs. led to the identification of aminobenzimidazoles as second-generation leads with micro- or sub-micromolar activities at both targets and excellent selectivity over hCB1 and AChE, resp.  Computational studies of the first- and second-generation lead structures by applying mol. dynamics (MD) on the active hCB2R model, along with docking and MD on hBChE, has enabled an explanation of their binding profiles at the protein levels and opened the way for further optimization.  Dual-acting compds. with "balanced" affinities and excellent selectivities could be obtained that represent leads for treatment of both cognitive and pathophysiol. impairment occurring in neurodegenerative disorders.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrP2lcUsRAXJ7Vg90H21EOLACvtfcHk0lgOBkJTgKGbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhslyms7%252FI&md5=dcd6f52f38134002413bd3d975ee9da3</span></div><a href="/servlet/linkout?suffix=cit58&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500418&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500418%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DScheiner%26aufirst%3DM.%26aulast%3DRamler%26aufirst%3DJ.%26aulast%3DStadtm%25C3%25BCller%26aufirst%3DP.%26aulast%3DSawatzky%26aufirst%3DE.%26aulast%3DDrakopoulos%26aufirst%3DA.%26aulast%3DSotriffer%26aufirst%3DC.%26aulast%3DWittmann%26aufirst%3DH.-J.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DAminobenzimidazoles%2520and%2520structural%2520isomers%2520as%2520templates%2520for%2520dual-acting%2520butyrylcholinesterase%2520inhibitors%2520and%2520hCB2R%2520ligands%2520to%2520combat%2520neurodegenerative%2520disorders%26jtitle%3DChemMedChem%26date%3D2016%26volume%3D11%26spage%3D1270%26epage%3D1283%26doi%3D10.1002%2Fcmdc.201500418" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref59"><div class="reference"><strong class="refLabel"><a href="#ref59" class="rightTabRefNumLink">59</a></strong><div class="NLM_citation" id="rightTab-cit59"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Dolles, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Strasser, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wittmann, H. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marinelli, O.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabissi, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">The first photochromic affinity switch for the human cannabinoid receptor 2</span>. <i>Adv. Ther.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">1700032</span>, <span class="refDoi"> DOI: 10.1002/adtp.201700032</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref59/cit59&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fadtp.201700032" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2018&pages=1700032&author=D.+Dollesauthor=A.+Strasserauthor=H.+J.+Wittmannauthor=O.+Marinelliauthor=M.+Nabissiauthor=R.+G.+Pertweeauthor=M.+Decker&title=The+first+photochromic+affinity+switch+for+the+human+cannabinoid+receptor+2&doi=10.1002%2Fadtp.201700032"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit59&amp;dbid=16384&amp;doi=10.1002%2Fadtp.201700032&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fadtp.201700032%26sid%3Dliteratum%253Aachs%26aulast%3DDolles%26aufirst%3DD.%26aulast%3DStrasser%26aufirst%3DA.%26aulast%3DWittmann%26aufirst%3DH.%2BJ.%26aulast%3DMarinelli%26aufirst%3DO.%26aulast%3DNabissi%26aufirst%3DM.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DThe%2520first%2520photochromic%2520affinity%2520switch%2520for%2520the%2520human%2520cannabinoid%2520receptor%25202%26jtitle%3DAdv.%2520Ther.%26date%3D2018%26volume%3D1%26spage%3D1700032%26doi%3D10.1002%2Fadtp.201700032" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref60"><div class="reference"><strong class="refLabel"><a href="#ref60" class="rightTabRefNumLink">60</a></strong><div class="NLM_citation" id="rightTab-cit60"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pemp, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Darras, F. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Heilmann, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2014</span>,  <span class="NLM_volume"><i>22</i></span>,  <span class="NLM_fpage">3938</span>– <span class="NLM_lpage">3946</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2014.06.008</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2014.06.008" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=24984935" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref60/cit60&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2cXhtVOntrbE" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=22&publication_year=2014&pages=3938-3946&author=M.+Nimczickauthor=D.+Pempauthor=F.+H.+Darrasauthor=X.+Chenauthor=J.+Heilmannauthor=M.+Decker&title=Synthesis+and+biological+evaluation+of+bivalent+cannabinoid+receptor+ligands+based+on+hCB2R+selective+benzimidazoles+reveal+unexpected+intrinsic+properties&doi=10.1016%2Fj.bmc.2014.06.008"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit60R"><div class="casContent"><span class="casTitleNuber">60</span><div class="casTitle"><span class="NLM_cas:atitle">Synthesis and biological evaluation of bivalent cannabinoid receptor ligands based on hCB2R selective benzimidazoles reveal unexpected intrinsic properties</span></div><div class="casAuthors">Nimczick, Martin; Pemp, Daniela; Darras, Fouad H.; Chen, Xinyu; Heilmann, Joerg; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2014</span>),
    <span class="NLM_cas:volume">22</span>
        (<span class="NLM_cas:issue">15</span>),
    <span class="NLM_cas:pages">3938-3946</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">The design of bivalent ligands targeting G protein-coupled receptors (GPCRs) often leads to the development of new, highly selective and potent compds.  To date, no bivalent ligands for the human cannabinoid receptor type 2 (hCB2R) of the endocannabinoid system (ECS) are described.  Therefore, two sets of homobivalent ligands contg. as parent structure the hCB2R selective agonist I and coupled at different attachment positions were synthesized.  Changes of the parent structure at these positions have a crucial effect on the potency and efficacy of the ligands.  However, the authors discovered that bivalency has an influence on the effect at both cannabinoid receptors.  Moreover, the authors found out that the spacer length and the attachment position altered the efficacy of the bivalent ligands at the receptors by turning agonists into antagonists and inverse agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoKDa1voY3HeLVg90H21EOLACvtfcHk0lgOBkJTgKGbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2cXhtVOntrbE&md5=1496bd99dbd6dd60d77fb5d24153ae17</span></div><a href="/servlet/linkout?suffix=cit60&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2014.06.008&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2014.06.008%26sid%3Dliteratum%253Aachs%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DPemp%26aufirst%3DD.%26aulast%3DDarras%26aufirst%3DF.%2BH.%26aulast%3DChen%26aufirst%3DX.%26aulast%3DHeilmann%26aufirst%3DJ.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DSynthesis%2520and%2520biological%2520evaluation%2520of%2520bivalent%2520cannabinoid%2520receptor%2520ligands%2520based%2520on%2520hCB2R%2520selective%2520benzimidazoles%2520reveal%2520unexpected%2520intrinsic%2520properties%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2014%26volume%3D22%26spage%3D3938%26epage%3D3946%26doi%3D10.1016%2Fj.bmc.2014.06.008" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref61"><div class="reference"><strong class="refLabel"><a href="#ref61" class="rightTabRefNumLink">61</a></strong><div class="NLM_citation" id="rightTab-cit61"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mishra, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kumar, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Panda, G.</span></span> <span> </span><span class="NLM_article-title">Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer’s disease (1998-2018)</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2019</span>,  <span class="NLM_volume"><i>27</i></span>,  <span class="NLM_fpage">895</span>– <span class="NLM_lpage">930</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2019.01.025</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2019.01.025" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=30744931" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref61/cit61&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1MXivVWlt7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=27&publication_year=2019&pages=895-930&author=P.+Mishraauthor=A.+Kumarauthor=G.+Panda&title=Anti-cholinesterase+hybrids+as+multi-target-directed+ligands+against+Alzheimer%E2%80%99s+disease+%281998-2018%29&doi=10.1016%2Fj.bmc.2019.01.025"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit61R"><div class="casContent"><span class="casTitleNuber">61</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-cholinesterase hybrids as multi-target-directed ligands against Alzheimer's disease (1998-2018)</span></div><div class="casAuthors">Mishra, Pankaj; Kumar, Amit; Panda, Gautam</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2019</span>),
    <span class="NLM_cas:volume">27</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">895-930</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">A review.  Alzheimer's disease (AD) is a genetically complex, progressive and irreversible neurodegenerative disorder of the brain which involves multiple assocd. etiol. targets.  The complex pathogenesis of AD gave rise to multi-target-directed ligands (MTDLs) principle to combat this dreaded disease.  Within this approach, the design and synthesis of hybrids prevailed greatly because of their capability to simultaneously target the intertwined pathogenesis components of the disease.  The hybrids include pharmacophoric hybridization of two or more established chem. scaffolds endowed with the desired pharmacol. properties into a single moiety.  In AD, the primary foundation of medication therapy and drug design strategies includes the inhibition of cholinesterase (ChE) enzymes.  Hence the development of ChE inhibition based hybrids is the central choice of AD medicinal chem. research.  To illustrate the progress of ChE inhibition based hybrids and novel targets, we reviewed the medicinal chem. and pharmacol. properties of the multi-target mols. published since 1998-Dec. 2018.  We hope that this article will allow the readers to easily follow the evolution of this prominent medicinal chem. approach to develop a more efficient inhibitor.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpp6n_9YGJjsrVg90H21EOLACvtfcHk0lgOBkJTgKGbOw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1MXivVWlt7g%253D&md5=5941878ce58266e56b041f4d239d2b63</span></div><a href="/servlet/linkout?suffix=cit61&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2019.01.025&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2019.01.025%26sid%3Dliteratum%253Aachs%26aulast%3DMishra%26aufirst%3DP.%26aulast%3DKumar%26aufirst%3DA.%26aulast%3DPanda%26aufirst%3DG.%26atitle%3DAnti-cholinesterase%2520hybrids%2520as%2520multi-target-directed%2520ligands%2520against%2520Alzheimer%25E2%2580%2599s%2520disease%2520%25281998-2018%2529%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2019%26volume%3D27%26spage%3D895%26epage%3D930%26doi%3D10.1016%2Fj.bmc.2019.01.025" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref62"><div class="reference"><strong class="refLabel"><a href="#ref62" class="rightTabRefNumLink">62</a></strong><div class="NLM_citation" id="rightTab-cit62"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Minarini, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Milelli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Tumiatti, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Rosini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Simoni, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Motori, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Angeloni, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hrelia, S.</span></span> <span> </span><span class="NLM_article-title">Cystamine-tacrine dimer: a new multi-target-directed ligand as potential therapeutic agent for Alzheimer’s disease treatment</span>. <i>Neuropharmacology</i> <span class="NLM_year" style="font-weight: bold;">2012</span>,  <span class="NLM_volume"><i>62</i></span>,  <span class="NLM_fpage">997</span>– <span class="NLM_lpage">1003</span>, <span class="refDoi"> DOI: 10.1016/j.neuropharm.2011.10.007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.neuropharm.2011.10.007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=22032870" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref62/cit62&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38XhtFCrsb0%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=62&publication_year=2012&pages=997-1003&author=A.+Minariniauthor=A.+Milelliauthor=V.+Tumiattiauthor=M.+Rosiniauthor=E.+Simoniauthor=M.+L.+Bolognesiauthor=V.+Andrisanoauthor=M.+Bartoliniauthor=E.+Motoriauthor=C.+Angeloniauthor=S.+Hrelia&title=Cystamine-tacrine+dimer%3A+a+new+multi-target-directed+ligand+as+potential+therapeutic+agent+for+Alzheimer%E2%80%99s+disease+treatment&doi=10.1016%2Fj.neuropharm.2011.10.007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit62R"><div class="casContent"><span class="casTitleNuber">62</span><div class="casTitle"><span class="NLM_cas:atitle">Cystamine-tacrine dimer: A new multi-target-directed ligand as potential therapeutic agent for Alzheimer's disease treatment</span></div><div class="casAuthors">Minarini, A.; Milelli, A.; Tumiatti, V.; Rosini, M.; Simoni, E.; Bolognesi, M. L.; Andrisano, V.; Bartolini, M.; Motori, E.; Angeloni, C.; Hrelia, S.</div><div class="citationInfo"><span class="NLM_cas:title">Neuropharmacology</span>
        (<span class="NLM_cas:date">2012</span>),
    <span class="NLM_cas:volume">62</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">997-1003</span>CODEN:
                <span class="NLM_cas:coden">NEPHBW</span>;
        ISSN:<span class="NLM_cas:issn">0028-3908</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is the most common cause of dementia, clin. characterized by loss of memory and progressive deficits in different cognitive domains.  An emerging disease-modifying approach to face the multifactorial nature of AD may be represented by the development of Multi-Target Directed Ligands (MTDLs), i.e., single compds. which may simultaneously modulate different targets involved in the neurodegenerative AD cascade.  The structure of tacrine, an acetylcholinesterase (AChE) inhibitor (AChEI), has been widely used as scaffold to provide new MTDLs.  In particular, its homodimer bis(7)tacrine represents an interesting lead compd. to design novel MTDLs.  Thus, in the search of new rationally designed MTDLs against AD, we replaced the heptamethylene linker of bis(7)tacrine with the structure of cystamine, leading to cystamine-tacrine dimer.  In this study we demonstrated that the cystamine-tacrine dimer is endowed with a lower toxicity in comparison to bis(7)tacrine, it is able to inhibit AChE, butyrylcholinesterase (BChE), self- and AChE-induced beta-amyloid aggregation in the same range of the ref. compd. and exerts a neuroprotective action on SH-SY5Y cell line against H2O2-induced oxidative injury.  The investigation of the mechanism of neuroprotection showed that the cystamine-tacrine dimer acts by activating kinase 1 and 2 (ERK1/2) and Akt/protein kinase B (PKB) pathways.  This article is part of a Special Issue entitled Post-Traumatic Stress Disorder'.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoMDhDTA4-1CrVg90H21EOLACvtfcHk0ljqnbmnMPtfNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38XhtFCrsb0%253D&md5=7e5f7b53dc8268218a4edc78e7dc48d8</span></div><a href="/servlet/linkout?suffix=cit62&amp;dbid=16384&amp;doi=10.1016%2Fj.neuropharm.2011.10.007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.neuropharm.2011.10.007%26sid%3Dliteratum%253Aachs%26aulast%3DMinarini%26aufirst%3DA.%26aulast%3DMilelli%26aufirst%3DA.%26aulast%3DTumiatti%26aufirst%3DV.%26aulast%3DRosini%26aufirst%3DM.%26aulast%3DSimoni%26aufirst%3DE.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DMotori%26aufirst%3DE.%26aulast%3DAngeloni%26aufirst%3DC.%26aulast%3DHrelia%26aufirst%3DS.%26atitle%3DCystamine-tacrine%2520dimer%253A%2520a%2520new%2520multi-target-directed%2520ligand%2520as%2520potential%2520therapeutic%2520agent%2520for%2520Alzheimer%25E2%2580%2599s%2520disease%2520treatment%26jtitle%3DNeuropharmacology%26date%3D2012%26volume%3D62%26spage%3D997%26epage%3D1003%26doi%3D10.1016%2Fj.neuropharm.2011.10.007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref63"><div class="reference"><strong class="refLabel"><a href="#ref63" class="rightTabRefNumLink">63</a></strong><div class="NLM_citation" id="rightTab-cit63"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Hu, M.-K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wu, L.-J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsiao, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yen, M.-H.</span></span> <span> </span><span class="NLM_article-title">Homodimeric tacrine congeners as acetylcholinesterase inhibitors</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>45</i></span>,  <span class="NLM_fpage">2277</span>– <span class="NLM_lpage">2282</span>, <span class="refDoi"> DOI: 10.1021/jm010308g</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm010308g" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref63/cit63&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XjtFagsL4%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=45&publication_year=2002&pages=2277-2282&author=M.-K.+Huauthor=L.-J.+Wuauthor=G.+Hsiaoauthor=M.-H.+Yen&title=Homodimeric+tacrine+congeners+as+acetylcholinesterase+inhibitors&doi=10.1021%2Fjm010308g"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit63R"><div class="casContent"><span class="casTitleNuber">63</span><div class="casTitle"><span class="NLM_cas:atitle">Homodimeric Tacrine Congeners as Acetylcholinesterase Inhibitors</span></div><div class="casAuthors">Wu, Li-Ju; Hsiao, George; Yen, Mao-Hsiung; Hu, Ming-Kuan</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">45</span>
        (<span class="NLM_cas:issue">11</span>),
    <span class="NLM_cas:pages">2277-2282</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">In the search for highly selective and potent derivs. of tacrine, a no. of homodimeric tacrine congeners were synthesized and conducted for their effects on rat acetylcholinesterase (AChE) and human butyrylcholinesterase (BChE) inhibitions.  Heptylene-linked bis-(6-chloro)tacrine I [R = Cl, X = (CH2)m, Y = CH, Z = (CH2)n, m = 2, n = 7] was found up to 3000- and 3-fold more potent in inhibiting rat AChE than tacrine and the unsubstituted bis-tacrine I [R = H, X = (CH2)m, Y = CH, Z = (CH2)n, m = 2, n = 7] (II), resp.  Changes in the size of the carbocyclic ring of the dimeric tacrine reduced both the selectivity and the potency of AChE inhibition as compared to II.  Inserting an aza into the tacrine nucleus as the desired isosteres I [R = H, X = (CH2)m, Y = N, Z = (CH2)n, m = 2, n = 6-8] resulted in moderate potency but tended to be detrimental to selectivity.  The pronounced enhancement of AChE inhibition potency and AChE/BChE selectivity was achieved with incorporation of a halogen at the 6-position of homodimeric tacrines.  The assay results of I (R = H, F, Cl, Y = CH, N, m = 1-3, n = 6-8) also provided evidence that the 7-methylene tether tended to be optimal to AChE inhibition potency.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr7H3dDhmCpn7Vg90H21EOLACvtfcHk0ljqnbmnMPtfNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XjtFagsL4%253D&md5=ed4e5a530df14b1402d6cc129c2c47c0</span></div><a href="/servlet/linkout?suffix=cit63&amp;dbid=16384&amp;doi=10.1021%2Fjm010308g&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm010308g%26sid%3Dliteratum%253Aachs%26aulast%3DHu%26aufirst%3DM.-K.%26aulast%3DWu%26aufirst%3DL.-J.%26aulast%3DHsiao%26aufirst%3DG.%26aulast%3DYen%26aufirst%3DM.-H.%26atitle%3DHomodimeric%2520tacrine%2520congeners%2520as%2520acetylcholinesterase%2520inhibitors%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2002%26volume%3D45%26spage%3D2277%26epage%3D2282%26doi%3D10.1021%2Fjm010308g" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref64"><div class="reference"><strong class="refLabel"><a href="#ref64" class="rightTabRefNumLink">64</a></strong><div class="NLM_citation" id="rightTab-cit64"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ellman, G. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Courtney, K. D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andres, V.,  Jr.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Featherstone, R. M.</span></span> <span> </span><span class="NLM_article-title">A new and rapid colorimetric determination of acetylcholinesterase activity</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1961</span>,  <span class="NLM_volume"><i>7</i></span>,  <span class="NLM_fpage">88</span>– <span class="NLM_lpage">95</span>, <span class="refDoi"> DOI: 10.1016/0006-2952(61)90145-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-2952%2861%2990145-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=13726518" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref64/cit64&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaF3MXht1Gns7o%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=7&publication_year=1961&pages=88-95&author=G.+L.+Ellmanauthor=K.+D.+Courtneyauthor=V.+Andresauthor=R.+M.+Featherstone&title=A+new+and+rapid+colorimetric+determination+of+acetylcholinesterase+activity&doi=10.1016%2F0006-2952%2861%2990145-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit64R"><div class="casContent"><span class="casTitleNuber">64</span><div class="casTitle"><span class="NLM_cas:atitle">A new and rapid colorimetric determination of acetylcholinesterase activity</span></div><div class="casAuthors">Ellman, George L.; Courtney, K. Diane; Andres, Valentino, Jr.; Featherstone, Robert M.</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">1961</span>),
    <span class="NLM_cas:volume">7</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">88-95</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    </div><div class="casAbstract">A photometric method for detg. acetylcholinesterase activity of tissue exts., homogenates, cell suspensions, etc. was described.  The enzyme activity of acetylcholinesterase was measured by following the increase of yellow color produced from thiocholine when it reacts with dithiobisnitrobenzoate ion, based on the reactions: acetylthiocholine (enzyme.rdblhar.) thioeholine + acetate.  Thiocholine + dithiobisnitrobenzoate .rdblhar. yellow color.  The method was used to study the enzyme in human erythrocytes and homogenates of rat brain, kidney, lungs, liver, and muscle tissue.  Hydrolysis rates [(moles/l./min.) × 10-6/g. tissue] by these homogenates of tissues on acetylthiocholine were 10.31, 0.28, 1.63, 1.07, and 1.82, and on butyrylthiocholine were 0.31, 0.21, 0.54, 0.65, and 0.12, resp.  Data obtained with acetylthiocholine as substrate were similar to those with acetylcholine.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpq21LY6gwNKrVg90H21EOLACvtfcHk0ljqnbmnMPtfNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaF3MXht1Gns7o%253D&md5=46f891b7e338036a7c7d4333b82b6874</span></div><a href="/servlet/linkout?suffix=cit64&amp;dbid=16384&amp;doi=10.1016%2F0006-2952%2861%2990145-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-2952%252861%252990145-9%26sid%3Dliteratum%253Aachs%26aulast%3DEllman%26aufirst%3DG.%2BL.%26aulast%3DCourtney%26aufirst%3DK.%2BD.%26aulast%3DAndres%26aufirst%3DV.%26aulast%3DFeatherstone%26aufirst%3DR.%2BM.%26atitle%3DA%2520new%2520and%2520rapid%2520colorimetric%2520determination%2520of%2520acetylcholinesterase%2520activity%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D1961%26volume%3D7%26spage%3D88%26epage%3D95%26doi%3D10.1016%2F0006-2952%2861%2990145-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref65"><div class="reference"><strong class="refLabel"><a href="#ref65" class="rightTabRefNumLink">65</a></strong><div class="NLM_citation" id="rightTab-cit65"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavrini, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span> <span> </span><span class="NLM_article-title">β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies</span>. <i>Biochem. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">407</span>– <span class="NLM_lpage">416</span>, <span class="refDoi"> DOI: 10.1016/S0006-2952(02)01514-9</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0006-2952%2802%2901514-9" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12527333" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref65/cit65&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXivVKitA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=2003&pages=407-416&author=M.+Bartoliniauthor=C.+Bertucciauthor=V.+Cavriniauthor=V.+Andrisano&title=%CE%B2-Amyloid+aggregation+induced+by+human+acetylcholinesterase%3A+inhibition+studies&doi=10.1016%2FS0006-2952%2802%2901514-9"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit65R"><div class="casContent"><span class="casTitleNuber">65</span><div class="casTitle"><span class="NLM_cas:atitle">β-Amyloid aggregation induced by human acetylcholinesterase: inhibition studies</span></div><div class="casAuthors">Bartolini, Manuela; Bertucci, Carlo; Cavrini, Vanni; Andrisano, Vincenza</div><div class="citationInfo"><span class="NLM_cas:title">Biochemical Pharmacology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">407-416</span>CODEN:
                <span class="NLM_cas:coden">BCPCA6</span>;
        ISSN:<span class="NLM_cas:issn">0006-2952</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Science Inc.</span>)
        </div><div class="casAbstract">The aggregation of β-amyloid (1-40) (Aβ) induced by human recombinant acetylcholinesterase (HuAChE) was studied by means of CD (CD) and by thioflavin T fluorescence spectroscopy.  Aβ was incubated alone and with HuAChE.  The kinetic of fibrils formation was followed for 48 h.  The increasing β-conformation content induced by HuAChE, preliminary to the formation of Aβ fibrils, was detd. by CD.  This phenomenon was found to be related to the thioflavin T emission of fluorescence at 490 nm.  Incubation expts. were performed in the presence of known AChE inhibitors (physostigmine, edrophonium, decamethonium, propidium) and drugs used for Alzheimer's disease (AD) (tacrine, donepezil), to test their capability of preventing the HuAChE-induced Aβ aggregation.  The non-competitive or mixed mode of AChE inhibition was confirmed to be an essential feature.  At 100 μM propidium, decamethonium, donepezil and physostigmine were found to inhibit the HuAChE-induced Aβ aggregation by 82, 25, 22 and 30%, resp.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq2eDGIBesVCbVg90H21EOLACvtfcHk0lhwBgyq2Hq2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXivVKitA%253D%253D&md5=51d1021e8be93014f0b15a61db241392</span></div><a href="/servlet/linkout?suffix=cit65&amp;dbid=16384&amp;doi=10.1016%2FS0006-2952%2802%2901514-9&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0006-2952%252802%252901514-9%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DCavrini%26aufirst%3DV.%26aulast%3DAndrisano%26aufirst%3DV.%26atitle%3D%25CE%25B2-Amyloid%2520aggregation%2520induced%2520by%2520human%2520acetylcholinesterase%253A%2520inhibition%2520studies%26jtitle%3DBiochem.%2520Pharmacol.%26date%3D2003%26volume%3D65%26spage%3D407%26epage%3D416%26doi%3D10.1016%2FS0006-2952%2802%2901514-9" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref66"><div class="reference"><strong class="refLabel"><a href="#ref66" class="rightTabRefNumLink">66</a></strong><div class="NLM_citation" id="rightTab-cit66"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Castro, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martinez, A.</span></span> <span> </span><span class="NLM_article-title">Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors</span>. <i>Curr. Pharm. Des.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">4377</span>– <span class="NLM_lpage">4387</span>, <span class="refDoi"> DOI: 10.2174/138161206778792985</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F138161206778792985" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17105433" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref66/cit66&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht1GntrbI" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=2006&pages=4377-4387&author=A.+Castroauthor=A.+Martinez&title=Targeting+beta-amyloid+pathogenesis+through+acetylcholinesterase+inhibitors&doi=10.2174%2F138161206778792985"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit66R"><div class="casContent"><span class="casTitleNuber">66</span><div class="casTitle"><span class="NLM_cas:atitle">Targeting beta-amyloid pathogenesis through acetylcholinesterase inhibitors</span></div><div class="casAuthors">Castro, Ana; Martinez, Ana</div><div class="citationInfo"><span class="NLM_cas:title">Current Pharmaceutical Design</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">33</span>),
    <span class="NLM_cas:pages">4377-4387</span>CODEN:
                <span class="NLM_cas:coden">CPDEFP</span>;
        ISSN:<span class="NLM_cas:issn">1381-6128</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review.  Although the hallmarks of neurodegeneration in Alzheimer's brains are well known, one of the current difficulties is related to the lack of solid evidence about the ultimate factors that give rise to the pathogenesis of this disease, creating a great challenge for the definition of efficient treatments for Alzheimer's disease (AD).  Current therapeutic option for AD patients is the use of acetylcholinesterase (AChE) inhibitors, which gives only a symptomatic relief.  However, recent studies show a long-lasting effect in a certain percentage of patients.  In fact, there is accumulating evidence that an AChE has secondary non-cholinergic functions including the processing and deposition of β-amyloid (Aβ).  AChE could play a role in the Aβ metab. and during an early step in the development of the senile plaque, as revealed by the finding that AChE accelerates Aβ deposition.  Considering the non-classical AChE functions, their relationships with AD hallmarks, and the putative role of peripheral anionic site in all these functions, the dual binding site AChE inhibitors may acquire importance for AD treatment.  On the other hand, the interference of AChE inhibitors with Aβ processing is not a general rule for this class of compds. with the involvement of other features such as chem. structure and/or genetic regulation.  This review highlights the collection of several compds. with an outstanding profile against AChE-induced amyloid aggregation and potent AChE inhibitory activity, indicating the possibility of targeting Aβ through the inhibition of AChE and reveals the emergence of a new generation of AChE inhibitors aiming to be excellent candidate drugs for the future cure of Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrisn7G_dIHxrVg90H21EOLACvtfcHk0lhwBgyq2Hq2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht1GntrbI&md5=fd41eca56c6433d9ee6a3989908ff2c5</span></div><a href="/servlet/linkout?suffix=cit66&amp;dbid=16384&amp;doi=10.2174%2F138161206778792985&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F138161206778792985%26sid%3Dliteratum%253Aachs%26aulast%3DCastro%26aufirst%3DA.%26aulast%3DMartinez%26aufirst%3DA.%26atitle%3DTargeting%2520beta-amyloid%2520pathogenesis%2520through%2520acetylcholinesterase%2520inhibitors%26jtitle%3DCurr.%2520Pharm.%2520Des.%26date%3D2006%26volume%3D12%26spage%3D4377%26epage%3D4387%26doi%3D10.2174%2F138161206778792985" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref67"><div class="reference"><strong class="refLabel"><a href="#ref67" class="rightTabRefNumLink">67</a></strong><div class="NLM_citation" id="rightTab-cit67"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zha, X.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lamba, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lou, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kang, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chen, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Xu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">De Simone, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Samez, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Persaresi, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stojan, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lopez, M. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Egea, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span> <span> </span><span class="NLM_article-title">Novel tacrine–benzofuran hybrids as potent multitarget-directed ligands for the treatment of Alzheimer’s disease: design, synthesis, biological evaluation, and X-ray crystallography</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">114</span>– <span class="NLM_lpage">131</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.5b01119</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.5b01119" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref67/cit67&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr%252FJ" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=114-131&author=X.+Zhaauthor=D.+Lambaauthor=L.+Zhangauthor=Y.+Louauthor=C.+Xuauthor=D.+Kangauthor=L.+Chenauthor=Y.+Xuauthor=L.+Zhangauthor=A.+De+Simoneauthor=S.+Samezauthor=A.+Persaresiauthor=J.+Stojanauthor=M.+G.+Lopezauthor=J.+Egeaauthor=V.+Andrisanoauthor=M.+Bartolini&title=Novel+tacrine%E2%80%93benzofuran+hybrids+as+potent+multitarget-directed+ligands+for+the+treatment+of+Alzheimer%E2%80%99s+disease%3A+design%2C+synthesis%2C+biological+evaluation%2C+and+X-ray+crystallography&doi=10.1021%2Facs.jmedchem.5b01119"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit67R"><div class="casContent"><span class="casTitleNuber">67</span><div class="casTitle"><span class="NLM_cas:atitle">Novel Tacrine-Benzofuran Hybrids as Potent Multitarget-Directed Ligands for the Treatment of Alzheimer's Disease: Design, Synthesis, Biological Evaluation, and X-ray Crystallography</span></div><div class="casAuthors">Zha, Xiaoming; Lamba, Doriano; Zhang, Lili; Lou, Yinghan; Xu, Changxu; Kang, Di; Chen, Li; Xu, Yungen; Zhang, Luyong; De Simone, Angela; Samez, Sarah; Pesaresi, Alessandro; Stojan, Jure; Lopez, Manuela G.; Egea, Javier; Andrisano, Vincenza; Bartolini, Manuela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">114-131</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Twenty-six new tacrine-benzofuran hybrids, I [R = H, OMe, X = (CH2)m, Y= (CH2)n, m = 1-3, n = 6, 7], II [R = H, OMe, X = CH2, Y = (CH2)6; R = OMe, X = (CH2)2, Y = (CH2)6; R = H, X = (CH2)m, m = 1, 2, Y = (CH2)7; R = H, X = (CH2)2, Y = (CH2)7; R = OMe, X = (CH2)3, Y = (CH2)7] and III [R = H, OMe, X = CH2, Y = (CH2)6; R = OMe, X = (CH2)m, m = 2, 3, Y = (CH2)6; R = H, X = (CH2)m, m = 1-3, Y = (CH2)7; R = OMe, X = (CH2)3, Y = (CH2)7] were designed, synthesized, and evaluated in vitro on key mol. targets for Alzheimer's disease.  Most hybrids exhibited good inhibitory activities on cholinesterases and β-amyloid self-aggregation.  Selected compds. displayed significant inhibition of human β-secretase-1 (hBACE-1).  Among the 26 hybrids, II [R = H, X = (CH2)2, Y = (CH2)7] (IV) showed the most interesting profile as a subnanomolar selective inhibitor of human acetylcholinesterase (hAChE) (IC50 = 0.86 nM) and a good inhibitor of both β-amyloid aggregation (hAChE- and self-induced, 61.3% and 58.4%, resp.) and hBACE-1 activity (IC50 = 1.35 μM).  Kinetic studies showed that IV acted as a slow, tight-binding, mixed-type inhibitor, while X-ray crystallog. studies highlighted the ability of IV to induce large-scale structural changes in the active-site gorge of Torpedo californica AChE (TcAChE), with significant implications for structure-based drug design.  In vivo studies confirmed that IV significantly ameliorates performances of scopolamine-treated ICR mice.  Finally, IV administration did not exhibit significant hepatotoxicity.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGowdWlshOsJO7Vg90H21EOLACvtfcHk0lhwBgyq2Hq2PA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXhvFGnsr%252FJ&md5=809e7be0412644a990920590f8a31125</span></div><a href="/servlet/linkout?suffix=cit67&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.5b01119&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.5b01119%26sid%3Dliteratum%253Aachs%26aulast%3DZha%26aufirst%3DX.%26aulast%3DLamba%26aufirst%3DD.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DLou%26aufirst%3DY.%26aulast%3DXu%26aufirst%3DC.%26aulast%3DKang%26aufirst%3DD.%26aulast%3DChen%26aufirst%3DL.%26aulast%3DXu%26aufirst%3DY.%26aulast%3DZhang%26aufirst%3DL.%26aulast%3DDe%2BSimone%26aufirst%3DA.%26aulast%3DSamez%26aufirst%3DS.%26aulast%3DPersaresi%26aufirst%3DA.%26aulast%3DStojan%26aufirst%3DJ.%26aulast%3DLopez%26aufirst%3DM.%2BG.%26aulast%3DEgea%26aufirst%3DJ.%26aulast%3DAndrisano%26aufirst%3DV.%26aulast%3DBartolini%26aufirst%3DM.%26atitle%3DNovel%2520tacrine%25E2%2580%2593benzofuran%2520hybrids%2520as%2520potent%2520multitarget-directed%2520ligands%2520for%2520the%2520treatment%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%253A%2520design%252C%2520synthesis%252C%2520biological%2520evaluation%252C%2520and%2520X-ray%2520crystallography%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D114%26epage%3D131%26doi%3D10.1021%2Facs.jmedchem.5b01119" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref68"><div class="reference"><strong class="refLabel"><a href="#ref68" class="rightTabRefNumLink">68</a></strong><div class="NLM_citation" id="rightTab-cit68"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Bartolini, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bertucci, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bolognesi, M. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cavalli, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Melchiorre, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Andrisano, V.</span></span> <span> </span><span class="NLM_article-title">Insight into the kinetic of amyloid β (1–42) peptide self-aggregation: elucidation of inhibitors’ mechanism of action</span>. <i>ChemBioChem</i> <span class="NLM_year" style="font-weight: bold;">2007</span>,  <span class="NLM_volume"><i>8</i></span>,  <span class="NLM_fpage">2152</span>– <span class="NLM_lpage">2161</span>, <span class="refDoi"> DOI: 10.1002/cbic.200700427</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcbic.200700427" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17939148" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref68/cit68&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2sXhsValu73F" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=8&publication_year=2007&pages=2152-2161&author=M.+Bartoliniauthor=C.+Bertucciauthor=M.+L.+Bolognesiauthor=A.+Cavalliauthor=C.+Melchiorreauthor=V.+Andrisano&title=Insight+into+the+kinetic+of+amyloid+%CE%B2+%281%E2%80%9342%29+peptide+self-aggregation%3A+elucidation+of+inhibitors%E2%80%99+mechanism+of+action&doi=10.1002%2Fcbic.200700427"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit68R"><div class="casContent"><span class="casTitleNuber">68</span><div class="casTitle"><span class="NLM_cas:atitle">Insight into the kinetic of amyloid β (1-42) peptide self-aggregation: elucidation of inhibitors' mechanism of action</span></div><div class="casAuthors">Bartolini, Manuela; Bertucci, Carlo; Bolognesi, Maria Laura; Cavalli, Andrea; Melchiorre, Carlo; Andrisano, Vincenza</div><div class="citationInfo"><span class="NLM_cas:title">ChemBioChem</span>
        (<span class="NLM_cas:date">2007</span>),
    <span class="NLM_cas:volume">8</span>
        (<span class="NLM_cas:issue">17</span>),
    <span class="NLM_cas:pages">2152-2161</span>CODEN:
                <span class="NLM_cas:coden">CBCHFX</span>;
        ISSN:<span class="NLM_cas:issn">1439-4227</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">The initial transition of amyloid β (1-42) (Aβ42) sol. monomers/small oligomers from unordered/α-helix to a β-sheet-rich conformation represents a suitable target to design new potent inhibitors and to obtain effective therapeutics for Alzheimer's disease.  Under optimized conditions, this reliable and reproducible CD kinetic study showed a 3-step sigmoid profile that was characterized by a lag phase (prevailing unordered/α-helix conformation), an exponential growth phase (increasing β-sheet secondary structure) and a plateau phase (prevailing β-sheet secondary structure).  This kinetic anal. brought insight into the inhibitors' mechanism of action.  In fact, an increase in the duration of the lag phase can be related to the formation of an inhibitor-Aβ complex, in which the non-amyloidogenic conformation is stabilized.  When the exponential rate is affected exclusively, such as in the case of Congo red and tetracycline, then the inhibitor affinity might be higher for the pleated β-sheet structure.  Finally, by adding the inhibitor at the end of the exponential phase, the sol. protofibrils can be disrupted and the Aβ amyloidogenic structure can revert into monomers/small oligomers.  Congo red and tetracycline preferentially bind to amyloid in the β-sheet conformation because both decreased the slope of the exponential growth, even if to a different extent, whereas no effect was obsd. for tacrine and galantamine.  Some very preliminary indications can be derived about the structural requirements for binding to nonamyloidogenic or β-sheet amyloid secondary structure for the development of potent antiaggregating agents.  On these premises, memoquin, a multifunctional mol. that was designed to become a drug candidate for the treatment of Alzheimer's disease, was investigated under the reported CD assay and its anti-amyloidogenic mechanism of action was elucidated.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoO9pwqFx_yuLVg90H21EOLACvtfcHk0li6ZZX867fR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2sXhsValu73F&md5=f7e4f04aeba478f5c7da03dcce6d1553</span></div><a href="/servlet/linkout?suffix=cit68&amp;dbid=16384&amp;doi=10.1002%2Fcbic.200700427&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcbic.200700427%26sid%3Dliteratum%253Aachs%26aulast%3DBartolini%26aufirst%3DM.%26aulast%3DBertucci%26aufirst%3DC.%26aulast%3DBolognesi%26aufirst%3DM.%2BL.%26aulast%3DCavalli%26aufirst%3DA.%26aulast%3DMelchiorre%26aufirst%3DC.%26aulast%3DAndrisano%26aufirst%3DV.%26atitle%3DInsight%2520into%2520the%2520kinetic%2520of%2520amyloid%2520%25CE%25B2%2520%25281%25E2%2580%259342%2529%2520peptide%2520self-aggregation%253A%2520elucidation%2520of%2520inhibitors%25E2%2580%2599%2520mechanism%2520of%2520action%26jtitle%3DChemBioChem%26date%3D2007%26volume%3D8%26spage%3D2152%26epage%3D2161%26doi%3D10.1002%2Fcbic.200700427" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref69"><div class="reference"><strong class="refLabel"><a href="#ref69" class="rightTabRefNumLink">69</a></strong><div class="NLM_citation" id="rightTab-cit69"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lange, J. H. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">van Stuivenberg, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coolen, H. K. A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adolfs, T. J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">McCreary, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keizer, H. G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wals, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Veerman, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Borst, A. J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">de Looff, W.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Verveer, P. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kruse, C. G.</span></span> <span> </span><span class="NLM_article-title">Bioisosteric replacements of the pyrazole moiety of rimonabant: synthesis, biological properties, and molecular modeling investigations of thiazoles, triazoles, and imidazoles as potent and selective CB1 cannabinoid receptor antagonists</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2005</span>,  <span class="NLM_volume"><i>48</i></span>,  <span class="NLM_fpage">1823</span>– <span class="NLM_lpage">1838</span>, <span class="refDoi"> DOI: 10.1021/jm040843r</span> </span><div class="citationLinks">[<a href="/doi/10.1021/jm040843r" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref69/cit69&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=48&publication_year=2005&pages=1823-1838&author=J.+H.+M.+Langeauthor=H.+H.+van+Stuivenbergauthor=H.+K.+A.+C.+Coolenauthor=T.+J.+P.+Adolfsauthor=A.+C.+McCrearyauthor=H.+G.+Keizerauthor=H.+C.+Walsauthor=W.+Veermanauthor=A.+J.+M.+Borstauthor=W.+de+Looffauthor=P.+C.+Verveerauthor=C.+G.+Kruse&title=Bioisosteric+replacements+of+the+pyrazole+moiety+of+rimonabant%3A+synthesis%2C+biological+properties%2C+and+molecular+modeling+investigations+of+thiazoles%2C+triazoles%2C+and+imidazoles+as+potent+and+selective+CB1+cannabinoid+receptor+antagonists&doi=10.1021%2Fjm040843r"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit69R"><div class="casContent"><span class="casTitleNuber">69</span><div class="casTitle"><span class="NLM_cas:atitle">Bioisosteric Replacements of the Pyrazole Moiety of Rimonabant: Synthesis, Biological Properties, and Molecular Modeling Investigations of Thiazoles, Triazoles, and Imidazoles as Potent and Selective CB1 Cannabinoid Receptor Antagonists</span></div><div class="casAuthors">Lange, Jos H. M.; van Stuivenberg, Herman H.; Coolen, Hein K. A. C.; Adolfs, Tiny J. P.; McCreary, Andrew C.; Keizer, Hiskias G.; Wals, Henri C.; Veerman, Willem; Borst, Alice J. M.; de Looff, Wouter; Verveer, Peter C.; Kruse, Chris G.</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2005</span>),
    <span class="NLM_cas:volume">48</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1823-1838</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Series of thiazoles, triazoles, and imidazoles were designed as bioisosteres, based on the 1,5-diarylpyrazole motif that is present in the potent CB1 receptor antagonist rimonabant.  A no. of target compds. were synthesized and evaluated in cannabinoid (hCB1 and hCB2) receptor assays.  The thiazoles, triazoles, and imidazoles elicited in vitro CB1 antagonistic activities and in general exhibited considerable CB1 vs CB2 receptor subtype selectivities, thereby demonstrating to be cannabinoid bioisosteres of the original diarylpyrazole class.  Some key representatives in the imidazole series showed potent pharmacol. in vivo activities after oral administration in both a CB agonist-induced hypotension model and a CB agonist-induced hypothermia model.  Mol. modeling studies showed a close three-dimensional structural overlap between the imidazole I and rimonabant.  A structure-activity relationship (SAR) study revealed a close correlation between the biol. results in the imidazole and pyrazole series.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp16SsR1EEEVbVg90H21EOLACvtfcHk0li6ZZX867fR1Q"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXnvFSrsLg%253D&md5=c3b80380a273d7f69a33c812a45e0154</span></div><a href="/servlet/linkout?suffix=cit69&amp;dbid=16384&amp;doi=10.1021%2Fjm040843r&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Fjm040843r%26sid%3Dliteratum%253Aachs%26aulast%3DLange%26aufirst%3DJ.%2BH.%2BM.%26aulast%3Dvan%2BStuivenberg%26aufirst%3DH.%2BH.%26aulast%3DCoolen%26aufirst%3DH.%2BK.%2BA.%2BC.%26aulast%3DAdolfs%26aufirst%3DT.%2BJ.%2BP.%26aulast%3DMcCreary%26aufirst%3DA.%2BC.%26aulast%3DKeizer%26aufirst%3DH.%2BG.%26aulast%3DWals%26aufirst%3DH.%2BC.%26aulast%3DVeerman%26aufirst%3DW.%26aulast%3DBorst%26aufirst%3DA.%2BJ.%2BM.%26aulast%3Dde%2BLooff%26aufirst%3DW.%26aulast%3DVerveer%26aufirst%3DP.%2BC.%26aulast%3DKruse%26aufirst%3DC.%2BG.%26atitle%3DBioisosteric%2520replacements%2520of%2520the%2520pyrazole%2520moiety%2520of%2520rimonabant%253A%2520synthesis%252C%2520biological%2520properties%252C%2520and%2520molecular%2520modeling%2520investigations%2520of%2520thiazoles%252C%2520triazoles%252C%2520and%2520imidazoles%2520as%2520potent%2520and%2520selective%2520CB1%2520cannabinoid%2520receptor%2520antagonists%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2005%26volume%3D48%26spage%3D1823%26epage%3D1838%26doi%3D10.1021%2Fjm040843r" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref70"><div class="reference"><strong class="refLabel"><a href="#ref70" class="rightTabRefNumLink">70</a></strong><div class="NLM_citation" id="rightTab-cit70"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsieh, G. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Frost, J. M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Fan, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Garrison, T. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A. V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Grayson, G. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhu, C. Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pai, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chandran, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Salyers, A. K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wensink, E. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Honore, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sullivan, J. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Dart, M. J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M. D.</span></span> <span> </span><span class="NLM_article-title">In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2008</span>,  <span class="NLM_volume"><i>153</i></span>,  <span class="NLM_fpage">390</span>– <span class="NLM_lpage">401</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0707568</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0707568" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17994110" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref70/cit70&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1cXhtlajsbs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=153&publication_year=2008&pages=390-401&author=B.+B.+Yaoauthor=G.+C.+Hsiehauthor=J.+M.+Frostauthor=Y.+Fanauthor=T.+R.+Garrisonauthor=A.+V.+Dazaauthor=G.+K.+Graysonauthor=C.+Z.+Zhuauthor=M.+Paiauthor=P.+Chandranauthor=A.+K.+Salyersauthor=E.+J.+Wensinkauthor=P.+Honoreauthor=J.+P.+Sullivanauthor=M.+J.+Dartauthor=M.+D.+Meyer&title=In+vitro+and+in+vivo+characterization+of+A-796260%3A+a+selective+cannabinoid+CB2+receptor+agonist+exhibiting+analgesic+activity+in+rodent+pain+models&doi=10.1038%2Fsj.bjp.0707568"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit70R"><div class="casContent"><span class="casTitleNuber">70</span><div class="casTitle"><span class="NLM_cas:atitle">In vitro and in vivo characterization of A-796260: a selective cannabinoid CB2 receptor agonist exhibiting analgesic activity in rodent pain models</span></div><div class="casAuthors">Yao, B. B.; Hsieh, G. C.; Frost, J. M.; Fan, Y.; Garrison, T. R.; Daza, A. V.; Grayson, G. K.; Zhu, C. Z.; Pai, M.; Chandran, P.; Salyers, A. K.; Wensink, E. J.; Honore, P.; Sullivan, J. P.; Dart, M. J.; Meyer, M. D.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2008</span>),
    <span class="NLM_cas:volume">153</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">390-401</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Selective cannabinoid CB2 receptor agonists have demonstrated analgesic activity across multiple preclin. pain models.  AM1241 is an indole deriv. that exhibits high affinity and selectivity for the CB2 binding site and broad spectrum analgesic activity in rodent models, but is not an antagonist of CB2 in vitro functional assays.  Addnl., its analgesic effects are -opioid receptor-dependent.  Herein, we describe the in vitro and in vivo pharmacol. properties of A-796260, a novel CB2 agonist.  Exptl. approach: A-796260 was characterized in radioligand binding and in vitro functional assays at rat and human CB1 and CB2 receptors.  The behavioral profile of A-796260 was assessed in models of inflammatory, post-operative, neuropathic, and osteoarthritic (OA) pain, as well as its effects on motor activity.  The receptor specificity was confirmed using selective CB1, CB2, and -opioid receptor antagonists.  A-796260 exhibited high affinity and agonist efficacy at human and rat CB2 receptors, and was selective for the CB2 vs CB1 subtype.  Efficacy in models of inflammatory, post-operative, neuropathic and OA pain was demonstrated, and these activities were selectively blocked by CB2, but not CB1, or -opioid receptor-selective antagonists.  Efficacy was achieved at doses that had no significant effects on motor activity.  These results further confirm the therapeutic potential of CB2 receptor-selective agonists for the treatment of pain.  In addn., they demonstrate that A-796260 may be a useful new pharmacol. compd. for further studying CB2 receptor pharmacol. and for evaluating its role in the modulation of pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrRpbBOoGZg27Vg90H21EOLACvtfcHk0lh06yr3W42IDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1cXhtlajsbs%253D&md5=c4d06d34da40f688a17aa15fffe03c64</span></div><a href="/servlet/linkout?suffix=cit70&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0707568&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0707568%26sid%3Dliteratum%253Aachs%26aulast%3DYao%26aufirst%3DB.%2BB.%26aulast%3DHsieh%26aufirst%3DG.%2BC.%26aulast%3DFrost%26aufirst%3DJ.%2BM.%26aulast%3DFan%26aufirst%3DY.%26aulast%3DGarrison%26aufirst%3DT.%2BR.%26aulast%3DDaza%26aufirst%3DA.%2BV.%26aulast%3DGrayson%26aufirst%3DG.%2BK.%26aulast%3DZhu%26aufirst%3DC.%2BZ.%26aulast%3DPai%26aufirst%3DM.%26aulast%3DChandran%26aufirst%3DP.%26aulast%3DSalyers%26aufirst%3DA.%2BK.%26aulast%3DWensink%26aufirst%3DE.%2BJ.%26aulast%3DHonore%26aufirst%3DP.%26aulast%3DSullivan%26aufirst%3DJ.%2BP.%26aulast%3DDart%26aufirst%3DM.%2BJ.%26aulast%3DMeyer%26aufirst%3DM.%2BD.%26atitle%3DIn%2520vitro%2520and%2520in%2520vivo%2520characterization%2520of%2520A-796260%253A%2520a%2520selective%2520cannabinoid%2520CB2%2520receptor%2520agonist%2520exhibiting%2520analgesic%2520activity%2520in%2520rodent%2520pain%2520models%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2008%26volume%3D153%26spage%3D390%26epage%3D401%26doi%3D10.1038%2Fsj.bjp.0707568" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref71"><div class="reference"><strong class="refLabel"><a href="#ref71" class="rightTabRefNumLink">71</a></strong><div class="NLM_citation" id="rightTab-cit71"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Nimczick, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">New approaches in the design and development of cannabinoid receptor ligands: multifunctional and bivalent compounds</span>. <i>ChemMedChem</i> <span class="NLM_year" style="font-weight: bold;">2015</span>,  <span class="NLM_volume"><i>10</i></span>,  <span class="NLM_fpage">773</span>– <span class="NLM_lpage">786</span>, <span class="refDoi"> DOI: 10.1002/cmdc.201500041</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fcmdc.201500041" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=25820617" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref71/cit71&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC2MXlt1alu7s%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=10&publication_year=2015&pages=773-786&author=M.+Nimczickauthor=M.+Decker&title=New+approaches+in+the+design+and+development+of+cannabinoid+receptor+ligands%3A+multifunctional+and+bivalent+compounds&doi=10.1002%2Fcmdc.201500041"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit71R"><div class="casContent"><span class="casTitleNuber">71</span><div class="casTitle"><span class="NLM_cas:atitle">New Approaches in the Design and Development of Cannabinoid Receptor Ligands: Multifunctional and Bivalent Compounds</span></div><div class="casAuthors">Nimczick, Martin; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">ChemMedChem</span>
        (<span class="NLM_cas:date">2015</span>),
    <span class="NLM_cas:volume">10</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">773-786</span>CODEN:
                <span class="NLM_cas:coden">CHEMGX</span>;
        ISSN:<span class="NLM_cas:issn">1860-7179</span>.
    
            (<span class="NLM_cas:orgname">Wiley-VCH Verlag GmbH & Co. KGaA</span>)
        </div><div class="casAbstract">A review.  Since the identification of the endocannabinoid system, two G protein-coupled receptors (GPCRs) of this complex system were identified and characterized: cannabinoid receptors type 1 (CB1R) and type 2 (CB2R).  In addn. to orthosteric and subsequently allosteric ligands, new strategies have been used to target CBRs.  Bivalent ligands and multifunctional ligands acting at diverse biol. targets have been designed, synthesized, and characterized for both CBRs.  Due to their altered receptor binding and pharmacol. profiles, they are interesting tools to explore CBR functions and their interactions with other physiol. systems.  Moreover, this approach may bear therapeutic advantages in the therapy of CBR-related disorders, esp. multifactorial diseases.  Promising prospects include anorectics with fewer side effects, analgesics with decreased tolerance, and therapeutics with multiple pharmacol. activities for the treatment of cancer, inflammation, multiple sclerosis, Huntington's and Alzheimer's diseases.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqO0S1iWc8qP7Vg90H21EOLACvtfcHk0lh06yr3W42IDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC2MXlt1alu7s%253D&md5=48866ef33207c0dcb703225d1e2e577e</span></div><a href="/servlet/linkout?suffix=cit71&amp;dbid=16384&amp;doi=10.1002%2Fcmdc.201500041&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fcmdc.201500041%26sid%3Dliteratum%253Aachs%26aulast%3DNimczick%26aufirst%3DM.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DNew%2520approaches%2520in%2520the%2520design%2520and%2520development%2520of%2520cannabinoid%2520receptor%2520ligands%253A%2520multifunctional%2520and%2520bivalent%2520compounds%26jtitle%3DChemMedChem%26date%3D2015%26volume%3D10%26spage%3D773%26epage%3D786%26doi%3D10.1002%2Fcmdc.201500041" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref72"><div class="reference"><strong class="refLabel"><a href="#ref72" class="rightTabRefNumLink">72</a></strong><div class="NLM_citation" id="rightTab-cit72"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Howlett, A. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Barth, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonner, T. I.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cabral, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Casellas, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Devane, W. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Felder, C. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Herkenham, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mackie, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Martin, B. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mechoulam, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span>. <i>Pharmacol. Rev.</i> <span class="NLM_year" style="font-weight: bold;">2002</span>,  <span class="NLM_volume"><i>54</i></span>,  <span class="NLM_fpage">161</span>– <span class="NLM_lpage">202</span>, <span class="refDoi"> DOI: 10.1124/pr.54.2.161</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1124%2Fpr.54.2.161" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12037135" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref72/cit72&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=54&publication_year=2002&pages=161-202&author=A.+C.+Howlettauthor=F.+Barthauthor=T.+I.+Bonnerauthor=G.+Cabralauthor=P.+Casellasauthor=W.+A.+Devaneauthor=C.+C.+Felderauthor=M.+Herkenhamauthor=K.+Mackieauthor=B.+R.+Martinauthor=R.+Mechoulamauthor=R.+G.+Pertwee&title=International+Union+of+Pharmacology.+XXVII.+Classification+of+cannabinoid+receptors&doi=10.1124%2Fpr.54.2.161"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit72R"><div class="casContent"><span class="casTitleNuber">72</span><div class="casTitle"><span class="NLM_cas:atitle">International Union of Pharmacology. XXVII. Classification of cannabinoid receptors</span></div><div class="casAuthors">Howlett, A. C.; Barth, F.; Bonner, T. I.; Cabral, G.; Casellas, P.; Devane, W. A.; Felder, C. C.; Herkenham, M.; Mackie, K.; Martin, B. R.; Mechoulam, R.; Pertwee, R. G.</div><div class="citationInfo"><span class="NLM_cas:title">Pharmacological Reviews</span>
        (<span class="NLM_cas:date">2002</span>),
    <span class="NLM_cas:volume">54</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">161-202</span>CODEN:
                <span class="NLM_cas:coden">PAREAQ</span>;
        ISSN:<span class="NLM_cas:issn">0031-6997</span>.
    
            (<span class="NLM_cas:orgname">American Society for Pharmacology and Experimental Therapeutics</span>)
        </div><div class="casAbstract">A review.  Two types of cannabinoid receptor have been discovered so far, CB1 (2.1: CBD:1:CB1:), cloned in 1990, and CB2 (2.1:CBD:2:CB2:), cloned in 1993.  Distinction between these receptors is based on differences in their predicted amino acid sequence, signaling mechanisms, tissue distribution, and sensitivity to certain potent agonists and antagonists that show marked selectivity for one or the other receptor type.  Cannabinoid receptors CB1 and CB2 exhibit 48% amino acid sequence identity.  Both receptor types are coupled through G proteins to adenylyl cyclase and mitogen-activated protein kinase.  CB1 receptors are also coupled through G proteins to several types of calcium and potassium channels.  These receptors exist primarily on central and peripheral neurons, one of their functions being to inhibit neurotransmitter release.  Indeed, endogenous CB1 agonists probably serve as retrograde synaptic messengers.  CB2 receptors are present mainly on immune cells.  Such cells also express CB1 receptors, albeit to a lesser extent, with both receptor types exerting a broad spectrum of immune effects that includes modulation of cytokine release.  Of several endogenous agonists for cannabinoid receptors identified thus far, the most notable are arachidonoylethanolamide, 2-arachidonoylglycerol, and 2-arachidonylglyceryl ether.  It is unclear whether these eicosanoid mols. are the only, or primary, endogenous agonists.  Hence, the authors consider it premature to rename cannabinoid receptors after an endogenous agonist as is recommended by the International Union of Pharmacol. Committee on Receptor Nomenclature and Drug Classification.  Although pharmacol. evidence for the existence of addnl. types of cannabinoid receptor is emerging, other kinds of supporting evidence are still lacking.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpeoe-6izzgsrVg90H21EOLACvtfcHk0lh06yr3W42IDg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD38XltVOiuro%253D&md5=4a8345d34b5724ee3cd999b71956ab54</span></div><a href="/servlet/linkout?suffix=cit72&amp;dbid=16384&amp;doi=10.1124%2Fpr.54.2.161&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1124%252Fpr.54.2.161%26sid%3Dliteratum%253Aachs%26aulast%3DHowlett%26aufirst%3DA.%2BC.%26aulast%3DBarth%26aufirst%3DF.%26aulast%3DBonner%26aufirst%3DT.%2BI.%26aulast%3DCabral%26aufirst%3DG.%26aulast%3DCasellas%26aufirst%3DP.%26aulast%3DDevane%26aufirst%3DW.%2BA.%26aulast%3DFelder%26aufirst%3DC.%2BC.%26aulast%3DHerkenham%26aufirst%3DM.%26aulast%3DMackie%26aufirst%3DK.%26aulast%3DMartin%26aufirst%3DB.%2BR.%26aulast%3DMechoulam%26aufirst%3DR.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DInternational%2520Union%2520of%2520Pharmacology.%2520XXVII.%2520Classification%2520of%2520cannabinoid%2520receptors%26jtitle%3DPharmacol.%2520Rev.%26date%3D2002%26volume%3D54%26spage%3D161%26epage%3D202%26doi%3D10.1124%2Fpr.54.2.161" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref73"><div class="reference"><strong class="refLabel"><a href="#ref73" class="rightTabRefNumLink">73</a></strong><div class="NLM_citation" id="rightTab-cit73"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Ross, R. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brockie, H. C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Stevenson, L. A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, V. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Templeton, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Makriyannis, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pertwee, R. G.</span></span> <span> </span><span class="NLM_article-title">Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">1999</span>,  <span class="NLM_volume"><i>126</i></span>,  <span class="NLM_fpage">665</span>– <span class="NLM_lpage">672</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0702351</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0702351" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10188977" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref73/cit73&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1MXhslWit78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=126&publication_year=1999&pages=665-672&author=R.+A.+Rossauthor=H.+C.+Brockieauthor=L.+A.+Stevensonauthor=V.+L.+Murphyauthor=F.+Templetonauthor=A.+Makriyannisauthor=R.+G.+Pertwee&title=Agonist-inverse+agonist+characterization+at+CB1+and+CB2+cannabinoid+receptors+of+L759633%2C+L759656+and+AM630&doi=10.1038%2Fsj.bjp.0702351"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit73R"><div class="casContent"><span class="casTitleNuber">73</span><div class="casTitle"><span class="NLM_cas:atitle">Agonist-inverse agonist characterization at CB1 and CB2 cannabinoid receptors of L759633, L759656 and AM630</span></div><div class="casAuthors">Ross, Ruth A.; Brockie, Heather C.; Stevenson, Lesley A.; Murphy, Vicki L.; Templeton, Fiona; Makriyannis, Alexandros; Pertwee, Roger G.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">1999</span>),
    <span class="NLM_cas:volume">126</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">665-672</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Stockton Press</span>)
        </div><div class="casAbstract">We have tested our prediction that AM630 is a CB2 cannabinoid receptor ligand and also investigated whether L759633 and L759656, are CB2 receptor agonists.  Binding assays with membranes from CHO cells stably transfected with human CB1 or CB2 receptors using [3H]-CP55940, confirmed the CB2-selectivity of L759633 and L759656 (CB2/CB1 affinity ratios = 163 and 414 resp.) and showed AM630 to have a Ki at CB2 receptors of 31.2 nM and a CB2/CB1 affinity ratio of 165.  In CB2-transfected cells, L759633 and L759656 were potent inhibitors of forskolin-stimulated cAMP prodn., with EC50 values of 8.1 and 3.1 nM resp. and CB1/CB2 EC50 ratios of > 1000 and > 3000 resp.  AM630 inhibited [35S]-GTPγS binding to CB2 receptor membranes (EC50 = 76.6 nM), enhanced forskolin-stimulated cAMP prodn. in CB2-transfected cells (5.2 fold by 1 μM), and antagonized the inhibition of forskolin-stimulated cAMP prodn. in this cell line induced by CP55940.  In CB1-transfected cells, forskolin-stimulated cAMP prodn. was significantly inhibited by AM630 (22.6% at 1 μM and 45.9% at 10 μM) and by L759633 at 10 μM (48%) but not 1 μM.  L759656 (10 μM) was not inhibitory.  AM630 also produced a slight decrease in the mean inhibitory effect of CP55940 on cAMP prodn. which was not statistically significant.  We conclude that AM630 is a CB2-selective ligand that behaves as an inverse agonist at CB2 receptors and as a weak partial agonist at CB1 receptors.  L759633 and L759656 are both potent CB2-selective agonists.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrSFP_3NFRGm7Vg90H21EOLACvtfcHk0ljNLj1s4N2hEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1MXhslWit78%253D&md5=6d0f811a461a91ebef93f45605fd3b11</span></div><a href="/servlet/linkout?suffix=cit73&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0702351&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0702351%26sid%3Dliteratum%253Aachs%26aulast%3DRoss%26aufirst%3DR.%2BA.%26aulast%3DBrockie%26aufirst%3DH.%2BC.%26aulast%3DStevenson%26aufirst%3DL.%2BA.%26aulast%3DMurphy%26aufirst%3DV.%2BL.%26aulast%3DTempleton%26aufirst%3DF.%26aulast%3DMakriyannis%26aufirst%3DA.%26aulast%3DPertwee%26aufirst%3DR.%2BG.%26atitle%3DAgonist-inverse%2520agonist%2520characterization%2520at%2520CB1%2520and%2520CB2%2520cannabinoid%2520receptors%2520of%2520L759633%252C%2520L759656%2520and%2520AM630%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D1999%26volume%3D126%26spage%3D665%26epage%3D672%26doi%3D10.1038%2Fsj.bjp.0702351" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref74"><div class="reference"><strong class="refLabel"><a href="#ref74" class="rightTabRefNumLink">74</a></strong><div class="NLM_citation" id="rightTab-cit74"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Williams, C.</span></span> <span> </span><span class="NLM_article-title">cAMP detection methods in HTS: selecting the best from the rest</span>. <i>Nat. Rev. Drug Discov.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>3</i></span>,  <span class="NLM_fpage">125</span>– <span class="NLM_lpage">135</span>, <span class="refDoi"> DOI: 10.1038/nrd1306</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnrd1306" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15040577" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref74/cit74&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXlsFegtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=3&publication_year=2004&pages=125-135&author=C.+Williams&title=cAMP+detection+methods+in+HTS%3A+selecting+the+best+from+the+rest&doi=10.1038%2Fnrd1306"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit74R"><div class="casContent"><span class="casTitleNuber">74</span><div class="casTitle"><span class="NLM_cas:atitle">cAMP detection methods in HTS: selecting the best from the rest</span></div><div class="casAuthors">Williams, Christine</div><div class="citationInfo"><span class="NLM_cas:title">Nature Reviews Drug Discovery</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">3</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">125-135</span>CODEN:
                <span class="NLM_cas:coden">NRDDAG</span>;
        ISSN:<span class="NLM_cas:issn">1474-1776</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">A review.  The no. of technologies that enable high-throughput functional screening of G-protein-coupled receptors has expanded markedly over the past 5 yr.  Consequently, choosing the most appropriate technol. can be a daunting task, particularly for Gi- or Gs-coupled receptors.  The most common systems for cAMP detection are reviewed, highlighting the practical and theor. aspects that are important in their application to high-throughput screening.  Current technologies can do the job, but it is likely that the future may require development of technologies that provide even greater biol. information.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpmmCj3Y5Nf5rVg90H21EOLACvtfcHk0ljNLj1s4N2hEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXlsFegtw%253D%253D&md5=521d70b04daba0ec620c2f72130a5458</span></div><a href="/servlet/linkout?suffix=cit74&amp;dbid=16384&amp;doi=10.1038%2Fnrd1306&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnrd1306%26sid%3Dliteratum%253Aachs%26aulast%3DWilliams%26aufirst%3DC.%26atitle%3DcAMP%2520detection%2520methods%2520in%2520HTS%253A%2520selecting%2520the%2520best%2520from%2520the%2520rest%26jtitle%3DNat.%2520Rev.%2520Drug%2520Discov.%26date%3D2004%26volume%3D3%26spage%3D125%26epage%3D135%26doi%3D10.1038%2Fnrd1306" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref75"><div class="reference"><strong class="refLabel"><a href="#ref75" class="rightTabRefNumLink">75</a></strong><div class="NLM_citation" id="rightTab-cit75"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Waeber, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thompson, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chautard, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Steinmann, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nicod, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Pralong, F. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Calandra, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gaillard, R. C.</span></span> <span> </span><span class="NLM_article-title">Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3′, 5′-monophosphate responsive element-binding protein CREB in pituitary cells</span>. <i>Mol. Endocrinol.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>12</i></span>,  <span class="NLM_fpage">698</span>– <span class="NLM_lpage">705</span>, <span class="refDoi"> DOI: 10.1210/mend.12.5.0109</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1210%2Fmend.12.5.0109" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9605932" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref75/cit75&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1cXivVSgs78%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=12&publication_year=1998&pages=698-705&author=G.+Waeberauthor=N.+Thompsonauthor=T.+Chautardauthor=M.+Steinmannauthor=P.+Nicodauthor=F.+P.+Pralongauthor=T.+Calandraauthor=R.+C.+Gaillard&title=Transcriptional+activation+of+the+macrophage+migration-inhibitory+factor+gene+by+the+corticotropin-releasing+factor+is+mediated+by+the+cyclic+adenosine+3%E2%80%B2%2C+5%E2%80%B2-monophosphate+responsive+element-binding+protein+CREB+in+pituitary+cells&doi=10.1210%2Fmend.12.5.0109"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit75R"><div class="casContent"><span class="casTitleNuber">75</span><div class="casTitle"><span class="NLM_cas:atitle">Transcriptional activation of the macrophage migration-inhibitory factor gene by the corticotropin-releasing factor is mediated by the cyclic adenosine 3',5'-monophosphate responsive element-binding protein CREB in pituitary cells</span></div><div class="casAuthors">Waeber, Gerard; Thompson, Nancy; Chautard, Thierry; Steinmann, Myriam; Nicod, Pascal; Pralong, Francois P.; Calandra, Thierry; Gaillard, Rolf C.</div><div class="citationInfo"><span class="NLM_cas:title">Molecular Endocrinology</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">12</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">698-705</span>CODEN:
                <span class="NLM_cas:coden">MOENEN</span>;
        ISSN:<span class="NLM_cas:issn">0888-8809</span>.
    
            (<span class="NLM_cas:orgname">Endocrine Society</span>)
        </div><div class="casAbstract">Macrophage migration-inhibitory factor (MIF) has recently been identified as a pituitary hormone that functions as a counterregulatory modulator of glucocorticoid action within the immune system.  In the anterior pituitary gland, MIF is expressed in TSH- and ACTH-producing cells, and its secretion is induced by CRF.  To investigate MIF function and regulation within pituitary cells, we initiated the characterization of the MIF 5'-regulatory region of the gene.  The -1033 to +63 bp of the murine MIF promoter was cloned 5' to a luciferase reporter gene and transiently transfected into freshly isolated rat anterior pituitary cells.  This construct drove high basal transcriptional activity that was further enhanced after stimulation with CRF or with an activator of adenylate cyclase.  These transcriptional effects were assocd. with a concomitant rise in ACTH secretion in the transfected cells and by an increase in MIF gene expression as assessed by Northern blot anal.  A cAMP-responsive element (CRE) was identified within the MIF promoter region which, once mutated, abolished the cAMP responsiveness of the gene.  Using this newly identified CRE, DNA-binding activity was detected by gel retardation assay in nuclear exts. prepd. from isolated anterior pituitary cells and AtT-20 corticotroph tumor cells.  Supershift expts. using antibodies against the CRE-binding protein CREB, together with competition assays and the use of recombinant CREB, allowed the detection of CREB-binding activity with the identified MIF CRE.  These data demonstrate that CREB is the mediator of the CRF-induced MIF gene transcription in pituitary cells through an identified CRE in the proximal region of the MIF promoter.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGr4ctiJbpNnCrVg90H21EOLACvtfcHk0ljNLj1s4N2hEQ"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXivVSgs78%253D&md5=770f5d527647a365076307134c26dd73</span></div><a href="/servlet/linkout?suffix=cit75&amp;dbid=16384&amp;doi=10.1210%2Fmend.12.5.0109&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1210%252Fmend.12.5.0109%26sid%3Dliteratum%253Aachs%26aulast%3DWaeber%26aufirst%3DG.%26aulast%3DThompson%26aufirst%3DN.%26aulast%3DChautard%26aufirst%3DT.%26aulast%3DSteinmann%26aufirst%3DM.%26aulast%3DNicod%26aufirst%3DP.%26aulast%3DPralong%26aufirst%3DF.%2BP.%26aulast%3DCalandra%26aufirst%3DT.%26aulast%3DGaillard%26aufirst%3DR.%2BC.%26atitle%3DTranscriptional%2520activation%2520of%2520the%2520macrophage%2520migration-inhibitory%2520factor%2520gene%2520by%2520the%2520corticotropin-releasing%2520factor%2520is%2520mediated%2520by%2520the%2520cyclic%2520adenosine%25203%25E2%2580%25B2%252C%25205%25E2%2580%25B2-monophosphate%2520responsive%2520element-binding%2520protein%2520CREB%2520in%2520pituitary%2520cells%26jtitle%3DMol.%2520Endocrinol.%26date%3D1998%26volume%3D12%26spage%3D698%26epage%3D705%26doi%3D10.1210%2Fmend.12.5.0109" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref76"><div class="reference"><strong class="refLabel"><a href="#ref76" class="rightTabRefNumLink">76</a></strong><div class="NLM_citation" id="rightTab-cit76"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Kato, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nomoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Izumi, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ise, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakano, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Niho, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kohno, K.</span></span> <span> </span><span class="NLM_article-title">Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells</span>. <i>Biochim. Biophys. Acta Gene Struct. Expr.</i> <span class="NLM_year" style="font-weight: bold;">2000</span>,  <span class="NLM_volume"><i>1493</i></span>,  <span class="NLM_fpage">91</span>– <span class="NLM_lpage">100</span>, <span class="refDoi"> DOI: 10.1016/S0167-4781(00)00168-8</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0167-4781%2800%2900168-8" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10978511" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref76/cit76&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3cXmt1Sns7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1493&publication_year=2000&pages=91-100&author=K.+Katoauthor=M.+Nomotoauthor=H.+Izumiauthor=T.+Iseauthor=S.+Nakanoauthor=Y.+Nihoauthor=K.+Kohno&title=Structure+and+functional+analysis+of+the+human+STAT3+gene+promoter%3A+alteration+of+chromatin+structure+as+a+possible+mechanism+for+the+upregulation+in+cisplatin-resistant+cells&doi=10.1016%2FS0167-4781%2800%2900168-8"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit76R"><div class="casContent"><span class="casTitleNuber">76</span><div class="casTitle"><span class="NLM_cas:atitle">Structure and functional analysis of the human STAT3 gene promoter: alteration of chromatin structure as a possible mechanism for the upregulation in cisplatin-resistant cells</span></div><div class="casAuthors">Kato, K.; Nomoto, M.; Izumi, H.; Ise, T.; Nakano, S.; Niho, Y.; Kohno, K.</div><div class="citationInfo"><span class="NLM_cas:title">Biochimica et Biophysica Acta, Gene Structure and Expression</span>
        (<span class="NLM_cas:date">2000</span>),
    <span class="NLM_cas:volume">1493</span>
        (<span class="NLM_cas:issue">1-2</span>),
    <span class="NLM_cas:pages">91-100</span>CODEN:
                <span class="NLM_cas:coden">BBGSD5</span>;
        ISSN:<span class="NLM_cas:issn">0167-4781</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">STAT3 is involved in the signal transduction activated by various cytokines and growth factors.  We found that the STAT3 gene is overexpressed in cisplatin-resistant cells.  We isolated a genomic fragment contg. the 5'-portion of the human STAT3 gene using a bubble PCR method.  Using the bubble PCR product as a probe, one genomic clone was isolated.  The nucleotide sequence of the first exon and the 1800 base pairs (bps) preceding it was detd.  The promoter region of the human STAT3 gene is highly homologous to the corresponding region of the mouse STAT3 gene; several potential factor binding sites such as CRE/ATF, SBE, and GC boxes are also well conserved between human and mouse.  A transient expression assay using the luciferase reporter gene showed that the sequence from -403 to +102 possesses maximal promoter activity, and transcription of the STAT3 gene was significantly higher in cisplatin-resistant cells than in parental cisplatin-sensitive cells.  Deletion of the region between -261 and -167 resulted in significant loss of promoter activity in both parental and cisplatin-resistant cells.  In vivo footprint anal. revealed several protein bindings; however, no significant differences were obsd. between drug-sensitive and drug-resistant cells.  MNase digestion revealed that several open or active nucleosomes were only detected in cisplatin-resistant cells.  These results suggest that STAT3 promoter function in a highly structured chromatin environment requires a complex interaction of several transcriptional factors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoUvgaeUQnDp7Vg90H21EOLACvtfcHk0lgkqMxxFI9eNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3cXmt1Sns7g%253D&md5=211aad8e6a379cb222e310918699f7a0</span></div><a href="/servlet/linkout?suffix=cit76&amp;dbid=16384&amp;doi=10.1016%2FS0167-4781%2800%2900168-8&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0167-4781%252800%252900168-8%26sid%3Dliteratum%253Aachs%26aulast%3DKato%26aufirst%3DK.%26aulast%3DNomoto%26aufirst%3DM.%26aulast%3DIzumi%26aufirst%3DH.%26aulast%3DIse%26aufirst%3DT.%26aulast%3DNakano%26aufirst%3DS.%26aulast%3DNiho%26aufirst%3DY.%26aulast%3DKohno%26aufirst%3DK.%26atitle%3DStructure%2520and%2520functional%2520analysis%2520of%2520the%2520human%2520STAT3%2520gene%2520promoter%253A%2520alteration%2520of%2520chromatin%2520structure%2520as%2520a%2520possible%2520mechanism%2520for%2520the%2520upregulation%2520in%2520cisplatin-resistant%2520cells%26jtitle%3DBiochim.%2520Biophys.%2520Acta%2520Gene%2520Struct.%2520Expr.%26date%3D2000%26volume%3D1493%26spage%3D91%26epage%3D100%26doi%3D10.1016%2FS0167-4781%2800%2900168-8" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref77"><div class="reference"><strong class="refLabel"><a href="#ref77" class="rightTabRefNumLink">77</a></strong><div class="NLM_citation" id="rightTab-cit77"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Alas, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bonavida, B.</span></span> <span> </span><span class="NLM_article-title">Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin’s lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis</span>. <i>Clin. Cancer. Res.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>9</i></span>,  <span class="NLM_fpage">316</span>– <span class="NLM_lpage">326</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12538484" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref77/cit77&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXnt1Ortw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=9&publication_year=2003&pages=316-326&author=S.+Alasauthor=B.+Bonavida&title=Inhibition+of+constitutive+STAT3+activity+sensitizes+resistant+non-Hodgkin%E2%80%99s+lymphoma+and+multiple+myeloma+to+chemotherapeutic+drug-mediated+apoptosis"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit77R"><div class="casContent"><span class="casTitleNuber">77</span><div class="casTitle"><span class="NLM_cas:atitle">Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis</span></div><div class="casAuthors">Alas, Steve; Bonavida, Benjamin</div><div class="citationInfo"><span class="NLM_cas:title">Clinical Cancer Research</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">9</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">316-326</span>CODEN:
                <span class="NLM_cas:coden">CCREF4</span>;
        ISSN:<span class="NLM_cas:issn">1078-0432</span>.
    
            (<span class="NLM_cas:orgname">American Association for Cancer Research</span>)
        </div><div class="casAbstract">Hematopoietic malignancies have been shown to depend on cytokine growth factor autocrine/paracrine loops for growth and differentiation.  This results in the constitutive activation of cytokine-mediated transcription factors like signal transducer and activators of transcription (STAT) 3 in non-Hodgkin's lymphoma (NHL) and multiple myeloma (MM).  Recent evidence demonstrates that cytokines also contribute to a drug-resistant phenotype in many tumor cell types.  We hypothesized that inhibitors of the STAT3 pathway would sensitize drug-resistant and endogenous cytokine-dependent NHL and MM tumor cells to the cytotoxic effects of chemotherapeutic drugs.  We examd. an AIDS-related NHL cell line, 2F7, known to be dependent on interleukin (IL)-10 for survival and an MM cell line, U266, known to be dependent on IL-6 for survival.  IL-10 and IL-6 signal the cells through the activation of Janus kinase (JAK)1 and JAK2, resp.  Thus, we investigated the effect of two chem. STAT3 pathway inhibitors, namely, piceatannol (JAK1/STAT3 inhibitor) and tyrphostin AG490 (JAK2/STAT3 inhibitor), on the tumor cells for sensitization to therapeutic drugs.  We demonstrate by phosphoprotein immunoblotting anal. and electrophoretic mobility shift anal. that piceatannol and AG490 inhibit the constitutive activity of STAT3 in 2F7 and U266, resp.  Furthermore, piceatannol and AG490 sensitize 2F7 and U266 cells, resp., to apoptosis by a range of therapeutic drugs including cisplatin, fludarabine, Adriamycin, and vinblastine.  The specificity of the inhibitors was corroborated in expts. showing that piceatannol had no effect on U266 and, likewise, AG490 has no effect on 2F7.  The sensitization obsd. by these inhibitors correlated with the inhibition of Bcl-2 expression in 2F7 and Bcl-xL expression in U266.  Altogether, these results demonstrate that STAT3 pathway inhibitors are a novel class of chemotherapeutic sensitizing agents capable of reversing the drug-resistant phenotype of cytokine-dependent tumor cells.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrA8FrtRMRcL7Vg90H21EOLACvtfcHk0lgkqMxxFI9eNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXnt1Ortw%253D%253D&md5=a8429459592fc28b78075df1baff89bf</span></div><a href="/servlet/linkout?suffix=cit77&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DAlas%26aufirst%3DS.%26aulast%3DBonavida%26aufirst%3DB.%26atitle%3DInhibition%2520of%2520constitutive%2520STAT3%2520activity%2520sensitizes%2520resistant%2520non-Hodgkin%25E2%2580%2599s%2520lymphoma%2520and%2520multiple%2520myeloma%2520to%2520chemotherapeutic%2520drug-mediated%2520apoptosis%26jtitle%3DClin.%2520Cancer.%2520Res.%26date%3D2003%26volume%3D9%26spage%3D316%26epage%3D326" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref78"><div class="reference"><strong class="refLabel"><a href="#ref78" class="rightTabRefNumLink">78</a></strong><div class="NLM_citation" id="rightTab-cit78"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zheng, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wang, Q.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qian, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lu, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Li, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Reu, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Qin, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Drazba, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hsi, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yang, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cai, Z.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yi, Q.</span></span> <span> </span><span class="NLM_article-title">Role of myeloma-derived MIF in myeloma cell adhesion to bone marrow and chemotherapy response</span>. <i>J. Natl. Cancer Inst.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>108</i></span>,  <span class="NLM_fpage">djw131</span>, <span class="refDoi"> DOI: 10.1093/jnci/djw131</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref78/cit78&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1093%2Fjnci%2Fdjw131" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=108&publication_year=2016&pages=djw131&author=Y.+Zhengauthor=Q.+Wangauthor=T.+Liauthor=J.+Qianauthor=Y.+Luauthor=Y.+Liauthor=E.+Biauthor=F.+Reuauthor=Y.+Qinauthor=J.+Drazbaauthor=E.+Hsiauthor=J.+Yangauthor=Z.+Caiauthor=Q.+Yi&title=Role+of+myeloma-derived+MIF+in+myeloma+cell+adhesion+to+bone+marrow+and+chemotherapy+response&doi=10.1093%2Fjnci%2Fdjw131"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit78&amp;dbid=16384&amp;doi=10.1093%2Fjnci%2Fdjw131&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1093%252Fjnci%252Fdjw131%26sid%3Dliteratum%253Aachs%26aulast%3DZheng%26aufirst%3DY.%26aulast%3DWang%26aufirst%3DQ.%26aulast%3DLi%26aufirst%3DT.%26aulast%3DQian%26aufirst%3DJ.%26aulast%3DLu%26aufirst%3DY.%26aulast%3DLi%26aufirst%3DY.%26aulast%3DBi%26aufirst%3DE.%26aulast%3DReu%26aufirst%3DF.%26aulast%3DQin%26aufirst%3DY.%26aulast%3DDrazba%26aufirst%3DJ.%26aulast%3DHsi%26aufirst%3DE.%26aulast%3DYang%26aufirst%3DJ.%26aulast%3DCai%26aufirst%3DZ.%26aulast%3DYi%26aufirst%3DQ.%26atitle%3DRole%2520of%2520myeloma-derived%2520MIF%2520in%2520myeloma%2520cell%2520adhesion%2520to%2520bone%2520marrow%2520and%2520chemotherapy%2520response%26jtitle%3DJ.%2520Natl.%2520Cancer%2520Inst.%26date%3D2016%26volume%3D108%26spage%3Ddjw131%26doi%3D10.1093%2Fjnci%2Fdjw131" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref79"><div class="reference"><strong class="refLabel"><a href="#ref79" class="rightTabRefNumLink">79</a></strong><div class="NLM_citation" id="rightTab-cit79"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Fulp, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Zhang, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Bortoff, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wiethe, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Amato, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span> <span> </span><span class="NLM_article-title">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span>. <i>Bioorg. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>24</i></span>,  <span class="NLM_fpage">1063</span>– <span class="NLM_lpage">1070</span>, <span class="refDoi"> DOI: 10.1016/j.bmc.2016.01.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.bmc.2016.01.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=26827137" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref79/cit79&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=24&publication_year=2016&pages=1063-1070&author=A.+Fulpauthor=Y.+Zhangauthor=K.+Bortoffauthor=H.+Seltzmanauthor=R.+Snyderauthor=R.+Wietheauthor=G.+Amatoauthor=R.+Maitra&title=Pyrazole+antagonists+of+the+CB1+receptor+with+reduced+brain+penetration&doi=10.1016%2Fj.bmc.2016.01.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit79R"><div class="casContent"><span class="casTitleNuber">79</span><div class="casTitle"><span class="NLM_cas:atitle">Pyrazole antagonists of the CB1 receptor with reduced brain penetration</span></div><div class="casAuthors">Fulp, Alan; Zhang, Yanan; Bortoff, Katherine; Seltzman, Herbert; Snyder, Rodney; Wiethe, Robert; Amato, George; Maitra, Rangan</div><div class="citationInfo"><span class="NLM_cas:title">Bioorganic & Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">24</span>
        (<span class="NLM_cas:issue">5</span>),
    <span class="NLM_cas:pages">1063-1070</span>CODEN:
                <span class="NLM_cas:coden">BMECEP</span>;
        ISSN:<span class="NLM_cas:issn">0968-0896</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Type 1 cannabinoid receptor (CB1) antagonists might be useful for treating obesity, liver disease, metabolic syndrome, and dyslipidemias.  Unfortunately, inhibition of CB1 in the central nervous system (CNS) produces adverse effects, including depression, anxiety and suicidal ideation in some patients, which led to withdrawal of the pyrazole inverse agonist rimonabant (SR141716A) from European markets.  Efforts are underway to produce peripherally selective CB1 antagonists to circumvent CNS-assocd. adverse effects.  In this study, novel analogs of rimonabant (1) were explored in which the 1-aminopiperidine group was switched to a 4-aminopiperidine, attached at the 4-amino position (5).  The piperidine nitrogen was functionalized with carbamates, amides, and sulfonamides, providing compds. that are potent inverse agonists of hCB1 with good selectivity for hCB1 over hCB2.  Select compds. were further studied using in vitro models of brain penetration, oral absorption and metabolic stability.  Several compds. were identified with predicted minimal brain penetration and good metabolic stability.  In vivo pharmacokinetic testing revealed that inverse agonist I is orally bioavailable and has vastly reduced brain penetration compared to rimonabant.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpQF0R_5pD887Vg90H21EOLACvtfcHk0lgkqMxxFI9eNg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28XhsFyltL8%253D&md5=6cf6e50b077db6b1767f2397e3a5e017</span></div><a href="/servlet/linkout?suffix=cit79&amp;dbid=16384&amp;doi=10.1016%2Fj.bmc.2016.01.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.bmc.2016.01.033%26sid%3Dliteratum%253Aachs%26aulast%3DFulp%26aufirst%3DA.%26aulast%3DZhang%26aufirst%3DY.%26aulast%3DBortoff%26aufirst%3DK.%26aulast%3DSeltzman%26aufirst%3DH.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DWiethe%26aufirst%3DR.%26aulast%3DAmato%26aufirst%3DG.%26aulast%3DMaitra%26aufirst%3DR.%26atitle%3DPyrazole%2520antagonists%2520of%2520the%2520CB1%2520receptor%2520with%2520reduced%2520brain%2520penetration%26jtitle%3DBioorg.%2520Med.%2520Chem.%26date%3D2016%26volume%3D24%26spage%3D1063%26epage%3D1070%26doi%3D10.1016%2Fj.bmc.2016.01.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref80"><div class="reference"><strong class="refLabel"><a href="#ref80" class="rightTabRefNumLink">80</a></strong><div class="NLM_citation" id="rightTab-cit80"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Seltzman, H. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Shiner, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Hirt, E. E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gilliam, A. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Thomas, B. F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maitra, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Snyder, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Black, S. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Patel, P. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Mulpuri, Y.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Spigelman, I.</span></span> <span> </span><span class="NLM_article-title">Peripherally selective cannabinoid 1 receptor (CB1R) agonists for the treatment of neuropathic pain</span>. <i>J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2016</span>,  <span class="NLM_volume"><i>59</i></span>,  <span class="NLM_fpage">7525</span>– <span class="NLM_lpage">7543</span>, <span class="refDoi"> DOI: 10.1021/acs.jmedchem.6b00516</span> </span><div class="citationLinks">[<a href="/doi/10.1021/acs.jmedchem.6b00516" title="">ACS Full Text <img src="/templates/jsp/_style2/_achs/images/acs-ref.gif" alt="ACS Full Text" /></img></a>], [<a href="/servlet/linkout?suffix=ref80/cit80&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=59&publication_year=2016&pages=7525-7543&author=H.+H.+Seltzmanauthor=C.+Shinerauthor=E.+E.+Hirtauthor=A.+F.+Gilliamauthor=B.+F.+Thomasauthor=R.+Maitraauthor=R.+Snyderauthor=S.+L.+Blackauthor=P.+R.+Patelauthor=Y.+Mulpuriauthor=I.+Spigelman&title=Peripherally+selective+cannabinoid+1+receptor+%28CB1R%29+agonists+for+the+treatment+of+neuropathic+pain&doi=10.1021%2Facs.jmedchem.6b00516"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit80R"><div class="casContent"><span class="casTitleNuber">80</span><div class="casTitle"><span class="NLM_cas:atitle">Peripherally Selective Cannabinoid 1 Receptor (CB1R) Agonists for the Treatment of Neuropathic Pain</span></div><div class="casAuthors">Seltzman, Herbert H.; Shiner, Craig; Hirt, Erin E.; Gilliam, Anne F.; Thomas, Brian F.; Maitra, Rangan; Snyder, Rod; Black, Sherry L.; Patel, Purvi R.; Mulpuri, Yatendra; Spigelman, Igor</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2016</span>),
    <span class="NLM_cas:volume">59</span>
        (<span class="NLM_cas:issue">16</span>),
    <span class="NLM_cas:pages">7525-7543</span>CODEN:
                <span class="NLM_cas:coden">JMCMAR</span>;
        ISSN:<span class="NLM_cas:issn">0022-2623</span>.
    
            (<span class="NLM_cas:orgname">American Chemical Society</span>)
        </div><div class="casAbstract">Alleviation of neuropathic pain by cannabinoids is limited by their central nervous system (CNS) side effects.  Indole and indene compds. were engineered for high hCB1R affinity, peripheral selectivity, metabolic stability, and in vivo efficacy.  An epithelial cell line assay identified candidates with <1% blood-brain barrier penetration for testing in a rat neuropathy induced by unilateral sciatic nerve entrapment (SNE).  The SNE-induced mech. allodynia was reversibly suppressed, partially or completely, after i.p. or oral administration of several indenes.  At doses that relieve neuropathy symptoms, the indenes completely lacked, while the brain-permeant CB1R agonist HU-210 (1) exhibited strong CNS side effects, in catalepsy, hypothermia, and motor incoordination assays.  Pharmacokinetic findings of ∼0.001 cerebrospinal fluid:plasma ratio further supported limited CNS penetration.  Pretreatment with selective CB1R or CB2R blockers suggested mainly CB1R contribution to an indene's anti-allodynic effects.  Therefore, this class of CB1R agonists holds promise as a viable treatment for neuropathic pain.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp2b16dl7mj8LVg90H21EOLACvtfcHk0lgSyevA7tMOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC28Xht1KktLrF&md5=34e913618d61c632bfb90f390af7142e</span></div><a href="/servlet/linkout?suffix=cit80&amp;dbid=16384&amp;doi=10.1021%2Facs.jmedchem.6b00516&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1021%252Facs.jmedchem.6b00516%26sid%3Dliteratum%253Aachs%26aulast%3DSeltzman%26aufirst%3DH.%2BH.%26aulast%3DShiner%26aufirst%3DC.%26aulast%3DHirt%26aufirst%3DE.%2BE.%26aulast%3DGilliam%26aufirst%3DA.%2BF.%26aulast%3DThomas%26aufirst%3DB.%2BF.%26aulast%3DMaitra%26aufirst%3DR.%26aulast%3DSnyder%26aufirst%3DR.%26aulast%3DBlack%26aufirst%3DS.%2BL.%26aulast%3DPatel%26aufirst%3DP.%2BR.%26aulast%3DMulpuri%26aufirst%3DY.%26aulast%3DSpigelman%26aufirst%3DI.%26atitle%3DPeripherally%2520selective%2520cannabinoid%25201%2520receptor%2520%2528CB1R%2529%2520agonists%2520for%2520the%2520treatment%2520of%2520neuropathic%2520pain%26jtitle%3DJ.%2520Med.%2520Chem.%26date%3D2016%26volume%3D59%26spage%3D7525%26epage%3D7543%26doi%3D10.1021%2Facs.jmedchem.6b00516" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref81"><div class="reference"><strong class="refLabel"><a href="#ref81" class="rightTabRefNumLink">81</a></strong><div class="NLM_citation" id="rightTab-cit81"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Huang, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Roa, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sabaté, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects</span>. <i>Eur. J. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>146</i></span>,  <span class="NLM_fpage">93</span>– <span class="NLM_lpage">107</span>, <span class="refDoi"> DOI: 10.1016/j.ejmech.2018.01.036</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejmech.2018.01.036" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=29407994" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref81/cit81&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC1cXisFehs7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=146&publication_year=2018&pages=93-107&author=S.+Schrammauthor=G.+Huangauthor=S.+Guneschauthor=F.+Langauthor=J.+Roaauthor=P.+H%C3%B6ggerauthor=R.+Sabat%C3%A9author=P.+Maherauthor=M.+Decker&title=Regioselective+synthesis+of+7-O-esters+of+the+flavonolignan+silibinin+and+SARs+lead+to+compounds+with+overadditive+neuroprotective+effects&doi=10.1016%2Fj.ejmech.2018.01.036"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit81R"><div class="casContent"><span class="casTitleNuber">81</span><div class="casTitle"><span class="NLM_cas:atitle">Regioselective synthesis of 7-O-esters of the flavonolignan silibinin and SARs lead to compounds with overadditive neuroprotective effects</span></div><div class="casAuthors">Schramm, Simon; Huang, Guozheng; Gunesch, Sandra; Lang, Florian; Roa, Judit; Hoegger, Petra; Sabate, Raimon; Maher, Pamela; Decker, Michael</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Medicinal Chemistry</span>
        (<span class="NLM_cas:date">2018</span>),
    <span class="NLM_cas:volume">146</span>
        (<span class="NLM_cas:issue"></span>),
    <span class="NLM_cas:pages">93-107</span>CODEN:
                <span class="NLM_cas:coden">EJMCA5</span>;
        ISSN:<span class="NLM_cas:issn">0223-5234</span>.
    
            (<span class="NLM_cas:orgname">Elsevier Masson SAS</span>)
        </div><div class="casAbstract">A series of neuroprotective hybrid compds. was synthesized by conjugation of the flavonolignan silibinin with natural phenolic acids, such as ferulic, cinnamic and syringic acid.  Selective 7-O-esterification without protection groups was achieved by applying the resp. acyl chlorides.  Sixteen compds. were obtained and SARs were established by evaluating antioxidative properties in the physicochem. FRAP assay, as well as in a cell-based neuroprotection assay using murine hippocampal HT-22 cells.  Despite weak activities in the FRAP assay, esters of the α,β-unsatd. acids showed pronounced overadditive effects at low concns. greatly exceeding the effects of equimolar mixts. of silibinin and the resp. acids in the neuroprotection assay.  Cinnamic and ferulic acid esters I and II also showed overadditive effects regarding inhibition of microglial activation, PC12 cell differentiation, in vitro ischemia as well as anti-aggregating abilities against Aβ42 peptide and τ protein.  Remarkably, the esters of ferulic acid with silybin A and silybin B showed a moderate but significant difference in both neuroprotection and in their anti-aggregating capacities.  The results demonstrate that non-toxic natural antioxidants can be regioselectively connected as esters with medium-term stability exhibiting very pronounced overadditive effects in a portfolio of biol. assays.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrb6hOBfuLx97Vg90H21EOLACvtfcHk0lgSyevA7tMOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC1cXisFehs7Y%253D&md5=a0472a18235e9d724ea4b2667be6863f</span></div><a href="/servlet/linkout?suffix=cit81&amp;dbid=16384&amp;doi=10.1016%2Fj.ejmech.2018.01.036&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejmech.2018.01.036%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DS.%26aulast%3DHuang%26aufirst%3DG.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DRoa%26aufirst%3DJ.%26aulast%3DH%25C3%25B6gger%26aufirst%3DP.%26aulast%3DSabat%25C3%25A9%26aufirst%3DR.%26aulast%3DMaher%26aufirst%3DP.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DRegioselective%2520synthesis%2520of%25207-O-esters%2520of%2520the%2520flavonolignan%2520silibinin%2520and%2520SARs%2520lead%2520to%2520compounds%2520with%2520overadditive%2520neuroprotective%2520effects%26jtitle%3DEur.%2520J.%2520Med.%2520Chem.%26date%3D2018%26volume%3D146%26spage%3D93%26epage%3D107%26doi%3D10.1016%2Fj.ejmech.2018.01.036" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref82"><div class="reference"><strong class="refLabel"><a href="#ref82" class="rightTabRefNumLink">82</a></strong><div class="NLM_citation" id="rightTab-cit82"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Schramm, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Gunesch, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lang, F.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saedtler, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meinel, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Högger, P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Decker, M.</span></span> <span> </span><span class="NLM_article-title">Investigations into neuroprotectivity, stability, and water solubility of 7-O-cinnamoylsilibinin, its hemisuccinate and dehydro derivatives</span>. <i>Arch. Pharm.</i> <span class="NLM_year" style="font-weight: bold;">2018</span>,  <span class="NLM_volume"><i>351</i></span>,  <span class="NLM_fpage">1800206</span>, <span class="refDoi"> DOI: 10.1002/ardp.201800206</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref82/cit82&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1002%2Fardp.201800206" title="">Crossref</a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=351&publication_year=2018&pages=1800206&author=S.+Schrammauthor=S.+Guneschauthor=F.+Langauthor=M.+Saedtlerauthor=L.+Meinelauthor=P.+H%C3%B6ggerauthor=M.+Decker&title=Investigations+into+neuroprotectivity%2C+stability%2C+and+water+solubility+of+7-O-cinnamoylsilibinin%2C+its+hemisuccinate+and+dehydro+derivatives&doi=10.1002%2Fardp.201800206"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit82&amp;dbid=16384&amp;doi=10.1002%2Fardp.201800206&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1002%252Fardp.201800206%26sid%3Dliteratum%253Aachs%26aulast%3DSchramm%26aufirst%3DS.%26aulast%3DGunesch%26aufirst%3DS.%26aulast%3DLang%26aufirst%3DF.%26aulast%3DSaedtler%26aufirst%3DM.%26aulast%3DMeinel%26aufirst%3DL.%26aulast%3DH%25C3%25B6gger%26aufirst%3DP.%26aulast%3DDecker%26aufirst%3DM.%26atitle%3DInvestigations%2520into%2520neuroprotectivity%252C%2520stability%252C%2520and%2520water%2520solubility%2520of%25207-O-cinnamoylsilibinin%252C%2520its%2520hemisuccinate%2520and%2520dehydro%2520derivatives%26jtitle%3DArch.%2520Pharm.%26date%3D2018%26volume%3D351%26spage%3D1800206%26doi%3D10.1002%2Fardp.201800206" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref83"><div class="reference"><strong class="refLabel"><a href="#ref83" class="rightTabRefNumLink">83</a></strong><div class="NLM_citation" id="rightTab-cit83"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Davis, J. B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1994</span>,  <span class="NLM_volume"><i>652</i></span>,  <span class="NLM_fpage">169</span>– <span class="NLM_lpage">173</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(94)90334-4</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-8993%2894%2990334-4" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7953717" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref83/cit83&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK2cXlt1Ogsbk%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=652&publication_year=1994&pages=169-173&author=J.+B.+Davisauthor=P.+Maher&title=Protein+kinase+C+activation+inhibits+glutamate-induced+cytotoxicity+in+a+neuronal+cell+line&doi=10.1016%2F0006-8993%2894%2990334-4"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit83R"><div class="casContent"><span class="casTitleNuber">83</span><div class="casTitle"><span class="NLM_cas:atitle">Protein kinase C activation inhibits glutamate-induced cytotoxicity in a neuronal cell line</span></div><div class="casAuthors">Davis, John B.; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1994</span>),
    <span class="NLM_cas:volume">652</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">169-73</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    </div><div class="casAbstract">A neuronal cell line, HT-22, is sensitive to glutamate cytotoxicity via a non-receptor mediated oxidative pathway. 12-O-tetradecanoylphorbol-13-acetate (TPA), an activator of protein kinase C, blocks this glutamate-induced cell death.  Down-regulation of protein kinase C eliminates the protection against glutamate cytotoxicity afforded by TPA.  The data suggest that protein kinase C activation blocks an early step in the cytotoxic pathway.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp6zoz4lIRjcbVg90H21EOLACvtfcHk0lgSyevA7tMOTA"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK2cXlt1Ogsbk%253D&md5=7e914f0eba8082ec6dbed0b6c8f0c444</span></div><a href="/servlet/linkout?suffix=cit83&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2894%2990334-4&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252894%252990334-4%26sid%3Dliteratum%253Aachs%26aulast%3DDavis%26aufirst%3DJ.%2BB.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DProtein%2520kinase%2520C%2520activation%2520inhibits%2520glutamate-induced%2520cytotoxicity%2520in%2520a%2520neuronal%2520cell%2520line%26jtitle%3DBrain%2520Res.%26date%3D1994%26volume%3D652%26spage%3D169%26epage%3D173%26doi%3D10.1016%2F0006-8993%2894%2990334-4" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref84"><div class="reference"><strong class="refLabel"><a href="#ref84" class="rightTabRefNumLink">84</a></strong><div class="NLM_citation" id="rightTab-cit84"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Murphy, T. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Miyamoto, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Sastre, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schnaar, R. L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Coyle, J. T.</span></span> <span> </span><span class="NLM_article-title">Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress</span>. <i>Neuron</i> <span class="NLM_year" style="font-weight: bold;">1989</span>,  <span class="NLM_volume"><i>2</i></span>,  <span class="NLM_fpage">1547</span>– <span class="NLM_lpage">1558</span>, <span class="refDoi"> DOI: 10.1016/0896-6273(89)90043-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0896-6273%2889%2990043-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=2576375" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref84/cit84&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK3cXltV2ksrg%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=2&publication_year=1989&pages=1547-1558&author=T.+H.+Murphyauthor=M.+Miyamotoauthor=A.+Sastreauthor=R.+L.+Schnaarauthor=J.+T.+Coyle&title=Glutamate+toxicity+in+a+neuronal+cell+line+involves+inhibition+of+cystine+transport+leading+to+oxidative+stress&doi=10.1016%2F0896-6273%2889%2990043-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit84R"><div class="casContent"><span class="casTitleNuber">84</span><div class="casTitle"><span class="NLM_cas:atitle">Glutamate toxicity in a neuronal cell line involves inhibition of cystine transport leading to oxidative stress</span></div><div class="casAuthors">Murphy, Timothy H.; Miyamoto, Masaomi; Sastre, Antonio; Schnaar, Ronald L.; Coyle, Joseph T.</div><div class="citationInfo"><span class="NLM_cas:title">Neuron</span>
        (<span class="NLM_cas:date">1989</span>),
    <span class="NLM_cas:volume">2</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1547-58</span>CODEN:
                <span class="NLM_cas:coden">NERNET</span>;
        ISSN:<span class="NLM_cas:issn">0896-6273</span>.
    </div><div class="casAbstract">Glutamate binds to both excitatory neurotransmitter binding sites and a Cl--dependent, quisqualate- and cystine-inhibited transport site on brain neurons.  The neuroblastoma-primary retina hybrid cells (N18-RE-105) are susceptible to glutamate-induced cytotoxicity.  The Cl--dependent transport site to which glutamate and quisqualate (but not kainate or NMDA) bind has a high affinity for cystine than for glutamate.  Lowering cystine concns. in the cell culture medium results in cytotoxicity similar to that induced by glutamate addn. in its morphol., kinetics, and Ca2+ dependence.  Glutamate-induced cytotoxicity is directly proportional to its ability to inhibit cystine uptake.  Exposure to glutamate (or lowered cystine) causes a decrease in glutathione levels and an accumulation of intracellular peroxides.  Like N18-RE-105 cells, primary rat hippocampal neurons (but not glia) in culture degenerate in medium with lowered cystine concn.  Thus, glutamate-induced cytotoxicity in N18-RE-105 cells is due to inhibition of cystine uptake, resulting in lowered glutathione levels leading to oxidative stress and cell death.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrKGHs5RF0MXbVg90H21EOLACvtfcHk0lhkqzgoEuZalg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK3cXltV2ksrg%253D&md5=af2faf651f0807f7c54e147915b91a9d</span></div><a href="/servlet/linkout?suffix=cit84&amp;dbid=16384&amp;doi=10.1016%2F0896-6273%2889%2990043-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0896-6273%252889%252990043-3%26sid%3Dliteratum%253Aachs%26aulast%3DMurphy%26aufirst%3DT.%2BH.%26aulast%3DMiyamoto%26aufirst%3DM.%26aulast%3DSastre%26aufirst%3DA.%26aulast%3DSchnaar%26aufirst%3DR.%2BL.%26aulast%3DCoyle%26aufirst%3DJ.%2BT.%26atitle%3DGlutamate%2520toxicity%2520in%2520a%2520neuronal%2520cell%2520line%2520involves%2520inhibition%2520of%2520cystine%2520transport%2520leading%2520to%2520oxidative%2520stress%26jtitle%3DNeuron%26date%3D1989%26volume%3D2%26spage%3D1547%26epage%3D1558%26doi%3D10.1016%2F0896-6273%2889%2990043-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref85"><div class="reference"><strong class="refLabel"><a href="#ref85" class="rightTabRefNumLink">85</a></strong><div class="NLM_citation" id="rightTab-cit85"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Wood, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells</span>. <i>J. Neurochem.</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>71</i></span>,  <span class="NLM_fpage">95</span>– <span class="NLM_lpage">105</span>, <span class="refDoi"> DOI: 10.1046/j.1471-4159.1998.71010095.x</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1046%2Fj.1471-4159.1998.71010095.x" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9648855" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref85/cit85&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK1cXktFams7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=71&publication_year=1998&pages=95-105&author=S.+Tanauthor=M.+Woodauthor=P.+Maher&title=Oxidative+stress+induces+a+form+of+programmed+cell+death+with+characteristics+of+both+apoptosis+and+necrosis+in+neuronal+cells&doi=10.1046%2Fj.1471-4159.1998.71010095.x"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit85R"><div class="casContent"><span class="casTitleNuber">85</span><div class="casTitle"><span class="NLM_cas:atitle">Oxidative stress induces a form of programmed cell death with characteristics of both apoptosis and necrosis in neuronal cells</span></div><div class="casAuthors">Tan, Shirlee; Wood, Malcolm; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurochemistry</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">71</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">95-105</span>CODEN:
                <span class="NLM_cas:coden">JONRA9</span>;
        ISSN:<span class="NLM_cas:issn">0022-3042</span>.
    
            (<span class="NLM_cas:orgname">Lippincott-Raven Publishers</span>)
        </div><div class="casAbstract">Oxidative stress is implicated in a no. of neurol. disorders including stroke, Parkinson's disease, and Alzheimer's disease.  To study the effects of oxidative stress on neuronal cells, the authors have used an immortalized mouse hippocampal cell line (HT-22) that is particularly sensitive to glutamate.  In these cells, glutamate competes for cystine uptake, leading to a redn. in glutathione and, ultimately, cell death.  As it has been reported that protein kinase C activation inhibits glutamate toxicity in these cells and is also assocd. with the inhibition of apoptosis in other cell types, the authors asked if glutamate toxicity was via apoptosis.  Morphol., glutamate-treated cells underwent plasma membrane blebbing and cell shrinkage, but no DNA fragmentation was obsd.  At the ultrastructural level, there was damage to mitochondria and other organelles although the nuclei remained intact.  Protein and RNA synthesis inhibitors as well as certain protease inhibitors protected the cells from glutamate toxicity.  Both the macromol. synthesis inhibitors and the protease inhibitors had to be added relatively soon after the addn. of glutamate, suggesting that protein synthesis and protease activation are early and distinct steps in the cell death pathway.  Thus, the oxidative stress brought about by treatment with glutamate initiates a series of events that lead to a form of cell death distinct from either necrosis or apoptosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpplvJv3Oe3UrVg90H21EOLACvtfcHk0lhkqzgoEuZalg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK1cXktFams7g%253D&md5=3e292281baa963ef7da1ae54ac6eb423</span></div><a href="/servlet/linkout?suffix=cit85&amp;dbid=16384&amp;doi=10.1046%2Fj.1471-4159.1998.71010095.x&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1046%252Fj.1471-4159.1998.71010095.x%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DWood%26aufirst%3DM.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DOxidative%2520stress%2520induces%2520a%2520form%2520of%2520programmed%2520cell%2520death%2520with%2520characteristics%2520of%2520both%2520apoptosis%2520and%2520necrosis%2520in%2520neuronal%2520cells%26jtitle%3DJ.%2520Neurochem.%26date%3D1998%26volume%3D71%26spage%3D95%26epage%3D105%26doi%3D10.1046%2Fj.1471-4159.1998.71010095.x" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref86"><div class="reference"><strong class="refLabel"><a href="#ref86" class="rightTabRefNumLink">86</a></strong><div class="NLM_citation" id="rightTab-cit86"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Tan, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Schubert, D.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maher, P.</span></span> <span> </span><span class="NLM_article-title">Oxytosis: a novel form of programmed cell death</span>. <i>Curr. Top. Med. Chem.</i> <span class="NLM_year" style="font-weight: bold;">2001</span>,  <span class="NLM_volume"><i>1</i></span>,  <span class="NLM_fpage">497</span>– <span class="NLM_lpage">506</span>, <span class="refDoi"> DOI: 10.2174/1568026013394741</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.2174%2F1568026013394741" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=11895126" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref86/cit86&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3MXos1aitrc%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=1&publication_year=2001&pages=497-506&author=S.+Tanauthor=D.+Schubertauthor=P.+Maher&title=Oxytosis%3A+a+novel+form+of+programmed+cell+death&doi=10.2174%2F1568026013394741"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit86R"><div class="casContent"><span class="casTitleNuber">86</span><div class="casTitle"><span class="NLM_cas:atitle">Oxytosis: a novel form of programmed cell death</span></div><div class="casAuthors">Tan, Shirlee; Schubert, David; Maher, Pamela</div><div class="citationInfo"><span class="NLM_cas:title">Current Topics in Medicinal Chemistry (Hilversum, Netherlands)</span>
        (<span class="NLM_cas:date">2001</span>),
    <span class="NLM_cas:volume">1</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">497-506</span>CODEN:
                <span class="NLM_cas:coden">CTMCCL</span>;
        ISSN:<span class="NLM_cas:issn">1568-0266</span>.
    
            (<span class="NLM_cas:orgname">Bentham Science Publishers Ltd.</span>)
        </div><div class="casAbstract">A review with refs.  Extensive nerve cell death occurs during the development of the central nervous system as well as in episodes of trauma and in neurodegenerative disease.  The mechanistic details of how these cells die are poorly understood.  Here we describe a unique oxidative stress-induced programmed cell death pathway called oxytosis, and outline pharmacol. approaches which interfere with its execution.  Oxidative glutamate toxicity, in which exogenous glutamate inhibits cystine uptake through the cystine/glutamate antiporter leading to a depletion of glutathione, is used as an example of oxytosis.  It is shown that there is a sequential requirement for de novo macromol. synthesis, lipoxygenase activation, reactive oxygen species prodn., and the opening of cGMP-gated channels which allow the influx of extracellular calcium.  The translation initiation factor eIF2α plays a central role in this pathway by regulating the levels of glutathione.  Finally, examples are given in which the redn. in glutathione, the prodn. of reactive oxygen species, and calcium influx can be exptl. manipulated to prevent cell death.  The reviewed data suggest that oxytosis may be involved in nerve cell death assocd. with nervous system trauma and disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq70jHZZ6C5Y7Vg90H21EOLACvtfcHk0lhkqzgoEuZalg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3MXos1aitrc%253D&md5=7fc6a76e10947ab5224d5c3c7d37979e</span></div><a href="/servlet/linkout?suffix=cit86&amp;dbid=16384&amp;doi=10.2174%2F1568026013394741&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.2174%252F1568026013394741%26sid%3Dliteratum%253Aachs%26aulast%3DTan%26aufirst%3DS.%26aulast%3DSchubert%26aufirst%3DD.%26aulast%3DMaher%26aufirst%3DP.%26atitle%3DOxytosis%253A%2520a%2520novel%2520form%2520of%2520programmed%2520cell%2520death%26jtitle%3DCurr.%2520Top.%2520Med.%2520Chem.%26date%3D2001%26volume%3D1%26spage%3D497%26epage%3D506%26doi%3D10.2174%2F1568026013394741" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref87"><div class="reference"><strong class="refLabel"><a href="#ref87" class="rightTabRefNumLink">87</a></strong><div class="NLM_citation" id="rightTab-cit87"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Lockhart, B. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, A.</span></span> <span> </span><span class="NLM_article-title">Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction</span>. <i>Brain Res.</i> <span class="NLM_year" style="font-weight: bold;">1996</span>,  <span class="NLM_volume"><i>706</i></span>,  <span class="NLM_fpage">181</span>– <span class="NLM_lpage">193</span>, <span class="refDoi"> DOI: 10.1016/0006-8993(95)01032-7</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2F0006-8993%2895%2901032-7" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=8822355" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref87/cit87&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaK28Xns1yitQ%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=706&publication_year=1996&pages=181-193&author=T.+Mauriceauthor=B.+P.+Lockhartauthor=A.+Privat&title=Amnesia+induced+in+mice+by+centrally+administered+%CE%B2-amyloid+peptides+involves+cholinergic+dysfunction&doi=10.1016%2F0006-8993%2895%2901032-7"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit87R"><div class="casContent"><span class="casTitleNuber">87</span><div class="casTitle"><span class="NLM_cas:atitle">Amnesia induced in mice by centrally administered β-amyloid peptides involves cholinergic dysfunction</span></div><div class="casAuthors">Maurice, Tangui; Lockhart, Brian P.; Privat, Alain</div><div class="citationInfo"><span class="NLM_cas:title">Brain Research</span>
        (<span class="NLM_cas:date">1996</span>),
    <span class="NLM_cas:volume">706</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">181-93</span>CODEN:
                <span class="NLM_cas:coden">BRREAP</span>;
        ISSN:<span class="NLM_cas:issn">0006-8993</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Substantial evidences suggest that the increased cerebral deposition, and neurotoxic action of the β-amyloid peptide, the major constituent of senile plaques, may represent the underlying cause of the cognitive deficits obsd. in Alzheimer's disease.  Herein, the authors attempted to verify this hypothesis by inducing a potential Alzheimer's-type amnesia after direct intracerebroventricular administration of aggregated β25-35-amyloid peptide in mice.  In this aim, amnesic capacities were evaluated after 6 to 13 days, using spontaneous alternation in the Y-maze, step-down type passive avoidance and place learning in a water-maze.  Pre-training administration of aggregated β25-35 peptide induced dose-dependent decreases in both alternation behavior and passive avoidance, at doses of 3 and 9 nmol/mouse.  A reduced but still significant impairment was obsd. when the peptide was not aggregated, or 'aged', by preincubation for 4 days at 37°.  The β1-28 peptide, at 3 nmol/mouse, also induced a marked decrease in step-down latency.  Post-training, but not pre-retention, administration of β25-35 peptide also significantly impaired learning.  The beneficial effects of cholinergic agents on β25-35-induced amnesia was examd. using the cholinesterase inhibitor tacrine (THA, 1.3 and 4.3 μmol/kg i.p.) and the nicotinic receptor agonist (-)-nicotine (NIC, 0.06 and 0.2 μmol/kg i.p.).  Both drugs induced a dose-dependent abrogation of the β25-35-induced decreases in alternation behavior and passive avoidance.  Furthermore, THA, at 1.3 μmol/kg, and NIC, at 0.2 μmol/kg, also reversed the β25-35-induced impairment of place learning and retention in the water-maze.  Histol. examn. of Cresyl violet-stained brain sections indicated a moderate but significant cell loss within the frontoparietal cortex and the hippocampal formation of mice treated with aged β25-35 peptide (9 nmol).  Examn. of Congo red-stained sections in the same animals demonstrated the presence of numerous amyloid deposits throughout these brain areas.  These results confirm that the deposition of β-amyloid peptide in the brain is in some way related to impairment of learning and cholinergic degeneration and suggest that the [25-35] fragment of the β-amyloid protein, sufficient to induce neuronal death in cultures, also induces an Alzheimer's-type amnesia in mice.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGqCsjUgNl1iVLVg90H21EOLACvtfcHk0limPC2LffYqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaK28Xns1yitQ%253D%253D&md5=5a0465719e2a405fcc1c6aae31ad0367</span></div><a href="/servlet/linkout?suffix=cit87&amp;dbid=16384&amp;doi=10.1016%2F0006-8993%2895%2901032-7&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252F0006-8993%252895%252901032-7%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DLockhart%26aufirst%3DB.%2BP.%26aulast%3DPrivat%26aufirst%3DA.%26atitle%3DAmnesia%2520induced%2520in%2520mice%2520by%2520centrally%2520administered%2520%25CE%25B2-amyloid%2520peptides%2520involves%2520cholinergic%2520dysfunction%26jtitle%3DBrain%2520Res.%26date%3D1996%26volume%3D706%26spage%3D181%26epage%3D193%26doi%3D10.1016%2F0006-8993%2895%2901032-7" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref88"><div class="reference"><strong class="refLabel"><a href="#ref88" class="rightTabRefNumLink">88</a></strong><div class="NLM_citation" id="rightTab-cit88"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Lahmy, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Malmström, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kim, S. H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Blockade of Tau hyperphosphorylation and Aβ 1–42 generation by the aminotetrahydrofuran derivative ANAVEX2-73, a mixed muscarinic and σ 1 receptor agonist, in a nontransgenic mouse model of Alzheimer’s disease</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>38</i></span>,  <span class="NLM_fpage">1706</span>– <span class="NLM_lpage">1723</span>, <span class="refDoi"> DOI: 10.1038/npp.2013.70</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnpp.2013.70" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=23493042" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref88/cit88&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=38&publication_year=2013&pages=1706-1723&author=V.+Lahmyauthor=J.+Meunierauthor=S.+Malmstr%C3%B6mauthor=G.+Naertauthor=L.+Givaloisauthor=S.+H.+Kimauthor=V.+Villardauthor=A.+Vamvakidesauthor=T.+Maurice&title=Blockade+of+Tau+hyperphosphorylation+and+A%CE%B2+1%E2%80%9342+generation+by+the+aminotetrahydrofuran+derivative+ANAVEX2-73%2C+a+mixed+muscarinic+and+%CF%83+1+receptor+agonist%2C+in+a+nontransgenic+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1038%2Fnpp.2013.70"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit88R"><div class="casContent"><span class="casTitleNuber">88</span><div class="casTitle"><span class="NLM_cas:atitle">Blockade of Tau Hyperphosphorylation and Aβ1-42 Generation by the Aminotetrahydrofuran Derivative ANAVEX2-73, a Mixed Muscarinic and σ1 Receptor Agonist, in a Nontransgenic Mouse Model of Alzheimer's Disease</span></div><div class="casAuthors">Lahmy, Valentine; Meunier, Johann; Malmstroem, Susanna; Naert, Gaelle; Givalois, Laurent; Kim, Seung Hyun; Villard, Vanessa; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">38</span>
        (<span class="NLM_cas:issue">9</span>),
    <span class="NLM_cas:pages">1706-1723</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The main objective of the present study was to establish whether the mixed σ1/muscarinic ligand ANAVEX2-73, shown to be neuroprotective in Alzheimer's disease (AD) models in vivo and currently in clin. phase I/IIa, could have the ability to reduce the appearance of hyperphosphorylated Tau and amyloid-β1-42 (Aβ1-42) in the Aβ25-35 mouse model of AD.  We therefore first confirmed that Aβ25-35 injection induced hyperphosphorylation of Tau protein, by showing that it rapidly decreased Akt activity and activated glycogen synthase kinase-3β (GSK-3β) in the mouse hippocampus.  Second, we showed that the kinase activation, and resulting Tau alteration, directly contributed to the amyloid toxicity, as co-administration of the selective GSK-3β inhibitor 2-thio(3-iodobenzyl)-5-(1-pyridyl)-[1,3,4]-oxidiazole blocked both Tau phosphorylation and Aβ25-35-induced memory impairments.  Third, we analyzed the ANAVEX2-73 effect on Tau phosphorylation and activation of the related kinase pathways (Akt and GSK-3β).  And fourth, we also addressed the impact of the drug on Aβ25-35-induced Aβ1-42 seeding and obsd. that the compd. significantly blocked the increase in Aβ1-42 and C99 levels in the hippocampus, suggesting that it may alleviate amyloid load in AD models.  The comparison with PRE-084, a selective and ref. σ1 receptor agonist, and xanomeline, a muscarinic ligand presenting similar profile as ANAVEX2-73 on M1 and M2 subtypes, confirmed that both muscarinic and σ1 targets are involved in the ANAVEX2-73 effects.  The drug, acting synergistically on both targets, but with moderate affinity, presents a promising pharmacol. profile.  Neuropsychopharmacol. (2013) 38, 1706-1723; doi:10.1038/npp.2013.70; published online 3 Apr. 2013.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp8Ullin5U0GbVg90H21EOLACvtfcHk0limPC2LffYqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3sXhtFCjs7nP&md5=84921702de85f5bc6152b178915adb44</span></div><a href="/servlet/linkout?suffix=cit88&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2013.70&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2013.70%26sid%3Dliteratum%253Aachs%26aulast%3DLahmy%26aufirst%3DV.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DMalmstr%25C3%25B6m%26aufirst%3DS.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DKim%26aufirst%3DS.%2BH.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DBlockade%2520of%2520Tau%2520hyperphosphorylation%2520and%2520A%25CE%25B2%25201%25E2%2580%259342%2520generation%2520by%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX2-73%252C%2520a%2520mixed%2520muscarinic%2520and%2520%25CF%2583%25201%2520receptor%2520agonist%252C%2520in%2520a%2520nontransgenic%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DNeuropsychopharmacology%26date%3D2013%26volume%3D38%26spage%3D1706%26epage%3D1723%26doi%3D10.1038%2Fnpp.2013.70" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref89"><div class="reference"><strong class="refLabel"><a href="#ref89" class="rightTabRefNumLink">89</a></strong><div class="NLM_citation" id="rightTab-cit89"><span><span class="NLM_contrib-group"><span class="NLM_string-name">McQuiston, A. R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Saggau, P.</span></span> <span> </span><span class="NLM_article-title">Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers</span>. <i>J. Neurophysiol.</i> <span class="NLM_year" style="font-weight: bold;">2003</span>,  <span class="NLM_volume"><i>90</i></span>,  <span class="NLM_fpage">1936</span>– <span class="NLM_lpage">1948</span>, <span class="refDoi"> DOI: 10.1152/jn.01150.2002</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1152%2Fjn.01150.2002" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=12750411" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref89/cit89&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD3sXotVelu7Y%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=90&publication_year=2003&pages=1936-1948&author=A.+R.+McQuistonauthor=P.+Saggau&title=Mu-opioid+receptors+facilitate+the+propagation+of+excitatory+activity+in+rat+hippocampal+area+CA1+by+disinhibition+of+all+anatomical+layers&doi=10.1152%2Fjn.01150.2002"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit89R"><div class="casContent"><span class="casTitleNuber">89</span><div class="casTitle"><span class="NLM_cas:atitle">Mu-opioid receptors facilitate the propagation of excitatory activity in rat hippocampal area CA1 by disinhibition of all anatomical layers</span></div><div class="casAuthors">McQuiston, A. Rory; Saggau, Peter</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Neurophysiology</span>
        (<span class="NLM_cas:date">2003</span>),
    <span class="NLM_cas:volume">90</span>
        (<span class="NLM_cas:issue">3</span>),
    <span class="NLM_cas:pages">1936-1948</span>CODEN:
                <span class="NLM_cas:coden">JONEA4</span>;
        ISSN:<span class="NLM_cas:issn">0022-3077</span>.
    
            (<span class="NLM_cas:orgname">American Physiological Society</span>)
        </div><div class="casAbstract">Hippocampal μ-opioid receptors (MORs) have been implicated in memory formation assocd. with opiate drug abuse.  MORs modulate hippocampal synaptic plasticity acutely, when chronically activated, and during drug withdrawal.  At the network level, MORs increase excitability in area CA1 by disinhibiting pyramidal cells.  The precise inhibitory interneuron subtypes affected by MOR activation are unknown; however, not all subtypes are inhibited, and specific interneuron subtypes have been shown to preferentially express MORs.  Here the authors investigate, using voltage-sensitive dye imaging in brain slices, the effect of MOR activation on the patterns of inhibition and on the propagation of excitatory activity in rat hippocampal CA1.  MOR activation augments excitatory activity evoked by stimulating inputs in stratum oriens [i.e., Schaffer collateral and commissural pathway (SCC) and antidromic], stratum radiatum (i.e., SCC), and stratum lacunosum-mol. (SLM; i.e., perforant path and thalamus).  The augmented excitatory activity is further facilitated as it propagates through the CA1 network.  This was obsd. as a proportionately larger increase in amplitudes of excitatory activity at sites distal from where the activity was evoked.  This facilitation was obsd. for excitatory activity propagating from all three stimulation sites.  The augmentation and facilitation were prevented by GABAA receptor antagonists (bicuculline, 30 μM), but not by GABAB receptor antagonists (CGP 55845, 10 μM).  Furthermore, MOR activation inhibited IPSPs in all layers of area CA1.  These findings suggest that MOR-induced suppression of GABA release onto GABAA receptors augments all inputs to CA1 pyramidal cells and facilitates the propagation of excitatory activity through the network of area CA1.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGo75MF7f_zyT7Vg90H21EOLACvtfcHk0limPC2LffYqIw"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD3sXotVelu7Y%253D&md5=3e058205251e582bcbd83d0f3ceaad19</span></div><a href="/servlet/linkout?suffix=cit89&amp;dbid=16384&amp;doi=10.1152%2Fjn.01150.2002&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1152%252Fjn.01150.2002%26sid%3Dliteratum%253Aachs%26aulast%3DMcQuiston%26aufirst%3DA.%2BR.%26aulast%3DSaggau%26aufirst%3DP.%26atitle%3DMu-opioid%2520receptors%2520facilitate%2520the%2520propagation%2520of%2520excitatory%2520activity%2520in%2520rat%2520hippocampal%2520area%2520CA1%2520by%2520disinhibition%2520of%2520all%2520anatomical%2520layers%26jtitle%3DJ.%2520Neurophysiol.%26date%3D2003%26volume%3D90%26spage%3D1936%26epage%3D1948%26doi%3D10.1152%2Fjn.01150.2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref90"><div class="reference"><strong class="refLabel"><a href="#ref90" class="rightTabRefNumLink">90</a></strong><div class="NLM_citation" id="rightTab-cit90"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Batts, K. P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ludwig, J.</span></span> <span> </span><span class="NLM_article-title">An update on terminology and reporting</span>. <i>Am. J. Surg. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">1995</span>,  <span class="NLM_volume"><i>19</i></span>,  <span class="NLM_fpage">1409</span>– <span class="NLM_lpage">1417</span>, <span class="refDoi"> DOI: 10.1097/00000478-199512000-00007</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1097%2F00000478-199512000-00007" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7503362" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref90/cit90&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK28%252FotlKkug%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=19&publication_year=1995&pages=1409-1417&author=K.+P.+Battsauthor=J.+Ludwig&title=An+update+on+terminology+and+reporting&doi=10.1097%2F00000478-199512000-00007"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit90R"><div class="casContent"><span class="casTitleNuber">90</span><div class="casTitle"><span class="NLM_cas:atitle">Chronic hepatitis. An update on terminology and reporting</span></div><div class="casAuthors">Batts K P; Ludwig J</div><div class="citationInfo"><span class="NLM_cas:title">The American journal of surgical pathology</span>
        (<span class="NLM_cas:date">1995</span>),
    <span class="NLM_cas:volume">19</span>
        (<span class="NLM_cas:issue">12</span>),
    <span class="NLM_cas:pages">1409-17</span>
        ISSN:<span class="NLM_cas:issn">0147-5185</span>.
    </div><div class="casAbstract">The terms chronic active hepatitis (CAH), chronic persistent hepatitis (CpH), and chronic lobular hepatitis (CLH) have become obsolete, and their use without further specifications should be discontinued.  This recommendation has become necessary because these names have changed from descriptive terms, intended for grading, to terms that are used either as morphologic diagnoses or disease designations or both, depending on individual preferences.  Because this practice has caused serious misunderstandings, many authors and two international groups have recommended the use of a clear etiologic terminology.  For the reporting practice of pathologists, we recommend that the pathologist routinely sign out biopsy samples with features of chronic hepatitis by indicating etiology, grade, and stage.  An example would be autoimmune hepatitis, severe, stage 3.  The stage in this case would indicate the presence of well-developed septal fibrosis but no nodular regeneration.  Obviously, for the etiologic diagnosis, morphologic findings must be integrated with clinical and laboratory data.  If this information is not available, clear morphologic diagnoses should be reported.  Thus, instead of CPH, the diagnosis should be portal hepatitis, cause undetermined.  This reporting practice eliminates ambiguous terminology and avoids the risk of inappropriate treatment as might occur, for example, when a term such as CAH is used to describe Wilson's disease and is misunderstood to mean autoimmune hepatitis.  For a transitional period and to facilitate relearning, the terms CAH, CPH, and CLH can be reported in parentheses behind the etiologic diagnosis.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcTdtB05sEuTX9yzdcP07UmufW6udTcc2eZhr9HBCOIAzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK28%252FotlKkug%253D%253D&md5=cc7f13cfcf5709d820c4cf408e576190</span></div><a href="/servlet/linkout?suffix=cit90&amp;dbid=16384&amp;doi=10.1097%2F00000478-199512000-00007&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1097%252F00000478-199512000-00007%26sid%3Dliteratum%253Aachs%26aulast%3DBatts%26aufirst%3DK.%2BP.%26aulast%3DLudwig%26aufirst%3DJ.%26atitle%3DAn%2520update%2520on%2520terminology%2520and%2520reporting%26jtitle%3DAm.%2520J.%2520Surg.%2520Pathol.%26date%3D1995%26volume%3D19%26spage%3D1409%26epage%3D1417%26doi%3D10.1097%2F00000478-199512000-00007" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref91"><div class="reference"><strong class="refLabel"><a href="#ref91" class="rightTabRefNumLink">91</a></strong><div class="NLM_citation" id="rightTab-cit91"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mathew, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Karunanithy, R.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yee, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Natarajan, P.</span></span> <span> </span><span class="NLM_article-title">Hepatotoxicity of dimethylformamide and dimethylsulfoxide at and above the levels used in some aflatoxin studies</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1980</span>,  <span class="NLM_volume"><i>42</i></span>,  <span class="NLM_fpage">257</span>– <span class="NLM_lpage">262</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=7354621" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref91/cit91&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADyaL3cXht1aqsrw%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=42&publication_year=1980&pages=257-262&author=T.+Mathewauthor=R.+Karunanithyauthor=M.+Yeeauthor=P.+Natarajan&title=Hepatotoxicity+of+dimethylformamide+and+dimethylsulfoxide+at+and+above+the+levels+used+in+some+aflatoxin+studies"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit91R"><div class="casContent"><span class="casTitleNuber">91</span><div class="casTitle"><span class="NLM_cas:atitle">Hepatotoxicity of dimethylformamide and dimethyl sulfoxide at and above the levels used in some aflatoxin studies</span></div><div class="casAuthors">Mathew, T.; Karunanithy, R.; Yee, M. H.; Natarajan, P. N.</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory Investigation</span>
        (<span class="NLM_cas:date">1980</span>),
    <span class="NLM_cas:volume">42</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">257-62</span>CODEN:
                <span class="NLM_cas:coden">LAINAW</span>;
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">Rats were treated with a single i.p. injection of DMF  [68-12-2] or DMSO  [67-68-5].  The doses of DMF administered were 0.6, 0.9, and 1.2 mL/kg, and those of DMSO were 1.2, 2.4, 3.6, and 4.8 mL/kg.  The animals were sacrificed at 24, 48, 72, and 120 h following administration of each dose.  The liver was investigated in all cases.  Treatment with DMF at 0.6 mL/kg caused some histol. lesions of the liver which became well defined at 0.9 and 1.2 mL/kg causing severe central phlebitis with centrilobular coagulative necrosis of the cells assocd. with a heavy inflammatory infiltrate.  Maximal liver lesions occurred at 48 h and started to regress after 72 h.  However, cellular atypism became a consistent finding after this inflammatory phase.  DMSO-treated animals showed minimal histol. lesions of the liver at 1.2 and 2.4 mL/kg.  Higher doses caused fatty infiltration with a predominantly periportal distribution.  It tended to produce its maximal effect in 12 h which then regressed rapidly after 24 h.  The development of histol. lesions in the liver even at 0.6 mL/kg suggested that DMF was not a suitable solvent for aflatoxin studies, and hence the results obtained from such studies need cautious interpretation.  DMSO appeared to be an ideal alternative for toxicol. studies at a much higher dose level compared to DMF.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq1GhpeIUvWj7Vg90H21EOLACvtfcHk0lireKTbLOiNMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADyaL3cXht1aqsrw%253D&md5=287c7ca6860471cdcc66fdcc07da7009</span></div><a href="/servlet/linkout?suffix=cit91&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DMathew%26aufirst%3DT.%26aulast%3DKarunanithy%26aufirst%3DR.%26aulast%3DYee%26aufirst%3DM.%26aulast%3DNatarajan%26aufirst%3DP.%26atitle%3DHepatotoxicity%2520of%2520dimethylformamide%2520and%2520dimethylsulfoxide%2520at%2520and%2520above%2520the%2520levels%2520used%2520in%2520some%2520aflatoxin%2520studies%26jtitle%3DLab.%2520Invest.%26date%3D1980%26volume%3D42%26spage%3D257%26epage%3D262" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref92"><div class="reference"><strong class="refLabel"><a href="#ref92" class="rightTabRefNumLink">92</a></strong><div class="NLM_citation" id="rightTab-cit92"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Silverman, R. B.</span></span> <i>The organic chemistry of enzyme-catalyzed reactions</i>. <span class="NLM_publisher-name">Academic Press</span>: <span class="NLM_publisher-loc">London</span>, <span class="NLM_year">2002</span>.</span><div class="citationLinks"><a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&publication_year=2002&author=R.+B.+Silverman&title=The+organic+chemistry+of+enzyme-catalyzed+reactions"target="_blank">Google Scholar</a><div class="casRecord empty" id="&#xA;                            rightTab-cas_R&#xA;                        "><div class="casContent">There is no corresponding record for this reference.</div></div><a href="/servlet/linkout?suffix=cit92&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Dbook%26sid%3Dliteratum%253Aachs%26aulast%3DSilverman%26aufirst%3DR.%2BB.%26btitle%3DThe%2520organic%2520chemistry%2520of%2520enzyme-catalyzed%2520reactions%26pub%3DAcademic%2520Press%26date%3D2002" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref93"><div class="reference"><strong class="refLabel"><a href="#ref93" class="rightTabRefNumLink">93</a></strong><div class="NLM_citation" id="rightTab-cit93"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Naiki, H.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Higuchi, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nakakuki, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Takeda, T.</span></span> <span> </span><span class="NLM_article-title">Kinetic analysis of amyloid fibril polymerization in vitro</span>. <i>Lab. Invest.</i> <span class="NLM_year" style="font-weight: bold;">1991</span>,  <span class="NLM_volume"><i>65</i></span>,  <span class="NLM_fpage">104</span>– <span class="NLM_lpage">110</span></span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1906561" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref93/cit93&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK3Mzgtl2mtw%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=65&publication_year=1991&pages=104-110&author=H.+Naikiauthor=K.+Higuchiauthor=K.+Nakakukiauthor=T.+Takeda&title=Kinetic+analysis+of+amyloid+fibril+polymerization+in+vitro"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit93R"><div class="casContent"><span class="casTitleNuber">93</span><div class="casTitle"><span class="NLM_cas:atitle">Kinetic analysis of amyloid fibril polymerization in vitro</span></div><div class="casAuthors">Naiki H; Higuchi K; Nakakuki K; Takeda T</div><div class="citationInfo"><span class="NLM_cas:title">Laboratory investigation; a journal of technical methods and pathology</span>
        (<span class="NLM_cas:date">1991</span>),
    <span class="NLM_cas:volume">65</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">104-10</span>
        ISSN:<span class="NLM_cas:issn">0023-6837</span>.
    </div><div class="casAbstract">We investigated the polymerization kinetics of murine senile amyloid fibrils (fASSAM) in vitro.  When sonicated murine senile amyloid fibrils was incubated with its constituent monomer protein, the extension of amyloid fibrils was observed in an electron microscopic analysis.  Quantitative fluorometric analysis with thioflavine T (Naiki H, Higuchi K, Hosokawa M, Takeda T: Anal Biochem 177:244, 1989) revealed that (a) extension of amyloid fibrils occurred by a pseudo-first-order exponential increase in the fluorescence of thioflavine T; (b) the rate of extension was maximal around pH 7.5, and was inhibited with the increase in KCl or NaCl concentration in the reaction mixture; (c) the rate of polymerization was proportional to the product of the murine senile amyloid fibrils number concentration and the constituent monomer protein concentration; (d) the net rate of extension was the sum of the rates of polymerization and depolymerization with the equilibrium association constant K of 5 x 10(7) M-1.  These results show that amyloid fibril formation can apparently be explained by a first-order kinetic model: that is, extension of amyloid fibrils proceeds by consecutive association of precursor proteins onto the ends of existing fibrils.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQzqvddojADZ77NkxioyDXTfW6udTcc2eZhr9HBCOIAzbntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK3Mzgtl2mtw%253D%253D&md5=f0bf34063b451a94204b8205d8a9f00e</span></div><a href="/servlet/linkout?suffix=cit93&amp;dbid=16384&amp;doi=&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26sid%3Dliteratum%253Aachs%26aulast%3DNaiki%26aufirst%3DH.%26aulast%3DHiguchi%26aufirst%3DK.%26aulast%3DNakakuki%26aufirst%3DK.%26aulast%3DTakeda%26aufirst%3DT.%26atitle%3DKinetic%2520analysis%2520of%2520amyloid%2520fibril%2520polymerization%2520in%2520vitro%26jtitle%3DLab.%2520Invest.%26date%3D1991%26volume%3D65%26spage%3D104%26epage%3D110" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref94"><div class="reference"><strong class="refLabel"><a href="#ref94" class="rightTabRefNumLink">94</a></strong><div class="NLM_citation" id="rightTab-cit94"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Mukherjee, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Adams, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Whiteaker, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Daza, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Kage, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Cassar, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meyer, M.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yao, B. B.</span></span> <span> </span><span class="NLM_article-title">Species comparison and pharmacological characterization of rat and human CB<sub>2</sub> cannabinoid receptors</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2004</span>,  <span class="NLM_volume"><i>505</i></span>,  <span class="NLM_fpage">1</span>– <span class="NLM_lpage">9</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2004.09.058</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejphar.2004.09.058" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=15556131" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref94/cit94&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLnL" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=505&publication_year=2004&pages=1-9&author=S.+Mukherjeeauthor=M.+Adamsauthor=K.+Whiteakerauthor=A.+Dazaauthor=K.+Kageauthor=S.+Cassarauthor=M.+Meyerauthor=B.+B.+Yao&title=Species+comparison+and+pharmacological+characterization+of+rat+and+human+CB2+cannabinoid+receptors&doi=10.1016%2Fj.ejphar.2004.09.058"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit94R"><div class="casContent"><span class="casTitleNuber">94</span><div class="casTitle"><span class="NLM_cas:atitle">Species comparison and pharmacological characterization of rat and human CB2 cannabinoid receptors</span></div><div class="casAuthors">Mukherjee, Sutapa; Adams, Monique; Whiteaker, Kristi; Daza, Anthony; Kage, Karen; Cassar, Steven; Meyer, Michael; Yao, Betty Bei</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2004</span>),
    <span class="NLM_cas:volume">505</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">1-9</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Pharmacol. effects of cannabinoid ligands are thought to be mediated through cannabinoid CB1 and CB2 receptor subtypes.  Sequence anal. revealed that rat and human cannabinoid CB2 receptors are divergent and share 81% amino acid homol.  Pharmacol. anal. of the possible species differences between rat and human cannabinoid CB2 receptors was performed using radioligand binding and functional assays.  Pronounced species selectivity at the rat cannabinoid CB2 receptor (50- to 140-fold) was obsd. with AM-1710 (3-(1,1-Dimethyl-heptyl)-1-hydroxy-9-methoxy-benzo[c]chromen-6-one) and AM-1714 (3-(1,1-Dimethyl-heptyl)-1-9-dihydroxy-benzo[c]chromen-6-one).  In contrast, JWH-015 ((2-Methyl-1-propyl-1H-indol-3-yl)-naphthalen-1-yl-methanone) was 3- to 10-fold selective at the human cannabinoid CB2 receptor.  Endocannabinoid ligands were more human receptor selective.  Cannabinoid CB2 receptor antagonist, AM-630 ((6-Iodo-2-methyl-1-(2-morpholin-4-yl-ethyl)-1H-indol-3-yl)-(4-methoxy-phenyl)-methanone) was more potent at the rat receptor in radioligand binding and functional assays than that of the human receptor.  The findings of the pharmacol. differences between the human and rat cannabinoid CB2 receptors in this study provide crit. information for characterizing cannabinoid ligands in in vivo rodent models for drug discovery purpose.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoxt0gttmCZzLVg90H21EOLACvtfcHk0lireKTbLOiNMg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD2cXhtVWjsLnL&md5=cd966d58f39b09919f824eb61b150196</span></div><a href="/servlet/linkout?suffix=cit94&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2004.09.058&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2004.09.058%26sid%3Dliteratum%253Aachs%26aulast%3DMukherjee%26aufirst%3DS.%26aulast%3DAdams%26aufirst%3DM.%26aulast%3DWhiteaker%26aufirst%3DK.%26aulast%3DDaza%26aufirst%3DA.%26aulast%3DKage%26aufirst%3DK.%26aulast%3DCassar%26aufirst%3DS.%26aulast%3DMeyer%26aufirst%3DM.%26aulast%3DYao%26aufirst%3DB.%2BB.%26atitle%3DSpecies%2520comparison%2520and%2520pharmacological%2520characterization%2520of%2520rat%2520and%2520human%2520CB2%2520cannabinoid%2520receptors%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2004%26volume%3D505%26spage%3D1%26epage%3D9%26doi%3D10.1016%2Fj.ejphar.2004.09.058" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref95"><div class="reference"><strong class="refLabel"><a href="#ref95" class="rightTabRefNumLink">95</a></strong><div class="NLM_citation" id="rightTab-cit95"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Su, T.-P.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Privat, A.</span></span> <span> </span><span class="NLM_article-title">Sigma1 (σ1) receptor agonists and neurosteroids attenuate β25–35-amyloid peptide-induced amnesia in mice through a common mechanism</span>. <i>Neuroscience</i> <span class="NLM_year" style="font-weight: bold;">1998</span>,  <span class="NLM_volume"><i>83</i></span>,  <span class="NLM_fpage">413</span>– <span class="NLM_lpage">428</span>, <span class="refDoi"> DOI: 10.1016/S0306-4522(97)00405-3</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2FS0306-4522%2897%2900405-3" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=9460750" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref95/cit95&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A280%3ADyaK1c7it1SrsA%253D%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=83&publication_year=1998&pages=413-428&author=T.+Mauriceauthor=T.-P.+Suauthor=A.+Privat&title=Sigma1+%28%CF%831%29+receptor+agonists+and+neurosteroids+attenuate+%CE%B225%E2%80%9335-amyloid+peptide-induced+amnesia+in+mice+through+a+common+mechanism&doi=10.1016%2FS0306-4522%2897%2900405-3"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit95R"><div class="casContent"><span class="casTitleNuber">95</span><div class="casTitle"><span class="NLM_cas:atitle">Sigma1 (sigma 1) receptor agonists and neurosteroids attenuate B25-35-amyloid peptide-induced amnesia in mice through a common mechanism</span></div><div class="casAuthors">Maurice T; Su T P; Privat A</div><div class="citationInfo"><span class="NLM_cas:title">Neuroscience</span>
        (<span class="NLM_cas:date">1998</span>),
    <span class="NLM_cas:volume">83</span>
        (<span class="NLM_cas:issue">2</span>),
    <span class="NLM_cas:pages">413-28</span>
        ISSN:<span class="NLM_cas:issn">0306-4522</span>.
    </div><div class="casAbstract">The sigma1 (sigma 1) receptor agonists exert potent anti-amnesic effects, as they apparently block the learning impairments either induced by the muscarinic receptor antagonist scopolamine, the N-methyl-D-aspartate receptor antagonist dizocilpine or inherently due to the age-related deficits in senescence-accelerated mice.  We recently described the amnesia induced by the beta-amyloid-related peptide beta 25-35, administered centrally in an aggregated form, in mice.  The deficits were sensitive to cholinomimetics or to N-methyl-D-aspartate/glycine modulatory site agonists.  Herein, we examined the effects of sigma 1 receptor ligands on the beta 25-35 peptide-induced amnesia.  The effects of neuro(active) steroids, which interact in vitro and in vivo with sigma 1 receptors were examined in parallel.  Mnesic capacity was evaluated seven days after administration of aggregated beta 25-35 peptide (3 nmol), using spontaneous alternation in the Y-maze for spatial short-term memory, or after 14 days, using the step-down type passive avoidance test for long-term memory.  The sigma 1 receptor agonists (+)-pentazocine, PRE-084, or SA4503 attenuated, in a dose-dependent and bell-shaped manner, the beta 25-35 peptide-induced deficits on both tests.  These effects were antagonized by haloperidol or BMY-14802, confirming the sigma 1 receptor pharmacology.  Pregnenolone, dehydroepiandrosterone, and their sulphate esters, but not progesterone, also dose-dependently attenuated the beta 25-35 peptide-induced deficits.  Progesterone blocked the beneficial effects of each other neurosteroid, behaving as an antagonist.  Furthermore, haloperidol blocked the effects induced by neurosteroids, whereas progesterone antagonized the effects of the non-steroidal sigma 1 receptor agonists, showing a clear crossed pharmacology of different drug classes.  These results demonstrate that: (i) the anti-amnesic effect of sigma 1 receptor agonists may be of therapeutic relevance in pathological states affecting the cholinergic and/or glutamatergic systems, such as in pathological aging; (ii) neurosteroids play an important role in learning processes and may collectively constitute a therapeutic target; (iii) the interaction between sigma 1 systems and neurosteroids appears indeed of behavioural relevance.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=LOZGTtr2ZcQk2M14yVWgsSA3UY9EwTNrfW6udTcc2eY9B9OvftK1drntkvexoksv"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A280%3ADyaK1c7it1SrsA%253D%253D&md5=b32d89a65019b0a50a3667b8626c60fa</span></div><a href="/servlet/linkout?suffix=cit95&amp;dbid=16384&amp;doi=10.1016%2FS0306-4522%2897%2900405-3&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252FS0306-4522%252897%252900405-3%26sid%3Dliteratum%253Aachs%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DSu%26aufirst%3DT.-P.%26aulast%3DPrivat%26aufirst%3DA.%26atitle%3DSigma1%2520%2528%25CF%25831%2529%2520receptor%2520agonists%2520and%2520neurosteroids%2520attenuate%2520%25CE%25B225%25E2%2580%259335-amyloid%2520peptide-induced%2520amnesia%2520in%2520mice%2520through%2520a%2520common%2520mechanism%26jtitle%3DNeuroscience%26date%3D1998%26volume%3D83%26spage%3D413%26epage%3D428%26doi%3D10.1016%2FS0306-4522%2897%2900405-3" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref96"><div class="reference"><strong class="refLabel"><a href="#ref96" class="rightTabRefNumLink">96</a></strong><div class="NLM_citation" id="rightTab-cit96"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ieni, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">The anti-amnesic and neuroprotective effects of donepezil against amyloid beta25-35 peptide-induced toxicity in mice involve an interaction with the sigma1 receptor</span>. <i>Br. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2006</span>,  <span class="NLM_volume"><i>149</i></span>,  <span class="NLM_fpage">998</span>– <span class="NLM_lpage">1012</span>, <span class="refDoi"> DOI: 10.1038/sj.bjp.0706927</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fsj.bjp.0706927" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=17057756" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref96/cit96&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD28Xht12gsLvN" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=149&publication_year=2006&pages=998-1012&author=J.+Meunierauthor=J.+Ieniauthor=T.+Maurice&title=The+anti-amnesic+and+neuroprotective+effects+of+donepezil+against+amyloid+beta25-35+peptide-induced+toxicity+in+mice+involve+an+interaction+with+the+sigma1+receptor&doi=10.1038%2Fsj.bjp.0706927"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit96R"><div class="casContent"><span class="casTitleNuber">96</span><div class="casTitle"><span class="NLM_cas:atitle">The anti-amnesic and neuroprotective effects of donepezil against amyloid β25-35 peptide-induced toxicity in mice involve an interaction with the σ1 receptor</span></div><div class="casAuthors">Meunier, J.; Ieni, J.; Maurice, T.</div><div class="citationInfo"><span class="NLM_cas:title">British Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2006</span>),
    <span class="NLM_cas:volume">149</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">998-1012</span>CODEN:
                <span class="NLM_cas:coden">BJPCBM</span>;
        ISSN:<span class="NLM_cas:issn">0007-1188</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">Background and purpose: The acetylcholinesterase inhibitor, donepezil, is also a high affinity σ1 receptor agonist.  We examd. the involvement of σ1 receptors in its anti-amnesic and neuroprotective properties against amyloid β25-35 peptide-induced toxicity in mice.  Exptl. approach:Mice were given an intracerebroventricular (i.c.v.) injection of Aβ25-35 peptide (9 nmol) 7-9 days before being tested for spontaneous alternation and passive avoidance.  Hippocampal lipid peroxidn. was measured 7 days after Aβ25-35 injection to evaluate oxidative stress.  Donepezil, the σ1 agonist PRE-084 or the cholinesterase (ChE) inhibitors tacrine, rivastigmine and galantamine were administered either 20 min before behavioral sessions to check their anti-amnesic effects, or 20 min before Aβ25-35 injection, or 24 h after Aβ25-35 injection and then once daily before behavioral sessions, to check their pre- and post-i.c.v. neuroprotective activity, resp.  Key results: All the drugs tested were anti-amnesic, but only the effects of PRE-084 and donepezil were prevented by the σ1 antagonist BD1047.  Only PRE-084 and donepezil showed neuroprotection when administered pre i.c.v.; they blocked lipid peroxidn. and learning deficits, effects inhibited by BD1047.  Post i.c.v., PRE-084 and donepezil showed complete neuroprotection whereas the other ChE inhibitors showed partial effects.  BD1047 blocked these effects of PRE-084, attenuated those of donepezil, but did not affect the partial effects of the other ChE inhibitors.Conclusions and implications.  The potent anti-amnesic and neuroprotective effects of donepezil against Aβ25-35-induced toxicity involve both its cholinergic and σ1 agonistic properties.  This dual action may explain its sustained activity compared to other ChE inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGoQnuVPGFVAubVg90H21EOLACvtfcHk0lg0kWYO8QO3xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD28Xht12gsLvN&md5=74e469485771b149a04d178a1890da79</span></div><a href="/servlet/linkout?suffix=cit96&amp;dbid=16384&amp;doi=10.1038%2Fsj.bjp.0706927&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fsj.bjp.0706927%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DIeni%26aufirst%3DJ.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DThe%2520anti-amnesic%2520and%2520neuroprotective%2520effects%2520of%2520donepezil%2520against%2520amyloid%2520beta25-35%2520peptide-induced%2520toxicity%2520in%2520mice%2520involve%2520an%2520interaction%2520with%2520the%2520sigma1%2520receptor%26jtitle%3DBr.%2520J.%2520Pharmacol.%26date%3D2006%26volume%3D149%26spage%3D998%26epage%3D1012%26doi%3D10.1038%2Fsj.bjp.0706927" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref97"><div class="reference"><strong class="refLabel"><a href="#ref97" class="rightTabRefNumLink">97</a></strong><div class="NLM_citation" id="rightTab-cit97"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl) sulfonyl](2, 5-difluorophenyl) amino] ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1–42 seeding and short-term memory deficits in the Aβ25–35 mouse model of Alzheimer’s disease</span>. <i>Eur. J. Pharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2013</span>,  <span class="NLM_volume"><i>698</i></span>,  <span class="NLM_fpage">193</span>– <span class="NLM_lpage">199</span>, <span class="refDoi"> DOI: 10.1016/j.ejphar.2012.10.033</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ejphar.2012.10.033" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=23123349" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref97/cit97&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC38Xhslaqu77J" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=698&publication_year=2013&pages=193-199&author=J.+Meunierauthor=V.+Villardauthor=L.+Givaloisauthor=T.+Maurice&title=The+%CE%B3-secretase+inhibitor+2-%5B%281R%29-1-%5B%284-chlorophenyl%29+sulfonyl%5D%282%2C+5-difluorophenyl%29+amino%5D+ethyl-5-fluorobenzenebutanoic+acid+%28BMS-299897%29+alleviates+A%CE%B21%E2%80%9342+seeding+and+short-term+memory+deficits+in+the+A%CE%B225%E2%80%9335+mouse+model+of+Alzheimer%E2%80%99s+disease&doi=10.1016%2Fj.ejphar.2012.10.033"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit97R"><div class="casContent"><span class="casTitleNuber">97</span><div class="casTitle"><span class="NLM_cas:atitle">The γ-secretase inhibitor 2-[(1R)-1-[(4-chlorophenyl)sulfonyl](2,5-difluorophenyl) amino]ethyl-5-fluorobenzenebutanoic acid (BMS-299897) alleviates Aβ1-42 seeding and short-term memory deficits in the Aβ25-35 mouse model of Alzheimer's disease</span></div><div class="casAuthors">Meunier, Johann; Villard, Vanessa; Givalois, Laurent; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">European Journal of Pharmacology</span>
        (<span class="NLM_cas:date">2013</span>),
    <span class="NLM_cas:volume">698</span>
        (<span class="NLM_cas:issue">1-3</span>),
    <span class="NLM_cas:pages">193-199</span>CODEN:
                <span class="NLM_cas:coden">EJPHAZ</span>;
        ISSN:<span class="NLM_cas:issn">0014-2999</span>.
    
            (<span class="NLM_cas:orgname">Elsevier B.V.</span>)
        </div><div class="casAbstract">Alzheimer's disease pathomimetic toxicity could be induced in mice within one week after the intracerebroventricular (i.c.v.) injection of an aggregated prepn. of the highly toxic and endogenous amyloid-β fragment Aβ25-35.  It was recently reported that Aβ25-35 also provokes a modification of APP processing with accumulation of endogenous Aβ1-42.  We here analyzed whether a γ-secretase inhibitor, BMS-299897, attenuated this Aβ25-35-induced Aβ1-42 seeding and toxicity.  The compd. was administered at 0.1-1 nmol/mouse, concomitantly with Aβ25-35 (9 nmol) in male Swiss mice.  After one week, the contents in Aβ1-42 and Aβ1-40, and the levels in lipid peroxidn. were analyzed in the mouse hippocampus.  Mice were submitted to spontaneous alternation, passive avoidance and object recognition to analyze their short- and long-term memory abilities.  Aβ25-35 increased Aβ1-42 content (+240%) but failed to affect Aβ1-40.  BMS-299897 blocked the increase in Aβ1-42 content and decreased Aβ1-40 levels significantly.  The compd. did not affect Aβ25-35-induced increase in hippocampal lipid peroxidn.  Behaviorally, BMS-299897 blocked the Aβ25-35-induced deficits in spontaneous alternation or novel object recognition, using a 1 h intertrial time interval.  BMS-299896 failed to affect the passive avoidance impairments or novel object recognition, using a 24 h intertrial time interval.  These results confirmed that Aβ25-35 injection provoked an accumulation in endogenous Aβ1-42, an effect blocked by γ-secretase inhibition.  This Aβ1-42 accumulation marginally contributed to the toxicity or long-term memory deficits.  However, since the seeded Aβ1-42 affected short-term memory, the rapid Aβ25-35 injection Alzheimer's disease model could be used to screen the activity of new secretase inhibitors.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGp-qM5cWq1c9rVg90H21EOLACvtfcHk0lg0kWYO8QO3xg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC38Xhslaqu77J&md5=0cdaf0d189845ae408aa5dbcca379cf5</span></div><a href="/servlet/linkout?suffix=cit97&amp;dbid=16384&amp;doi=10.1016%2Fj.ejphar.2012.10.033&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ejphar.2012.10.033%26sid%3Dliteratum%253Aachs%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DGivalois%26aufirst%3DL.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DThe%2520%25CE%25B3-secretase%2520inhibitor%25202-%255B%25281R%2529-1-%255B%25284-chlorophenyl%2529%2520sulfonyl%255D%25282%252C%25205-difluorophenyl%2529%2520amino%255D%2520ethyl-5-fluorobenzenebutanoic%2520acid%2520%2528BMS-299897%2529%2520alleviates%2520A%25CE%25B21%25E2%2580%259342%2520seeding%2520and%2520short-term%2520memory%2520deficits%2520in%2520the%2520A%25CE%25B225%25E2%2580%259335%2520mouse%2520model%2520of%2520Alzheimer%25E2%2580%2599s%2520disease%26jtitle%3DEur.%2520J.%2520Pharmacol.%26date%3D2013%26volume%3D698%26spage%3D193%26epage%3D199%26doi%3D10.1016%2Fj.ejphar.2012.10.033" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref98"><div class="reference"><strong class="refLabel"><a href="#ref98" class="rightTabRefNumLink">98</a></strong><div class="NLM_citation" id="rightTab-cit98"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Alkam, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nitta, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Yamada, K.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Nabeshima, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Antiamnesic and neuroprotective effects of the aminotetrahydrofuran derivative ANAVEX1-41 against amyloid β 25–35-induced toxicity in mice</span>. <i>Neuropsychopharmacology</i> <span class="NLM_year" style="font-weight: bold;">2009</span>,  <span class="NLM_volume"><i>34</i></span>,  <span class="NLM_fpage">1552</span>– <span class="NLM_lpage">1566</span>, <span class="refDoi"> DOI: 10.1038/npp.2008.212</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1038%2Fnpp.2008.212" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=19052542" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref98/cit98&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BD1MXksFagurs%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=34&publication_year=2009&pages=1552-1566&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=T.+Alkamauthor=A.+Nittaauthor=K.+Yamadaauthor=T.+Nabeshimaauthor=A.+Vamvakidesauthor=T.+Maurice&title=Antiamnesic+and+neuroprotective+effects+of+the+aminotetrahydrofuran+derivative+ANAVEX1-41+against+amyloid+%CE%B2+25%E2%80%9335-induced+toxicity+in+mice&doi=10.1038%2Fnpp.2008.212"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit98R"><div class="casContent"><span class="casTitleNuber">98</span><div class="casTitle"><span class="NLM_cas:atitle">Antiamnesic and Neuroprotective Effects of the Aminotetrahydrofuran Derivative ANAVEX1-41 Against Amyloid β25-35-Induced Toxicity in Mice</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Alkam, Tursun; Nitta, Atsumi; Yamada, Kiyofumi; Nabeshima, Toshitaka; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Neuropsychopharmacology</span>
        (<span class="NLM_cas:date">2009</span>),
    <span class="NLM_cas:volume">34</span>
        (<span class="NLM_cas:issue">6</span>),
    <span class="NLM_cas:pages">1552-1566</span>CODEN:
                <span class="NLM_cas:coden">NEROEW</span>;
        ISSN:<span class="NLM_cas:issn">0893-133X</span>.
    
            (<span class="NLM_cas:orgname">Nature Publishing Group</span>)
        </div><div class="casAbstract">The antiamnesic and neuroprotective activities of the new aminotetrahydrofuran deriv. tetrahydro-N,N-dimethyl-5,5-diphenyl-3-furanmethanamine hydrochloride (ANAVEX1-41), a nonselective muscarinic receptor ligand and σ1 protein activator, were examd. in mice injected intracerebroventricularly with amyloid β25-35 (Aβ25-35) peptide (9 nmol).  Aβ25-35 impaired significantly spontaneous alternation performance, a spatial working memory, and passive avoidance response.  When ANAVEX1-41 (1-1000 μg/kg i.p.) was administered 7 days after Aβ25-35, ie, 20 min before the behavioral tests, it significantly reversed the Aβ25-35-induced deficits, the most active doses being in the 3-100 μg/kg range.  When the compd. was preadministered 20 min before Aβ25-35, ie, 7 days before the tests, it prevented the learning impairments at 30-100 μg/kg.  Morphol. anal. of corticolimbic structures showed that Aβ25-35 induced a significant cell loss in the CA1 pyramidal cell layer of the hippocampus that was prevented by ANAVEX1-41 (100 μg/kg).  Increased no. of glial fibrillary acidic protein immunopos. cells in the retrosplenial cortex or throughout the hippocampus revealed an Aβ25-35-induced inflammation that was prevented by ANAVEX1-41.  The drug also prevented the parameters of Aβ25-35-induced oxidative stress measured in hippocampus exts., ie, the increases in lipid peroxidn. and protein nitration.  ANAVEX1-41, however, failed to prevent Aβ25-35-induced caspase-9 expression.  The compd. also blocked the Aβ25-35-induced caspase-3 expression, a marker of apoptosis.  Both the muscarinic antagonist scopolamine and the σ1 protein inactivator BD1047 prevented the beneficial effects of ANAVEX1-41 (30 or 100 μg/kg) against Aβ25-35-induced learning impairments, suggesting that muscarinic and σ1 targets are involved in the drug effect.  A synergic effect could indeed account for the very low active doses measured in vivo.  These data outline the therapeutic potential of ANAVEX1-41 as a neuroprotective agent in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGq0XFhD0QttH7Vg90H21EOLACvtfcHk0lg-Z_IWXwcrdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BD1MXksFagurs%253D&md5=6ee3c75c6065592454fe6b00ebc5bdab</span></div><a href="/servlet/linkout?suffix=cit98&amp;dbid=16384&amp;doi=10.1038%2Fnpp.2008.212&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1038%252Fnpp.2008.212%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DAlkam%26aufirst%3DT.%26aulast%3DNitta%26aufirst%3DA.%26aulast%3DYamada%26aufirst%3DK.%26aulast%3DNabeshima%26aufirst%3DT.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAntiamnesic%2520and%2520neuroprotective%2520effects%2520of%2520the%2520aminotetrahydrofuran%2520derivative%2520ANAVEX1-41%2520against%2520amyloid%2520%25CE%25B2%252025%25E2%2580%259335-induced%2520toxicity%2520in%2520mice%26jtitle%3DNeuropsychopharmacology%26date%3D2009%26volume%3D34%26spage%3D1552%26epage%3D1566%26doi%3D10.1038%2Fnpp.2008.212" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref99"><div class="reference"><strong class="refLabel"><a href="#ref99" class="rightTabRefNumLink">99</a></strong><div class="NLM_citation" id="rightTab-cit99"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Villard, V.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Espallergues, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Vamvakides, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span> <span> </span><span class="NLM_article-title">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma<sub>1</sub> (σ<sub>1</sub>) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span>. <i>J. Psychopharmacol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>25</i></span>,  <span class="NLM_fpage">1101</span>– <span class="NLM_lpage">1117</span>, <span class="refDoi"> DOI: 10.1177/0269881110379286</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1177%2F0269881110379286" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=20829307" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref99/cit99&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=25&publication_year=2011&pages=1101-1117&author=V.+Villardauthor=J.+Espallerguesauthor=E.+Kellerauthor=A.+Vamvakidesauthor=T.+Maurice&title=Anti-amnesic+and+neuroprotective+potentials+of+the+mixed+muscarinic+receptor%2Fsigma1+%28%CF%831%29+ligand+ANAVEX2-73%2C+a+novel+aminotetrahydrofuran+derivative&doi=10.1177%2F0269881110379286"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit99R"><div class="casContent"><span class="casTitleNuber">99</span><div class="casTitle"><span class="NLM_cas:atitle">Anti-amnesic and neuroprotective potentials of the mixed muscarinic receptor/sigma1 (σ1) ligand ANAVEX2-73, a novel aminotetrahydrofuran derivative</span></div><div class="casAuthors">Villard, Vanessa; Espallergues, Julie; Keller, Emeline; Vamvakides, Alexandre; Maurice, Tangui</div><div class="citationInfo"><span class="NLM_cas:title">Journal of Psychopharmacology (London, United Kingdom)</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">25</span>
        (<span class="NLM_cas:issue">8</span>),
    <span class="NLM_cas:pages">1101-1117</span>CODEN:
                <span class="NLM_cas:coden">JOPSEQ</span>;
        ISSN:<span class="NLM_cas:issn">0269-8811</span>.
    
            (<span class="NLM_cas:orgname">Sage Publications Ltd.</span>)
        </div><div class="casAbstract">Tetrahydro-N,N-dimethyl-2,2-diphenyl-3-furanmethanamine hydrochloride (ANAVEX2-73) binds to muscarinic acetylcholine and sigma1 (σ1) receptors with affinities in the low micromolar range.  We characterized its anti-amnesic and neuroprotective potentials in pharmacol. and pathol. amnesia models.  Spatial working memory was evaluated using spontaneous alternation in the Y-maze and non-spatial memory using passive avoidance procedures.  ANAVEX2-73 (0.01-3.0 mg/kg i.p.) alleviated the scopolamine- and dizocilpine-induced learning impairments.  ANAVEX2-73 (300 μg/kg) also reversed the learning deficits in mice injected with Aβ25-35 peptide, a non-transgenic Alzheimer's disease model.  When the drug was injected simultaneously with Aβ25-35, 7 days before the tests, it blocked the appearance of learning impairments.  This protective activity was confirmed since ANAVEX2-73 blocked the Aβ25-35-induced oxidative stress in the hippocampus.  This effect was differentially sensitive to the muscarinic receptor antagonist scopolamine or the σ1 protein antagonist BD1047, confirming the mixed muscarinic/σ1 pharmacol. action.  Finally, its unique demethyl metabolite, ANAVEX19-144, was also effective and ANAVEX2-73 presented a longer duration of action, effective 12 h before Aβ25-35, than its related compd. ANAVEX1-41.  The neuroprotective activity of ANAVEX2-73, its mixed cholinergic/σ1 activity, its low active dose range and its long duration of action together reinforce its therapeutic potential in Alzheimer's disease.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGrWVEQ6V9EfObVg90H21EOLACvtfcHk0lg-Z_IWXwcrdg"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXht1Gkur%252FF&md5=4a9ed81d07ba7a7e11b72385f60d941f</span></div><a href="/servlet/linkout?suffix=cit99&amp;dbid=16384&amp;doi=10.1177%2F0269881110379286&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1177%252F0269881110379286%26sid%3Dliteratum%253Aachs%26aulast%3DVillard%26aufirst%3DV.%26aulast%3DEspallergues%26aufirst%3DJ.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DVamvakides%26aufirst%3DA.%26aulast%3DMaurice%26aufirst%3DT.%26atitle%3DAnti-amnesic%2520and%2520neuroprotective%2520potentials%2520of%2520the%2520mixed%2520muscarinic%2520receptor%252Fsigma1%2520%2528%25CF%25831%2529%2520ligand%2520ANAVEX2-73%252C%2520a%2520novel%2520aminotetrahydrofuran%2520derivative%26jtitle%3DJ.%2520Psychopharmacol.%26date%3D2011%26volume%3D25%26spage%3D1101%26epage%3D1117%26doi%3D10.1177%2F0269881110379286" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li><li id="rightTab-ref100"><div class="reference"><strong class="refLabel"><a href="#ref100" class="rightTabRefNumLink">100</a></strong><div class="NLM_citation" id="rightTab-cit100"><span><span class="NLM_contrib-group"><span class="NLM_string-name">Zussy, C.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Brureau, A.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Delair, B.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Marchal, S.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Keller, E.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Ixart, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Naert, G.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Meunier, J.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Chevallier, N.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Maurice, T.</span></span>; <span class="NLM_contrib-group"><span class="NLM_string-name">Givalois, L.</span></span> <span> </span><span class="NLM_article-title">Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats</span>. <i>Am. J. Pathol.</i> <span class="NLM_year" style="font-weight: bold;">2011</span>,  <span class="NLM_volume"><i>179</i></span>,  <span class="NLM_fpage">315</span>– <span class="NLM_lpage">334</span>, <span class="refDoi"> DOI: 10.1016/j.ajpath.2011.03.021</span> </span><div class="citationLinks">[<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=16&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=10.1016%2Fj.ajpath.2011.03.021" title="">Crossref</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=8&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=21703413" title="">PubMed</a>], [<a href="/servlet/linkout?suffix=ref100/cit100&amp;dbid=32&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;key=1%3ACAS%3A528%3ADC%252BC3MXpvVKks7g%253D" title="">CAS</a></a>], <a class="google-scholar" href="http://scholar.google.com/scholar_lookup?hl=en&volume=179&publication_year=2011&pages=315-334&author=C.+Zussyauthor=A.+Brureauauthor=B.+Delairauthor=S.+Marchalauthor=E.+Kellerauthor=G.+Ixartauthor=G.+Naertauthor=J.+Meunierauthor=N.+Chevallierauthor=T.+Mauriceauthor=L.+Givalois&title=Time-course+and+regional+analyses+of+the+physiopathological+changes+induced+after+cerebral+injection+of+an+amyloid+%CE%B2+fragment+in+rats&doi=10.1016%2Fj.ajpath.2011.03.021"target="_blank">Google Scholar</a><div class="casRecord" id="&#xA;                        rightTab-cas_cit100R"><div class="casContent"><span class="casTitleNuber">100</span><div class="casTitle"><span class="NLM_cas:atitle">Time-course and regional analyses of the physiopathological changes induced after cerebral injection of an amyloid β fragment in rats</span></div><div class="casAuthors">Zussy, Charleine; Brureau, Anthony; Delair, Brice; Marchal, Stephane; Keller, Emeline; Ixart, Guy; Naert, Gaelle; Meunier, Johann; Chevallier, Nathalie; Maurice, Tangui; Givalois, Laurent</div><div class="citationInfo"><span class="NLM_cas:title">American Journal of Pathology</span>
        (<span class="NLM_cas:date">2011</span>),
    <span class="NLM_cas:volume">179</span>
        (<span class="NLM_cas:issue">1</span>),
    <span class="NLM_cas:pages">315-334</span>CODEN:
                <span class="NLM_cas:coden">AJPAA4</span>;
        ISSN:<span class="NLM_cas:issn">0002-9440</span>.
    
            (<span class="NLM_cas:orgname">Elsevier</span>)
        </div><div class="casAbstract">Alzheimer's disease (AD) is a neurodegenerative pathol. characterized by the presence of senile plaques and neurofibrillary tangles, accompanied by synaptic and neuronal loss.  The major component of senile plaques is an amyloid β protein (Aβ) formed by pathol. processing of the Aβ precursor protein.  We assessed the time-course and regional effects of a single intracerebroventricular injection of aggregated Aβ fragment 25-35 (Aβ25-35) in rats.  Using a combined biochem., behavioral, and morphol. approach, we analyzed the peptide effects after 1, 2, and 3 wk in the hippocampus, cortex, amygdala, and hypothalamus.  The scrambled Aβ25-35 peptide was used as neg. control.  The aggregated forms of Aβ peptides were first characterized using electron microscopy, IR spectroscopy, and Congo Red staining.  Intracerebroventricular injection of Aβ25-35 decreased body wt., induced short- and long-term memory impairments, increased endocrine stress, cerebral oxidative and cellular stress, neuroinflammation, and neuroprotective reactions, and modified endogenous amyloid processing, with specific time-course and regional responses.  Moreover, Aβ25-35, the presence of which was shown in the different brain structures and over 3 wk, provoked a rapid glial activation, acetylcholine homeostasis perturbation, and hippocampal morphol. alterations.  In conclusion, the acute intracerebroventricular Aβ25-35 injection induced substantial central modifications in rats, highly reminiscent of the human physiopathol., that could contribute to physiol. and cognitive deficits obsd. in AD.</div></div><div class="moreSciFi"><a title="Retrieve detailed record, substances, reactions and more for this article from SciFinder &#174;" href="https://scifinder.cas.org/scifinder/view/link_v1/reference.jsf?l=BmxxGlm8wGpSrf9_FMhbsbVg90H21EOLACvtfcHk0ljnd8E59CxD7A"> >> More from SciFinder <sup>®</sup></a></div><span class="casRefUrl">https://chemport.cas.org/services/resolver?origin=ACS&resolution=options&coi=1%3ACAS%3A528%3ADC%252BC3MXpvVKks7g%253D&md5=a73269e690a9e6b92f2e8ccd4513830a</span></div><a href="/servlet/linkout?suffix=cit100&amp;dbid=16384&amp;doi=10.1016%2Fj.ajpath.2011.03.021&amp;type=refOpenUrl&amp;url=http%3A%2F%2Flbdiscover.ust.hk%2Furesolver%3Fgenre%3Darticle%26id%3Ddoi%3A10.1016%252Fj.ajpath.2011.03.021%26sid%3Dliteratum%253Aachs%26aulast%3DZussy%26aufirst%3DC.%26aulast%3DBrureau%26aufirst%3DA.%26aulast%3DDelair%26aufirst%3DB.%26aulast%3DMarchal%26aufirst%3DS.%26aulast%3DKeller%26aufirst%3DE.%26aulast%3DIxart%26aufirst%3DG.%26aulast%3DNaert%26aufirst%3DG.%26aulast%3DMeunier%26aufirst%3DJ.%26aulast%3DChevallier%26aufirst%3DN.%26aulast%3DMaurice%26aufirst%3DT.%26aulast%3DGivalois%26aufirst%3DL.%26atitle%3DTime-course%2520and%2520regional%2520analyses%2520of%2520the%2520physiopathological%2520changes%2520induced%2520after%2520cerebral%2520injection%2520of%2520an%2520amyloid%2520%25CE%25B2%2520fragment%2520in%2520rats%26jtitle%3DAm.%2520J.%2520Pathol.%26date%3D2011%26volume%3D179%26spage%3D315%26epage%3D334%26doi%3D10.1016%2Fj.ajpath.2011.03.021" title="OpenURL HONG KONG UNIV SCIENCE TECHLGY" onclick="newWindow(this.href);return false" class="issue-item_open-url sfxLink"><img src="/userimages/4265000/sfxbutton" alt="OpenURL HONG KONG UNIV SCIENCE TECHLGY" /></img></a></div></div></div></li></ol></li><li id="pane-m3" aria-labelledby="pane-m3" class="tab__pane tab__pane-suppInfo empty"><h2 class="supp-info-label">Supporting Information</h2><div class="article_supporting-info" id="rightTab-notes1"><div class="article_content-header"><div class="article_content-header-row"><div class="article_content-title"><h2 id="rightTab-rightTab-_i129"><a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00623">Supporting Information</a></h2></div><div class="article_content-sections"><span>ARTICLE SECTIONS</span><div class="article_sections-dropBlock"><a class="" href="#"><span>Jump To</span><i class="icon-angle-down"></i></a><div class="dropBlock__holder" data-db-target-of="sectionsDB_61402"></div></div></div></div></div><hr /></hr><p class="last">The Supporting Information is available free of charge on the <a class="ext-link" href="/">ACS Publications website</a> at DOI: <a class="ext-link" href="/doi/abs/10.1021/acs.jmedchem.9b00623">10.1021/acs.jmedchem.9b00623</a>.<ul id="rightTab-silist" class="NLM_list-list_type-label"><li><p class="inline">RP-HPLC chromatograms of the lead compounds (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf">PDF</a>)</p></li><li><p class="inline">Molecular formula stings (<a class="ext-link" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_002.csv">CSV</a>)</p></li></ul></p><div class="supInfoBoxOnFTP "><div class="sup-info-attachments"><ul><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_001.pdf">jm9b00623_si_001.pdf (794.52 kb)</a></li><li><a class="suppl-anchor" href="/doi/suppl/10.1021/acs.jmedchem.9b00623/suppl_file/jm9b00623_si_002.csv">jm9b00623_si_002.csv (4.25 kb)</a></li></ul></div></div><div id="rightTab-figshare-widget"></div><br /></br><div class="TermsAndConditionsDropzoneRight" data-pb-dropzone="TermsAndConditionsDropzoneRight"><div data-widget-def="UX3HTMLWidget" data-widget-id="b84e6b6c-b4d0-4427-b286-3cf14d52d013" class="mb-4">
        



        
        <h2 style="font-size: 1rem;margin-bottom: 10px;">Terms & Conditions</h2>
<p>Most electronic Supporting Information files are available without a subscription to ACS Web Editions. Such files may be downloaded by article for research use (if there is a public use license linked to the relevant article, that license may permit other uses). Permission may be obtained from ACS for other uses through requests via the RightsLink permission system:
<a href="/page/copyright/permissions.html" title="RightsLink">http://pubs.acs.org/page/copyright/permissions.html</a>.</p>

        </div></div></div></li></ul><div class="recommendedDropzone7" data-pb-dropzone="recommendedDropzone7"><div data-ajaxurl="/pb/widgets/ux3/ux3-showRecommend?widgetId=b272b1fe-ab4e-454f-940c-a3deaf223d23&amp;doi=10.1021%2Facs.jmedchem.9b00623&amp;pbContext=%3Barticle%3Aarticle%3A10.1021%2Facs.jmedchem.9b00623%3BrequestedJournal%3Ajournal%3Ajmcmar%3Bjournal%3Ajournal%3Ajmcmar%3Bpage%3Astring%3AArticle%2FChapter+View%3Bctype%3Astring%3AJournal+Content%3Bwgroup%3Astring%3AACHS+website+Group%3Bwebsite%3Awebsite%3Aacspubs%3Bissue%3Aissue%3A10.1021%2Fjmcmar.2019.62.issue-20%3BpageGroup%3Astring%3APublication+Pages%3BsubPage%3Astring%3AFull+Text" class="show-recommended-placeholder"></div>




        
        <script>
$(document).ready(function() {
  setTimeout(function() {
    var myLink = $(".show-recommended").find("a").not("[href='http://acsmediakit.org']").not("[href='javascript:void(0);']");
    myLink.attr("href", function(i, href) {
        return href + '?ref=recommended';
    });
  }, 5000);
});
</script></div></div></div></div></div></div></div><div class="col-xs-12.clearfix"><div class="article_qv-xs-container"><div class="article_qv-xs"><ul><li><a href="#" title="In This Article"><span>In This Article</span></a></li><li><a href="#" title="Figures" data-slide-target=".tab__pane-figures" class="w-slide__btn slide-active"><i class="icon-image"></i><span>Figures</span></a></li><li><a href="#" title="References" data-slide-target=".tab__pane-references" class="w-slide__btn slide-active"><i class="icon-link"></i><span>References</span></a></li><li><a href="#" title="Supporting Information" data-slide-target=".tab__pane-suppInfo" class="w-slide__btn slide-active"><i class="icon-supporting-info"></i><span>Supporting Information</span></a></li><li><a href="#" title="Recommended Articles" data-slide-target=".recommendedDropzone7" class="show-recommended-qv w-slide__btn slide-active" target="_self"><i class="icon-newspaper-o"></i><span>Recommended Articles</span></a></li></ul><a title="PDF" href="/doi/pdf/10.1021/acs.jmedchem.9b00623" class="button_primary"><i class="icon-file-pdf-o"></i>PDF  <span class="filesize">[
                6MB]
            </span></a></div></div></div></div></div></div></article></main>




        
        <footer class="footer">



        
        <div class="footer_first-row" id="partners">
	<div class="container">
		<div class="row">
			<div class="col-xs-12">
				<div class="footer_first-row_title">
					<h2>
						Partners
					</h2>
				</div>
				<div class="footer_first-row_logos">
					<div>
						<a href="http://www.atypon.com/">
							<img src="/pb-assets/images/footer_logos/logo-atypon-1525376610217.png" alt="Atypon">
						</a>
					</div>
					<div>
						<a href="http://www.chorusaccess.org/">
							<img src="/pb-assets/images/footer_logos/logo-chorus-1525375622947.png" alt="Chorus">
						</a>
					</div>
					<div>
						<a href="http://publicationethics.org/">
							<img src="/pb-assets/images/footer_logos/logo-cope-1525375622977.png" alt="Cope publication ethics">
						</a>
					</div>
					<div>
						<a href="http://www.projectcounter.org/">
							<img src="/pb-assets/images/footer_logos/logo-counter-1523044519173.jpg" alt="Project Counter">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/">
							<img src="/pb-assets/images/footer_logos/logo-crossref-1525377362093.png" alt="Crossref">
						</a>
					</div>
					<div>
						<a href="http://www.crossref.org/crosscheck/index.html">
							<img src="/pb-assets/images/footer_logos/logo-crosscheck-1525375623000.png" alt="Crossref similarity check">
						</a>
					</div>
					<div>
						<a href="http://www.orcid.org/">
							<img src="/pb-assets/images/footer_logos/logo-orcid-1525375623187.png" alt="Orcid Connecting Research and Researchers">
						</a>
					</div>
					<div>
						<a href="http://www.portico.org/">
							<img src="/pb-assets/images/footer_logos/logo-portico-1525375623203.png" alt="Portico digital preservation service">
						</a>
					</div>
				</div>
			</div>
		</div>
	</div>
</div>





        
        <div class="footer_second-row col-xs-12 gutterless ">









        <div data-widget-def="ux3-layout-widget" data-widget-id="f963f9aa-5ade-4a09-8515-e6cd8e6364cf" class="row container">
        



        
        <div class="col-xs-12">



        
        <div class="footer_second-row_left col-md-2 gutterless ">



        
        <a href="/"><img src="/pb-assets/images/pubslogo-small-1444685090580.png" alt="ACS Publications"></a>
<div class="footer_menu">
	<ul>
		<li class="footer_menu_address">
			<span>
				1155 Sixteenth Street N.W.
			</span>
		</li>
		<li class="footer_menu_address">
			<span>
				Washington, DC 20036
			</span>
		</li>

		<li class="footer_menu_copyright">
			<a href="http://www.acs.org/content/acs/en/copyright.html">
				Copyright © 2021<br>
				American Chemical Society
			</a>
		</li>
	</ul>
</div>
</div><div class="footer_second-row_middle col-md-2 gutterless "></div><div class="footer_second-row_right col-md-8 gutterless ">



        
        <div class="footer_second-row_about col-xs-4">



        
        <h2>About</h2>
<ul>
    <li><a href="/page/about-us.html">About ACS Publications</a></li>
    <li><a href="http://acsopenscience.org">ACS & Open Access</a></li>
    <li><a href="https://www.acs.org/content/acs/en/membership/member-benefits/publications-discounts.html">ACS Membership</a></li>
</ul>
</div><div class="footer_second-row_resources col-xs-5">



        
        <h2>Resources and Information</h2>
<ul>
	<li><a href="/action/showPublications?pubType=journal">Journals A-Z</a></li>
	<li><a href="/action/showPublications?pubType=book">Books and Reference</a></li>
    <li><a href="http://acsmediakit.org/digital/acs-pubs/?utm_source=Footer&amp;utm_medium=Pubs&amp;utm_campaign=CEN">Advertising Media Kit</a></li>
    <li><a href="https://solutions.acs.org">Institutional Sales</a></li>
    <li><a href="https://publish.acs.org/publish/">ACS Publishing Center</a></li>
    <li><a href="http://www.acs.org/content/acs/en/privacy.html">Privacy Policy</a></li>
    <li><a href="https://www.acs.org/content/acs/en/terms.html">Terms of Use</a></li>
</ul>
</div><div class="footer_second-row_support col-xs-3">



        
        <h2>Support & Contact</h2>
<ul>
    <li><a href="https://acs.service-now.com/acs">Help</a></li>
    <li><a href="#" onclick="SnapEngage.startLink();return false;" class="help help-chat">Live Chat</a></li>
    <li><a href="https://acs.service-now.com/acs">FAQ</a></li>
</ul>
</div>
</div>




        
        <div class="footer_social_section col-xs-12">



        
        <div class="footer_social_header">
	<h2>Connect with ACS Publications</h2>
</div>
<div class="footer_social">
	<ul>
		<li>
			<a href="https://preferences.acspubs.org/journals" class="icon-envelope-o" aria-label="email">
			</a>
		</li>
		<li>
			<a href="https://www.facebook.com/ACSPublications/" class="icon-facebook" aria-label="facebook" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://twitter.com/ACSPublications" class="icon-twitter" aria-label="twitter" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="https://www.youtube.com/user/AmerChemSoc" class="icon-youtube-play" aria-label="youtube" target="_blank" rel="noreferrer">
			</a>
		</li>
		<li>
			<a href="/page/follow.html?widget=follow-pane-rss" class="icon-rss" aria-label="rss feed">
			</a>
		</li>
	</ul>
</div>

</div>
</div>

        </div>
    
</div>
</footer>




        
        <script>
(function(){
	
	/*Event Tracking for RIS menu dropdown - Article pages*/

	$('.cit-download-dropdown_button').on('click',function(e)
	{	
		e.preventDefault();
	    ga('send', 'event', 'Citation', 'Export', 'Main');
	});


	$('.cit-download-dropdown_content ul li').on('click',function(e)
	{	
	//	e.preventDefault();
	    var idx = $(this).index();
	    
	    var label = '';
	    if (idx === 0 ) {
	    	label = 'Citation';
	    } else if (idx === 1 ) {
	    	label = 'Abstract';
	    } else if (idx === 2 ) {
	    	label = 'Reference';
	    } else if (idx === 3 ) {
	    	label = 'More Options';
	    }
	   ga('send', 'event', 'Citation', 'Export', label);
	});

	$('.header_contnav-next a').on('click', function(e){
        e.preventDefault();
        ga('send', 'event', 'Article', 'Top', 'Right Arrow');
	}); 

 	$('.header_contnav-pre a').on('click', function(e){
	    e.preventDefault();
	     ga('send', 'event', 'Article', 'Top', 'Left Arrow');
	}); 

	$('.share_button').on('click', function(e){
		e.preventDefault();
		ga('send', 'event', 'Article', 'Top', 'Share');
	});

	$("#pane-m1con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Figures');
	});

	$("#pane-m2con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'References');
	});

	$("#pane-m3con").on('click', function(e) {
		e.preventDefault();
		ga('send', 'event', 'Article', 'Sidebar', 'Supporting Info');
	});

	$('.tab__close').on('click', function(){
		ga('send', 'event', 'Article', 'Sidebar', 'Close');
	}); 



})();

</script>






        
        <div aria-live="polite" aria-atomic="true" class="achs-mendeley"><input type="hidden" name="tokenEndpoint" value="https://sso.acs.org/mendeley/token" class="tokenEndpoint"/></input><input type="hidden" name="appID" value="literatum" class="appID"/></input><input type="hidden" name="reopen-mendeley-modal-after-reload" class="reopen-mendeley-modal-after-reload"/></input><input type="hidden" name="statusEndpoint" value="https://sso.acs.org/idp/status" class="statusEndpoint"/></input><input type="hidden" name="clientID" value="atypon-lives" class="clientID"/></input><div class="achs-mendeley_table"><div class="achs-mendeley_row"><div class="achs-mendeley_cell loop-trap"><div class="achs-mendeley_container"><a title="Close" aria-label="close" tabindex="0" class="achs-mendeley_close"><i aria-hidden="true" class="icon-close"></i></a><div class="achs-mendeley_dropzone1"><div class="achs-mendeley_dropzone1_state1">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state2">



        
        <p style="font-weight: bold;">Pair your accounts.</p>
<p>Export articles to Mendeley</p>
<p>Get article recommendations from ACS based on references in your Mendeley library.</p>
</div><div class="achs-mendeley_dropzone1_state3">



        
        <p style="font-weight: bold;">You’ve supercharged your research process with ACS and Mendeley!</p>
</div></div><div class="achs-mendeley_continue-header"><button class="achs-mendeley_continue-btn"><span class="achs-mendeley_buttonText">Continue</span></button></div><div class="achs-mendeley_steps"><div class="achs-mendeley_steps_row"><div class="achs-mendeley_steps_cell achs-mendeley_acsLogin"><h6>STEP 1:</h6><button class="button_primary achs-mendeley_acsLogin_button"><span class="achs-mendeley_buttonText">Login with ACS ID</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><span class="achs-mendeley_acsLogin_label">Click to create an ACS ID</span><i class="icon-if-arrow-right"></i></div><div class="achs-mendeley_steps_cell achs-mendeley_login"><h6>STEP 2:</h6><button class="button_primary achs-mendeley_login_button"><i class="icon-mendeley"></i><span class="achs-mendeley_buttonText">Login with Mendeley</span><span class="achs-mendeley_success_buttonText">Logged in Success</span></button><a href="https://id.elsevier.com/as/authorization.oauth2?state=c33c27125763433d4d32a15accaacc18&amp;prompt=login&amp;scope=openid%20email%20profile%20els_auth_info&amp;authType=SINGLE_SIGN_IN&amp;response_type=code&amp;platSite=MDY%2Fmendeley&amp;redirect_uri=https%3A%2F%2Fwww.mendeley.com%2Fcallback%2F&amp;client_id=MENDELEY" title="Create a Mendeley account">Create a Mendeley account</a></div></div></div><div class="achs-mendeley_dropzone2"><div class="achs-mendeley_dropzone2_state1">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state2">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div><div class="achs-mendeley_dropzone2_state3">



        
        <p style="font-weight: bold;font-style:italic;">Please note: If you switch to a different device, you may be asked to login again with only your ACS ID.
</p>
</div></div></div></div></div></div></div><div class="achs-mendeley_alert"><div class="achs-mendeley_alert_table"><div class="achs-mendeley_alert_row"><div class="achs-mendeley_alert_cell"><div class="achs-mendeley_alert_container"><a title="Close" aria-label="close" class="achs-mendeley_alert_close"><i aria-hidden="true" class="icon-close"></i></a><div role="alert" aria-live="polite" aria-atomic="true" class="achs-mendeley_alert_dropzone">



        
        <p>Please login with your ACS ID before connecting to your Mendeley account.</p><button class="button_tertiary achs-mendeley_acsLogin_button mendeley-acs-custom-login-btn" onclick="loginToAcsSso(event); return false;">Login with ACS ID</button>

<script>
 function loginToAcsSso(event){
 event.preventDefault();
 $('.achs-mendeley_acsLogin .achs-mendeley_acsLogin_button').trigger('click');
 }
</script>
</div><div class="achs-mendeley_alert_error-msg"></div></div></div></div></div><div class="pairing-expired-dialog-container"><div class="pairing-expired-dialog"><div class="pairing-expired-dialog_top-btns"><span class="pairing-expired-dialog_heading">MENDELEY PAIRING EXPIRED</span><button onClick="UX.achsMendeley.reconnectOnClickHandler();" class="pairing-expired-dialog_reconnect">Reconnect</button></div><div class="pairing-expired-dialog_content"><span>Your Mendeley pairing has expired. Please reconnect</span></div></div></div></div>




        
        <style type="text/css">
#gdpr-message-modal {
    display: none;
    /* Hidden by default */
    position: fixed;
    /* Stay in place */
    z-index: 2;
    /* Sit on top */
    /*padding-top: 100px;*/
    /* Location of the box */
    left: 0;
    bottom: 0;
    width: 100%;
    /* Full width */
    /*height: 100%;*/
    /* Full height */
    overflow: auto;
    /* Enable scroll if needed */
    /*background-color: rgb(0,0,0);*/
    /* Fallback color */
    /*background-color: rgba(0,0,0,0.4);*/
    /* Black w/ opacity */
}
#gdpr-message-content {
    font-family: Arial;
    background-color: #005083;
    color: #fff;
    margin: auto;
    padding: 5px 0 10px 0;
    /*border: 1px solid #888;*/
    box-shadow: 0 -1px 3px #666;
    width: 100%;
    display: block;
    bottom: 0;
}
#gdpr-message-container {
    /*width: 1130px;*/
    margin: 0 auto;
}
.gdpr-innerwrap {
    display: block;
    /*width: 1100px;*/
    margin: 0 auto;
    text-align: center;
}
#gdpr-message-content h1 {
    color: #0629b5;
    font-size: 26px;
    margin: 0.5em 0 0 0;
    border-bottom: solid 2px #4c7fb9;
    display: inline;
    padding-bottom: 10px;
}
#gdpr-message-content h4 {
    display: inline-block;
    margin-left: 0;
    margin-right: 14px;
    margin-top: 13px;
    /*width: 980px;*/
    font-size: 14px;
    font-weight: normal;
}
#gdpr-message-content p {
    font-size: 14px;
    margin: 2em 2em 0.5em 0em;
    text-align: left;
    font-weight: bold;
}
#gdpr-message-content a,
#gdpr-message-content a:hover {
    color: #9bcfff;
}
.gdpr-listwrap {
    display: block;
    margin-bottom: 10px;
    min-height: 100px;
    min-width: 200px;
}
#gdpr-message-content ul {
    margin-top: 20px;
    font-size: 13px;
}
#gdpr-ul1 {
    display: inline-block;
    float: left;
}
#gdpr-ul2 {
    display: inline-block;
    margin-left: 10px;
}
#gdpr-message-content ul li {
    margin-top: 4px;
}
a#gdpr-con-btn,
a#gdpr-con-btn:hover {
    width: 110px;
    height: 35px;
    background: #fec82a;
    background-image: none;
    background-image: -webkit-gradient(linear, 50% 0%, 50% 100%, color-stop(0%, #fec82a), color-stop(100%, #daa301));
    background-image: -webkit-linear-gradient(top, #fec82a, #daa301);
    background-image: -moz-linear-gradient(top, #fec82a, #daa301);
    background-image: -o-linear-gradient(top, #fec82a, #daa301);
    background-image: linear-gradient(top, #fec82a, #daa301);
    border-radius: 4px;
    color: #004a7b;
    display: inline-block;
    text-decoration: none;
    line-height: 35px;
    text-align: center;
    margin-top: 5px;
    /*margin-right: 14px;*/
    /*float: right;*/
    font-weight: bold;
}
#gdpr-message-btn {
    width: 60px;
    height: 38px;
    background: #4b8fc2;
    border-radius: 4px;
    color: white;
    display: inline-block;
    margin-top: -4px;
    font-size: 12px;
}
a#closebtn {
    float: right;
    color: #d4e5ef;
}
#gdpr-input {
    width: 200px;
    height: 30px;
    border-radius: 3px;
    border-width: 1px;
    box-shadow: none;
    margin-right: 10px;
    font-size: 14px;
    outline: none;
    padding-left: 2px;
    display: inline-block;
    float: left;
}
#gdpr-message-content p.gdpr_err {
    font-size: 15px;
    margin-top: 10px;
}
#gdpr-message-modal.mobile, #gdpr-message-modal.mobile .gdpr-message-content {
    height: 160px;
}
@media only screen and (min-width: 1026px) and (max-width: 1368px) {
	#gdpr-message-content h4 {
		width: 80%;
		text-align: left;
	}
}
</style>

<div id="gdpr-message-modal">
    <div id="gdpr-message-content">
        
	        <div class="gdpr-innerwrap container">
	            <h4>This website uses cookies to improve your user experience. By continuing to use the site, you are accepting our use of cookies. <a href="http://www.acs.org/content/acs/en/privacy.html">Read the ACS privacy policy</a>.</h4>
	            <a href="#" id="gdpr-con-btn">CONTINUE</a>
	        </div>
        
    </div>
</div>

<script type="text/javascript">
"use strict"
//Script checks gdpr cookie and submits form
	/* 
	Create an in-page pop-up message, only for the InfoCentral homepage, that will gather email registrants for the library marketing list.
	 
	Needs the end point
	*/

var infoCentralCapture = (function() {

    //Detect mobile device
    window.mobilecheck = function() {
        var check = false;
        (function(a){if(/(android|bb\d+|meego).+mobile|avantgo|bada\/|blackberry|blazer|compal|elaine|fennec|hiptop|iemobile|ip(hone|od)|iris|kindle|lge |maemo|midp|mmp|mobile.+firefox|netfront|opera m(ob|in)i|palm( os)?|phone|p(ixi|re)\/|plucker|pocket|psp|series(4|6)0|symbian|treo|up\.(browser|link)|vodafone|wap|windows ce|xda|xiino/i.test(a)||/1207|6310|6590|3gso|4thp|50[1-6]i|770s|802s|a wa|abac|ac(er|oo|s\-)|ai(ko|rn)|al(av|ca|co)|amoi|an(ex|ny|yw)|aptu|ar(ch|go)|as(te|us)|attw|au(di|\-m|r |s )|avan|be(ck|ll|nq)|bi(lb|rd)|bl(ac|az)|br(e|v)w|bumb|bw\-(n|u)|c55\/|capi|ccwa|cdm\-|cell|chtm|cldc|cmd\-|co(mp|nd)|craw|da(it|ll|ng)|dbte|dc\-s|devi|dica|dmob|do(c|p)o|ds(12|\-d)|el(49|ai)|em(l2|ul)|er(ic|k0)|esl8|ez([4-7]0|os|wa|ze)|fetc|fly(\-|_)|g1 u|g560|gene|gf\-5|g\-mo|go(\.w|od)|gr(ad|un)|haie|hcit|hd\-(m|p|t)|hei\-|hi(pt|ta)|hp( i|ip)|hs\-c|ht(c(\-| |_|a|g|p|s|t)|tp)|hu(aw|tc)|i\-(20|go|ma)|i230|iac( |\-|\/)|ibro|idea|ig01|ikom|im1k|inno|ipaq|iris|ja(t|v)a|jbro|jemu|jigs|kddi|keji|kgt( |\/)|klon|kpt |kwc\-|kyo(c|k)|le(no|xi)|lg( g|\/(k|l|u)|50|54|\-[a-w])|libw|lynx|m1\-w|m3ga|m50\/|ma(te|ui|xo)|mc(01|21|ca)|m\-cr|me(rc|ri)|mi(o8|oa|ts)|mmef|mo(01|02|bi|de|do|t(\-| |o|v)|zz)|mt(50|p1|v )|mwbp|mywa|n10[0-2]|n20[2-3]|n30(0|2)|n50(0|2|5)|n7(0(0|1)|10)|ne((c|m)\-|on|tf|wf|wg|wt)|nok(6|i)|nzph|o2im|op(ti|wv)|oran|owg1|p800|pan(a|d|t)|pdxg|pg(13|\-([1-8]|c))|phil|pire|pl(ay|uc)|pn\-2|po(ck|rt|se)|prox|psio|pt\-g|qa\-a|qc(07|12|21|32|60|\-[2-7]|i\-)|qtek|r380|r600|raks|rim9|ro(ve|zo)|s55\/|sa(ge|ma|mm|ms|ny|va)|sc(01|h\-|oo|p\-)|sdk\/|se(c(\-|0|1)|47|mc|nd|ri)|sgh\-|shar|sie(\-|m)|sk\-0|sl(45|id)|sm(al|ar|b3|it|t5)|so(ft|ny)|sp(01|h\-|v\-|v )|sy(01|mb)|t2(18|50)|t6(00|10|18)|ta(gt|lk)|tcl\-|tdg\-|tel(i|m)|tim\-|t\-mo|to(pl|sh)|ts(70|m\-|m3|m5)|tx\-9|up(\.b|g1|si)|utst|v400|v750|veri|vi(rg|te)|vk(40|5[0-3]|\-v)|vm40|voda|vulc|vx(52|53|60|61|70|80|81|83|85|98)|w3c(\-| )|webc|whit|wi(g |nc|nw)|wmlb|wonu|x700|yas\-|your|zeto|zte\-/i.test(a.substr(0,4))) check = true;})(navigator.userAgent||navigator.vendor||window.opera);
              return check;
        };

    var _isMobile = window.mobilecheck();
    if (_isMobile) {
        $('#gdpr-message-modal').addClass('mobile');
    }

    var emailValid = "",
        time = 3000,
        btnStatus = true,
        errorStatus = false,
        errormessage = "<p class='gdpr_err'><b>Please Enter a valid email address<b><p>";

    function init() {
        setTimeout(function() {
            var cookieExist = getCookie("gdpr");
            if (cookieExist) {
                //console.log("gdpr cookie exist");
                return false;
            } else {
                //console.log("gdpr cookie does not exist")
                gdprMessage();
            }
            //Events
            $('#closebtn').on("click", hideForm);

            //Handle submit
            $('#gdpr-message-btn').on("click", function(event) {
                handleClick();
            });

            // //Hide if clicked outside div - TO DO stop handling click after submit
            // $(document).click(function(event) {
            // 	event.stopPropagation();
            //   console.log(event.target);
            //   if (!$(event.target).closest("#gdpr-message-content").length) {
            //     $("body").find("#gdpr-message-modal").hide();
            //     $(this).off();
            //   }
            // });
            $('#gdpr-con-btn').click(function() {
                setCookie("gdpr", "true");
                hideForm();
            });
        }, time);
    }

    //Show the message
    function gdprMessage() {
        //console.log("Show GDPR Message");
        var tMessage, emailInput, messageButton, ewrap;

        $('#gdpr-message-modal').show();
    }

    function handleClick() {
        //console.log($("#gdpr-input").val());
        emailValid = validateEmail($("#gdpr-input").val());
        if (emailValid) {
            //Submit the form
            //Hide form
            if ($('.gdpr_err')) {
                $('.gdpr_err').hide();
            }

            $("#gdpr-message-content")
                //If successful then...
            setCookie("gdpr", "true");
            //console.log("emailValid " + emailValid + " submiting form");
        } else {
            //Show error message
            gdprErrorMessage();
            //console.log("emailValid " + emailValid);
        }
    }

    function gdprErrorMessage() {
        if (errorStatus) {
            return false;
        } else {
            errorStatus = true;
            $("#gdpr-message-content").append(errormessage);
        }
    }

    function validateEmail(email) {
        var re = /^(([^<>()\[\]\\.,;:\s@"]+(\.[^<>()\[\]\\.,;:\s@"]+)*)|(".+"))@((\[[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\.[0-9]{1,3}\])|(([a-zA-Z\-0-9]+\.)+[a-zA-Z]{2,}))$/;
        return re.test(String(email).toLowerCase());
    }

    function setCookie(name, value) {
        var expires = "";
        expires = "; expires=Fri, 31 Dec 9999 23:59:59 GMT";
        document.cookie = name + "=" + (value || "") + expires + "; path=/";
    }

    function getCookie(name) {
        var match = document.cookie.match(new RegExp(name + '=([^;]+)'));
        if (match) return match[1];
    }

    function hideForm() { //And set cookie
        $('#gdpr-message-modal').hide();
        setCookie("gdpr", "false");
        ga('send', 'event', 'Pubs GDPR', 'GDPR Modal', 'GDPR Dismissal');
    }

    return {
        init: init
    }
})();

$(document).ready(infoCentralCapture.init);
</script>





        
        <script>
    //Top nav tracking

    (function(){
        $('.header_my-activity a:first').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Activity')
            ga('send', 'event', 'Top Nav', 'Button', 'Activity');
        })


        $('.pubModal_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Publications')
            ga('send', 'event', 'Top Nav', 'Button', 'Publications');
        }) 

        $('.header_burger-menu_button').on('click', function(e){
            e.preventDefault();
            //console.log('Button , Hamburger');
            ga('send', 'event', 'Top Nav', 'Button', 'Hamburger');
        }) 

        // $('.header_burger-menu_content ul li').on('click', function(e){
        //     // e.preventDefault();
        //     var idx = $(this).index();
        //     console.log('Menu item' + idx)
        // })
    })();
    
    
</script>




        
        
<script type="text/javascript">
    adroll_adv_id = "3LBZJ4KXKBF2PJ46QCMT3X";
    adroll_pix_id = "6EITYRDI4FFGJPSZQ62UJJ";

    (function () {
        var _onload = function(){
            if (document.readyState && !/loaded|complete/.test(document.readyState)){setTimeout(_onload, 10);return}
            if (!window.__adroll_loaded){__adroll_loaded=true;setTimeout(_onload, 50);return}
            var scr = document.createElement("script");
            var host = (("https:" == document.location.protocol) ? "https://s.adroll.com" : "http://a.adroll.com");
            scr.setAttribute('async', 'true');
            scr.type = "text/javascript";
            scr.src = host + "/j/roundtrip.js";
            ((document.getElementsByTagName('head') || [null])[0] ||
                document.getElementsByTagName('script')[0].parentNode).appendChild(scr);
        };
        if (window.addEventListener) {window.addEventListener('load', _onload, false);}
        else {window.attachEvent('onload', _onload)}
    }());
</script>










        
        <div class="activity-container hidden-lg hidden-md"><div class="recentlyViewed" style="right: -100%;"><div class="activity_title_container"><span class="activity_title">Recently Viewed</span><a href="javascript:void(0)" class="activity_back"><i class="icon-angle-left"></i></a></div></div></div>




        
        <script>
$(document).ready(function(){
    var cookie = "";
    var uri = "/doi/full/10.1021/html_original_uri?id=123";
    console.log("ACSPubs2 start");
    $.getJSON('https://extreme-ip-lookup.com/json/', function(data, status) {
            if ( status == 'success' ) {
                $.each(data, function(i, field){
                    cookie=cookie.concat(i+' = '+field+" - ");
                });
                
            } else {
                    cookie=status;
            }

            cookie1 = cookie;
            cookie = cookie1 + "; path=/; domain=.acs.org";
            //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
            $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
            //TODO send cookie val to the controller for logging
            console.log("ACSPubs2 success");
    })
    .fail(function(xx, status, err){
        cookie="error: 127.0.0.1";
        //document.cookie = "ACSPubs2= "+ btoa(cookie) ;
        $.cookie("ACSPubs2", btoa(cookie), {path: '/'}); // Session cookie valid across the entire site.
        console.log("ACSPubs2 failed");
        //TODO send cookie val to the controller for logging
    });
});    
</script>





        
        



        
    

        </div>
    </div>





	

    <script>if (typeof define !== 'undefined')
    if (define.amd)
        define.amd = false</script><script src="/products/achs/releasedAssets/js/build.lazyload.bundle-191cb5c7d88ed9894acd.js"></script><script src="/products/achs/releasedAssets/js/main.bundle-524acd43b3dccf6df3df.js"></script>

<script type="text/javascript" src="/wro/kfa7~product.js"></script>































    












<script defer src="https://static.cloudflareinsights.com/beacon.min.js" data-cf-beacon='{"rayId":"67999ab3b99a3d9a","token":"d4e766cffbf14806ad37e095398b9c5f","version":"2021.7.0","si":10}'></script>
</body>
</html>
